[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9DDN88Vn92UXpVNyby13t5Dy_2_Z9EN2oaHq9olKwF4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"National Cancer Institute (NCI)",[4],1177,true,255,71,22113789,227,187,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Unspecified Adult Solid Tumor, Protocol Specific",58,{"name":18,"count":19},"Breast Cancer",37,{"name":21,"count":22},"Advanced Malignant Solid Neoplasm",32,{"name":24,"count":25},"Prostate Cancer",31,{"name":27,"count":28},"Lymphoma",30,{"name":30,"count":31},"Refractory Malignant Solid Neoplasm",28,{"name":33,"count":34},"Recurrent Adult Acute Myeloid Leukemia",26,{"name":36,"count":37},"Melanoma",25,[39,44,49,54,59,64,69,73,78,82],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT00265798","Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","2010-02-11","Sorafenib Tosylate",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT01303341","Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","2012-05-01","Riluzole",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT01081262","Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer","2015-02-25","Bevacizumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT01829568","Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","2015-05-11","Ibrutinib",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT00792948","Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","2016-06-01","Cyclophosphamide",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT01064648","Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","2018-06-01","Cediranib Maleate",{"nctId":70,"briefTitle":71,"date":72,"intervention":53},"NCT00588770","Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","2018-06-05",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT01575548","Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery","2018-07-17","Pazopanib Hydrochloride",{"nctId":79,"briefTitle":80,"date":81,"intervention":68},"NCT01116648","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","2018-10-31",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT02381561","Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy","2018-11-08","Ropidoxuridine",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,608,1516,2171,2400,2553,2822,3051,3503,3737,3929,4021,4249,4348,4515,4754,4918,5182,5652,5830,6014,6146,6230,6350,6408,6467,6633,6747,6823,6901,6943,7074,7162,7204,7238,7264,7316,7461,7547,7618,7738,7776,7823,7853,7887,7917,7943,7969,8000,8022,8044,8185,8316,8354,8401,8437,8466,8495,8517,8539,8561,8579,8597,8615,8633,8651,8669,8687,8705,8723,8837,8899,8963,9029,9121,9181,9229,9271,9301,9357,9387,9549,9654,9719,9753,9795,9825,9855,9903,9934,9985,10014,10046,10081,10107,10323,10455,10543,10585,10627,10665,10701,10737,10759,10800,10822,10848,10878,10900,10930,10962,10992,11026,11048,11200,11229,11403,11484,11546,11591,11629,11671,11716,11742,11775,11804,11826,11851,11891,11913,11935,11957,11979,12003,12025,12047,12073,12096,12122,12140,12158,12176,12194,12217,12235,12253,12271,12289,12313,12338,12362,12380,12398,12416,12434,12456,12486,12510,12538,12556,12574,12592,12614,12635,12653,12679,12697,12715,12759,12784,12802,12820,12838,12862,12887,12905,12928,12956,12974,12992,13015,13033,13051,13078,13096,13119,13137,13163,13181,13204,13228,13246,13321,13373,13472,13501,13523,13644,13687,13717,13748,13774,13800,13824,13856,13878,13900,13925,13950,13968,13991,14009,14027,14045,14063,14087,14105,14123,14146,14164,14182,14200,14251,14269,14292,14310,14333,14351,14560,14640,14714,14787,14854,14905,14965,14995,15025,15051,15077,15103,15125,15150,15174,15200,15218,15236,15254,15272,15298,15316,15334,15352,15370,15395,15413,15431,15449,15467,15485,15503,15521,15546,15564,15582,15600,15618,15636,15725,15800,15861,15928,15994,16059,16129,16173,16235,16296,16337,16375,16417,16458,16504,16555,16608,16646,16686,16722,16768,16823,16857,16899,16950,16981,17007,17033,17065,17097,17130,17156,17182,17217,17251,17285,17321,17350,17385,17422,17448,17474,17506,17542,17571,17593,17623,17650,17672,17694,17716,17738,17760,17785,17809,17831,17856,17878,17902,17932,17958,17985,18007,18043,18065,18097,18119,18141,18168,18198,18220,18242,18264,18286,18310,18332,18364,18394,18416,18438,18465,18483,18501,18519,18537,18555,18573,18598,18616,18634,18652,18676,18698,18716,18741,18759,18777,18795,18813,18831,18852,18870,18891,18909,18927,18945,18970,18993,19011,19032,19053,19083,19108,19130,19148,19166,19194,19233,19257,19275,19293,19317,19342,19365,19387,19405,19423,19450,19476,19494,19524,19542,19560,19578,19596,19619,19637,19655,19676,19694,19712,19737,19755,19780,19798,19819,19842,19860,19878,19896,19914,19932,19950,19968,19986,20004,20022,20045,20071,20093,20111,20129,20147,20165,20190,20208,20226,20248,20266,20284,20302,20320,20338,20356,20374,20392,20410,20428,20446,20464,20488,20506,20531,20554,20572,20590,20608,20626,20644,20662,20680,20698,20716,20734,20752,20770,20797,20815,20833,20851,20874,20892,20910,20928,20949,20974,20999,21017,21035,21053,21074,21092,21110,21128,21146,21168,21190,21208,21230,21248,21266,21290,21308,21332,21360,21378,21396,21418,21439,21465,21489,21512,21530,21548,21573,21591,21609,21627,21645,21663,21681,21704,21722,21743,21761,21779,21807,21825,21848,21871,21889,21907,21925,21943,21961,21979,21997,22015,22039,22057,22075,22093,22111,22129,22153,22171,22194,22212,22230,22248,22269,22295,22313,22331,22349,22367,22385,22403,22428,22462,22492,22518,22556,22582,22604,22631,22660,22682,22700,22726,22744,22770,22788,22806,22824,22842,22860,22881,22912,22933,22955,22980,22998,23021,23042,23060,23078,23096,23117,23135,23153,23175,23193,23211,23229,23247,23268,23296,23318,23336,23357,23378,23406,23428,23452,23476,23494,23516,23539,23557,23579,23604,23622,23647,23665,23683,23707,23725,23743,23761,23787,23805,23823,23841,23859,23877,23895,23913,23934,23952,23980,24003,24021,24043,24061,24083,24105,24132,24150,24168,24186,24204,24222,24240,24258,24276,24299,24322,24344,24368,24389,24411,24429,24451,24469,24487,24509,24527,24549,24574,24598,24622,24646,24664,24690,24708,24726,24748,24818,24852,24878,24901,24922,24945,24967,24989],{"intervention":96,"totalTrials":97,"cells":98},"Nivolumab",33,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":215,"PHASE3":558,"PHASE4":604,"NA":606},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":214,"soonestReadout":185},[104,125,139,152,168,181],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":101,"conditions":111,"interventions":123},"NCT04500548","Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed\u002FRefractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","WITHDRAWN",[89],"2022-06-21","2021-01-28",[112,113,114,115,116,117,118,119,30,120,121,122],"Constitutional Mismatch Repair Deficiency Syndrome","Hematopoietic and Lymphoid Cell Neoplasm","Lynch Syndrome","Recurrent Lymphoma","Recurrent Malignant Solid Neoplasm","Recurrent Neuroblastoma","Recurrent Primary Central Nervous System Neoplasm","Refractory Lymphoma","Refractory Neuroblastoma","Refractory Primary Central Nervous System Neoplasm","Xeroderma Pigmentosum",[124,96],"Ipilimumab",{"nctId":126,"briefTitle":127,"status":128,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":16,"conditions":133,"interventions":137},"NCT04902443","Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV","RECRUITING",[89],"2026-12-01","2027-12-01","2021-12-10",[134,135,136],"Viral Associated Malignancies","Kaposi Sarcoma","EBV\u002FKSHV-associated Lymphomas",[138,96],"Pomalidomide",{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":22,"conditions":147,"interventions":150},"NCT02311920","Ipilimumab and\u002For Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","COMPLETED",[89],"2017-12-31","2022-12-22","2015-04-16",[148,149],"Gliosarcoma","Supratentorial Glioblastoma",[124,96,151],"Temozolomide",{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":165},"NCT03816358","Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","ACTIVE_NOT_RECRUITING",[89],"2027-01-31","2019-12-09",74,[161,162,163,164],"Pancreatic Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8",[166,167,124,96],"Anetumab Ravtansine","Gemcitabine Hydrochloride",{"nctId":169,"briefTitle":170,"status":155,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":179},"NCT04652960","Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome",[89],"2026-12-03","2021-10-21",38,[176,177,178],"Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8",[180,96],"Duvelisib",{"nctId":182,"briefTitle":183,"status":155,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":211},"NCT03816332","Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",[89],"2022-10-11","2026-09-19","2019-11-08",12,[190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210],"Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Metastatic Basal Cell Carcinoma","Metastatic Melanoma","Metastatic Merkel Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Unresectable Basal Cell Carcinoma","Unresectable Melanoma","Unresectable Merkel Cell Carcinoma",[124,96,212,213],"Prednisone","Tacrolimus",4,{"trials":216,"activeCount":455,"soonestReadout":505},[217,228,241,254,265,280,291,303,319,332,344,357,368,387,400,414,427,436,450,461,477,490,501,546],{"nctId":218,"briefTitle":219,"status":155,"phases":220,"primaryCompletion":221,"completion":221,"start":222,"enrollment":174,"conditions":223,"interventions":227},"NCT03604978","Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma",[89,90],"2027-03-19","2019-06-17",[224,225,226],"Grade 2 Meningioma","Grade 3 Meningioma","Recurrent Meningioma",[124,96],{"nctId":229,"briefTitle":230,"status":128,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":239},"NCT05904080","Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer",[90],"2028-06-16","2024-02-19",50,[236,237,238],"Metastatic Nasopharyngeal Carcinoma","Recurrent Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma AJCC v8",[240,124,96],"Cabozantinib S-malate",{"nctId":242,"briefTitle":243,"status":142,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":253},"NCT02498600","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[90],"2018-09-05","2025-07-26","2015-08-10",100,[250,251,252],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma",[124,96],{"nctId":255,"briefTitle":256,"status":155,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":264},"NCT02275533","Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial",[90],"2025-07-28","2026-10-08","2015-07-02",82,[263],"Acute Myeloid Leukemia",[96],{"nctId":266,"briefTitle":267,"status":142,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":276},"NCT03382561","Cisplatin\u002FCarboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer",[90],"2022-02-16","2025-01-31","2018-05-21",160,[274,275],"Extensive Stage Lung Small Cell Carcinoma","Recurrent Lung Small Cell Carcinoma",[277,278,279,96],"Carboplatin","Cisplatin","Etoposide",{"nctId":281,"briefTitle":282,"status":128,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":288},"NCT06029270","Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer",[90],"2029-04-30","2024-07-15",156,[236,237,238],[277,278,289,96,290],"Gemcitabine","Relatlimab",{"nctId":292,"briefTitle":293,"status":142,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":302},"NCT04439214","Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)",[90],"2018-10-11","2020-05-17","2016-05-31",47,[300,21,113,119,30,301],"Advanced Lymphoma","Refractory Plasma Cell Myeloma",[96],{"nctId":304,"briefTitle":305,"status":155,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":317},"NCT03595124","A Study to Compare Treatments for a Type of Kidney Cancer Called TFE\u002FTranslocation Renal Cell Carcinoma (tRCC)",[90],"2024-09-30","2026-11-13","2019-01-08",15,[312,313,314,315,316],"Metastatic Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","TFE3-Rearranged Renal Cell Carcinoma","Unresectable Renal Cell Carcinoma",[318,96],"Axitinib",{"nctId":320,"briefTitle":321,"status":155,"phases":322,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":331},"NCT02314169","Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer",[90],"2025-02-15","2027-03-20","2015-05-13",143,[328,329,330],"Anal Canal Squamous Cell Carcinoma","Metastatic Anal Canal Carcinoma","Stage IV Anal Cancer AJCC v8",[124,96],{"nctId":333,"briefTitle":334,"status":142,"phases":335,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":341},"NCT02933255","PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer",[89,90],"2023-06-20","2023-12-01","2017-04-18",24,[24],[342,96,343],"PROSTVAC-V\u002FF","Tylenol",{"nctId":345,"briefTitle":346,"status":347,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":355},"NCT06325683","Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","SUSPENDED",[90],"2028-07-15","2024-11-08",184,[353,354],"Progressive Glioblastoma","Recurrent Glioblastoma",[356,96,290],"Lomustine",{"nctId":358,"briefTitle":359,"status":155,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":25,"conditions":363,"interventions":367},"NCT04751370","Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer",[90],"2026-12-31","2022-02-08",[364,365,366],"Locally Advanced Rectal Adenocarcinoma","Stage II Rectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8",[124,96],{"nctId":369,"briefTitle":370,"status":155,"phases":371,"primaryCompletion":372,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":386},"NCT03914300","Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",[90],"2024-10-17","2026-12-17","2020-02-10",11,[377,378,379,380,381,382,383,384,385],"Differentiated Thyroid Gland Carcinoma","Follicular Variant Thyroid Gland Papillary Carcinoma","Poorly Differentiated Thyroid Gland Carcinoma","Refractory Differentiated Thyroid Gland Carcinoma","Refractory Thyroid Gland Carcinoma","Tall Cell Variant Thyroid Gland Papillary Carcinoma","Thyroid Gland Follicular Carcinoma","Thyroid Gland Oncocytic Carcinoma","Thyroid Gland Papillary Carcinoma",[240,124,96],{"nctId":388,"briefTitle":389,"status":142,"phases":390,"primaryCompletion":391,"completion":391,"start":392,"enrollment":298,"conditions":393,"interventions":396},"NCT04817254","Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma",[90],"2026-03-20","2021-12-08",[394,148,395],"Glioblastoma","Malignant Glioma",[397,398,96,399],"TMZ","ipilimumab 3mg\u002Fkg","ipilimumab 1mg\u002Fkg",{"nctId":401,"briefTitle":402,"status":155,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":413},"NCT04079712","Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors",[90],"2025-01-10","2026-08-19","2020-08-06",17,[409,410,411,412],"Metastatic Large Cell Neuroendocrine Carcinoma","Metastatic Neuroendocrine Carcinoma","Metastatic Neuroendocrine Neoplasm","Metastatic Small Cell Neuroendocrine Carcinoma",[240,124,96],{"nctId":415,"briefTitle":416,"status":128,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":426},"NCT03258567","Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas",[90],"2029-06-01","2031-06-01","2018-04-26",40,[423,27,424,425],"Epstein-Barr Virus Infections","Lymphoproliferative Disorder","Disorders, Lymphoproliferative",[96],{"nctId":428,"briefTitle":429,"status":128,"phases":430,"primaryCompletion":361,"completion":361,"start":431,"enrollment":234,"conditions":432,"interventions":435},"NCT06064097","A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)",[90],"2024-06-25",[433,434,238],"Stage II Nasopharyngeal Carcinoma AJCC v8","Stage III Nasopharyngeal Carcinoma AJCC v8",[278,289,96],{"nctId":437,"briefTitle":438,"status":155,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":448},"NCT04339738","Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma",[90],"2025-03-30","2027-01-21","2020-11-04",90,[445,446,447],"Skin Angiosarcoma","Skin Radiation-Related Angiosarcoma","Visceral Angiosarcoma",[240,96,449],"Paclitaxel",{"nctId":451,"briefTitle":452,"status":128,"phases":453,"primaryCompletion":157,"completion":157,"start":454,"enrollment":455,"conditions":456,"interventions":459},"NCT05896839","Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",[89,90],"2024-07-24",16,[190,191,192,193,194,457,195,196,197,208,209,210,458],"Metastatic Carcinoma in the Skin","Unresectable Skin Squamous Cell Carcinoma",[124,96,212,460],"Sirolimus",{"nctId":462,"briefTitle":463,"status":107,"phases":464,"primaryCompletion":465,"completion":465,"start":465,"enrollment":101,"conditions":466,"interventions":473},"NCT05898828","Phase I\u002FII Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer",[89,90],"2024-08-02",[467,468,469,470,471,472],"Neoplasms","Esophageal Neoplasms","Esophagus Neoplasm","Esophagus Cancer","Neoplasms, Esophageal","Esophageal Cancer (EsC)",[96,474,475,476],"Entinostat","Montanide(R) ISA-51 VG Adjuvant","H1299 Cell Lysates",{"nctId":478,"briefTitle":479,"status":155,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":488},"NCT04317105","Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN",[89,90],"2025-10-01","2027-05-06","2020-07-17",54,[21,486,487],"Metastatic Malignant Solid Neoplasm","Unresectable Malignant Solid Neoplasm",[489,124,96],"Copanlisib Hydrochloride",{"nctId":491,"briefTitle":492,"status":155,"phases":493,"primaryCompletion":361,"completion":361,"start":494,"enrollment":19,"conditions":495,"interventions":500},"NCT04145115","A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden",[90],"2020-12-24",[496,497,498,499],"Astrocytoma, IDH-Mutant, Grade 4","Diffuse Glioma","Glioblastoma, IDH-Wildtype","Secondary Glioblastoma",[124,96],{"nctId":502,"briefTitle":503,"status":155,"phases":504,"primaryCompletion":505,"completion":506,"start":507,"enrollment":484,"conditions":508,"interventions":544},"NCT03038672","Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas",[90],"2023-05-26","2026-10-24","2018-12-21",[509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543],"ALK-Positive Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Mucocutaneous Ulcer","HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and\u002For BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Intravascular Large B-Cell Lymphoma","Large B-Cell Lymphoma With 11q Aberration","Large B-Cell Lymphoma With IRF4 Rearrangement","Plasmablastic Lymphoma","Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","Primary Effusion Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Burkitt Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Gray-Zone Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Recurrent Lymphomatoid Granulomatosis","Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Recurrent T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Burkitt Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Gray-Zone Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","Refractory Primary Mediastinal Large B-Cell Lymphoma","Refractory T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma",[96,545],"Varlilumab",{"nctId":547,"briefTitle":548,"status":142,"phases":549,"primaryCompletion":550,"completion":110,"start":551,"enrollment":552,"conditions":553,"interventions":557},"NCT02428192","Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma",[90],"2018-09-20","2015-05-19",20,[554,555,556],"Metastatic Leiomyosarcoma","Unresectable Leiomyosarcoma","Uterine Corpus Leiomyosarcoma",[124,96],{"trials":559,"activeCount":603,"soonestReadout":564},[560,578,588],{"nctId":561,"briefTitle":562,"status":155,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":577},"NCT03952585","De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer",[90,91],"2024-03-01","2026-12-11","2019-10-09",384,[569,570,571,572,573,574,575,576],"Basaloid Squamous Cell Carcinoma","Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Oropharyngeal Squamous Cell Carcinoma","Papillary Squamous Cell Carcinoma","Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Squamous Cell Carcinoma",[278,96],{"nctId":579,"briefTitle":580,"status":155,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":587},"NCT03811015","Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer",[91],"2027-01-01","2019-08-16",636,[571,586],"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",[278,96],{"nctId":589,"briefTitle":590,"status":155,"phases":591,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":602},"NCT04444921","EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +\u002F- Nivolumab in Metastatic Anal Cancer Patients",[91],"2027-03-31","2020-11-17",205,[596,597,598,599,600,330,601],"Anal Basaloid Carcinoma","Anal Canal Cloacogenic Carcinoma","Metastatic Anal Squamous Cell Carcinoma","Recurrent Anal Squamous Cell Carcinoma","Stage III Anal Cancer AJCC v8","Unresectable Anal Squamous Cell Carcinoma",[277,96,449],3,{"trials":605,"activeCount":101},[],{"trials":607,"activeCount":101},[],{"intervention":63,"totalTrials":609,"cells":610},64,{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":806,"PHASE3":1350,"PHASE4":1512,"NA":1514},{"trials":612,"activeCount":101},[],{"trials":614,"activeCount":603,"soonestReadout":635},[615,631,645,668,678,694,711,723,741,752,765,782,795],{"nctId":616,"briefTitle":617,"status":618,"phases":619,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":624,"interventions":628},"NCT01341496","Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal","TERMINATED",[89],"2016-05-12","2016-07-21","2011-04-18",41,[625,36,626,627],"Sarcoma","Epithelial Malignancies","Pleural Malignancy",[629,63,630],"Epigenetically Modified Autologous Tumor","Celecoxib",{"nctId":632,"briefTitle":633,"status":155,"phases":634,"primaryCompletion":635,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":642},"NCT03602612","T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma",[89],"2023-01-01","2026-04-21","2018-09-14",35,[640,641],"Myeloma-Multiple","Myeloma, Plasma-Cell",[63,643,644],"Fludarabine","Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells",{"nctId":646,"briefTitle":647,"status":618,"phases":648,"primaryCompletion":649,"start":650,"enrollment":651,"conditions":652,"interventions":665},"NCT01076556","Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[89],"2010-07","2010-04",9,[653,654,655,656,657,658,659,660,661,662,663,664],"Chronic Lymphocytic Leukemia","Prolymphocytic Leukemia","Recurrent Small Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia","Stage I Chronic Lymphocytic Leukemia","Stage I Small Lymphocytic Lymphoma","Stage II Chronic Lymphocytic Leukemia","Stage II Small Lymphocytic Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Small Lymphocytic Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Small Lymphocytic Lymphoma",[666,63,667],"Alvocidib Hydrochloride","Rituximab",{"nctId":669,"briefTitle":670,"status":107,"phases":671,"primaryCompletion":672,"completion":672,"start":673,"enrollment":101,"conditions":674,"interventions":675},"NCT02489266","In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma",[89],"2016-06-29","2015-06-24",[195],[676,63,643,677],"AKTi-treated TIL","Aldesleukin",{"nctId":679,"briefTitle":680,"status":618,"phases":681,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":691},"NCT01143545","Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas",[89],"2015-02-09","2020-02-26","2010-12-07",10,[687,688,689,625,690],"Lung Cancer","Esophageal Cancer","Malignant Pleural Mesothelioma","Thymic Carcinoma",[692,630,693],"Allogeneic Tumor Cell Vaccine","cyclophosphamide",{"nctId":695,"briefTitle":696,"status":618,"phases":697,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT05035407","T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers",[89],"2025-07-16","2022-03-08",36,[702],"Kita-kyushu Lung Cancer Antigen 1, Human",[704,63,705,643,706,707,708,709,710],"IL-2","KK-LC-1 TCR","Acetaminophen","Ondansetron","Meperidine","Indomethacin","Famotidine",{"nctId":712,"briefTitle":713,"status":618,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":603,"conditions":718,"interventions":720},"NCT00091611","Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer",[89],"2006-04","2008-03","2004-09",[719],"Kidney Neoplasms",[704,721,63,643,722],"OKT3","Mesna",{"nctId":724,"briefTitle":725,"status":155,"phases":726,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":736},"NCT03220022","Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas",[89],"2024-10-10","2026-07-16","2018-03-16",46,[732,733,734,735],"AIDS-Related Lymphoma","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma",[63,737,279,738,58,739,212,667,740],"Doxorubicin Hydrochloride","Filgrastim","Pegfilgrastim","Vincristine Sulfate",{"nctId":742,"briefTitle":743,"status":142,"phases":744,"primaryCompletion":745,"start":746,"enrollment":188,"conditions":747,"interventions":749},"NCT00003288","Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors",[89],"2003-06","1998-08",[748],"Unspecified Childhood Solid Tumor, Protocol Specific",[750,693,751],"filgrastim","tirapazamine",{"nctId":753,"briefTitle":754,"status":618,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":763},"NCT04160195","T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma",[89],"2021-06-11","2019-12-20",2,[760,761,653,762],"Lymphoma, B-Cell","Lymphoma, Non-hodgkins","B-Cell Chronic Lymphocytic Leukemia",[764,63,643],"Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells",{"nctId":766,"briefTitle":767,"status":618,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":778},"NCT04933617","Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas",[89],"2023-11-30","2022-03-24",8,[773,774,775,776,777],"Burkitt Lymphoma","High-grade B-cell Lymphoma","T-cell\u002FHistocyte-rich Large B-cell Lymphoma","Diffuse Large B-Cell Lymphoma (DLBCL)","Germinal Center B-cell Type (GCB)",[667,279,779,63,780,781,212],"Copanlisib","Doxorubicin","Vincristine",{"nctId":783,"briefTitle":784,"status":142,"phases":785,"primaryCompletion":786,"completion":787,"start":788,"enrollment":310,"conditions":789,"interventions":792},"NCT02107963","A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors",[89],"2016-08-15","2017-01-31","2014-02-28",[625,790,791,36],"Osteosarcoma","Neuroblastoma",[793,794,63],"Anti-GD2-CAR engineered T cells","AP1903",{"nctId":796,"briefTitle":797,"status":128,"phases":798,"primaryCompletion":361,"completion":799,"start":392,"enrollment":174,"conditions":800,"interventions":804},"NCT05003895","GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies",[89],"2027-12-31",[801,802,803],"Hepatocellular Carcinoma","Hepatocellular Cancer","Metastatic Hepatocellular Carcinoma",[63,805,643],"CAR-T cell",{"trials":807,"activeCount":889,"soonestReadout":62},[808,820,832,847,861,873,884,894,906,922,943,953,964,983,996,1006,1017,1034,1048,1067,1085,1104,1115,1124,1143,1155,1166,1177,1189,1200,1212,1226,1236,1253,1271,1284,1295,1305,1314,1325,1336],{"nctId":809,"briefTitle":810,"status":142,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":188,"conditions":814,"interventions":816},"NCT00393029","Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes",[90],"2008-11","2006-10",[815],"Anti-p53 TCR-Gene",[817,818,750,693,819],"anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes","aldesleukin","fludarabine phosphate",{"nctId":821,"briefTitle":822,"status":142,"phases":823,"primaryCompletion":824,"completion":825,"start":826,"enrollment":827,"conditions":828,"interventions":830},"NCT00924170","Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia",[89,90],"2016-01-02","2021-05-05","2008-10-31",18,[829],"Adult T-Cell Leukemia (ATL)",[831,643,63],"LMB-2",{"nctId":833,"briefTitle":834,"status":618,"phases":835,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":845},"NCT03745326","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients",[89,90],"2022-08-23","2019-05-16",5,[840,841,842,843,844],"Gastrointestinal Cancer","Pancreatic Cancer","Gastric Cancer","Colon Cancer","Rectal Cancer",[63,643,677,846],"anti-Kirsten rat sarcoma virus",{"nctId":848,"briefTitle":849,"status":107,"phases":850,"primaryCompletion":851,"completion":851,"start":851,"enrollment":101,"conditions":852,"interventions":859},"NCT06690281","A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies",[90],"2025-09-09",[853,841,802,854,855,856,857,858],"Gastrointestinal Carcinoma","Cholangiocarcinoma","Duodenal Cancer","Colorectal Cancer","Small Bowel Cancer","Metastatic Cancers",[860,677,643,63],"KRAS TCR-Transduced PBL",{"nctId":862,"briefTitle":863,"status":618,"phases":864,"primaryCompletion":865,"completion":866,"start":867,"enrollment":339,"conditions":868,"interventions":871},"NCT01218867","CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer",[89,90],"2014-09-03","2015-12-15","2010-11-10",[869,195,870],"Metastatic Cancer","Renal Cancer",[872,63,677,643],"Anti-VEGFR2 CAR CD8 plus PBL",{"nctId":874,"briefTitle":875,"status":128,"phases":876,"primaryCompletion":232,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":881},"NCT02621021","A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab",[90],"2029-06-16","2015-12-04",170,[36],[882,883,677,643,63],"young TIL","Pembrolizumab",{"nctId":885,"briefTitle":886,"status":618,"phases":887,"primaryCompletion":621,"completion":621,"start":888,"enrollment":889,"conditions":890,"interventions":892},"NCT02111863","Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma",[90],"2014-02-21",6,[36,891],"Skin Cancer",[677,643,63,893],"4-1BB Selected Tumor Infiltrating Lymphocytes",{"nctId":895,"briefTitle":896,"status":128,"phases":897,"primaryCompletion":898,"completion":899,"start":900,"enrollment":552,"conditions":901,"interventions":904},"NCT07328503","CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia",[90],"2030-01-31","2031-01-31","2026-06-07",[902,903],"Acute Lymphoblastic Leukemia","B-All",[905,63,643],"CD22 CAR-transduced T cells",{"nctId":907,"briefTitle":908,"status":142,"phases":909,"primaryCompletion":910,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":918},"NCT01362790","SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma",[89,90],"2016-08-03","2017-08-07","2011-05-11",55,[915,916,917],"Mesothelioma","Adenocarcinoma of Lung","Pancreatic Neoplasms",[919,63,920,921],"Pentostatin","SS1(dsFv)PE38 - lot 073I0809","SS1(dsFv)PE38 - lot FIL129J01",{"nctId":923,"briefTitle":924,"status":142,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":941},"NCT01193842","Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",[89,90],"2016-11-12","2022-05-19","2010-10-06",107,[931,932,933,934,733,935,936,734,937,735,938,939,522,524,527,940],"AIDS-Related Plasmablastic Lymphoma","AIDS-Related Primary Effusion Lymphoma","Ann Arbor Stage I Diffuse Large B-Cell Lymphoma","Ann Arbor Stage I Grade 3 Follicular Lymphoma","Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma","Ann Arbor Stage III Grade 3 Follicular Lymphoma","Ann Arbor Stage IV Grade 3 Follicular Lymphoma","HIV Infection","Recurrent Grade 3 Follicular Lymphoma",[63,737,279,212,667,740,942],"Vorinostat",{"nctId":944,"briefTitle":945,"status":142,"phases":946,"primaryCompletion":947,"completion":947,"start":948,"enrollment":949,"conditions":950,"interventions":951},"NCT01319565","Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...",[90],"2024-09-10","2011-03-24",102,[195,891],[677,63,643,952],"Young TIL",{"nctId":954,"briefTitle":955,"status":618,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":603,"conditions":959,"interventions":962},"NCT02153905","T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive",[89,90],"2018-09-10","2014-07-03",[18,960,870,36,961],"Cervical Cancer","Bladder Cancer",[677,643,63,963],"Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group",{"nctId":965,"briefTitle":966,"status":128,"phases":967,"primaryCompletion":968,"completion":969,"start":970,"enrollment":971,"conditions":972,"interventions":978},"NCT04339777","Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity",[90],"2026-10-01","2027-11-30","2020-09-22",66,[973,974,975,976,977],"Lymphoproliferative Disorders","Autoimmune Lymphoproliferative","Immune System Diseases","Common Variable Immunodeficiency","Primary T-cell Immunodeficiency Disorders",[979,643,980,981,213,982,63],"Busulfan test dose","Busulfan","Alemtuzumab","Mycophenolate mofetil",{"nctId":984,"briefTitle":985,"status":142,"phases":986,"completion":987,"start":988,"conditions":989,"interventions":990},"NCT00052351","Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer",[90],"2007-10","2002-09",[18],[991,992,993,693,994,995],"recombinant fowlpox-CEA(6D)\u002FTRICOM vaccine","recombinant vaccinia-CEA(6D)-TRICOM vaccine","sargramostim","doxorubicin hydrochloride","paclitaxel",{"nctId":997,"briefTitle":998,"status":618,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":310,"conditions":1002,"interventions":1004},"NCT01583686","CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer",[89,90],"2018-12-17","2012-05-04",[960,841,1003,915,687],"Ovarian Cancer",[643,1005,63,677],"Anti-mesothelin chimeric T cell receptor",{"nctId":1007,"briefTitle":1008,"status":155,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":407,"conditions":1013,"interventions":1015},"NCT02911142","Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma",[89,90],"2024-10-01","2027-10-01","2017-07-03",[524,1014],"B-Cell Neoplasm",[1016,667,212,279,780,781,63],"Lenalidomide",{"nctId":1018,"briefTitle":1019,"status":142,"phases":1020,"primaryCompletion":1021,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1030},"NCT00516295","Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma",[90],"2009-08","2010-01","2008-02",7,[1026,1027,1028,1029],"Ewing Sarcoma of Bone","Extraosseous Ewing Sarcoma","Peripheral Primitive Neuroectodermal Tumor","Recurrent Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor",[1031,1032,693,1033],"topotecan hydrochloride","vincristine sulfate","bevacizumab",{"nctId":1035,"briefTitle":1036,"status":142,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1047},"NCT01585428","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers",[90],"2016-04-09","2016-08-01","2012-04-13",29,[960,1043,1044,1045,1046],"Oropharyngeal Cancer","Vaginal Cancer","Anal Cancer","Penile Cancer",[643,63,952,677],{"nctId":1049,"briefTitle":1050,"status":142,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1061},"NCT00433537","Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma",[90],"2013-06","2007-05",77,[1056,1057,1058,1059,1060],"Contiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Stage I Mantle Cell Lymphoma","Stage III Mantle Cell Lymphoma","Stage IV Mantle Cell Lymphoma",[1062,1063,693,994,1064,1065,750,1066],"bortezomib","rituximab","vincristine","dexamethasone","pegfilgrastim",{"nctId":1068,"briefTitle":1069,"status":142,"phases":1070,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1076},"NCT00043979","Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas",[90],"2009-05-01","2011-12-14","2002-09-19",60,[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],"F-18 Fluorodeoxyglucose","therapeutic allogeneic lymphocytes","cyclosporine","etoposide","melphalan","prednisone","sirolimus","tacrolimus",{"nctId":1086,"briefTitle":1087,"status":142,"phases":1088,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":1091,"interventions":1098},"NCT01055314","Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma",[90],"2016-06",175,[1092,1093,1094,1095,1096,1097],"Adult Rhabdomyosarcoma","Childhood Alveolar Rhabdomyosarcoma","Childhood Embryonal Rhabdomyosarcoma","Metastatic Childhood Soft Tissue Sarcoma","Stage IV Adult Soft Tissue Sarcoma","Untreated Childhood Rhabdomyosarcoma",[1099,63,1100,737,279,1101,1102,151,1103],"Cixutumumab","Dactinomycin","Ifosfamide","Irinotecan Hydrochloride","Vincristine Sulfate Liposome",{"nctId":1105,"briefTitle":1106,"status":155,"phases":1107,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT01176006","Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency",[90],"2026-10-31","2028-10-31","2010-10-05",70,[1113],"DOCK8 Deficiency",[643,63,980],{"nctId":1116,"briefTitle":1117,"status":142,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":188,"conditions":1121,"interventions":1122},"NCT02280811","T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers",[89,90],"2016-06-28","2014-10-14",[1044,960,1045,1046,1043],[643,63,1123,677],"E6 TCR",{"nctId":60,"briefTitle":61,"status":155,"phases":1125,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1136},[90],"2027-01-06","2009-09-01",97,[902,1130,1131,1132,1133,1134,1135],"Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia",[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],"Cytarabine","Dasatinib","Dexamethasone","Leucovorin Calcium","Methotrexate","Methylprednisolone",{"nctId":1144,"briefTitle":1145,"status":142,"phases":1146,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":37,"conditions":1150,"interventions":1154},"NCT00923845","Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer",[90],"2015-06-01","2017-06-22","2008-03-01",[1151,1152,1153],"Renal Cell Carcinoma","Graft-Versus-Host Disease","Engraftment Syndrome",[919,460,63],{"nctId":1156,"briefTitle":1157,"status":142,"phases":1158,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1164},"NCT00602459","Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia",[90],"2014-12-01","2023-04-15","2008-01-15",418,[657,659,661,663],[63,1165,1016,667],"Fludarabine Phosphate",{"nctId":1167,"briefTitle":1168,"status":142,"phases":1169,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":234,"conditions":1173,"interventions":1175},"NCT00054665","PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma",[90],"2008-09","2009-07","2003-02",[1174],"B-Cell Lymphoma",[1176,279,780,781,63,212,738],"PS-341",{"nctId":1178,"briefTitle":1179,"status":142,"phases":1180,"primaryCompletion":987,"start":1181,"enrollment":248,"conditions":1182,"interventions":1184},"NCT00025038","Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia",[90],"2001-06",[1183],"Juvenile Myelomonocytic Leukemia",[1185,1186,819,1187,693,1188],"tipifarnib","isotretinoin","cytarabine","anti-thymocyte globulin",{"nctId":1190,"briefTitle":1191,"status":142,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1198},"NCT02111850","T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive",[89,90],"2021-03-24","2014-02-07",21,[960,870,1197,36,18],"Urothelial Cancer",[1199,63,643,677],"Anti-MAGE-A3-DP4 T Cell Receptor",{"nctId":1201,"briefTitle":1202,"status":142,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1211},"NCT00001337","Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma",[90],"2024-05-24","1993-05-08",348,[776,1208,773,1209,1210],"Primary Mediastinal Large B-cell Lymphoma","Anaplastic Large-Cell Lymphoma","Gray Zone Lymphoma",[279,667,212,63,781,780],{"nctId":1213,"briefTitle":1214,"status":142,"phases":1215,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":1074,"conditions":1218,"interventions":1224},"NCT00470301","Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer",[89,90],"2013-09","2007-04",[18,1219,1220,1221,1222,1223],"Male Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[1185,995,1225,693],"doxorubicin",{"nctId":1227,"briefTitle":1228,"status":618,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":603,"conditions":1232,"interventions":1233},"NCT00610311","Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma",[90],"2011-02","2008-01",[195,891],[693,819,677,1234,1235],"ALVAC gp100 Vaccine","anti-gp100:154-162 Tcell receptor",{"nctId":1237,"briefTitle":1238,"status":618,"phases":1239,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1252},"NCT00088881","Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",[90],"2011-03","2004-12",62,[1244,1245,1246,1247,1248,1249,1250,1251],"Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Nodal Marginal Zone B-cell Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Splenic Marginal Zone Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Testicular Lymphoma","Waldenström Macroglobulinemia",[1063,1082,693,1225,1064],{"nctId":1254,"briefTitle":1255,"status":142,"phases":1256,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":1259,"interventions":1261},"NCT00002704","Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia",[90],"2004-06","1996-01",[1260],"Leukemia",[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],"asparaginase","daunorubicin hydrochloride","leucovorin calcium","liposomal cytarabine","mercaptopurine","mesna","methotrexate","therapeutic hydrocortisone","thiotepa",{"nctId":1272,"briefTitle":1273,"status":142,"phases":1274,"primaryCompletion":1275,"completion":1275,"start":1276,"enrollment":1277,"conditions":1278,"interventions":1283},"NCT00049036","Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",[90],"2009-05","2003-03",106,[1279,1280,1281,1282],"AIDS-related Diffuse Large Cell Lymphoma","AIDS-related Immunoblastic Large Cell Lymphoma","AIDS-related Peripheral\u002FSystemic Lymphoma","AIDS-related Small Noncleaved Cell Lymphoma",[1063,1080,994,1032,1082,693],{"nctId":1285,"briefTitle":1286,"status":142,"phases":1287,"completion":1288,"start":1289,"enrollment":913,"conditions":1290,"interventions":1292},"NCT00001498","A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer",[90],"2000-12","1996-02",[18,1291],"Breast Neoplasms",[1268,1293,1294,693,995,1225],"leucovorin","5-fluorouracil",{"nctId":1296,"briefTitle":1297,"status":618,"phases":1298,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":1301,"interventions":1303},"NCT00048893","Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer",[89,90],"2011-06","2002-11",[1291,1302],"Metastases, Neoplasm",[991,1304,750,993,693,994,819,995,722],"recombinant vaccinia-CEA(6D)\u002FTRICOM vaccine",{"nctId":1306,"briefTitle":1307,"status":142,"phases":1308,"primaryCompletion":1309,"completion":1310,"start":715,"enrollment":34,"conditions":1311,"interventions":1312},"NCT00314106","Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma",[90],"2009-02","2009-03",[195],[1313,63,704,643],"Melanoma Reactive TIL",{"nctId":1315,"briefTitle":1316,"status":142,"phases":1317,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":339,"conditions":1321,"interventions":1322},"NCT00509288","Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes",[90],"2011-07","2012-07","2007-06",[36,891],[1323,63,643,677,1324],"autologous anti-MART-1 F5 T-cell receptor","autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes",{"nctId":1326,"briefTitle":1327,"status":142,"phases":1328,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":1331,"conditions":1332,"interventions":1335},"NCT00121199","Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma",[90],"2010-12","2005-06",73,[1244,1247,1333,1334],"Stage III Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma",[1063,1033,693,994,1032,1082],{"nctId":1337,"briefTitle":1338,"status":618,"phases":1339,"primaryCompletion":1340,"start":1341,"enrollment":16,"conditions":1342,"interventions":1345},"NCT00303836","Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma",[90],"2007-01","2005-11",[1343,1344],"Recurrent Melanoma","Stage IV Melanoma",[693,819,1346,1347,1348,1349,750,818],"therapeutic autologous lymphocytes","gp100 antigen","MART-1 antigen","incomplete Freund's adjuvant",{"trials":1351,"activeCount":838,"soonestReadout":1460},[1352,1361,1377,1392,1408,1422,1436,1456,1473,1494],{"nctId":1353,"briefTitle":1354,"status":142,"phases":1355,"primaryCompletion":715,"start":1356,"enrollment":1357,"conditions":1358,"interventions":1359},"NCT00003595","Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma",[91],"1999-01",120,[27],[750,1063,1360,693,994,1082,1032],"CHOP regimen",{"nctId":1362,"briefTitle":1363,"status":155,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1371},"NCT02003222","Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia",[91],"2023-06-23","2027-02-25","2014-05-19",488,[902,1370],"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative",[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],"Blinatumomab","Daunorubicin","Daunorubicin Hydrochloride","Mercaptopurine","Pegaspargase",{"nctId":1378,"briefTitle":1379,"status":142,"phases":1380,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1388},"NCT00408005","Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma",[91],"2017-09-30","2025-03-31","2007-01-30",1895,[1386,1387],"T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma",[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],"Asparaginase","Nelarabine","Thioguanine",{"nctId":1393,"briefTitle":1394,"status":128,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1401},"NCT06172296","Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma",[91],"2029-12-31","2024-04-19",478,[1400,791],"Ganglioneuroblastoma, Nodular",[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],"Dinutuximab","Irinotecan","Isotretinoin","Melphalan","Thiotepa","Topotecan",{"nctId":1409,"briefTitle":1410,"status":142,"phases":1411,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":1074,"conditions":1415,"interventions":1418},"NCT00590785","Phase III Comparison of Adjuvant Chemotherapy W\u002FHigh-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)",[91],"1997-06-10","2015-01-13","1996-08-13",[1416,18,1417,63,780],"High Risk","Positive Nodes",[780,63,1419,1420,1421],"G-CSF","tamoxifen","ciprofloxacin",{"nctId":1423,"briefTitle":1424,"status":142,"phases":1425,"primaryCompletion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1433},"NCT00002556","Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma",[91],"2006-01","1994-07",312,[1430,1431,1432],"Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[1032,1434,1081,693,1082,1435],"carmustine","recombinant interferon alfa-2b",{"nctId":1437,"briefTitle":1438,"status":142,"phases":1439,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":1443,"conditions":1444,"interventions":1452},"NCT00005970","Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer",[91],"2005-04-25","2010-01-27","2000-05-19",3436,[1445,1446,1447,1448,1449,1450,1451],"Breast Adenocarcinoma","HER2 Positive Breast Carcinoma","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7","Stage IIIA Breast Cancer AJCC v7",[1453,63,737,449,1454,1455],"Aromatase Inhibition Therapy","Tamoxifen Citrate","Trastuzumab",{"nctId":1457,"briefTitle":1458,"status":155,"phases":1459,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":1463,"interventions":1470},"NCT02306161","Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma",[91],"2021-03-31","2026-09-17","2014-12-12",[1464,1465,1466,1467,1468,1469],"Metastatic Ewing Sarcoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Bone Marrow","Metastatic Malignant Neoplasm in the Lung","Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone","Peripheral Primitive Neuroectodermal Tumor of Soft Tissues",[63,780,737,279,1471,1472,1101,781,740],"Etoposide Phosphate","Ganitumab",{"nctId":1474,"briefTitle":1475,"status":155,"phases":1476,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":1480,"interventions":1491},"NCT04799275","Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma",[90,91],"2027-03-01","2021-05-20",422,[734,1481,735,510,511,512,513,514,1482,516,517,1483,1484,518,519,1485,1486,1487,1488,1489,1490],"Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma","Grade 3b Follicular Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Lymphoplasmacytic Lymphoma","Nodular Lymphocyte Predominant B-Cell Lymphoma","Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma",[63,737,1492,212,667,1493,740],"Oral Azacitidine","Rituximab and Hyaluronidase Human",{"nctId":1495,"briefTitle":1496,"status":155,"phases":1497,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1509},"NCT02166463","Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma",[91],"2021-12-31","2026-10-03","2015-03-19",600,[1503,1504,1505,1506,1507,1508],"Ann Arbor Stage IIB Hodgkin Lymphoma","Ann Arbor Stage IIIB Hodgkin Lymphoma","Ann Arbor Stage IVA Hodgkin Lymphoma","Ann Arbor Stage IVB Hodgkin Lymphoma","Childhood Hodgkin Lymphoma","Classic Hodgkin Lymphoma",[1510,1511,63,737,279,1142,212,740],"Bleomycin Sulfate","Brentuximab Vedotin",{"trials":1513,"activeCount":101},[],{"trials":1515,"activeCount":101},[],{"intervention":278,"totalTrials":1517,"cells":1518},42,{"EARLY_PHASE1":1519,"PHASE1":1521,"PHASE2":1801,"PHASE3":2046,"PHASE4":2167,"NA":2169},{"trials":1520,"activeCount":101},[],{"trials":1522,"activeCount":758,"soonestReadout":1658},[1523,1556,1571,1599,1641,1654,1672,1691,1698,1711,1759,1777,1792],{"nctId":1524,"briefTitle":1525,"status":618,"phases":1526,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":685,"conditions":1529,"interventions":1554},"NCT03345784","Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers",[89],"2022-05-10","2018-05-29",[1530,1531,1532,1533,1534,1535,1536,1537,1538,1539,1540,1541,1542,1543,1544,1545,1546,1547,1548,1549,1550,1551,1552,1553],"Cervical Carcinoma","Endometrioid Adenocarcinoma","Malignant Female Reproductive System Neoplasm","Recurrent Cervical Carcinoma","Stage I Uterine Corpus Cancer AJCC v7","Stage I Vaginal Cancer AJCC v6 and v7","Stage IA Uterine Corpus Cancer AJCC v7","Stage IB Cervical Cancer AJCC v6 and v7","Stage IB Uterine Corpus Cancer AJCC v7","Stage IB2 Cervical Cancer AJCC v6 and v7","Stage II Cervical Cancer AJCC v7","Stage II Uterine Corpus Cancer AJCC v7","Stage II Vaginal Cancer AJCC v6 and v7","Stage IIA Cervical Cancer AJCC v7","Stage IIB Cervical Cancer AJCC v6 and v7","Stage III Cervical Cancer AJCC v6 and v7","Stage III Uterine Corpus Cancer AJCC v7","Stage III Vaginal Cancer AJCC v6 and v7","Stage IIIA Cervical Cancer AJCC v6 and v7","Stage IIIA Uterine Corpus Cancer AJCC v7","Stage IIIB Cervical Cancer AJCC v6 and v7","Stage IIIB Uterine Corpus Cancer AJCC v7","Stage IIIC Uterine Corpus Cancer AJCC v7","Vaginal Carcinoma",[1555,278],"Adavosertib",{"nctId":1557,"briefTitle":1558,"status":142,"phases":1559,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":603,"conditions":1562,"interventions":1568},"NCT01445405","Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer",[89],"2010-08-27","2008-02-05",[1563,1564,1565,1566,1567],"Carcinoma, Squamous","Head and Neck Cancer","Oral Cancer","Laryngeal Cancer","Pharyngeal Cancer",[1569,1570,278],"Bortezomib","Cetuximab",{"nctId":1572,"briefTitle":1573,"status":142,"phases":1574,"primaryCompletion":1575,"start":1576,"enrollment":339,"conditions":1577,"interventions":1596},"NCT00335998","Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies",[89],"2008-10","2006-03",[1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594,1595],"Recurrent Cervical Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Vaginal Cancer","Recurrent Vulvar Cancer","Stage III Vaginal Cancer","Stage IIIA Cervical Cancer","Stage IIIA Ovarian Epithelial Cancer","Stage IIIA Vulvar Cancer","Stage IIIB Cervical Cancer","Stage IIIB Ovarian Epithelial Cancer","Stage IIIB Vulvar Cancer","Stage IIIC Ovarian Epithelial Cancer","Stage IIIC Vulvar Cancer","Stage IV Ovarian Epithelial Cancer","Stage IVA Cervical Cancer","Stage IVA Vaginal Cancer","Stage IVB Cervical Cancer","Stage IVB Vaginal Cancer",[1597,1598],"triapine","cisplatin",{"nctId":1600,"briefTitle":1601,"status":155,"phases":1602,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":159,"conditions":1605,"interventions":1639},"NCT04491942","Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",[89],"2026-06-30","2021-08-25",[1606,1607,1608,1609,1610,1611,1612,1613,1614,21,1615,1616,1617,1618,1619,1620,1621,1622,1623,1624,1625,1626,1627,1628,1629,1630,1631,1632,1633,1634,1635,1636,1637,1638],"Advanced Bile Duct Carcinoma","Advanced Breast Carcinoma","Advanced Cervical Carcinoma","Advanced Endometrial Carcinoma","Advanced Esophageal Carcinoma","Advanced Gastric Carcinoma","Advanced Head and Neck Carcinoma","Advanced Lung Non-Small Cell Carcinoma","Advanced Lung Small Cell Carcinoma","Advanced Ovarian Carcinoma","Advanced Penile Carcinoma","Advanced Pleural Malignant Mesothelioma","Advanced Urothelial Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Stage III Cervical Cancer AJCC v8","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Intrahepatic Bile Duct Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Penile Cancer AJCC v8","Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8","Stage IV Cervical Cancer AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Intrahepatic Bile Duct Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Penile Cancer AJCC v8","Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8","Triple-Negative Breast Carcinoma","Unresectable Urothelial Carcinoma",[278,1640,167],"Elimusertib",{"nctId":1642,"briefTitle":1643,"status":142,"phases":1644,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":19,"conditions":1647,"interventions":1652},"NCT01281852","Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer",[89],"2017-02-11","2011-03-14",[1648,1649,1650,1533,1651],"Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma, Not Otherwise Specified","Stage IVB Cervical Cancer AJCC v6 and v7",[278,449,1653],"Veliparib",{"nctId":1655,"briefTitle":1656,"status":155,"phases":1657,"primaryCompletion":1658,"completion":1659,"start":1660,"enrollment":1195,"conditions":1661,"interventions":1670},"NCT02595879","Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer",[89],"2023-06-04","2027-04-29","2019-09-18",[1662,1663,1664,1665,1666,1667,1539,1540,1542,1547,1550,1668,1669],"Advanced Cervical Adenocarcinoma","Advanced Cervical Adenosquamous Carcinoma","Advanced Cervical Squamous Cell Carcinoma","Advanced Vaginal Adenocarcinoma","Advanced Vaginal Adenosquamous Carcinoma","Advanced Vaginal Squamous Cell Carcinoma","Stage IVA Cervical Cancer AJCC v6 and v7","Stage IVA Vaginal Cancer AJCC v6 and v7",[278,1671],"Triapine",{"nctId":1673,"briefTitle":1674,"status":142,"phases":1675,"primaryCompletion":1676,"completion":1677,"start":1678,"enrollment":421,"conditions":1679,"interventions":1689},"NCT03738228","Atezolizumab Before and\u002For With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer",[89],"2022-05-01","2025-09-12","2019-01-07",[1648,1649,1680,1681,1682,1683,1684,1685,1686,1687,1688],"Cervical Squamous Cell Carcinoma","Stage IB2 Cervical Cancer AJCC v8","Stage II Cervical Cancer AJCC v8","Stage IIA Cervical Cancer AJCC v8","Stage IIA1 Cervical Cancer AJCC v8","Stage IIA2 Cervical Cancer AJCC v8","Stage IIB Cervical Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IVA Cervical Cancer AJCC v8",[1690,278],"Atezolizumab",{"nctId":1692,"briefTitle":1693,"status":142,"phases":1694,"primaryCompletion":1329,"start":987,"enrollment":730,"conditions":1695,"interventions":1696},"NCT00629226","Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer",[89],[1564],[1697,1062,1598],"cetuximab",{"nctId":1699,"briefTitle":1700,"status":142,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":31,"conditions":1705,"interventions":1709},"NCT00926640","A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers",[89],"2017-06-16","2018-04-20","2009-07-01",[1706,1707,1708],"Carcinoma Neuroendocrine","Small Cell Lung Carcinoma","Malignant Epithelial Neoplasms",[1710,278,279],"Belinostat",{"nctId":1712,"briefTitle":1713,"status":142,"phases":1714,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":1718,"conditions":1719,"interventions":1758},"NCT00989651","Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",[89],"2016-09-02","2020-04-10","2009-10-28",431,[1720,1721,1722,1723,1724,1725,1726,1727,1728,1729,1730,1731,1732,1733,1734,1735,1736,1737,1738,1739,1740,1741,1742,1743,1744,1745,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757],"Fallopian Tube Carcinoma","Fallopian Tube Carcinosarcoma","Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Mucinous Adenocarcinoma","Fallopian Tube Serous Neoplasm","Fallopian Tube Transitional Cell Carcinoma","Fallopian Tube Undifferentiated Carcinoma","Ovarian Brenner Tumor","Ovarian Carcinoma","Ovarian Carcinosarcoma","Ovarian Clear Cell Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Mucinous Adenocarcinoma","Ovarian Seromucinous Tumor","Ovarian Serous Adenocarcinoma","Ovarian Transitional Cell Carcinoma","Ovarian Undifferentiated Carcinoma","Primary Peritoneal Carcinoma","Primary Peritoneal Serous Adenocarcinoma","Stage IIA Fallopian Tube Cancer AJCC v6 and v7","Stage IIA Ovarian Cancer AJCC V6 and v7","Stage IIB Fallopian Tube Cancer AJCC v6 and v7","Stage IIB Ovarian Cancer AJCC v6 and v7","Stage IIC Fallopian Tube Cancer AJCC v6 and v7","Stage IIC Ovarian Cancer AJCC v6 and v7","Stage IIIA Fallopian Tube Cancer AJCC v7","Stage IIIA Ovarian Cancer AJCC v6 and v7","Stage IIIA Primary Peritoneal Cancer AJCC v7","Stage IIIB Fallopian Tube Cancer AJCC v7","Stage IIIB Ovarian Cancer AJCC v6 and v7","Stage IIIB Primary Peritoneal Cancer AJCC v7","Stage IIIC Fallopian Tube Cancer AJCC v7","Stage IIIC Ovarian Cancer AJCC v6 and v7","Stage IIIC Primary Peritoneal Cancer AJCC v7","Stage IV Fallopian Tube Cancer AJCC v6 and v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Primary Peritoneal Cancer AJCC v7",[53,277,278,449,1653],{"nctId":1760,"briefTitle":1761,"status":618,"phases":1762,"primaryCompletion":1763,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1773},"NCT00042835","Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer",[89],"2008-12","2002-05",48,[1767,1768,1769,1770,1771,1772],"Adenocarcinoma of the Lung","Bronchoalveolar Cell Lung Cancer","Large Cell Lung Cancer","Squamous Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[1598,1080,1774,1775,995,1776],"erlotinib hydrochloride","docetaxel","carboplatin",{"nctId":1778,"briefTitle":1779,"status":142,"phases":1780,"primaryCompletion":1781,"start":1782,"enrollment":28,"conditions":1783,"interventions":1791},"NCT00002913","Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer",[89],"2007-07","1996-12",[1784,1785,1732,1786,1787,1788,1789,1790,1591],"Brenner Tumor","Ovarian Clear Cell Cystadenocarcinoma","Ovarian Mixed Epithelial Carcinoma","Ovarian Mucinous Cystadenocarcinoma","Ovarian Serous Cystadenocarcinoma","Ovarian Undifferentiated Adenocarcinoma","Stage III Ovarian Epithelial Cancer",[995,1598,1031,750],{"nctId":1793,"briefTitle":1794,"status":142,"phases":1795,"primaryCompletion":1796,"completion":483,"start":1797,"enrollment":1798,"conditions":1799,"interventions":1800},"NCT01711515","Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer",[89],"2017-02-09","2012-10-01",34,[1648,1649,1650,1539,1540,1543,1544,1550,1668],[278,124],{"trials":1802,"activeCount":838,"soonestReadout":67},[1803,1815,1823,1833,1846,1860,1898,1902,1906,1920,1933,1948,1957,1969,1973,1984,2000,2013,2022,2035],{"nctId":1804,"briefTitle":1805,"status":142,"phases":1806,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1813},"NCT00887159","A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage",[90],"2016-11-15","2009-07-16",168,[1811,1812],"Extensive Stage Small Cell Lung Carcinoma","Recurrent Small Cell Lung Carcinoma",[278,1099,279,1814],"Vismodegib",{"nctId":1816,"briefTitle":1817,"status":142,"phases":1818,"primaryCompletion":1340,"start":1819,"enrollment":1765,"conditions":1820,"interventions":1822},"NCT00081276","3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer",[90],"2005-07",[1821,1579,1790,1591],"Primary Peritoneal Cavity Cancer",[1597,1598],{"nctId":1824,"briefTitle":1825,"status":142,"phases":1826,"primaryCompletion":1827,"completion":1828,"start":1829,"enrollment":286,"conditions":1830,"interventions":1831},"NCT00453154","Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[89,90],"2013-06-30","2015-08-20","2007-03-15",[274,275],[277,278,279,1832],"Sunitinib Malate",{"nctId":1834,"briefTitle":1835,"status":128,"phases":1836,"primaryCompletion":1837,"completion":1838,"start":900,"enrollment":1074,"conditions":1839,"interventions":1845},"NCT06406465","A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity",[90],"2027-07-30","2028-07-30",[1840,1841,1842,1843,1844],"Carcinoma, Neuroendocrine","Tumor, Neuroendocrine","Tumors, Neuroendocrine","Neuroendocrine; Carcinoma","Small Cell; Receptors",[1710,278,279],{"nctId":1847,"briefTitle":1848,"status":142,"phases":1849,"primaryCompletion":1850,"completion":1851,"start":787,"enrollment":1852,"conditions":1853,"interventions":1858},"NCT02567409","Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer",[90],"2023-04-21","2023-04-25",87,[1854,1855,1856,1857],"Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis and Ureter Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Stage IV Bladder Urothelial Carcinoma AJCC v7",[1859,278,167],"Berzosertib",{"nctId":1861,"briefTitle":1862,"status":618,"phases":1863,"primaryCompletion":1864,"completion":1864,"start":1865,"enrollment":889,"conditions":1866,"interventions":1896},"NCT02196168","Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",[90],"2016-04","2014-03",[1867,1868,1869,1870,1871,1872,1873,1874,1875,1876,1877,1878,1879,1880,1881,1882,1883,1884,1885,1886,1887,1888,1889,1890,1891,1892,1893,1894,1895],"Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Laryngeal Verrucous Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary","Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Recurrent Oral Cavity Verrucous Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary","Stage IV Hypopharyngeal Squamous Cell Carcinoma","Stage IVA Laryngeal Squamous Cell Carcinoma","Stage IVA Laryngeal Verrucous Carcinoma","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVA Oral Cavity Verrucous Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma","Stage IVB Laryngeal Squamous Cell Carcinoma","Stage IVB Laryngeal Verrucous Carcinoma","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVB Oral Cavity Verrucous Carcinoma","Stage IVB Oropharyngeal Squamous Cell Carcinoma","Stage IVC Laryngeal Squamous Cell Carcinoma","Stage IVC Laryngeal Verrucous Carcinoma","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVC Oral Cavity Verrucous Carcinoma","Stage IVC Oropharyngeal Squamous Cell Carcinoma","Tongue Carcinoma",[278,1897],"WEE1 Inhibitor AZD1775",{"nctId":266,"briefTitle":267,"status":142,"phases":1899,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":1900,"interventions":1901},[90],[274,275],[277,278,279,96],{"nctId":281,"briefTitle":282,"status":128,"phases":1903,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":1904,"interventions":1905},[90],[236,237,238],[277,278,289,96,290],{"nctId":1907,"briefTitle":1908,"status":142,"phases":1909,"primaryCompletion":1910,"completion":1911,"start":1912,"enrollment":1913,"conditions":1914,"interventions":1918},"NCT00253370","Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer",[90],"2008-05","2010-09","2005-10",44,[1915,1916,1917],"Adenocarcinoma of the Gastroesophageal Junction","Metastatic Gastric Cancer","Advanced Unresectable Gastric Cancer",[1919,1775,1598],"BAY 43-9006",{"nctId":1921,"briefTitle":1922,"status":142,"phases":1923,"primaryCompletion":1924,"completion":1925,"start":1926,"enrollment":286,"conditions":1927,"interventions":1932},"NCT01642251","Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer",[89,90],"2016-12-08","2018-07-02","2012-09-28",[1811,1928,1929,1930,1931],"Large Cell Lung Carcinoma","Neuroendocrine Carcinoma","Small Cell Carcinoma","Stage IV Non-Small Cell Lung Cancer AJCC v7",[278,279,1653],{"nctId":1934,"briefTitle":1935,"status":142,"phases":1936,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1798,"conditions":1940,"interventions":1947},"NCT01005329","Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer",[90],"2012-06-30","2013-09-22","2009-11-06",[1941,1942,1943,1944,1536,1538,1541,1549,1551,1552,1945,1946],"Endometrial Adenocarcinoma","Endometrial Adenosquamous Carcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Stage IVA Uterine Corpus Cancer AJCC v7","Stage IVB Uterine Corpus Cancer AJCC v7",[53,277,278,449],{"nctId":1949,"briefTitle":1950,"status":142,"phases":1951,"primaryCompletion":1021,"completion":1021,"start":1952,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT00066742","Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer",[90],"2003-09",72,[1955],"Limited Stage Small Cell Lung Cancer",[751,1598,1080],{"nctId":1958,"briefTitle":1959,"status":155,"phases":1960,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":1964,"conditions":1965,"interventions":1968},"NCT01585805","Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[90],"2024-12-31","2027-03-09","2012-05-15",83,[1966,1967,163,164],"Locally Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma",[278,289,167,1653],{"nctId":428,"briefTitle":429,"status":128,"phases":1970,"primaryCompletion":361,"completion":361,"start":431,"enrollment":234,"conditions":1971,"interventions":1972},[90],[433,434,238],[278,289,96],{"nctId":1974,"briefTitle":1975,"status":618,"phases":1976,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":248,"conditions":1980,"interventions":1982},"NCT00019864","Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma",[90],"2006-12","2011-10","2000-03",[1981,625],"Cardiac Toxicity",[750,1598,1983,994,1264,1268],"dexrazoxane hydrochloride",{"nctId":1985,"briefTitle":1986,"status":142,"phases":1987,"primaryCompletion":649,"completion":1988,"start":1989,"enrollment":1990,"conditions":1991,"interventions":1997},"NCT00083122","Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer",[90],"2012-05","2004-04",45,[1579,1992,1584,1993,1587,1994,1589,1995,1591,1996],"Recurrent Primary Peritoneal Cavity Cancer","Stage IIIA Primary Peritoneal Cavity Cancer","Stage IIIB Primary Peritoneal Cavity Cancer","Stage IIIC Primary Peritoneal Cavity Cancer","Stage IV Primary Peritoneal Cavity Cancer",[1598,1998,1999],"alvocidib","cisplatin\u002Fflavopiridol",{"nctId":2001,"briefTitle":2002,"status":142,"phases":2003,"primaryCompletion":2004,"completion":1319,"start":1171,"enrollment":34,"conditions":2005,"interventions":2012},"NCT00941070","Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer",[90],"2012-04",[1578,1580,2006,2007,2008,2009,2010,1582,1592,1593,1594,1595,2011],"Stage IB Cervical Cancer","Stage II Vaginal Cancer","Stage IIA Cervical Cancer","Stage IIB Cervical Cancer","Stage III Cervical Cancer","Therapy-related Toxicity",[1597,1598],{"nctId":2014,"briefTitle":2015,"status":618,"phases":2016,"primaryCompletion":2017,"completion":2017,"start":1310,"enrollment":1024,"conditions":2018,"interventions":2021},"NCT00924209","A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer",[90],"2011-09",[2019,2020],"NSCLC","Stage IIIA (N2)",[289,278,53,279],{"nctId":2023,"briefTitle":2024,"status":142,"phases":2025,"primaryCompletion":2026,"completion":2027,"start":2028,"enrollment":2029,"conditions":2030,"interventions":2033},"NCT01240590","A Phase I\u002FII Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)",[89,90],"2015-08-31","2016-12-31","2011-01-26",27,[2031,2032],"Solid Tumor","Anaplastic Thyroid Cancer",[2034,278],"Crolibulin",{"nctId":65,"briefTitle":66,"status":155,"phases":2036,"primaryCompletion":67,"completion":592,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2044},[89,90],"2010-03-15",117,[2040,2041,2042,2043],"Epithelioid Mesothelioma","Pleural Malignant Mesothelioma","Recurrent Malignant Mesothelioma","Sarcomatoid Mesothelioma",[68,278,2045],"Pemetrexed Disodium",{"trials":2047,"activeCount":1024,"soonestReadout":72},[2048,2085,2102,2106,2110,2125,2129,2144,2156],{"nctId":70,"briefTitle":71,"status":155,"phases":2049,"primaryCompletion":72,"completion":2050,"start":2051,"enrollment":2052,"conditions":2053,"interventions":2082},[91],"2027-02-20","2008-08-08",403,[2054,1867,1868,1869,1870,2055,1873,1874,2056,2057,2058,2059,2060,2061,2062,2063,2064,2065,2066,2067,2068,2069,2070,2071,2072,2073,2074,2075,2076,2077,2078,2079,2080,2081,1895],"Neck Squamous Cell Carcinoma of Unknown Primary","Recurrent Neck Squamous Cell Carcinoma of Unknown Primary","Recurrent Salivary Gland Carcinoma","Recurrent Sinonasal Squamous Cell Carcinoma","Salivary Gland Squamous Cell Carcinoma","Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Major Salivary Gland Cancer AJCC v7","Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Laryngeal Verrucous Carcinoma AJCC v7","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVA Major Salivary Gland Cancer AJCC v7","Stage IVA Oral Cavity Cancer AJCC v6 and v7","Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Verrucous Carcinoma AJCC v7","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVB Major Salivary Gland Cancer AJCC v7","Stage IVB Oral Cavity Cancer AJCC v6 and v7","Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Verrucous Carcinoma AJCC v7","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVC Major Salivary Gland Cancer AJCC v7","Stage IVC Oral Cavity Cancer AJCC v6 and v7","Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7",[53,277,278,2083,2084],"Docetaxel","Fluorouracil",{"nctId":2086,"briefTitle":2087,"status":128,"phases":2088,"primaryCompletion":2089,"completion":2089,"start":2090,"enrollment":2091,"conditions":2092,"interventions":2101},"NCT07061977","Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer",[91],"2030-12-31","2025-11-05",336,[2093,2094,2095,2096,2097,2098,2099,2100],"Locally Advanced Cervical Adenocarcinoma","Locally Advanced Cervical Adenosquamous Carcinoma","Locally Advanced Cervical Squamous Cell Carcinoma","Stage IIIA Cervical Cancer FIGO 2018","Stage IIIB Cervical Cancer FIGO 2018","Stage IIIC1 Cervical Cancer FIGO 2018","Stage IIIC2 Cervical Cancer FIGO 2018","Stage IVA Cervical Cancer FIGO 2018",[277,278,449,883],{"nctId":1393,"briefTitle":1394,"status":128,"phases":2103,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":2104,"interventions":2105},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":561,"briefTitle":562,"status":155,"phases":2107,"primaryCompletion":564,"completion":565,"start":566,"enrollment":567,"conditions":2108,"interventions":2109},[90,91],[569,570,571,572,573,574,575,576],[278,96],{"nctId":2111,"briefTitle":2112,"status":155,"phases":2113,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":2117,"interventions":2123},"NCT04092283","Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer",[91],"2028-12-31","2020-04-29",660,[2118,1626,2119,2120,2121,2122],"Recurrent Lung Non-Small Cell Carcinoma","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Unresectable Lung Non-Small Cell Carcinoma",[277,278,2124,279,449,2045],"Durvalumab",{"nctId":579,"briefTitle":580,"status":155,"phases":2126,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":2127,"interventions":2128},[91],[571,586],[278,96],{"nctId":2130,"briefTitle":2131,"status":155,"phases":2132,"primaryCompletion":2133,"completion":592,"start":2134,"enrollment":2135,"conditions":2136,"interventions":2141},"NCT00980460","Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer",[91],"2020-06-30","2009-09-14",236,[2137,2138,2139,2140],"PRETEXT I Hepatoblastoma","PRETEXT II Hepatoblastoma","PRETEXT III Hepatoblastoma","PRETEXT IV Hepatoblastoma",[278,2142,737,2084,1102,2143,740],"Dexrazoxane","Temsirolimus",{"nctId":2145,"briefTitle":2146,"status":142,"phases":2147,"primaryCompletion":2148,"completion":2149,"start":1717,"enrollment":2150,"conditions":2151,"interventions":2153},"NCT01004978","Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",[91],"2021-02-11","2022-12-21",235,[801,2152],"Unresectable Hepatocellular Carcinoma",[278,737,2154,2155,43],"Doxorubicin-Eluting Beads","Mitomycin",{"nctId":2157,"briefTitle":2158,"status":142,"phases":2159,"primaryCompletion":2160,"start":1979,"enrollment":2161,"conditions":2162,"interventions":2164},"NCT00005838","Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery",[91],"2007-02",756,[1767,2163,1769,1770,1771,1772],"Adenosquamous Cell Lung Cancer",[2165,1598,2166,1776,995],"shark cartilage extract AE-941","vinorelbine tartrate",{"trials":2168,"activeCount":101},[],{"trials":2170,"activeCount":101},[],{"intervention":212,"totalTrials":28,"cells":2172},{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2228,"PHASE3":2370,"PHASE4":2396,"NA":2398},{"trials":2174,"activeCount":101},[],{"trials":2176,"activeCount":214,"soonestReadout":185},[2177,2185,2201,2205,2220,2224],{"nctId":2178,"briefTitle":2179,"status":142,"phases":2180,"primaryCompletion":1022,"start":2181,"conditions":2182,"interventions":2183},"NCT00045500","UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma",[89],"2002-06",[27,15],[2184,1082],"7-hydroxystaurosporine",{"nctId":2186,"briefTitle":2187,"status":155,"phases":2188,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1798,"conditions":2192,"interventions":2195},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[89],"2026-05-07","2031-06-18","2021-07-09",[27,2193,2194,773],"Non-Hodgkin Lymphoma","Diffuse Large B-Cell Lymphoma",[2196,1082,2197,2198,2199,2200],"obinutuzumab","Revlimid","Polatuzumab","ibrutinib","venetoclax",{"nctId":724,"briefTitle":725,"status":155,"phases":2202,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":2203,"interventions":2204},[89],[732,733,734,735],[63,737,279,738,58,739,212,667,740],{"nctId":2206,"briefTitle":2207,"status":155,"phases":2208,"primaryCompletion":2209,"completion":418,"start":2210,"enrollment":2211,"conditions":2212,"interventions":2215},"NCT05211336","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System",[89],"2024-06-01","2022-04-19",14,[2213,2214],"Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)","Aggressive B-cell Lymphoma With Secondary Involvement of the CNS",[2216,212,1016,2217,58,706,2218,2219],"Obinutuzumab","Venetoclax","Diphenhydramine","EKG",{"nctId":766,"briefTitle":767,"status":618,"phases":2221,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":2222,"interventions":2223},[89],[773,774,775,776,777],[667,279,779,63,780,781,212],{"nctId":182,"briefTitle":183,"status":155,"phases":2225,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":2226,"interventions":2227},[89],[190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210],[124,96,212,213],{"trials":2229,"activeCount":889,"soonestReadout":62},[2230,2245,2258,2273,2284,2288,2300,2314,2325,2329,2333,2337,2341,2350,2354,2358,2362,2366],{"nctId":2231,"briefTitle":2232,"status":128,"phases":2233,"primaryCompletion":2234,"completion":2234,"start":2235,"enrollment":1357,"conditions":2236,"interventions":2244},"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma",[90],"2027-09-01","2025-10-07",[2237,527,2238,2239,529,530,2240,534,537,2241,2242,539,540,2243,543],"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified",[58,1016,2216,212,2217],{"nctId":2246,"briefTitle":2247,"status":128,"phases":2248,"primaryCompletion":361,"completion":361,"start":2249,"enrollment":2250,"conditions":2251,"interventions":2254},"NCT04633252","A Phase I\u002FII Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer",[89,90],"2021-02-23",86,[2252,2253],"Cancer Of Prostate","Prostate Neoplasms",[2255,2083,2256,212,2257],"PDS01ADC","M7824","ADT",{"nctId":2259,"briefTitle":2260,"status":155,"phases":2261,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":2266,"interventions":2271},"NCT02143414","Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia",[90],"2022-06-01","2027-01-26","2015-06-30",53,[902,2267,2268,2269,2270],"B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Recurrent Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia",[1372,1138,1375,1141,2272,212,781,740],"Methotrexate Sodium",{"nctId":2274,"briefTitle":2275,"status":142,"phases":2276,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":2281,"interventions":2282},"NCT00436956","AZD2171 to Treat Prostate Cancer",[90],"2010-02-01","2014-02-05","2006-10-16",59,[24],[2283,212],"AZD2171",{"nctId":923,"briefTitle":924,"status":142,"phases":2285,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":2286,"interventions":2287},[89,90],[931,932,933,934,733,935,936,734,937,735,938,939,522,524,527,940],[63,737,279,212,667,740,942],{"nctId":2289,"briefTitle":2290,"status":618,"phases":2291,"primaryCompletion":1319,"completion":2292,"start":2293,"enrollment":2294,"conditions":2295,"interventions":2298},"NCT00527124","Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy",[90],"2013-11","2007-11",57,[2296,2297],"Adenocarcinoma of the Prostate","Stage IV Prostate Cancer",[2299,1775,1082],"cediranib maleate",{"nctId":2301,"briefTitle":2302,"status":142,"phases":2303,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2312},"NCT01576172","Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",[90],"2019-10-23","2020-04-23","2012-03-30",159,[2309,2310,2311],"Castration-Resistant Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer AJCC v7",[2313,212,1653],"Abiraterone Acetate",{"nctId":2315,"briefTitle":2316,"status":142,"phases":2317,"primaryCompletion":2318,"start":1276,"enrollment":2319,"conditions":2320,"interventions":2322},"NCT00058084","Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer",[90],"2007-10-01",80,[2296,2321,2297],"Recurrent Prostate Cancer",[2323,2324,1082],"ixabepilone","mitoxantrone hydrochloride",{"nctId":1007,"briefTitle":1008,"status":155,"phases":2326,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":407,"conditions":2327,"interventions":2328},[89,90],[524,1014],[1016,667,212,279,780,781,63],{"nctId":1068,"briefTitle":1069,"status":142,"phases":2330,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":2331,"interventions":2332},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":60,"briefTitle":61,"status":155,"phases":2334,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":2335,"interventions":2336},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":1167,"briefTitle":1168,"status":142,"phases":2338,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":234,"conditions":2339,"interventions":2340},[90],[1174],[1176,279,780,781,63,212,738],{"nctId":2342,"briefTitle":2343,"status":142,"phases":2344,"primaryCompletion":2345,"completion":2345,"start":1808,"enrollment":2346,"conditions":2347,"interventions":2349},"NCT00942578","A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer",[90],"2017-07-31",63,[2348],"Metastatic Prostate Cancer",[53,1016,2083,212],{"nctId":1201,"briefTitle":1202,"status":142,"phases":2351,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":2352,"interventions":2353},[90],[776,1208,773,1209,1210],[279,667,212,63,781,780],{"nctId":451,"briefTitle":452,"status":128,"phases":2355,"primaryCompletion":157,"completion":157,"start":454,"enrollment":455,"conditions":2356,"interventions":2357},[89,90],[190,191,192,193,194,457,195,196,197,208,209,210,458],[124,96,212,460],{"nctId":1237,"briefTitle":1238,"status":618,"phases":2359,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":2360,"interventions":2361},[90],[1244,1245,1246,1247,1248,1249,1250,1251],[1063,1082,693,1225,1064],{"nctId":1272,"briefTitle":1273,"status":142,"phases":2363,"primaryCompletion":1275,"completion":1275,"start":1276,"enrollment":1277,"conditions":2364,"interventions":2365},[90],[1279,1280,1281,1282],[1063,1080,994,1032,1082,693],{"nctId":1326,"briefTitle":1327,"status":142,"phases":2367,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":1331,"conditions":2368,"interventions":2369},[90],[1244,1247,1333,1334],[1063,1033,693,994,1032,1082],{"trials":2371,"activeCount":603,"soonestReadout":1498},[2372,2376,2380,2384,2388,2392],{"nctId":1353,"briefTitle":1354,"status":142,"phases":2373,"primaryCompletion":715,"start":1356,"enrollment":1357,"conditions":2374,"interventions":2375},[91],[27],[750,1063,1360,693,994,1082,1032],{"nctId":1362,"briefTitle":1363,"status":155,"phases":2377,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":2378,"interventions":2379},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1378,"briefTitle":1379,"status":142,"phases":2381,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":2382,"interventions":2383},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"nctId":1423,"briefTitle":1424,"status":142,"phases":2385,"primaryCompletion":1426,"start":1427,"enrollment":1428,"conditions":2386,"interventions":2387},[91],[1430,1431,1432],[1032,1434,1081,693,1082,1435],{"nctId":1474,"briefTitle":1475,"status":155,"phases":2389,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":2390,"interventions":2391},[90,91],[734,1481,735,510,511,512,513,514,1482,516,517,1483,1484,518,519,1485,1486,1487,1488,1489,1490],[63,737,1492,212,667,1493,740],{"nctId":1495,"briefTitle":1496,"status":155,"phases":2393,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":2394,"interventions":2395},[91],[1503,1504,1505,1506,1507,1508],[1510,1511,63,737,279,1142,212,740],{"trials":2397,"activeCount":101},[],{"trials":2399,"activeCount":101},[],{"intervention":124,"totalTrials":2401,"cells":2402},22,{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2464,"PHASE3":2528,"PHASE4":2549,"NA":2551},{"trials":2404,"activeCount":101},[],{"trials":2406,"activeCount":603,"soonestReadout":185},[2407,2411,2415,2419,2436,2446,2456,2460],{"nctId":105,"briefTitle":106,"status":107,"phases":2408,"primaryCompletion":109,"completion":109,"start":110,"enrollment":101,"conditions":2409,"interventions":2410},[89],[112,113,114,115,116,117,118,119,30,120,121,122],[124,96],{"nctId":140,"briefTitle":141,"status":142,"phases":2412,"primaryCompletion":144,"completion":145,"start":146,"enrollment":22,"conditions":2413,"interventions":2414},[89],[148,149],[124,96,151],{"nctId":153,"briefTitle":154,"status":155,"phases":2416,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":2417,"interventions":2418},[89],[161,162,163,164],[166,167,124,96],{"nctId":2420,"briefTitle":2421,"status":155,"phases":2422,"primaryCompletion":2423,"completion":405,"start":2424,"enrollment":484,"conditions":2425,"interventions":2434},"NCT02890329","Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia",[89],"2022-10-24","2017-09-05",[2426,2427,2428,2429,2430,2431,2432,2433],"Previously Treated Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia","Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related","Recurrent Myelodysplastic Syndrome","Refractory Acute Myeloid Leukemia","Refractory Myelodysplastic Syndrome","Secondary Acute Myeloid Leukemia","Secondary Myelodysplastic Syndrome",[2435,124],"Decitabine",{"nctId":2437,"briefTitle":2438,"status":618,"phases":2439,"primaryCompletion":2440,"completion":2441,"start":756,"enrollment":758,"conditions":2442,"interventions":2443},"NCT04840615","Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma",[89],"2021-12-06","2022-01-12",[915],[2444,2445,2218,710,706,1139],"LMB-100","ipilimumab",{"nctId":2447,"briefTitle":2448,"status":142,"phases":2449,"primaryCompletion":2027,"start":2450,"enrollment":1517,"conditions":2451,"interventions":2455},"NCT01757639","Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia",[89],"2012-12-14",[2452,2453,2454,2426,33,2433],"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome",[124],{"nctId":1793,"briefTitle":1794,"status":142,"phases":2457,"primaryCompletion":1796,"completion":483,"start":1797,"enrollment":1798,"conditions":2458,"interventions":2459},[89],[1648,1649,1650,1539,1540,1543,1544,1550,1668],[278,124],{"nctId":182,"briefTitle":183,"status":155,"phases":2461,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":2462,"interventions":2463},[89],[190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210],[124,96,212,213],{"trials":2465,"activeCount":651,"soonestReadout":372},[2466,2475,2479,2483,2492,2496,2500,2504,2508,2512,2516,2520,2524],{"nctId":2467,"briefTitle":2468,"status":107,"phases":2469,"primaryCompletion":2470,"completion":2470,"start":2471,"enrollment":101,"conditions":2472,"interventions":2474},"NCT01913691","Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma",[90],"2014-02-03","2013-07-09",[2473],"Merkel Cell Carcinoma",[124],{"nctId":218,"briefTitle":219,"status":155,"phases":2476,"primaryCompletion":221,"completion":221,"start":222,"enrollment":174,"conditions":2477,"interventions":2478},[89,90],[224,225,226],[124,96],{"nctId":229,"briefTitle":230,"status":128,"phases":2480,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":2481,"interventions":2482},[90],[236,237,238],[240,124,96],{"nctId":2484,"briefTitle":2485,"status":142,"phases":2486,"completion":2487,"start":1172,"conditions":2488,"interventions":2491},"NCT00058279","Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma",[89,90],"2006-08",[2489,2490],"Intraocular Melanoma","Melanoma (Skin)",[818,2445],{"nctId":242,"briefTitle":243,"status":142,"phases":2493,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":2494,"interventions":2495},[90],[250,251,252],[124,96],{"nctId":320,"briefTitle":321,"status":155,"phases":2497,"primaryCompletion":323,"completion":324,"start":325,"enrollment":326,"conditions":2498,"interventions":2499},[90],[328,329,330],[124,96],{"nctId":358,"briefTitle":359,"status":155,"phases":2501,"primaryCompletion":361,"completion":361,"start":362,"enrollment":25,"conditions":2502,"interventions":2503},[90],[364,365,366],[124,96],{"nctId":369,"briefTitle":370,"status":155,"phases":2505,"primaryCompletion":372,"completion":373,"start":374,"enrollment":375,"conditions":2506,"interventions":2507},[90],[377,378,379,380,381,382,383,384,385],[240,124,96],{"nctId":401,"briefTitle":402,"status":155,"phases":2509,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":2510,"interventions":2511},[90],[409,410,411,412],[240,124,96],{"nctId":451,"briefTitle":452,"status":128,"phases":2513,"primaryCompletion":157,"completion":157,"start":454,"enrollment":455,"conditions":2514,"interventions":2515},[89,90],[190,191,192,193,194,457,195,196,197,208,209,210,458],[124,96,212,460],{"nctId":478,"briefTitle":479,"status":155,"phases":2517,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":2518,"interventions":2519},[89,90],[21,486,487],[489,124,96],{"nctId":491,"briefTitle":492,"status":155,"phases":2521,"primaryCompletion":361,"completion":361,"start":494,"enrollment":19,"conditions":2522,"interventions":2523},[90],[496,497,498,499],[124,96],{"nctId":547,"briefTitle":548,"status":142,"phases":2525,"primaryCompletion":550,"completion":110,"start":551,"enrollment":552,"conditions":2526,"interventions":2527},[90],[554,555,556],[124,96],{"trials":2529,"activeCount":2548,"soonestReadout":2534},[2530],{"nctId":2531,"briefTitle":2532,"status":155,"phases":2533,"primaryCompletion":2534,"completion":2535,"start":2536,"enrollment":2537,"conditions":2538,"interventions":2546},"NCT02506153","Physician\u002FPatient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",[91],"2023-09-15","2027-01-23","2015-11-10",1301,[190,192,2539,2540,2541,2542,2543,2544,2545],"Metastatic Cutaneous Melanoma","Metastatic Mucosal Melanoma","Metastatic Non-Cutaneous Melanoma","Non-Cutaneous Melanoma","Recurrent Cutaneous Melanoma","Recurrent Mucosal Melanoma","Recurrent Non-Cutaneous Melanoma",[124,883,2547],"Recombinant Interferon Alfa-2b",1,{"trials":2550,"activeCount":101},[],{"trials":2552,"activeCount":101},[],{"intervention":2554,"totalTrials":407,"cells":2555},"Olaparib",{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2635,"PHASE3":2791,"PHASE4":2818,"NA":2820},{"trials":2557,"activeCount":101},[],{"trials":2559,"activeCount":603,"soonestReadout":2576},[2560,2572,2580,2589,2599,2626],{"nctId":2561,"briefTitle":2562,"status":142,"phases":2563,"primaryCompletion":2564,"completion":2565,"start":2566,"enrollment":1054,"conditions":2567,"interventions":2571},"NCT01237067","Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers",[89],"2014-11-16","2019-12-12","2011-02-07",[1003,18,2568,2569,2570],"Primary Peritoneal Cancer","Fallopian Tube Cancer","Endometrial Cancer",[277,2554],{"nctId":2573,"briefTitle":2574,"status":155,"phases":2575,"primaryCompletion":2576,"completion":361,"start":2133,"enrollment":2577,"conditions":2578,"interventions":2579},"NCT04197713","Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study",[89],"2023-02-22",13,[21,486,30,487],[1555,2554],{"nctId":2581,"briefTitle":2582,"status":155,"phases":2583,"primaryCompletion":2584,"completion":361,"start":2585,"enrollment":2586,"conditions":2587,"interventions":2588},"NCT03842228","Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations",[89],"2024-07-29","2019-11-21",39,[21,486,487],[489,2124,2554],{"nctId":2590,"briefTitle":2591,"status":107,"phases":2592,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":101,"conditions":2595,"interventions":2597},"NCT05807126","Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations",[89],"2026-12-06","2024-03-05",[1620,2309,2596],"Stage IVB Prostate Cancer AJCC v8",[2598,2554],"Magrolimab",{"nctId":2600,"briefTitle":2601,"status":142,"phases":2602,"primaryCompletion":2603,"completion":2604,"start":2605,"enrollment":31,"conditions":2606,"interventions":2624},"NCT02898207","Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",[89],"2020-07-29","2022-01-14","2017-05-19",[2607,486,2608,2609,2610,2611,2612,2613,2614,2615,2616,2617,2618,2619,2620,2621,2622,487,2623],"Metastatic High Grade Fallopian Tube Serous Adenocarcinoma","Metastatic Primary Peritoneal Serous Adenocarcinoma","Metastatic Triple-Negative Breast Carcinoma","Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Ovarian Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Recurrent Breast Carcinoma","Recurrent High Grade Fallopian Tube Serous Adenocarcinoma","Recurrent High Grade Ovarian Serous Adenocarcinoma","Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma","Recurrent Triple-Negative Breast Carcinoma","Refractory Fallopian Tube Serous Adenocarcinoma","Refractory Ovarian Serous Adenocarcinoma","Refractory Primary Peritoneal Serous Adenocarcinoma","Refractory Triple-Negative Breast Carcinoma","Unresectable High Grade Fallopian Tube Serous Adenocarcinoma","Unresectable Primary Peritoneal Serous Adenocarcinoma",[2554,2625],"Onalespib",{"nctId":2627,"briefTitle":2628,"status":128,"phases":2629,"primaryCompletion":361,"completion":361,"start":2630,"enrollment":913,"conditions":2631,"interventions":2633},"NCT04585958","Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer",[89],"2021-05-21",[486,2632,487],"Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma",[2554,2634],"Trastuzumab Deruxtecan",{"trials":2636,"activeCount":1024,"soonestReadout":81},[2637,2650,2666,2673,2685,2699,2709,2723,2733],{"nctId":2638,"briefTitle":2639,"status":155,"phases":2640,"primaryCompletion":2641,"completion":2642,"start":2643,"enrollment":1111,"conditions":2644,"interventions":2649},"NCT02345265","Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer",[90],"2022-07-07","2027-03-04","2016-05-23",[1720,1723,2645,1729,2646,2647,1738,2648,1739],"Fallopian Tube Serous Adenocarcinoma","Ovarian High Grade Endometrioid Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma","Primary Peritoneal Endometrioid Adenocarcinoma",[68,2554],{"nctId":2651,"briefTitle":2652,"status":128,"phases":2653,"primaryCompletion":2654,"completion":2654,"start":2655,"enrollment":2656,"conditions":2657,"interventions":2665},"NCT04858334","APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",[90],"2027-10-31","2021-06-22",152,[2658,2659,2660,2661,2662,2663,2664],"Pancreatic Acinar Cell Carcinoma","Pancreatic Adenosquamous Carcinoma","Pancreatic Squamous Cell Carcinoma","Resectable Pancreatic Acinar Cell Carcinoma","Resectable Pancreatic Adenocarcinoma","Resectable Pancreatic Adenosquamous Carcinoma","Resectable Pancreatic Carcinoma",[2554],{"nctId":79,"briefTitle":80,"status":155,"phases":2667,"primaryCompletion":81,"completion":2642,"start":2668,"enrollment":2669,"conditions":2670,"interventions":2672},[89,90],"2010-04-14",155,[1720,1732,2647,1735,2671,1739,1637],"Ovarian Serous Surface Papillary Adenocarcinoma",[68,2554],{"nctId":2674,"briefTitle":2675,"status":155,"phases":2676,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":339,"conditions":2680,"interventions":2683},"NCT03878095","Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors",[90],"2025-03-12","2026-07-10","2020-01-30",[2681,2682,30],"Malignant Solid Neoplasm","Refractory Cholangiocarcinoma",[2684,2554],"Ceralasertib",{"nctId":2686,"briefTitle":2687,"status":347,"phases":2688,"primaryCompletion":2689,"completion":2689,"start":2690,"enrollment":1074,"conditions":2691,"interventions":2698},"NCT03375307","Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes",[90],"2026-12-16","2020-11-03",[2692,2693,2694,2695,2696,2697],"Advanced Bladder Carcinoma","Advanced Genitourinary System Carcinoma","Metastatic Bladder Carcinoma","Metastatic Genitourinary System Carcinoma","Stage III Bladder Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8",[2554],{"nctId":2700,"briefTitle":2701,"status":128,"phases":2702,"primaryCompletion":2703,"completion":2703,"start":1851,"enrollment":2704,"conditions":2705,"interventions":2707},"NCT05554328","Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial",[90],"2028-10-01",165,[2706,250,251,252],"Recurrent Endometrial Carcinoma",[2554,2708],"Selumetinib Sulfate",{"nctId":2710,"briefTitle":2711,"status":142,"phases":2712,"primaryCompletion":2713,"completion":2714,"start":2715,"enrollment":1990,"conditions":2716,"interventions":2720},"NCT02769962","Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed\u002FRefractory Small Cell Lung Cancer",[89,90],"2023-04-19","2025-03-04","2016-05-09",[2717,1197,2718,2719,24],"Urothelial Carcinoma","Lung Neoplasms","Small Cell Lung Cancer",[2721,2722],"EP0057","olaparib",{"nctId":2724,"briefTitle":2725,"status":155,"phases":2726,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":1111,"conditions":2730,"interventions":2731},"NCT02974621","Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma",[90],"2022-12-31","2026-07-17","2017-12-07",[354],[53,2732,68,2554],"Cediranib",{"nctId":2734,"briefTitle":2735,"status":155,"phases":2736,"primaryCompletion":2737,"completion":2642,"start":2738,"enrollment":1357,"conditions":2739,"interventions":2788},"NCT04739800","Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents",[90],"2023-01-26","2021-06-10",[1724,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2616,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2782,2783,2784,2785,2786,2787],"Ovarian Seromucinous Carcinoma","Platinum-Refractory Fallopian Tube Carcinoma","Platinum-Refractory Ovarian Carcinoma","Platinum-Refractory Primary Peritoneal Carcinoma","Recurrent Fallopian Tube Clear Cell Adenocarcinoma","Recurrent Fallopian Tube Endometrioid Adenocarcinoma","Recurrent Fallopian Tube High Grade Serous Adenocarcinoma","Recurrent Fallopian Tube Mucinous Adenocarcinoma","Recurrent Fallopian Tube Transitional Cell Carcinoma","Recurrent Fallopian Tube Undifferentiated Carcinoma","Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma","Recurrent Ovarian Clear Cell Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian High Grade Serous Adenocarcinoma","Recurrent Ovarian Low Grade Serous Adenocarcinoma","Recurrent Ovarian Mucinous Adenocarcinoma","Recurrent Ovarian Seromucinous Carcinoma","Recurrent Ovarian Transitional Cell Carcinoma","Recurrent Ovarian Undifferentiated Carcinoma","Recurrent Platinum-Resistant Fallopian Tube Carcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma","Recurrent Platinum-Resistant Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Clear Cell Adenocarcinoma","Recurrent Primary Peritoneal Endometrioid Adenocarcinoma","Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma","Recurrent Primary Peritoneal Transitional Cell Carcinoma","Recurrent Primary Peritoneal Undifferentiated Carcinoma","Refractory Fallopian Tube Clear Cell Adenocarcinoma","Refractory Fallopian Tube Endometrioid Adenocarcinoma","Refractory Fallopian Tube High Grade Serous Adenocarcinoma","Refractory Fallopian Tube Mucinous Adenocarcinoma","Refractory Fallopian Tube Transitional Cell Carcinoma","Refractory Fallopian Tube Undifferentiated Carcinoma","Refractory Low Grade Fallopian Tube Serous Adenocarcinoma","Refractory Ovarian Clear Cell Adenocarcinoma","Refractory Ovarian Endometrioid Adenocarcinoma","Refractory Ovarian High Grade Serous Adenocarcinoma","Refractory Ovarian Low Grade Serous Adenocarcinoma","Refractory Ovarian Mucinous Adenocarcinoma","Refractory Ovarian Seromucinous Carcinoma","Refractory Ovarian Transitional Cell Carcinoma","Refractory Ovarian Undifferentiated Carcinoma","Refractory Primary Peritoneal Clear Cell Adenocarcinoma","Refractory Primary Peritoneal Endometrioid Adenocarcinoma","Refractory Primary Peritoneal High Grade Serous Adenocarcinoma","Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma","Refractory Primary Peritoneal Transitional Cell Carcinoma","Refractory Primary Peritoneal Undifferentiated Carcinoma",[68,2124,2554,449,2789,2790],"Pegylated Liposomal Doxorubicin Hydrochloride","Topotecan Hydrochloride",{"trials":2792,"activeCount":758,"soonestReadout":2813},[2793,2809],{"nctId":2794,"briefTitle":2795,"status":155,"phases":2796,"primaryCompletion":2797,"completion":2798,"start":2799,"enrollment":159,"conditions":2800,"interventions":2806},"NCT05432791","Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working",[90,91],"2024-08-13","2027-01-30","2023-03-30",[2801,2802,2803,2804,2805],"Locally Advanced Uterine Corpus Leiomyosarcoma","Metastatic Uterine Corpus Leiomyosarcoma","Stage III Uterine Corpus Leiomyosarcoma AJCC v8","Stage IV Uterine Corpus Leiomyosarcoma AJCC v8","Unresectable Uterine Corpus Leiomyosarcoma",[2554,2807,151,2808],"Pazopanib","Trabectedin",{"nctId":2810,"briefTitle":2811,"status":155,"phases":2812,"primaryCompletion":2813,"completion":2642,"start":2814,"enrollment":2815,"conditions":2816,"interventions":2817},"NCT02502266","Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer",[90,91],"2023-06-12","2016-05-03",582,[1722,1723,2645,1726,1727,1731,1732,2740,1735,1736,1737,1739,250,251,252],[2732,68,2554,449,2789,1407,2790],{"trials":2819,"activeCount":101},[],{"trials":2821,"activeCount":101},[],{"intervention":1690,"totalTrials":407,"cells":2823},{"EARLY_PHASE1":2824,"PHASE1":2826,"PHASE2":2850,"PHASE3":3013,"PHASE4":3047,"NA":3049},{"trials":2825,"activeCount":101},[],{"trials":2827,"activeCount":2548,"soonestReadout":2832},[2828,2836,2846],{"nctId":2829,"briefTitle":2830,"status":155,"phases":2831,"primaryCompletion":2832,"completion":2832,"start":2833,"enrollment":421,"conditions":2834,"interventions":2835},"NCT02862275","Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer",[89],"2026-11-21","2017-05-24",[113,486,487],[1690],{"nctId":2837,"briefTitle":2838,"status":142,"phases":2839,"primaryCompletion":2840,"completion":2841,"start":2842,"enrollment":603,"conditions":2843,"interventions":2845},"NCT04631029","Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread",[89],"2021-12-30","2023-07-11","2021-04-27",[274,2681,2844],"Metastatic Malignant Neoplasm in the Brain",[1690,277,474,279],{"nctId":1673,"briefTitle":1674,"status":142,"phases":2847,"primaryCompletion":1676,"completion":1677,"start":1678,"enrollment":421,"conditions":2848,"interventions":2849},[89],[1648,1649,1680,1681,1682,1683,1684,1685,1686,1687,1688],[1690,278],{"trials":2851,"activeCount":1024,"soonestReadout":2959},[2852,2867,2877,2889,2907,2926,2955,2969,2979,2988,3002],{"nctId":2853,"briefTitle":2854,"status":107,"phases":2855,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":101,"conditions":2858,"interventions":2865},"NCT05564416","Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial",[90],"2024-01-01","2023-10-12",[2859,2860,2861,2862,2863,2696,2864,2717],"Bladder Carcinoma","Bladder Urothelial Carcinoma","Muscle Invasive Bladder Carcinoma","Renal Pelvis and Ureter Urothelial Carcinoma","Stage II Bladder Cancer AJCC v8","Stage IVA Bladder Cancer AJCC v8",[1690,2866],"Erdafitinib",{"nctId":2868,"briefTitle":2869,"status":142,"phases":2870,"primaryCompletion":2871,"completion":2872,"start":2873,"enrollment":375,"conditions":2874,"interventions":2876},"NCT02921269","Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer",[90],"2020-10-01","2021-01-13","2017-03-10",[1648,1649,1650,1533,2875,1668,1651],"Stage IV Cervical Cancer AJCC v6 and v7",[1690,53],{"nctId":2878,"briefTitle":2879,"status":155,"phases":2880,"primaryCompletion":2881,"completion":1499,"start":2882,"enrollment":2883,"conditions":2884,"interventions":2887},"NCT03600701","Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer",[90],"2025-07-14","2018-11-29",51,[2885,2118,2886,1633],"Metastatic Lung Non-Small Cell Carcinoma","Refractory Lung Non-Small Cell Carcinoma",[1690,2888],"Cobimetinib",{"nctId":2890,"briefTitle":2891,"status":128,"phases":2892,"primaryCompletion":2893,"completion":2894,"start":2895,"enrollment":1074,"conditions":2896,"interventions":2905},"NCT06161532","Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder\u002FUrinary Tract Cancer, Renal Medullary Carcinoma and Penile C...",[90],"2027-11-01","2028-11-01","2024-08-01",[2897,2898,2899,2900,2901,2902,2903,2904],"Small Cell Carcinoma of the Bladder","Small Cell Carcinoma of the Urinary Tract","Squamous Cell Carcinoma of the Bladder","Squamous Cell Carcinoma of the Urinary Tract","Primary Adenocarcinoma of the Bladder","Primary Adenocarcinoma of the Urinary Tract","Renal Medullary Carcinoma","Squamous Cell Carcinoma of the Penis",[2906,1690],"Sacituzumab govitecan",{"nctId":2908,"briefTitle":2909,"status":155,"phases":2910,"primaryCompletion":2654,"completion":2654,"start":2911,"enrollment":2912,"conditions":2913,"interventions":2923},"NCT05836584","Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H\u002FdMMR Gastric and Gastroesophageal Junction (GEJ) Cancer",[90],"2023-12-06",240,[2914,2915,2916,2917,1621,2918,2919,2920,2921,2922],"Clinical Stage I Gastric Cancer AJCC v8","Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage II Gastric Cancer AJCC v8","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[1690,2924,2083,2084,1140,2925],"Capecitabine","Oxaliplatin",{"nctId":2927,"briefTitle":2928,"status":155,"phases":2929,"primaryCompletion":2930,"completion":2930,"start":2931,"enrollment":1953,"conditions":2932,"interventions":2953},"NCT03237780","Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer",[90],"2027-06-30","2018-07-20",[2933,2934,2935,2936,1854,2937,1856,2938,2939,2940,2941,2942,2696,2943,2944,2945,2697,2946,2947,2948,2949,2950,2951,2952],"Locally Advanced Bladder Urothelial Carcinoma","Locally Advanced Renal Pelvis Urothelial Carcinoma","Locally Advanced Ureter Urothelial Carcinoma","Locally Advanced Urethral Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Recurrent Bladder Urothelial Carcinoma","Recurrent Renal Pelvis Urothelial Carcinoma","Recurrent Ureter Urothelial Carcinoma","Recurrent Urethral Urothelial Carcinoma","Stage III Renal Pelvis Cancer AJCC v8","Stage III Ureter Cancer AJCC v8","Stage III Urethral Cancer AJCC v8","Stage IV Renal Pelvis Cancer AJCC v8","Stage IV Ureter Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8","Unresectable Bladder Urothelial Carcinoma","Unresectable Renal Pelvis Urothelial Carcinoma","Unresectable Ureter Urothelial Carcinoma","Unresectable Urethral Urothelial Carcinoma",[1690,2954],"Eribulin Mesylate",{"nctId":2956,"briefTitle":2957,"status":155,"phases":2958,"primaryCompletion":2959,"completion":373,"start":2960,"enrollment":2029,"conditions":2961,"interventions":2968},"NCT04458922","Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma",[90],"2022-11-28","2020-10-05",[2962,2963,2964,2965,2966,2967],"Central Chondrosarcoma, Grade 2","Central Chondrosarcoma, Grade 3","Dedifferentiated Chondrosarcoma","Metastatic Clear Cell Sarcoma of Soft Tissue","Metastatic Primary Central Chondrosarcoma","Unresectable Primary Central Chondrosarcoma",[1690],{"nctId":2970,"briefTitle":2971,"status":107,"phases":2972,"primaryCompletion":2973,"completion":2973,"start":2974,"enrollment":101,"conditions":2975,"interventions":2977},"NCT06328036","Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma",[90],"2025-07-01","2025-04-30",[2976],"Recurrent Glioblastoma, IDH-Wildtype",[1690,2978],"Tiragolumab",{"nctId":2980,"briefTitle":2981,"status":155,"phases":2982,"primaryCompletion":2983,"completion":2983,"start":2872,"enrollment":298,"conditions":2984,"interventions":2987},"NCT04310020","Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients",[90],"2026-09-01",[2985,2986,1626],"Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8",[1690],{"nctId":2989,"briefTitle":2990,"status":128,"phases":2991,"primaryCompletion":2992,"completion":2992,"start":2993,"enrollment":2029,"conditions":2994,"interventions":3000},"NCT05333458","Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial",[90],"2027-05-01","2022-08-29",[2995,2996,2997,2998,2999],"Advanced Alveolar Soft Part Sarcoma","Advanced Soft Tissue Sarcoma","Metastatic Alveolar Soft Part Sarcoma","Refractory Alveolar Soft Part Sarcoma","Unresectable Alveolar Soft Part Sarcoma",[1690,3001],"Selinexor",{"nctId":3003,"briefTitle":3004,"status":142,"phases":3005,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":188,"conditions":3008,"interventions":3009},"NCT03206047","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[89,90],"2020-11-10","2017-11-08",[2610,2611,2612,250,251,252],[1690,3010,3011,3012],"DEC-205\u002FNY-ESO-1 Fusion Protein CDX-1401","Guadecitabine","Poly ICLC",{"trials":3014,"activeCount":603,"soonestReadout":3038},[3015,3024,3034],{"nctId":3016,"briefTitle":3017,"status":128,"phases":3018,"primaryCompletion":3019,"completion":3019,"start":3020,"enrollment":3021,"conditions":3022,"interventions":3023},"NCT04402788","Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial",[90,91],"2027-04-30","2021-01-07",138,[274],[1690],{"nctId":3025,"briefTitle":3026,"status":3027,"phases":3028,"primaryCompletion":3029,"completion":3029,"start":3030,"enrollment":2091,"conditions":3031,"interventions":3032},"NCT07388524","Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","NOT_YET_RECRUITING",[91],"2029-09-30","2026-06-05",[2985],[1690,3033],"Atezolizumab and Recombinant Human Hyaluronidase",{"nctId":3035,"briefTitle":3036,"status":155,"phases":3037,"primaryCompletion":3038,"completion":3039,"start":3040,"enrollment":3041,"conditions":3042,"interventions":3046},"NCT02912559","Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair",[91],"2025-02-04","2026-12-18","2017-10-16",712,[3043,3044,114,3045],"Colon Adenocarcinoma","DNA Repair Disorder","Stage III Colon Cancer AJCC v8",[1690,2084,1140,2925],{"trials":3048,"activeCount":101},[],{"trials":3050,"activeCount":101},[],{"intervention":449,"totalTrials":1913,"cells":3052},{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3220,"PHASE3":3402,"PHASE4":3499,"NA":3501},{"trials":3054,"activeCount":101},[],{"trials":3056,"activeCount":101},[3057,3067,3071,3084,3094,3103,3111,3124,3139,3143,3147,3151],{"nctId":3058,"briefTitle":3059,"status":3060,"phases":3061,"start":3062,"conditions":3063,"interventions":3064},"NCT00004097","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and\u002For Recurrent Head and Neck Cancer","UNKNOWN",[89],"1999-08",[1564],[3065,3066,995],"fluorouracil","gemcitabine hydrochloride",{"nctId":1642,"briefTitle":1643,"status":142,"phases":3068,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":19,"conditions":3069,"interventions":3070},[89],[1648,1649,1650,1533,1651],[278,449,1653],{"nctId":3072,"briefTitle":3073,"status":618,"phases":3074,"primaryCompletion":3075,"completion":3075,"start":3076,"enrollment":25,"conditions":3077,"interventions":3083},"NCT02474173","Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer",[89],"2022-10-26","2016-01-15",[1607,3078,3079,1451,3080,3081,3082,1637],"Metastatic Breast Carcinoma","Stage III Breast Cancer AJCC v7","Stage IIIB Breast Cancer AJCC v7","Stage IIIC Breast Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7",[2625,449],{"nctId":3085,"briefTitle":3086,"status":142,"phases":3087,"primaryCompletion":3088,"start":3089,"enrollment":28,"conditions":3090,"interventions":3091},"NCT00002734","Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer",[89],"2001-04","1996-03",[1003,1821],[3092,3093,995,1031],"recombinant interferon alfa","chemotherapy",{"nctId":3095,"briefTitle":3096,"status":142,"phases":3097,"primaryCompletion":3098,"start":3099,"enrollment":188,"conditions":3100,"interventions":3101},"NCT00005065","Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer",[89],"2003-12","2000-01",[1771],[995,1776,3102],"motexafin gadolinium",{"nctId":3104,"briefTitle":3105,"status":142,"phases":3106,"start":3107,"conditions":3108,"interventions":3109},"NCT00020007","Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery",[89],"1999-12",[687,869],[3110,995],"isolated perfusion",{"nctId":3112,"briefTitle":3113,"status":142,"phases":3114,"primaryCompletion":1309,"start":3115,"enrollment":827,"conditions":3116,"interventions":3121},"NCT00028535","Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors",[89],"2001-11",[1219,3117,2706,3118,3119,1579,3120],"Recurrent Breast Cancer","Recurrent Gastric Cancer","Recurrent Non-small Cell Lung Cancer","Recurrent Small Cell Lung Cancer",[3122,995,3123],"trastuzumab","recombinant interleukin-12",{"nctId":3125,"briefTitle":3126,"status":142,"phases":3127,"primaryCompletion":3128,"start":3129,"enrollment":2401,"conditions":3130,"interventions":3138},"NCT01281150","Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2015-04","2011-01",[3131,3132,3133,3134,3135,3136,2613,1222,1223,3137,1637],"Adult Solid Neoplasm","Estrogen Receptor Negative","Estrogen Receptor Positive","HER2\u002FNeu Negative","Male Breast Carcinoma","Progesterone Receptor Negative","Stage IV Breast Cancer",[277,449,1653],{"nctId":1712,"briefTitle":1713,"status":142,"phases":3140,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":1718,"conditions":3141,"interventions":3142},[89],[1720,1721,1722,1723,1724,1725,1726,1727,1728,1729,1730,1731,1732,1733,1734,1735,1736,1737,1738,1739,1740,1741,1742,1743,1744,1745,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757],[53,277,278,449,1653],{"nctId":1760,"briefTitle":1761,"status":618,"phases":3144,"primaryCompletion":1763,"start":1764,"enrollment":1765,"conditions":3145,"interventions":3146},[89],[1767,1768,1769,1770,1771,1772],[1598,1080,1774,1775,995,1776],{"nctId":1778,"briefTitle":1779,"status":142,"phases":3148,"primaryCompletion":1781,"start":1782,"enrollment":28,"conditions":3149,"interventions":3150},[89],[1784,1785,1732,1786,1787,1788,1789,1790,1591],[995,1598,1031,750],{"nctId":3152,"briefTitle":3153,"status":142,"phases":3154,"primaryCompletion":3155,"completion":3155,"start":1171,"enrollment":700,"conditions":3156,"interventions":3218},"NCT00891072","Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",[89],"2011-04",[3157,3158,3159,1244,3160,3161,3162,3163,3164,3165,3166,1056,3167,3168,1245,1246,3169,1247,3170,3171,3172,3173,3174,3175,3176,1057,3177,3178,3179,3180,3181,3182,3183,3184,3185,3186,3187,3188,940,3189,3190,655,1248,3191,1249,3192,3193,3194,3195,3196,3197,3198,1058,3199,658,3200,1333,3201,3202,3203,3204,3205,3206,3207,1059,3208,662,3209,1334,3210,3211,3212,3213,3214,3215,3216,1060,3217,664,15,1251],"Adult Grade III Lymphomatoid Granulomatosis","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Peripheral T-cell Lymphoma","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Marginal Zone Lymphoma","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Marginal Zone Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Marginal Zone Lymphoma",[3219,995,1776],"R-(-)-gossypol acetic acid",{"trials":3221,"activeCount":214,"soonestReadout":2737},[3222,3232,3240,3250,3264,3268,3278,3287,3291,3300,3311,3324,3335,3343,3347,3351,3355,3377,3381,3385,3393],{"nctId":3223,"briefTitle":3224,"status":142,"phases":3225,"primaryCompletion":3226,"completion":3226,"start":3227,"enrollment":1517,"conditions":3228,"interventions":3230},"NCT01100931","A Phase I\u002FII Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)",[89,90],"2012-12","2010-02",[2019,3229],"Solid Tumors",[3231,277,449],"YM155",{"nctId":3233,"briefTitle":3234,"status":155,"phases":3235,"primaryCompletion":1603,"completion":1603,"start":3236,"enrollment":1111,"conditions":3237,"interventions":3239},"NCT04090398","Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones",[90],"2020-08-04",[1620,3238,1465],"Metastatic HER2-Negative Breast Carcinoma",[449],{"nctId":3241,"briefTitle":3242,"status":347,"phases":3243,"primaryCompletion":3244,"completion":3244,"start":3245,"enrollment":97,"conditions":3246,"interventions":3248},"NCT05554380","Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN\u002FAKT Mutations, A ComboMATCH Treatment Trial",[90],"2026-08-31","2023-09-22",[3247,486,487],"Locally Advanced Malignant Solid Neoplasm",[3249,449],"Ipatasertib",{"nctId":3251,"briefTitle":3252,"status":142,"phases":3253,"primaryCompletion":650,"completion":650,"start":3254,"enrollment":3255,"conditions":3256,"interventions":3262},"NCT00031694","Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer",[90],"2002-03",19,[3257,3258,3259,3260,3261],"Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer","Stage III Pancreatic Cancer","Stage IV Pancreatic Cancer",[995,3263],"bryostatin 1",{"nctId":984,"briefTitle":985,"status":142,"phases":3265,"completion":987,"start":988,"conditions":3266,"interventions":3267},[90],[18],[991,992,993,693,994,995],{"nctId":3269,"briefTitle":3270,"status":142,"phases":3271,"primaryCompletion":3272,"completion":3272,"start":3273,"enrollment":3274,"conditions":3275,"interventions":3276},"NCT00059787","Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma",[90],"2010-05","2003-04",56,[1784,2569,1785,1732,1787,1788,1789,1790,1591],[995,1776,3277],"erlotinib",{"nctId":3279,"briefTitle":3280,"status":142,"phases":3281,"primaryCompletion":3282,"completion":3282,"start":2487,"enrollment":3283,"conditions":3284,"interventions":3286},"NCT00368992","S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer",[90],"2010-10",110,[1767,2163,1768,1769,3119,1770,1772,3285],"Stage IV Non-small Cell Lung Cancer",[1697,995,1033],{"nctId":1934,"briefTitle":1935,"status":142,"phases":3288,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1798,"conditions":3289,"interventions":3290},[90],[1941,1942,1943,1944,1536,1538,1541,1549,1551,1552,1945,1946],[53,277,278,449],{"nctId":3292,"briefTitle":3293,"status":142,"phases":3294,"primaryCompletion":3295,"completion":786,"start":1319,"enrollment":827,"conditions":3296,"interventions":3298},"NCT01688609","Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer",[90],"2013-12",[3297,1220,1221],"HER2-positive Breast Cancer",[3299,995,3122],"lapatinib ditosylate",{"nctId":3301,"briefTitle":3302,"status":142,"phases":3303,"primaryCompletion":3304,"start":1912,"enrollment":700,"conditions":3305,"interventions":3310},"NCT00288041","Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma",[90],"2007-09",[3306,3307,3308,3309,1343,1344],"Ciliary Body and Choroid Melanoma, Medium\u002FLarge Size","Extraocular Extension Melanoma","Iris Melanoma","Recurrent Intraocular Melanoma",[1776,995,1062],{"nctId":3312,"briefTitle":3313,"status":618,"phases":3314,"primaryCompletion":3315,"completion":3316,"start":3317,"enrollment":1090,"conditions":3318,"interventions":3323},"NCT00955305","Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",[90],"2016-01","2016-11","2010-03",[1928,3319,3320,3321,3322],"Lung Adenocarcinoma","Recurrent Non-Small Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer","Bronchioloalveolar Lung Carcinoma",[53,277,1099,449],{"nctId":3325,"briefTitle":3326,"status":142,"phases":3327,"primaryCompletion":3328,"completion":3329,"start":1329,"enrollment":1331,"conditions":3330,"interventions":3333},"NCT01280058","Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer",[90],"2016-01-19","2016-01-20",[2658,3331,3332,3261],"Pancreatic Ductal Adenocarcinoma","Recurrent Pancreatic Carcinoma",[277,449,3334],"Wild-type Reovirus",{"nctId":3336,"briefTitle":3337,"status":142,"phases":3338,"primaryCompletion":1576,"start":1764,"enrollment":3339,"conditions":3340,"interventions":3341},"NCT00040794","Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer",[90],144,[1767,2163,1768,1769,1770,1771,1772],[995,1776,3342],"gefitinib",{"nctId":2734,"briefTitle":2735,"status":155,"phases":3344,"primaryCompletion":2737,"completion":2642,"start":2738,"enrollment":1357,"conditions":3345,"interventions":3346},[90],[1724,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2616,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2782,2783,2784,2785,2786,2787],[68,2124,2554,449,2789,2790],{"nctId":1213,"briefTitle":1214,"status":142,"phases":3348,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":1074,"conditions":3349,"interventions":3350},[89,90],[18,1219,1220,1221,1222,1223],[1185,995,1225,693],{"nctId":437,"briefTitle":438,"status":155,"phases":3352,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":3353,"interventions":3354},[90],[445,446,447],[240,96,449],{"nctId":3356,"briefTitle":3357,"status":155,"phases":3358,"primaryCompletion":3359,"completion":1108,"start":3360,"enrollment":421,"conditions":3361,"interventions":3375},"NCT04175912","Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver",[90],"2023-11-27","2020-03-16",[3362,803,3363,3364,3365,3366,3367,3368,3369,3370,3371,3372,3373,2152,3374],"Metastatic Cholangiocarcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8","Unresectable Cholangiocarcinoma","Unresectable Intrahepatic Cholangiocarcinoma",[277,449,3376],"Pevonedistat",{"nctId":1285,"briefTitle":1286,"status":142,"phases":3378,"completion":1288,"start":1289,"enrollment":913,"conditions":3379,"interventions":3380},[90],[18,1291],[1268,1293,1294,693,995,1225],{"nctId":1296,"briefTitle":1297,"status":618,"phases":3382,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":3383,"interventions":3384},[89,90],[1291,1302],[991,1304,750,993,693,994,819,995,722],{"nctId":3386,"briefTitle":3387,"status":142,"phases":3388,"primaryCompletion":3389,"completion":3317,"start":3390,"enrollment":638,"conditions":3391,"interventions":3392},"NCT00057863","Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer",[90],"2009-12","2003-01",[1648,1649,1680,1533,1592,1594],[449,2925],{"nctId":3394,"briefTitle":3395,"status":142,"phases":3396,"completion":3397,"start":3398,"conditions":3399,"interventions":3400},"NCT00020449","Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma",[90],"2004-05","2001-01",[625],[3123,995,3401],"pegylated liposomal doxorubicin hydrochloride",{"trials":3403,"activeCount":889,"soonestReadout":52},[3404,3408,3421,3437,3441,3445,3449,3459,3463,3471,3475],{"nctId":2086,"briefTitle":2087,"status":128,"phases":3405,"primaryCompletion":2089,"completion":2089,"start":2090,"enrollment":2091,"conditions":3406,"interventions":3407},[91],[2093,2094,2095,2096,2097,2098,2099,2100],[277,278,449,883],{"nctId":50,"briefTitle":51,"status":155,"phases":3409,"primaryCompletion":52,"completion":3410,"start":3411,"enrollment":234,"conditions":3412,"interventions":3420},[91],"2027-03-12","2010-10-12",[3413,1787,250,251,3414,3415,3416,3417,3418,3419,1740,1741,1742,1743,1744,1745,1746,1747,1749,1750,1752,1753,1755,1756],"Borderline Ovarian Mucinous Tumor","Stage IA Fallopian Tube Cancer AJCC v6 and v7","Stage IA Ovarian Cancer AJCC v6 and v7","Stage IB Fallopian Tube Cancer AJCC v6 and v7","Stage IB Ovarian Cancer AJCC v6 and v7","Stage IC Fallopian Tube Cancer AJCC v6 and v7","Stage IC Ovarian Cancer AJCC v6 and v7",[53,2924,277,2925,449],{"nctId":3422,"briefTitle":3423,"status":128,"phases":3424,"primaryCompletion":2654,"completion":2654,"start":3425,"enrollment":3426,"conditions":3427,"interventions":3434},"NCT05256225","Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma",[91],"2022-11-16",360,[3428,1943,3429,3430,3431,1944,3432,3433],"Endometrial Carcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor",[277,3435,449,3436],"Hyaluronidase-zzxf\u002FPertuzumab\u002FTrastuzumab","Trastuzumab\u002FHyaluronidase-oysk",{"nctId":2810,"briefTitle":2811,"status":155,"phases":3438,"primaryCompletion":2813,"completion":2642,"start":2814,"enrollment":2815,"conditions":3439,"interventions":3440},[90,91],[1722,1723,2645,1726,1727,1731,1732,2740,1735,1736,1737,1739,250,251,252],[2732,68,2554,449,2789,1407,2790],{"nctId":1437,"briefTitle":1438,"status":142,"phases":3442,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":1443,"conditions":3443,"interventions":3444},[91],[1445,1446,1447,1448,1449,1450,1451],[1453,63,737,449,1454,1455],{"nctId":2111,"briefTitle":2112,"status":155,"phases":3446,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":3447,"interventions":3448},[91],[2118,1626,2119,2120,2121,2122],[277,278,2124,279,449,2045],{"nctId":3450,"briefTitle":3451,"status":142,"phases":3452,"primaryCompletion":3453,"start":3454,"enrollment":3455,"conditions":3456,"interventions":3458},"NCT00002852","Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer",[91],"2004-07","1996-10",500,[1767,2163,1768,1769,1770,3457],"Stage IB Non-small Cell Lung Cancer",[995,1776],{"nctId":589,"briefTitle":590,"status":155,"phases":3460,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":3461,"interventions":3462},[91],[596,597,598,599,600,330,601],[277,96,449],{"nctId":3464,"briefTitle":3465,"status":618,"phases":3466,"primaryCompletion":3389,"completion":3317,"start":3099,"enrollment":3467,"conditions":3468,"interventions":3469},"NCT00004859","Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer",[91],589,[687],[1776,995,3470],"thalidomide",{"nctId":2157,"briefTitle":2158,"status":142,"phases":3472,"primaryCompletion":2160,"start":1979,"enrollment":2161,"conditions":3473,"interventions":3474},[91],[1767,2163,1769,1770,1771,1772],[2165,1598,2166,1776,995],{"nctId":3476,"briefTitle":3477,"status":142,"phases":3478,"primaryCompletion":3479,"completion":3128,"start":3480,"enrollment":3481,"conditions":3482,"interventions":3498},"NCT00262847","Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",[91],"2010-11","2005-09",1873,[1722,1723,1724,2645,1726,3483,1728,1731,1732,1733,1735,1736,1739,3484,3485,3486,3487,3488,3489,3490,3491,3492,3493,3494,3495,3496,3497],"Malignant Ovarian Mixed Epithelial Tumor","Stage IIIA Fallopian Tube Cancer","Stage IIIA Ovarian Cancer","Stage IIIA Primary Peritoneal Cancer","Stage IIIB Fallopian Tube Cancer","Stage IIIB Ovarian Cancer","Stage IIIB Primary Peritoneal Cancer","Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Cancer","Stage IIIC Primary Peritoneal Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Cancer","Stage IV Primary Peritoneal Cancer","Undifferentiated Fallopian Tube Carcinoma","Undifferentiated Ovarian Carcinoma",[53,277,449],{"trials":3500,"activeCount":101},[],{"trials":3502,"activeCount":101},[],{"intervention":277,"totalTrials":421,"cells":3504},{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3573,"PHASE3":3675,"PHASE4":3733,"NA":3735},{"trials":3506,"activeCount":101},[],{"trials":3508,"activeCount":101},[3509,3522,3529,3536,3540,3544,3548,3552,3556,3560,3564],{"nctId":3510,"briefTitle":3511,"status":142,"phases":3512,"primaryCompletion":3513,"completion":3514,"start":3515,"enrollment":827,"conditions":3516,"interventions":3521},"NCT01352962","Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced\u002FMetastatic Urothelial Cancer and Other Solid Tumors",[89],"2017-02-07","2018-07-06","2011-09-26",[3517,3518,3519,3520],"Urethral Neoplasms","Neoplasms, Urethral","Cancer of the Urethra","Urethral Cancer",[289,277,1016],{"nctId":3523,"briefTitle":3524,"status":142,"phases":3525,"primaryCompletion":3526,"start":3254,"enrollment":28,"conditions":3527,"interventions":3528},"NCT00036777","UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors",[89],"2004-10",[15],[1776,2184],{"nctId":3530,"briefTitle":3531,"status":142,"phases":3532,"primaryCompletion":1426,"start":3533,"enrollment":2029,"conditions":3534,"interventions":3535},"NCT00027898","Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors",[89],"2002-01",[15],[1062,1776,1080],{"nctId":2561,"briefTitle":2562,"status":142,"phases":3537,"primaryCompletion":2564,"completion":2565,"start":2566,"enrollment":1054,"conditions":3538,"interventions":3539},[89],[1003,18,2568,2569,2570],[277,2554],{"nctId":2837,"briefTitle":2838,"status":142,"phases":3541,"primaryCompletion":2840,"completion":2841,"start":2842,"enrollment":603,"conditions":3542,"interventions":3543},[89],[274,2681,2844],[1690,277,474,279],{"nctId":3095,"briefTitle":3096,"status":142,"phases":3545,"primaryCompletion":3098,"start":3099,"enrollment":188,"conditions":3546,"interventions":3547},[89],[1771],[995,1776,3102],{"nctId":3125,"briefTitle":3126,"status":142,"phases":3549,"primaryCompletion":3128,"start":3129,"enrollment":2401,"conditions":3550,"interventions":3551},[89],[3131,3132,3133,3134,3135,3136,2613,1222,1223,3137,1637],[277,449,1653],{"nctId":1712,"briefTitle":1713,"status":142,"phases":3553,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":1718,"conditions":3554,"interventions":3555},[89],[1720,1721,1722,1723,1724,1725,1726,1727,1728,1729,1730,1731,1732,1733,1734,1735,1736,1737,1738,1739,1740,1741,1742,1743,1744,1745,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757],[53,277,278,449,1653],{"nctId":1760,"briefTitle":1761,"status":618,"phases":3557,"primaryCompletion":1763,"start":1764,"enrollment":1765,"conditions":3558,"interventions":3559},[89],[1767,1768,1769,1770,1771,1772],[1598,1080,1774,1775,995,1776],{"nctId":3152,"briefTitle":3153,"status":142,"phases":3561,"primaryCompletion":3155,"completion":3155,"start":1171,"enrollment":700,"conditions":3562,"interventions":3563},[89],[3157,3158,3159,1244,3160,3161,3162,3163,3164,3165,3166,1056,3167,3168,1245,1246,3169,1247,3170,3171,3172,3173,3174,3175,3176,1057,3177,3178,3179,3180,3181,3182,3183,3184,3185,3186,3187,3188,940,3189,3190,655,1248,3191,1249,3192,3193,3194,3195,3196,3197,3198,1058,3199,658,3200,1333,3201,3202,3203,3204,3205,3206,3207,1059,3208,662,3209,1334,3210,3211,3212,3213,3214,3215,3216,1060,3217,664,15,1251],[3219,995,1776],{"nctId":3565,"briefTitle":3566,"status":142,"phases":3567,"primaryCompletion":3568,"completion":3568,"start":3569,"enrollment":34,"conditions":3570,"interventions":3572},"NCT02219737","Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",[89],"2017-05-11","2014-09-12",[3571,527,537],"CD20 Positive",[277,279,58,1101,667],{"trials":3574,"activeCount":603,"soonestReadout":3621},[3575,3579,3583,3592,3596,3605,3609,3613,3617,3630,3634,3642,3646,3650,3654,3658,3667],{"nctId":1824,"briefTitle":1825,"status":142,"phases":3576,"primaryCompletion":1827,"completion":1828,"start":1829,"enrollment":286,"conditions":3577,"interventions":3578},[89,90],[274,275],[277,278,279,1832],{"nctId":3223,"briefTitle":3224,"status":142,"phases":3580,"primaryCompletion":3226,"completion":3226,"start":3227,"enrollment":1517,"conditions":3581,"interventions":3582},[89,90],[2019,3229],[3231,277,449],{"nctId":3584,"briefTitle":3585,"status":142,"phases":3586,"primaryCompletion":3587,"start":3397,"enrollment":37,"conditions":3588,"interventions":3589},"NCT00086944","Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",[89,90],"2006-07",[3181,940,3189],[3590,1063,3591,1776,1080,750,1066],"oblimersen sodium","ifosfamide",{"nctId":266,"briefTitle":267,"status":142,"phases":3593,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":3594,"interventions":3595},[90],[274,275],[277,278,279,96],{"nctId":3597,"briefTitle":3598,"status":142,"phases":3599,"primaryCompletion":307,"completion":307,"start":3600,"enrollment":1054,"conditions":3601,"interventions":3604},"NCT01149083","Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer",[90],"2010-06-30",[1619,1620,3602,3078,3603],"Locally Advanced Breast Carcinoma","Unresectable Breast Carcinoma",[277,1653],{"nctId":281,"briefTitle":282,"status":128,"phases":3606,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":3607,"interventions":3608},[90],[236,237,238],[277,278,289,96,290],{"nctId":3269,"briefTitle":3270,"status":142,"phases":3610,"primaryCompletion":3272,"completion":3272,"start":3273,"enrollment":3274,"conditions":3611,"interventions":3612},[90],[1784,2569,1785,1732,1787,1788,1789,1790,1591],[995,1776,3277],{"nctId":1934,"briefTitle":1935,"status":142,"phases":3614,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1798,"conditions":3615,"interventions":3616},[90],[1941,1942,1943,1944,1536,1538,1541,1549,1551,1552,1945,1946],[53,277,278,449],{"nctId":3618,"briefTitle":3619,"status":155,"phases":3620,"primaryCompletion":3621,"completion":3039,"start":3622,"enrollment":37,"conditions":3623,"interventions":3629},"NCT03289910","Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia",[90],"2023-05-31","2018-09-24",[263,2452,3624,2453,3625,3626,3627,3628,2427,2430],"Atypical Chronic Myeloid Leukemia","Essential Thrombocythemia","Myelodysplastic\u002FMyeloproliferative Neoplasm","Myelofibrosis","Polycythemia Vera",[277,1407,2790,1653],{"nctId":3301,"briefTitle":3302,"status":142,"phases":3631,"primaryCompletion":3304,"start":1912,"enrollment":700,"conditions":3632,"interventions":3633},[90],[3306,3307,3308,3309,1343,1344],[1776,995,1062],{"nctId":3635,"briefTitle":3636,"status":142,"phases":3637,"primaryCompletion":1781,"start":3638,"enrollment":3639,"conditions":3640,"interventions":3641},"NCT00075751","Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer",[90],"2004-01",99,[3119,1772,3285],[3066,1776,1062],{"nctId":3312,"briefTitle":3313,"status":618,"phases":3643,"primaryCompletion":3315,"completion":3316,"start":3317,"enrollment":1090,"conditions":3644,"interventions":3645},[90],[1928,3319,3320,3321,3322],[53,277,1099,449],{"nctId":3325,"briefTitle":3326,"status":142,"phases":3647,"primaryCompletion":3328,"completion":3329,"start":1329,"enrollment":1331,"conditions":3648,"interventions":3649},[90],[2658,3331,3332,3261],[277,449,3334],{"nctId":3336,"briefTitle":3337,"status":142,"phases":3651,"primaryCompletion":1576,"start":1764,"enrollment":3339,"conditions":3652,"interventions":3653},[90],[1767,2163,1768,1769,1770,1771,1772],[995,1776,3342],{"nctId":3356,"briefTitle":3357,"status":155,"phases":3655,"primaryCompletion":3359,"completion":1108,"start":3360,"enrollment":421,"conditions":3656,"interventions":3657},[90],[3362,803,3363,3364,3365,3366,3367,3368,3369,3370,3371,3372,3373,2152,3374],[277,449,3376],{"nctId":3659,"briefTitle":3660,"status":142,"phases":3661,"primaryCompletion":1977,"completion":1217,"start":3662,"enrollment":1074,"conditions":3663,"interventions":3665},"NCT00005976","Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma",[90],"2000-05",[3664],"Brain and Central Nervous System Tumors",[1776,3666],"pyrazoloacridine",{"nctId":3668,"briefTitle":3669,"status":142,"phases":3670,"primaryCompletion":3671,"start":3273,"enrollment":913,"conditions":3672,"interventions":3674},"NCT00042978","Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer",[90],"2005-05",[3673,3120],"Extensive Stage Small Cell Lung Cancer",[3590,1776,1080],{"trials":3676,"activeCount":1024,"soonestReadout":52},[3677,3681,3685,3689,3693,3697,3709,3713,3717,3721,3725,3729],{"nctId":70,"briefTitle":71,"status":155,"phases":3678,"primaryCompletion":72,"completion":2050,"start":2051,"enrollment":2052,"conditions":3679,"interventions":3680},[91],[2054,1867,1868,1869,1870,2055,1873,1874,2056,2057,2058,2059,2060,2061,2062,2063,2064,2065,2066,2067,2068,2069,2070,2071,2072,2073,2074,2075,2076,2077,2078,2079,2080,2081,1895],[53,277,278,2083,2084],{"nctId":2086,"briefTitle":2087,"status":128,"phases":3682,"primaryCompletion":2089,"completion":2089,"start":2090,"enrollment":2091,"conditions":3683,"interventions":3684},[91],[2093,2094,2095,2096,2097,2098,2099,2100],[277,278,449,883],{"nctId":1393,"briefTitle":1394,"status":128,"phases":3686,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":3687,"interventions":3688},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":50,"briefTitle":51,"status":155,"phases":3690,"primaryCompletion":52,"completion":3410,"start":3411,"enrollment":234,"conditions":3691,"interventions":3692},[91],[3413,1787,250,251,3414,3415,3416,3417,3418,3419,1740,1741,1742,1743,1744,1745,1746,1747,1749,1750,1752,1753,1755,1756],[53,2924,277,2925,449],{"nctId":3422,"briefTitle":3423,"status":128,"phases":3694,"primaryCompletion":2654,"completion":2654,"start":3425,"enrollment":3426,"conditions":3695,"interventions":3696},[91],[3428,1943,3429,3430,3431,1944,3432,3433],[277,3435,449,3436],{"nctId":3698,"briefTitle":3699,"status":107,"phases":3700,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":3703,"interventions":3706},"NCT05711628","A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed\u002FRefractory Classical Hodgkin Lymphoma",[91],"2028-06-30","2023-08-10",[3704,3705],"Recurrent Classic Hodgkin Lymphoma","Refractory Classic Hodgkin Lymphoma",[3707,1511,277,279,289,1101,2789,883,3708],"Bendamustine","Vinorelbine",{"nctId":2111,"briefTitle":2112,"status":155,"phases":3710,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":3711,"interventions":3712},[91],[2118,1626,2119,2120,2121,2122],[277,278,2124,279,449,2045],{"nctId":3450,"briefTitle":3451,"status":142,"phases":3714,"primaryCompletion":3453,"start":3454,"enrollment":3455,"conditions":3715,"interventions":3716},[91],[1767,2163,1768,1769,1770,3457],[995,1776],{"nctId":589,"briefTitle":590,"status":155,"phases":3718,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":3719,"interventions":3720},[91],[596,597,598,599,600,330,601],[277,96,449],{"nctId":3464,"briefTitle":3465,"status":618,"phases":3722,"primaryCompletion":3389,"completion":3317,"start":3099,"enrollment":3467,"conditions":3723,"interventions":3724},[91],[687],[1776,995,3470],{"nctId":2157,"briefTitle":2158,"status":142,"phases":3726,"primaryCompletion":2160,"start":1979,"enrollment":2161,"conditions":3727,"interventions":3728},[91],[1767,2163,1769,1770,1771,1772],[2165,1598,2166,1776,995],{"nctId":3476,"briefTitle":3477,"status":142,"phases":3730,"primaryCompletion":3479,"completion":3128,"start":3480,"enrollment":3481,"conditions":3731,"interventions":3732},[91],[1722,1723,1724,2645,1726,3483,1728,1731,1732,1733,1735,1736,1739,3484,3485,3486,3487,3488,3489,3490,3491,3492,3493,3494,3495,3496,3497],[53,277,449],{"trials":3734,"activeCount":101},[],{"trials":3736,"activeCount":101},[],{"intervention":883,"totalTrials":455,"cells":3738},{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3757,"PHASE3":3883,"PHASE4":3925,"NA":3927},{"trials":3740,"activeCount":101},[],{"trials":3742,"activeCount":101},[3743],{"nctId":3744,"briefTitle":3745,"status":142,"phases":3746,"primaryCompletion":3747,"completion":3748,"start":3749,"enrollment":16,"conditions":3750,"interventions":3755},"NCT02595866","Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer",[89],"2023-10-04","2024-03-25","2016-04-04",[3751,190,192,801,939,135,3752,3247,2885,486,195,2193,3704,3753,3705,3754,1626,1633,209],"AIDS-Related Non-Hodgkin Lymphoma","Locally Advanced Lung Non-Small Cell Carcinoma","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm",[3756,883],"Antiretroviral Therapy",{"trials":3758,"activeCount":889,"soonestReadout":3767},[3759,3763,3775,3785,3794,3803,3829,3842,3851,3864],{"nctId":874,"briefTitle":875,"status":128,"phases":3760,"primaryCompletion":232,"completion":877,"start":878,"enrollment":879,"conditions":3761,"interventions":3762},[90],[36],[882,883,677,643,63],{"nctId":3764,"briefTitle":3765,"status":155,"phases":3766,"primaryCompletion":3767,"completion":3768,"start":3769,"enrollment":3770,"conditions":3771,"interventions":3774},"NCT03698019","A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma",[90],"2022-09-01","2026-10-30","2019-02-15",313,[3772,190,192,3773],"Acral Lentiginous Melanoma","Mucosal Melanoma",[883],{"nctId":3776,"briefTitle":3777,"status":155,"phases":3778,"primaryCompletion":3779,"completion":3780,"start":3781,"enrollment":2294,"conditions":3782,"interventions":3784},"NCT02775851","Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery",[90],"2023-04-14","2027-05-15","2017-02-06",[3783],"Desmoplastic Melanoma",[883],{"nctId":3786,"briefTitle":3787,"status":155,"phases":3788,"primaryCompletion":361,"completion":361,"start":3789,"enrollment":1074,"conditions":3790,"interventions":3792},"NCT04708418","A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma",[90],"2021-10-15",[190,3791,202,204,205,2543],"Melanoma of Unknown Primary",[883,3793],"VLP-encapsulated TLR9 Agonist CMP-001",{"nctId":3795,"briefTitle":3796,"status":155,"phases":3797,"primaryCompletion":3798,"completion":1366,"start":3799,"enrollment":3800,"conditions":3801,"interventions":3802},"NCT03126630","Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma",[89,90],"2023-05-04","2018-10-04",49,[2041],[166,883],{"nctId":3804,"briefTitle":3805,"status":142,"phases":3806,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":31,"conditions":3810,"interventions":3827},"NCT03063632","Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma",[90],"2021-04-08","2023-03-14","2017-12-14",[3811,3812,3813,3814,3815,3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826],"Metastatic Myxoid Liposarcoma","Metastatic Round Cell Liposarcoma","Metastatic Synovial Sarcoma","Recurrent Mycosis Fungoides and Sezary Syndrome","Refractory Mycosis Fungoides and Sezary Syndrome","Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7","Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7","Unresectable Synovial Sarcoma",[3828,883],"Interferon Gamma-1b",{"nctId":3830,"briefTitle":3831,"status":107,"phases":3832,"primaryCompletion":3833,"completion":3833,"start":3833,"enrollment":101,"conditions":3834,"interventions":3839},"NCT05879484","Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent\u002FMetastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS",[89,90],"2025-07-09",[3835,3836,687,3837,3838,1564],"Sinonasal Cancer","Squamous Non-small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Head and Neck Carcnimona",[3840,3841],"pembrolizumab","valemetostat",{"nctId":3843,"briefTitle":3844,"status":618,"phases":3845,"primaryCompletion":3846,"completion":3846,"start":3847,"enrollment":443,"conditions":3848,"interventions":3849},"NCT03018288","Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)",[90],"2022-12-20","2017-09-21",[394],[883,3850,151],"HSPPC-96",{"nctId":3852,"briefTitle":3853,"status":142,"phases":3854,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":375,"conditions":3858,"interventions":3863},"NCT03111732","Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",[90],"2020-07-22","2021-11-08","2017-06-14",[3859,854,3860,3861,3862],"Biliary Tract Neoplasms","Bile Duct Cancer","Liver Cancer","Gallbladder Cancer",[883,2925,2924],{"nctId":3865,"briefTitle":3866,"status":155,"phases":3867,"primaryCompletion":2930,"completion":2930,"start":3868,"enrollment":3869,"conditions":3870,"interventions":3882},"NCT05172258","Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck",[90],"2022-07-26",52,[3837,3871,3872,3873,3874,3875,3876,1867,1868,3877,1874,3878,3879,3880,3881],"Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hypopharyngeal Squamous Cell Carcinoma","Metastatic Laryngeal Squamous Cell Carcinoma","Metastatic Oral Cavity Squamous Cell Carcinoma","Metastatic Oropharyngeal Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8",[3249,883],{"trials":3884,"activeCount":214,"soonestReadout":2534},[3885,3900,3913,3917,3921],{"nctId":3886,"briefTitle":3887,"status":128,"phases":3888,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":3891,"conditions":3892,"interventions":3899},"NCT06589804","Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment",[91],"2029-11-30","2025-03-27",158,[3871,3872,3873,3874,3875,3876,1867,1868,2055,3877,1874,3893,3894,3895,3896,3897,3898,3878,3879,3880,3881],"Refractory Head and Neck Squamous Cell Carcinoma","Refractory Hypopharyngeal Squamous Cell Carcinoma","Refractory Laryngeal Squamous Cell Carcinoma","Refractory Oral Cavity Squamous Cell Carcinoma","Refractory Oropharyngeal Squamous Cell Carcinoma","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",[1570,883],{"nctId":3901,"briefTitle":3902,"status":155,"phases":3903,"primaryCompletion":3904,"completion":3904,"start":3905,"enrollment":3906,"conditions":3907,"interventions":3912},"NCT02954874","Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer",[91],"2027-05-31","2017-01-18",1155,[3908,3909,3910,3911,3079,1637],"Breast Carcinoma In Situ","Invasive Breast Carcinoma","Stage I Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7",[883],{"nctId":2086,"briefTitle":2087,"status":128,"phases":3914,"primaryCompletion":2089,"completion":2089,"start":2090,"enrollment":2091,"conditions":3915,"interventions":3916},[91],[2093,2094,2095,2096,2097,2098,2099,2100],[277,278,449,883],{"nctId":2531,"briefTitle":2532,"status":155,"phases":3918,"primaryCompletion":2534,"completion":2535,"start":2536,"enrollment":2537,"conditions":3919,"interventions":3920},[91],[190,192,2539,2540,2541,2542,2543,2544,2545],[124,883,2547],{"nctId":3698,"briefTitle":3699,"status":107,"phases":3922,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":3923,"interventions":3924},[91],[3704,3705],[3707,1511,277,279,289,1101,2789,883,3708],{"trials":3926,"activeCount":101},[],{"trials":3928,"activeCount":101},[],{"intervention":2217,"totalTrials":685,"cells":3930},{"EARLY_PHASE1":3931,"PHASE1":3933,"PHASE2":3951,"PHASE3":4006,"PHASE4":4017,"NA":4019},{"trials":3932,"activeCount":101},[],{"trials":3934,"activeCount":603,"soonestReadout":2209},[3935,3943,3947],{"nctId":3936,"briefTitle":3937,"status":155,"phases":3938,"primaryCompletion":1603,"completion":1603,"start":3939,"enrollment":16,"conditions":3940,"interventions":3941},"NCT03041688","Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia",[89],"2018-02-08",[263,2427,2430,2432],[2435,3942,2217],"Navtemadlin",{"nctId":2186,"briefTitle":2187,"status":155,"phases":3944,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1798,"conditions":3945,"interventions":3946},[89],[27,2193,2194,773],[2196,1082,2197,2198,2199,2200],{"nctId":2206,"briefTitle":2207,"status":155,"phases":3948,"primaryCompletion":2209,"completion":418,"start":2210,"enrollment":2211,"conditions":3949,"interventions":3950},[89],[2213,2214],[2216,212,1016,2217,58,706,2218,2219],{"trials":3952,"activeCount":889,"soonestReadout":3971},[3953,3957,3967,3977,3987,3995],{"nctId":2231,"briefTitle":2232,"status":128,"phases":3954,"primaryCompletion":2234,"completion":2234,"start":2235,"enrollment":1357,"conditions":3955,"interventions":3956},[90],[2237,527,2238,2239,529,530,2240,534,537,2241,2242,539,540,2243,543],[58,1016,2216,212,2217],{"nctId":3958,"briefTitle":3959,"status":128,"phases":3960,"primaryCompletion":3961,"completion":3961,"start":3962,"enrollment":552,"conditions":3963,"interventions":3966},"NCT06311227","Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia",[90],"2027-05-20","2024-12-16",[3964,3965],"Recurrent Hairy Cell Leukemia","Recurrent Hairy Cell Leukemia Variant",[2217],{"nctId":3968,"briefTitle":3969,"status":155,"phases":3970,"primaryCompletion":3971,"completion":3972,"start":3973,"enrollment":838,"conditions":3974,"interventions":3975},"NCT04817241","Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients",[89,90],"2025-06-06","2026-11-05","2022-02-10",[263],[1137,1373,3976,2217],"Decitabine and Cedazuridine",{"nctId":3978,"briefTitle":3979,"status":3027,"phases":3980,"primaryCompletion":3981,"completion":3981,"start":3982,"enrollment":3983,"conditions":3984,"interventions":3985},"NCT07153497","Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)",[90],"2030-04-26","2026-05-27",132,[263,2454],[3976,3986,2217],"Olutasidenib",{"nctId":3988,"briefTitle":3989,"status":3027,"phases":3990,"primaryCompletion":3991,"completion":3991,"start":2728,"enrollment":3992,"conditions":3993,"interventions":3994},"NCT06954987","Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow\u002FBlood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)",[90],"2028-05-15",244,[263],[980,643,1405,2217],{"nctId":3996,"briefTitle":3997,"status":128,"phases":3998,"primaryCompletion":3999,"completion":3999,"start":4000,"enrollment":4001,"conditions":4002,"interventions":4004},"NCT04840602","Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia\u002FLymphoplasmacytic Lymphoma",[90],"2028-03-31","2022-01-05",92,[1485,4003],"Waldenstrom Macroglobulinemia",[58,667,2217,4005],"Zanubrutinib",{"trials":4007,"activeCount":2548,"soonestReadout":2703},[4008],{"nctId":4009,"briefTitle":4010,"status":128,"phases":4011,"primaryCompletion":2703,"completion":2703,"start":4012,"enrollment":4013,"conditions":4014,"interventions":4016},"NCT04269902","Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL\u002FSLL Study",[91],"2021-03-02",247,[653,4015],"Small Lymphocytic Lymphoma",[2216,2217],{"trials":4018,"activeCount":101},[],{"trials":4020,"activeCount":101},[],{"intervention":279,"totalTrials":700,"cells":4022},{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4092,"PHASE3":4209,"PHASE4":4245,"NA":4247},{"trials":4024,"activeCount":101},[],{"trials":4026,"activeCount":2548,"soonestReadout":727},[4027,4064,4068,4072,4076,4080,4084,4088],{"nctId":4028,"briefTitle":4029,"status":142,"phases":4030,"primaryCompletion":4031,"start":4032,"enrollment":37,"conditions":4033,"interventions":4062},"NCT00357305","Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and\u002For Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders",[89],"2011-11","2006-05",[4034,4035,4036,4037,4038,4039,4040,4041,4042,4043,4044,4045,4046,4047,4048,4049,4050,4051,4052,4053,4054,2453,4055,4056,3625,4057,3628,4058,4059,1135,33,4060,2432,4061],"Accelerated Phase Chronic Myelogenous Leukemia","Adult Acute Basophilic Leukemia","Adult Acute Eosinophilic Leukemia","Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Acute Promyelocytic Leukemia (M3)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Blastic Phase Chronic Myelogenous Leukemia","Chronic Eosinophilic Leukemia","Chronic Neutrophilic Leukemia","de Novo Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Previously Treated Myelodysplastic Syndromes","Primary Myelofibrosis","Relapsing Chronic Myelogenous Leukemia","Secondary Myelodysplastic Syndromes",[4063,1187,1080],"vorinostat",{"nctId":3530,"briefTitle":3531,"status":142,"phases":4065,"primaryCompletion":1426,"start":3533,"enrollment":2029,"conditions":4066,"interventions":4067},[89],[15],[1062,1776,1080],{"nctId":2837,"briefTitle":2838,"status":142,"phases":4069,"primaryCompletion":2840,"completion":2841,"start":2842,"enrollment":603,"conditions":4070,"interventions":4071},[89],[274,2681,2844],[1690,277,474,279],{"nctId":724,"briefTitle":725,"status":155,"phases":4073,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":4074,"interventions":4075},[89],[732,733,734,735],[63,737,279,738,58,739,212,667,740],{"nctId":1699,"briefTitle":1700,"status":142,"phases":4077,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":31,"conditions":4078,"interventions":4079},[89],[1706,1707,1708],[1710,278,279],{"nctId":766,"briefTitle":767,"status":618,"phases":4081,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":4082,"interventions":4083},[89],[773,774,775,776,777],[667,279,779,63,780,781,212],{"nctId":1760,"briefTitle":1761,"status":618,"phases":4085,"primaryCompletion":1763,"start":1764,"enrollment":1765,"conditions":4086,"interventions":4087},[89],[1767,1768,1769,1770,1771,1772],[1598,1080,1774,1775,995,1776],{"nctId":3565,"briefTitle":3566,"status":142,"phases":4089,"primaryCompletion":3568,"completion":3568,"start":3569,"enrollment":34,"conditions":4090,"interventions":4091},[89],[3571,527,537],[277,279,58,1101,667],{"trials":4093,"activeCount":603,"soonestReadout":62},[4094,4098,4102,4106,4110,4114,4118,4134,4138,4145,4149,4153,4157,4161,4181,4185,4189,4193,4197,4201,4205],{"nctId":1804,"briefTitle":1805,"status":142,"phases":4095,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":4096,"interventions":4097},[90],[1811,1812],[278,1099,279,1814],{"nctId":1824,"briefTitle":1825,"status":142,"phases":4099,"primaryCompletion":1827,"completion":1828,"start":1829,"enrollment":286,"conditions":4100,"interventions":4101},[89,90],[274,275],[277,278,279,1832],{"nctId":3584,"briefTitle":3585,"status":142,"phases":4103,"primaryCompletion":3587,"start":3397,"enrollment":37,"conditions":4104,"interventions":4105},[89,90],[3181,940,3189],[3590,1063,3591,1776,1080,750,1066],{"nctId":1834,"briefTitle":1835,"status":128,"phases":4107,"primaryCompletion":1837,"completion":1838,"start":900,"enrollment":1074,"conditions":4108,"interventions":4109},[90],[1840,1841,1842,1843,1844],[1710,278,279],{"nctId":923,"briefTitle":924,"status":142,"phases":4111,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":4112,"interventions":4113},[89,90],[931,932,933,934,733,935,936,734,937,735,938,939,522,524,527,940],[63,737,279,212,667,740,942],{"nctId":266,"briefTitle":267,"status":142,"phases":4115,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":4116,"interventions":4117},[90],[274,275],[277,278,279,96],{"nctId":4119,"briefTitle":4120,"status":142,"phases":4121,"primaryCompletion":4122,"completion":4123,"start":4124,"enrollment":4125,"conditions":4126,"interventions":4133},"NCT00416598","Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia",[90],"2011-01-31","2016-12-01","2006-11-15",546,[263,4127,4128,4129,4130,4131,4132],"Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A","Untreated Adult Acute Myeloid Leukemia",[980,1137,1374,2435,279,738],{"nctId":1007,"briefTitle":1008,"status":155,"phases":4135,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":407,"conditions":4136,"interventions":4137},[89,90],[524,1014],[1016,667,212,279,780,781,63],{"nctId":4139,"briefTitle":4140,"status":142,"phases":4141,"primaryCompletion":4142,"start":1356,"enrollment":421,"conditions":4143,"interventions":4144},"NCT00003575","Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma",[90],"2002-04",[27],[750,3123,1080,3591],{"nctId":1068,"briefTitle":1069,"status":142,"phases":4146,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":4147,"interventions":4148},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":1086,"briefTitle":1087,"status":142,"phases":4150,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":4151,"interventions":4152},[90],[1092,1093,1094,1095,1096,1097],[1099,63,1100,737,279,1101,1102,151,1103],{"nctId":1921,"briefTitle":1922,"status":142,"phases":4154,"primaryCompletion":1924,"completion":1925,"start":1926,"enrollment":286,"conditions":4155,"interventions":4156},[89,90],[1811,1928,1929,1930,1931],[278,279,1653],{"nctId":1949,"briefTitle":1950,"status":142,"phases":4158,"primaryCompletion":1021,"completion":1021,"start":1952,"enrollment":1953,"conditions":4159,"interventions":4160},[90],[1955],[751,1598,1080],{"nctId":4162,"briefTitle":4163,"status":142,"phases":4164,"primaryCompletion":3226,"completion":3226,"start":4165,"enrollment":3869,"conditions":4166,"interventions":4179},"NCT00666588","Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia",[90],"2008-04",[4039,4040,4041,4042,4043,4167,4045,4046,4048,4168,4169,4170,4171,4172,4173,4174,4175,4176,4177,33,4178,2432],"Adult Acute Myeloid Leukemia With Del(5q)","Childhood Acute Basophilic Leukemia","Childhood Acute Eosinophilic Leukemia","Childhood Acute Erythroleukemia (M6)","Childhood Acute Megakaryocytic Leukemia (M7)","Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)","Childhood Acute Monoblastic Leukemia (M5a)","Childhood Acute Monocytic Leukemia (M5b)","Childhood Acute Myeloblastic Leukemia With Maturation (M2)","Childhood Acute Myeloblastic Leukemia Without Maturation (M1)","Childhood Acute Myelomonocytic Leukemia (M4)","Recurrent Childhood Acute Myeloid Leukemia",[4180,1187,1062,1080],"idarubicin",{"nctId":60,"briefTitle":61,"status":155,"phases":4182,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":4183,"interventions":4184},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":1167,"briefTitle":1168,"status":142,"phases":4186,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":234,"conditions":4187,"interventions":4188},[90],[1174],[1176,279,780,781,63,212,738],{"nctId":1201,"briefTitle":1202,"status":142,"phases":4190,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":4191,"interventions":4192},[90],[776,1208,773,1209,1210],[279,667,212,63,781,780],{"nctId":2014,"briefTitle":2015,"status":618,"phases":4194,"primaryCompletion":2017,"completion":2017,"start":1310,"enrollment":1024,"conditions":4195,"interventions":4196},[90],[2019,2020],[289,278,53,279],{"nctId":1254,"briefTitle":1255,"status":142,"phases":4198,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":4199,"interventions":4200},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"nctId":1272,"briefTitle":1273,"status":142,"phases":4202,"primaryCompletion":1275,"completion":1275,"start":1276,"enrollment":1277,"conditions":4203,"interventions":4204},[90],[1279,1280,1281,1282],[1063,1080,994,1032,1082,693],{"nctId":3668,"briefTitle":3669,"status":142,"phases":4206,"primaryCompletion":3671,"start":3273,"enrollment":913,"conditions":4207,"interventions":4208},[90],[3673,3120],[3590,1776,1080],{"trials":4210,"activeCount":838,"soonestReadout":1460},[4211,4215,4219,4223,4227,4237,4241],{"nctId":1362,"briefTitle":1363,"status":155,"phases":4212,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":4213,"interventions":4214},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1393,"briefTitle":1394,"status":128,"phases":4216,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":4217,"interventions":4218},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":3698,"briefTitle":3699,"status":107,"phases":4220,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":4221,"interventions":4222},[91],[3704,3705],[3707,1511,277,279,289,1101,2789,883,3708],{"nctId":1457,"briefTitle":1458,"status":155,"phases":4224,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":4225,"interventions":4226},[91],[1464,1465,1466,1467,1468,1469],[63,780,737,279,1471,1472,1101,781,740],{"nctId":4228,"briefTitle":4229,"status":142,"phases":4230,"primaryCompletion":4231,"start":4232,"enrollment":4233,"conditions":4234,"interventions":4235},"NCT00003190","Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia",[91],"2002-08","1998-01",640,[4037,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,4132],[1187,1263,1080,4236],"valspodar",{"nctId":2111,"briefTitle":2112,"status":155,"phases":4238,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":4239,"interventions":4240},[91],[2118,1626,2119,2120,2121,2122],[277,278,2124,279,449,2045],{"nctId":1495,"briefTitle":1496,"status":155,"phases":4242,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":4243,"interventions":4244},[91],[1503,1504,1505,1506,1507,1508],[1510,1511,63,737,279,1142,212,740],{"trials":4246,"activeCount":101},[],{"trials":4248,"activeCount":101},[],{"intervention":740,"totalTrials":3255,"cells":4250},{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4276,"PHASE3":4310,"PHASE4":4344,"NA":4346},{"trials":4252,"activeCount":101},[],{"trials":4254,"activeCount":2548,"soonestReadout":727},[4255,4264,4268],{"nctId":4256,"briefTitle":4257,"status":142,"phases":4258,"primaryCompletion":4259,"start":4260,"enrollment":827,"conditions":4261,"interventions":4263},"NCT00003166","Bryostatin and Vincristine in B-Cell Malignancies",[89],"2001-07","1998-05",[3180,3181,3182,3185,3186,940,3189,656,4262,1432],"Refractory Multiple Myeloma",[3263,1032],{"nctId":724,"briefTitle":725,"status":155,"phases":4265,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":4266,"interventions":4267},[89],[732,733,734,735],[63,737,279,738,58,739,212,667,740],{"nctId":4269,"briefTitle":4270,"status":142,"phases":4271,"primaryCompletion":4272,"start":3115,"enrollment":188,"conditions":4273,"interventions":4275},"NCT00022555","Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma",[89],"2003-07",[1279,4274,1281,1282],"AIDS-related Diffuse Mixed Cell Lymphoma",[3263,1032],{"trials":4277,"activeCount":758,"soonestReadout":62},[4278,4282,4286,4290,4294,4298,4302,4306],{"nctId":2259,"briefTitle":2260,"status":155,"phases":4279,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":4280,"interventions":4281},[90],[902,2267,2268,2269,2270],[1372,1138,1375,1141,2272,212,781,740],{"nctId":923,"briefTitle":924,"status":142,"phases":4283,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":4284,"interventions":4285},[89,90],[931,932,933,934,733,935,936,734,937,735,938,939,522,524,527,940],[63,737,279,212,667,740,942],{"nctId":1018,"briefTitle":1019,"status":142,"phases":4287,"primaryCompletion":1021,"completion":1022,"start":1023,"enrollment":1024,"conditions":4288,"interventions":4289},[90],[1026,1027,1028,1029],[1031,1032,693,1033],{"nctId":1068,"briefTitle":1069,"status":142,"phases":4291,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":4292,"interventions":4293},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":60,"briefTitle":61,"status":155,"phases":4295,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":4296,"interventions":4297},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":1254,"briefTitle":1255,"status":142,"phases":4299,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":4300,"interventions":4301},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"nctId":1272,"briefTitle":1273,"status":142,"phases":4303,"primaryCompletion":1275,"completion":1275,"start":1276,"enrollment":1277,"conditions":4304,"interventions":4305},[90],[1279,1280,1281,1282],[1063,1080,994,1032,1082,693],{"nctId":1326,"briefTitle":1327,"status":142,"phases":4307,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":1331,"conditions":4308,"interventions":4309},[90],[1244,1247,1333,1334],[1063,1033,693,994,1032,1082],{"trials":4311,"activeCount":838,"soonestReadout":2133},[4312,4316,4320,4324,4328,4332,4336,4340],{"nctId":1353,"briefTitle":1354,"status":142,"phases":4313,"primaryCompletion":715,"start":1356,"enrollment":1357,"conditions":4314,"interventions":4315},[91],[27],[750,1063,1360,693,994,1082,1032],{"nctId":1362,"briefTitle":1363,"status":155,"phases":4317,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":4318,"interventions":4319},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1378,"briefTitle":1379,"status":142,"phases":4321,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":4322,"interventions":4323},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"nctId":1423,"briefTitle":1424,"status":142,"phases":4325,"primaryCompletion":1426,"start":1427,"enrollment":1428,"conditions":4326,"interventions":4327},[91],[1430,1431,1432],[1032,1434,1081,693,1082,1435],{"nctId":1457,"briefTitle":1458,"status":155,"phases":4329,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":4330,"interventions":4331},[91],[1464,1465,1466,1467,1468,1469],[63,780,737,279,1471,1472,1101,781,740],{"nctId":2130,"briefTitle":2131,"status":155,"phases":4333,"primaryCompletion":2133,"completion":592,"start":2134,"enrollment":2135,"conditions":4334,"interventions":4335},[91],[2137,2138,2139,2140],[278,2142,737,2084,1102,2143,740],{"nctId":1474,"briefTitle":1475,"status":155,"phases":4337,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":4338,"interventions":4339},[90,91],[734,1481,735,510,511,512,513,514,1482,516,517,1483,1484,518,519,1485,1486,1487,1488,1489,1490],[63,737,1492,212,667,1493,740],{"nctId":1495,"briefTitle":1496,"status":155,"phases":4341,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":4342,"interventions":4343},[91],[1503,1504,1505,1506,1507,1508],[1510,1511,63,737,279,1142,212,740],{"trials":4345,"activeCount":101},[],{"trials":4347,"activeCount":101},[],{"intervention":737,"totalTrials":4349,"cells":4350},23,{"EARLY_PHASE1":4351,"PHASE1":4353,"PHASE2":4373,"PHASE3":4431,"PHASE4":4511,"NA":4513},{"trials":4352,"activeCount":101},[],{"trials":4354,"activeCount":2548,"soonestReadout":727},[4355,4362,4369],{"nctId":4356,"briefTitle":4357,"status":142,"phases":4358,"primaryCompletion":4359,"start":1576,"enrollment":421,"conditions":4360,"interventions":4361},"NCT00331955","Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors",[89],"2012-06",[15],[994,4063],{"nctId":4363,"briefTitle":4364,"status":142,"phases":4365,"primaryCompletion":4366,"start":3638,"enrollment":700,"conditions":4367,"interventions":4368},"NCT00079014","3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors",[89],"2008-07",[15],[1597,994],{"nctId":724,"briefTitle":725,"status":155,"phases":4370,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":4371,"interventions":4372},[89],[732,733,734,735],[63,737,279,738,58,739,212,667,740],{"trials":4374,"activeCount":2548,"soonestReadout":62},[4375,4379,4383,4387,4391,4395,4399,4403,4407,4423,4427],{"nctId":923,"briefTitle":924,"status":142,"phases":4376,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":4377,"interventions":4378},[89,90],[931,932,933,934,733,935,936,734,937,735,938,939,522,524,527,940],[63,737,279,212,667,740,942],{"nctId":984,"briefTitle":985,"status":142,"phases":4380,"completion":987,"start":988,"conditions":4381,"interventions":4382},[90],[18],[991,992,993,693,994,995],{"nctId":1049,"briefTitle":1050,"status":142,"phases":4384,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":4385,"interventions":4386},[90],[1056,1057,1058,1059,1060],[1062,1063,693,994,1064,1065,750,1066],{"nctId":1068,"briefTitle":1069,"status":142,"phases":4388,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":4389,"interventions":4390},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":1086,"briefTitle":1087,"status":142,"phases":4392,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":4393,"interventions":4394},[90],[1092,1093,1094,1095,1096,1097],[1099,63,1100,737,279,1101,1102,151,1103],{"nctId":60,"briefTitle":61,"status":155,"phases":4396,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":4397,"interventions":4398},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":1974,"briefTitle":1975,"status":618,"phases":4400,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":248,"conditions":4401,"interventions":4402},[90],[1981,625],[750,1598,1983,994,1264,1268],{"nctId":1272,"briefTitle":1273,"status":142,"phases":4404,"primaryCompletion":1275,"completion":1275,"start":1276,"enrollment":1277,"conditions":4405,"interventions":4406},[90],[1279,1280,1281,1282],[1063,1080,994,1032,1082,693],{"nctId":4408,"briefTitle":4409,"status":142,"phases":4410,"primaryCompletion":3789,"completion":4411,"start":4412,"enrollment":623,"conditions":4413,"interventions":4420},"NCT01771107","Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma",[89,90],"2024-03-21","2013-03-08",[4414,4415,4416,1503,4417,4418,1504,4419,1505,1506,1508,939],"AIDS-Related Hodgkin Lymphoma","Ann Arbor Stage II Hodgkin Lymphoma","Ann Arbor Stage IIA Hodgkin Lymphoma","Ann Arbor Stage III Hodgkin Lymphoma","Ann Arbor Stage IIIA Hodgkin Lymphoma","Ann Arbor Stage IV Hodgkin Lymphoma",[1511,4421,737,4422],"Dacarbazine","Vinblastine",{"nctId":1296,"briefTitle":1297,"status":618,"phases":4424,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":4425,"interventions":4426},[89,90],[1291,1302],[991,1304,750,993,693,994,819,995,722],{"nctId":1326,"briefTitle":1327,"status":142,"phases":4428,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":1331,"conditions":4429,"interventions":4430},[90],[1244,1247,1333,1334],[1063,1033,693,994,1032,1082],{"trials":4432,"activeCount":838,"soonestReadout":4445},[4433,4437,4441,4487,4491,4495,4499,4503,4507],{"nctId":1353,"briefTitle":1354,"status":142,"phases":4434,"primaryCompletion":715,"start":1356,"enrollment":1357,"conditions":4435,"interventions":4436},[91],[27],[750,1063,1360,693,994,1082,1032],{"nctId":1378,"briefTitle":1379,"status":142,"phases":4438,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":4439,"interventions":4440},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"nctId":4442,"briefTitle":4443,"status":155,"phases":4444,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":4449,"interventions":4486},"NCT02180867","Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery",[90,91],"2019-06-30","2026-12-24","2014-07-11",140,[4450,4451,4452,4453,4454,4455,4456,4457,4458,4459,4460,4461,4462,4463,4464,4465,4466,4467,4468,4469,4470,4471,4472,4473,4474,4475,4476,4477,4478,4479,4480,4481,4482,4483,4484,4485],"Alveolar Soft Part Sarcoma","Angiomatoid Fibrous Histiocytoma","Atypical Fibroxanthoma","Clear Cell Sarcoma of Soft Tissue","Epithelioid Malignant Peripheral Nerve Sheath Tumor","Epithelioid Sarcoma","Extraskeletal Myxoid Chondrosarcoma","Extraskeletal Osteosarcoma","Fibrohistiocytic Neoplasm","Fibrosarcoma","Inflammatory Myofibroblastic Tumor","Intimal Sarcoma","Leiomyosarcoma","Liposarcoma","Liver Embryonal Sarcoma","Low Grade Fibromyxoid Sarcoma","Low Grade Myofibroblastic Sarcoma","Malignant Peripheral Nerve Sheath Tumor","Malignant Skin Granular Cell Tumor","Malignant Triton Tumor","Mesenchymal Chondrosarcoma","Myxofibrosarcoma","Myxoid Chondrosarcoma","Myxoinflammatory Fibroblastic Sarcoma","Nerve Sheath Neoplasm","PEComa","Pericytic Neoplasm","Plexiform Fibrohistiocytic Tumor","Sclerosing Epithelioid Fibrosarcoma","Skin Glomus Tumor","Stage IB Soft Tissue Sarcoma AJCC v7","Stage IIB Soft Tissue Sarcoma AJCC v7","Stage III Soft Tissue Sarcoma AJCC v7","Stage IV Soft Tissue Sarcoma AJCC v7","Synovial Sarcoma","Undifferentiated High Grade Pleomorphic Sarcoma of Bone",[780,737,1101,2807,77],{"nctId":1437,"briefTitle":1438,"status":142,"phases":4488,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":1443,"conditions":4489,"interventions":4490},[91],[1445,1446,1447,1448,1449,1450,1451],[1453,63,737,449,1454,1455],{"nctId":1457,"briefTitle":1458,"status":155,"phases":4492,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":4493,"interventions":4494},[91],[1464,1465,1466,1467,1468,1469],[63,780,737,279,1471,1472,1101,781,740],{"nctId":2130,"briefTitle":2131,"status":155,"phases":4496,"primaryCompletion":2133,"completion":592,"start":2134,"enrollment":2135,"conditions":4497,"interventions":4498},[91],[2137,2138,2139,2140],[278,2142,737,2084,1102,2143,740],{"nctId":2145,"briefTitle":2146,"status":142,"phases":4500,"primaryCompletion":2148,"completion":2149,"start":1717,"enrollment":2150,"conditions":4501,"interventions":4502},[91],[801,2152],[278,737,2154,2155,43],{"nctId":1474,"briefTitle":1475,"status":155,"phases":4504,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":4505,"interventions":4506},[90,91],[734,1481,735,510,511,512,513,514,1482,516,517,1483,1484,518,519,1485,1486,1487,1488,1489,1490],[63,737,1492,212,667,1493,740],{"nctId":1495,"briefTitle":1496,"status":155,"phases":4508,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":4509,"interventions":4510},[91],[1503,1504,1505,1506,1507,1508],[1510,1511,63,737,279,1142,212,740],{"trials":4512,"activeCount":101},[],{"trials":4514,"activeCount":101},[],{"intervention":1016,"totalTrials":1195,"cells":4516},{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4668,"PHASE3":4728,"PHASE4":4750,"NA":4752},{"trials":4518,"activeCount":101},[],{"trials":4520,"activeCount":603,"soonestReadout":57},[4521,4542,4557,4567,4581,4585,4596,4607,4620,4624,4635],{"nctId":4522,"briefTitle":4523,"status":142,"phases":4524,"primaryCompletion":4525,"completion":4525,"start":1807,"enrollment":638,"conditions":4526,"interventions":4541},"NCT02568553","Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",[89],"2025-11-24",[526,527,3187,3188,940,4527,4528,528,3189,3190,4529,4530,655,536,537,4531,4532,4533,4534,4535,538,4536,4537,4538,4539,4540],"Recurrent Grade 3a Follicular Lymphoma","Recurrent Grade 3b Follicular Lymphoma","Recurrent Mediastinal Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Follicular Lymphoma","Refractory Grade 1 Follicular Lymphoma","Refractory Grade 2 Follicular Lymphoma","Refractory Grade 3 Follicular Lymphoma","Refractory Grade 3a Follicular Lymphoma","Refractory Mantle Cell Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Mediastinal Lymphoma","Refractory Non-Hodgkin Lymphoma","Refractory Small Lymphocytic Lymphoma",[1372,1016],{"nctId":4543,"briefTitle":4544,"status":142,"phases":4545,"primaryCompletion":4546,"completion":4547,"start":4548,"enrollment":34,"conditions":4549,"interventions":4554},"NCT04447027","Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed\u002FRefractory T-cell Malignancies",[89],"2024-07-01","2025-12-17","2020-12-17",[4550,4551,4552,4553],"Cutaneous T-Cell Lymphoma","Mature T-cell Malignancies","Peripheral T-Cell Lymphoma","Relapsed\u002F Refractory T-cell Malignancies",[4555,1016,4556,1139],"Romidepsin","CC-486",{"nctId":4558,"briefTitle":4559,"status":142,"phases":4560,"primaryCompletion":4561,"start":4562,"enrollment":37,"conditions":4563,"interventions":4564},"NCT00398515","Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma",[89],"2012-02","2007-03",[4262,1431,1432],[4565,4566],"lenalidomide","temsirolimus",{"nctId":55,"briefTitle":56,"status":155,"phases":4568,"primaryCompletion":57,"completion":4569,"start":4570,"enrollment":97,"conditions":4571,"interventions":4580},[89],"2026-06-06","2013-06-26",[4572,4573,4574,4575,935,936,4576,4577,937,4578,4579,938],"Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma","Ann Arbor Stage III Grade 1 Follicular Lymphoma","Ann Arbor Stage III Grade 2 Follicular Lymphoma","Ann Arbor Stage IV Grade 1 Follicular Lymphoma","Ann Arbor Stage IV Grade 2 Follicular Lymphoma",[58,1016,667],{"nctId":3510,"briefTitle":3511,"status":142,"phases":4582,"primaryCompletion":3513,"completion":3514,"start":3515,"enrollment":827,"conditions":4583,"interventions":4584},[89],[3517,3518,3519,3520],[289,277,1016],{"nctId":4586,"briefTitle":4587,"status":155,"phases":4588,"primaryCompletion":4589,"completion":482,"start":4590,"enrollment":2586,"conditions":4591,"interventions":4595},"NCT01955499","Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",[89],"2024-11-06","2013-09-24",[527,4592,4593,3189,3190,537,4531,4594,4536,4537],"Recurrent Follicular Lymphoma","Recurrent Lymphoplasmacytic Lymphoma","Refractory Lymphoplasmacytic Lymphoma",[58,1016],{"nctId":4597,"briefTitle":4598,"status":618,"phases":4599,"primaryCompletion":454,"completion":454,"start":4600,"enrollment":638,"conditions":4601,"interventions":4604},"NCT03031730","Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma",[89],"2018-06-14",[4602,4603,4262],"Plasmacytoma","Recurrent Multiple Myeloma",[4605,1139,4606,1016,3942],"Carfilzomib","Dexamethasone Sodium Phosphate",{"nctId":4608,"briefTitle":4609,"status":142,"phases":4610,"primaryCompletion":4611,"completion":4611,"start":4612,"enrollment":339,"conditions":4613,"interventions":4619},"NCT00104962","Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes",[89],"2009-06","2005-03",[4614,4056,4058,4615,4616,4617,4618,4061,748],"Childhood Myelodysplastic Syndromes","Refractory Anemia","Refractory Anemia With Excess Blasts","Refractory Anemia With Ringed Sideroblasts","Refractory Cytopenia With Multilineage Dysplasia",[4565],{"nctId":2206,"briefTitle":2207,"status":155,"phases":4621,"primaryCompletion":2209,"completion":418,"start":2210,"enrollment":2211,"conditions":4622,"interventions":4623},[89],[2213,2214],[2216,212,1016,2217,58,706,2218,2219],{"nctId":4625,"briefTitle":4626,"status":142,"phases":4627,"primaryCompletion":4628,"completion":4628,"start":4629,"enrollment":1041,"conditions":4630,"interventions":4634},"NCT01222754","Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas",[89],"2019-04-17","2010-11-23",[4631,4632,4633],"Diffuse Intrinsic Pontine Glioma","Anaplastic Astrocytoma","High Grade Glioma",[1016],{"nctId":4636,"briefTitle":4637,"status":142,"phases":4638,"primaryCompletion":3479,"start":4639,"enrollment":1990,"conditions":4640,"interventions":4667},"NCT00100880","Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors",[89],"2004-11",[4641,4642,4643,4644,4645,4646,4647,4648,4649,4650,4651,4652,4653,4654,4655,4656,4657,4658,4659,4660,4661,4662,4663,4664,4665,4666],"Childhood Atypical Teratoid\u002FRhabdoid Tumor","Childhood Central Nervous System Germ Cell Tumor","Childhood Choroid Plexus Tumor","Childhood Craniopharyngioma","Childhood Ependymoblastoma","Childhood Grade I Meningioma","Childhood Grade II Meningioma","Childhood Grade III Meningioma","Childhood High-grade Cerebellar Astrocytoma","Childhood High-grade Cerebral Astrocytoma","Childhood Infratentorial Ependymoma","Childhood Low-grade Cerebellar Astrocytoma","Childhood Low-grade Cerebral Astrocytoma","Childhood Medulloepithelioma","Childhood Mixed Glioma","Childhood Oligodendroglioma","Childhood Supratentorial Ependymoma","Recurrent Childhood Brain Tumor","Recurrent Childhood Cerebellar Astrocytoma","Recurrent Childhood Cerebral Astrocytoma","Recurrent Childhood Ependymoma","Recurrent Childhood Medulloblastoma","Recurrent Childhood Pineoblastoma","Recurrent Childhood Subependymal Giant Cell Astrocytoma","Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor","Recurrent Childhood Visual Pathway and Hypothalamic Glioma",[4565],{"trials":4669,"activeCount":603,"soonestReadout":1010},[4670,4674,4684,4688,4701,4705,4709,4719],{"nctId":2231,"briefTitle":2232,"status":128,"phases":4671,"primaryCompletion":2234,"completion":2234,"start":2235,"enrollment":1357,"conditions":4672,"interventions":4673},[90],[2237,527,2238,2239,529,530,2240,534,537,2241,2242,539,540,2243,543],[58,1016,2216,212,2217],{"nctId":4675,"briefTitle":4676,"status":142,"phases":4677,"primaryCompletion":144,"completion":4678,"start":4679,"enrollment":3283,"conditions":4680,"interventions":4683},"NCT01076543","Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma",[89,90],"2018-09-30","2010-04-15",[4414,4681,4592,4593,3190,4530,4682,4003],"Recurrent Adult Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma",[1016,2143],{"nctId":1007,"briefTitle":1008,"status":155,"phases":4685,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":407,"conditions":4686,"interventions":4687},[89,90],[524,1014],[1016,667,212,279,780,781,63],{"nctId":4689,"briefTitle":4690,"status":3027,"phases":4691,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":159,"conditions":4694,"interventions":4696},"NCT07605416","Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial",[90],"2032-11-06","2026-07-01",[4695],"Plasma Cell Leukemia",[4605,4697,1139,1016,1405,4698,4699,4700],"Daratumumab and Recombinant Human Hyaluronidase","Plerixafor","Recombinant Granulocyte Colony-Stimulating Factor","Teclistamab",{"nctId":1156,"briefTitle":1157,"status":142,"phases":4702,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":4703,"interventions":4704},[90],[657,659,661,663],[63,1165,1016,667],{"nctId":2342,"briefTitle":2343,"status":142,"phases":4706,"primaryCompletion":2345,"completion":2345,"start":1808,"enrollment":2346,"conditions":4707,"interventions":4708},[90],[2348],[53,1016,2083,212],{"nctId":4710,"briefTitle":4711,"status":142,"phases":4712,"primaryCompletion":4713,"completion":4714,"start":4715,"enrollment":2586,"conditions":4716,"interventions":4718},"NCT00410605","Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma",[90],"2011-12","2014-06","2006-11",[4717,1431,1432],"Multiple Myeloma in Relapse",[1033,4565,1065],{"nctId":4720,"briefTitle":4721,"status":142,"phases":4722,"primaryCompletion":4723,"completion":4723,"start":1560,"enrollment":174,"conditions":4724,"interventions":4727},"NCT01057121","Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma",[89,90],"2014-08-04",[4725,4726],"AIDS-Related Kaposi Sarcoma","Recurrent Kaposi Sarcoma",[1016],{"trials":4729,"activeCount":2548,"soonestReadout":4734},[4730,4741],{"nctId":4731,"briefTitle":4732,"status":155,"phases":4733,"primaryCompletion":4734,"completion":592,"start":4735,"enrollment":4736,"conditions":4737,"interventions":4740},"NCT01169337","Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma",[91],"2019-01-25","2011-01-24",226,[4738,4739],"Light Chain Deposition Disease","Smoldering Multiple Myeloma",[1016],{"nctId":4742,"briefTitle":4743,"status":142,"phases":4744,"primaryCompletion":4745,"completion":270,"start":269,"enrollment":2548,"conditions":4746,"interventions":4748},"NCT03941860","Testing the Addition of Ixazomib\u002FPlacebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial",[91],"2023-08-06",[4747],"Multiple Myeloma",[4749,1016],"Ixazomib Citrate",{"trials":4751,"activeCount":101},[],{"trials":4753,"activeCount":101},[],{"intervention":68,"totalTrials":2211,"cells":4755},{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4850,"PHASE3":4908,"PHASE4":4914,"NA":4916},{"trials":4757,"activeCount":101},[],{"trials":4759,"activeCount":2548,"soonestReadout":4764},[4760,4770,4807],{"nctId":4761,"briefTitle":4762,"status":155,"phases":4763,"primaryCompletion":4764,"completion":592,"start":4765,"enrollment":3255,"conditions":4766,"interventions":4768},"NCT01364051","Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies",[89],"2019-06-06","2011-05-25",[195,30,4767,487],"Stage IV Cutaneous Melanoma AJCC v6 and v7",[2732,68,4769,2708],"Selumetinib",{"nctId":4771,"briefTitle":4772,"status":142,"phases":4773,"primaryCompletion":3295,"start":1053,"enrollment":2294,"conditions":4774,"interventions":4806},"NCT00458731","Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma",[89],[3157,3158,4775,4776,4777,4778,4779,4780,4781,4782,1245,4783,4784,1246,4785,3179,4786,3180,3181,3182,3183,4681,3185,3186,4787,4788,4789,4790,4791,3187,3188,940,3189,4792,4793,4794,4795,1248,3209,1334,3210,3211,4796,3212,3213,4797,4798,4799,4800,4801,4802,3214,3215,3216,1060,4803,4804,4805,1250,15,748,1251],"Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Childhood Burkitt Lymphoma","Childhood Diffuse Large Cell Lymphoma","Childhood Grade III Lymphomatoid Granulomatosis","Childhood Immunoblastic Large Cell Lymphoma","Childhood Nasal Type Extranodal NK\u002FT-cell Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Hepatosplenic T-cell Lymphoma","Intraocular Lymphoma","Noncutaneous Extranodal Lymphoma","Progressive Hairy Cell Leukemia, Initial Treatment","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Childhood Anaplastic Large Cell Lymphoma","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent\u002FRefractory Childhood Hodgkin Lymphoma","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Stage IV Adult Hodgkin Lymphoma","Stage IV Adult T-cell Leukemia\u002FLymphoma","Stage IV Childhood Anaplastic Large Cell Lymphoma","Stage IV Childhood Hodgkin Lymphoma","Stage IV Childhood Large Cell Lymphoma","Stage IV Childhood Lymphoblastic Lymphoma","Stage IV Childhood Small Noncleaved Cell Lymphoma","Stage IVA Mycosis Fungoides\u002FSezary Syndrome","Stage IVB Mycosis Fungoides\u002FSezary Syndrome","T-cell Large Granular Lymphocyte Leukemia",[1033,2299],{"nctId":4808,"briefTitle":4809,"status":142,"phases":4810,"primaryCompletion":4811,"completion":4811,"start":3272,"enrollment":552,"conditions":4812,"interventions":4848},"NCT01131234","Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors",[89],"2014-09",[4813,4814,4815,4816,4817,4818,4819,4820,3131,3135,4821,2613,4822,1343,3320,251,4823,3332,4824,4825,3260,4826,4827,4828,3485,4829,4830,4831,1222,4832,4833,3488,4834,4835,4836,1223,4837,3491,4838,4839,4840,3137,3321,3494,4841,3261,4842,4843,4844,4845,4846,4847],"Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Mixed Glioma","Recurrent Adult Brain Neoplasm","Recurrent Colon Carcinoma","Recurrent Ovarian Germ Cell Tumor","Recurrent Rectal Carcinoma","Recurrent Renal Cell Carcinoma","Stage III Renal Cell Cancer","Stage IIIA Colon Cancer","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIA Ovarian Germ Cell Tumor","Stage IIIA Rectal Cancer","Stage IIIA Skin Melanoma","Stage IIIB Colon Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IIIB Ovarian Germ Cell Tumor","Stage IIIB Rectal Cancer","Stage IIIB Skin Melanoma","Stage IIIC Colon Cancer","Stage IIIC Ovarian Germ Cell Tumor","Stage IIIC Rectal Cancer","Stage IIIC Skin Melanoma","Stage IV Ovarian Germ Cell Tumor","Stage IV Renal Cell Cancer","Stage IV Skin Melanoma","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer",[4849,68],"Gamma-Secretase Inhibitor RO4929097",{"trials":4851,"activeCount":838,"soonestReadout":67},[4852,4856,4866,4870,4874,4881,4885,4892,4896,4904],{"nctId":2638,"briefTitle":2639,"status":155,"phases":4853,"primaryCompletion":2641,"completion":2642,"start":2643,"enrollment":1111,"conditions":4854,"interventions":4855},[90],[1720,1723,2645,1729,2646,2647,1738,2648,1739],[68,2554],{"nctId":4857,"briefTitle":4858,"status":142,"phases":4859,"primaryCompletion":4562,"start":4860,"enrollment":1913,"conditions":4861,"interventions":4865},"NCT00238394","Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer",[90],"2005-12",[4862,4863,4864],"Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Localized Unresectable Adult Primary Liver Cancer",[2299],{"nctId":2289,"briefTitle":2290,"status":618,"phases":4867,"primaryCompletion":1319,"completion":2292,"start":2293,"enrollment":2294,"conditions":4868,"interventions":4869},[90],[2296,2297],[2299,1775,1082],{"nctId":79,"briefTitle":80,"status":155,"phases":4871,"primaryCompletion":81,"completion":2642,"start":2668,"enrollment":2669,"conditions":4872,"interventions":4873},[89,90],[1720,1732,2647,1735,2671,1739,1637],[68,2554],{"nctId":4875,"briefTitle":4876,"status":142,"phases":4877,"primaryCompletion":1318,"completion":4878,"start":1910,"enrollment":2586,"conditions":4879,"interventions":4880},"NCT00475150","Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[90],"2012-03",[4043,4044,4045,4046,4047,4056,4058,33,2432,4061,4132],[2299],{"nctId":2724,"briefTitle":2725,"status":155,"phases":4882,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":1111,"conditions":4883,"interventions":4884},[90],[354],[53,2732,68,2554],{"nctId":4886,"briefTitle":4887,"status":618,"phases":4888,"primaryCompletion":650,"completion":4878,"start":1275,"enrollment":407,"conditions":4889,"interventions":4891},"NCT00427973","AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer",[90],[4862,4863,4864,4890],"Recurrent Adult Primary Liver Cancer",[2299],{"nctId":2734,"briefTitle":2735,"status":155,"phases":4893,"primaryCompletion":2737,"completion":2642,"start":2738,"enrollment":1357,"conditions":4894,"interventions":4895},[90],[1724,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2616,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2782,2783,2784,2785,2786,2787],[68,2124,2554,449,2789,2790],{"nctId":4897,"briefTitle":4898,"status":142,"phases":4899,"primaryCompletion":4900,"completion":1865,"start":813,"enrollment":1074,"conditions":4901,"interventions":4902},"NCT00410904","AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer",[90],"2013-07",[3119],[2299,4903],"pemetrexed disodium",{"nctId":65,"briefTitle":66,"status":155,"phases":4905,"primaryCompletion":67,"completion":592,"start":2037,"enrollment":2038,"conditions":4906,"interventions":4907},[89,90],[2040,2041,2042,2043],[68,278,2045],{"trials":4909,"activeCount":2548,"soonestReadout":2813},[4910],{"nctId":2810,"briefTitle":2811,"status":155,"phases":4911,"primaryCompletion":2813,"completion":2642,"start":2814,"enrollment":2815,"conditions":4912,"interventions":4913},[90,91],[1722,1723,2645,1726,1727,1731,1732,2740,1735,1736,1737,1739,250,251,252],[2732,68,2554,449,2789,1407,2790],{"trials":4915,"activeCount":101},[],{"trials":4917,"activeCount":101},[],{"intervention":3065,"totalTrials":31,"cells":4919},{"EARLY_PHASE1":4920,"PHASE1":4922,"PHASE2":5019,"PHASE3":5097,"PHASE4":5172,"NA":5174},{"trials":4921,"activeCount":101},[],{"trials":4923,"activeCount":2548,"soonestReadout":5011},[4924,4932,4936,4949,4968,4978,4986,4992,5000,5007],{"nctId":4925,"briefTitle":4926,"status":142,"phases":4927,"primaryCompletion":4928,"completion":4928,"start":4929,"enrollment":407,"conditions":4930,"interventions":4931},"NCT01383343","Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer",[89],"2017-02","2011-08",[4822,4824,4844,4845,4846,4847],[53,2084,1102,1140,43],{"nctId":3058,"briefTitle":3059,"status":3060,"phases":4933,"start":3062,"conditions":4934,"interventions":4935},[89],[1564],[3065,3066,995],{"nctId":4937,"briefTitle":4938,"status":142,"phases":4939,"primaryCompletion":4929,"start":1819,"enrollment":484,"conditions":4940,"interventions":4947},"NCT00138177","Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors",[89],[4941,4942,4943,4944,4945,4946,15],"Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage III Colon Cancer","Stage III Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer",[4948,1264,4063,3065],"oxaliplatin",{"nctId":4950,"briefTitle":4951,"status":618,"phases":4952,"primaryCompletion":4953,"completion":4953,"start":4954,"enrollment":603,"conditions":4955,"interventions":4965},"NCT03300544","Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer",[89],"2022-03-22","2019-05-14",[364,4956,4957,4958,4959,4960,4961,4962,4963,4964],"Metastatic Rectal Adenocarcinoma","Rectal Adenocarcinoma","Stage III Rectal Cancer AJCC v7","Stage IIIA Rectal Cancer AJCC v7","Stage IIIB Rectal Cancer AJCC v7","Stage IIIC Rectal Cancer AJCC v7","Stage IV Rectal Cancer AJCC v7","Stage IVA Rectal Cancer AJCC v7","Stage IVB Rectal Cancer AJCC v7",[2924,2084,4966,2925,4967],"Leucovorin","Talimogene Laherparepvec",{"nctId":4969,"briefTitle":4970,"status":142,"phases":4971,"primaryCompletion":4972,"completion":4972,"start":4973,"enrollment":2211,"conditions":4974,"interventions":4976},"NCT02319018","Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors",[89],"2018-09-29","2015-08-27",[4975],"Malignant Digestive System Neoplasm",[4977,2084,1140,2925],"Alisertib",{"nctId":4979,"briefTitle":4980,"status":142,"phases":4981,"primaryCompletion":3273,"start":4231,"enrollment":22,"conditions":4982,"interventions":4985},"NCT00052559","Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer",[89],[4983,4984,4944],"Adenocarcinoma of the Rectum","Stage II Rectal Cancer",[1033,3065],{"nctId":4987,"briefTitle":4988,"status":142,"phases":4989,"start":4231,"conditions":4990,"interventions":4991},"NCT00042861","UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors",[89],[15],[2184,3065,1264],{"nctId":4993,"briefTitle":4994,"status":142,"phases":4995,"primaryCompletion":4996,"start":4997,"enrollment":730,"conditions":4998,"interventions":4999},"NCT00080990","Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors",[89],"2009-04","2004-02",[15],[1998,3065,4948,1264],{"nctId":5001,"briefTitle":5002,"status":142,"phases":5003,"primaryCompletion":1231,"start":5004,"enrollment":28,"conditions":5005,"interventions":5006},"NCT00007878","Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",[89],"2000-09",[15],[1062,3065,1264],{"nctId":5008,"briefTitle":5009,"status":128,"phases":5010,"primaryCompletion":5011,"completion":5011,"start":5012,"enrollment":2586,"conditions":5013,"interventions":5017},"NCT06654037","Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer",[89],"2027-04-01","2025-04-18",[5014,5015,5016],"Metastatic Microsatellite Stable Colorectal Carcinoma","Refractory Microsatellite Stable Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v8",[5018,2084],"Abemaciclib",{"trials":5020,"activeCount":758,"soonestReadout":968},[5021,5025,5045,5053,5060,5067,5073,5083],{"nctId":2908,"briefTitle":2909,"status":155,"phases":5022,"primaryCompletion":2654,"completion":2654,"start":2911,"enrollment":2912,"conditions":5023,"interventions":5024},[90],[2914,2915,2916,2917,1621,2918,2919,2920,2921,2922],[1690,2924,2083,2084,1140,2925],{"nctId":5026,"briefTitle":5027,"status":155,"phases":5028,"primaryCompletion":968,"completion":968,"start":5029,"enrollment":971,"conditions":5030,"interventions":5043},"NCT05564403","Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)",[90],"2024-02-09",[5031,5032,5033,5034,5035,5036,1624,5037,5038,3364,1631,5039,5040,3370,5041,5042,3374],"Advanced Biliary Tract Carcinoma","Advanced Gallbladder Carcinoma","Advanced Intrahepatic Cholangiocarcinoma","Recurrent Biliary Tract Carcinoma","Recurrent Gallbladder Carcinoma","Recurrent Intrahepatic Cholangiocarcinoma","Stage III Gallbladder Cancer AJCC v8","Stage III Hilar Cholangiocarcinoma AJCC v8","Stage IV Gallbladder Cancer AJCC v8","Stage IV Hilar Cholangiocarcinoma AJCC v8","Unresectable Biliary Tract Carcinoma","Unresectable Gallbladder Carcinoma",[5044,2084,1140,2925],"Binimetinib",{"nctId":5046,"briefTitle":5047,"status":142,"phases":5048,"primaryCompletion":1318,"completion":1318,"start":4639,"enrollment":971,"conditions":5049,"interventions":5052},"NCT00100841","Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer",[90],[4983,5050,4941,4942,5051,4945,4946],"Mucinous Adenocarcinoma of the Colon","Signet Ring Adenocarcinoma of the Colon",[1697,1033,4948,1264,3065],{"nctId":5054,"briefTitle":5055,"status":142,"phases":5056,"completion":1781,"start":5057,"conditions":5058,"interventions":5059},"NCT00066846","Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy",[90],"2003-08",[856],[1033,3065,1264],{"nctId":5061,"briefTitle":5062,"status":142,"phases":5063,"completion":3587,"start":1241,"conditions":5064,"interventions":5065},"NCT00103298","Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer",[90],[856,869],[5066,3065,3110,1264,1081,4948],"FOLFOX regimen",{"nctId":5068,"briefTitle":5069,"status":142,"phases":5070,"primaryCompletion":1320,"start":3088,"enrollment":421,"conditions":5071,"interventions":5072},"NCT00016978","Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan",[90],[856],[5066,3065,1264,4948],{"nctId":5074,"briefTitle":5075,"status":142,"phases":5076,"primaryCompletion":5077,"completion":5078,"start":5079,"enrollment":2294,"conditions":5080,"interventions":5082},"NCT00321685","Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer",[90],"2013-08-12","2019-02-11","2006-07-25",[4957,5081,4958],"Stage II Rectal Cancer AJCC v7",[53,2924,2084,1140,2925],{"nctId":5084,"briefTitle":5085,"status":142,"phases":5086,"primaryCompletion":5087,"completion":5087,"start":4611,"enrollment":700,"conditions":5088,"interventions":5096},"NCT00957905","Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors",[90],"2014-08",[5089,5090,5091,5092,4823,5093,5094,5095,4841],"Recurrent Extragonadal Seminoma","Recurrent Malignant Extragonadal Germ Cell Tumor","Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor","Recurrent Malignant Testicular Germ Cell Tumor","Stage III Testicular Cancer","Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor","Stage IV Extragonadal Seminoma",[666,2084,1140,2925],{"trials":5098,"activeCount":214,"soonestReadout":72},[5099,5107,5111,5120,5130,5138,5151,5155,5159],{"nctId":5100,"briefTitle":5101,"status":618,"phases":5102,"primaryCompletion":5103,"completion":5103,"start":1320,"enrollment":1953,"conditions":5104,"interventions":5105},"NCT00499369","Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy",[91],"2012-11",[4941,4942,4844,4845,4846,4847],[5106,1264,3065,1697,1033],"irinotecan hydrochloride",{"nctId":70,"briefTitle":71,"status":155,"phases":5108,"primaryCompletion":72,"completion":2050,"start":2051,"enrollment":2052,"conditions":5109,"interventions":5110},[91],[2054,1867,1868,1869,1870,2055,1873,1874,2056,2057,2058,2059,2060,2061,2062,2063,2064,2065,2066,2067,2068,2069,2070,2071,2072,2073,2074,2075,2076,2077,2078,2079,2080,2081,1895],[53,277,278,2083,2084],{"nctId":5112,"briefTitle":5113,"status":142,"phases":5114,"primaryCompletion":3480,"start":5115,"enrollment":5116,"conditions":5117,"interventions":5119},"NCT00004931","Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer",[91],"2000-02",2472,[5118,4943],"Stage II Colon Cancer",[1264,3065,4948],{"nctId":5121,"briefTitle":5122,"status":142,"phases":5123,"primaryCompletion":1781,"start":5124,"enrollment":5125,"conditions":5126,"interventions":5128},"NCT00003873","Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer",[91],"1999-04",950,[5127,4983,4941,4942,4945,4946],"Adenocarcinoma of the Colon",[3065,5129],"eniluracil",{"nctId":5131,"briefTitle":5132,"status":142,"phases":5133,"primaryCompletion":5103,"completion":5103,"start":4997,"enrollment":5134,"conditions":5135,"interventions":5136},"NCT00079274","Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer",[91],3397,[5127,4943],[5106,4948,1264,3065,1697,5137],"Locally Directed Therapy",{"nctId":5139,"briefTitle":5140,"status":142,"phases":5141,"primaryCompletion":1807,"completion":1807,"start":5142,"enrollment":5143,"conditions":5144,"interventions":5150},"NCT00068692","Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II\u002FIII Rectal Cancer",[91],"2003-10-15",225,[5145,5146,4824,5147,5148,5149,4959,4960,4961,4963,4964],"Rectal Mucinous Adenocarcinoma","Rectal Signet Ring Cell Adenocarcinoma","Stage IIA Rectal Cancer AJCC v7","Stage IIB Rectal Cancer AJCC v7","Stage IIC Rectal Cancer AJCC v7",[2084,1140,2925,1403],{"nctId":3035,"briefTitle":3036,"status":155,"phases":5152,"primaryCompletion":3038,"completion":3039,"start":3040,"enrollment":3041,"conditions":5153,"interventions":5154},[91],[3043,3044,114,3045],[1690,2084,1140,2925],{"nctId":2130,"briefTitle":2131,"status":155,"phases":5156,"primaryCompletion":2133,"completion":592,"start":2134,"enrollment":2135,"conditions":5157,"interventions":5158},[91],[2137,2138,2139,2140],[278,2142,737,2084,1102,2143,740],{"nctId":5160,"briefTitle":5161,"status":155,"phases":5162,"primaryCompletion":5163,"completion":5164,"start":5165,"enrollment":5166,"conditions":5167,"interventions":5171},"NCT00217737","Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer",[91],"2024-02-22","2027-04-11","2005-09-06",2431,[3043,5168,5169,5170],"Stage IIA Colon Cancer AJCC v7","Stage IIB Colon Cancer AJCC v7","Stage IIC Colon Cancer AJCC v7",[53,2084,4966,2925],{"trials":5173,"activeCount":101},[],{"trials":5175,"activeCount":101},[5176],{"nctId":5177,"briefTitle":5178,"status":142,"phases":5179,"completion":987,"start":1764,"conditions":5180,"interventions":5181},"NCT00039611","Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer",[93],[856],[5066,3065,1264,4948],{"intervention":53,"totalTrials":234,"cells":5183},{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5251,"PHASE3":5592,"PHASE4":5648,"NA":5650},{"trials":5185,"activeCount":101},[],{"trials":5187,"activeCount":2548,"soonestReadout":5218},[5188,5192,5198,5206,5210,5214,5226,5238,5247],{"nctId":4925,"briefTitle":4926,"status":142,"phases":5189,"primaryCompletion":4928,"completion":4928,"start":4929,"enrollment":407,"conditions":5190,"interventions":5191},[89],[4822,4824,4844,4845,4846,4847],[53,2084,1102,1140,43],{"nctId":5193,"briefTitle":5194,"status":142,"phases":5195,"primaryCompletion":1912,"start":3098,"enrollment":339,"conditions":5196,"interventions":5197},"NCT00085111","Bevacizumab in Treating Young Patients With Refractory Solid Tumors",[89],[748],[1033],{"nctId":5199,"briefTitle":5200,"status":142,"phases":5201,"primaryCompletion":5202,"completion":550,"start":5203,"enrollment":234,"conditions":5204,"interventions":5205},"NCT01445509","Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors",[89],"2017-12-18","2008-12-29",[3229],[53,1138],{"nctId":4979,"briefTitle":4980,"status":142,"phases":5207,"primaryCompletion":3273,"start":4231,"enrollment":22,"conditions":5208,"interventions":5209},[89],[4983,4984,4944],[1033,3065],{"nctId":4771,"briefTitle":4772,"status":142,"phases":5211,"primaryCompletion":3295,"start":1053,"enrollment":2294,"conditions":5212,"interventions":5213},[89],[3157,3158,4775,4776,4777,4778,4779,4780,4781,4782,1245,4783,4784,1246,4785,3179,4786,3180,3181,3182,3183,4681,3185,3186,4787,4788,4789,4790,4791,3187,3188,940,3189,4792,4793,4794,4795,1248,3209,1334,3210,3211,4796,3212,3213,4797,4798,4799,4800,4801,4802,3214,3215,3216,1060,4803,4804,4805,1250,15,748,1251],[1033,2299],{"nctId":5215,"briefTitle":5216,"status":155,"phases":5217,"primaryCompletion":5218,"completion":5219,"start":5220,"enrollment":234,"conditions":5221,"interventions":5224},"NCT02142803","TORC1\u002F2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors",[89],"2020-12-31","2026-10-16","2014-05-20",[4818,1943,1944,1785,1732,1787,1788,250,5222,251,252,5223,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757],"Recurrent Malignant Uterine Corpus Neoplasm","Solid Neoplasm",[53,5225],"Sapanisertib",{"nctId":5227,"briefTitle":5228,"status":142,"phases":5229,"primaryCompletion":5230,"start":3282,"enrollment":889,"conditions":5231,"interventions":5236},"NCT01243359","Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies",[89],"2014-02",[5232,5233,5234,5235,4826,4842,15],"Clear Cell Renal Cell Carcinoma","Recurrent Renal Cell Cancer","Stage I Renal Cell Cancer","Stage II Renal Cell Cancer",[5237,1033],"sunitinib malate",{"nctId":5239,"briefTitle":5240,"status":142,"phases":5241,"completion":5242,"start":5243,"enrollment":188,"conditions":5244,"interventions":5245},"NCT01251926","EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors",[89],"2014-04-23","2010-11-15",[467],[5246,53],"EZN-2208",{"nctId":1712,"briefTitle":1713,"status":142,"phases":5248,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":1718,"conditions":5249,"interventions":5250},[89],[1720,1721,1722,1723,1724,1725,1726,1727,1728,1729,1730,1731,1732,1733,1734,1735,1736,1737,1738,1739,1740,1741,1742,1743,1744,1745,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757],[53,277,278,449,1653],{"trials":5252,"activeCount":758,"soonestReadout":2727},[5253,5262,5266,5355,5365,5374,5381,5385,5389,5393,5402,5406,5421,5425,5429,5436,5440,5448,5457,5464,5468,5472,5476,5482,5493,5500,5504,5514,5524,5558,5565,5579,5588],{"nctId":5254,"briefTitle":5255,"status":142,"phases":5256,"primaryCompletion":325,"completion":3007,"start":5257,"enrollment":455,"conditions":5258,"interventions":5260},"NCT00923936","Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma",[90],"2009-04-23",[5259],"Sarcoma, Kaposi",[5261,53],"Liposomal Doxorubicin",{"nctId":2868,"briefTitle":2869,"status":142,"phases":5263,"primaryCompletion":2871,"completion":2872,"start":2873,"enrollment":375,"conditions":5264,"interventions":5265},[90],[1648,1649,1650,1533,2875,1668,1651],[1690,53],{"nctId":5267,"briefTitle":5268,"status":142,"phases":5269,"primaryCompletion":5270,"completion":5270,"start":1320,"enrollment":375,"conditions":5271,"interventions":5354},"NCT00492089","Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer",[90],"2010-08",[4813,4814,5272,4815,4816,5273,5274,5275,5276,5277,5278,5279,4820,5280,5281,5282,5283,5284,5285,5286,5287,5288,5289,5290,5291,5292,5293,5294,5295,5296,5297,5298,5299,5300,5301,5302,5303,5304,5305,5306,5307,5308,5309,5310,5311,5312,5313,5314,5315,5316,5317,5318,5319,5320,5321,5322,5323,5324,5325,5326,5327,5328,5329,5330,5331,5332,5333,5334,5335,5336,5337,5338,5339,5340,5341,5342,5343,5344,5345,5346,5347,5348,5349,5350,5351,5352,5353],"Adult Anaplastic Meningioma","Adult Central Nervous System Germ Cell Tumor","Adult Choroid Plexus Tumor","Adult Diffuse Astrocytoma","Adult Ependymoma","Adult Grade II Meningioma","Adult Grade III Meningioma","Adult Malignant Hemangiopericytoma","Adult Oligodendroglioma","Adult Papillary Meningioma","Adult Pineocytoma","Malignant Neoplasm","Meningeal Melanocytoma","Radiation Toxicity","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adult Brain Tumor","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage I Adenoid Cystic Carcinoma of the Oral Cavity","Stage I Basal Cell Carcinoma of the Lip","Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage I Lymphoepithelioma of the Nasopharynx","Stage I Lymphoepithelioma of the Oropharynx","Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage I Mucoepidermoid Carcinoma of the Oral Cavity","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Hypopharynx","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Nasopharynx","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Basal Cell Carcinoma of the Lip","Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity",[1033],{"nctId":5356,"briefTitle":5357,"status":142,"phases":5358,"primaryCompletion":5359,"completion":5359,"start":2487,"enrollment":1128,"conditions":5360,"interventions":5364},"NCT00381797","Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma",[90],"2015-10",[5361,4656,5362,5363,4661,4662],"Childhood Cerebral Anaplastic Astrocytoma","Childhood Spinal Cord Neoplasm","Recurrent Childhood Brain Stem Glioma",[53,1102],{"nctId":5366,"briefTitle":5367,"status":155,"phases":5368,"primaryCompletion":5369,"completion":4693,"start":5370,"enrollment":838,"conditions":5371,"interventions":5372},"NCT02971501","Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases",[90],"2025-02-18","2018-06-27",[2885,2844,1633],[53,5373],"Osimertinib",{"nctId":5375,"briefTitle":5376,"status":618,"phases":5377,"primaryCompletion":4715,"start":3526,"enrollment":1357,"conditions":5378,"interventions":5380},"NCT00096148","Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[90],[4035,4036,4037,4038,4039,4040,4041,4042,4043,4048,4050,4051,4168,4169,4170,4171,4173,4174,4175,4176,4177,2432,4132,5379],"Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies",[4180,1187,1033],{"nctId":1018,"briefTitle":1019,"status":142,"phases":5382,"primaryCompletion":1021,"completion":1022,"start":1023,"enrollment":1024,"conditions":5383,"interventions":5384},[90],[1026,1027,1028,1029],[1031,1032,693,1033],{"nctId":3279,"briefTitle":3280,"status":142,"phases":5386,"primaryCompletion":3282,"completion":3282,"start":2487,"enrollment":3283,"conditions":5387,"interventions":5388},[90],[1767,2163,1768,1769,3119,1770,1772,3285],[1697,995,1033],{"nctId":1934,"briefTitle":1935,"status":142,"phases":5390,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1798,"conditions":5391,"interventions":5392},[90],[1941,1942,1943,1944,1536,1538,1541,1549,1551,1552,1945,1946],[53,277,278,449],{"nctId":5394,"briefTitle":5395,"status":618,"phases":5396,"primaryCompletion":1022,"completion":3317,"start":5397,"enrollment":25,"conditions":5398,"interventions":5400},"NCT00393094","Bevacizumab and Irinotecan to Treat Brain Tumors",[90],"2006-09",[5399],"High-Grade Gliomas",[53,5401],"Irinotecan hydrochloride",{"nctId":5046,"briefTitle":5047,"status":142,"phases":5403,"primaryCompletion":1318,"completion":1318,"start":4639,"enrollment":971,"conditions":5404,"interventions":5405},[90],[4983,5050,4941,4942,5051,4945,4946],[1697,1033,4948,1264,3065],{"nctId":5407,"briefTitle":5408,"status":142,"phases":5409,"primaryCompletion":144,"completion":5410,"start":5411,"enrollment":5412,"conditions":5413,"interventions":5420},"NCT01217437","Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors",[90],"2021-06-30","2010-11-22",108,[5414,5415,5416,5417,5418,5419],"Central Nervous System Neoplasm","Pineoblastoma","Recurrent Medulloblastoma","Recurrent Primitive Neuroectodermal Tumor","Refractory Medulloblastoma","Refractory Peripheral Primitive Neuroectodermal Tumor",[53,1102,151],{"nctId":5054,"briefTitle":5055,"status":142,"phases":5422,"completion":1781,"start":5057,"conditions":5423,"interventions":5424},[90],[856],[1033,3065,1264],{"nctId":3312,"briefTitle":3313,"status":618,"phases":5426,"primaryCompletion":3315,"completion":3316,"start":3317,"enrollment":1090,"conditions":5427,"interventions":5428},[90],[1928,3319,3320,3321,3322],[53,277,1099,449],{"nctId":5430,"briefTitle":5431,"status":142,"phases":5432,"completion":4639,"start":5433,"conditions":5434,"interventions":5435},"NCT00019539","Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer",[90],"1998-11",[4842,5233],[1033,3470],{"nctId":2342,"briefTitle":2343,"status":142,"phases":5437,"primaryCompletion":2345,"completion":2345,"start":1808,"enrollment":2346,"conditions":5438,"interventions":5439},[90],[2348],[53,1016,2083,212],{"nctId":5441,"briefTitle":5442,"status":142,"phases":5443,"primaryCompletion":5444,"completion":5445,"start":2487,"enrollment":2029,"conditions":5446,"interventions":5447},"NCT00365391","Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer",[90],"2008-08","2010-06",[4862,4863,4864,4890],[1033,1774],{"nctId":5449,"briefTitle":5450,"status":142,"phases":5451,"primaryCompletion":1171,"completion":1171,"start":5452,"enrollment":421,"conditions":5453,"interventions":5455},"NCT00074308","Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers",[89,90],"2003-10",[1343,5454,1344,15],"Stage III Melanoma",[5456,1033],"imatinib mesylate",{"nctId":5458,"briefTitle":5459,"status":142,"phases":5460,"primaryCompletion":5461,"completion":1170,"start":3088,"enrollment":1074,"conditions":5462,"interventions":5463},"NCT00016094","S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma",[90],"2005-08",[4775,3180,3181,3189],[1033],{"nctId":2724,"briefTitle":2725,"status":155,"phases":5465,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":1111,"conditions":5466,"interventions":5467},[90],[354],[53,2732,68,2554],{"nctId":5074,"briefTitle":5075,"status":142,"phases":5469,"primaryCompletion":5077,"completion":5078,"start":5079,"enrollment":2294,"conditions":5470,"interventions":5471},[90],[4957,5081,4958],[53,2924,2084,1140,2925],{"nctId":4710,"briefTitle":4711,"status":142,"phases":5473,"primaryCompletion":4713,"completion":4714,"start":4715,"enrollment":2586,"conditions":5474,"interventions":5475},[90],[4717,1431,1432],[1033,4565,1065],{"nctId":5477,"briefTitle":5478,"status":142,"phases":5479,"primaryCompletion":4561,"completion":4561,"start":5397,"enrollment":1765,"conditions":5480,"interventions":5481},"NCT00409565","A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer",[90],[1564,576],[1570,53],{"nctId":5483,"briefTitle":5484,"status":142,"phases":5485,"primaryCompletion":5486,"completion":5486,"start":5487,"enrollment":2280,"conditions":5488,"interventions":5491},"NCT01727089","Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer",[90],"2017-08-08","2012-11-01",[5232,4825,4842,5489,5490],"Type 1 Papillary Renal Cell Carcinoma","Type 2 Papillary Renal Cell Carcinoma",[5492,53],"Anti-Endoglin Chimeric Monoclonal Antibody TRC105",{"nctId":5494,"briefTitle":5495,"status":142,"phases":5496,"primaryCompletion":2292,"completion":2292,"start":3115,"enrollment":2294,"conditions":5497,"interventions":5498},"NCT00026221","Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma",[90],[1343,4843],[5499,53],"Recombinant Interferon Alfa",{"nctId":2014,"briefTitle":2015,"status":618,"phases":5501,"primaryCompletion":2017,"completion":2017,"start":1310,"enrollment":1024,"conditions":5502,"interventions":5503},[90],[2019,2020],[289,278,53,279],{"nctId":5505,"briefTitle":5506,"status":142,"phases":5507,"primaryCompletion":1320,"start":3390,"enrollment":1913,"conditions":5508,"interventions":5512},"NCT00055809","Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors",[90],[5509,5510,5511],"Metastatic Gastrointestinal Carcinoid Tumor","Recurrent Gastrointestinal Carcinoid Tumor","Regional Gastrointestinal Carcinoid Tumor",[5513,1033],"PEG-interferon alfa-2b",{"nctId":5515,"briefTitle":5516,"status":142,"phases":5517,"primaryCompletion":5518,"completion":5519,"start":5520,"enrollment":913,"conditions":5521,"interventions":5523},"NCT00436215","Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer",[90],"2014-06-26","2014-09-27","2006-12-12",[5522,2569,2568],"Ovarian Neoplasm",[53,1919],{"nctId":5525,"briefTitle":5526,"status":142,"phases":5527,"primaryCompletion":5528,"completion":5528,"start":5529,"enrollment":5530,"conditions":5531,"interventions":5557},"NCT01010126","Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer",[90],"2017-03-13","2009-09-08",252,[5532,5533,1944,5534,5535,5536,5537,5538,5539,5540,1730,1732,2740,2671,5541,5542,5543,5544,5545,5546,5547,250,251,5548,252,5549,5550,3484,3485,3486,5551,3487,3488,3489,5552,3490,3491,3492,5553,3493,3494,3495,5554,5555,5556],"Adult Hepatocellular Carcinoma","Advanced Adult Hepatocellular Carcinoma","Localized Non-Resectable Adult Liver Carcinoma","Lung Carcinoid Tumor","Malignant Pancreatic Gastrinoma","Malignant Pancreatic Glucagonoma","Malignant Pancreatic Insulinoma","Malignant Pancreatic Somatostatinoma","Metastatic Digestive System Neuroendocrine Tumor G1","Pancreatic Alpha Cell Adenoma","Pancreatic Beta Cell Adenoma","Pancreatic Delta Cell Adenoma","Pancreatic G-Cell Adenoma","Pancreatic Polypeptide Tumor","Recurrent Adult Liver Carcinoma","Recurrent Digestive System Neuroendocrine Tumor G1","Recurrent Pancreatic Neuroendocrine Carcinoma","Recurrent Uterine Corpus Carcinoma","Regional Digestive System Neuroendocrine Tumor G1","Stage IIIA Uterine Corpus Cancer","Stage IIIB Uterine Corpus Cancer","Stage IIIC Uterine Corpus Cancer","Stage IVA Uterine Corpus Cancer","Stage IVB Uterine Corpus Cancer","Uterine Carcinosarcoma",[53,2143],{"nctId":5559,"briefTitle":5560,"status":142,"phases":5561,"primaryCompletion":4359,"completion":5562,"start":4612,"enrollment":3255,"conditions":5563,"interventions":5564},"NCT00126490","Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer",[90],"2013-08",[4825,4842],[677,53],{"nctId":5566,"briefTitle":5567,"status":618,"phases":5568,"primaryCompletion":1604,"completion":1604,"start":5569,"enrollment":28,"conditions":5570,"interventions":5575},"NCT03050814","Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004",[90],"2017-04-05",[5571,5572,5573,5574,856],"Colorectal Tumors","Colorectal Neoplasms","Colorectal Carcinoma","Colorectal Adenocarcinoma",[5576,5577,53,5578,4966,2925,2924,5578],"Avelumab","Ad-CEA vaccine","5-Fluorouracil",{"nctId":5580,"briefTitle":5581,"status":142,"phases":5582,"primaryCompletion":5583,"completion":5584,"start":5103,"enrollment":5585,"conditions":5586,"interventions":5587},"NCT01648348","Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme",[89,90],"2016-05-11","2017-04-15",116,[4813,4815,4817,4818,4819,4820,4821],[5492,53],{"nctId":1326,"briefTitle":1327,"status":142,"phases":5589,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":1331,"conditions":5590,"interventions":5591},[90],[1244,1247,1333,1334],[1063,1033,693,994,1032,1082],{"trials":5593,"activeCount":603,"soonestReadout":52},[5594,5598,5602,5606,5618,5630,5640,5644],{"nctId":5100,"briefTitle":5101,"status":618,"phases":5595,"primaryCompletion":5103,"completion":5103,"start":1320,"enrollment":1953,"conditions":5596,"interventions":5597},[91],[4941,4942,4844,4845,4846,4847],[5106,1264,3065,1697,1033],{"nctId":70,"briefTitle":71,"status":155,"phases":5599,"primaryCompletion":72,"completion":2050,"start":2051,"enrollment":2052,"conditions":5600,"interventions":5601},[91],[2054,1867,1868,1869,1870,2055,1873,1874,2056,2057,2058,2059,2060,2061,2062,2063,2064,2065,2066,2067,2068,2069,2070,2071,2072,2073,2074,2075,2076,2077,2078,2079,2080,2081,1895],[53,277,278,2083,2084],{"nctId":50,"briefTitle":51,"status":155,"phases":5603,"primaryCompletion":52,"completion":3410,"start":3411,"enrollment":234,"conditions":5604,"interventions":5605},[91],[3413,1787,250,251,3414,3415,3416,3417,3418,3419,1740,1741,1742,1743,1744,1745,1746,1747,1749,1750,1752,1753,1755,1756],[53,2924,277,2925,449],{"nctId":5607,"briefTitle":5608,"status":142,"phases":5609,"primaryCompletion":5610,"completion":5611,"start":2028,"enrollment":5612,"conditions":5613,"interventions":5617},"NCT01236560","Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma",[90,91],"2023-06-30","2023-12-31",101,[5614,5615,5616,5361,5362],"Brain Stem Glioma","Cerebral Astrocytoma","Childhood Cerebellar Anaplastic Astrocytoma",[53,151,942],{"nctId":5619,"briefTitle":5620,"status":142,"phases":5621,"primaryCompletion":5622,"completion":5623,"start":5624,"enrollment":5625,"conditions":5626,"interventions":5628},"NCT00601900","Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer",[91],"2014-06-30","2025-05-01","2008-09-24",394,[3909,2613,5627,3082],"Stage III Breast Cancer AJCC v6",[53,5629,1454],"Letrozole",{"nctId":5631,"briefTitle":5632,"status":142,"phases":5633,"primaryCompletion":5634,"start":1257,"enrollment":5635,"conditions":5636,"interventions":5639},"NCT00088894","Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[91],"2006-06",590,[5637,3259,5638,3260,3261],"Adenocarcinoma of the Pancreas","Stage II Pancreatic Cancer",[3066,1033],{"nctId":3476,"briefTitle":3477,"status":142,"phases":5641,"primaryCompletion":3479,"completion":3128,"start":3480,"enrollment":3481,"conditions":5642,"interventions":5643},[91],[1722,1723,1724,2645,1726,3483,1728,1731,1732,1733,1735,1736,1739,3484,3485,3486,3487,3488,3489,3490,3491,3492,3493,3494,3495,3496,3497],[53,277,449],{"nctId":5160,"briefTitle":5161,"status":155,"phases":5645,"primaryCompletion":5163,"completion":5164,"start":5165,"enrollment":5166,"conditions":5646,"interventions":5647},[91],[3043,5168,5169,5170],[53,2084,4966,2925],{"trials":5649,"activeCount":101},[],{"trials":5651,"activeCount":101},[],{"intervention":667,"totalTrials":1041,"cells":5653},{"EARLY_PHASE1":5654,"PHASE1":5656,"PHASE2":5686,"PHASE3":5812,"PHASE4":5826,"NA":5828},{"trials":5655,"activeCount":101},[],{"trials":5657,"activeCount":758,"soonestReadout":57},[5658,5666,5670,5674,5678,5682],{"nctId":5659,"briefTitle":5660,"status":618,"phases":5661,"primaryCompletion":4900,"start":1231,"enrollment":31,"conditions":5662,"interventions":5664},"NCT00612612","Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia",[89],[5663,1260,654,656,657,659,661,663],"B-cell Chronic Lymphocytic Leukemia",[5665,819,1063],"obatoclax mesylate",{"nctId":646,"briefTitle":647,"status":618,"phases":5667,"primaryCompletion":649,"start":650,"enrollment":651,"conditions":5668,"interventions":5669},[89],[653,654,655,656,657,658,659,660,661,662,663,664],[666,63,667],{"nctId":55,"briefTitle":56,"status":155,"phases":5671,"primaryCompletion":57,"completion":4569,"start":4570,"enrollment":97,"conditions":5672,"interventions":5673},[89],[4572,4573,4574,4575,935,936,4576,4577,937,4578,4579,938],[58,1016,667],{"nctId":724,"briefTitle":725,"status":155,"phases":5675,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":5676,"interventions":5677},[89],[732,733,734,735],[63,737,279,738,58,739,212,667,740],{"nctId":766,"briefTitle":767,"status":618,"phases":5679,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":5680,"interventions":5681},[89],[773,774,775,776,777],[667,279,779,63,780,781,212],{"nctId":3565,"briefTitle":3566,"status":142,"phases":5683,"primaryCompletion":3568,"completion":3568,"start":3569,"enrollment":34,"conditions":5684,"interventions":5685},[89],[3571,527,537],[277,279,58,1101,667],{"trials":5687,"activeCount":758,"soonestReadout":1010},[5688,5694,5698,5702,5710,5720,5727,5731,5737,5741,5748,5759,5763,5767,5774,5778,5782,5786,5798,5802],{"nctId":5689,"briefTitle":5690,"status":142,"phases":5691,"primaryCompletion":1022,"completion":1022,"start":3390,"enrollment":1765,"conditions":5692,"interventions":5693},"NCT00054639","Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",[90],[4782,1245,4784,1246,3180,3181,3182,3183,3184,3185,3186,3187,3188,940,3189,3190,655,4795,1248,1250,1251],[3590,1063],{"nctId":3584,"briefTitle":3585,"status":142,"phases":5695,"primaryCompletion":3587,"start":3397,"enrollment":37,"conditions":5696,"interventions":5697},[89,90],[3181,940,3189],[3590,1063,3591,1776,1080,750,1066],{"nctId":923,"briefTitle":924,"status":142,"phases":5699,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":5700,"interventions":5701},[89,90],[931,932,933,934,733,935,936,734,937,735,938,939,522,524,527,940],[63,737,279,212,667,740,942],{"nctId":5703,"briefTitle":5704,"status":142,"phases":5705,"primaryCompletion":5706,"start":5707,"enrollment":3639,"conditions":5708,"interventions":5709},"NCT00026182","Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",[90],"2005-02","2001-10",[1245,1246,3187,3188,3189,655,1248],[1063,3123],{"nctId":5711,"briefTitle":5712,"status":618,"phases":5713,"primaryCompletion":650,"completion":650,"start":3088,"enrollment":5714,"conditions":5715,"interventions":5716},"NCT00012298","Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[89,90],81,[1245,1246,3187,3188,940,3190,655,1248,1251],[1063,5717,5718,5719,750],"yttrium Y 90 ibritumomab tiuxetan","indium In 111 ibritumomab tiuxetan","oprelvekin",{"nctId":5721,"briefTitle":5722,"status":142,"phases":5723,"primaryCompletion":5724,"completion":4878,"start":3671,"enrollment":9,"conditions":5725,"interventions":5726},"NCT00109967","CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],"2009-09",[3189],[1063,4566],{"nctId":1007,"briefTitle":1008,"status":155,"phases":5728,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":407,"conditions":5729,"interventions":5730},[89,90],[524,1014],[1016,667,212,279,780,781,63],{"nctId":5732,"briefTitle":5733,"status":618,"phases":5734,"primaryCompletion":2293,"start":1576,"enrollment":3869,"conditions":5735,"interventions":5736},"NCT00301795","Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma",[90],[3205,3206,3207,3214,3215,3216],[3590,1063],{"nctId":1049,"briefTitle":1050,"status":142,"phases":5738,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":5739,"interventions":5740},[90],[1056,1057,1058,1059,1060],[1062,1063,693,994,1064,1065,750,1066],{"nctId":5742,"briefTitle":5743,"status":142,"phases":5744,"primaryCompletion":1230,"completion":1230,"start":3526,"enrollment":949,"conditions":5745,"interventions":5746},"NCT00098670","Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia",[90],[5663,657,659,661,663],[5747,1063,819],"alemtuzumab",{"nctId":5749,"briefTitle":5750,"status":142,"phases":5751,"primaryCompletion":5752,"completion":5752,"start":5753,"enrollment":2586,"conditions":5754,"interventions":5757},"NCT00001563","EPOCH Chemotherapy +\u002F- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma",[90],"2005-05-05","1997-01-08",[5755,5756],"AIDS Related Lymphoma","AIDS-Associated Lymphoma",[738,667,5758],"EPOCH",{"nctId":1156,"briefTitle":1157,"status":142,"phases":5760,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":5761,"interventions":5762},[90],[657,659,661,663],[63,1165,1016,667],{"nctId":1201,"briefTitle":1202,"status":142,"phases":5764,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":5765,"interventions":5766},[90],[776,1208,773,1209,1210],[279,667,212,63,781,780],{"nctId":5768,"briefTitle":5769,"status":107,"phases":5770,"primaryCompletion":2004,"start":3282,"enrollment":101,"conditions":5771,"interventions":5772},"NCT01238146","Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",[89,90],[1245,1246,3187,3188,3189,3190,1248],[5773,5665,1063],"bendamustine hydrochloride",{"nctId":3996,"briefTitle":3997,"status":128,"phases":5775,"primaryCompletion":3999,"completion":3999,"start":4000,"enrollment":4001,"conditions":5776,"interventions":5777},[90],[1485,4003],[58,667,2217,4005],{"nctId":1237,"briefTitle":1238,"status":618,"phases":5779,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":5780,"interventions":5781},[90],[1244,1245,1246,1247,1248,1249,1250,1251],[1063,1082,693,1225,1064],{"nctId":1272,"briefTitle":1273,"status":142,"phases":5783,"primaryCompletion":1275,"completion":1275,"start":1276,"enrollment":1277,"conditions":5784,"interventions":5785},[90],[1279,1280,1281,1282],[1063,1080,994,1032,1082,693],{"nctId":5787,"briefTitle":5788,"status":142,"phases":5789,"primaryCompletion":5790,"completion":5791,"start":5792,"enrollment":2265,"conditions":5793,"interventions":5796},"NCT00114738","EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma",[90],"2016-08-11","2022-08-11","2005-06-15",[5794,5795],"Lymphoma, Mantle Cell","Mantle Cell Lymphoma",[667,5758,1569,1569,5797],"Bortezomib or observation",{"nctId":1326,"briefTitle":1327,"status":142,"phases":5799,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":1331,"conditions":5800,"interventions":5801},[90],[1244,1247,1333,1334],[1063,1033,693,994,1032,1082],{"nctId":5803,"briefTitle":5804,"status":142,"phases":5805,"primaryCompletion":5806,"completion":5807,"start":5808,"enrollment":651,"conditions":5809,"interventions":5811},"NCT01381692","Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma",[89,90],"2014-12-08","2021-09-01","2011-07-20",[4592,3189,3190,4530,655,5810,4531,4536,4537,4539,4540],"Recurrent Waldenstrom Macroglobulinemia",[1569,1139,667,2143],{"trials":5813,"activeCount":758,"soonestReadout":1365},[5814,5818,5822],{"nctId":1353,"briefTitle":1354,"status":142,"phases":5815,"primaryCompletion":715,"start":1356,"enrollment":1357,"conditions":5816,"interventions":5817},[91],[27],[750,1063,1360,693,994,1082,1032],{"nctId":1362,"briefTitle":1363,"status":155,"phases":5819,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":5820,"interventions":5821},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1474,"briefTitle":1475,"status":155,"phases":5823,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":5824,"interventions":5825},[90,91],[734,1481,735,510,511,512,513,514,1482,516,517,1483,1484,518,519,1485,1486,1487,1488,1489,1490],[63,737,1492,212,667,1493,740],{"trials":5827,"activeCount":101},[],{"trials":5829,"activeCount":101},[],{"intervention":151,"totalTrials":1195,"cells":5831},{"EARLY_PHASE1":5832,"PHASE1":5834,"PHASE2":5902,"PHASE3":5996,"PHASE4":6010,"NA":6012},{"trials":5833,"activeCount":101},[],{"trials":5835,"activeCount":758,"soonestReadout":5879},[5836,5840,5854,5862,5875,5886,5896],{"nctId":140,"briefTitle":141,"status":142,"phases":5837,"primaryCompletion":144,"completion":145,"start":146,"enrollment":22,"conditions":5838,"interventions":5839},[89],[148,149],[124,96,151],{"nctId":5841,"briefTitle":5842,"status":142,"phases":5843,"completion":5844,"start":5845,"enrollment":651,"conditions":5846,"interventions":5852},"NCT00994071","A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent\u002FRefractory CNS Tumors",[89],"2013-03-19","2009-09-22",[5847,5848,5849,5850,5851],"Medulloblastoma","Pontine Glioma","Ependymoma","Astrocytoma","PNET",[151,5853],"ABT-888",{"nctId":5855,"briefTitle":5856,"status":142,"phases":5857,"primaryCompletion":1320,"completion":5858,"start":988,"enrollment":3255,"conditions":5859,"interventions":5860},"NCT02227901","Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[89],"2014-04",[4817,4818,4819],[5861,151],"Tipifarnib",{"nctId":5863,"briefTitle":5864,"status":142,"phases":5865,"primaryCompletion":3304,"start":4997,"enrollment":5866,"conditions":5867,"interventions":5873},"NCT00077454","Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors",[89],95,[5868,4658,4659,4660,4661,5869,4662,5870,5871,4665,117,5872],"Previously Treated Childhood Rhabdomyosarcoma","Recurrent Childhood Malignant Germ Cell Tumor","Recurrent Childhood Rhabdomyosarcoma","Recurrent Childhood Soft Tissue Sarcoma","Recurrent Osteosarcoma",[1774,5874],"temozolomide",{"nctId":5876,"briefTitle":5877,"status":155,"phases":5878,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":421,"conditions":5881,"interventions":5884},"NCT03528642","Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma",[89],"2026-09-11","2019-05-01",[5882,5883],"Astrocytoma, IDH-Mutant, Grade 2","Astrocytoma, IDH-Mutant, Grade 3",[5885,151],"Telaglenastat Hydrochloride",{"nctId":5887,"briefTitle":5888,"status":128,"phases":5889,"primaryCompletion":5890,"completion":418,"start":5891,"enrollment":421,"conditions":5892,"interventions":5893},"NCT06995872","Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan\u002FTemozolomide for Children and Young Adults With Relapsed\u002FRefractory Neuroblastoma",[89],"2028-06-01","2025-10-21",[791],[5894,5895,151,1102],"rhIL-15","Dinituximab",{"nctId":5897,"briefTitle":5898,"status":142,"phases":5899,"primaryCompletion":1320,"completion":1320,"start":988,"enrollment":3255,"conditions":5900,"interventions":5901},"NCT00049387","Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",[89],[4817,4818,4819],[1185,5874],{"trials":5903,"activeCount":758,"soonestReadout":1477},[5904,5912,5923,5934,5938,5949,5953,5962,5972,5981,5992],{"nctId":5905,"briefTitle":5906,"status":128,"phases":5907,"primaryCompletion":2930,"completion":2930,"start":5908,"enrollment":1128,"conditions":5909,"interventions":5911},"NCT05432804","Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment",[89,90],"2023-03-20",[2976,5910],"Recurrent MGMT-Methylated Glioblastoma",[3001,151],{"nctId":5913,"briefTitle":5914,"status":128,"phases":5915,"primaryCompletion":1477,"completion":1477,"start":5916,"enrollment":16,"conditions":5917,"interventions":5921},"NCT05691491","Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness",[89,90],"2023-09-28",[21,5918,5919,486,5014,5920,5016],"Advanced Microsatellite Stable Colorectal Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Stage III Colorectal Cancer AJCC v8",[151,5922],"Tuvusertib",{"nctId":5924,"briefTitle":5925,"status":142,"phases":5926,"primaryCompletion":5927,"completion":5928,"start":5929,"enrollment":1331,"conditions":5930,"interventions":5932},"NCT01767194","Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma",[90],"2018-06-30","2022-09-30","2013-02-12",[5931,117],"Ganglioneuroblastoma",[1402,1102,5933,151,2143],"Sargramostim",{"nctId":1086,"briefTitle":1087,"status":142,"phases":5935,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":5936,"interventions":5937},[90],[1092,1093,1094,1095,1096,1097],[1099,63,1100,737,279,1101,1102,151,1103],{"nctId":5939,"briefTitle":5940,"status":142,"phases":5941,"primaryCompletion":2262,"completion":5942,"start":5943,"enrollment":19,"conditions":5944,"interventions":5946},"NCT03554473","M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers",[89,90],"2025-03-13","2018-09-11",[5945,687,2719],"Carcinoma, Small Cell",[2256,1407,151,706,5947,2218,1139,5948],"Antihistamines","Epinephrine",{"nctId":5407,"briefTitle":5408,"status":142,"phases":5950,"primaryCompletion":144,"completion":5410,"start":5411,"enrollment":5412,"conditions":5951,"interventions":5952},[90],[5414,5415,5416,5417,5418,5419],[53,1102,151],{"nctId":5954,"briefTitle":5955,"status":142,"phases":5956,"primaryCompletion":5957,"completion":1329,"start":5958,"enrollment":623,"conditions":5959,"interventions":5960},"NCT00275002","O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors",[90],"2010-12-01","2006-02",[3664],[5961,5874],"O6-benzylguanine",{"nctId":5963,"briefTitle":5964,"status":347,"phases":5965,"primaryCompletion":361,"completion":799,"start":5966,"enrollment":609,"conditions":5967,"interventions":5970},"NCT04890093","Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors",[89,90],"2024-10-31",[5968,5969],"Sarcoma, Ewing","Rhabdomyosarcoma",[5971,781,151],"PEN-866",{"nctId":5973,"briefTitle":5974,"status":142,"phases":5975,"primaryCompletion":5103,"completion":5103,"start":5976,"enrollment":5977,"conditions":5978,"interventions":5979},"NCT00085254","Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[89,90],"2005-04",112,[4817,4818,4819],[5980,5874],"cilengitide",{"nctId":5982,"briefTitle":5983,"status":142,"phases":5984,"primaryCompletion":1052,"completion":5985,"start":1576,"enrollment":5986,"conditions":5987,"interventions":5990},"NCT00302159","Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors",[90],"2014-11",43,[5988,5989],"High Grade Gliomas","Brain Tumors",[151,5991],"Valproic Acid",{"nctId":3843,"briefTitle":3844,"status":618,"phases":5993,"primaryCompletion":3846,"completion":3846,"start":3847,"enrollment":443,"conditions":5994,"interventions":5995},[90],[394],[883,3850,151],{"trials":5997,"activeCount":758,"soonestReadout":2797},[5998,6002,6006],{"nctId":2794,"briefTitle":2795,"status":155,"phases":5999,"primaryCompletion":2797,"completion":2798,"start":2799,"enrollment":159,"conditions":6000,"interventions":6001},[90,91],[2801,2802,2803,2804,2805],[2554,2807,151,2808],{"nctId":1393,"briefTitle":1394,"status":128,"phases":6003,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":6004,"interventions":6005},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":5607,"briefTitle":5608,"status":142,"phases":6007,"primaryCompletion":5610,"completion":5611,"start":2028,"enrollment":5612,"conditions":6008,"interventions":6009},[90,91],[5614,5615,5616,5361,5362],[53,151,942],{"trials":6011,"activeCount":101},[],{"trials":6013,"activeCount":101},[],{"intervention":1139,"totalTrials":3255,"cells":6015},{"EARLY_PHASE1":6016,"PHASE1":6018,"PHASE2":6049,"PHASE3":6114,"PHASE4":6142,"NA":6144},{"trials":6017,"activeCount":101},[],{"trials":6019,"activeCount":2548,"soonestReadout":5879},[6020,6030,6034,6038,6042],{"nctId":6021,"briefTitle":6022,"status":142,"phases":6023,"primaryCompletion":6024,"completion":6024,"start":6025,"enrollment":623,"conditions":6026,"interventions":6028},"NCT01711528","Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",[89],"2016-11-22","2012-12-19",[6027],"Recurrent Plasma Cell Myeloma",[1569,1139,6029],"Dinaciclib",{"nctId":4543,"briefTitle":4544,"status":142,"phases":6031,"primaryCompletion":4546,"completion":4547,"start":4548,"enrollment":34,"conditions":6032,"interventions":6033},[89],[4550,4551,4552,4553],[4555,1016,4556,1139],{"nctId":2437,"briefTitle":2438,"status":618,"phases":6035,"primaryCompletion":2440,"completion":2441,"start":756,"enrollment":758,"conditions":6036,"interventions":6037},[89],[915],[2444,2445,2218,710,706,1139],{"nctId":4597,"briefTitle":4598,"status":618,"phases":6039,"primaryCompletion":454,"completion":454,"start":4600,"enrollment":638,"conditions":6040,"interventions":6041},[89],[4602,4603,4262],[4605,1139,4606,1016,3942],{"nctId":6043,"briefTitle":6044,"status":155,"phases":6045,"primaryCompletion":5879,"completion":5879,"start":6046,"enrollment":700,"conditions":6047,"interventions":6048},"NCT03798678","CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma",[89],"2019-07-08",[4603,4262],[4605,1139,5885],{"trials":6050,"activeCount":214,"soonestReadout":62},[6051,6062,6066,6070,6074,6078,6086,6090,6094,6110],{"nctId":6052,"briefTitle":6053,"status":618,"phases":6054,"primaryCompletion":6055,"completion":6055,"start":6056,"enrollment":1517,"conditions":6057,"interventions":6059},"NCT00923273","Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer",[89,90],"2013-03-10","2008-02-29",[6058],"Carcinoma, Non-Small-Cell Lung",[6060,6061,460,1139],"FDG-PET","Pemetrexed",{"nctId":4689,"briefTitle":4690,"status":3027,"phases":6063,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":159,"conditions":6064,"interventions":6065},[90],[4695],[4605,4697,1139,1016,1405,4698,4699,4700],{"nctId":1049,"briefTitle":1050,"status":142,"phases":6067,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":6068,"interventions":6069},[90],[1056,1057,1058,1059,1060],[1062,1063,693,994,1064,1065,750,1066],{"nctId":5939,"briefTitle":5940,"status":142,"phases":6071,"primaryCompletion":2262,"completion":5942,"start":5943,"enrollment":19,"conditions":6072,"interventions":6073},[89,90],[5945,687,2719],[2256,1407,151,706,5947,2218,1139,5948],{"nctId":60,"briefTitle":61,"status":155,"phases":6075,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":6076,"interventions":6077},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":6079,"briefTitle":6080,"status":3027,"phases":6081,"primaryCompletion":3244,"completion":3244,"start":6082,"enrollment":6083,"conditions":6084,"interventions":6085},"NCT07463807","Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment",[89,90],"2026-06-26",162,[4603,4262],[4605,1139,138,4700],{"nctId":4710,"briefTitle":4711,"status":142,"phases":6087,"primaryCompletion":4713,"completion":4714,"start":4715,"enrollment":2586,"conditions":6088,"interventions":6089},[90],[4717,1431,1432],[1033,4565,1065],{"nctId":1254,"briefTitle":1255,"status":142,"phases":6091,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":6092,"interventions":6093},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"nctId":6095,"briefTitle":6096,"status":128,"phases":6097,"primaryCompletion":799,"completion":2114,"start":2423,"enrollment":1111,"conditions":6098,"interventions":6108},"NCT05286814","PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma",[90],[6099,6100,6101,5572,856,854,6102,3860,6103,6104,6105,6106,6107],"Metastatic Colorectal Cancer (Mcrc)","Intrahepatic Cholangiocarcinoma (Icc)","Intrahepatic Bile Duct Cancer","Bile Duct Neoplasms","Adrenocortical Carcinoma (ACC)","Adrenal Cortical Carcinoma","Adrenal Gland Cancer","Adrenal Gland Neoplasms","Adrenal Cortex Neoplasms",[1139,2255,6109],"Floxuridine",{"nctId":5803,"briefTitle":5804,"status":142,"phases":6111,"primaryCompletion":5806,"completion":5807,"start":5808,"enrollment":651,"conditions":6112,"interventions":6113},[89,90],[4592,3189,3190,4530,655,5810,4531,4536,4537,4539,4540],[1569,1139,667,2143],{"trials":6115,"activeCount":2548,"soonestReadout":1365},[6116,6120,6124,6133],{"nctId":1362,"briefTitle":1363,"status":155,"phases":6117,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":6118,"interventions":6119},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1378,"briefTitle":1379,"status":142,"phases":6121,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":6122,"interventions":6123},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"nctId":6125,"briefTitle":6126,"status":142,"phases":6127,"primaryCompletion":1576,"completion":5634,"start":4142,"conditions":6128,"interventions":6130},"NCT00033332","Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",[91],[6129],"Multiple Myeloma and Plasma Cell Neoplasm",[1065,6131,3470,6132],"pamidronate disodium","zoledronic acid",{"nctId":6134,"briefTitle":6135,"status":142,"phases":6136,"primaryCompletion":6137,"completion":6138,"start":3479,"enrollment":375,"conditions":6139,"interventions":6141},"NCT01078454","Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis",[91],"2012-11-12","2012-11-27",[4738,6140],"Primary Systemic Amyloidosis",[1081,1065,1062],{"trials":6143,"activeCount":101},[],{"trials":6145,"activeCount":101},[],{"intervention":240,"totalTrials":651,"cells":6147},{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6162,"PHASE3":6209,"PHASE4":6226,"NA":6228},{"trials":6149,"activeCount":101},[],{"trials":6151,"activeCount":101},[6152],{"nctId":6153,"briefTitle":6154,"status":142,"phases":6155,"primaryCompletion":6156,"completion":6157,"start":6158,"enrollment":700,"conditions":6159,"interventions":6161},"NCT01822522","Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus",[89],"2019-05-22","2021-05-12","2013-06-21",[21,939,486,116,6160],"Unresectable Solid Neoplasm",[240],{"trials":6163,"activeCount":838,"soonestReadout":372},[6164,6168,6177,6181,6185,6193,6197],{"nctId":229,"briefTitle":230,"status":128,"phases":6165,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":6166,"interventions":6167},[90],[236,237,238],[240,124,96],{"nctId":6169,"briefTitle":6170,"status":128,"phases":6171,"primaryCompletion":6172,"completion":6172,"start":6173,"enrollment":4001,"conditions":6174,"interventions":6176},"NCT06811116","Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial",[89,90],"2027-08-31","2025-11-17",[6175,803,3363,3369],"Advanced Hepatocellular Carcinoma",[240,5225],{"nctId":369,"briefTitle":370,"status":155,"phases":6178,"primaryCompletion":372,"completion":373,"start":374,"enrollment":375,"conditions":6179,"interventions":6180},[90],[377,378,379,380,381,382,383,384,385],[240,124,96],{"nctId":401,"briefTitle":402,"status":155,"phases":6182,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":6183,"interventions":6184},[90],[409,410,411,412],[240,124,96],{"nctId":6186,"briefTitle":6187,"status":142,"phases":6188,"primaryCompletion":6189,"completion":6189,"start":6190,"enrollment":2577,"conditions":6191,"interventions":6192},"NCT02315430","Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90],"2019-02-09","2015-04-01",[1722,1731,250,251,252],[240],{"nctId":437,"briefTitle":438,"status":155,"phases":6194,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":6195,"interventions":6196},[90],[445,446,447],[240,96,449],{"nctId":6198,"briefTitle":6199,"status":142,"phases":6200,"primaryCompletion":6201,"start":6202,"enrollment":6203,"conditions":6204,"interventions":6208},"NCT01835158","Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer",[90],"2016-04-18","2013-07-08",157,[5232,6205,6206,6207],"Metastatic Kidney Carcinoma","Stage III Renal Cell Cancer AJCC v7","Stage IV Renal Cell Cancer AJCC v7",[240,1832],{"trials":6210,"activeCount":2548,"soonestReadout":6215},[6211],{"nctId":6212,"briefTitle":6213,"status":155,"phases":6214,"primaryCompletion":6215,"completion":6215,"start":6216,"enrollment":6217,"conditions":6218,"interventions":6225},"NCT05092958","Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study",[91],"2026-06-15","2022-06-03",654,[6219,6220,6221,6222,1854,2937,1856,2938,2696,6223,2943,2944,2945,2697,6224,2946,2947,2948],"Advanced Bladder Urothelial Carcinoma","Advanced Renal Pelvis Urothelial Carcinoma","Advanced Ureter Urothelial Carcinoma","Advanced Urethral Urothelial Carcinoma","Stage III Renal Pelvis and Ureter Cancer AJCC v8","Stage IV Renal Pelvis and Ureter Cancer AJCC v8",[5576,240],{"trials":6227,"activeCount":101},[],{"trials":6229,"activeCount":101},[],{"intervention":1137,"totalTrials":407,"cells":6231},{"EARLY_PHASE1":6232,"PHASE1":6234,"PHASE2":6297,"PHASE3":6332,"PHASE4":6346,"NA":6348},{"trials":6233,"activeCount":101},[],{"trials":6235,"activeCount":758,"soonestReadout":1382},[6236,6243,6252,6261,6265,6280,6288],{"nctId":6237,"briefTitle":6238,"status":142,"phases":6239,"primaryCompletion":1309,"start":1952,"enrollment":2883,"conditions":6240,"interventions":6241},"NCT00070551","GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia",[89],[4043,4044,4045,4046,4047,33],[6242,1187],"GTI-2040",{"nctId":6244,"briefTitle":6245,"status":155,"phases":6246,"primaryCompletion":1603,"completion":1603,"start":6247,"enrollment":1765,"conditions":6248,"interventions":6249},"NCT03983824","Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia",[89],"2020-05-05",[2427,2430],[1137,1471,6250,6251],"Mitoxantrone Hydrochloride","Peposertib",{"nctId":6253,"briefTitle":6254,"status":142,"phases":6255,"primaryCompletion":6256,"start":6257,"enrollment":407,"conditions":6258,"interventions":6260},"NCT01130506","Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",[89],"2012-11-19","2010-05-17",[2426,33,2430,2432,6259,4132],"Therapy-Related Acute Myeloid Leukemia",[1137,2435,942],{"nctId":4028,"briefTitle":4029,"status":142,"phases":6262,"primaryCompletion":4031,"start":4032,"enrollment":37,"conditions":6263,"interventions":6264},[89],[4034,4035,4036,4037,4038,4039,4040,4041,4042,4043,4044,4045,4046,4047,4048,4049,4050,4051,4052,4053,4054,2453,4055,4056,3625,4057,3628,4058,4059,1135,33,4060,2432,4061],[4063,1187,1080],{"nctId":6266,"briefTitle":6267,"status":155,"phases":6268,"primaryCompletion":1382,"completion":6269,"start":6270,"enrollment":771,"conditions":6271,"interventions":6277},"NCT05146739","Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane",[89],"2027-05-09","2023-10-10",[6272,6273,6274,2427,6275,2429,2430,6276,2431],"Acute Myeloid Leukemia Post Cytotoxic Therapy","Myelodysplastic Syndrome Post Cytotoxic Therapy","Myeloid Leukemia Associated With Down Syndrome","Recurrent Mixed Phenotype Acute Leukemia","Refractory Mixed Phenotype Acute Leukemia",[1137,643,4966,6278,6279],"Triple Intrathecal Chemotherapy","Uproleselan",{"nctId":6281,"briefTitle":6282,"status":142,"phases":6283,"primaryCompletion":1275,"start":4639,"enrollment":1517,"conditions":6284,"interventions":6286},"NCT00098423","Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes",[89],[4034,4035,4036,4037,4038,4039,4040,4041,4042,4043,4044,4046,4047,4048,4050,4051,4053,2453,4056,4058,1135,33,6285,4060,2432,4061],"Refractory Anemia With Excess Blasts in Transformation",[6287,1187],"tanespimycin",{"nctId":6289,"briefTitle":6290,"status":142,"phases":6291,"primaryCompletion":6292,"completion":6292,"start":6293,"enrollment":339,"conditions":6294,"interventions":6295},"NCT01249430","Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[89],"2013-05-24","2011-01-20",[33,2430],[6296,1137,1471,6250],"Azacitidine",{"trials":6298,"activeCount":758,"soonestReadout":62},[6299,6308,6312,6316,6320,6324,6328],{"nctId":6300,"briefTitle":6301,"status":142,"phases":6302,"primaryCompletion":6303,"completion":6303,"start":3155,"enrollment":6304,"conditions":6305,"interventions":6307},"NCT01349972","Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[90],"2014-05",172,[6306,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,2432,4132],"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome",[1998,1263,2324,1187],{"nctId":4119,"briefTitle":4120,"status":142,"phases":6309,"primaryCompletion":4122,"completion":4123,"start":4124,"enrollment":4125,"conditions":6310,"interventions":6311},[90],[263,4127,4128,4129,4130,4131,4132],[980,1137,1374,2435,279,738],{"nctId":5375,"briefTitle":5376,"status":618,"phases":6313,"primaryCompletion":4715,"start":3526,"enrollment":1357,"conditions":6314,"interventions":6315},[90],[4035,4036,4037,4038,4039,4040,4041,4042,4043,4048,4050,4051,4168,4169,4170,4171,4173,4174,4175,4176,4177,2432,4132,5379],[4180,1187,1033],{"nctId":4162,"briefTitle":4163,"status":142,"phases":6317,"primaryCompletion":3226,"completion":3226,"start":4165,"enrollment":3869,"conditions":6318,"interventions":6319},[90],[4039,4040,4041,4042,4043,4167,4045,4046,4048,4168,4169,4170,4171,4172,4173,4174,4175,4176,4177,33,4178,2432],[4180,1187,1062,1080],{"nctId":60,"briefTitle":61,"status":155,"phases":6321,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":6322,"interventions":6323},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":3968,"briefTitle":3969,"status":155,"phases":6325,"primaryCompletion":3971,"completion":3972,"start":3973,"enrollment":838,"conditions":6326,"interventions":6327},[89,90],[263],[1137,1373,3976,2217],{"nctId":1178,"briefTitle":1179,"status":142,"phases":6329,"primaryCompletion":987,"start":1181,"enrollment":248,"conditions":6330,"interventions":6331},[90],[1183],[1185,1186,819,1187,693,1188],{"trials":6333,"activeCount":2548,"soonestReadout":1365},[6334,6338,6342],{"nctId":1362,"briefTitle":1363,"status":155,"phases":6335,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":6336,"interventions":6337},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1378,"briefTitle":1379,"status":142,"phases":6339,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":6340,"interventions":6341},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"nctId":4228,"briefTitle":4229,"status":142,"phases":6343,"primaryCompletion":4231,"start":4232,"enrollment":4233,"conditions":6344,"interventions":6345},[91],[4037,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,4132],[1187,1263,1080,4236],{"trials":6347,"activeCount":101},[],{"trials":6349,"activeCount":101},[],{"intervention":781,"totalTrials":375,"cells":6351},{"EARLY_PHASE1":6352,"PHASE1":6354,"PHASE2":6360,"PHASE3":6390,"PHASE4":6404,"NA":6406},{"trials":6353,"activeCount":101},[],{"trials":6355,"activeCount":101},[6356],{"nctId":766,"briefTitle":767,"status":618,"phases":6357,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":6358,"interventions":6359},[89],[773,774,775,776,777],[667,279,779,63,780,781,212],{"trials":6361,"activeCount":758,"soonestReadout":2262},[6362,6366,6370,6374,6378,6382,6386],{"nctId":2259,"briefTitle":2260,"status":155,"phases":6363,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":6364,"interventions":6365},[90],[902,2267,2268,2269,2270],[1372,1138,1375,1141,2272,212,781,740],{"nctId":1007,"briefTitle":1008,"status":155,"phases":6367,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":407,"conditions":6368,"interventions":6369},[89,90],[524,1014],[1016,667,212,279,780,781,63],{"nctId":1049,"briefTitle":1050,"status":142,"phases":6371,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":6372,"interventions":6373},[90],[1056,1057,1058,1059,1060],[1062,1063,693,994,1064,1065,750,1066],{"nctId":1167,"briefTitle":1168,"status":142,"phases":6375,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":234,"conditions":6376,"interventions":6377},[90],[1174],[1176,279,780,781,63,212,738],{"nctId":1201,"briefTitle":1202,"status":142,"phases":6379,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":6380,"interventions":6381},[90],[776,1208,773,1209,1210],[279,667,212,63,781,780],{"nctId":5963,"briefTitle":5964,"status":347,"phases":6383,"primaryCompletion":361,"completion":799,"start":5966,"enrollment":609,"conditions":6384,"interventions":6385},[89,90],[5968,5969],[5971,781,151],{"nctId":1237,"briefTitle":1238,"status":618,"phases":6387,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":6388,"interventions":6389},[90],[1244,1245,1246,1247,1248,1249,1250,1251],[1063,1082,693,1225,1064],{"trials":6391,"activeCount":603,"soonestReadout":1460},[6392,6396,6400],{"nctId":1362,"briefTitle":1363,"status":155,"phases":6393,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":6394,"interventions":6395},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1393,"briefTitle":1394,"status":128,"phases":6397,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":6398,"interventions":6399},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":1457,"briefTitle":1458,"status":155,"phases":6401,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":6402,"interventions":6403},[91],[1464,1465,1466,1467,1468,1469],[63,780,737,279,1471,1472,1101,781,740],{"trials":6405,"activeCount":101},[],{"trials":6407,"activeCount":101},[],{"intervention":2124,"totalTrials":889,"cells":6409},{"EARLY_PHASE1":6410,"PHASE1":6412,"PHASE2":6418,"PHASE3":6449,"PHASE4":6463,"NA":6465},{"trials":6411,"activeCount":101},[],{"trials":6413,"activeCount":2548,"soonestReadout":2584},[6414],{"nctId":2581,"briefTitle":2582,"status":155,"phases":6415,"primaryCompletion":2584,"completion":361,"start":2585,"enrollment":2586,"conditions":6416,"interventions":6417},[89],[21,486,487],[489,2124,2554],{"trials":6419,"activeCount":758,"soonestReadout":2737},[6420,6432,6436],{"nctId":6421,"briefTitle":6422,"status":142,"phases":6423,"primaryCompletion":2304,"completion":5218,"start":6424,"enrollment":6425,"conditions":6426,"interventions":6430},"NCT02311361","Immune Checkpoint Inhibition (Tremelimumab and\u002For MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer",[89,90],"2015-03-25",65,[917,841,6427,6428,6429],"Cancer of Pancreas","Cancer of the Pancreas","Pancreas Cancer",[2124,6431],"Tremelimumab",{"nctId":2734,"briefTitle":2735,"status":155,"phases":6433,"primaryCompletion":2737,"completion":2642,"start":2738,"enrollment":1357,"conditions":6434,"interventions":6435},[90],[1724,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2616,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2782,2783,2784,2785,2786,2787],[68,2124,2554,449,2789,2790],{"nctId":6437,"briefTitle":6438,"status":155,"phases":6439,"primaryCompletion":5611,"completion":6440,"start":6441,"enrollment":3283,"conditions":6442,"interventions":6448},"NCT02888743","Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer",[90],"2027-01-02","2017-08-14",[6443,2885,6444,6445,6446,6447],"Metastatic Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v7","Stage IV Lung Non-Small Cell Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7",[2124,6431],{"trials":6450,"activeCount":758,"soonestReadout":3701},[6451,6459],{"nctId":6452,"briefTitle":6453,"status":155,"phases":6454,"primaryCompletion":3701,"completion":3701,"start":6455,"enrollment":6456,"conditions":6457,"interventions":6458},"NCT06732401","Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer",[91],"2025-08-07",630,[2985,2986,2119,2120],[2684,2124],{"nctId":2111,"briefTitle":2112,"status":155,"phases":6460,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":6461,"interventions":6462},[91],[2118,1626,2119,2120,2121,2122],[277,278,2124,279,449,2045],{"trials":6464,"activeCount":101},[],{"trials":6466,"activeCount":101},[],{"intervention":4948,"totalTrials":31,"cells":6468},{"EARLY_PHASE1":6469,"PHASE1":6471,"PHASE2":6524,"PHASE3":6599,"PHASE4":6625,"NA":6627},{"trials":6470,"activeCount":101},[],{"trials":6472,"activeCount":101},[6473,6482,6486,6490,6494,6498,6509],{"nctId":6474,"briefTitle":6475,"status":142,"phases":6476,"completion":6477,"start":6478,"enrollment":1074,"conditions":6479,"interventions":6481},"NCT00006062","Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction",[89],"2001-05","2000-07",[6480],"Liver Disease",[4948],{"nctId":4937,"briefTitle":4938,"status":142,"phases":6483,"primaryCompletion":4929,"start":1819,"enrollment":484,"conditions":6484,"interventions":6485},[89],[4941,4942,4943,4944,4945,4946,15],[4948,1264,4063,3065],{"nctId":4950,"briefTitle":4951,"status":618,"phases":6487,"primaryCompletion":4953,"completion":4953,"start":4954,"enrollment":603,"conditions":6488,"interventions":6489},[89],[364,4956,4957,4958,4959,4960,4961,4962,4963,4964],[2924,2084,4966,2925,4967],{"nctId":4969,"briefTitle":4970,"status":142,"phases":6491,"primaryCompletion":4972,"completion":4972,"start":4973,"enrollment":2211,"conditions":6492,"interventions":6493},[89],[4975],[4977,2084,1140,2925],{"nctId":4993,"briefTitle":4994,"status":142,"phases":6495,"primaryCompletion":4996,"start":4997,"enrollment":730,"conditions":6496,"interventions":6497},[89],[15],[1998,3065,4948,1264],{"nctId":6499,"briefTitle":6500,"status":142,"phases":6501,"primaryCompletion":3304,"start":4612,"enrollment":339,"conditions":6502,"interventions":6508},"NCT00101270","Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas",[89],[4777,4642,4778,4779,4780,5363,4659,4660,4661,6503,4789,6504,4790,5869,4662,5870,4791,5871,4665,6505,4941,1029,1343,6506,117,5872,6507,4793,748],"Recurrent Childhood Grade III Lymphomatoid Granulomatosis","Recurrent Childhood Liver Cancer","Recurrent Childhood Visual Pathway Glioma","Recurrent Nasopharyngeal Cancer","Recurrent Wilms Tumor and Other Childhood Kidney Tumors",[5106,4948],{"nctId":6510,"briefTitle":6511,"status":618,"phases":6512,"primaryCompletion":6513,"start":3282,"enrollment":455,"conditions":6514,"interventions":6521},"NCT01233505","Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors",[89],"2013-10",[5637,6515,6516,6517,1787,3117,4941,3118,1579,4823,3259,4942,6518,6519,1220,1221,1222,1223,3137,4945,6520,1591,4841,3261,4946,15],"Adenocarcinoma of the Stomach","BRCA1 Mutation Carrier","BRCA2 Mutation Carrier","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage IV Gastric Cancer",[6522,6523,4948],"veliparib","capecitabine",{"trials":6525,"activeCount":758,"soonestReadout":968},[6526,6539,6543,6547,6551,6557,6561,6565,6573,6579,6583,6587,6591,6595],{"nctId":6527,"briefTitle":6528,"status":142,"phases":6529,"primaryCompletion":1575,"completion":1763,"start":6530,"enrollment":2586,"conditions":6531,"interventions":6538},"NCT00084617","Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric\u002FGastroesophageal Junction Carcinoma",[90],"2004-03",[1915,6532,6533,6534,3118,6535,6536,6537,6520],"Diffuse Adenocarcinoma of the Stomach","Intestinal Adenocarcinoma of the Stomach","Mixed Adenocarcinoma of the Stomach","Stage IIIA Gastric Cancer","Stage IIIB Gastric Cancer","Stage IIIC Gastric Cancer",[4948,5106,6523],{"nctId":2908,"briefTitle":2909,"status":155,"phases":6540,"primaryCompletion":2654,"completion":2654,"start":2911,"enrollment":2912,"conditions":6541,"interventions":6542},[90],[2914,2915,2916,2917,1621,2918,2919,2920,2921,2922],[1690,2924,2083,2084,1140,2925],{"nctId":5026,"briefTitle":5027,"status":155,"phases":6544,"primaryCompletion":968,"completion":968,"start":5029,"enrollment":971,"conditions":6545,"interventions":6546},[90],[5031,5032,5033,5034,5035,5036,1624,5037,5038,3364,1631,5039,5040,3370,5041,5042,3374],[5044,2084,1140,2925],{"nctId":5046,"briefTitle":5047,"status":142,"phases":6548,"primaryCompletion":1318,"completion":1318,"start":4639,"enrollment":971,"conditions":6549,"interventions":6550},[90],[4983,5050,4941,4942,5051,4945,4946],[1697,1033,4948,1264,3065],{"nctId":6552,"briefTitle":6553,"status":142,"phases":6554,"primaryCompletion":1426,"start":988,"enrollment":22,"conditions":6555,"interventions":6556},"NCT00052364","Oxaliplatin in Treating Patients With Liver Cancer",[90],[4862,4863,4864,4890],[4948],{"nctId":5061,"briefTitle":5062,"status":142,"phases":6558,"completion":3587,"start":1241,"conditions":6559,"interventions":6560},[90],[856,869],[5066,3065,3110,1264,1081,4948],{"nctId":5068,"briefTitle":5069,"status":142,"phases":6562,"primaryCompletion":1320,"start":3088,"enrollment":421,"conditions":6563,"interventions":6564},[90],[856],[5066,3065,1264,4948],{"nctId":6566,"briefTitle":6567,"status":618,"phases":6568,"primaryCompletion":6569,"completion":3226,"start":1426,"enrollment":2586,"conditions":6570,"interventions":6571},"NCT00313612","Oxaliplatin and Topotecan in Advance Ovarian Cancer",[90],"2011-05",[1579],[4948,6572],"topotecan",{"nctId":6574,"briefTitle":6575,"status":618,"phases":6576,"primaryCompletion":1340,"start":1288,"enrollment":2280,"conditions":6577,"interventions":6578},"NCT00005856","Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[89,90],[4817,4818,4819],[4948],{"nctId":5074,"briefTitle":5075,"status":142,"phases":6580,"primaryCompletion":5077,"completion":5078,"start":5079,"enrollment":2294,"conditions":6581,"interventions":6582},[90],[4957,5081,4958],[53,2924,2084,1140,2925],{"nctId":3386,"briefTitle":3387,"status":142,"phases":6584,"primaryCompletion":3389,"completion":3317,"start":3390,"enrollment":638,"conditions":6585,"interventions":6586},[90],[1648,1649,1680,1533,1592,1594],[449,2925],{"nctId":5566,"briefTitle":5567,"status":618,"phases":6588,"primaryCompletion":1604,"completion":1604,"start":5569,"enrollment":28,"conditions":6589,"interventions":6590},[90],[5571,5572,5573,5574,856],[5576,5577,53,5578,4966,2925,2924,5578],{"nctId":5084,"briefTitle":5085,"status":142,"phases":6592,"primaryCompletion":5087,"completion":5087,"start":4611,"enrollment":700,"conditions":6593,"interventions":6594},[90],[5089,5090,5091,5092,4823,5093,5094,5095,4841],[666,2084,1140,2925],{"nctId":3852,"briefTitle":3853,"status":142,"phases":6596,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":375,"conditions":6597,"interventions":6598},[90],[3859,854,3860,3861,3862],[883,2925,2924],{"trials":6600,"activeCount":603,"soonestReadout":52},[6601,6605,6609,6613,6617,6621],{"nctId":5112,"briefTitle":5113,"status":142,"phases":6602,"primaryCompletion":3480,"start":5115,"enrollment":5116,"conditions":6603,"interventions":6604},[91],[5118,4943],[1264,3065,4948],{"nctId":50,"briefTitle":51,"status":155,"phases":6606,"primaryCompletion":52,"completion":3410,"start":3411,"enrollment":234,"conditions":6607,"interventions":6608},[91],[3413,1787,250,251,3414,3415,3416,3417,3418,3419,1740,1741,1742,1743,1744,1745,1746,1747,1749,1750,1752,1753,1755,1756],[53,2924,277,2925,449],{"nctId":5131,"briefTitle":5132,"status":142,"phases":6610,"primaryCompletion":5103,"completion":5103,"start":4997,"enrollment":5134,"conditions":6611,"interventions":6612},[91],[5127,4943],[5106,4948,1264,3065,1697,5137],{"nctId":5139,"briefTitle":5140,"status":142,"phases":6614,"primaryCompletion":1807,"completion":1807,"start":5142,"enrollment":5143,"conditions":6615,"interventions":6616},[91],[5145,5146,4824,5147,5148,5149,4959,4960,4961,4963,4964],[2084,1140,2925,1403],{"nctId":3035,"briefTitle":3036,"status":155,"phases":6618,"primaryCompletion":3038,"completion":3039,"start":3040,"enrollment":3041,"conditions":6619,"interventions":6620},[91],[3043,3044,114,3045],[1690,2084,1140,2925],{"nctId":5160,"briefTitle":5161,"status":155,"phases":6622,"primaryCompletion":5163,"completion":5164,"start":5165,"enrollment":5166,"conditions":6623,"interventions":6624},[91],[3043,5168,5169,5170],[53,2084,4966,2925],{"trials":6626,"activeCount":101},[],{"trials":6628,"activeCount":101},[6629],{"nctId":5177,"briefTitle":5178,"status":142,"phases":6630,"completion":987,"start":1764,"conditions":6631,"interventions":6632},[93],[856],[5066,3065,1264,4948],{"intervention":1264,"totalTrials":37,"cells":6634},{"EARLY_PHASE1":6635,"PHASE1":6637,"PHASE2":6663,"PHASE3":6709,"PHASE4":6739,"NA":6741},{"trials":6636,"activeCount":101},[],{"trials":6638,"activeCount":101},[6639,6643,6647,6651,6655,6659],{"nctId":4925,"briefTitle":4926,"status":142,"phases":6640,"primaryCompletion":4928,"completion":4928,"start":4929,"enrollment":407,"conditions":6641,"interventions":6642},[89],[4822,4824,4844,4845,4846,4847],[53,2084,1102,1140,43],{"nctId":4937,"briefTitle":4938,"status":142,"phases":6644,"primaryCompletion":4929,"start":1819,"enrollment":484,"conditions":6645,"interventions":6646},[89],[4941,4942,4943,4944,4945,4946,15],[4948,1264,4063,3065],{"nctId":4969,"briefTitle":4970,"status":142,"phases":6648,"primaryCompletion":4972,"completion":4972,"start":4973,"enrollment":2211,"conditions":6649,"interventions":6650},[89],[4975],[4977,2084,1140,2925],{"nctId":4987,"briefTitle":4988,"status":142,"phases":6652,"start":4231,"conditions":6653,"interventions":6654},[89],[15],[2184,3065,1264],{"nctId":4993,"briefTitle":4994,"status":142,"phases":6656,"primaryCompletion":4996,"start":4997,"enrollment":730,"conditions":6657,"interventions":6658},[89],[15],[1998,3065,4948,1264],{"nctId":5001,"briefTitle":5002,"status":142,"phases":6660,"primaryCompletion":1231,"start":5004,"enrollment":28,"conditions":6661,"interventions":6662},[89],[15],[1062,3065,1264],{"trials":6664,"activeCount":603,"soonestReadout":62},[6665,6669,6673,6677,6681,6685,6689,6693,6697,6701,6705],{"nctId":2908,"briefTitle":2909,"status":155,"phases":6666,"primaryCompletion":2654,"completion":2654,"start":2911,"enrollment":2912,"conditions":6667,"interventions":6668},[90],[2914,2915,2916,2917,1621,2918,2919,2920,2921,2922],[1690,2924,2083,2084,1140,2925],{"nctId":5026,"briefTitle":5027,"status":155,"phases":6670,"primaryCompletion":968,"completion":968,"start":5029,"enrollment":971,"conditions":6671,"interventions":6672},[90],[5031,5032,5033,5034,5035,5036,1624,5037,5038,3364,1631,5039,5040,3370,5041,5042,3374],[5044,2084,1140,2925],{"nctId":5046,"briefTitle":5047,"status":142,"phases":6674,"primaryCompletion":1318,"completion":1318,"start":4639,"enrollment":971,"conditions":6675,"interventions":6676},[90],[4983,5050,4941,4942,5051,4945,4946],[1697,1033,4948,1264,3065],{"nctId":60,"briefTitle":61,"status":155,"phases":6678,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":6679,"interventions":6680},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":5054,"briefTitle":5055,"status":142,"phases":6682,"completion":1781,"start":5057,"conditions":6683,"interventions":6684},[90],[856],[1033,3065,1264],{"nctId":5061,"briefTitle":5062,"status":142,"phases":6686,"completion":3587,"start":1241,"conditions":6687,"interventions":6688},[90],[856,869],[5066,3065,3110,1264,1081,4948],{"nctId":5068,"briefTitle":5069,"status":142,"phases":6690,"primaryCompletion":1320,"start":3088,"enrollment":421,"conditions":6691,"interventions":6692},[90],[856],[5066,3065,1264,4948],{"nctId":5074,"briefTitle":5075,"status":142,"phases":6694,"primaryCompletion":5077,"completion":5078,"start":5079,"enrollment":2294,"conditions":6695,"interventions":6696},[90],[4957,5081,4958],[53,2924,2084,1140,2925],{"nctId":1974,"briefTitle":1975,"status":618,"phases":6698,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":248,"conditions":6699,"interventions":6700},[90],[1981,625],[750,1598,1983,994,1264,1268],{"nctId":1254,"briefTitle":1255,"status":142,"phases":6702,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":6703,"interventions":6704},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"nctId":5084,"briefTitle":5085,"status":142,"phases":6706,"primaryCompletion":5087,"completion":5087,"start":4611,"enrollment":700,"conditions":6707,"interventions":6708},[90],[5089,5090,5091,5092,4823,5093,5094,5095,4841],[666,2084,1140,2925],{"trials":6710,"activeCount":758,"soonestReadout":1365},[6711,6715,6719,6723,6727,6731,6735],{"nctId":5100,"briefTitle":5101,"status":618,"phases":6712,"primaryCompletion":5103,"completion":5103,"start":1320,"enrollment":1953,"conditions":6713,"interventions":6714},[91],[4941,4942,4844,4845,4846,4847],[5106,1264,3065,1697,1033],{"nctId":1362,"briefTitle":1363,"status":155,"phases":6716,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":6717,"interventions":6718},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":5112,"briefTitle":5113,"status":142,"phases":6720,"primaryCompletion":3480,"start":5115,"enrollment":5116,"conditions":6721,"interventions":6722},[91],[5118,4943],[1264,3065,4948],{"nctId":1378,"briefTitle":1379,"status":142,"phases":6724,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":6725,"interventions":6726},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"nctId":5131,"briefTitle":5132,"status":142,"phases":6728,"primaryCompletion":5103,"completion":5103,"start":4997,"enrollment":5134,"conditions":6729,"interventions":6730},[91],[5127,4943],[5106,4948,1264,3065,1697,5137],{"nctId":5139,"briefTitle":5140,"status":142,"phases":6732,"primaryCompletion":1807,"completion":1807,"start":5142,"enrollment":5143,"conditions":6733,"interventions":6734},[91],[5145,5146,4824,5147,5148,5149,4959,4960,4961,4963,4964],[2084,1140,2925,1403],{"nctId":3035,"briefTitle":3036,"status":155,"phases":6736,"primaryCompletion":3038,"completion":3039,"start":3040,"enrollment":3041,"conditions":6737,"interventions":6738},[91],[3043,3044,114,3045],[1690,2084,1140,2925],{"trials":6740,"activeCount":101},[],{"trials":6742,"activeCount":101},[6743],{"nctId":5177,"briefTitle":5178,"status":142,"phases":6744,"completion":987,"start":1764,"conditions":6745,"interventions":6746},[93],[856],[5066,3065,1264,4948],{"intervention":780,"totalTrials":2577,"cells":6748},{"EARLY_PHASE1":6749,"PHASE1":6751,"PHASE2":6768,"PHASE3":6801,"PHASE4":6819,"NA":6821},{"trials":6750,"activeCount":101},[],{"trials":6752,"activeCount":101},[6753,6764],{"nctId":6754,"briefTitle":6755,"status":107,"phases":6756,"primaryCompletion":6757,"completion":6757,"start":6757,"enrollment":101,"conditions":6758,"interventions":6763},"NCT04639843","Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma",[89],"2022-11-03",[6759,6760,6761,6762,4783],"Adult T-cell Leukemia\u002FLymphoma","Extranodal NK-\u002FT-cell Lymphoma, Nasal Type","Enteropathy-Associated T-Cell Lymphoma","Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma",[4556,180,4555,780],{"nctId":766,"briefTitle":767,"status":618,"phases":6765,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":6766,"interventions":6767},[89],[773,774,775,776,777],[667,279,779,63,780,781,212],{"trials":6769,"activeCount":2548,"soonestReadout":1010},[6770,6774,6778,6785,6789,6793,6797],{"nctId":1007,"briefTitle":1008,"status":155,"phases":6771,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":407,"conditions":6772,"interventions":6773},[89,90],[524,1014],[1016,667,212,279,780,781,63],{"nctId":1167,"briefTitle":1168,"status":142,"phases":6775,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":234,"conditions":6776,"interventions":6777},[90],[1174],[1176,279,780,781,63,212,738],{"nctId":6779,"briefTitle":6780,"status":142,"phases":6781,"primaryCompletion":1230,"completion":6782,"start":6530,"enrollment":1517,"conditions":6783,"interventions":6784},"NCT00083226","Doxorubicin and Bortezomib in Treating Patients With Liver Cancer",[90],"2012-08",[4862,4863,4864,4890],[1225,1062],{"nctId":1201,"briefTitle":1202,"status":142,"phases":6786,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":6787,"interventions":6788},[90],[776,1208,773,1209,1210],[279,667,212,63,781,780],{"nctId":1213,"briefTitle":1214,"status":142,"phases":6790,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":1074,"conditions":6791,"interventions":6792},[89,90],[18,1219,1220,1221,1222,1223],[1185,995,1225,693],{"nctId":1237,"briefTitle":1238,"status":618,"phases":6794,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":1242,"conditions":6795,"interventions":6796},[90],[1244,1245,1246,1247,1248,1249,1250,1251],[1063,1082,693,1225,1064],{"nctId":1285,"briefTitle":1286,"status":142,"phases":6798,"completion":1288,"start":1289,"enrollment":913,"conditions":6799,"interventions":6800},[90],[18,1291],[1268,1293,1294,693,995,1225],{"trials":6802,"activeCount":603,"soonestReadout":4445},[6803,6807,6811,6815],{"nctId":1393,"briefTitle":1394,"status":128,"phases":6804,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":6805,"interventions":6806},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":1409,"briefTitle":1410,"status":142,"phases":6808,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":1074,"conditions":6809,"interventions":6810},[91],[1416,18,1417,63,780],[780,63,1419,1420,1421],{"nctId":4442,"briefTitle":4443,"status":155,"phases":6812,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":6813,"interventions":6814},[90,91],[4450,4451,4452,4453,4454,4455,4456,4457,4458,4459,4460,4461,4462,4463,4464,4465,4466,4467,4468,4469,4470,4471,4472,4473,4474,4475,4476,4477,4478,4479,4480,4481,4482,4483,4484,4485],[780,737,1101,2807,77],{"nctId":1457,"briefTitle":1458,"status":155,"phases":6816,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":6817,"interventions":6818},[91],[1464,1465,1466,1467,1468,1469],[63,780,737,279,1471,1472,1101,781,740],{"trials":6820,"activeCount":101},[],{"trials":6822,"activeCount":101},[],{"intervention":1031,"totalTrials":375,"cells":6824},{"EARLY_PHASE1":6825,"PHASE1":6827,"PHASE2":6845,"PHASE3":6891,"PHASE4":6897,"NA":6899},{"trials":6826,"activeCount":101},[],{"trials":6828,"activeCount":101},[6829,6837,6841],{"nctId":6830,"briefTitle":6831,"status":142,"phases":6832,"primaryCompletion":6833,"completion":5004,"start":6834,"enrollment":838,"conditions":6835,"interventions":6836},"NCT00002625","Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma",[89],"2000-04","1995-03",[688,687,27],[1031],{"nctId":3085,"briefTitle":3086,"status":142,"phases":6838,"primaryCompletion":3088,"start":3089,"enrollment":28,"conditions":6839,"interventions":6840},[89],[1003,1821],[3092,3093,995,1031],{"nctId":1778,"briefTitle":1779,"status":142,"phases":6842,"primaryCompletion":1781,"start":1782,"enrollment":28,"conditions":6843,"interventions":6844},[89],[1784,1785,1732,1786,1787,1788,1789,1790,1591],[995,1598,1031,750],{"trials":6846,"activeCount":603,"soonestReadout":6851},[6847,6857,6865,6872,6876,6880,6887],{"nctId":6848,"briefTitle":6849,"status":155,"phases":6850,"primaryCompletion":6851,"completion":6852,"start":6853,"enrollment":6854,"conditions":6855,"interventions":6856},"NCT01012817","Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",[89,90],"2019-01-13","2027-03-10","2009-11-03",88,[486,250,251,252,6160],[2790,1653],{"nctId":6858,"briefTitle":6859,"status":142,"phases":6860,"primaryCompletion":745,"start":6861,"enrollment":6862,"conditions":6863,"interventions":6864},"NCT00003745","Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas",[90],"1999-05",125,[625],[1031],{"nctId":6866,"briefTitle":6867,"status":142,"phases":6868,"primaryCompletion":5445,"completion":5445,"start":6869,"enrollment":3255,"conditions":6870,"interventions":6871},"NCT00098956","7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer",[90],"2005-01",[3673,3120],[1031,2184],{"nctId":1018,"briefTitle":1019,"status":142,"phases":6873,"primaryCompletion":1021,"completion":1022,"start":1023,"enrollment":1024,"conditions":6874,"interventions":6875},[90],[1026,1027,1028,1029],[1031,1032,693,1033],{"nctId":3618,"briefTitle":3619,"status":155,"phases":6877,"primaryCompletion":3621,"completion":3039,"start":3622,"enrollment":37,"conditions":6878,"interventions":6879},[90],[263,2452,3624,2453,3625,3626,3627,3628,2427,2430],[277,1407,2790,1653],{"nctId":6881,"briefTitle":6882,"status":142,"phases":6883,"primaryCompletion":5985,"completion":5985,"start":4561,"enrollment":1913,"conditions":6884,"interventions":6885},"NCT01533181","Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer",[90],[1812],[6886,2790],"Linsitinib",{"nctId":2734,"briefTitle":2735,"status":155,"phases":6888,"primaryCompletion":2737,"completion":2642,"start":2738,"enrollment":1357,"conditions":6889,"interventions":6890},[90],[1724,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2616,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2782,2783,2784,2785,2786,2787],[68,2124,2554,449,2789,2790],{"trials":6892,"activeCount":2548,"soonestReadout":2813},[6893],{"nctId":2810,"briefTitle":2811,"status":155,"phases":6894,"primaryCompletion":2813,"completion":2642,"start":2814,"enrollment":2815,"conditions":6895,"interventions":6896},[90,91],[1722,1723,2645,1726,1727,1731,1732,2740,1735,1736,1737,1739,250,251,252],[2732,68,2554,449,2789,1407,2790],{"trials":6898,"activeCount":101},[],{"trials":6900,"activeCount":101},[],{"intervention":2216,"totalTrials":838,"cells":6902},{"EARLY_PHASE1":6903,"PHASE1":6905,"PHASE2":6927,"PHASE3":6933,"PHASE4":6939,"NA":6941},{"trials":6904,"activeCount":101},[],{"trials":6906,"activeCount":758,"soonestReadout":2209},[6907,6919,6923],{"nctId":6908,"briefTitle":6909,"status":618,"phases":6910,"primaryCompletion":6911,"completion":6912,"start":6913,"enrollment":2548,"conditions":6914,"interventions":6918},"NCT03759184","Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia",[89],"2019-12-15","2021-10-22","2019-07-11",[1260,6915,6916,6917],"Lymphocytic","Chronic","B-Cell",[5894,5894,2216],{"nctId":2186,"briefTitle":2187,"status":155,"phases":6920,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1798,"conditions":6921,"interventions":6922},[89],[27,2193,2194,773],[2196,1082,2197,2198,2199,2200],{"nctId":2206,"briefTitle":2207,"status":155,"phases":6924,"primaryCompletion":2209,"completion":418,"start":2210,"enrollment":2211,"conditions":6925,"interventions":6926},[89],[2213,2214],[2216,212,1016,2217,58,706,2218,2219],{"trials":6928,"activeCount":2548,"soonestReadout":2234},[6929],{"nctId":2231,"briefTitle":2232,"status":128,"phases":6930,"primaryCompletion":2234,"completion":2234,"start":2235,"enrollment":1357,"conditions":6931,"interventions":6932},[90],[2237,527,2238,2239,529,530,2240,534,537,2241,2242,539,540,2243,543],[58,1016,2216,212,2217],{"trials":6934,"activeCount":2548,"soonestReadout":2703},[6935],{"nctId":4009,"briefTitle":4010,"status":128,"phases":6936,"primaryCompletion":2703,"completion":2703,"start":4012,"enrollment":4013,"conditions":6937,"interventions":6938},[91],[653,4015],[2216,2217],{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[],{"intervention":1775,"totalTrials":407,"cells":6944},{"EARLY_PHASE1":6945,"PHASE1":6947,"PHASE2":6997,"PHASE3":7064,"PHASE4":7070,"NA":7072},{"trials":6946,"activeCount":101},[],{"trials":6948,"activeCount":101},[6949,6955,6961,6968,6993],{"nctId":6950,"briefTitle":6951,"status":142,"phases":6952,"primaryCompletion":1231,"completion":3317,"start":1172,"enrollment":2319,"conditions":6953,"interventions":6954},"NCT00058253","Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors",[89],[2321,2297,15],[6287,1775],{"nctId":6956,"briefTitle":6957,"status":618,"phases":6958,"primaryCompletion":2293,"start":1257,"enrollment":1074,"conditions":6959,"interventions":6960},"NCT00088933","Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer",[89],[3673,4941,3119,4942,3120,4945,3285,4946],[991,992,1775,993],{"nctId":6962,"briefTitle":6963,"status":142,"phases":6964,"primaryCompletion":716,"start":4272,"enrollment":339,"conditions":6965,"interventions":6966},"NCT00066768","Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer",[89],[3119,1772,3285],[6967,1775,3066],"suramin",{"nctId":6969,"briefTitle":6970,"status":142,"phases":6971,"primaryCompletion":6972,"completion":6973,"start":3622,"enrollment":4349,"conditions":6974,"interventions":6991},"NCT03218826","PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery",[89],"2022-07-25","2025-10-13",[1607,21,6975,1619,6976,6977,6978,1620,2309,3078,486,6979,6980,6981,6982,6983,6984,6985,6986,6987,6988,6989,6990,2596,1637,6160],"Advanced Prostate Carcinoma","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Metastatic Prostate Carcinoma","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8",[2083,6992],"PI3Kbeta Inhibitor AZD8186",{"nctId":1760,"briefTitle":1761,"status":618,"phases":6994,"primaryCompletion":1763,"start":1764,"enrollment":1765,"conditions":6995,"interventions":6996},[89],[1767,1768,1769,1770,1771,1772],[1598,1080,1774,1775,995,1776],{"trials":6998,"activeCount":758,"soonestReadout":361},[6999,7003,7010,7014,7023,7027,7031,7038,7042,7050,7057],{"nctId":2246,"briefTitle":2247,"status":128,"phases":7000,"primaryCompletion":361,"completion":361,"start":2249,"enrollment":2250,"conditions":7001,"interventions":7002},[89,90],[2252,2253],[2255,2083,2256,212,2257],{"nctId":7004,"briefTitle":7005,"status":142,"phases":7006,"primaryCompletion":2293,"start":5452,"enrollment":1765,"conditions":7007,"interventions":7009},"NCT00074022","GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors",[89,90],[3119,2321,7008,1771,1772,3285,2297,15],"Stage III Prostate Cancer",[6242,1775],{"nctId":2289,"briefTitle":2290,"status":618,"phases":7011,"primaryCompletion":1319,"completion":2292,"start":2293,"enrollment":2294,"conditions":7012,"interventions":7013},[90],[2296,2297],[2299,1775,1082],{"nctId":7015,"briefTitle":7016,"status":142,"phases":7017,"primaryCompletion":7018,"completion":6513,"start":3480,"enrollment":1765,"conditions":7019,"interventions":7020},"NCT00179309","Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer",[90],"2013-02",[18],[2083,7021,7022,5933],"PANVAC-V","PANVAC-F",{"nctId":2908,"briefTitle":2909,"status":155,"phases":7024,"primaryCompletion":2654,"completion":2654,"start":2911,"enrollment":2912,"conditions":7025,"interventions":7026},[90],[2914,2915,2916,2917,1621,2918,2919,2920,2921,2922],[1690,2924,2083,2084,1140,2925],{"nctId":1907,"briefTitle":1908,"status":142,"phases":7028,"primaryCompletion":1910,"completion":1911,"start":1912,"enrollment":1913,"conditions":7029,"interventions":7030},[90],[1915,1916,1917],[1919,1775,1598],{"nctId":7032,"briefTitle":7033,"status":142,"phases":7034,"completion":1276,"start":7035,"conditions":7036,"interventions":7037},"NCT00020332","Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer",[89,90],"2000-10",[18],[1998,1775],{"nctId":2342,"briefTitle":2343,"status":142,"phases":7039,"primaryCompletion":2345,"completion":2345,"start":1808,"enrollment":2346,"conditions":7040,"interventions":7041},[90],[2348],[53,1016,2083,212],{"nctId":7043,"briefTitle":7044,"status":618,"phases":7045,"primaryCompletion":7046,"completion":7046,"start":7047,"enrollment":407,"conditions":7048,"interventions":7049},"NCT01935947","Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer",[90],"2017-04","2013-05",[3320,4828,4833,3321],[6296,6296,2083,474,167,1102,2045],{"nctId":7051,"briefTitle":7052,"status":142,"phases":7053,"primaryCompletion":649,"completion":649,"start":3587,"enrollment":5714,"conditions":7054,"interventions":7056},"NCT00362882","Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer",[90],[7055,3119,3285],"Non-small Cell Lung Cancer",[1775,1062],{"nctId":7058,"briefTitle":7059,"status":142,"phases":7060,"primaryCompletion":1241,"start":7061,"enrollment":552,"conditions":7062,"interventions":7063},"NCT00002825","Docetaxel in Treating Children With Recurrent Solid Tumors",[90],"1997-01",[3664,791,625],[750,1775],{"trials":7065,"activeCount":2548,"soonestReadout":72},[7066],{"nctId":70,"briefTitle":71,"status":155,"phases":7067,"primaryCompletion":72,"completion":2050,"start":2051,"enrollment":2052,"conditions":7068,"interventions":7069},[91],[2054,1867,1868,1869,1870,2055,1873,1874,2056,2057,2058,2059,2060,2061,2062,2063,2064,2065,2066,2067,2068,2069,2070,2071,2072,2073,2074,2075,2076,2077,2078,2079,2080,2081,1895],[53,277,278,2083,2084],{"trials":7071,"activeCount":101},[],{"trials":7073,"activeCount":101},[],{"intervention":1081,"totalTrials":188,"cells":7075},{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7090,"PHASE3":7134,"PHASE4":7158,"NA":7160},{"trials":7077,"activeCount":101},[],{"trials":7079,"activeCount":101},[7080],{"nctId":7081,"briefTitle":7082,"status":142,"phases":7083,"completion":3254,"start":7084,"enrollment":31,"conditions":7085,"interventions":7089},"NCT00001576","A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver",[89],"1997-07",[7086,7087,7088],"Colorectal Neoplasm","Liver Neoplasm","Neoplasm Metastasis",[1405,6109,4966],{"trials":7091,"activeCount":758,"soonestReadout":3991},[7092,7096,7100,7109,7119,7123,7127],{"nctId":4689,"briefTitle":4690,"status":3027,"phases":7093,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":159,"conditions":7094,"interventions":7095},[90],[4695],[4605,4697,1139,1016,1405,4698,4699,4700],{"nctId":1068,"briefTitle":1069,"status":142,"phases":7097,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":7098,"interventions":7099},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":7101,"briefTitle":7102,"status":107,"phases":7103,"primaryCompletion":1319,"start":1329,"enrollment":101,"conditions":7104,"interventions":7108},"NCT01251172","RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma",[90],[7105,7106,7107,301],"DS Stage I Plasma Cell Myeloma","DS Stage II Plasma Cell Myeloma","DS Stage III Plasma Cell Myeloma",[4849,1405],{"nctId":7110,"briefTitle":7111,"status":142,"phases":7112,"completion":4562,"start":7113,"conditions":7114,"interventions":7116},"NCT00019097","Vaccine Therapy in Treating Patients With Multiple Myeloma",[90],"1995-07",[1431,1432,7115],"Refractory Plasma Cell Neoplasm",[7117,7118,1081,993],"autologous tumor cell vaccine","keyhole limpet hemocyanin",{"nctId":5061,"briefTitle":5062,"status":142,"phases":7120,"completion":3587,"start":1241,"conditions":7121,"interventions":7122},[90],[856,869],[5066,3065,3110,1264,1081,4948],{"nctId":3988,"briefTitle":3989,"status":3027,"phases":7124,"primaryCompletion":3991,"completion":3991,"start":2728,"enrollment":3992,"conditions":7125,"interventions":7126},[90],[263],[980,643,1405,2217],{"nctId":7128,"briefTitle":7129,"status":618,"phases":7130,"primaryCompletion":5230,"completion":5858,"start":1319,"enrollment":603,"conditions":7131,"interventions":7133},"NCT01658904","Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma",[89,90],[4747,7132],"Leukemia, Plasma Cell",[4605,1405,738],{"trials":7135,"activeCount":2548,"soonestReadout":1396},[7136,7146,7150,7154],{"nctId":7137,"briefTitle":7138,"status":142,"phases":7139,"completion":7035,"start":7140,"enrollment":7141,"conditions":7142,"interventions":7143},"NCT00001296","A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma",[91],"1992-02",122,[36],[1081,7144,7145],"tumor necrosis factor","interferon-gamma",{"nctId":1393,"briefTitle":1394,"status":128,"phases":7147,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":7148,"interventions":7149},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":1423,"briefTitle":1424,"status":142,"phases":7151,"primaryCompletion":1426,"start":1427,"enrollment":1428,"conditions":7152,"interventions":7153},[91],[1430,1431,1432],[1032,1434,1081,693,1082,1435],{"nctId":6134,"briefTitle":6135,"status":142,"phases":7155,"primaryCompletion":6137,"completion":6138,"start":3479,"enrollment":375,"conditions":7156,"interventions":7157},[91],[4738,6140],[1081,1065,1062],{"trials":7159,"activeCount":101},[],{"trials":7161,"activeCount":101},[],{"intervention":1141,"totalTrials":1024,"cells":7163},{"EARLY_PHASE1":7164,"PHASE1":7166,"PHASE2":7168,"PHASE3":7190,"PHASE4":7200,"NA":7202},{"trials":7165,"activeCount":101},[],{"trials":7167,"activeCount":101},[],{"trials":7169,"activeCount":758,"soonestReadout":62},[7170,7174,7178,7182,7186],{"nctId":2259,"briefTitle":2260,"status":155,"phases":7171,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":7172,"interventions":7173},[90],[902,2267,2268,2269,2270],[1372,1138,1375,1141,2272,212,781,740],{"nctId":60,"briefTitle":61,"status":155,"phases":7175,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":7176,"interventions":7177},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":1974,"briefTitle":1975,"status":618,"phases":7179,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":248,"conditions":7180,"interventions":7181},[90],[1981,625],[750,1598,1983,994,1264,1268],{"nctId":1254,"briefTitle":1255,"status":142,"phases":7183,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":7184,"interventions":7185},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"nctId":1285,"briefTitle":1286,"status":142,"phases":7187,"completion":1288,"start":1289,"enrollment":913,"conditions":7188,"interventions":7189},[90],[18,1291],[1268,1293,1294,693,995,1225],{"trials":7191,"activeCount":2548,"soonestReadout":1365},[7192,7196],{"nctId":1362,"briefTitle":1363,"status":155,"phases":7193,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":7194,"interventions":7195},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1378,"briefTitle":1379,"status":142,"phases":7197,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":7198,"interventions":7199},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"trials":7201,"activeCount":101},[],{"trials":7203,"activeCount":101},[],{"intervention":1407,"totalTrials":838,"cells":7205},{"EARLY_PHASE1":7206,"PHASE1":7208,"PHASE2":7210,"PHASE3":7224,"PHASE4":7234,"NA":7236},{"trials":7207,"activeCount":101},[],{"trials":7209,"activeCount":101},[],{"trials":7211,"activeCount":2548,"soonestReadout":3621},[7212,7216,7220],{"nctId":3618,"briefTitle":3619,"status":155,"phases":7213,"primaryCompletion":3621,"completion":3039,"start":3622,"enrollment":37,"conditions":7214,"interventions":7215},[90],[263,2452,3624,2453,3625,3626,3627,3628,2427,2430],[277,1407,2790,1653],{"nctId":5939,"briefTitle":5940,"status":142,"phases":7217,"primaryCompletion":2262,"completion":5942,"start":5943,"enrollment":19,"conditions":7218,"interventions":7219},[89,90],[5945,687,2719],[2256,1407,151,706,5947,2218,1139,5948],{"nctId":6566,"briefTitle":6567,"status":618,"phases":7221,"primaryCompletion":6569,"completion":3226,"start":1426,"enrollment":2586,"conditions":7222,"interventions":7223},[90],[1579],[4948,6572],{"trials":7225,"activeCount":758,"soonestReadout":2813},[7226,7230],{"nctId":1393,"briefTitle":1394,"status":128,"phases":7227,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":7228,"interventions":7229},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":2810,"briefTitle":2811,"status":155,"phases":7231,"primaryCompletion":2813,"completion":2642,"start":2814,"enrollment":2815,"conditions":7232,"interventions":7233},[90,91],[1722,1723,2645,1726,1727,1731,1732,2740,1735,1736,1737,1739,250,251,252],[2732,68,2554,449,2789,1407,2790],{"trials":7235,"activeCount":101},[],{"trials":7237,"activeCount":101},[],{"intervention":2732,"totalTrials":603,"cells":7239},{"EARLY_PHASE1":7240,"PHASE1":7242,"PHASE2":7248,"PHASE3":7254,"PHASE4":7260,"NA":7262},{"trials":7241,"activeCount":101},[],{"trials":7243,"activeCount":2548,"soonestReadout":4764},[7244],{"nctId":4761,"briefTitle":4762,"status":155,"phases":7245,"primaryCompletion":4764,"completion":592,"start":4765,"enrollment":3255,"conditions":7246,"interventions":7247},[89],[195,30,4767,487],[2732,68,4769,2708],{"trials":7249,"activeCount":2548,"soonestReadout":2727},[7250],{"nctId":2724,"briefTitle":2725,"status":155,"phases":7251,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":1111,"conditions":7252,"interventions":7253},[90],[354],[53,2732,68,2554],{"trials":7255,"activeCount":2548,"soonestReadout":2813},[7256],{"nctId":2810,"briefTitle":2811,"status":155,"phases":7257,"primaryCompletion":2813,"completion":2642,"start":2814,"enrollment":2815,"conditions":7258,"interventions":7259},[90,91],[1722,1723,2645,1726,1727,1731,1732,2740,1735,1736,1737,1739,250,251,252],[2732,68,2554,449,2789,1407,2790],{"trials":7261,"activeCount":101},[],{"trials":7263,"activeCount":101},[],{"intervention":2684,"totalTrials":603,"cells":7265},{"EARLY_PHASE1":7266,"PHASE1":7268,"PHASE2":7300,"PHASE3":7306,"PHASE4":7312,"NA":7314},{"trials":7267,"activeCount":101},[],{"trials":7269,"activeCount":2548,"soonestReadout":592},[7270],{"nctId":7271,"briefTitle":7272,"status":155,"phases":7273,"primaryCompletion":592,"completion":592,"start":7274,"enrollment":2883,"conditions":7275,"interventions":7299},"NCT04704661","Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",[89],"2021-08-09",[1607,7276,7277,1609,1611,7278,21,7279,1619,1620,1621,2918,1622,7280,7281,7282,3078,7283,6443,7284,7285,7286,486,7287,3045,5920,7288,7289,7290,5016,7291,7292,3603,7293,7294,7295,7296,7297,487,7298],"Advanced Colon Carcinoma","Advanced Colorectal Carcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Salivary Gland Carcinoma","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","HER2-Positive Breast Carcinoma","Malignant Hepatobiliary Neoplasm","Metastatic Colon Carcinoma","Metastatic Endometrial Carcinoma","Metastatic Gastric Carcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Metastatic Salivary Gland Carcinoma","Stage III Major Salivary Gland Cancer AJCC v8","Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Major Salivary Gland Cancer AJCC v8","Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Unresectable Colon Carcinoma","Unresectable Colorectal Carcinoma","Unresectable Endometrial Carcinoma","Unresectable Gastric Carcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma","Unresectable Salivary Gland Carcinoma",[2684,2634],{"trials":7301,"activeCount":2548,"soonestReadout":2677},[7302],{"nctId":2674,"briefTitle":2675,"status":155,"phases":7303,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":339,"conditions":7304,"interventions":7305},[90],[2681,2682,30],[2684,2554],{"trials":7307,"activeCount":2548,"soonestReadout":3701},[7308],{"nctId":6452,"briefTitle":6453,"status":155,"phases":7309,"primaryCompletion":3701,"completion":3701,"start":6455,"enrollment":6456,"conditions":7310,"interventions":7311},[91],[2985,2986,2119,2120],[2684,2124],{"trials":7313,"activeCount":101},[],{"trials":7315,"activeCount":101},[],{"intervention":1102,"totalTrials":827,"cells":7317},{"EARLY_PHASE1":7318,"PHASE1":7320,"PHASE2":7371,"PHASE3":7443,"PHASE4":7457,"NA":7459},{"trials":7319,"activeCount":101},[],{"trials":7321,"activeCount":2548,"soonestReadout":5890},[7322,7326,7332,7336,7367],{"nctId":4925,"briefTitle":4926,"status":142,"phases":7323,"primaryCompletion":4928,"completion":4928,"start":4929,"enrollment":407,"conditions":7324,"interventions":7325},[89],[4822,4824,4844,4845,4846,4847],[53,2084,1102,1140,43],{"nctId":7327,"briefTitle":7328,"status":142,"phases":7329,"primaryCompletion":1575,"start":3671,"enrollment":1765,"conditions":7330,"interventions":7331},"NCT00119236","17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[89],[15],[6287,5106],{"nctId":6499,"briefTitle":6500,"status":142,"phases":7333,"primaryCompletion":3304,"start":4612,"enrollment":339,"conditions":7334,"interventions":7335},[89],[4777,4642,4778,4779,4780,5363,4659,4660,4661,6503,4789,6504,4790,5869,4662,5870,4791,5871,4665,6505,4941,1029,1343,6506,117,5872,6507,4793,748],[5106,4948],{"nctId":7337,"briefTitle":7338,"status":142,"phases":7339,"primaryCompletion":3129,"start":7340,"enrollment":623,"conditions":7341,"interventions":7366},"NCT00031681","7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6\u002F8\u002F2007)",[89],"2001-12",[4863,7342,7343,3673,7344,7345,5509,7346,7347,7348,5286,4890,7349,5288,7350,3117,1578,4941,2706,7351,5289,7352,7353,3118,5510,5290,5291,5292,7354,5293,5294,3119,1579,4823,3259,2321,4942,5295,3120,7355,5296,5297,5298,5299,5300,5301,5302,5303,7356,7357,4795,5337,7358,5338,7359,3137,4945,7360,7361,5339,6520,5340,5341,5342,5343,5344,3285,1591,4841,3261,2297,4946,5345,5346,5347,5348,5349,5350,5351,5352,5353,1592,1594,7362,7363,7364,15,7365],"Carcinoma of the Appendix","Estrogen Receptor-negative Breast Cancer","Gastrointestinal Stromal Tumor","HER2-negative Breast Cancer","Ovarian Sarcoma","Ovarian Stromal Cancer","Progesterone Receptor-negative Breast Cancer","Recurrent Anal Cancer","Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor","Recurrent Esophageal Cancer","Recurrent Extrahepatic Bile Duct Cancer","Recurrent Gallbladder Cancer","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Small Intestine Cancer","Small Intestine Adenocarcinoma","Small Intestine Leiomyosarcoma","Stage IV Anal Cancer","Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor","Stage IV Endometrial Carcinoma","Stage IV Esophageal Cancer","Triple-negative Breast Cancer","Unresectable Extrahepatic Bile Duct Cancer","Unresectable Gallbladder Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary",[2184,5106],{"nctId":5887,"briefTitle":5888,"status":128,"phases":7368,"primaryCompletion":5890,"completion":418,"start":5891,"enrollment":421,"conditions":7369,"interventions":7370},[89],[791],[5894,5895,151,1102],{"trials":7372,"activeCount":101},[7373,7389,7393,7397,7401,7405,7409,7413,7417,7436],{"nctId":7374,"briefTitle":7375,"status":142,"phases":7376,"primaryCompletion":5218,"completion":5610,"start":7377,"enrollment":7378,"conditions":7379,"interventions":7388},"NCT02095132","Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors",[89,90],"2014-03-28",76,[7380,7381,7382,7383,5415,7384,7385,116,5416,117,7386,30,5418,120,7387],"Central Nervous System Embryonal Tumor With Rhabdoid Features","Central Nervous System Embryonal Tumor, Not Otherwise Specified","Central Nervous System Ganglioneuroblastoma","Embryonal Tumor With Multilayered Rosettes, C19MC-Altered","Primary Central Nervous System Neoplasm","Recurrent Childhood Central Nervous System Embryonal Neoplasm","Recurrent Rhabdomyosarcoma","Refractory Rhabdomyosarcoma",[1555,1102],{"nctId":5924,"briefTitle":5925,"status":142,"phases":7390,"primaryCompletion":5927,"completion":5928,"start":5929,"enrollment":1331,"conditions":7391,"interventions":7392},[90],[5931,117],[1402,1102,5933,151,2143],{"nctId":5356,"briefTitle":5357,"status":142,"phases":7394,"primaryCompletion":5359,"completion":5359,"start":2487,"enrollment":1128,"conditions":7395,"interventions":7396},[90],[5361,4656,5362,5363,4661,4662],[53,1102],{"nctId":6527,"briefTitle":6528,"status":142,"phases":7398,"primaryCompletion":1575,"completion":1763,"start":6530,"enrollment":2586,"conditions":7399,"interventions":7400},[90],[1915,6532,6533,6534,3118,6535,6536,6537,6520],[4948,5106,6523],{"nctId":1086,"briefTitle":1087,"status":142,"phases":7402,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":7403,"interventions":7404},[90],[1092,1093,1094,1095,1096,1097],[1099,63,1100,737,279,1101,1102,151,1103],{"nctId":5394,"briefTitle":5395,"status":618,"phases":7406,"primaryCompletion":1022,"completion":3317,"start":5397,"enrollment":25,"conditions":7407,"interventions":7408},[90],[5399],[53,5401],{"nctId":5407,"briefTitle":5408,"status":142,"phases":7410,"primaryCompletion":144,"completion":5410,"start":5411,"enrollment":5412,"conditions":7411,"interventions":7412},[90],[5414,5415,5416,5417,5418,5419],[53,1102,151],{"nctId":7043,"briefTitle":7044,"status":618,"phases":7414,"primaryCompletion":7046,"completion":7046,"start":7047,"enrollment":407,"conditions":7415,"interventions":7416},[90],[3320,4828,4833,3321],[6296,6296,2083,474,167,1102,2045],{"nctId":7418,"briefTitle":7419,"status":142,"phases":7420,"primaryCompletion":4031,"completion":4031,"start":1819,"enrollment":9,"conditions":7421,"interventions":7435},"NCT00103259","Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[90],[5296,5297,5298,5299,5300,5301,5302,5303,5346,5347,5349,5352,7422,7423,7424,7425,7426,7427,7428,7429,7430,7431,7432,7433,7434],"Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer",[1062,5106],{"nctId":7437,"briefTitle":7438,"status":142,"phases":7439,"primaryCompletion":3479,"completion":4359,"start":987,"enrollment":407,"conditions":7440,"interventions":7441},"NCT00551421","Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer",[89,90],[5127,4983,4941,4942,4943,4944,4945,4946],[7442,1697,5106],"pertuzumab",{"trials":7444,"activeCount":2548,"soonestReadout":2133},[7445,7449,7453],{"nctId":5100,"briefTitle":5101,"status":618,"phases":7446,"primaryCompletion":5103,"completion":5103,"start":1320,"enrollment":1953,"conditions":7447,"interventions":7448},[91],[4941,4942,4844,4845,4846,4847],[5106,1264,3065,1697,1033],{"nctId":5131,"briefTitle":5132,"status":142,"phases":7450,"primaryCompletion":5103,"completion":5103,"start":4997,"enrollment":5134,"conditions":7451,"interventions":7452},[91],[5127,4943],[5106,4948,1264,3065,1697,5137],{"nctId":2130,"briefTitle":2131,"status":155,"phases":7454,"primaryCompletion":2133,"completion":592,"start":2134,"enrollment":2135,"conditions":7455,"interventions":7456},[91],[2137,2138,2139,2140],[278,2142,737,2084,1102,2143,740],{"trials":7458,"activeCount":101},[],{"trials":7460,"activeCount":101},[],{"intervention":2924,"totalTrials":188,"cells":7462},{"EARLY_PHASE1":7463,"PHASE1":7465,"PHASE2":7475,"PHASE3":7537,"PHASE4":7543,"NA":7545},{"trials":7464,"activeCount":101},[],{"trials":7466,"activeCount":101},[7467,7471],{"nctId":4950,"briefTitle":4951,"status":618,"phases":7468,"primaryCompletion":4953,"completion":4953,"start":4954,"enrollment":603,"conditions":7469,"interventions":7470},[89],[364,4956,4957,4958,4959,4960,4961,4962,4963,4964],[2924,2084,4966,2925,4967],{"nctId":6510,"briefTitle":6511,"status":618,"phases":7472,"primaryCompletion":6513,"start":3282,"enrollment":455,"conditions":7473,"interventions":7474},[89],[5637,6515,6516,6517,1787,3117,4941,3118,1579,4823,3259,4942,6518,6519,1220,1221,1222,1223,3137,4945,6520,1591,4841,3261,4946,15],[6522,6523,4948],{"trials":7476,"activeCount":2548,"soonestReadout":2654},[7477,7492,7496,7500,7510,7518,7525,7529,7533],{"nctId":7478,"briefTitle":7479,"status":618,"phases":7480,"primaryCompletion":7481,"completion":7482,"start":1329,"enrollment":37,"conditions":7483,"interventions":7491},"NCT01267240","Capecitabine and Vorinostat in Treating Patients With Recurrent and\u002For Metastatic Head and Neck Cancer",[90],"2015-06","2016-10",[7484,1867,1868,3877,1874,7485,1877,7486,1882,7487,1883,7488,1888,7489,1889,7490,1894],"Paranasal Sinus Squamous Cell Carcinoma","Stage IVA Hypopharyngeal Squamous Cell Carcinoma","Stage IVA Oral Cavity Squamous Cell Carcinoma","Stage IVB Hypopharyngeal Squamous Cell Carcinoma","Stage IVB Oral Cavity Squamous Cell Carcinoma","Stage IVC Hypopharyngeal Squamous Cell Carcinoma","Stage IVC Oral Cavity Squamous Cell Carcinoma",[2924,942],{"nctId":6527,"briefTitle":6528,"status":142,"phases":7493,"primaryCompletion":1575,"completion":1763,"start":6530,"enrollment":2586,"conditions":7494,"interventions":7495},[90],[1915,6532,6533,6534,3118,6535,6536,6537,6520],[4948,5106,6523],{"nctId":2908,"briefTitle":2909,"status":155,"phases":7497,"primaryCompletion":2654,"completion":2654,"start":2911,"enrollment":2912,"conditions":7498,"interventions":7499},[90],[2914,2915,2916,2917,1621,2918,2919,2920,2921,2922],[1690,2924,2083,2084,1140,2925],{"nctId":7501,"briefTitle":7502,"status":142,"phases":7503,"primaryCompletion":7504,"completion":7505,"start":7506,"enrollment":609,"conditions":7507,"interventions":7508},"NCT00684983","Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer",[90],"2014-01-07","2019-10-15","2008-07-30",[1446,2613,3080,3081,3082],[2924,1099,7509],"Lapatinib Ditosylate",{"nctId":7511,"briefTitle":7512,"status":142,"phases":7513,"primaryCompletion":7514,"completion":7514,"start":7515,"enrollment":407,"conditions":7516,"interventions":7517},"NCT00121251","Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and\u002For Metastatic Kidney Cancer",[89,90],"2017-03-14","2005-06-03",[4825,6206,6207],[2924,167,43],{"nctId":7519,"briefTitle":7520,"status":142,"phases":7521,"primaryCompletion":1763,"completion":1763,"start":1257,"enrollment":2029,"conditions":7522,"interventions":7523},"NCT00087152","S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer",[90],[18],[2924,7524],"Imatinib mesylate",{"nctId":5074,"briefTitle":5075,"status":142,"phases":7526,"primaryCompletion":5077,"completion":5078,"start":5079,"enrollment":2294,"conditions":7527,"interventions":7528},[90],[4957,5081,4958],[53,2924,2084,1140,2925],{"nctId":5566,"briefTitle":5567,"status":618,"phases":7530,"primaryCompletion":1604,"completion":1604,"start":5569,"enrollment":28,"conditions":7531,"interventions":7532},[90],[5571,5572,5573,5574,856],[5576,5577,53,5578,4966,2925,2924,5578],{"nctId":3852,"briefTitle":3853,"status":142,"phases":7534,"primaryCompletion":3855,"completion":3856,"start":3857,"enrollment":375,"conditions":7535,"interventions":7536},[90],[3859,854,3860,3861,3862],[883,2925,2924],{"trials":7538,"activeCount":2548,"soonestReadout":52},[7539],{"nctId":50,"briefTitle":51,"status":155,"phases":7540,"primaryCompletion":52,"completion":3410,"start":3411,"enrollment":234,"conditions":7541,"interventions":7542},[91],[3413,1787,250,251,3414,3415,3416,3417,3418,3419,1740,1741,1742,1743,1744,1745,1746,1747,1749,1750,1752,1753,1755,1756],[53,2924,277,2925,449],{"trials":7544,"activeCount":101},[],{"trials":7546,"activeCount":101},[],{"intervention":1101,"totalTrials":651,"cells":7548},{"EARLY_PHASE1":7549,"PHASE1":7551,"PHASE2":7563,"PHASE3":7600,"PHASE4":7614,"NA":7616},{"trials":7550,"activeCount":101},[],{"trials":7552,"activeCount":101},[7553,7559],{"nctId":7554,"briefTitle":7555,"status":618,"phases":7556,"primaryCompletion":1341,"start":1257,"enrollment":22,"conditions":7557,"interventions":7558},"NCT00086970","Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors",[89],[15],[3591,5961],{"nctId":3565,"briefTitle":3566,"status":142,"phases":7560,"primaryCompletion":3568,"completion":3568,"start":3569,"enrollment":34,"conditions":7561,"interventions":7562},[89],[3571,527,537],[277,279,58,1101,667],{"trials":7564,"activeCount":101},[7565,7569,7573,7577],{"nctId":3584,"briefTitle":3585,"status":142,"phases":7566,"primaryCompletion":3587,"start":3397,"enrollment":37,"conditions":7567,"interventions":7568},[89,90],[3181,940,3189],[3590,1063,3591,1776,1080,750,1066],{"nctId":4139,"briefTitle":4140,"status":142,"phases":7570,"primaryCompletion":4142,"start":1356,"enrollment":421,"conditions":7571,"interventions":7572},[90],[27],[750,3123,1080,3591],{"nctId":1086,"briefTitle":1087,"status":142,"phases":7574,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":7575,"interventions":7576},[90],[1092,1093,1094,1095,1096,1097],[1099,63,1100,737,279,1101,1102,151,1103],{"nctId":7578,"briefTitle":7579,"status":142,"phases":7580,"primaryCompletion":7581,"completion":2027,"start":1340,"enrollment":34,"conditions":7582,"interventions":7599},"NCT00381940","Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy",[90],"2008-06",[7583,7584,7585,7586,7587,7588,7589,7590,7591,7592,4681,4793,7593,7594,7595,7596,7597,7598,4796,4799],"Adult Lymphocyte Depletion Hodgkin Lymphoma","Adult Lymphocyte Predominant Hodgkin Lymphoma","Adult Mixed Cellularity Hodgkin Lymphoma","Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma","Adult Nodular Sclerosis Hodgkin Lymphoma","Childhood Lymphocyte Depletion Hodgkin Lymphoma","Childhood Lymphocyte Predominant Hodgkin Lymphoma","Childhood Mixed Cellularity Hodgkin Lymphoma","Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma","Childhood Nodular Sclerosis Hodgkin Lymphoma","Stage I Adult Hodgkin Lymphoma","Stage I Childhood Hodgkin Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage II Childhood Hodgkin Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage III Childhood Hodgkin Lymphoma",[3591,1062,2166,750],{"trials":7601,"activeCount":758,"soonestReadout":4445},[7602,7606,7610],{"nctId":3698,"briefTitle":3699,"status":107,"phases":7603,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":7604,"interventions":7605},[91],[3704,3705],[3707,1511,277,279,289,1101,2789,883,3708],{"nctId":4442,"briefTitle":4443,"status":155,"phases":7607,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":7608,"interventions":7609},[90,91],[4450,4451,4452,4453,4454,4455,4456,4457,4458,4459,4460,4461,4462,4463,4464,4465,4466,4467,4468,4469,4470,4471,4472,4473,4474,4475,4476,4477,4478,4479,4480,4481,4482,4483,4484,4485],[780,737,1101,2807,77],{"nctId":1457,"briefTitle":1458,"status":155,"phases":7611,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":7612,"interventions":7613},[91],[1464,1465,1466,1467,1468,1469],[63,780,737,279,1471,1472,1101,781,740],{"trials":7615,"activeCount":101},[],{"trials":7617,"activeCount":101},[],{"intervention":77,"totalTrials":651,"cells":7619},{"EARLY_PHASE1":7620,"PHASE1":7622,"PHASE2":7639,"PHASE3":7722,"PHASE4":7734,"NA":7736},{"trials":7621,"activeCount":101},[],{"trials":7623,"activeCount":101},[7624],{"nctId":7625,"briefTitle":7626,"status":142,"phases":7627,"primaryCompletion":7628,"start":4611,"enrollment":913,"conditions":7629,"interventions":7637},"NCT00929903","Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment",[89],"2013-04",[7630,7631,4642,7632,7633,7634,7635,1095,5363,7636,5871,6505,748],"Childhood Central Nervous System Choriocarcinoma","Childhood Central Nervous System Embryonal Tumor","Childhood Central Nervous System Germinoma","Childhood Central Nervous System Mixed Germ Cell Tumor","Childhood Central Nervous System Teratoma","Childhood Central Nervous System Yolk Sac Tumor","Recurrent Childhood Central Nervous System Embryonal Tumor",[7638],"pazopanib hydrochloride",{"trials":7640,"activeCount":101},[7641,7648,7669,7679,7693,7716],{"nctId":7642,"briefTitle":7643,"status":142,"phases":7644,"primaryCompletion":650,"completion":5270,"start":7645,"enrollment":97,"conditions":7646,"interventions":7647},"NCT00454142","Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer",[90],"2007-08",[5291,5299,5341,5349],[7638],{"nctId":7649,"briefTitle":7650,"status":142,"phases":7651,"primaryCompletion":507,"completion":7652,"start":7653,"enrollment":2656,"conditions":7654,"interventions":7668},"NCT00625846","Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer",[90],"2019-08-13","2008-02-22",[7655,7656,7657,7658,7659,7660,7661,7662,7663,7664,7665,7666,7667],"Recurrent Thyroid Gland Carcinoma","Stage III Differentiated Thyroid Gland Carcinoma AJCC v7","Stage III Thyroid Gland Medullary Carcinoma AJCC v7","Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7","Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7","Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7","Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7","Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7","Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7","Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7","Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7","Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7","Thyroid Gland Anaplastic Carcinoma",[77],{"nctId":7670,"briefTitle":7671,"status":618,"phases":7672,"primaryCompletion":5985,"completion":5985,"start":6569,"enrollment":1024,"conditions":7673,"interventions":7678},"NCT01340794","Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma",[90],[7674,7675,7676,7677],"Extra-Adrenal Paraganglioma","Metastatic Adrenal Gland Pheochromocytoma","Paraganglioma","Recurrent Adrenal Gland Pheochromocytoma",[77],{"nctId":7680,"briefTitle":7681,"status":142,"phases":7682,"primaryCompletion":649,"completion":3295,"start":5444,"enrollment":3255,"conditions":7683,"interventions":7692},"NCT00471536","Pazopanib in Treating Patients With Metastatic Urothelial Cancer",[90],[7684,7685,7686,7687,7688,7689,7690,7691],"Distal Urethral Cancer","Proximal Urethral Cancer","Recurrent Bladder Cancer","Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter","Recurrent Urethral Cancer","Stage IV Bladder Cancer","Transitional Cell Carcinoma of the Bladder","Urethral Cancer Associated With Invasive Bladder Cancer",[7638],{"nctId":7694,"briefTitle":7695,"status":618,"phases":7696,"primaryCompletion":7697,"completion":7698,"start":7699,"enrollment":7700,"conditions":7701,"interventions":7715},"NCT02601209","Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma",[89,90],"2018-12-07","2022-07-11","2015-11-30",151,[7702,554,7703,3813,7704,7705,4471,7706,7707,7708,7709,2803,7710,7711,7712,2804,7713,7714,555],"High Grade Sarcoma","Metastatic Malignant Peripheral Nerve Sheath Tumor","Metastatic Undifferentiated Pleomorphic Sarcoma","Metastatic Unresectable Sarcoma","Recurrent Leiomyosarcoma","Recurrent Malignant Peripheral Nerve Sheath Tumor","Recurrent Synovial Sarcoma","Recurrent Undifferentiated Pleomorphic Sarcoma","Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8","Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8","Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8","Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8","Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8",[2807,77,5225],{"nctId":7717,"briefTitle":7718,"status":142,"phases":7719,"primaryCompletion":1763,"completion":1763,"start":1053,"enrollment":638,"conditions":7720,"interventions":7721},"NCT00459381","Pazopanib in Treating Patients With Recurrent Glioblastoma",[90],[4817,4818,4819,5287],[7638],{"trials":7723,"activeCount":758,"soonestReadout":76},[7724,7728],{"nctId":4442,"briefTitle":4443,"status":155,"phases":7725,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":7726,"interventions":7727},[90,91],[4450,4451,4452,4453,4454,4455,4456,4457,4458,4459,4460,4461,4462,4463,4464,4465,4466,4467,4468,4469,4470,4471,4472,4473,4474,4475,4476,4477,4478,4479,4480,4481,4482,4483,4484,4485],[780,737,1101,2807,77],{"nctId":74,"briefTitle":75,"status":155,"phases":7729,"primaryCompletion":76,"completion":2050,"start":7730,"enrollment":7731,"conditions":7732,"interventions":7733},[91],"2012-08-08",129,[5232,6207],[77],{"trials":7735,"activeCount":101},[],{"trials":7737,"activeCount":101},[],{"intervention":4966,"totalTrials":889,"cells":7739},{"EARLY_PHASE1":7740,"PHASE1":7742,"PHASE2":7756,"PHASE3":7766,"PHASE4":7772,"NA":7774},{"trials":7741,"activeCount":101},[],{"trials":7743,"activeCount":2548,"soonestReadout":1382},[7744,7748,7752],{"nctId":4950,"briefTitle":4951,"status":618,"phases":7745,"primaryCompletion":4953,"completion":4953,"start":4954,"enrollment":603,"conditions":7746,"interventions":7747},[89],[364,4956,4957,4958,4959,4960,4961,4962,4963,4964],[2924,2084,4966,2925,4967],{"nctId":6266,"briefTitle":6267,"status":155,"phases":7749,"primaryCompletion":1382,"completion":6269,"start":6270,"enrollment":771,"conditions":7750,"interventions":7751},[89],[6272,6273,6274,2427,6275,2429,2430,6276,2431],[1137,643,4966,6278,6279],{"nctId":7081,"briefTitle":7082,"status":142,"phases":7753,"completion":3254,"start":7084,"enrollment":31,"conditions":7754,"interventions":7755},[89],[7086,7087,7088],[1405,6109,4966],{"trials":7757,"activeCount":101},[7758,7762],{"nctId":1285,"briefTitle":1286,"status":142,"phases":7759,"completion":1288,"start":1289,"enrollment":913,"conditions":7760,"interventions":7761},[90],[18,1291],[1268,1293,1294,693,995,1225],{"nctId":5566,"briefTitle":5567,"status":618,"phases":7763,"primaryCompletion":1604,"completion":1604,"start":5569,"enrollment":28,"conditions":7764,"interventions":7765},[90],[5571,5572,5573,5574,856],[5576,5577,53,5578,4966,2925,2924,5578],{"trials":7767,"activeCount":2548,"soonestReadout":5163},[7768],{"nctId":5160,"briefTitle":5161,"status":155,"phases":7769,"primaryCompletion":5163,"completion":5164,"start":5165,"enrollment":5166,"conditions":7770,"interventions":7771},[91],[3043,5168,5169,5170],[53,2084,4966,2925],{"trials":7773,"activeCount":101},[],{"trials":7775,"activeCount":101},[],{"intervention":2789,"totalTrials":889,"cells":7777},{"EARLY_PHASE1":7778,"PHASE1":7780,"PHASE2":7782,"PHASE3":7809,"PHASE4":7819,"NA":7821},{"trials":7779,"activeCount":101},[],{"trials":7781,"activeCount":101},[],{"trials":7783,"activeCount":2548,"soonestReadout":2737},[7784,7792,7801,7805],{"nctId":7785,"briefTitle":7786,"status":142,"phases":7787,"primaryCompletion":1170,"completion":7788,"start":715,"enrollment":28,"conditions":7789,"interventions":7790},"NCT00337194","SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",[90],"2014-10",[7583,7584,7585,7587,4681],[7791,2166,3401,3066],"monoclonal antibody SGN-30",{"nctId":7793,"briefTitle":7794,"status":142,"phases":7795,"primaryCompletion":7796,"completion":7797,"start":7798,"enrollment":913,"conditions":7799,"interventions":7800},"NCT00088855","Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma",[90],"2006-10-31","2008-01-08","2004-06-15",[7105,7106,7107],[1569,2789],{"nctId":2734,"briefTitle":2735,"status":155,"phases":7802,"primaryCompletion":2737,"completion":2642,"start":2738,"enrollment":1357,"conditions":7803,"interventions":7804},[90],[1724,2740,2741,2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2616,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773,2774,2775,2776,2777,2778,2779,2780,2781,2782,2783,2784,2785,2786,2787],[68,2124,2554,449,2789,2790],{"nctId":3394,"briefTitle":3395,"status":142,"phases":7806,"completion":3397,"start":3398,"conditions":7807,"interventions":7808},[90],[625],[3123,995,3401],{"trials":7810,"activeCount":2548,"soonestReadout":2813},[7811,7815],{"nctId":3698,"briefTitle":3699,"status":107,"phases":7812,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":7813,"interventions":7814},[91],[3704,3705],[3707,1511,277,279,289,1101,2789,883,3708],{"nctId":2810,"briefTitle":2811,"status":155,"phases":7816,"primaryCompletion":2813,"completion":2642,"start":2814,"enrollment":2815,"conditions":7817,"interventions":7818},[90,91],[1722,1723,2645,1726,1727,1731,1732,2740,1735,1736,1737,1739,250,251,252],[2732,68,2554,449,2789,1407,2790],{"trials":7820,"activeCount":101},[],{"trials":7822,"activeCount":101},[],{"intervention":1375,"totalTrials":214,"cells":7824},{"EARLY_PHASE1":7825,"PHASE1":7827,"PHASE2":7829,"PHASE3":7839,"PHASE4":7849,"NA":7851},{"trials":7826,"activeCount":101},[],{"trials":7828,"activeCount":101},[],{"trials":7830,"activeCount":2548,"soonestReadout":2262},[7831,7835],{"nctId":2259,"briefTitle":2260,"status":155,"phases":7832,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":7833,"interventions":7834},[90],[902,2267,2268,2269,2270],[1372,1138,1375,1141,2272,212,781,740],{"nctId":1254,"briefTitle":1255,"status":142,"phases":7836,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":7837,"interventions":7838},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"trials":7840,"activeCount":2548,"soonestReadout":1365},[7841,7845],{"nctId":1362,"briefTitle":1363,"status":155,"phases":7842,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":7843,"interventions":7844},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1378,"briefTitle":1379,"status":142,"phases":7846,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":7847,"interventions":7848},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"trials":7850,"activeCount":101},[],{"trials":7852,"activeCount":101},[],{"intervention":2807,"totalTrials":214,"cells":7854},{"EARLY_PHASE1":7855,"PHASE1":7857,"PHASE2":7867,"PHASE3":7873,"PHASE4":7883,"NA":7885},{"trials":7856,"activeCount":101},[],{"trials":7858,"activeCount":101},[7859],{"nctId":7860,"briefTitle":7861,"status":142,"phases":7862,"primaryCompletion":7863,"completion":7863,"start":7864,"enrollment":771,"conditions":7865,"interventions":7866},"NCT00674024","Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function",[89],"2013-01-22","2008-10-07",[467,27],[2807,2807],{"trials":7868,"activeCount":101},[7869],{"nctId":7694,"briefTitle":7695,"status":618,"phases":7870,"primaryCompletion":7697,"completion":7698,"start":7699,"enrollment":7700,"conditions":7871,"interventions":7872},[89,90],[7702,554,7703,3813,7704,7705,4471,7706,7707,7708,7709,2803,7710,7711,7712,2804,7713,7714,555],[2807,77,5225],{"trials":7874,"activeCount":758,"soonestReadout":4445},[7875,7879],{"nctId":2794,"briefTitle":2795,"status":155,"phases":7876,"primaryCompletion":2797,"completion":2798,"start":2799,"enrollment":159,"conditions":7877,"interventions":7878},[90,91],[2801,2802,2803,2804,2805],[2554,2807,151,2808],{"nctId":4442,"briefTitle":4443,"status":155,"phases":7880,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":7881,"interventions":7882},[90,91],[4450,4451,4452,4453,4454,4455,4456,4457,4458,4459,4460,4461,4462,4463,4464,4465,4466,4467,4468,4469,4470,4471,4472,4473,4474,4475,4476,4477,4478,4479,4480,4481,4482,4483,4484,4485],[780,737,1101,2807,77],{"trials":7884,"activeCount":101},[],{"trials":7886,"activeCount":101},[],{"intervention":2045,"totalTrials":214,"cells":7888},{"EARLY_PHASE1":7889,"PHASE1":7891,"PHASE2":7893,"PHASE3":7907,"PHASE4":7913,"NA":7915},{"trials":7890,"activeCount":101},[],{"trials":7892,"activeCount":101},[],{"trials":7894,"activeCount":2548,"soonestReadout":67},[7895,7899,7903],{"nctId":7043,"briefTitle":7044,"status":618,"phases":7896,"primaryCompletion":7046,"completion":7046,"start":7047,"enrollment":407,"conditions":7897,"interventions":7898},[90],[3320,4828,4833,3321],[6296,6296,2083,474,167,1102,2045],{"nctId":4897,"briefTitle":4898,"status":142,"phases":7900,"primaryCompletion":4900,"completion":1865,"start":813,"enrollment":1074,"conditions":7901,"interventions":7902},[90],[3119],[2299,4903],{"nctId":65,"briefTitle":66,"status":155,"phases":7904,"primaryCompletion":67,"completion":592,"start":2037,"enrollment":2038,"conditions":7905,"interventions":7906},[89,90],[2040,2041,2042,2043],[68,278,2045],{"trials":7908,"activeCount":2548,"soonestReadout":2114},[7909],{"nctId":2111,"briefTitle":2112,"status":155,"phases":7910,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":7911,"interventions":7912},[91],[2118,1626,2119,2120,2121,2122],[277,278,2124,279,449,2045],{"trials":7914,"activeCount":101},[],{"trials":7916,"activeCount":101},[],{"intervention":1372,"totalTrials":603,"cells":7918},{"EARLY_PHASE1":7919,"PHASE1":7921,"PHASE2":7927,"PHASE3":7933,"PHASE4":7939,"NA":7941},{"trials":7920,"activeCount":101},[],{"trials":7922,"activeCount":101},[7923],{"nctId":4522,"briefTitle":4523,"status":142,"phases":7924,"primaryCompletion":4525,"completion":4525,"start":1807,"enrollment":638,"conditions":7925,"interventions":7926},[89],[526,527,3187,3188,940,4527,4528,528,3189,3190,4529,4530,655,536,537,4531,4532,4533,4534,4535,538,4536,4537,4538,4539,4540],[1372,1016],{"trials":7928,"activeCount":2548,"soonestReadout":2262},[7929],{"nctId":2259,"briefTitle":2260,"status":155,"phases":7930,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":7931,"interventions":7932},[90],[902,2267,2268,2269,2270],[1372,1138,1375,1141,2272,212,781,740],{"trials":7934,"activeCount":2548,"soonestReadout":1365},[7935],{"nctId":1362,"briefTitle":1363,"status":155,"phases":7936,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":7937,"interventions":7938},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"trials":7940,"activeCount":101},[],{"trials":7942,"activeCount":101},[],{"intervention":1471,"totalTrials":603,"cells":7944},{"EARLY_PHASE1":7945,"PHASE1":7947,"PHASE2":7957,"PHASE3":7959,"PHASE4":7965,"NA":7967},{"trials":7946,"activeCount":101},[],{"trials":7948,"activeCount":2548,"soonestReadout":1603},[7949,7953],{"nctId":6244,"briefTitle":6245,"status":155,"phases":7950,"primaryCompletion":1603,"completion":1603,"start":6247,"enrollment":1765,"conditions":7951,"interventions":7952},[89],[2427,2430],[1137,1471,6250,6251],{"nctId":6289,"briefTitle":6290,"status":142,"phases":7954,"primaryCompletion":6292,"completion":6292,"start":6293,"enrollment":339,"conditions":7955,"interventions":7956},[89],[33,2430],[6296,1137,1471,6250],{"trials":7958,"activeCount":101},[],{"trials":7960,"activeCount":2548,"soonestReadout":1460},[7961],{"nctId":1457,"briefTitle":1458,"status":155,"phases":7962,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":7963,"interventions":7964},[91],[1464,1465,1466,1467,1468,1469],[63,780,737,279,1471,1472,1101,781,740],{"trials":7966,"activeCount":101},[],{"trials":7968,"activeCount":101},[],{"intervention":5576,"totalTrials":603,"cells":7970},{"EARLY_PHASE1":7971,"PHASE1":7973,"PHASE2":7975,"PHASE3":7990,"PHASE4":7996,"NA":7998},{"trials":7972,"activeCount":101},[],{"trials":7974,"activeCount":101},[],{"trials":7976,"activeCount":2548,"soonestReadout":3019},[7977,7986],{"nctId":7978,"briefTitle":7979,"status":128,"phases":7980,"primaryCompletion":3019,"completion":3019,"start":7981,"enrollment":443,"conditions":7982,"interventions":7985},"NCT04071236","Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy",[89,90],"2020-10-14",[7983,1465,7984,2596],"Metastatic Castration-Resistant Prostate Carcinoma","Metastatic Malignant Neoplasm in the Lymph Nodes",[5576,6251],{"nctId":5566,"briefTitle":5567,"status":618,"phases":7987,"primaryCompletion":1604,"completion":1604,"start":5569,"enrollment":28,"conditions":7988,"interventions":7989},[90],[5571,5572,5573,5574,856],[5576,5577,53,5578,4966,2925,2924,5578],{"trials":7991,"activeCount":2548,"soonestReadout":6215},[7992],{"nctId":6212,"briefTitle":6213,"status":155,"phases":7993,"primaryCompletion":6215,"completion":6215,"start":6216,"enrollment":6217,"conditions":7994,"interventions":7995},[91],[6219,6220,6221,6222,1854,2937,1856,2938,2696,6223,2943,2944,2945,2697,6224,2946,2947,2948],[5576,240],{"trials":7997,"activeCount":101},[],{"trials":7999,"activeCount":101},[],{"intervention":1373,"totalTrials":758,"cells":8001},{"EARLY_PHASE1":8002,"PHASE1":8004,"PHASE2":8006,"PHASE3":8012,"PHASE4":8018,"NA":8020},{"trials":8003,"activeCount":101},[],{"trials":8005,"activeCount":101},[],{"trials":8007,"activeCount":2548,"soonestReadout":3971},[8008],{"nctId":3968,"briefTitle":3969,"status":155,"phases":8009,"primaryCompletion":3971,"completion":3972,"start":3973,"enrollment":838,"conditions":8010,"interventions":8011},[89,90],[263],[1137,1373,3976,2217],{"trials":8013,"activeCount":2548,"soonestReadout":1365},[8014],{"nctId":1362,"briefTitle":1363,"status":155,"phases":8015,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":8016,"interventions":8017},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"trials":8019,"activeCount":101},[],{"trials":8021,"activeCount":101},[],{"intervention":1142,"totalTrials":758,"cells":8023},{"EARLY_PHASE1":8024,"PHASE1":8026,"PHASE2":8028,"PHASE3":8034,"PHASE4":8040,"NA":8042},{"trials":8025,"activeCount":101},[],{"trials":8027,"activeCount":101},[],{"trials":8029,"activeCount":2548,"soonestReadout":62},[8030],{"nctId":60,"briefTitle":61,"status":155,"phases":8031,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":8032,"interventions":8033},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"trials":8035,"activeCount":2548,"soonestReadout":1498},[8036],{"nctId":1495,"briefTitle":1496,"status":155,"phases":8037,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":8038,"interventions":8039},[91],[1503,1504,1505,1506,1507,1508],[1510,1511,63,737,279,1142,212,740],{"trials":8041,"activeCount":101},[],{"trials":8043,"activeCount":101},[],{"intervention":4566,"totalTrials":552,"cells":8045},{"EARLY_PHASE1":8046,"PHASE1":8048,"PHASE2":8070,"PHASE3":8175,"PHASE4":8181,"NA":8183},{"trials":8047,"activeCount":101},[],{"trials":8049,"activeCount":101},[8050,8054,8062],{"nctId":4558,"briefTitle":4559,"status":142,"phases":8051,"primaryCompletion":4561,"start":4562,"enrollment":37,"conditions":8052,"interventions":8053},[89],[4262,1431,1432],[4565,4566],{"nctId":8055,"briefTitle":8056,"status":618,"phases":8057,"primaryCompletion":5445,"start":5976,"enrollment":1195,"conditions":8058,"interventions":8061},"NCT00101088","Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",[89],[4034,4053,8059,8060,4060],"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Chronic Phase Chronic Myelogenous Leukemia",[5456,4566],{"nctId":8063,"briefTitle":8064,"status":142,"phases":8065,"primaryCompletion":4561,"completion":4561,"start":715,"enrollment":8066,"conditions":8067,"interventions":8068},"NCT00349206","Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",[89],69,[36,1343,5454,1344],[8069,4566],"sorafenib tosylate",{"trials":8071,"activeCount":101},[8072,8079,8083,8087,8094,8105,8109,8115,8121,8130,8137,8142,8151,8159,8163,8171],{"nctId":8073,"briefTitle":8074,"status":142,"phases":8075,"primaryCompletion":1329,"completion":3129,"start":7645,"enrollment":8076,"conditions":8077,"interventions":8078},"NCT00281957","Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery",[90],109,[1343,1344],[8069,1185,4566],{"nctId":5924,"briefTitle":5925,"status":142,"phases":8080,"primaryCompletion":5927,"completion":5928,"start":5929,"enrollment":1331,"conditions":8081,"interventions":8082},[90],[5931,117],[1402,1102,5933,151,2143],{"nctId":4675,"briefTitle":4676,"status":142,"phases":8084,"primaryCompletion":144,"completion":4678,"start":4679,"enrollment":3283,"conditions":8085,"interventions":8086},[89,90],[4414,4681,4592,4593,3190,4530,4682,4003],[1016,2143],{"nctId":8088,"briefTitle":8089,"status":142,"phases":8090,"primaryCompletion":650,"completion":650,"start":6530,"enrollment":8091,"conditions":8092,"interventions":8093},"NCT00290472","CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",[90],89,[5663,1245,5283,1246,3180,3181,3182,3183,3185,3186,3187,3188,940,3190,655,656,1248,1251],[4566],{"nctId":8095,"briefTitle":8096,"status":142,"phases":8097,"primaryCompletion":3295,"completion":3295,"start":3479,"enrollment":2250,"conditions":8098,"interventions":8104},"NCT01256385","Temsirolimus With or Without Cetuximab in Patients With Recurrent and\u002For Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy",[90],[1867,1868,1869,1870,1871,1872,8099,1873,1874,2056,2058,1875,1876,8100,1877,1878,1879,8101,1880,1881,1882,1883,1884,1885,8102,1886,1887,1888,1889,1890,1891,8103,1892,1893,1894,1895],"Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Stage IVA Major Salivary Gland Carcinoma","Stage IVB Major Salivary Gland Carcinoma","Stage IVC Major Salivary Gland Carcinoma",[1570,2143],{"nctId":5721,"briefTitle":5722,"status":142,"phases":8106,"primaryCompletion":5724,"completion":4878,"start":3671,"enrollment":9,"conditions":8107,"interventions":8108},[90],[3189],[1063,4566],{"nctId":8110,"briefTitle":8111,"status":142,"phases":8112,"primaryCompletion":5461,"start":6477,"enrollment":97,"conditions":8113,"interventions":8114},"NCT00016328","CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme",[90],[4817,4818,4819,5287],[4566],{"nctId":8116,"briefTitle":8117,"status":618,"phases":8118,"primaryCompletion":5461,"start":3397,"enrollment":1074,"conditions":8119,"interventions":8120},"NCT00086840","CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",[90],[3181,4681,656],[4566],{"nctId":8122,"briefTitle":8123,"status":142,"phases":8124,"primaryCompletion":4928,"completion":4928,"start":1170,"enrollment":1331,"conditions":8125,"interventions":8128},"NCT00729586","Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer",[90],[3428,5549,5551,5552,8126,8127,5554,5555],"Stage IIIC1 Uterine Corpus Cancer","Stage IIIC2 Uterine Corpus Cancer",[8129,1454,2143],"Megestrol Acetate",{"nctId":8131,"briefTitle":8132,"status":142,"phases":8133,"primaryCompletion":3227,"completion":8134,"start":715,"enrollment":4001,"conditions":8135,"interventions":8136},"NCT00335764","Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma",[89,90],"2012-09",[4817,4818,4819,5287],[8069,1774,1185,4566],{"nctId":8138,"briefTitle":8064,"status":107,"phases":8139,"primaryCompletion":4561,"completion":4561,"start":715,"enrollment":101,"conditions":8140,"interventions":8141},"NCT01851408",[90],[36,1343,5454,1344],[8069,4566],{"nctId":8143,"briefTitle":8144,"status":142,"phases":8145,"primaryCompletion":650,"completion":5858,"start":5976,"enrollment":8066,"conditions":8146,"interventions":8150},"NCT00112736","Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma",[89,90],[4813,4815,5275,4817,4818,4819,4820,8147,8148,8149,5287],"Adult Pilocytic Astrocytoma","Adult Pineal Gland Astrocytoma","Adult Subependymal Giant Cell Astrocytoma",[3277,4566],{"nctId":8152,"briefTitle":8153,"status":142,"phases":8154,"primaryCompletion":8155,"completion":8156,"start":826,"enrollment":1765,"conditions":8157,"interventions":8158},"NCT00699491","Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",[89,90],"2013-09-09","2018-02-14",[3135,2613,3082],[1099,2143],{"nctId":5525,"briefTitle":5526,"status":142,"phases":8160,"primaryCompletion":5528,"completion":5528,"start":5529,"enrollment":5530,"conditions":8161,"interventions":8162},[90],[5532,5533,1944,5534,5535,5536,5537,5538,5539,5540,1730,1732,2740,2671,5541,5542,5543,5544,5545,5546,5547,250,251,5548,252,5549,5550,3484,3485,3486,5551,3487,3488,3489,5552,3490,3491,3492,5553,3493,3494,3495,5554,5555,5556],[53,2143],{"nctId":8164,"briefTitle":8165,"status":618,"phases":8166,"primaryCompletion":2004,"completion":8167,"start":1022,"enrollment":771,"conditions":8168,"interventions":8170},"NCT01061606","Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus",[90],"2012-10",[8169,5556],"Recurrent Uterine Sarcoma",[4566],{"nctId":5803,"briefTitle":5804,"status":142,"phases":8172,"primaryCompletion":5806,"completion":5807,"start":5808,"enrollment":651,"conditions":8173,"interventions":8174},[89,90],[4592,3189,3190,4530,655,5810,4531,4536,4537,4539,4540],[1569,1139,667,2143],{"trials":8176,"activeCount":2548,"soonestReadout":2133},[8177],{"nctId":2130,"briefTitle":2131,"status":155,"phases":8178,"primaryCompletion":2133,"completion":592,"start":2134,"enrollment":2135,"conditions":8179,"interventions":8180},[91],[2137,2138,2139,2140],[278,2142,737,2084,1102,2143,740],{"trials":8182,"activeCount":101},[],{"trials":8184,"activeCount":101},[],{"intervention":1697,"totalTrials":407,"cells":8186},{"EARLY_PHASE1":8187,"PHASE1":8189,"PHASE2":8238,"PHASE3":8298,"PHASE4":8312,"NA":8314},{"trials":8188,"activeCount":101},[],{"trials":8190,"activeCount":101},[8191,8198,8202,8209,8222,8226],{"nctId":8192,"briefTitle":8193,"status":142,"phases":8194,"primaryCompletion":3226,"completion":6303,"start":8167,"enrollment":97,"conditions":8195,"interventions":8196},"NCT01217450","Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors",[89],[4941,4942,4844,4845,4846,4847,15],[8197,1697],"selumetinib",{"nctId":1557,"briefTitle":1558,"status":142,"phases":8199,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":603,"conditions":8200,"interventions":8201},[89],[1563,1564,1565,1566,1567],[1569,1570,278],{"nctId":8203,"briefTitle":8204,"status":142,"phases":8205,"primaryCompletion":1052,"completion":1052,"start":1340,"enrollment":5986,"conditions":8206,"interventions":8208},"NCT00397384","Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",[89],[5127,4983,4863,7342,7344,5509,8207,5286,4890,7349,5288,4941,7351,5289,7352,7353,3118,5510,5290,5291,5292,7354,5293,5294,3119,3259,4942,5295,7355,5296,5297,5298,5299,5300,5301,5302,5303,7356,7357,4795,5337,7358,5338,4945,7361,5339,6520,5340,5341,5342,5343,5344,3285,3261,4946,5345,5346,5347,5348,5349,5350,5351,5352,5353,7434,7363,7364],"Metastatic Squamous Neck Cancer With Occult Primary",[1697,1774],{"nctId":8210,"briefTitle":8211,"status":142,"phases":8212,"primaryCompletion":8213,"completion":8213,"start":8214,"enrollment":685,"conditions":8215,"interventions":8220},"NCT01287130","AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer",[89],"2013-08-27","2011-01-07",[8216,8217,843,8218,8219],"Colonic Neoplasms","Cancer of the Colon","Colon Neoplasms","Colonic Cancer",[1570,8221],"AZD6244",{"nctId":1692,"briefTitle":1693,"status":142,"phases":8223,"primaryCompletion":1329,"start":987,"enrollment":730,"conditions":8224,"interventions":8225},[89],[1564],[1697,1062,1598],{"nctId":8227,"briefTitle":8228,"status":347,"phases":8229,"primaryCompletion":2798,"completion":2798,"start":8230,"enrollment":28,"conditions":8231,"interventions":8235},"NCT06102902","Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer",[89],"2024-06-05",[8232,8233,8234,5016],"Metastatic Colorectal Adenocarcinoma","Recurrent Colorectal Adenocarcinoma","Refractory Colorectal Adenocarcinoma",[8236,1570,8237],"BET Bromodomain Inhibitor ZEN-3694","Encorafenib",{"trials":8239,"activeCount":101},[8240,8244,8254,8258,8262,8280,8284,8294],{"nctId":8095,"briefTitle":8096,"status":142,"phases":8241,"primaryCompletion":3295,"completion":3295,"start":3479,"enrollment":2250,"conditions":8242,"interventions":8243},[90],[1867,1868,1869,1870,1871,1872,8099,1873,1874,2056,2058,1875,1876,8100,1877,1878,1879,8101,1880,1881,1882,1883,1884,1885,8102,1886,1887,1888,1889,1890,1891,8103,1892,1893,1894,1895],[1570,2143],{"nctId":8245,"briefTitle":8246,"status":142,"phases":8247,"primaryCompletion":8248,"completion":8248,"start":8249,"enrollment":5714,"conditions":8250,"interventions":8252},"NCT01696955","Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery",[90],"2017-05-05","2012-08-20",[3837,8251],"Recurrent Head and Neck Carcinoma",[1570,8253],"Tivantinib",{"nctId":3279,"briefTitle":3280,"status":142,"phases":8255,"primaryCompletion":3282,"completion":3282,"start":2487,"enrollment":3283,"conditions":8256,"interventions":8257},[90],[1767,2163,1768,1769,3119,1770,1772,3285],[1697,995,1033],{"nctId":5046,"briefTitle":5047,"status":142,"phases":8259,"primaryCompletion":1318,"completion":1318,"start":4639,"enrollment":971,"conditions":8260,"interventions":8261},[90],[4983,5050,4941,4942,5051,4945,4946],[1697,1033,4948,1264,3065],{"nctId":8263,"briefTitle":8264,"status":142,"phases":8265,"primaryCompletion":8266,"completion":8267,"start":1171,"enrollment":913,"conditions":8268,"interventions":8279},"NCT00939627","Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab",[90],"2013-01","2014-01",[8269,7354,5295,5296,5297,5298,5299,5300,5301,5302,5303,2058,5346,5349,8270,8271,7422,7423,7424,8272,7425,8273,8274,7426,7427,7428,8275,7429,8276,8277,7430,7431,7432,8278,7433,7434,7365],"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Larynx",[1697,8069],{"nctId":5477,"briefTitle":5478,"status":142,"phases":8281,"primaryCompletion":4561,"completion":4561,"start":5397,"enrollment":1765,"conditions":8282,"interventions":8283},[90],[1564,576],[1570,53],{"nctId":8285,"briefTitle":8286,"status":347,"phases":8287,"primaryCompletion":8288,"completion":8288,"start":8289,"enrollment":2250,"conditions":8290,"interventions":8292},"NCT07042295","Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System",[90],"2029-02-28","2026-03-23",[8291,197],"Locally Recurrent Skin Squamous Cell Carcinoma",[8293,1570],"Amivantamab and Recombinant Human Hyaluronidase",{"nctId":7437,"briefTitle":7438,"status":142,"phases":8295,"primaryCompletion":3479,"completion":4359,"start":987,"enrollment":407,"conditions":8296,"interventions":8297},[89,90],[5127,4983,4941,4942,4943,4944,4945,4946],[7442,1697,5106],{"trials":8299,"activeCount":2548,"soonestReadout":3889},[8300,8304,8308],{"nctId":3886,"briefTitle":3887,"status":128,"phases":8301,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":3891,"conditions":8302,"interventions":8303},[91],[3871,3872,3873,3874,3875,3876,1867,1868,2055,3877,1874,3893,3894,3895,3896,3897,3898,3878,3879,3880,3881],[1570,883],{"nctId":5100,"briefTitle":5101,"status":618,"phases":8305,"primaryCompletion":5103,"completion":5103,"start":1320,"enrollment":1953,"conditions":8306,"interventions":8307},[91],[4941,4942,4844,4845,4846,4847],[5106,1264,3065,1697,1033],{"nctId":5131,"briefTitle":5132,"status":142,"phases":8309,"primaryCompletion":5103,"completion":5103,"start":4997,"enrollment":5134,"conditions":8310,"interventions":8311},[91],[5127,4943],[5106,4948,1264,3065,1697,5137],{"trials":8313,"activeCount":101},[],{"trials":8315,"activeCount":101},[],{"intervention":1374,"totalTrials":889,"cells":8317},{"EARLY_PHASE1":8318,"PHASE1":8320,"PHASE2":8322,"PHASE3":8336,"PHASE4":8350,"NA":8352},{"trials":8319,"activeCount":101},[],{"trials":8321,"activeCount":101},[],{"trials":8323,"activeCount":101},[8324,8328,8332],{"nctId":6300,"briefTitle":6301,"status":142,"phases":8325,"primaryCompletion":6303,"completion":6303,"start":3155,"enrollment":6304,"conditions":8326,"interventions":8327},[90],[6306,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,2432,4132],[1998,1263,2324,1187],{"nctId":4119,"briefTitle":4120,"status":142,"phases":8329,"primaryCompletion":4122,"completion":4123,"start":4124,"enrollment":4125,"conditions":8330,"interventions":8331},[90],[263,4127,4128,4129,4130,4131,4132],[980,1137,1374,2435,279,738],{"nctId":1254,"briefTitle":1255,"status":142,"phases":8333,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":8334,"interventions":8335},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"trials":8337,"activeCount":2548,"soonestReadout":1365},[8338,8342,8346],{"nctId":1362,"briefTitle":1363,"status":155,"phases":8339,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":8340,"interventions":8341},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1378,"briefTitle":1379,"status":142,"phases":8343,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":8344,"interventions":8345},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"nctId":4228,"briefTitle":4229,"status":142,"phases":8347,"primaryCompletion":4231,"start":4232,"enrollment":4233,"conditions":8348,"interventions":8349},[91],[4037,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,4132],[1187,1263,1080,4236],{"trials":8351,"activeCount":101},[],{"trials":8353,"activeCount":101},[],{"intervention":1186,"totalTrials":838,"cells":8355},{"EARLY_PHASE1":8356,"PHASE1":8358,"PHASE2":8379,"PHASE3":8391,"PHASE4":8397,"NA":8399},{"trials":8357,"activeCount":101},[],{"trials":8359,"activeCount":101},[8360,8369],{"nctId":8361,"briefTitle":8362,"status":142,"phases":8363,"primaryCompletion":5724,"completion":5724,"start":5461,"enrollment":1074,"conditions":8364,"interventions":8368},"NCT00217412","Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia",[89],[8365,4641,4777,8366,4778,4780,1183,8367,4178,6503,4789,4790,4662,4791,4665,117,4793,4060,748],"Childhood Acute Promyelocytic Leukemia (M3)","Childhood Chronic Myelogenous Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia",[4063,1186],{"nctId":8370,"briefTitle":8371,"status":142,"phases":8372,"primaryCompletion":4811,"start":1329,"enrollment":1041,"conditions":8373,"interventions":8378},"NCT01208454","Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma",[89],[8374,117,8375,8376,8377],"Localized Unresectable Neuroblastoma","Regional Neuroblastoma","Stage 4 Neuroblastoma","Stage 4S Neuroblastoma",[1404,942],{"trials":8380,"activeCount":101},[8381,8385],{"nctId":1178,"briefTitle":1179,"status":142,"phases":8382,"primaryCompletion":987,"start":1181,"enrollment":248,"conditions":8383,"interventions":8384},[90],[1183],[1185,1186,819,1187,693,1188],{"nctId":8386,"briefTitle":8387,"status":618,"phases":8388,"primaryCompletion":1230,"completion":6303,"start":1576,"enrollment":2211,"conditions":8389,"interventions":8390},"NCT00324740","Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer",[89,90],[5233,4826,4842],[4063,1186],{"trials":8392,"activeCount":2548,"soonestReadout":1396},[8393],{"nctId":1393,"briefTitle":1394,"status":128,"phases":8394,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":8395,"interventions":8396},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"trials":8398,"activeCount":101},[],{"trials":8400,"activeCount":101},[],{"intervention":1511,"totalTrials":214,"cells":8402},{"EARLY_PHASE1":8403,"PHASE1":8405,"PHASE2":8407,"PHASE3":8423,"PHASE4":8433,"NA":8435},{"trials":8404,"activeCount":101},[],{"trials":8406,"activeCount":101},[],{"trials":8408,"activeCount":101},[8409,8419],{"nctId":8410,"briefTitle":8411,"status":142,"phases":8412,"primaryCompletion":1381,"completion":8413,"start":8414,"enrollment":730,"conditions":8415,"interventions":8418},"NCT01780662","Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma",[89,90],"2021-09-30","2013-01-31",[4681,8416,8417],"Recurrent Childhood Hodgkin Lymphoma","Refractory Childhood Hodgkin Lymphoma",[1511,167],{"nctId":4408,"briefTitle":4409,"status":142,"phases":8420,"primaryCompletion":3789,"completion":4411,"start":4412,"enrollment":623,"conditions":8421,"interventions":8422},[89,90],[4414,4415,4416,1503,4417,4418,1504,4419,1505,1506,1508,939],[1511,4421,737,4422],{"trials":8424,"activeCount":2548,"soonestReadout":1498},[8425,8429],{"nctId":3698,"briefTitle":3699,"status":107,"phases":8426,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":8427,"interventions":8428},[91],[3704,3705],[3707,1511,277,279,289,1101,2789,883,3708],{"nctId":1495,"briefTitle":1496,"status":155,"phases":8430,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":8431,"interventions":8432},[91],[1503,1504,1505,1506,1507,1508],[1510,1511,63,737,279,1142,212,740],{"trials":8434,"activeCount":101},[],{"trials":8436,"activeCount":101},[],{"intervention":1403,"totalTrials":603,"cells":8438},{"EARLY_PHASE1":8439,"PHASE1":8441,"PHASE2":8443,"PHASE3":8452,"PHASE4":8462,"NA":8464},{"trials":8440,"activeCount":101},[],{"trials":8442,"activeCount":101},[],{"trials":8444,"activeCount":101},[8445],{"nctId":8446,"briefTitle":8447,"status":142,"phases":8448,"primaryCompletion":3389,"completion":2292,"start":3273,"enrollment":623,"conditions":8449,"interventions":8450},"NCT00061932","Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach",[90],[1915,6532,6533,6534,3118,6536,6537,6520],[1062,8451],"irinotecan",{"trials":8453,"activeCount":2548,"soonestReadout":1396},[8454,8458],{"nctId":1393,"briefTitle":1394,"status":128,"phases":8455,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":8456,"interventions":8457},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"nctId":5139,"briefTitle":5140,"status":142,"phases":8459,"primaryCompletion":1807,"completion":1807,"start":5142,"enrollment":5143,"conditions":8460,"interventions":8461},[91],[5145,5146,4824,5147,5148,5149,4959,4960,4961,4963,4964],[2084,1140,2925,1403],{"trials":8463,"activeCount":101},[],{"trials":8465,"activeCount":101},[],{"intervention":1435,"totalTrials":603,"cells":8467},{"EARLY_PHASE1":8468,"PHASE1":8470,"PHASE2":8479,"PHASE3":8481,"PHASE4":8491,"NA":8493},{"trials":8469,"activeCount":101},[],{"trials":8471,"activeCount":101},[8472],{"nctId":8473,"briefTitle":8474,"status":142,"phases":8475,"primaryCompletion":4366,"start":1819,"enrollment":1517,"conditions":8476,"interventions":8477},"NCT00217542","Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery",[89],[1343,5233,5454,1344,4842],[1435,8478],"amifostine\u002Fazacitidine",{"trials":8480,"activeCount":101},[],{"trials":8482,"activeCount":2548,"soonestReadout":2534},[8483,8487],{"nctId":2531,"briefTitle":2532,"status":155,"phases":8484,"primaryCompletion":2534,"completion":2535,"start":2536,"enrollment":2537,"conditions":8485,"interventions":8486},[91],[190,192,2539,2540,2541,2542,2543,2544,2545],[124,883,2547],{"nctId":1423,"briefTitle":1424,"status":142,"phases":8488,"primaryCompletion":1426,"start":1427,"enrollment":1428,"conditions":8489,"interventions":8490},[91],[1430,1431,1432],[1032,1434,1081,693,1082,1435],{"trials":8492,"activeCount":101},[],{"trials":8494,"activeCount":101},[],{"intervention":1376,"totalTrials":758,"cells":8496},{"EARLY_PHASE1":8497,"PHASE1":8499,"PHASE2":8501,"PHASE3":8503,"PHASE4":8513,"NA":8515},{"trials":8498,"activeCount":101},[],{"trials":8500,"activeCount":101},[],{"trials":8502,"activeCount":101},[],{"trials":8504,"activeCount":2548,"soonestReadout":1365},[8505,8509],{"nctId":1362,"briefTitle":1363,"status":155,"phases":8506,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":8507,"interventions":8508},[91],[902,1370],[1372,63,1137,1373,1374,1139,279,1140,1375,1141,1376,212,667,781,740],{"nctId":1378,"briefTitle":1379,"status":142,"phases":8510,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":8511,"interventions":8512},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"trials":8514,"activeCount":101},[],{"trials":8516,"activeCount":101},[],{"intervention":1402,"totalTrials":758,"cells":8518},{"EARLY_PHASE1":8519,"PHASE1":8521,"PHASE2":8523,"PHASE3":8529,"PHASE4":8535,"NA":8537},{"trials":8520,"activeCount":101},[],{"trials":8522,"activeCount":101},[],{"trials":8524,"activeCount":101},[8525],{"nctId":5924,"briefTitle":5925,"status":142,"phases":8526,"primaryCompletion":5927,"completion":5928,"start":5929,"enrollment":1331,"conditions":8527,"interventions":8528},[90],[5931,117],[1402,1102,5933,151,2143],{"trials":8530,"activeCount":2548,"soonestReadout":1396},[8531],{"nctId":1393,"briefTitle":1394,"status":128,"phases":8532,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":8533,"interventions":8534},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"trials":8536,"activeCount":101},[],{"trials":8538,"activeCount":101},[],{"intervention":1406,"totalTrials":758,"cells":8540},{"EARLY_PHASE1":8541,"PHASE1":8543,"PHASE2":8545,"PHASE3":8551,"PHASE4":8557,"NA":8559},{"trials":8542,"activeCount":101},[],{"trials":8544,"activeCount":101},[],{"trials":8546,"activeCount":101},[8547],{"nctId":1254,"briefTitle":1255,"status":142,"phases":8548,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":8549,"interventions":8550},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"trials":8552,"activeCount":2548,"soonestReadout":1396},[8553],{"nctId":1393,"briefTitle":1394,"status":128,"phases":8554,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":8555,"interventions":8556},[91],[1400,791],[277,278,63,1402,780,279,1403,1404,1405,151,1406,1407,781],{"trials":8558,"activeCount":101},[],{"trials":8560,"activeCount":101},[],{"intervention":2808,"totalTrials":2548,"cells":8562},{"EARLY_PHASE1":8563,"PHASE1":8565,"PHASE2":8567,"PHASE3":8569,"PHASE4":8575,"NA":8577},{"trials":8564,"activeCount":101},[],{"trials":8566,"activeCount":101},[],{"trials":8568,"activeCount":101},[],{"trials":8570,"activeCount":2548,"soonestReadout":2797},[8571],{"nctId":2794,"briefTitle":2795,"status":155,"phases":8572,"primaryCompletion":2797,"completion":2798,"start":2799,"enrollment":159,"conditions":8573,"interventions":8574},[90,91],[2801,2802,2803,2804,2805],[2554,2807,151,2808],{"trials":8576,"activeCount":101},[],{"trials":8578,"activeCount":101},[],{"intervention":3435,"totalTrials":2548,"cells":8580},{"EARLY_PHASE1":8581,"PHASE1":8583,"PHASE2":8585,"PHASE3":8587,"PHASE4":8593,"NA":8595},{"trials":8582,"activeCount":101},[],{"trials":8584,"activeCount":101},[],{"trials":8586,"activeCount":101},[],{"trials":8588,"activeCount":2548,"soonestReadout":2654},[8589],{"nctId":3422,"briefTitle":3423,"status":128,"phases":8590,"primaryCompletion":2654,"completion":2654,"start":3425,"enrollment":3426,"conditions":8591,"interventions":8592},[91],[3428,1943,3429,3430,3431,1944,3432,3433],[277,3435,449,3436],{"trials":8594,"activeCount":101},[],{"trials":8596,"activeCount":101},[],{"intervention":3436,"totalTrials":2548,"cells":8598},{"EARLY_PHASE1":8599,"PHASE1":8601,"PHASE2":8603,"PHASE3":8605,"PHASE4":8611,"NA":8613},{"trials":8600,"activeCount":101},[],{"trials":8602,"activeCount":101},[],{"trials":8604,"activeCount":101},[],{"trials":8606,"activeCount":2548,"soonestReadout":2654},[8607],{"nctId":3422,"briefTitle":3423,"status":128,"phases":8608,"primaryCompletion":2654,"completion":2654,"start":3425,"enrollment":3426,"conditions":8609,"interventions":8610},[91],[3428,1943,3429,3430,3431,1944,3432,3433],[277,3435,449,3436],{"trials":8612,"activeCount":101},[],{"trials":8614,"activeCount":101},[],{"intervention":3033,"totalTrials":2548,"cells":8616},{"EARLY_PHASE1":8617,"PHASE1":8619,"PHASE2":8621,"PHASE3":8623,"PHASE4":8629,"NA":8631},{"trials":8618,"activeCount":101},[],{"trials":8620,"activeCount":101},[],{"trials":8622,"activeCount":101},[],{"trials":8624,"activeCount":2548,"soonestReadout":3029},[8625],{"nctId":3025,"briefTitle":3026,"status":3027,"phases":8626,"primaryCompletion":3029,"completion":3029,"start":3030,"enrollment":2091,"conditions":8627,"interventions":8628},[91],[2985],[1690,3033],{"trials":8630,"activeCount":101},[],{"trials":8632,"activeCount":101},[],{"intervention":1472,"totalTrials":2548,"cells":8634},{"EARLY_PHASE1":8635,"PHASE1":8637,"PHASE2":8639,"PHASE3":8641,"PHASE4":8647,"NA":8649},{"trials":8636,"activeCount":101},[],{"trials":8638,"activeCount":101},[],{"trials":8640,"activeCount":101},[],{"trials":8642,"activeCount":2548,"soonestReadout":1460},[8643],{"nctId":1457,"briefTitle":1458,"status":155,"phases":8644,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1428,"conditions":8645,"interventions":8646},[91],[1464,1465,1466,1467,1468,1469],[63,780,737,279,1471,1472,1101,781,740],{"trials":8648,"activeCount":101},[],{"trials":8650,"activeCount":101},[],{"intervention":2142,"totalTrials":2548,"cells":8652},{"EARLY_PHASE1":8653,"PHASE1":8655,"PHASE2":8657,"PHASE3":8659,"PHASE4":8665,"NA":8667},{"trials":8654,"activeCount":101},[],{"trials":8656,"activeCount":101},[],{"trials":8658,"activeCount":101},[],{"trials":8660,"activeCount":2548,"soonestReadout":2133},[8661],{"nctId":2130,"briefTitle":2131,"status":155,"phases":8662,"primaryCompletion":2133,"completion":592,"start":2134,"enrollment":2135,"conditions":8663,"interventions":8664},[91],[2137,2138,2139,2140],[278,2142,737,2084,1102,2143,740],{"trials":8666,"activeCount":101},[],{"trials":8668,"activeCount":101},[],{"intervention":1492,"totalTrials":2548,"cells":8670},{"EARLY_PHASE1":8671,"PHASE1":8673,"PHASE2":8675,"PHASE3":8677,"PHASE4":8683,"NA":8685},{"trials":8672,"activeCount":101},[],{"trials":8674,"activeCount":101},[],{"trials":8676,"activeCount":101},[],{"trials":8678,"activeCount":2548,"soonestReadout":1477},[8679],{"nctId":1474,"briefTitle":1475,"status":155,"phases":8680,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":8681,"interventions":8682},[90,91],[734,1481,735,510,511,512,513,514,1482,516,517,1483,1484,518,519,1485,1486,1487,1488,1489,1490],[63,737,1492,212,667,1493,740],{"trials":8684,"activeCount":101},[],{"trials":8686,"activeCount":101},[],{"intervention":1493,"totalTrials":2548,"cells":8688},{"EARLY_PHASE1":8689,"PHASE1":8691,"PHASE2":8693,"PHASE3":8695,"PHASE4":8701,"NA":8703},{"trials":8690,"activeCount":101},[],{"trials":8692,"activeCount":101},[],{"trials":8694,"activeCount":101},[],{"trials":8696,"activeCount":2548,"soonestReadout":1477},[8697],{"nctId":1474,"briefTitle":1475,"status":155,"phases":8698,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":8699,"interventions":8700},[90,91],[734,1481,735,510,511,512,513,514,1482,516,517,1483,1484,518,519,1485,1486,1487,1488,1489,1490],[63,737,1492,212,667,1493,740],{"trials":8702,"activeCount":101},[],{"trials":8704,"activeCount":101},[],{"intervention":1510,"totalTrials":2548,"cells":8706},{"EARLY_PHASE1":8707,"PHASE1":8709,"PHASE2":8711,"PHASE3":8713,"PHASE4":8719,"NA":8721},{"trials":8708,"activeCount":101},[],{"trials":8710,"activeCount":101},[],{"trials":8712,"activeCount":101},[],{"trials":8714,"activeCount":2548,"soonestReadout":1498},[8715],{"nctId":1495,"briefTitle":1496,"status":155,"phases":8716,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":8717,"interventions":8718},[91],[1503,1504,1505,1506,1507,1508],[1510,1511,63,737,279,1142,212,740],{"trials":8720,"activeCount":101},[],{"trials":8722,"activeCount":101},[],{"intervention":643,"totalTrials":37,"cells":8724},{"EARLY_PHASE1":8725,"PHASE1":8727,"PHASE2":8757,"PHASE3":8831,"PHASE4":8833,"NA":8835},{"trials":8726,"activeCount":101},[],{"trials":8728,"activeCount":603,"soonestReadout":635},[8729,8733,8737,8741,8745,8749,8753],{"nctId":632,"briefTitle":633,"status":155,"phases":8730,"primaryCompletion":635,"completion":636,"start":637,"enrollment":638,"conditions":8731,"interventions":8732},[89],[640,641],[63,643,644],{"nctId":669,"briefTitle":670,"status":107,"phases":8734,"primaryCompletion":672,"completion":672,"start":673,"enrollment":101,"conditions":8735,"interventions":8736},[89],[195],[676,63,643,677],{"nctId":6266,"briefTitle":6267,"status":155,"phases":8738,"primaryCompletion":1382,"completion":6269,"start":6270,"enrollment":771,"conditions":8739,"interventions":8740},[89],[6272,6273,6274,2427,6275,2429,2430,6276,2431],[1137,643,4966,6278,6279],{"nctId":695,"briefTitle":696,"status":618,"phases":8742,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":8743,"interventions":8744},[89],[702],[704,63,705,643,706,707,708,709,710],{"nctId":712,"briefTitle":713,"status":618,"phases":8746,"primaryCompletion":715,"completion":716,"start":717,"enrollment":603,"conditions":8747,"interventions":8748},[89],[719],[704,721,63,643,722],{"nctId":753,"briefTitle":754,"status":618,"phases":8750,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":8751,"interventions":8752},[89],[760,761,653,762],[764,63,643],{"nctId":796,"briefTitle":797,"status":128,"phases":8754,"primaryCompletion":361,"completion":799,"start":392,"enrollment":174,"conditions":8755,"interventions":8756},[89],[801,802,803],[63,805,643],{"trials":8758,"activeCount":838,"soonestReadout":968},[8759,8763,8767,8771,8775,8779,8783,8787,8791,8795,8799,8803,8807,8811,8815,8819,8823,8827],{"nctId":821,"briefTitle":822,"status":142,"phases":8760,"primaryCompletion":824,"completion":825,"start":826,"enrollment":827,"conditions":8761,"interventions":8762},[89,90],[829],[831,643,63],{"nctId":833,"briefTitle":834,"status":618,"phases":8764,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":8765,"interventions":8766},[89,90],[840,841,842,843,844],[63,643,677,846],{"nctId":848,"briefTitle":849,"status":107,"phases":8768,"primaryCompletion":851,"completion":851,"start":851,"enrollment":101,"conditions":8769,"interventions":8770},[90],[853,841,802,854,855,856,857,858],[860,677,643,63],{"nctId":862,"briefTitle":863,"status":618,"phases":8772,"primaryCompletion":865,"completion":866,"start":867,"enrollment":339,"conditions":8773,"interventions":8774},[89,90],[869,195,870],[872,63,677,643],{"nctId":874,"briefTitle":875,"status":128,"phases":8776,"primaryCompletion":232,"completion":877,"start":878,"enrollment":879,"conditions":8777,"interventions":8778},[90],[36],[882,883,677,643,63],{"nctId":885,"briefTitle":886,"status":618,"phases":8780,"primaryCompletion":621,"completion":621,"start":888,"enrollment":889,"conditions":8781,"interventions":8782},[90],[36,891],[677,643,63,893],{"nctId":895,"briefTitle":896,"status":128,"phases":8784,"primaryCompletion":898,"completion":899,"start":900,"enrollment":552,"conditions":8785,"interventions":8786},[90],[902,903],[905,63,643],{"nctId":944,"briefTitle":945,"status":142,"phases":8788,"primaryCompletion":947,"completion":947,"start":948,"enrollment":949,"conditions":8789,"interventions":8790},[90],[195,891],[677,63,643,952],{"nctId":954,"briefTitle":955,"status":618,"phases":8792,"primaryCompletion":957,"completion":957,"start":958,"enrollment":603,"conditions":8793,"interventions":8794},[89,90],[18,960,870,36,961],[677,643,63,963],{"nctId":965,"briefTitle":966,"status":128,"phases":8796,"primaryCompletion":968,"completion":969,"start":970,"enrollment":971,"conditions":8797,"interventions":8798},[90],[973,974,975,976,977],[979,643,980,981,213,982,63],{"nctId":997,"briefTitle":998,"status":618,"phases":8800,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":310,"conditions":8801,"interventions":8802},[89,90],[960,841,1003,915,687],[643,1005,63,677],{"nctId":1035,"briefTitle":1036,"status":142,"phases":8804,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":8805,"interventions":8806},[90],[960,1043,1044,1045,1046],[643,63,952,677],{"nctId":1105,"briefTitle":1106,"status":155,"phases":8808,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":8809,"interventions":8810},[90],[1113],[643,63,980],{"nctId":1116,"briefTitle":1117,"status":142,"phases":8812,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":188,"conditions":8813,"interventions":8814},[89,90],[1044,960,1045,1046,1043],[643,63,1123,677],{"nctId":1190,"briefTitle":1191,"status":142,"phases":8816,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1195,"conditions":8817,"interventions":8818},[89,90],[960,870,1197,36,18],[1199,63,643,677],{"nctId":3988,"briefTitle":3989,"status":3027,"phases":8820,"primaryCompletion":3991,"completion":3991,"start":2728,"enrollment":3992,"conditions":8821,"interventions":8822},[90],[263],[980,643,1405,2217],{"nctId":1306,"briefTitle":1307,"status":142,"phases":8824,"primaryCompletion":1309,"completion":1310,"start":715,"enrollment":34,"conditions":8825,"interventions":8826},[90],[195],[1313,63,704,643],{"nctId":1315,"briefTitle":1316,"status":142,"phases":8828,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":339,"conditions":8829,"interventions":8830},[90],[36,891],[1323,63,643,677,1324],{"trials":8832,"activeCount":101},[],{"trials":8834,"activeCount":101},[],{"trials":8836,"activeCount":101},[],{"intervention":58,"totalTrials":651,"cells":8838},{"EARLY_PHASE1":8839,"PHASE1":8841,"PHASE2":8867,"PHASE3":8893,"PHASE4":8895,"NA":8897},{"trials":8840,"activeCount":101},[],{"trials":8842,"activeCount":838,"soonestReadout":57},[8843,8847,8851,8855,8859,8863],{"nctId":55,"briefTitle":56,"status":155,"phases":8844,"primaryCompletion":57,"completion":4569,"start":4570,"enrollment":97,"conditions":8845,"interventions":8846},[89],[4572,4573,4574,4575,935,936,4576,4577,937,4578,4579,938],[58,1016,667],{"nctId":4586,"briefTitle":4587,"status":155,"phases":8848,"primaryCompletion":4589,"completion":482,"start":4590,"enrollment":2586,"conditions":8849,"interventions":8850},[89],[527,4592,4593,3189,3190,537,4531,4594,4536,4537],[58,1016],{"nctId":2186,"briefTitle":2187,"status":155,"phases":8852,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1798,"conditions":8853,"interventions":8854},[89],[27,2193,2194,773],[2196,1082,2197,2198,2199,2200],{"nctId":724,"briefTitle":725,"status":155,"phases":8856,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":8857,"interventions":8858},[89],[732,733,734,735],[63,737,279,738,58,739,212,667,740],{"nctId":2206,"briefTitle":2207,"status":155,"phases":8860,"primaryCompletion":2209,"completion":418,"start":2210,"enrollment":2211,"conditions":8861,"interventions":8862},[89],[2213,2214],[2216,212,1016,2217,58,706,2218,2219],{"nctId":3565,"briefTitle":3566,"status":142,"phases":8864,"primaryCompletion":3568,"completion":3568,"start":3569,"enrollment":34,"conditions":8865,"interventions":8866},[89],[3571,527,537],[277,279,58,1101,667],{"trials":8868,"activeCount":758,"soonestReadout":2234},[8869,8873,8877],{"nctId":2231,"briefTitle":2232,"status":128,"phases":8870,"primaryCompletion":2234,"completion":2234,"start":2235,"enrollment":1357,"conditions":8871,"interventions":8872},[90],[2237,527,2238,2239,529,530,2240,534,537,2241,2242,539,540,2243,543],[58,1016,2216,212,2217],{"nctId":3996,"briefTitle":3997,"status":128,"phases":8874,"primaryCompletion":3999,"completion":3999,"start":4000,"enrollment":4001,"conditions":8875,"interventions":8876},[90],[1485,4003],[58,667,2217,4005],{"nctId":8878,"briefTitle":8879,"status":142,"phases":8880,"primaryCompletion":8881,"completion":1010,"start":8882,"enrollment":685,"conditions":8883,"interventions":8885},"NCT04294641","Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease",[90],"2024-06-24","2021-05-10",[8884],"Chronic GVHD",[58,8886,8887,8888,8889,8890,8891,8892],"Steroid pulse","Voriconazole","Posaconazole","Azithromycin","Montelukast","Budesonide","Beclomethasone",{"trials":8894,"activeCount":101},[],{"trials":8896,"activeCount":101},[],{"trials":8898,"activeCount":101},[],{"intervention":5225,"totalTrials":1024,"cells":8900},{"EARLY_PHASE1":8901,"PHASE1":8903,"PHASE2":8930,"PHASE3":8957,"PHASE4":8959,"NA":8961},{"trials":8902,"activeCount":101},[],{"trials":8904,"activeCount":603,"soonestReadout":5218},[8905,8915,8919],{"nctId":8906,"briefTitle":8907,"status":155,"phases":8908,"primaryCompletion":3030,"completion":3030,"start":8909,"enrollment":700,"conditions":8910,"interventions":8914},"NCT02503722","Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer",[89],"2017-03-23",[2885,2118,8911,8912,8913,6445],"Stage III Lung Non-Small Cell Cancer AJCC v7","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Non-Small Cell Cancer AJCC v7",[5373,5225],{"nctId":5215,"briefTitle":5216,"status":155,"phases":8916,"primaryCompletion":5218,"completion":5219,"start":5220,"enrollment":234,"conditions":8917,"interventions":8918},[89],[4818,1943,1944,1785,1732,1787,1788,250,5222,251,252,5223,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757],[53,5225],{"nctId":8920,"briefTitle":8921,"status":155,"phases":8922,"primaryCompletion":8923,"completion":2832,"start":8924,"enrollment":2401,"conditions":8925,"interventions":8929},"NCT04250545","Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer",[89],"2025-11-21","2020-10-26",[8926,2885,2844,2118,1633,8927,8928],"Leptomeningeal Neoplasm","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[5225,5885],{"trials":8931,"activeCount":758,"soonestReadout":361},[8932,8939,8943,8953],{"nctId":8933,"briefTitle":8934,"status":155,"phases":8935,"primaryCompletion":361,"completion":361,"start":8936,"enrollment":638,"conditions":8937,"interventions":8938},"NCT06385496","Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)",[90],"2017-03-12",[300,21,119,30,4262],[5225],{"nctId":6169,"briefTitle":6170,"status":128,"phases":8940,"primaryCompletion":6172,"completion":6172,"start":6173,"enrollment":4001,"conditions":8941,"interventions":8942},[89,90],[6175,803,3363,3369],[240,5225],{"nctId":8944,"briefTitle":8945,"status":142,"phases":8946,"primaryCompletion":8947,"completion":8947,"start":8948,"enrollment":1798,"conditions":8949,"interventions":8952},"NCT02417701","Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer",[90],"2020-12-28","2016-10-06",[8950,8951],"Recurrent Lung Squamous Cell Carcinoma","Stage IV Lung Squamous Cell Carcinoma AJCC v7",[5225],{"nctId":7694,"briefTitle":7695,"status":618,"phases":8954,"primaryCompletion":7697,"completion":7698,"start":7699,"enrollment":7700,"conditions":8955,"interventions":8956},[89,90],[7702,554,7703,3813,7704,7705,4471,7706,7707,7708,7709,2803,7710,7711,7712,2804,7713,7714,555],[2807,77,5225],{"trials":8958,"activeCount":101},[],{"trials":8960,"activeCount":101},[],{"trials":8962,"activeCount":101},[],{"intervention":289,"totalTrials":771,"cells":8964},{"EARLY_PHASE1":8965,"PHASE1":8967,"PHASE2":9001,"PHASE3":9019,"PHASE4":9025,"NA":9027},{"trials":8966,"activeCount":101},[],{"trials":8968,"activeCount":2548,"soonestReadout":8986},[8969,8978,8982],{"nctId":8970,"briefTitle":8971,"status":142,"phases":8972,"primaryCompletion":8973,"completion":8973,"start":2028,"enrollment":1024,"conditions":8974,"interventions":8977},"NCT01294358","Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial",[89],"2014-07-23",[8975,8976],"Histologically or Cytologically Confirmed Pancreatic Ca","Unresectable or Borderline Resectable Pancreatic Ca",[289],{"nctId":3510,"briefTitle":3511,"status":142,"phases":8979,"primaryCompletion":3513,"completion":3514,"start":3515,"enrollment":827,"conditions":8980,"interventions":8981},[89],[3517,3518,3519,3520],[289,277,1016],{"nctId":8983,"briefTitle":8984,"status":155,"phases":8985,"primaryCompletion":8986,"completion":8987,"start":8988,"enrollment":2211,"conditions":8989,"interventions":9000},"NCT04616534","Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors",[89],"2025-04-01","2026-05-20","2021-06-01",[8990,21,1615,8991,8992,8993,1967,2647,2610,2611,2612,8994,162,8995,1627,163,8996,8997,1634,164,8998,8999],"Advanced Fallopian Tube Carcinoma","Advanced Pancreatic Adenocarcinoma","Advanced Primary Peritoneal Carcinoma","Fallopian Tube High Grade Serous Adenocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Stage III Fallopian Tube Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma",[1640,289],{"trials":9002,"activeCount":603,"soonestReadout":1961},[9003,9007,9011,9015],{"nctId":281,"briefTitle":282,"status":128,"phases":9004,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":9005,"interventions":9006},[90],[236,237,238],[277,278,289,96,290],{"nctId":1958,"briefTitle":1959,"status":155,"phases":9008,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":1964,"conditions":9009,"interventions":9010},[90],[1966,1967,163,164],[278,289,167,1653],{"nctId":428,"briefTitle":429,"status":128,"phases":9012,"primaryCompletion":361,"completion":361,"start":431,"enrollment":234,"conditions":9013,"interventions":9014},[90],[433,434,238],[278,289,96],{"nctId":2014,"briefTitle":2015,"status":618,"phases":9016,"primaryCompletion":2017,"completion":2017,"start":1310,"enrollment":1024,"conditions":9017,"interventions":9018},[90],[2019,2020],[289,278,53,279],{"trials":9020,"activeCount":101},[9021],{"nctId":3698,"briefTitle":3699,"status":107,"phases":9022,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":9023,"interventions":9024},[91],[3704,3705],[3707,1511,277,279,289,1101,2789,883,3708],{"trials":9026,"activeCount":101},[],{"trials":9028,"activeCount":101},[],{"intervention":1653,"totalTrials":2211,"cells":9030},{"EARLY_PHASE1":9031,"PHASE1":9033,"PHASE2":9080,"PHASE3":9115,"PHASE4":9117,"NA":9119},{"trials":9032,"activeCount":101},[],{"trials":9034,"activeCount":2548,"soonestReadout":9056},[9035,9048,9052,9062,9068,9072,9076],{"nctId":9036,"briefTitle":9037,"status":142,"phases":9038,"primaryCompletion":2605,"completion":2605,"start":9039,"enrollment":9040,"conditions":9041,"interventions":9047},"NCT00892736","Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy",[89],"2009-04-20",98,[9042,6516,6517,9043,3132,3134,9044,1729,9045,3136,9046,2613,250,251,252,5223,1637],"Basal-Like Breast Carcinoma","Breast Carcinoma","Hereditary Breast and Ovarian Cancer Syndrome","Pancreatic Carcinoma","Prostate Carcinoma",[1653],{"nctId":1642,"briefTitle":1643,"status":142,"phases":9049,"primaryCompletion":1645,"completion":1645,"start":1646,"enrollment":19,"conditions":9050,"interventions":9051},[89],[1648,1649,1650,1533,1651],[278,449,1653],{"nctId":9053,"briefTitle":9054,"status":155,"phases":9055,"primaryCompletion":9056,"completion":9057,"start":9058,"enrollment":9059,"conditions":9060,"interventions":9061},"NCT01434316","Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors",[89],"2023-03-28","2026-08-02","2011-11-11",121,[21],[6029,1653],{"nctId":9063,"briefTitle":9064,"status":142,"phases":9065,"primaryCompletion":6513,"completion":6513,"start":3272,"enrollment":25,"conditions":9066,"interventions":9067},"NCT01154426","ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors",[89],[3131,6516,6517],[167,1653],{"nctId":3125,"briefTitle":3126,"status":142,"phases":9069,"primaryCompletion":3128,"start":3129,"enrollment":2401,"conditions":9070,"interventions":9071},[89],[3131,3132,3133,3134,3135,3136,2613,1222,1223,3137,1637],[277,449,1653],{"nctId":1712,"briefTitle":1713,"status":142,"phases":9073,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":1718,"conditions":9074,"interventions":9075},[89],[1720,1721,1722,1723,1724,1725,1726,1727,1728,1729,1730,1731,1732,1733,1734,1735,1736,1737,1738,1739,1740,1741,1742,1743,1744,1745,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757],[53,277,278,449,1653],{"nctId":6510,"briefTitle":6511,"status":618,"phases":9077,"primaryCompletion":6513,"start":3282,"enrollment":455,"conditions":9078,"interventions":9079},[89],[5637,6515,6516,6517,1787,3117,4941,3118,1579,4823,3259,4942,6518,6519,1220,1221,1222,1223,3137,4945,6520,1591,4841,3261,4946,15],[6522,6523,4948],{"trials":9081,"activeCount":603,"soonestReadout":6851},[9082,9086,9090,9094,9103,9107,9111],{"nctId":6848,"briefTitle":6849,"status":155,"phases":9083,"primaryCompletion":6851,"completion":6852,"start":6853,"enrollment":6854,"conditions":9084,"interventions":9085},[89,90],[486,250,251,252,6160],[2790,1653],{"nctId":3597,"briefTitle":3598,"status":142,"phases":9087,"primaryCompletion":307,"completion":307,"start":3600,"enrollment":1054,"conditions":9088,"interventions":9089},[90],[1619,1620,3602,3078,3603],[277,1653],{"nctId":2301,"briefTitle":2302,"status":142,"phases":9091,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":9092,"interventions":9093},[90],[2309,2310,2311],[2313,212,1653],{"nctId":9095,"briefTitle":9096,"status":142,"phases":9097,"primaryCompletion":9098,"completion":9098,"start":9099,"enrollment":3869,"conditions":9100,"interventions":9102},"NCT01540565","Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90],"2018-01-27","2012-04-09",[6516,6517,9101,250,251,252],"Ovarian Epithelial Tumor",[1653],{"nctId":1921,"briefTitle":1922,"status":142,"phases":9104,"primaryCompletion":1924,"completion":1925,"start":1926,"enrollment":286,"conditions":9105,"interventions":9106},[89,90],[1811,1928,1929,1930,1931],[278,279,1653],{"nctId":3618,"briefTitle":3619,"status":155,"phases":9108,"primaryCompletion":3621,"completion":3039,"start":3622,"enrollment":37,"conditions":9109,"interventions":9110},[90],[263,2452,3624,2453,3625,3626,3627,3628,2427,2430],[277,1407,2790,1653],{"nctId":1958,"briefTitle":1959,"status":155,"phases":9112,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":1964,"conditions":9113,"interventions":9114},[90],[1966,1967,163,164],[278,289,167,1653],{"trials":9116,"activeCount":101},[],{"trials":9118,"activeCount":101},[],{"trials":9120,"activeCount":101},[],{"intervention":2256,"totalTrials":889,"cells":9122},{"EARLY_PHASE1":9123,"PHASE1":9125,"PHASE2":9137,"PHASE3":9175,"PHASE4":9177,"NA":9179},{"trials":9124,"activeCount":101},[],{"trials":9126,"activeCount":2548,"soonestReadout":131},[9127],{"nctId":9128,"briefTitle":9129,"status":128,"phases":9130,"primaryCompletion":131,"completion":131,"start":9131,"enrollment":248,"conditions":9132,"interventions":9136},"NCT04235777","Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies",[89],"2020-07-13",[1197,961,9133,9134,9135],"Genitourinary Cancer","Urogenital Neoplasms","Urogenital Cancer",[2255,2256],{"trials":9138,"activeCount":603,"soonestReadout":3868},[9139,9143,9147,9158,9168],{"nctId":2246,"briefTitle":2247,"status":128,"phases":9140,"primaryCompletion":361,"completion":361,"start":2249,"enrollment":2250,"conditions":9141,"interventions":9142},[89,90],[2252,2253],[2255,2083,2256,212,2257],{"nctId":5939,"briefTitle":5940,"status":142,"phases":9144,"primaryCompletion":2262,"completion":5942,"start":5943,"enrollment":19,"conditions":9145,"interventions":9146},[89,90],[5945,687,2719],[2256,1407,151,706,5947,2218,1139,5948],{"nctId":9148,"briefTitle":9149,"status":155,"phases":9150,"primaryCompletion":3868,"completion":4693,"start":9151,"enrollment":2883,"conditions":9152,"interventions":9155},"NCT04287868","Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies",[89,90],"2020-06-09",[960,9153,1045,1043,9154],"HPV Cancers","Vulvar, Vaginal, Penile, Rectal Cancer",[9156,2256,9157],"PDS0101","NHS-IL12",{"nctId":9159,"briefTitle":9160,"status":142,"phases":9161,"primaryCompletion":9162,"completion":2813,"start":9151,"enrollment":1195,"conditions":9163,"interventions":9165},"NCT04247282","Anti-PD-L1\u002FTGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection",[89,90],"2021-08-24",[1564,9164],"Head and Neck Neoplasms",[2256,9166,9167],"N803","TriAd vaccine",{"nctId":9169,"briefTitle":9170,"status":128,"phases":9171,"primaryCompletion":9172,"completion":9172,"start":9131,"enrollment":2319,"conditions":9173,"interventions":9174},"NCT04303117","PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma",[89,90],"2028-12-01",[135],[2255,2256],{"trials":9176,"activeCount":101},[],{"trials":9178,"activeCount":101},[],{"trials":9180,"activeCount":101},[],{"intervention":5373,"totalTrials":838,"cells":9182},{"EARLY_PHASE1":9183,"PHASE1":9185,"PHASE2":9202,"PHASE3":9223,"PHASE4":9225,"NA":9227},{"trials":9184,"activeCount":101},[],{"trials":9186,"activeCount":2548,"soonestReadout":3030},[9187,9191],{"nctId":8906,"briefTitle":8907,"status":155,"phases":9188,"primaryCompletion":3030,"completion":3030,"start":8909,"enrollment":700,"conditions":9189,"interventions":9190},[89],[2885,2118,8911,8912,8913,6445],[5373,5225],{"nctId":9192,"briefTitle":9193,"status":142,"phases":9194,"primaryCompletion":3075,"completion":9195,"start":9196,"enrollment":2029,"conditions":9197,"interventions":9200},"NCT02520778","Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer",[89],"2023-12-04","2016-08-30",[9198,9199,8911,8912,8913,6445],"Advanced Lung Non-Squamous Non-Small Cell Carcinoma","Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",[9201,5373],"Navitoclax",{"trials":9203,"activeCount":603,"soonestReadout":9212},[9204,9208,9216],{"nctId":5366,"briefTitle":5367,"status":155,"phases":9205,"primaryCompletion":5369,"completion":4693,"start":5370,"enrollment":838,"conditions":9206,"interventions":9207},[90],[2885,2844,1633],[53,5373],{"nctId":9209,"briefTitle":9210,"status":155,"phases":9211,"primaryCompletion":9212,"completion":9213,"start":3360,"enrollment":2401,"conditions":9214,"interventions":9215},"NCT03831932","Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer",[89,90],"2024-06-12","2027-03-13",[1613,2885,1633],[5373,5885],{"nctId":9217,"briefTitle":9218,"status":128,"phases":9219,"primaryCompletion":2930,"completion":2930,"start":9220,"enrollment":730,"conditions":9221,"interventions":9222},"NCT03191149","Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change",[90],"2018-04-25",[1613,2118,8913,6445],[5373],{"trials":9224,"activeCount":101},[],{"trials":9226,"activeCount":101},[],{"trials":9228,"activeCount":101},[],{"intervention":489,"totalTrials":214,"cells":9230},{"EARLY_PHASE1":9231,"PHASE1":9233,"PHASE2":9250,"PHASE3":9265,"PHASE4":9267,"NA":9269},{"trials":9232,"activeCount":101},[],{"trials":9234,"activeCount":758,"soonestReadout":9239},[9235,9246],{"nctId":9236,"briefTitle":9237,"status":155,"phases":9238,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":339,"conditions":9242,"interventions":9244},"NCT03939897","Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer",[89],"2023-06-22","2026-08-14","2020-06-17",[1620,3078,3238,9243,2613],"Metastatic Hormone Receptor-Positive Breast Carcinoma",[5018,489,9245],"Fulvestrant",{"nctId":2581,"briefTitle":2582,"status":155,"phases":9247,"primaryCompletion":2584,"completion":361,"start":2585,"enrollment":2586,"conditions":9248,"interventions":9249},[89],[21,486,487],[489,2124,2554],{"trials":9251,"activeCount":758,"soonestReadout":9256},[9252,9261],{"nctId":9253,"briefTitle":9254,"status":155,"phases":9255,"primaryCompletion":9256,"completion":3904,"start":9257,"enrollment":339,"conditions":9258,"interventions":9260},"NCT04345913","Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer",[89,90],"2024-03-28","2021-03-01",[1619,1620,2609,9259],"Unresectable Triple-Negative Breast Carcinoma",[489,2954],{"nctId":478,"briefTitle":479,"status":155,"phases":9262,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":9263,"interventions":9264},[89,90],[21,486,487],[489,124,96],{"trials":9266,"activeCount":101},[],{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":101},[],{"intervention":2255,"totalTrials":214,"cells":9272},{"EARLY_PHASE1":9273,"PHASE1":9275,"PHASE2":9281,"PHASE3":9295,"PHASE4":9297,"NA":9299},{"trials":9274,"activeCount":101},[],{"trials":9276,"activeCount":2548,"soonestReadout":131},[9277],{"nctId":9128,"briefTitle":9129,"status":128,"phases":9278,"primaryCompletion":131,"completion":131,"start":9131,"enrollment":248,"conditions":9279,"interventions":9280},[89],[1197,961,9133,9134,9135],[2255,2256],{"trials":9282,"activeCount":603,"soonestReadout":361},[9283,9287,9291],{"nctId":2246,"briefTitle":2247,"status":128,"phases":9284,"primaryCompletion":361,"completion":361,"start":2249,"enrollment":2250,"conditions":9285,"interventions":9286},[89,90],[2252,2253],[2255,2083,2256,212,2257],{"nctId":9169,"briefTitle":9170,"status":128,"phases":9288,"primaryCompletion":9172,"completion":9172,"start":9131,"enrollment":2319,"conditions":9289,"interventions":9290},[89,90],[135],[2255,2256],{"nctId":6095,"briefTitle":6096,"status":128,"phases":9292,"primaryCompletion":799,"completion":2114,"start":2423,"enrollment":1111,"conditions":9293,"interventions":9294},[90],[6099,6100,6101,5572,856,854,6102,3860,6103,6104,6105,6106,6107],[1139,2255,6109],{"trials":9296,"activeCount":101},[],{"trials":9298,"activeCount":101},[],{"trials":9300,"activeCount":101},[],{"intervention":9302,"totalTrials":214,"cells":9303},"Trametinib Dimethyl Sulfoxide",{"EARLY_PHASE1":9304,"PHASE1":9306,"PHASE2":9308,"PHASE3":9351,"PHASE4":9353,"NA":9355},{"trials":9305,"activeCount":101},[],{"trials":9307,"activeCount":101},[],{"trials":9309,"activeCount":214,"soonestReadout":9323},[9310,9319,9327,9338],{"nctId":9311,"briefTitle":9312,"status":155,"phases":9313,"primaryCompletion":9314,"completion":9315,"start":9316,"enrollment":214,"conditions":9317,"interventions":9318},"NCT04439357","Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)",[90],"2020-09-01","2027-01-15","2016-02-25",[300,21,113,119,30,4262],[9302],{"nctId":9320,"briefTitle":9321,"status":155,"phases":9322,"primaryCompletion":9323,"completion":592,"start":9324,"enrollment":638,"conditions":9325,"interventions":9326},"NCT04439279","Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)",[90],"2019-03-18","2015-08-12",[300,21,113,119,30,4262],[9302],{"nctId":9328,"briefTitle":9329,"status":155,"phases":9330,"primaryCompletion":9331,"completion":9331,"start":9332,"enrollment":9333,"conditions":9334,"interventions":9336},"NCT02196181","Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread",[90],"2027-03-15","2014-09-19",280,[9335,4767,209],"Stage III Cutaneous Melanoma AJCC v7",[9337,9302],"Dabrafenib Mesylate",{"nctId":9339,"briefTitle":9340,"status":155,"phases":9341,"primaryCompletion":9342,"completion":9342,"start":9343,"enrollment":16,"conditions":9344,"interventions":9350},"NCT03919071","Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma",[90],"2027-09-30","2020-02-20",[4632,9345,9346,9347,394,395,9348,9349],"Anaplastic Astrocytoma, Not Otherwise Specified","Anaplastic Ganglioglioma","Anaplastic Pleomorphic Xanthoastrocytoma","WHO Grade 3 Glioma","WHO Grade 4 Glioma",[9337,9302],{"trials":9352,"activeCount":101},[],{"trials":9354,"activeCount":101},[],{"trials":9356,"activeCount":101},[],{"intervention":5885,"totalTrials":214,"cells":9358},{"EARLY_PHASE1":9359,"PHASE1":9361,"PHASE2":9375,"PHASE3":9381,"PHASE4":9383,"NA":9385},{"trials":9360,"activeCount":101},[],{"trials":9362,"activeCount":603,"soonestReadout":8923},[9363,9367,9371],{"nctId":5876,"briefTitle":5877,"status":155,"phases":9364,"primaryCompletion":5879,"completion":5879,"start":5880,"enrollment":421,"conditions":9365,"interventions":9366},[89],[5882,5883],[5885,151],{"nctId":6043,"briefTitle":6044,"status":155,"phases":9368,"primaryCompletion":5879,"completion":5879,"start":6046,"enrollment":700,"conditions":9369,"interventions":9370},[89],[4603,4262],[4605,1139,5885],{"nctId":8920,"briefTitle":8921,"status":155,"phases":9372,"primaryCompletion":8923,"completion":2832,"start":8924,"enrollment":2401,"conditions":9373,"interventions":9374},[89],[8926,2885,2844,2118,1633,8927,8928],[5225,5885],{"trials":9376,"activeCount":2548,"soonestReadout":9212},[9377],{"nctId":9209,"briefTitle":9210,"status":155,"phases":9378,"primaryCompletion":9212,"completion":9213,"start":3360,"enrollment":2401,"conditions":9379,"interventions":9380},[89,90],[1613,2885,1633],[5373,5885],{"trials":9382,"activeCount":101},[],{"trials":9384,"activeCount":101},[],{"trials":9386,"activeCount":101},[],{"intervention":3066,"totalTrials":34,"cells":9388},{"EARLY_PHASE1":9389,"PHASE1":9391,"PHASE2":9480,"PHASE3":9539,"PHASE4":9545,"NA":9547},{"trials":9390,"activeCount":101},[],{"trials":9392,"activeCount":758,"soonestReadout":1603},[9393,9397,9403,9413,9417,9421,9428,9438,9444,9452,9458,9462,9469,9476],{"nctId":3058,"briefTitle":3059,"status":3060,"phases":9394,"start":3062,"conditions":9395,"interventions":9396},[89],[1564],[3065,3066,995],{"nctId":9398,"briefTitle":9399,"status":142,"phases":9400,"primaryCompletion":2293,"start":3638,"enrollment":421,"conditions":9401,"interventions":9402},"NCT00078962","GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors",[89],[15],[6242,3066],{"nctId":9404,"briefTitle":9405,"status":142,"phases":9406,"primaryCompletion":9407,"completion":9407,"start":9408,"enrollment":1990,"conditions":9409,"interventions":9412},"NCT00410553","Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery",[89],"2012-10-24","2006-11-14",[3131,251,5549,9410,1546,1756,9411],"Stage III Ovarian Cancer AJCC v6 and v7","Stage IV Uterine Corpus Cancer AJCC v7",[2954,167],{"nctId":153,"briefTitle":154,"status":155,"phases":9414,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":9415,"interventions":9416},[89],[161,162,163,164],[166,167,124,96],{"nctId":1600,"briefTitle":1601,"status":155,"phases":9418,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":159,"conditions":9419,"interventions":9420},[89],[1606,1607,1608,1609,1610,1611,1612,1613,1614,21,1615,1616,1617,1618,1619,1620,1621,1622,1623,1624,1625,1626,1627,1628,1629,1630,1631,1632,1633,1634,1635,1636,1637,1638],[278,1640,167],{"nctId":9422,"briefTitle":9423,"status":142,"phases":9424,"primaryCompletion":1309,"start":9425,"enrollment":31,"conditions":9426,"interventions":9427},"NCT00063947","Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer",[89],"2003-05",[5637,3259,5638,3260],[1774,3066],{"nctId":9429,"briefTitle":9430,"status":347,"phases":9431,"primaryCompletion":3019,"completion":3019,"start":2813,"enrollment":5986,"conditions":9432,"interventions":9435},"NCT05685602","CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer",[89],[9433,163,164,9434],"Metastatic Pancreatic Ductal Adenocarcinoma","Unresectable Pancreatic Ductal Adenocarcinoma",[9436,167,9437],"Emavusertib","Nab-paclitaxel",{"nctId":9439,"briefTitle":9440,"status":142,"phases":9441,"primaryCompletion":1310,"start":1952,"enrollment":16,"conditions":9442,"interventions":9443},"NCT00072436","Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors",[89],[15],[3066,1998],{"nctId":9445,"briefTitle":9446,"status":618,"phases":9447,"primaryCompletion":3389,"start":1276,"enrollment":310,"conditions":9448,"interventions":9451},"NCT00060112","Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma",[89],[1245,1246,3180,3181,3182,3183,4681,3185,3186,4787,9449,3187,3188,940,3189,3190,655,1248,3209,1334,3210,3211,4796,3212,3213,4797,9450,3214,3215,3216,1060,3217,664,15],"Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma",[3590,3066],{"nctId":9453,"briefTitle":9454,"status":142,"phases":9455,"primaryCompletion":5445,"start":4562,"enrollment":19,"conditions":9456,"interventions":9457},"NCT00462553","Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors",[89],[5637,3259,3260,3261,15],[5237,3066],{"nctId":6962,"briefTitle":6963,"status":142,"phases":9459,"primaryCompletion":716,"start":4272,"enrollment":339,"conditions":9460,"interventions":9461},[89],[3119,1772,3285],[6967,1775,3066],{"nctId":9463,"briefTitle":9464,"status":142,"phases":9465,"primaryCompletion":2292,"start":5445,"enrollment":827,"conditions":9466,"interventions":9467},"NCT01145456","Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors",[89],[5637,3259,3260,3261,15],[9468,3066],"gamma-secretase\u002FNotch signalling pathway inhibitor RO4929097",{"nctId":9470,"briefTitle":9471,"status":142,"phases":9472,"primaryCompletion":988,"start":9473,"enrollment":28,"conditions":9474,"interventions":9475},"NCT00005577","Gemcitabine in Treating Children With Refractory Solid Tumors",[89],"1996-08",[748],[3066],{"nctId":9063,"briefTitle":9064,"status":142,"phases":9477,"primaryCompletion":6513,"completion":6513,"start":3272,"enrollment":25,"conditions":9478,"interventions":9479},[89],[3131,6516,6517],[167,1653],{"trials":9481,"activeCount":2548,"soonestReadout":1961},[9482,9488,9492,9498,9502,9506,9510,9514,9524,9528,9532],{"nctId":9483,"briefTitle":9484,"status":142,"phases":9485,"primaryCompletion":650,"completion":4878,"start":987,"enrollment":1041,"conditions":9486,"interventions":9487},"NCT00093496","Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer",[90],[1821,1579,1790,1591],[3066,6287],{"nctId":1847,"briefTitle":1848,"status":142,"phases":9489,"primaryCompletion":1850,"completion":1851,"start":787,"enrollment":1852,"conditions":9490,"interventions":9491},[90],[1854,1855,1856,1857],[1859,278,167],{"nctId":9493,"briefTitle":9494,"status":142,"phases":9495,"primaryCompletion":1911,"completion":1911,"start":1241,"enrollment":3869,"conditions":9496,"interventions":9497},"NCT00114244","Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer",[90],[3261],[8069,3066],{"nctId":7785,"briefTitle":7786,"status":142,"phases":9499,"primaryCompletion":1170,"completion":7788,"start":715,"enrollment":28,"conditions":9500,"interventions":9501},[90],[7583,7584,7585,7587,4681],[7791,2166,3401,3066],{"nctId":8410,"briefTitle":8411,"status":142,"phases":9503,"primaryCompletion":1381,"completion":8413,"start":8414,"enrollment":730,"conditions":9504,"interventions":9505},[89,90],[4681,8416,8417],[1511,167],{"nctId":1958,"briefTitle":1959,"status":155,"phases":9507,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":1964,"conditions":9508,"interventions":9509},[90],[1966,1967,163,164],[278,289,167,1653],{"nctId":3635,"briefTitle":3636,"status":142,"phases":9511,"primaryCompletion":1781,"start":3638,"enrollment":3639,"conditions":9512,"interventions":9513},[90],[3119,1772,3285],[3066,1776,1062],{"nctId":9515,"briefTitle":9516,"status":142,"phases":9517,"primaryCompletion":9518,"completion":8414,"start":9519,"enrollment":9520,"conditions":9521,"interventions":9523},"NCT01064622","Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer",[90],"2012-12-09","2009-09-03",118,[161,3332,9522],"Stage IV Pancreatic Cancer AJCC v6 and v7",[167,1814],{"nctId":7511,"briefTitle":7512,"status":142,"phases":9525,"primaryCompletion":7514,"completion":7514,"start":7515,"enrollment":407,"conditions":9526,"interventions":9527},[89,90],[4825,6206,6207],[2924,167,43],{"nctId":7043,"briefTitle":7044,"status":618,"phases":9529,"primaryCompletion":7046,"completion":7046,"start":7047,"enrollment":407,"conditions":9530,"interventions":9531},[90],[3320,4828,4833,3321],[6296,6296,2083,474,167,1102,2045],{"nctId":9533,"briefTitle":9534,"status":142,"phases":9535,"primaryCompletion":1781,"start":2487,"enrollment":234,"conditions":9536,"interventions":9538},"NCT00305734","Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer",[90],[6506,9537],"Stage IV Nasopharyngeal Cancer",[1062,3066],{"trials":9540,"activeCount":101},[9541],{"nctId":5631,"briefTitle":5632,"status":142,"phases":9542,"primaryCompletion":5634,"start":1257,"enrollment":5635,"conditions":9543,"interventions":9544},[91],[5637,3259,5638,3260,3261],[3066,1033],{"trials":9546,"activeCount":101},[],{"trials":9548,"activeCount":101},[],{"intervention":750,"totalTrials":2401,"cells":9550},{"EARLY_PHASE1":9551,"PHASE1":9553,"PHASE2":9574,"PHASE3":9644,"PHASE4":9650,"NA":9652},{"trials":9552,"activeCount":101},[],{"trials":9554,"activeCount":758,"soonestReadout":727},[9555,9559,9563,9567],{"nctId":724,"briefTitle":725,"status":155,"phases":9556,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":9557,"interventions":9558},[89],[732,733,734,735],[63,737,279,738,58,739,212,667,740],{"nctId":742,"briefTitle":743,"status":142,"phases":9560,"primaryCompletion":745,"start":746,"enrollment":188,"conditions":9561,"interventions":9562},[89],[748],[750,693,751],{"nctId":1778,"briefTitle":1779,"status":142,"phases":9564,"primaryCompletion":1781,"start":1782,"enrollment":28,"conditions":9565,"interventions":9566},[89],[1784,1785,1732,1786,1787,1788,1789,1790,1591],[995,1598,1031,750],{"nctId":9568,"briefTitle":9569,"status":128,"phases":9570,"primaryCompletion":592,"completion":592,"start":9571,"enrollment":298,"conditions":9572,"interventions":9573},"NCT07012044","A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia",[89],"2026-07-26",[6272,2427,2430],[2435,3976,738],{"trials":9575,"activeCount":2548,"soonestReadout":62},[9576,9580,9584,9588,9592,9596,9600,9604,9608,9612,9616,9620,9624,9628,9632,9636,9640],{"nctId":809,"briefTitle":810,"status":142,"phases":9577,"primaryCompletion":812,"completion":812,"start":813,"enrollment":188,"conditions":9578,"interventions":9579},[90],[815],[817,818,750,693,819],{"nctId":3584,"briefTitle":3585,"status":142,"phases":9581,"primaryCompletion":3587,"start":3397,"enrollment":37,"conditions":9582,"interventions":9583},[89,90],[3181,940,3189],[3590,1063,3591,1776,1080,750,1066],{"nctId":4119,"briefTitle":4120,"status":142,"phases":9585,"primaryCompletion":4122,"completion":4123,"start":4124,"enrollment":4125,"conditions":9586,"interventions":9587},[90],[263,4127,4128,4129,4130,4131,4132],[980,1137,1374,2435,279,738],{"nctId":5711,"briefTitle":5712,"status":618,"phases":9589,"primaryCompletion":650,"completion":650,"start":3088,"enrollment":5714,"conditions":9590,"interventions":9591},[89,90],[1245,1246,3187,3188,940,3190,655,1248,1251],[1063,5717,5718,5719,750],{"nctId":4139,"briefTitle":4140,"status":142,"phases":9593,"primaryCompletion":4142,"start":1356,"enrollment":421,"conditions":9594,"interventions":9595},[90],[27],[750,3123,1080,3591],{"nctId":1049,"briefTitle":1050,"status":142,"phases":9597,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":9598,"interventions":9599},[90],[1056,1057,1058,1059,1060],[1062,1063,693,994,1064,1065,750,1066],{"nctId":1068,"briefTitle":1069,"status":142,"phases":9601,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":9602,"interventions":9603},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":60,"briefTitle":61,"status":155,"phases":9605,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":9606,"interventions":9607},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":5749,"briefTitle":5750,"status":142,"phases":9609,"primaryCompletion":5752,"completion":5752,"start":5753,"enrollment":2586,"conditions":9610,"interventions":9611},[90],[5755,5756],[738,667,5758],{"nctId":7578,"briefTitle":7579,"status":142,"phases":9613,"primaryCompletion":7581,"completion":2027,"start":1340,"enrollment":34,"conditions":9614,"interventions":9615},[90],[7583,7584,7585,7586,7587,7588,7589,7590,7591,7592,4681,4793,7593,7594,7595,7596,7597,7598,4796,4799],[3591,1062,2166,750],{"nctId":1167,"briefTitle":1168,"status":142,"phases":9617,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":234,"conditions":9618,"interventions":9619},[90],[1174],[1176,279,780,781,63,212,738],{"nctId":1974,"briefTitle":1975,"status":618,"phases":9621,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":248,"conditions":9622,"interventions":9623},[90],[1981,625],[750,1598,1983,994,1264,1268],{"nctId":1254,"briefTitle":1255,"status":142,"phases":9625,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":9626,"interventions":9627},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"nctId":7128,"briefTitle":7129,"status":618,"phases":9629,"primaryCompletion":5230,"completion":5858,"start":1319,"enrollment":603,"conditions":9630,"interventions":9631},[89,90],[4747,7132],[4605,1405,738],{"nctId":1296,"briefTitle":1297,"status":618,"phases":9633,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":9634,"interventions":9635},[89,90],[1291,1302],[991,1304,750,993,693,994,819,995,722],{"nctId":7058,"briefTitle":7059,"status":142,"phases":9637,"primaryCompletion":1241,"start":7061,"enrollment":552,"conditions":9638,"interventions":9639},[90],[3664,791,625],[750,1775],{"nctId":1337,"briefTitle":1338,"status":618,"phases":9641,"primaryCompletion":1340,"start":1341,"enrollment":16,"conditions":9642,"interventions":9643},[90],[1343,1344],[693,819,1346,1347,1348,1349,750,818],{"trials":9645,"activeCount":101},[9646],{"nctId":1353,"briefTitle":1354,"status":142,"phases":9647,"primaryCompletion":715,"start":1356,"enrollment":1357,"conditions":9648,"interventions":9649},[91],[27],[750,1063,1360,693,994,1082,1032],{"trials":9651,"activeCount":101},[],{"trials":9653,"activeCount":101},[],{"intervention":2954,"totalTrials":1024,"cells":9655},{"EARLY_PHASE1":9656,"PHASE1":9658,"PHASE2":9685,"PHASE3":9713,"PHASE4":9715,"NA":9717},{"trials":9657,"activeCount":101},[],{"trials":9659,"activeCount":101},[9660,9664,9671],{"nctId":9404,"briefTitle":9405,"status":142,"phases":9661,"primaryCompletion":9407,"completion":9407,"start":9408,"enrollment":1990,"conditions":9662,"interventions":9663},[89],[3131,251,5549,9410,1546,1756,9411],[2954,167],{"nctId":9665,"briefTitle":9666,"status":142,"phases":9667,"primaryCompletion":987,"start":4231,"enrollment":25,"conditions":9668,"interventions":9669},"NCT00047034","E7389 in Treating Patients With Advanced Solid Tumors",[89],[15],[9670],"eribulin mesylate",{"nctId":9672,"briefTitle":9673,"status":107,"phases":9674,"primaryCompletion":9675,"completion":9675,"start":9676,"enrollment":101,"conditions":9677,"interventions":9683},"NCT06590558","Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer",[89],"2027-05-17","2025-08-04",[1619,1620,3909,9678,9679,9680,3238,9243,2609,9681,9682,9259],"Locally Advanced HER2-Negative Breast Carcinoma","Locally Advanced Hormone Receptor-Positive Breast Carcinoma","Locally Advanced Triple-Negative Breast Carcinoma","Unresectable HER2-Negative Breast Carcinoma","Unresectable Hormone Receptor-Positive Breast Carcinoma",[2954,9684],"Tolinapant",{"trials":9686,"activeCount":603,"soonestReadout":9256},[9687,9693,9705,9709],{"nctId":9688,"briefTitle":9689,"status":142,"phases":9690,"primaryCompletion":3129,"completion":3129,"start":4715,"enrollment":971,"conditions":9691,"interventions":9692},"NCT00400829","E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],[3119,1772,3285],[9670],{"nctId":9694,"briefTitle":9695,"status":155,"phases":9696,"primaryCompletion":3833,"completion":9697,"start":9698,"enrollment":3983,"conditions":9699,"interventions":9704},"NCT00365157","Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction",[89,90],"2026-07-09","2006-10-23",[1618,9700,9701,9702,9703,1857,1638],"Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Recurrent Urothelial Carcinoma","Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",[2954],{"nctId":2927,"briefTitle":2928,"status":155,"phases":9706,"primaryCompletion":2930,"completion":2930,"start":2931,"enrollment":1953,"conditions":9707,"interventions":9708},[90],[2933,2934,2935,2936,1854,2937,1856,2938,2939,2940,2941,2942,2696,2943,2944,2945,2697,2946,2947,2948,2949,2950,2951,2952],[1690,2954],{"nctId":9253,"briefTitle":9254,"status":155,"phases":9710,"primaryCompletion":9256,"completion":3904,"start":9257,"enrollment":339,"conditions":9711,"interventions":9712},[89,90],[1619,1620,2609,9259],[489,2954],{"trials":9714,"activeCount":101},[],{"trials":9716,"activeCount":101},[],{"trials":9718,"activeCount":101},[],{"intervention":4605,"totalTrials":838,"cells":9720},{"EARLY_PHASE1":9721,"PHASE1":9723,"PHASE2":9733,"PHASE3":9747,"PHASE4":9749,"NA":9751},{"trials":9722,"activeCount":101},[],{"trials":9724,"activeCount":2548,"soonestReadout":5879},[9725,9729],{"nctId":4597,"briefTitle":4598,"status":618,"phases":9726,"primaryCompletion":454,"completion":454,"start":4600,"enrollment":638,"conditions":9727,"interventions":9728},[89],[4602,4603,4262],[4605,1139,4606,1016,3942],{"nctId":6043,"briefTitle":6044,"status":155,"phases":9730,"primaryCompletion":5879,"completion":5879,"start":6046,"enrollment":700,"conditions":9731,"interventions":9732},[89],[4603,4262],[4605,1139,5885],{"trials":9734,"activeCount":758,"soonestReadout":3244},[9735,9739,9743],{"nctId":4689,"briefTitle":4690,"status":3027,"phases":9736,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":159,"conditions":9737,"interventions":9738},[90],[4695],[4605,4697,1139,1016,1405,4698,4699,4700],{"nctId":6079,"briefTitle":6080,"status":3027,"phases":9740,"primaryCompletion":3244,"completion":3244,"start":6082,"enrollment":6083,"conditions":9741,"interventions":9742},[89,90],[4603,4262],[4605,1139,138,4700],{"nctId":7128,"briefTitle":7129,"status":618,"phases":9744,"primaryCompletion":5230,"completion":5858,"start":1319,"enrollment":603,"conditions":9745,"interventions":9746},[89,90],[4747,7132],[4605,1405,738],{"trials":9748,"activeCount":101},[],{"trials":9750,"activeCount":101},[],{"trials":9752,"activeCount":101},[],{"intervention":138,"totalTrials":214,"cells":9754},{"EARLY_PHASE1":9755,"PHASE1":9757,"PHASE2":9763,"PHASE3":9789,"PHASE4":9791,"NA":9793},{"trials":9756,"activeCount":101},[],{"trials":9758,"activeCount":2548,"soonestReadout":130},[9759],{"nctId":126,"briefTitle":127,"status":128,"phases":9760,"primaryCompletion":130,"completion":131,"start":132,"enrollment":16,"conditions":9761,"interventions":9762},[89],[134,135,136],[138,96],{"trials":9764,"activeCount":758,"soonestReadout":9777},[9765,9773,9785],{"nctId":9766,"briefTitle":9767,"status":142,"phases":9768,"primaryCompletion":9769,"completion":9769,"start":9770,"enrollment":31,"conditions":9771,"interventions":9772},"NCT01495598","Pomalidomide for Kaposi Sarcoma in People With or Without HIV",[89,90],"2022-05-17","2012-01-10",[135,5259],[138],{"nctId":9774,"briefTitle":9775,"status":155,"phases":9776,"primaryCompletion":9777,"completion":9778,"start":9779,"enrollment":234,"conditions":9780,"interventions":9783},"NCT04802161","Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes",[90],"2024-11-21","2026-04-25","2022-08-24",[263,6272,9781,2453,2454,9782],"Acute Myeloid Leukemia With Multilineage Dysplasia","Myeloproliferative Neoplasm",[9784,138],"Liposome-encapsulated Daunorubicin-Cytarabine",{"nctId":6079,"briefTitle":6080,"status":3027,"phases":9786,"primaryCompletion":3244,"completion":3244,"start":6082,"enrollment":6083,"conditions":9787,"interventions":9788},[89,90],[4603,4262],[4605,1139,138,4700],{"trials":9790,"activeCount":101},[],{"trials":9792,"activeCount":101},[],{"trials":9794,"activeCount":101},[],{"intervention":980,"totalTrials":214,"cells":9796},{"EARLY_PHASE1":9797,"PHASE1":9799,"PHASE2":9801,"PHASE3":9819,"PHASE4":9821,"NA":9823},{"trials":9798,"activeCount":101},[],{"trials":9800,"activeCount":101},[],{"trials":9802,"activeCount":603,"soonestReadout":968},[9803,9807,9811,9815],{"nctId":965,"briefTitle":966,"status":128,"phases":9804,"primaryCompletion":968,"completion":969,"start":970,"enrollment":971,"conditions":9805,"interventions":9806},[90],[973,974,975,976,977],[979,643,980,981,213,982,63],{"nctId":4119,"briefTitle":4120,"status":142,"phases":9808,"primaryCompletion":4122,"completion":4123,"start":4124,"enrollment":4125,"conditions":9809,"interventions":9810},[90],[263,4127,4128,4129,4130,4131,4132],[980,1137,1374,2435,279,738],{"nctId":1105,"briefTitle":1106,"status":155,"phases":9812,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":9813,"interventions":9814},[90],[1113],[643,63,980],{"nctId":3988,"briefTitle":3989,"status":3027,"phases":9816,"primaryCompletion":3991,"completion":3991,"start":2728,"enrollment":3992,"conditions":9817,"interventions":9818},[90],[263],[980,643,1405,2217],{"trials":9820,"activeCount":101},[],{"trials":9822,"activeCount":101},[],{"trials":9824,"activeCount":101},[],{"intervention":213,"totalTrials":214,"cells":9826},{"EARLY_PHASE1":9827,"PHASE1":9829,"PHASE2":9835,"PHASE3":9849,"PHASE4":9851,"NA":9853},{"trials":9828,"activeCount":101},[],{"trials":9830,"activeCount":2548,"soonestReadout":185},[9831],{"nctId":182,"briefTitle":183,"status":155,"phases":9832,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":9833,"interventions":9834},[89],[190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210],[124,96,212,213],{"trials":9836,"activeCount":758,"soonestReadout":62},[9837,9841,9845],{"nctId":965,"briefTitle":966,"status":128,"phases":9838,"primaryCompletion":968,"completion":969,"start":970,"enrollment":971,"conditions":9839,"interventions":9840},[90],[973,974,975,976,977],[979,643,980,981,213,982,63],{"nctId":1068,"briefTitle":1069,"status":142,"phases":9842,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":9843,"interventions":9844},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":60,"briefTitle":61,"status":155,"phases":9846,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":9847,"interventions":9848},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"trials":9850,"activeCount":101},[],{"trials":9852,"activeCount":101},[],{"trials":9854,"activeCount":101},[],{"intervention":5044,"totalTrials":214,"cells":9856},{"EARLY_PHASE1":9857,"PHASE1":9859,"PHASE2":9861,"PHASE3":9897,"PHASE4":9899,"NA":9901},{"trials":9858,"activeCount":101},[],{"trials":9860,"activeCount":101},[],{"trials":9862,"activeCount":603,"soonestReadout":9867},[9863,9875,9879,9887],{"nctId":9864,"briefTitle":9865,"status":155,"phases":9866,"primaryCompletion":9867,"completion":9867,"start":9868,"enrollment":9869,"conditions":9870,"interventions":9873},"NCT05554367","Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial",[90],"2026-08-26","2023-12-13",199,[9871,2681,9872,1634,164],"Exocrine Pancreas Carcinoma","Ovarian Low Grade Serous Adenocarcinoma",[5044,9874],"Palbociclib",{"nctId":5026,"briefTitle":5027,"status":155,"phases":9876,"primaryCompletion":968,"completion":968,"start":5029,"enrollment":971,"conditions":9877,"interventions":9878},[90],[5031,5032,5033,5034,5035,5036,1624,5037,5038,3364,1631,5039,5040,3370,5041,5042,3374],[5044,2084,1140,2925],{"nctId":9880,"briefTitle":9881,"status":618,"phases":9882,"primaryCompletion":9883,"completion":9883,"start":9884,"enrollment":2548,"conditions":9885,"interventions":9886},"NCT05554354","Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)",[90],"2025-04-04","2024-09-13",[1620,3238,9243],[5044,9245],{"nctId":9888,"briefTitle":9889,"status":128,"phases":9890,"primaryCompletion":9891,"completion":9892,"start":3020,"enrollment":421,"conditions":9893,"interventions":9895},"NCT04322383","Binimetinib for People With Relapsed\u002FRefractory BRAF Wild Type Hairy Cell Leukemia and Variant",[90],"2028-04-30","2028-07-31",[9894],"Hairy Cell Leukemia",[9896],"binimetinib",{"trials":9898,"activeCount":101},[],{"trials":9900,"activeCount":101},[],{"trials":9902,"activeCount":101},[],{"intervention":5018,"totalTrials":603,"cells":9904},{"EARLY_PHASE1":9905,"PHASE1":9907,"PHASE2":9917,"PHASE3":9928,"PHASE4":9930,"NA":9932},{"trials":9906,"activeCount":101},[],{"trials":9908,"activeCount":758,"soonestReadout":9239},[9909,9913],{"nctId":9236,"briefTitle":9237,"status":155,"phases":9910,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":339,"conditions":9911,"interventions":9912},[89],[1620,3078,3238,9243,2613],[5018,489,9245],{"nctId":5008,"briefTitle":5009,"status":128,"phases":9914,"primaryCompletion":5011,"completion":5011,"start":5012,"enrollment":2586,"conditions":9915,"interventions":9916},[89],[5014,5015,5016],[5018,2084],{"trials":9918,"activeCount":2548,"soonestReadout":9923},[9919],{"nctId":9920,"briefTitle":9921,"status":128,"phases":9922,"primaryCompletion":9923,"completion":5890,"start":9924,"enrollment":9925,"conditions":9926,"interventions":9927},"NCT04941274","Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma",[89,90],"2028-03-01","2021-09-29",111,[135],[5018],{"trials":9929,"activeCount":101},[],{"trials":9931,"activeCount":101},[],{"trials":9933,"activeCount":101},[],{"intervention":9935,"totalTrials":603,"cells":9936},"Lutetium Lu 177 Dotatate",{"EARLY_PHASE1":9937,"PHASE1":9939,"PHASE2":9964,"PHASE3":9979,"PHASE4":9981,"NA":9983},{"trials":9938,"activeCount":101},[],{"trials":9940,"activeCount":758,"soonestReadout":9958},[9941,9954],{"nctId":9942,"briefTitle":9943,"status":128,"phases":9944,"primaryCompletion":9945,"completion":9945,"start":9946,"enrollment":339,"conditions":9947,"interventions":9953},"NCT05687123","Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors",[89],"2026-12-14","2024-08-14",[9948,9949,9950,9951,9952],"Metastatic Pancreatic Neuroendocrine Tumor","Pancreatic Neoplasm","Stage III Pancreatic Neuroendocrine Tumor AJCC v8","Stage IV Pancreatic Neuroendocrine Tumor AJCC v8","Unresectable Pancreatic Neuroendocrine Tumor",[9935,1832],{"nctId":9955,"briefTitle":9956,"status":155,"phases":9957,"primaryCompletion":9958,"completion":9213,"start":9959,"enrollment":25,"conditions":9960,"interventions":9963},"NCT04234568","Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors",[89],"2024-09-17","2020-07-20",[9961,9962],"Metastatic Digestive System Neuroendocrine Neoplasm","Metastatic Neuroendocrine Tumor",[9935,1671],{"trials":9965,"activeCount":2548,"soonestReadout":284},[9966],{"nctId":9967,"briefTitle":9968,"status":128,"phases":9969,"primaryCompletion":284,"completion":284,"start":9970,"enrollment":248,"conditions":9971,"interventions":9975},"NCT05773274","Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial",[90],"2024-01-12",[5540,9972,9973,9974],"Metastatic Digestive System Neuroendocrine Tumor G2","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Digestive System Neuroendocrine Tumor G2",[9976,9977,9935,9978],"Cabozantinib","Everolimus","Sunitinib",{"trials":9980,"activeCount":101},[],{"trials":9982,"activeCount":101},[],{"trials":9984,"activeCount":101},[],{"intervention":3001,"totalTrials":603,"cells":9986},{"EARLY_PHASE1":9987,"PHASE1":9989,"PHASE2":9991,"PHASE3":10008,"PHASE4":10010,"NA":10012},{"trials":9988,"activeCount":101},[],{"trials":9990,"activeCount":101},[],{"trials":9992,"activeCount":603,"soonestReadout":2992},[9993,9997,10004],{"nctId":5905,"briefTitle":5906,"status":128,"phases":9994,"primaryCompletion":2930,"completion":2930,"start":5908,"enrollment":1128,"conditions":9995,"interventions":9996},[89,90],[2976,5910],[3001,151],{"nctId":9998,"briefTitle":9999,"status":128,"phases":10000,"primaryCompletion":2930,"completion":2930,"start":10001,"enrollment":3983,"conditions":10002,"interventions":10003},"NCT05099003","A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)",[89,90],"2022-05-31",[395],[3001],{"nctId":2989,"briefTitle":2990,"status":128,"phases":10005,"primaryCompletion":2992,"completion":2992,"start":2993,"enrollment":2029,"conditions":10006,"interventions":10007},[90],[2995,2996,2997,2998,2999],[1690,3001],{"trials":10009,"activeCount":101},[],{"trials":10011,"activeCount":101},[],{"trials":10013,"activeCount":101},[],{"intervention":4700,"totalTrials":603,"cells":10015},{"EARLY_PHASE1":10016,"PHASE1":10018,"PHASE2":10030,"PHASE3":10040,"PHASE4":10042,"NA":10044},{"trials":10017,"activeCount":101},[],{"trials":10019,"activeCount":2548,"soonestReadout":10024},[10020],{"nctId":10021,"briefTitle":10022,"status":3027,"phases":10023,"primaryCompletion":10024,"completion":10024,"start":10025,"enrollment":28,"conditions":10026,"interventions":10029},"NCT07332507","Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma",[89],"2027-02-28","2026-05-29",[10027,10028],"Recurrent Plasmablastic Lymphoma","Refractory Plasmablastic Lymphoma",[4700],{"trials":10031,"activeCount":758,"soonestReadout":3244},[10032,10036],{"nctId":4689,"briefTitle":4690,"status":3027,"phases":10033,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":159,"conditions":10034,"interventions":10035},[90],[4695],[4605,4697,1139,1016,1405,4698,4699,4700],{"nctId":6079,"briefTitle":6080,"status":3027,"phases":10037,"primaryCompletion":3244,"completion":3244,"start":6082,"enrollment":6083,"conditions":10038,"interventions":10039},[89,90],[4603,4262],[4605,1139,138,4700],{"trials":10041,"activeCount":101},[],{"trials":10043,"activeCount":101},[],{"trials":10045,"activeCount":101},[],{"intervention":9874,"totalTrials":603,"cells":10047},{"EARLY_PHASE1":10048,"PHASE1":10050,"PHASE2":10052,"PHASE3":10075,"PHASE4":10077,"NA":10079},{"trials":10049,"activeCount":101},[],{"trials":10051,"activeCount":101},[],{"trials":10053,"activeCount":603,"soonestReadout":10062},[10054,10058,10066],{"nctId":9864,"briefTitle":9865,"status":155,"phases":10055,"primaryCompletion":9867,"completion":9867,"start":9868,"enrollment":9869,"conditions":10056,"interventions":10057},[90],[9871,2681,9872,1634,164],[5044,9874],{"nctId":10059,"briefTitle":10060,"status":155,"phases":10061,"primaryCompletion":10062,"completion":9315,"start":10063,"enrollment":5986,"conditions":10064,"interventions":10065},"NCT06390839","Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)",[90],"2022-01-15","2017-03-22",[300,21,119,30],[9874],{"nctId":10067,"briefTitle":10068,"status":128,"phases":10069,"primaryCompletion":2050,"completion":2050,"start":10070,"enrollment":1111,"conditions":10071,"interventions":10073},"NCT06126276","Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)",[90],"2024-05-07",[1532,2681,10072,116],"Recurrent Malignant Female Reproductive System Neoplasm",[10074,9874],"Neratinib Maleate",{"trials":10076,"activeCount":101},[],{"trials":10078,"activeCount":101},[],{"trials":10080,"activeCount":101},[],{"intervention":3976,"totalTrials":603,"cells":10082},{"EARLY_PHASE1":10083,"PHASE1":10085,"PHASE2":10091,"PHASE3":10101,"PHASE4":10103,"NA":10105},{"trials":10084,"activeCount":101},[],{"trials":10086,"activeCount":2548,"soonestReadout":592},[10087],{"nctId":9568,"briefTitle":9569,"status":128,"phases":10088,"primaryCompletion":592,"completion":592,"start":9571,"enrollment":298,"conditions":10089,"interventions":10090},[89],[6272,2427,2430],[2435,3976,738],{"trials":10092,"activeCount":758,"soonestReadout":3971},[10093,10097],{"nctId":3968,"briefTitle":3969,"status":155,"phases":10094,"primaryCompletion":3971,"completion":3972,"start":3973,"enrollment":838,"conditions":10095,"interventions":10096},[89,90],[263],[1137,1373,3976,2217],{"nctId":3978,"briefTitle":3979,"status":3027,"phases":10098,"primaryCompletion":3981,"completion":3981,"start":3982,"enrollment":3983,"conditions":10099,"interventions":10100},[90],[263,2454],[3976,3986,2217],{"trials":10102,"activeCount":101},[],{"trials":10104,"activeCount":101},[],{"trials":10106,"activeCount":101},[],{"intervention":8069,"totalTrials":34,"cells":10108},{"EARLY_PHASE1":10109,"PHASE1":10111,"PHASE2":10184,"PHASE3":10303,"PHASE4":10319,"NA":10321},{"trials":10110,"activeCount":101},[],{"trials":10112,"activeCount":2548,"soonestReadout":47},[10113,10120,10124,10145,10149,10163,10169,10176],{"nctId":10114,"briefTitle":10115,"status":142,"phases":10116,"primaryCompletion":10117,"start":1021,"enrollment":1195,"conditions":10118,"interventions":10119},"NCT01008566","Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer",[89],"2016-05",[5532,5533,5534,5546],[1099,43],{"nctId":4925,"briefTitle":4926,"status":142,"phases":10121,"primaryCompletion":4928,"completion":4928,"start":4929,"enrollment":407,"conditions":10122,"interventions":10123},[89],[4822,4824,4844,4845,4846,4847],[53,2084,1102,1140,43],{"nctId":10125,"briefTitle":10126,"status":142,"phases":10127,"primaryCompletion":1329,"start":1912,"enrollment":700,"conditions":10128,"interventions":10144},"NCT00217646","Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia",[89],[4035,4036,10129,10130,10131,4128,10132,10133,4129,10134,10135,10136,10137,10138,10139,10140,10141,10142,10143,2426,1135,33,2432,2433],"Adult Acute Megakaryoblastic Leukemia","Adult Acute Monoblastic Leukemia","Adult Acute Monocytic Leukemia","Adult Acute Myeloid Leukemia With Maturation","Adult Acute Myeloid Leukemia With Minimal Differentiation","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1","Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL","Adult Acute Myeloid Leukemia Without Maturation","Adult Acute Myelomonocytic Leukemia","Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA","Adult Erythroleukemia","Adult Pure Erythroid Leukemia","Alkylating Agent-Related Acute Myeloid Leukemia","Blastic Phase","de Novo Myelodysplastic Syndrome",[43],{"nctId":8063,"briefTitle":8064,"status":142,"phases":10146,"primaryCompletion":4561,"completion":4561,"start":715,"enrollment":8066,"conditions":10147,"interventions":10148},[89],[36,1343,5454,1344],[8069,4566],{"nctId":10150,"briefTitle":10151,"status":142,"phases":10152,"primaryCompletion":10153,"completion":4411,"start":10154,"enrollment":1041,"conditions":10155,"interventions":10161},"NCT02143401","Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors",[89],"2022-11-30","2015-01-30",[10156,10157,10158,486,10159,116,3754,10160,6160],"Cirrhosis","Hepatitis B Infection","Hepatitis C Infection","Recurrent Hepatocellular Carcinoma","Stage IV Hepatocellular Carcinoma AJCC v7",[9201,10162,43],"Sorafenib",{"nctId":10164,"briefTitle":10165,"status":618,"phases":10166,"primaryCompletion":2017,"start":1340,"enrollment":3283,"conditions":10167,"interventions":10168},"NCT00436579","Sorafenib in Treating Patients With Advanced Solid Tumors",[89],[15],[8069],{"nctId":10170,"briefTitle":10171,"status":142,"phases":10172,"primaryCompletion":3272,"start":4860,"enrollment":234,"conditions":10173,"interventions":10174},"NCT00303797","Sorafenib and Bortezomib in Treating Patients With Advanced Cancer",[89],[656,4262,1432,663,15],[10175,8069],"17-N-allylamino-17-demethoxygeldanamycin\u002Fbortezomib",{"nctId":45,"briefTitle":46,"status":155,"phases":10177,"primaryCompletion":47,"completion":1461,"start":10178,"enrollment":638,"conditions":10179,"interventions":10183},[89],"2011-02-18",[21,1343,30,9335,10180,10181,10182,4767],"Stage IIIA Cutaneous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7",[48,43],{"trials":10185,"activeCount":2548,"soonestReadout":42},[10186,10194,10206,10210,10215,10231,10235,10239,10245,10249,10255,10259,10263,10273,10286,10293],{"nctId":10187,"briefTitle":10188,"status":142,"phases":10189,"primaryCompletion":649,"completion":649,"start":5706,"enrollment":3274,"conditions":10190,"interventions":10193},"NCT00238121","Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer",[90],[8169,10191,10192,5556],"Stage III Uterine Sarcoma","Stage IV Uterine Sarcoma",[8069],{"nctId":10195,"briefTitle":10196,"status":142,"phases":10197,"primaryCompletion":1340,"start":1912,"enrollment":234,"conditions":10198,"interventions":10205},"NCT00238212","S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma",[90],[10199,10200,10201,10202,10203,7352,7353,10204,7363,7364],"Adenocarcinoma of the Extrahepatic Bile Duct","Adenocarcinoma of the Gallbladder","Adenocarcinoma With Squamous Metaplasia of the Gallbladder","Cholangiocarcinoma of the Extrahepatic Bile Duct","Cholangiocarcinoma of the Gallbladder","Squamous Cell Carcinoma of the Gallbladder",[8069],{"nctId":8073,"briefTitle":8074,"status":142,"phases":10207,"primaryCompletion":1329,"completion":3129,"start":7645,"enrollment":8076,"conditions":10208,"interventions":10209},[90],[1343,1344],[8069,1185,4566],{"nctId":40,"briefTitle":41,"status":155,"phases":10211,"primaryCompletion":42,"completion":592,"start":10212,"enrollment":174,"conditions":10213,"interventions":10214},[90],"2005-09-14",[7344],[43],{"nctId":10216,"briefTitle":10217,"status":142,"phases":10218,"primaryCompletion":1240,"completion":1240,"start":3480,"enrollment":10219,"conditions":10220,"interventions":10230},"NCT00245102","Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma",[90],147,[10221,10222,10223,10224,10225,10226,7346,10227,8169,10228,10191,1096,10192,5556,10229],"Adult Angiosarcoma","Adult Epithelioid Sarcoma","Adult Leiomyosarcoma","Adult Malignant Fibrous Histiocytoma","Adult Neurofibrosarcoma","Adult Synovial Sarcoma","Recurrent Adult Soft Tissue Sarcoma","Stage III Adult Soft Tissue Sarcoma","Uterine Leiomyosarcoma",[8069],{"nctId":9493,"briefTitle":9494,"status":142,"phases":10232,"primaryCompletion":1911,"completion":1911,"start":1241,"enrollment":3869,"conditions":10233,"interventions":10234},[90],[3261],[8069,3066],{"nctId":8263,"briefTitle":8264,"status":142,"phases":10236,"primaryCompletion":8266,"completion":8267,"start":1171,"enrollment":913,"conditions":10237,"interventions":10238},[90],[8269,7354,5295,5296,5297,5298,5299,5300,5301,5302,5303,2058,5346,5349,8270,8271,7422,7423,7424,8272,7425,8273,8274,7426,7427,7428,8275,7429,8276,8277,7430,7431,7432,8278,7433,7434,7365],[1697,8069],{"nctId":10240,"briefTitle":10241,"status":618,"phases":10242,"primaryCompletion":6569,"completion":6569,"start":1341,"enrollment":838,"conditions":10243,"interventions":10244},"NCT00303966","Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia",[90],[656,657,659,661,663],[8069],{"nctId":8131,"briefTitle":8132,"status":142,"phases":10246,"primaryCompletion":3227,"completion":8134,"start":715,"enrollment":4001,"conditions":10247,"interventions":10248},[89,90],[4817,4818,4819,5287],[8069,1774,1185,4566],{"nctId":10250,"briefTitle":10251,"status":142,"phases":10252,"primaryCompletion":4032,"start":3526,"enrollment":421,"conditions":10253,"interventions":10254},"NCT00096512","S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",[90],[8269,7354,5295,5296,5297,5298,5299,5300,5301,5302,5303,2058,5346,5349,8270,8271,7422,7423,7424,8272,7425,8273,8274,7426,7427,7428,8275,7429,8276,8277,7430,7431,7432,8278,7433,7434,7365],[8069],{"nctId":8138,"briefTitle":8064,"status":107,"phases":10256,"primaryCompletion":4561,"completion":4561,"start":715,"enrollment":101,"conditions":10257,"interventions":10258},[90],[36,1343,5454,1344],[8069,4566],{"nctId":7511,"briefTitle":7512,"status":142,"phases":10260,"primaryCompletion":7514,"completion":7514,"start":7515,"enrollment":407,"conditions":10261,"interventions":10262},[89,90],[4825,6206,6207],[2924,167,43],{"nctId":10264,"briefTitle":10265,"status":142,"phases":10266,"primaryCompletion":4714,"completion":4714,"start":10267,"enrollment":552,"conditions":10268,"interventions":10272},"NCT01502410","Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",[90],"2012-01",[10269,10270,5868,6504,5870,10271,6507],"Childhood Hepatocellular Carcinoma","Papillary Thyroid Cancer","Recurrent Thyroid Cancer",[8069],{"nctId":10274,"briefTitle":10275,"status":142,"phases":10276,"primaryCompletion":1320,"start":3526,"enrollment":1913,"conditions":10277,"interventions":10285},"NCT00107432","Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.",[90],[10278,2042,10279,10280,10281,10282,10283,10284],"Epithelial Mesothelioma","Sarcomatous Mesothelioma","Stage IA Malignant Mesothelioma","Stage IB Malignant Mesothelioma","Stage II Malignant Mesothelioma","Stage III Malignant Mesothelioma","Stage IV Malignant Mesothelioma",[8069],{"nctId":10287,"briefTitle":10288,"status":142,"phases":10289,"primaryCompletion":1171,"completion":8266,"start":1330,"enrollment":638,"conditions":10290,"interventions":10291},"NCT00217399","Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer",[89,90],[3117,3137],[8069,10292],"anastrozole",{"nctId":10294,"briefTitle":10295,"status":618,"phases":10296,"primaryCompletion":716,"completion":716,"start":1912,"enrollment":2029,"conditions":10297,"interventions":10302},"NCT00112905","Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium",[90],[10298,7684,10299,7685,7686,7687,7688,10300,2899,10301,7689,7690,7691],"Adenocarcinoma of the Bladder","Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter","Regional Transitional Cell Cancer of the Renal Pelvis and Ureter","Stage III Bladder Cancer",[8069],{"trials":10304,"activeCount":101},[10305,10315],{"nctId":10306,"briefTitle":10307,"status":142,"phases":10308,"primaryCompletion":10309,"completion":10310,"start":10311,"enrollment":1852,"conditions":10312,"interventions":10314},"NCT02066181","Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis",[91],"2019-07-03","2022-12-01","2014-03-21",[10313],"Desmoid Fibromatosis",[43],{"nctId":2145,"briefTitle":2146,"status":142,"phases":10316,"primaryCompletion":2148,"completion":2149,"start":1717,"enrollment":2150,"conditions":10317,"interventions":10318},[91],[801,2152],[278,737,2154,2155,43],{"trials":10320,"activeCount":101},[],{"trials":10322,"activeCount":101},[],{"intervention":5933,"totalTrials":2211,"cells":10324},{"EARLY_PHASE1":10325,"PHASE1":10327,"PHASE2":10357,"PHASE3":10426,"PHASE4":10451,"NA":10453},{"trials":10326,"activeCount":101},[],{"trials":10328,"activeCount":2548,"soonestReadout":10333},[10329,10340,10344],{"nctId":10330,"briefTitle":10331,"status":155,"phases":10332,"primaryCompletion":10333,"completion":10334,"start":2277,"enrollment":827,"conditions":10335,"interventions":10337},"NCT00669734","Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery",[89],"2021-09-02","2027-04-21",[1966,2658,3331,10336,9522],"Stage III Pancreatic Cancer AJCC v6 and v7",[10338,10339,5933],"Falimarev","Inalimarev",{"nctId":6956,"briefTitle":6957,"status":618,"phases":10341,"primaryCompletion":2293,"start":1257,"enrollment":1074,"conditions":10342,"interventions":10343},[89],[3673,4941,3119,4942,3120,4945,3285,4946],[991,992,1775,993],{"nctId":10345,"briefTitle":10346,"status":142,"phases":10347,"primaryCompletion":10348,"completion":10349,"start":10350,"enrollment":28,"conditions":10351,"interventions":10353},"NCT00113984","Vaccine and Antibody Treatment of Prostate Cancer",[89],"2008-02-01","2011-12-01","2005-06-08",[10352],"Prostatic Neoplasms",[10354,10355,10356,5933],"PROSTVAC-V\u002FTRICOM","PROSTVAC-F\u002FTRICOM","MDX-010",{"trials":10358,"activeCount":2548,"soonestReadout":10406},[10359,10367,10371,10375,10379,10383,10394,10402,10413,10417],{"nctId":10360,"briefTitle":10361,"status":142,"phases":10362,"completion":745,"start":4232,"conditions":10363,"interventions":10364},"NCT00019383","Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma",[90],[2490],[818,1349,993,10365,10366],"tyrosinase peptide","tyrosinase-related protein-1",{"nctId":5924,"briefTitle":5925,"status":142,"phases":10368,"primaryCompletion":5927,"completion":5928,"start":5929,"enrollment":1331,"conditions":10369,"interventions":10370},[90],[5931,117],[1402,1102,5933,151,2143],{"nctId":984,"briefTitle":985,"status":142,"phases":10372,"completion":987,"start":988,"conditions":10373,"interventions":10374},[90],[18],[991,992,993,693,994,995],{"nctId":7015,"briefTitle":7016,"status":142,"phases":10376,"primaryCompletion":7018,"completion":6513,"start":3480,"enrollment":1765,"conditions":10377,"interventions":10378},[90],[18],[2083,7021,7022,5933],{"nctId":7110,"briefTitle":7111,"status":142,"phases":10380,"completion":4562,"start":7113,"conditions":10381,"interventions":10382},[90],[1431,1432,7115],[7117,7118,1081,993],{"nctId":10384,"briefTitle":10385,"status":142,"phases":10386,"primaryCompletion":3526,"start":10387,"conditions":10388,"interventions":10389},"NCT00020254","Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer",[90],"2000-06",[24],[818,10390,10391,10392,993,10393],"recombinant fowlpox-prostate specific antigen vaccine","recombinant vaccinia prostate-specific antigen vaccine","recombinant vaccinia-B7.1 vaccine","nilutamide",{"nctId":10395,"briefTitle":10396,"status":142,"phases":10397,"primaryCompletion":5103,"completion":5103,"start":2160,"enrollment":1913,"conditions":10398,"interventions":10399},"NCT00450619","153Sm-EDTMP With or Without a PSA\u002FTRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer",[90],[24],[5933,10400,10401],"Recombinant vaccinia-TRICOM vaccine","Recombinant fowlpox-TRICOM vaccine",{"nctId":10403,"briefTitle":10404,"status":3027,"phases":10405,"primaryCompletion":10406,"completion":3029,"start":10407,"enrollment":2319,"conditions":10408,"interventions":10410},"NCT07169617","Testing the SurVaxM Vaccine for Lung Cancer Prevention",[90],"2029-03-30","2026-06-01",[10409],"Lung Carcinoma",[10411,5933,10412],"Montanide ISA 51 VG","SVN53-67\u002FM57-KLH Peptide Vaccine",{"nctId":1296,"briefTitle":1297,"status":618,"phases":10414,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":10415,"interventions":10416},[89,90],[1291,1302],[991,1304,750,993,693,994,819,995,722],{"nctId":10418,"briefTitle":10419,"status":142,"phases":10420,"primaryCompletion":1240,"completion":1240,"start":1217,"enrollment":339,"conditions":10421,"interventions":10424},"NCT00462605","MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and\u002For Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia",[90],[10422,4037,4038,4039,4040,4041,4042,4043,4044,4046,4047,4048,4050,4051,2453,4056,4057,4058,1135,33,4615,4616,4617,4618,2432,4061,10423,4132],"Adult Acute Lymphoblastic Leukemia in Remission","Untreated Adult Acute Lymphoblastic Leukemia",[10425,993],"entinostat",{"trials":10427,"activeCount":101},[10428],{"nctId":10429,"briefTitle":10430,"status":142,"phases":10431,"primaryCompletion":10432,"completion":8414,"start":10433,"enrollment":10434,"conditions":10435,"interventions":10449},"NCT01989572","Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery",[91],"2012-10-08","2000-02-23",815,[3308,10436,3773,10437,1343,10438,10439,10440,10441,10442,10443,10444,10180,10445,10181,10446,10182,10447,4767,10448],"Medium\u002FLarge Size Posterior Uveal Melanoma","Ocular Melanoma With Extraocular Extension","Recurrent Uveal Melanoma","Small Size Posterior Uveal Melanoma","Stage IIA Cutaneous Melanoma AJCC v6 and v7","Stage IIA Uveal Melanoma AJCC v7","Stage IIB Cutaneous Melanoma AJCC v6 and v7","Stage IIB Uveal Melanoma AJCC v7","Stage IIC Cutaneous Melanoma AJCC v6 and v7","Stage IIIA Uveal Melanoma AJCC v7","Stage IIIB Uveal Melanoma AJCC v7","Stage IIIC Uveal Melanoma AJCC v7","Stage IV Uveal Melanoma AJCC v7",[5933,10450],"Tyrosinase Peptide",{"trials":10452,"activeCount":101},[],{"trials":10454,"activeCount":101},[],{"intervention":4769,"totalTrials":651,"cells":10456},{"EARLY_PHASE1":10457,"PHASE1":10459,"PHASE2":10482,"PHASE3":10537,"PHASE4":10539,"NA":10541},{"trials":10458,"activeCount":101},[],{"trials":10460,"activeCount":2548,"soonestReadout":4764},[10461,10465,10469],{"nctId":8192,"briefTitle":8193,"status":142,"phases":10462,"primaryCompletion":3226,"completion":6303,"start":8167,"enrollment":97,"conditions":10463,"interventions":10464},[89],[4941,4942,4844,4845,4846,4847,15],[8197,1697],{"nctId":4761,"briefTitle":4762,"status":155,"phases":10466,"primaryCompletion":4764,"completion":592,"start":4765,"enrollment":3255,"conditions":10467,"interventions":10468},[89],[195,30,4767,487],[2732,68,4769,2708],{"nctId":10470,"briefTitle":10471,"status":142,"phases":10472,"primaryCompletion":787,"completion":10473,"start":10474,"enrollment":421,"conditions":10475,"interventions":10480},"NCT02188264","Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer",[89],"2019-04-26","2014-08-29",[10476,5223,10477,10478,10479,6446,6447],"Recurrent Colorectal Carcinoma","Stage IIIA Colorectal Cancer AJCC v7","Stage IIIB Colorectal Cancer AJCC v7","Stage IIIC Colorectal Cancer AJCC v7",[10481,4769],"Cyclosporine",{"trials":10483,"activeCount":2548,"soonestReadout":10501},[10484,10491,10497,10508,10514,10523],{"nctId":10485,"briefTitle":10486,"status":142,"phases":10487,"primaryCompletion":8266,"completion":8266,"start":2293,"enrollment":1041,"conditions":10488,"interventions":10490},"NCT00553332","Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery",[90],[10489,7352,7363],"Liver and Intrahepatic Biliary Tract Cancer",[8197],{"nctId":10492,"briefTitle":10493,"status":618,"phases":10494,"primaryCompletion":5230,"completion":6303,"start":1329,"enrollment":455,"conditions":10495,"interventions":10496},"NCT01278615","Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",[90],[3181],[4769],{"nctId":10498,"briefTitle":10499,"status":155,"phases":10500,"primaryCompletion":10501,"completion":10502,"start":10503,"enrollment":700,"conditions":10504,"interventions":10507},"NCT02407405","MEK 1\u002F2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas",[90],"2028-01-01","2030-01-01","2016-01-07",[10505,10506],"Neurofibromatosis 1 (NF1)","Plexiform Neurofibromas (PN)",[4769],{"nctId":10509,"briefTitle":10510,"status":142,"phases":10511,"primaryCompletion":3315,"completion":3315,"start":5724,"enrollment":484,"conditions":10512,"interventions":10513},"NCT01011933","Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer",[90],[1941,1942,1943,5549],[4769],{"nctId":10515,"briefTitle":10516,"status":142,"phases":10517,"primaryCompletion":2004,"completion":3226,"start":10518,"enrollment":298,"conditions":10519,"interventions":10522},"NCT00588809","Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia",[90],"2007-12",[4045,4049,10520,10521,33,2432],"Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms",[8197],{"nctId":10524,"briefTitle":10525,"status":142,"phases":10526,"primaryCompletion":10527,"completion":10528,"start":10529,"enrollment":3869,"conditions":10530,"interventions":10536},"NCT00551070","Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer",[90],"2013-07-23","2020-11-13","2007-12-17",[10531,10532,10533,1738,10534,10535],"Borderline Ovarian Serous Tumor","Low Grade Ovarian Serous Adenocarcinoma","Micropapillary Serous Carcinoma","Primary Peritoneal Low Grade Serous Adenocarcinoma","Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor",[4769,2708],{"trials":10538,"activeCount":101},[],{"trials":10540,"activeCount":101},[],{"trials":10542,"activeCount":101},[],{"intervention":460,"totalTrials":889,"cells":10544},{"EARLY_PHASE1":10545,"PHASE1":10547,"PHASE2":10549,"PHASE3":10579,"PHASE4":10581,"NA":10583},{"trials":10546,"activeCount":101},[],{"trials":10548,"activeCount":101},[],{"trials":10550,"activeCount":758,"soonestReadout":62},[10551,10555,10563,10567,10571,10575],{"nctId":6052,"briefTitle":6053,"status":618,"phases":10552,"primaryCompletion":6055,"completion":6055,"start":6056,"enrollment":1517,"conditions":10553,"interventions":10554},[89,90],[6058],[6060,6061,460,1139],{"nctId":10556,"briefTitle":10557,"status":142,"phases":10558,"primaryCompletion":8167,"completion":8167,"start":4366,"enrollment":827,"conditions":10559,"interventions":10562},"NCT00971789","Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes",[90],[10560,10561],"Cowden's Disease","Hamartoma Syndrome, Multiple",[1083],{"nctId":1068,"briefTitle":1069,"status":142,"phases":10564,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":10565,"interventions":10566},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":60,"briefTitle":61,"status":155,"phases":10568,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":10569,"interventions":10570},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":1144,"briefTitle":1145,"status":142,"phases":10572,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":37,"conditions":10573,"interventions":10574},[90],[1151,1152,1153],[919,460,63],{"nctId":451,"briefTitle":452,"status":128,"phases":10576,"primaryCompletion":157,"completion":157,"start":454,"enrollment":455,"conditions":10577,"interventions":10578},[89,90],[190,191,192,193,194,457,195,196,197,208,209,210,458],[124,96,212,460],{"trials":10580,"activeCount":101},[],{"trials":10582,"activeCount":101},[],{"trials":10584,"activeCount":101},[],{"intervention":1138,"totalTrials":838,"cells":10586},{"EARLY_PHASE1":10587,"PHASE1":10589,"PHASE2":10595,"PHASE3":10621,"PHASE4":10623,"NA":10625},{"trials":10588,"activeCount":101},[],{"trials":10590,"activeCount":101},[10591],{"nctId":5199,"briefTitle":5200,"status":142,"phases":10592,"primaryCompletion":5202,"completion":550,"start":5203,"enrollment":234,"conditions":10593,"interventions":10594},[89],[3229],[53,1138],{"trials":10596,"activeCount":758,"soonestReadout":62},[10597,10601,10605,10614],{"nctId":2259,"briefTitle":2260,"status":155,"phases":10598,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":10599,"interventions":10600},[90],[902,2267,2268,2269,2270],[1372,1138,1375,1141,2272,212,781,740],{"nctId":60,"briefTitle":61,"status":155,"phases":10602,"primaryCompletion":62,"completion":1126,"start":1127,"enrollment":1128,"conditions":10603,"interventions":10604},[90],[902,1130,1131,1132,1133,1134,1135],[63,1137,1138,1139,737,279,738,1140,1141,1142,212,460,213,740],{"nctId":10606,"briefTitle":10607,"status":142,"phases":10608,"primaryCompletion":10609,"completion":10610,"start":10611,"enrollment":609,"conditions":10612,"interventions":10613},"NCT00423735","Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma",[90],"2011-03-09","2018-09-04","2007-01-24",[4817,4818,4819,4821],[1138],{"nctId":10615,"briefTitle":10616,"status":142,"phases":10617,"primaryCompletion":2004,"completion":2004,"start":4562,"enrollment":638,"conditions":10618,"interventions":10619},"NCT00459342","Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",[90],[7055,3119,1772,3285],[10620],"dasatinib",{"trials":10622,"activeCount":101},[],{"trials":10624,"activeCount":101},[],{"trials":10626,"activeCount":101},[],{"intervention":706,"totalTrials":838,"cells":10628},{"EARLY_PHASE1":10629,"PHASE1":10631,"PHASE2":10645,"PHASE3":10659,"PHASE4":10661,"NA":10663},{"trials":10630,"activeCount":101},[],{"trials":10632,"activeCount":2548,"soonestReadout":2209},[10633,10637,10641],{"nctId":2437,"briefTitle":2438,"status":618,"phases":10634,"primaryCompletion":2440,"completion":2441,"start":756,"enrollment":758,"conditions":10635,"interventions":10636},[89],[915],[2444,2445,2218,710,706,1139],{"nctId":695,"briefTitle":696,"status":618,"phases":10638,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":10639,"interventions":10640},[89],[702],[704,63,705,643,706,707,708,709,710],{"nctId":2206,"briefTitle":2207,"status":155,"phases":10642,"primaryCompletion":2209,"completion":418,"start":2210,"enrollment":2211,"conditions":10643,"interventions":10644},[89],[2213,2214],[2216,212,1016,2217,58,706,2218,2219],{"trials":10646,"activeCount":2548,"soonestReadout":10651},[10647,10655],{"nctId":10648,"briefTitle":10649,"status":155,"phases":10650,"primaryCompletion":10651,"completion":2893,"start":9195,"enrollment":1953,"conditions":10652,"interventions":10654},"NCT06009926","Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters",[90],"2026-02-28",[5919,2681,10653],"Occupational Malignant Neoplasm",[706],{"nctId":5939,"briefTitle":5940,"status":142,"phases":10656,"primaryCompletion":2262,"completion":5942,"start":5943,"enrollment":19,"conditions":10657,"interventions":10658},[89,90],[5945,687,2719],[2256,1407,151,706,5947,2218,1139,5948],{"trials":10660,"activeCount":101},[],{"trials":10662,"activeCount":101},[],{"trials":10664,"activeCount":101},[],{"intervention":2708,"totalTrials":214,"cells":10666},{"EARLY_PHASE1":10667,"PHASE1":10669,"PHASE2":10675,"PHASE3":10695,"PHASE4":10697,"NA":10699},{"trials":10668,"activeCount":101},[],{"trials":10670,"activeCount":2548,"soonestReadout":4764},[10671],{"nctId":4761,"briefTitle":4762,"status":155,"phases":10672,"primaryCompletion":4764,"completion":592,"start":4765,"enrollment":3255,"conditions":10673,"interventions":10674},[89],[195,30,4767,487],[2732,68,4769,2708],{"trials":10676,"activeCount":2548,"soonestReadout":2703},[10677,10681,10691],{"nctId":2700,"briefTitle":2701,"status":128,"phases":10678,"primaryCompletion":2703,"completion":2703,"start":1851,"enrollment":2704,"conditions":10679,"interventions":10680},[90],[2706,250,251,252],[2554,2708],{"nctId":10682,"briefTitle":10683,"status":142,"phases":10684,"primaryCompletion":10685,"completion":10686,"start":10687,"enrollment":771,"conditions":10688,"interventions":10690},"NCT03040986","Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations",[90],"2018-08-10","2020-10-15","2017-07-21",[10689,10336,9522],"KRAS NP_004976.2:p.G12R",[2708],{"nctId":10524,"briefTitle":10525,"status":142,"phases":10692,"primaryCompletion":10527,"completion":10528,"start":10529,"enrollment":3869,"conditions":10693,"interventions":10694},[90],[10531,10532,10533,1738,10534,10535],[4769,2708],{"trials":10696,"activeCount":101},[],{"trials":10698,"activeCount":101},[],{"trials":10700,"activeCount":101},[],{"intervention":9978,"totalTrials":603,"cells":10702},{"EARLY_PHASE1":10703,"PHASE1":10705,"PHASE2":10707,"PHASE3":10731,"PHASE4":10733,"NA":10735},{"trials":10704,"activeCount":101},[],{"trials":10706,"activeCount":101},[],{"trials":10708,"activeCount":758,"soonestReadout":10727},[10709,10713,10723],{"nctId":9967,"briefTitle":9968,"status":128,"phases":10710,"primaryCompletion":284,"completion":284,"start":9970,"enrollment":248,"conditions":10711,"interventions":10712},[90],[5540,9972,9973,9974],[9976,9977,9935,9978],{"nctId":10714,"briefTitle":10715,"status":142,"phases":10716,"primaryCompletion":10717,"completion":10718,"start":1963,"enrollment":3274,"conditions":10719,"interventions":10722},"NCT01621568","Sunitinib for Advanced Thymus Cancer Following Earlier Treatment",[90],"2021-04-30","2024-07-31",[10720,10721],"Thymoma","Thymus Neoplasms",[9978,9978],{"nctId":10724,"briefTitle":10725,"status":155,"phases":10726,"primaryCompletion":10727,"completion":9315,"start":10728,"enrollment":685,"conditions":10729,"interventions":10730},"NCT06390826","Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)",[90],"2023-04-05","2016-11-01",[300,21,119,30,4262],[9978],{"trials":10732,"activeCount":101},[],{"trials":10734,"activeCount":101},[],{"trials":10736,"activeCount":101},[],{"intervention":6251,"totalTrials":758,"cells":10738},{"EARLY_PHASE1":10739,"PHASE1":10741,"PHASE2":10747,"PHASE3":10753,"PHASE4":10755,"NA":10757},{"trials":10740,"activeCount":101},[],{"trials":10742,"activeCount":2548,"soonestReadout":1603},[10743],{"nctId":6244,"briefTitle":6245,"status":155,"phases":10744,"primaryCompletion":1603,"completion":1603,"start":6247,"enrollment":1765,"conditions":10745,"interventions":10746},[89],[2427,2430],[1137,1471,6250,6251],{"trials":10748,"activeCount":2548,"soonestReadout":3019},[10749],{"nctId":7978,"briefTitle":7979,"status":128,"phases":10750,"primaryCompletion":3019,"completion":3019,"start":7981,"enrollment":443,"conditions":10751,"interventions":10752},[89,90],[7983,1465,7984,2596],[5576,6251],{"trials":10754,"activeCount":101},[],{"trials":10756,"activeCount":101},[],{"trials":10758,"activeCount":101},[],{"intervention":10760,"totalTrials":758,"cells":10761},"GVHD Prophylaxis",{"EARLY_PHASE1":10762,"PHASE1":10764,"PHASE2":10766,"PHASE3":10794,"PHASE4":10796,"NA":10798},{"trials":10763,"activeCount":101},[],{"trials":10765,"activeCount":101},[],{"trials":10767,"activeCount":758,"soonestReadout":10785},[10768,10781],{"nctId":10769,"briefTitle":10770,"status":128,"phases":10771,"primaryCompletion":10772,"completion":10773,"start":10774,"enrollment":10775,"conditions":10776,"interventions":10777},"NCT02579967","Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies",[90],"2031-12-31","2036-12-31","2015-11-19",354,[977,976,975,974,973],[10778,10779,10780,10760],"Immunosuppression Only Conditioning -Closed with amendment L","Reduced Intensity Conditioning","Myeloablative Conditioning-Closed with amendment L",{"nctId":10782,"briefTitle":10783,"status":128,"phases":10784,"primaryCompletion":10785,"completion":1837,"start":2737,"enrollment":10786,"conditions":10787,"interventions":10790},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[89,90],"2026-07-30",265,[10788,10789],"HIV","Hematologic Malignancies",[10791,10792,4698,10793],"RIC","GVHD prophylaxis","Maraviroc",{"trials":10795,"activeCount":101},[],{"trials":10797,"activeCount":101},[],{"trials":10799,"activeCount":101},[],{"intervention":4698,"totalTrials":758,"cells":10801},{"EARLY_PHASE1":10802,"PHASE1":10804,"PHASE2":10806,"PHASE3":10816,"PHASE4":10818,"NA":10820},{"trials":10803,"activeCount":101},[],{"trials":10805,"activeCount":101},[],{"trials":10807,"activeCount":758,"soonestReadout":10785},[10808,10812],{"nctId":10782,"briefTitle":10783,"status":128,"phases":10809,"primaryCompletion":10785,"completion":1837,"start":2737,"enrollment":10786,"conditions":10810,"interventions":10811},[89,90],[10788,10789],[10791,10792,4698,10793],{"nctId":4689,"briefTitle":4690,"status":3027,"phases":10813,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":159,"conditions":10814,"interventions":10815},[90],[4695],[4605,4697,1139,1016,1405,4698,4699,4700],{"trials":10817,"activeCount":101},[],{"trials":10819,"activeCount":101},[],{"trials":10821,"activeCount":101},[],{"intervention":5922,"totalTrials":758,"cells":10823},{"EARLY_PHASE1":10824,"PHASE1":10826,"PHASE2":10828,"PHASE3":10842,"PHASE4":10844,"NA":10846},{"trials":10825,"activeCount":101},[],{"trials":10827,"activeCount":101},[],{"trials":10829,"activeCount":758,"soonestReadout":582},[10830,10834],{"nctId":5913,"briefTitle":5914,"status":128,"phases":10831,"primaryCompletion":1477,"completion":1477,"start":5916,"enrollment":16,"conditions":10832,"interventions":10833},[89,90],[21,5918,5919,486,5014,5920,5016],[151,5922],{"nctId":10835,"briefTitle":10836,"status":155,"phases":10837,"primaryCompletion":582,"completion":582,"start":10838,"enrollment":552,"conditions":10839,"interventions":10841},"NCT05828082","Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer",[90],"2023-10-16",[2309,7983,10840,2596],"Refractory Prostate Carcinoma",[5922],{"trials":10843,"activeCount":101},[],{"trials":10845,"activeCount":101},[],{"trials":10847,"activeCount":101},[],{"intervention":2888,"totalTrials":758,"cells":10849},{"EARLY_PHASE1":10850,"PHASE1":10852,"PHASE2":10866,"PHASE3":10872,"PHASE4":10874,"NA":10876},{"trials":10851,"activeCount":101},[],{"trials":10853,"activeCount":2548,"soonestReadout":10858},[10854],{"nctId":10855,"briefTitle":10856,"status":155,"phases":10857,"primaryCompletion":10858,"completion":10858,"start":10859,"enrollment":1517,"conditions":10860,"interventions":10864},"NCT05691504","Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers",[89],"2027-02-01","2023-09-14",[1609,7284,10861,10862,10863,2706,250,2760,252,7289,7292],"Metastatic Fallopian Tube Carcinoma","Metastatic Platinum-Resistant Ovarian Carcinoma","Metastatic Primary Peritoneal Carcinoma",[2888,10865],"Pelcitoclax",{"trials":10867,"activeCount":2548,"soonestReadout":2881},[10868],{"nctId":2878,"briefTitle":2879,"status":155,"phases":10869,"primaryCompletion":2881,"completion":1499,"start":2882,"enrollment":2883,"conditions":10870,"interventions":10871},[90],[2885,2118,2886,1633],[1690,2888],{"trials":10873,"activeCount":101},[],{"trials":10875,"activeCount":101},[],{"trials":10877,"activeCount":101},[],{"intervention":166,"totalTrials":758,"cells":10879},{"EARLY_PHASE1":10880,"PHASE1":10882,"PHASE2":10888,"PHASE3":10894,"PHASE4":10896,"NA":10898},{"trials":10881,"activeCount":101},[],{"trials":10883,"activeCount":2548,"soonestReadout":157},[10884],{"nctId":153,"briefTitle":154,"status":155,"phases":10885,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":10886,"interventions":10887},[89],[161,162,163,164],[166,167,124,96],{"trials":10889,"activeCount":2548,"soonestReadout":3798},[10890],{"nctId":3795,"briefTitle":3796,"status":155,"phases":10891,"primaryCompletion":3798,"completion":1366,"start":3799,"enrollment":3800,"conditions":10892,"interventions":10893},[89,90],[2041],[166,883],{"trials":10895,"activeCount":101},[],{"trials":10897,"activeCount":101},[],{"trials":10899,"activeCount":101},[],{"intervention":10901,"totalTrials":758,"cells":10902},"Sacituzumab Govitecan",{"EARLY_PHASE1":10903,"PHASE1":10905,"PHASE2":10907,"PHASE3":10924,"PHASE4":10926,"NA":10928},{"trials":10904,"activeCount":101},[],{"trials":10906,"activeCount":101},[],{"trials":10908,"activeCount":758,"soonestReadout":2893},[10909,10920],{"nctId":10910,"briefTitle":10911,"status":155,"phases":10912,"primaryCompletion":9923,"completion":10913,"start":10914,"enrollment":638,"conditions":10915,"interventions":10919},"NCT04826341","A Phase I\u002FII Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors",[89,90],"2029-03-01","2021-09-20",[10916,10917,10918],"HRD Cancer","SCLC","Advanced Solid Tumors",[1859,10901],{"nctId":2890,"briefTitle":2891,"status":128,"phases":10921,"primaryCompletion":2893,"completion":2894,"start":2895,"enrollment":1074,"conditions":10922,"interventions":10923},[90],[2897,2898,2899,2900,2901,2902,2903,2904],[2906,1690],{"trials":10925,"activeCount":101},[],{"trials":10927,"activeCount":101},[],{"trials":10929,"activeCount":101},[],{"intervention":10931,"totalTrials":758,"cells":10932},"pacritinib",{"EARLY_PHASE1":10933,"PHASE1":10935,"PHASE2":10937,"PHASE3":10956,"PHASE4":10958,"NA":10960},{"trials":10934,"activeCount":101},[],{"trials":10936,"activeCount":101},[],{"trials":10938,"activeCount":758,"soonestReadout":10950},[10939,10946],{"nctId":10940,"briefTitle":10941,"status":128,"phases":10942,"primaryCompletion":10502,"completion":10943,"start":900,"enrollment":272,"conditions":10944,"interventions":10945},"NCT06303193","Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic\u002FMyeloproliferative Neoplasms",[89,90],"2035-01-01",[10520],[10931],{"nctId":10947,"briefTitle":10948,"status":128,"phases":10949,"primaryCompletion":10950,"completion":10950,"start":10951,"enrollment":234,"conditions":10952,"interventions":10954},"NCT05531786","Phase I\u002FII Study of Pacritinib, A JAK2\u002FIRAK1\u002FCSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[89,90],"2027-07-22","2023-03-06",[10953],"Graft vs Host Disease",[10955],"Pacritinib",{"trials":10957,"activeCount":101},[],{"trials":10959,"activeCount":101},[],{"trials":10961,"activeCount":101},[],{"intervention":10963,"totalTrials":758,"cells":10964},"Crizotinib",{"EARLY_PHASE1":10965,"PHASE1":10967,"PHASE2":10969,"PHASE3":10986,"PHASE4":10988,"NA":10990},{"trials":10966,"activeCount":101},[],{"trials":10968,"activeCount":101},[],{"trials":10970,"activeCount":758,"soonestReadout":10975},[10971,10979],{"nctId":10972,"briefTitle":10973,"status":155,"phases":10974,"primaryCompletion":10975,"completion":10976,"start":9324,"enrollment":838,"conditions":10977,"interventions":10978},"NCT04439266","Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)",[90],"2020-03-20","2027-03-30",[300,21,113,119,30,4262],[10963],{"nctId":10980,"briefTitle":10981,"status":155,"phases":10982,"primaryCompletion":10975,"completion":10983,"start":9324,"enrollment":214,"conditions":10984,"interventions":10985},"NCT04439253","Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)",[90],"2027-03-17",[300,21,113,119,30,4262],[10963],{"trials":10987,"activeCount":101},[],{"trials":10989,"activeCount":101},[],{"trials":10991,"activeCount":101},[],{"intervention":10993,"totalTrials":758,"cells":10994},"Recombinant Human Papillomavirus Nonavalent Vaccine",{"EARLY_PHASE1":10995,"PHASE1":10997,"PHASE2":11009,"PHASE3":11020,"PHASE4":11022,"NA":11024},{"trials":10996,"activeCount":101},[],{"trials":10998,"activeCount":2548,"soonestReadout":10407},[10999],{"nctId":11000,"briefTitle":11001,"status":128,"phases":11002,"primaryCompletion":10407,"completion":11003,"start":11004,"enrollment":827,"conditions":11005,"interventions":11007},"NCT05985681","Testing RG1-VLP Vaccine to Prevent HPV-related Cancers",[89],"2027-06-01","2025-02-27",[11006],"Human Papillomavirus-Related Carcinoma",[11008,10993],"HPV16 RG1 VLP Vaccine",{"trials":11010,"activeCount":2548,"soonestReadout":11015},[11011],{"nctId":11012,"briefTitle":11013,"status":155,"phases":11014,"primaryCompletion":11015,"completion":6852,"start":11016,"enrollment":2883,"conditions":11017,"interventions":11019},"NCT03036930","Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients",[90],"2024-03-04","2017-06-23",[11018,11006],"Human Papillomavirus Infection",[10993],{"trials":11021,"activeCount":101},[],{"trials":11023,"activeCount":101},[],{"trials":11025,"activeCount":101},[],{"intervention":9337,"totalTrials":758,"cells":11027},{"EARLY_PHASE1":11028,"PHASE1":11030,"PHASE2":11032,"PHASE3":11042,"PHASE4":11044,"NA":11046},{"trials":11029,"activeCount":101},[],{"trials":11031,"activeCount":101},[],{"trials":11033,"activeCount":758,"soonestReadout":9331},[11034,11038],{"nctId":9328,"briefTitle":9329,"status":155,"phases":11035,"primaryCompletion":9331,"completion":9331,"start":9332,"enrollment":9333,"conditions":11036,"interventions":11037},[90],[9335,4767,209],[9337,9302],{"nctId":9339,"briefTitle":9340,"status":155,"phases":11039,"primaryCompletion":9342,"completion":9342,"start":9343,"enrollment":16,"conditions":11040,"interventions":11041},[90],[4632,9345,9346,9347,394,395,9348,9349],[9337,9302],{"trials":11043,"activeCount":101},[],{"trials":11045,"activeCount":101},[],{"trials":11047,"activeCount":101},[],{"intervention":4063,"totalTrials":1195,"cells":11049},{"EARLY_PHASE1":11050,"PHASE1":11052,"PHASE2":11103,"PHASE3":11190,"PHASE4":11196,"NA":11198},{"trials":11051,"activeCount":101},[],{"trials":11053,"activeCount":101},[11054,11058,11065,11069,11073,11079,11083,11087,11091],{"nctId":8361,"briefTitle":8362,"status":142,"phases":11055,"primaryCompletion":5724,"completion":5724,"start":5461,"enrollment":1074,"conditions":11056,"interventions":11057},[89],[8365,4641,4777,8366,4778,4780,1183,8367,4178,6503,4789,4790,4662,4791,4665,117,4793,4060,748],[4063,1186],{"nctId":11059,"briefTitle":11060,"status":142,"phases":11061,"primaryCompletion":11062,"start":1426,"enrollment":339,"conditions":11063,"interventions":11064},"NCT00278330","Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia",[89],"2009-10",[4053,1135,33,4616,4060,10423,4132],[1998,4063],{"nctId":4356,"briefTitle":4357,"status":142,"phases":11066,"primaryCompletion":4359,"start":1576,"enrollment":421,"conditions":11067,"interventions":11068},[89],[15],[994,4063],{"nctId":8370,"briefTitle":8371,"status":142,"phases":11070,"primaryCompletion":4811,"start":1329,"enrollment":1041,"conditions":11071,"interventions":11072},[89],[8374,117,8375,8376,8377],[1404,942],{"nctId":11074,"briefTitle":11075,"status":142,"phases":11076,"primaryCompletion":4996,"start":1576,"enrollment":1074,"conditions":11077,"interventions":11078},"NCT00324480","Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors",[89],[15],[1998,4063],{"nctId":6253,"briefTitle":6254,"status":142,"phases":11080,"primaryCompletion":6256,"start":6257,"enrollment":407,"conditions":11081,"interventions":11082},[89],[2426,33,2430,2432,6259,4132],[1137,2435,942],{"nctId":4937,"briefTitle":4938,"status":142,"phases":11084,"primaryCompletion":4929,"start":1819,"enrollment":484,"conditions":11085,"interventions":11086},[89],[4941,4942,4943,4944,4945,4946,15],[4948,1264,4063,3065],{"nctId":4028,"briefTitle":4029,"status":142,"phases":11088,"primaryCompletion":4031,"start":4032,"enrollment":37,"conditions":11089,"interventions":11090},[89],[4034,4035,4036,4037,4038,4039,4040,4041,4042,4043,4044,4045,4046,4047,4048,4049,4050,4051,4052,4053,4054,2453,4055,4056,3625,4057,3628,4058,4059,1135,33,4060,2432,4061],[4063,1187,1080],{"nctId":11092,"briefTitle":11093,"status":142,"phases":11094,"primaryCompletion":4929,"start":1320,"enrollment":310,"conditions":11095,"interventions":11102},"NCT00499811","Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction",[89],[3157,3158,4775,4776,4782,1245,4784,1246,11096,11097,3180,3181,3182,3183,3184,4681,3185,3186,4787,9449,3187,3188,940,3189,3190,4792,655,4795,1248,3200,1333,3201,3202,7597,3203,3204,11098,11099,3205,3206,3207,1059,3208,11100,662,3209,1334,3210,3211,4796,3212,3213,4797,9450,3214,3215,3216,1060,3217,11101,664,15,1251],"Primary Central Nervous System Hodgkin Lymphoma","Primary Central Nervous System Non-Hodgkin Lymphoma","Stage III Adult T-cell Leukemia\u002FLymphoma","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage III Mycosis Fungoides\u002FSezary Syndrome","Stage IV Mycosis Fungoides\u002FSezary Syndrome",[4063],{"trials":11104,"activeCount":2548,"soonestReadout":361},[11105,11117,11133,11137,11141,11149,11155,11161,11167,11171,11178],{"nctId":11106,"briefTitle":11107,"status":155,"phases":11108,"primaryCompletion":361,"completion":361,"start":11109,"enrollment":11110,"conditions":11111,"interventions":11116},"NCT00392353","Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia",[89,90],"2006-11-22",135,[11112,11113,2452,2453,2454,11114,11115,33,4615],"Acute Erythroid Leukemia","Acute Megakaryoblastic Leukemia","Myelodysplastic Syndrome With Excess Blasts","Myelodysplastic Syndrome With Ring Sideroblasts",[6296,942],{"nctId":11118,"briefTitle":11119,"status":142,"phases":11120,"primaryCompletion":11121,"completion":11122,"start":11123,"enrollment":28,"conditions":11124,"interventions":11132},"NCT01175980","Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma",[90],"2018-06-08","2018-08-01","2010-08-06",[11125,2056,11126,11127,11128,2064,11129,2071,11130,2078,11131,1895],"Recurrent Oral Cavity Adenoid Cystic Carcinoma","Salivary Gland Adenoid Cystic Carcinoma","Stage III Major Salivary Gland Cancer AJCC v7","Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7",[942],{"nctId":923,"briefTitle":924,"status":142,"phases":11134,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":11135,"interventions":11136},[89,90],[931,932,933,934,733,935,936,734,937,735,938,939,522,524,527,940],[63,737,279,212,667,740,942],{"nctId":7478,"briefTitle":7479,"status":618,"phases":11138,"primaryCompletion":7481,"completion":7482,"start":1329,"enrollment":37,"conditions":11139,"interventions":11140},[90],[7484,1867,1868,3877,1874,7485,1877,7486,1882,7487,1883,7488,1888,7489,1889,7490,1894],[2924,942],{"nctId":11142,"briefTitle":11143,"status":142,"phases":11144,"primaryCompletion":1275,"completion":1275,"start":3480,"enrollment":2029,"conditions":11145,"interventions":11148},"NCT00132028","Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma",[90],[11146,7583,7584,7585,7586,7587,11147,4681],"Adult Favorable Prognosis Hodgkin Lymphoma","Adult Unfavorable Prognosis Hodgkin Lymphoma",[4063],{"nctId":11150,"briefTitle":11151,"status":142,"phases":11152,"primaryCompletion":5270,"completion":1299,"start":4611,"enrollment":455,"conditions":11153,"interventions":11154},"NCT00937495","Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma",[90],[10227,10228,1096],[4063,1062],{"nctId":11156,"briefTitle":11157,"status":142,"phases":11158,"primaryCompletion":649,"completion":3479,"start":4366,"enrollment":1913,"conditions":11159,"interventions":11160},"NCT00641706","Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme",[90],[4817,4818,4819,5287],[4063,1062],{"nctId":11162,"briefTitle":11163,"status":142,"phases":11164,"primaryCompletion":5724,"completion":6569,"start":1576,"enrollment":1041,"conditions":11165,"interventions":11166},"NCT00330161","Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer",[90],[2321,2297],[4063],{"nctId":8386,"briefTitle":8387,"status":618,"phases":11168,"primaryCompletion":1230,"completion":6303,"start":1576,"enrollment":2211,"conditions":11169,"interventions":11170},[89,90],[5233,4826,4842],[4063,1186],{"nctId":11172,"briefTitle":11173,"status":142,"phases":11174,"primaryCompletion":1275,"completion":1022,"start":1426,"enrollment":19,"conditions":11175,"interventions":11177},"NCT00305773","Vorinostat in Treating Patients With Acute Myeloid Leukemia",[90],[11176,4037,4038,4039,4040,4041,4042,4043,4044,4045,4046,4047,4048,4049,33,4618,2432,4132],"Adult Acute Erythroid Leukemia (M6)",[4063,4063],{"nctId":11179,"briefTitle":11180,"status":142,"phases":11181,"primaryCompletion":1310,"completion":1310,"start":4860,"enrollment":3255,"conditions":11182,"interventions":11189},"NCT00134043","Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and\u002For Locally Advanced or Locally Recurrent Thyroid Cancer",[90],[11183,10271,11184,11185,11186,11187,11188],"Insular Thyroid Cancer","Stage II Follicular Thyroid Cancer","Stage II Papillary Thyroid Cancer","Stage IV Follicular Thyroid Cancer","Stage IV Papillary Thyroid Cancer","Thyroid Gland Medullary Carcinoma",[4063],{"trials":11191,"activeCount":101},[11192],{"nctId":5607,"briefTitle":5608,"status":142,"phases":11193,"primaryCompletion":5610,"completion":5611,"start":2028,"enrollment":5612,"conditions":11194,"interventions":11195},[90,91],[5614,5615,5616,5361,5362],[53,151,942],{"trials":11197,"activeCount":101},[],{"trials":11199,"activeCount":101},[],{"intervention":11201,"totalTrials":758,"cells":11202},"Tamoxifen",{"EARLY_PHASE1":11203,"PHASE1":11205,"PHASE2":11207,"PHASE3":11219,"PHASE4":11225,"NA":11227},{"trials":11204,"activeCount":101},[],{"trials":11206,"activeCount":101},[],{"trials":11208,"activeCount":2548,"soonestReadout":582},[11209],{"nctId":11210,"briefTitle":11211,"status":128,"phases":11212,"primaryCompletion":582,"completion":10501,"start":258,"enrollment":971,"conditions":11213,"interventions":11217},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[90],[11214,9043,11215,11216],"Breast Atypical Hyperplasia","Breast Ductal Carcinoma In Situ","Breast Lobular Carcinoma In Situ",[11218,11201],"Omega-3-Acid Ethyl Esters",{"trials":11220,"activeCount":101},[11221],{"nctId":1409,"briefTitle":1410,"status":142,"phases":11222,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":1074,"conditions":11223,"interventions":11224},[91],[1416,18,1417,63,780],[780,63,1419,1420,1421],{"trials":11226,"activeCount":101},[],{"trials":11228,"activeCount":101},[],{"intervention":677,"totalTrials":25,"cells":11230},{"EARLY_PHASE1":11231,"PHASE1":11233,"PHASE2":11271,"PHASE3":11397,"PHASE4":11399,"NA":11401},{"trials":11232,"activeCount":101},[],{"trials":11234,"activeCount":101},[11235,11242,11249,11261,11265],{"nctId":11236,"briefTitle":11237,"status":618,"phases":11238,"primaryCompletion":4031,"completion":4031,"start":1763,"enrollment":603,"conditions":11239,"interventions":11240},"NCT00923806","Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer",[89],[869],[11241,677],"PG13-CEA_TCR",{"nctId":11243,"briefTitle":11244,"status":618,"phases":11245,"primaryCompletion":1275,"start":11246,"enrollment":421,"conditions":11247,"interventions":11248},"NCT00054405","Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma",[89],"2002-12",[117],[3123,818],{"nctId":11250,"briefTitle":11251,"status":618,"phases":11252,"primaryCompletion":4954,"completion":11253,"start":11254,"enrollment":2548,"conditions":11255,"interventions":11259},"NCT03197025","Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions",[89],"2020-10-16","2018-01-09",[11256,11257,11258],"Human Papillomavirus","HPV-16","High Grade Squamous Intraepithelial Lesion",[677,11260],"E6 T Cell Receptor",{"nctId":669,"briefTitle":670,"status":107,"phases":11262,"primaryCompletion":672,"completion":672,"start":673,"enrollment":101,"conditions":11263,"interventions":11264},[89],[195],[676,63,643,677],{"nctId":11266,"briefTitle":11267,"status":142,"phases":11268,"primaryCompletion":4272,"start":1979,"enrollment":37,"conditions":11269,"interventions":11270},"NCT00005604","Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors",[89],[15],[3123,818],{"trials":11272,"activeCount":2548,"soonestReadout":232},[11273,11277,11285,11289,11293,11297,11301,11305,11309,11313,11317,11321,11325,11329,11333,11341,11345,11352,11356,11362,11368,11372,11379,11383,11387,11393],{"nctId":809,"briefTitle":810,"status":142,"phases":11274,"primaryCompletion":812,"completion":812,"start":813,"enrollment":188,"conditions":11275,"interventions":11276},[90],[815],[817,818,750,693,819],{"nctId":11278,"briefTitle":11279,"status":3060,"phases":11280,"start":1427,"enrollment":443,"conditions":11281,"interventions":11283},"NCT00002589","Lymphocyte Therapy in Treating Patients With Kidney Cancer",[90],[11282],"Kidney Cancer",[818,11284,1346],"muromonab-CD3",{"nctId":833,"briefTitle":834,"status":618,"phases":11286,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":11287,"interventions":11288},[89,90],[840,841,842,843,844],[63,643,677,846],{"nctId":848,"briefTitle":849,"status":107,"phases":11290,"primaryCompletion":851,"completion":851,"start":851,"enrollment":101,"conditions":11291,"interventions":11292},[90],[853,841,802,854,855,856,857,858],[860,677,643,63],{"nctId":862,"briefTitle":863,"status":618,"phases":11294,"primaryCompletion":865,"completion":866,"start":867,"enrollment":339,"conditions":11295,"interventions":11296},[89,90],[869,195,870],[872,63,677,643],{"nctId":874,"briefTitle":875,"status":128,"phases":11298,"primaryCompletion":232,"completion":877,"start":878,"enrollment":879,"conditions":11299,"interventions":11300},[90],[36],[882,883,677,643,63],{"nctId":885,"briefTitle":886,"status":618,"phases":11302,"primaryCompletion":621,"completion":621,"start":888,"enrollment":889,"conditions":11303,"interventions":11304},[90],[36,891],[677,643,63,893],{"nctId":10360,"briefTitle":10361,"status":142,"phases":11306,"completion":745,"start":4232,"conditions":11307,"interventions":11308},[90],[2490],[818,1349,993,10365,10366],{"nctId":2484,"briefTitle":2485,"status":142,"phases":11310,"completion":2487,"start":1172,"conditions":11311,"interventions":11312},[89,90],[2489,2490],[818,2445],{"nctId":944,"briefTitle":945,"status":142,"phases":11314,"primaryCompletion":947,"completion":947,"start":948,"enrollment":949,"conditions":11315,"interventions":11316},[90],[195,891],[677,63,643,952],{"nctId":954,"briefTitle":955,"status":618,"phases":11318,"primaryCompletion":957,"completion":957,"start":958,"enrollment":603,"conditions":11319,"interventions":11320},[89,90],[18,960,870,36,961],[677,643,63,963],{"nctId":997,"briefTitle":998,"status":618,"phases":11322,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":310,"conditions":11323,"interventions":11324},[89,90],[960,841,1003,915,687],[643,1005,63,677],{"nctId":1035,"briefTitle":1036,"status":142,"phases":11326,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":11327,"interventions":11328},[90],[960,1043,1044,1045,1046],[643,63,952,677],{"nctId":1116,"briefTitle":1117,"status":142,"phases":11330,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":188,"conditions":11331,"interventions":11332},[89,90],[1044,960,1045,1046,1043],[643,63,1123,677],{"nctId":11334,"briefTitle":11335,"status":142,"phases":11336,"completion":1341,"start":11337,"conditions":11338,"interventions":11339},"NCT00019591","Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer",[89,90],"1999-03",[856],[818,11340],"ras peptide cancer vaccine",{"nctId":10384,"briefTitle":10385,"status":142,"phases":11342,"primaryCompletion":3526,"start":10387,"conditions":11343,"interventions":11344},[90],[24],[818,10390,10391,10392,993,10393],{"nctId":11346,"briefTitle":11347,"status":142,"phases":11348,"completion":3397,"start":6477,"conditions":11349,"interventions":11350},"NCT00021164","Vaccine Therapy in Treating Patients With Metastatic Cancer",[90],[2490,15],[818,1349,11351],"telomerase: 540-548 peptide vaccine",{"nctId":1190,"briefTitle":1191,"status":142,"phases":11353,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1195,"conditions":11354,"interventions":11355},[89,90],[960,870,1197,36,18],[1199,63,643,677],{"nctId":11357,"briefTitle":11358,"status":142,"phases":11359,"primaryCompletion":4272,"start":6478,"enrollment":19,"conditions":11360,"interventions":11361},"NCT00006228","Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer",[90],[3297,1219,3117,3137],[3122,818],{"nctId":11363,"briefTitle":11364,"status":142,"phases":11365,"completion":987,"start":5004,"conditions":11366,"interventions":11367},"NCT00020358","Vaccine Therapy in Treating Patients With Melanoma",[90],[2490],[818,1347,1349,10365],{"nctId":1227,"briefTitle":1228,"status":618,"phases":11369,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":603,"conditions":11370,"interventions":11371},[90],[195,891],[693,819,677,1234,1235],{"nctId":11373,"briefTitle":11374,"status":142,"phases":11375,"primaryCompletion":2004,"completion":2004,"start":650,"enrollment":188,"conditions":11376,"interventions":11377},"NCT01118091","Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...",[90],[891,36,195],[677,11378],"CD8 enriched Young TIL",{"nctId":5559,"briefTitle":5560,"status":142,"phases":11380,"primaryCompletion":4359,"completion":5562,"start":4612,"enrollment":3255,"conditions":11381,"interventions":11382},[90],[4825,4842],[677,53],{"nctId":1315,"briefTitle":1316,"status":142,"phases":11384,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":339,"conditions":11385,"interventions":11386},[90],[36,891],[1323,63,643,677,1324],{"nctId":11388,"briefTitle":11389,"status":142,"phases":11390,"completion":3587,"start":1952,"conditions":11391,"interventions":11392},"NCT00072085","Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma",[90],[2490],[818,1347,1349],{"nctId":1337,"briefTitle":1338,"status":618,"phases":11394,"primaryCompletion":1340,"start":1341,"enrollment":16,"conditions":11395,"interventions":11396},[90],[1343,1344],[693,819,1346,1347,1348,1349,750,818],{"trials":11398,"activeCount":101},[],{"trials":11400,"activeCount":101},[],{"trials":11402,"activeCount":101},[],{"intervention":474,"totalTrials":651,"cells":11404},{"EARLY_PHASE1":11405,"PHASE1":11407,"PHASE2":11438,"PHASE3":11478,"PHASE4":11480,"NA":11482},{"trials":11406,"activeCount":101},[],{"trials":11408,"activeCount":101},[11409,11426,11430],{"nctId":11410,"briefTitle":11411,"status":107,"phases":11412,"primaryCompletion":11413,"completion":11413,"start":11413,"enrollment":101,"conditions":11414,"interventions":11424},"NCT03925428","Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas",[89],"2020-09-18",[300,21,11415,11416,11417,11418,535,119,30,11419,11420,162,11421,11422,163,164,11423],"Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma","Refractory Pancreatic Carcinoma","Refractory T-Cell Non-Hodgkin Lymphoma","Stage IIA Pancreatic Cancer AJCC v8","Stage IIB Pancreatic Cancer AJCC v8","Unresectable Pancreatic Carcinoma",[474,11425],"Molibresib",{"nctId":2837,"briefTitle":2838,"status":142,"phases":11427,"primaryCompletion":2840,"completion":2841,"start":2842,"enrollment":603,"conditions":11428,"interventions":11429},[89],[274,2681,2844],[1690,277,474,279],{"nctId":11431,"briefTitle":11432,"status":142,"phases":11433,"primaryCompletion":11434,"completion":11434,"start":9770,"enrollment":19,"conditions":11435,"interventions":11437},"NCT01434303","Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",[89],"2016-02-16",[11436,3909,2613,3082],"HER2\u002FNeu Positive",[474,7509,1455],{"trials":11439,"activeCount":2548,"soonestReadout":4693},[11440,11449,11457,11461,11465,11474],{"nctId":11441,"briefTitle":11442,"status":142,"phases":11443,"primaryCompletion":6303,"completion":5985,"start":2487,"enrollment":11444,"conditions":11445,"interventions":11446},"NCT00387465","Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer",[89,90],94,[3320,4828,4833,3321],[11447,474,11448],"Azacitidine 30mg\u002Fm2","Azacitidine 40mg\u002Fm2",{"nctId":11450,"briefTitle":11451,"status":128,"phases":11452,"primaryCompletion":4693,"completion":4693,"start":3425,"enrollment":3800,"conditions":11453,"interventions":11456},"NCT05053971","Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors",[89,90],[21,11454,11455,30,11419,162,163,164,11423],"Locally Advanced Pancreatic Carcinoma","Metastatic Pancreatic Carcinoma",[8236,474],{"nctId":7043,"briefTitle":7044,"status":618,"phases":11458,"primaryCompletion":7046,"completion":7046,"start":7047,"enrollment":407,"conditions":11459,"interventions":11460},[90],[3320,4828,4833,3321],[6296,6296,2083,474,167,1102,2045],{"nctId":462,"briefTitle":463,"status":107,"phases":11462,"primaryCompletion":465,"completion":465,"start":465,"enrollment":101,"conditions":11463,"interventions":11464},[89,90],[467,468,469,470,471,472],[96,474,475,476],{"nctId":11466,"briefTitle":11467,"status":142,"phases":11468,"primaryCompletion":11469,"completion":11470,"start":11471,"enrollment":16,"conditions":11472,"interventions":11473},"NCT01349959","Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer",[90],"2014-03-27","2023-11-07","2011-08-15",[3135,2613,3081,3082,1637],[6296,474],{"nctId":10418,"briefTitle":10419,"status":142,"phases":11475,"primaryCompletion":1240,"completion":1240,"start":1217,"enrollment":339,"conditions":11476,"interventions":11477},[90],[10422,4037,4038,4039,4040,4041,4042,4043,4044,4046,4047,4048,4050,4051,2453,4056,4057,4058,1135,33,4615,4616,4617,4618,2432,4061,10423,4132],[10425,993],{"trials":11479,"activeCount":101},[],{"trials":11481,"activeCount":101},[],{"trials":11483,"activeCount":101},[],{"intervention":1710,"totalTrials":1024,"cells":11485},{"EARLY_PHASE1":11486,"PHASE1":11488,"PHASE2":11522,"PHASE3":11540,"PHASE4":11542,"NA":11544},{"trials":11487,"activeCount":101},[],{"trials":11489,"activeCount":101},[11490,11499,11510,11518],{"nctId":11491,"briefTitle":11492,"status":142,"phases":11493,"primaryCompletion":11494,"completion":11494,"start":11495,"enrollment":1953,"conditions":11496,"interventions":11498},"NCT01273155","Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction",[89],"2017-10-25","2011-01-10",[467,11497],"Lymphomas",[1710],{"nctId":11500,"briefTitle":11501,"status":618,"phases":11502,"primaryCompletion":11503,"completion":11503,"start":11504,"enrollment":552,"conditions":11505,"interventions":11509},"NCT02381548","Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia",[89],"2018-05-23","2015-08-18",[263,6272,11506,2454,33,11507,2430,11508,2432],"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive","Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive",[1555,1710],{"nctId":11511,"briefTitle":11512,"status":618,"phases":11513,"primaryCompletion":1023,"start":4032,"enrollment":700,"conditions":11514,"interventions":11516},"NCT00354185","PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma",[89],[3158,4775,4776,1245,4784,1246,11515,3180,3181,3182,3183,3184,4681,3185,3186,4787,9449,3187,3188,940,3189,3190,4792,655,4795,1248,3200,1333,3201,3202,7597,3203,3204,11098,11099,3205,3206,3207,1059,3208,11100,662,3209,1334,3210,3211,4796,3212,3213,4797,9450,3214,3215,3216,1060,3217,11101,664,15,1251],"Post-transplant Lymphoproliferative Disorder",[6287,11517],"belinostat",{"nctId":1699,"briefTitle":1700,"status":142,"phases":11519,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":31,"conditions":11520,"interventions":11521},[89],[1706,1707,1708],[1710,278,279],{"trials":11523,"activeCount":2548,"soonestReadout":1837},[11524,11528,11534],{"nctId":1834,"briefTitle":1835,"status":128,"phases":11525,"primaryCompletion":1837,"completion":1838,"start":900,"enrollment":1074,"conditions":11526,"interventions":11527},[90],[1840,1841,1842,1843,1844],[1710,278,279],{"nctId":11529,"briefTitle":11530,"status":142,"phases":11531,"primaryCompletion":5270,"completion":8167,"start":4032,"enrollment":484,"conditions":11532,"interventions":11533},"NCT00321594","Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery",[89,90],[4862,4863,4864,4890],[11517],{"nctId":11535,"briefTitle":11536,"status":142,"phases":11537,"primaryCompletion":1171,"completion":649,"start":4032,"enrollment":188,"conditions":11538,"interventions":11539},"NCT00357032","PXD101 in Treating Patients With Acute Myeloid Leukemia",[90],[4043,4167,4044,4045,4046,4047,33,4132],[11517],{"trials":11541,"activeCount":101},[],{"trials":11543,"activeCount":101},[],{"trials":11545,"activeCount":101},[],{"intervention":1814,"totalTrials":838,"cells":11547},{"EARLY_PHASE1":11548,"PHASE1":11550,"PHASE2":11559,"PHASE3":11585,"PHASE4":11587,"NA":11589},{"trials":11549,"activeCount":101},[],{"trials":11551,"activeCount":101},[11552],{"nctId":11553,"briefTitle":11554,"status":618,"phases":11555,"primaryCompletion":4714,"completion":4714,"start":11556,"enrollment":2577,"conditions":11557,"interventions":11558},"NCT01071564","RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery",[89],"2009-11",[3132,3134,3136,2613,1222,1223,3137,1637],[4849,1814],{"trials":11560,"activeCount":2548,"soonestReadout":11565},[11561,11569,11573,11577],{"nctId":11562,"briefTitle":11563,"status":155,"phases":11564,"primaryCompletion":11565,"completion":361,"start":11566,"enrollment":1798,"conditions":11567,"interventions":11568},"NCT06357988","Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)",[90],"2022-11-04","2016-06-20",[300,21,5919,119,30,4262],[1814],{"nctId":1804,"briefTitle":1805,"status":142,"phases":11570,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":11571,"interventions":11572},[90],[1811,1812],[278,1099,279,1814],{"nctId":9515,"briefTitle":9516,"status":142,"phases":11574,"primaryCompletion":9518,"completion":8414,"start":9519,"enrollment":9520,"conditions":11575,"interventions":11576},[90],[161,3332,9522],[167,1814],{"nctId":11578,"briefTitle":11579,"status":142,"phases":11580,"primaryCompletion":7047,"completion":11581,"start":4611,"enrollment":25,"conditions":11582,"interventions":11584},"NCT00939484","Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma",[90],"2015-08",[11583],"Adult Medulloblastoma",[1814],{"trials":11586,"activeCount":101},[],{"trials":11588,"activeCount":101},[],{"trials":11590,"activeCount":101},[],{"intervention":6296,"totalTrials":838,"cells":11592},{"EARLY_PHASE1":11593,"PHASE1":11595,"PHASE2":11601,"PHASE3":11623,"PHASE4":11625,"NA":11627},{"trials":11594,"activeCount":101},[],{"trials":11596,"activeCount":101},[11597],{"nctId":6289,"briefTitle":6290,"status":142,"phases":11598,"primaryCompletion":6292,"completion":6292,"start":6293,"enrollment":339,"conditions":11599,"interventions":11600},[89],[33,2430],[6296,1137,1471,6250],{"trials":11602,"activeCount":2548,"soonestReadout":361},[11603,11607,11615,11619],{"nctId":11106,"briefTitle":11107,"status":155,"phases":11604,"primaryCompletion":361,"completion":361,"start":11109,"enrollment":11110,"conditions":11605,"interventions":11606},[89,90],[11112,11113,2452,2453,2454,11114,11115,33,4615],[6296,942],{"nctId":11608,"briefTitle":11609,"status":107,"phases":11610,"primaryCompletion":11611,"completion":11611,"start":11612,"enrollment":101,"conditions":11613,"interventions":11614},"NCT03745352","Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90],"2021-08-19","2019-05-20",[2427,2430],[6296,3376],{"nctId":7043,"briefTitle":7044,"status":618,"phases":11616,"primaryCompletion":7046,"completion":7046,"start":7047,"enrollment":407,"conditions":11617,"interventions":11618},[90],[3320,4828,4833,3321],[6296,6296,2083,474,167,1102,2045],{"nctId":11466,"briefTitle":11467,"status":142,"phases":11620,"primaryCompletion":11469,"completion":11470,"start":11471,"enrollment":16,"conditions":11621,"interventions":11622},[90],[3135,2613,3081,3082,1637],[6296,474],{"trials":11624,"activeCount":101},[],{"trials":11626,"activeCount":101},[],{"trials":11628,"activeCount":101},[],{"intervention":5747,"totalTrials":214,"cells":11630},{"EARLY_PHASE1":11631,"PHASE1":11633,"PHASE2":11648,"PHASE3":11665,"PHASE4":11667,"NA":11669},{"trials":11632,"activeCount":101},[],{"trials":11634,"activeCount":101},[11635],{"nctId":11636,"briefTitle":11637,"status":142,"phases":11638,"primaryCompletion":11639,"completion":11639,"start":11640,"enrollment":375,"conditions":11641,"interventions":11646},"NCT02689453","Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)",[89],"2021-06-15","2017-01-19",[11642,829,11643,11644,11645],"T-Cell Lymphoma Relapsed","Peripheral T-Cell Lymphoma (PTCL)","Cutaneous T Cell Lymphoma (CTCL)","T-Cell Prolymphocytic Leukemia",[11647,5747],"IL-15 plus",{"trials":11649,"activeCount":2548,"soonestReadout":968},[11650,11654,11658],{"nctId":965,"briefTitle":966,"status":128,"phases":11651,"primaryCompletion":968,"completion":969,"start":970,"enrollment":971,"conditions":11652,"interventions":11653},[90],[973,974,975,976,977],[979,643,980,981,213,982,63],{"nctId":5742,"briefTitle":5743,"status":142,"phases":11655,"primaryCompletion":1230,"completion":1230,"start":3526,"enrollment":949,"conditions":11656,"interventions":11657},[90],[5663,657,659,661,663],[5747,1063,819],{"nctId":11659,"briefTitle":11660,"status":142,"phases":11661,"primaryCompletion":1171,"completion":1319,"start":9425,"enrollment":1041,"conditions":11662,"interventions":11664},"NCT00061048","Campath-1H for Treating Adult T-Cell Leukemia\u002FLymphoma",[90],[11663],"Acute T-Cell Leukemia-Lymphoma",[981],{"trials":11666,"activeCount":101},[],{"trials":11668,"activeCount":101},[],{"trials":11670,"activeCount":101},[],{"intervention":11672,"totalTrials":603,"cells":11673},"Aspirin",{"EARLY_PHASE1":11674,"PHASE1":11676,"PHASE2":11678,"PHASE3":11710,"PHASE4":11712,"NA":11714},{"trials":11675,"activeCount":101},[],{"trials":11677,"activeCount":101},[],{"trials":11679,"activeCount":2548,"soonestReadout":11684},[11680,11689,11700],{"nctId":11681,"briefTitle":11682,"status":155,"phases":11683,"primaryCompletion":11684,"completion":10976,"start":3076,"enrollment":1195,"conditions":11685,"interventions":11688},"NCT02521285","Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation",[90],"2019-06-18",[11686,11687],"Barrett Esophagus","Esophageal Adenocarcinoma",[11672],{"nctId":11690,"briefTitle":11691,"status":142,"phases":11692,"primaryCompletion":11693,"completion":11694,"start":11695,"enrollment":2346,"conditions":11696,"interventions":11698},"NCT02348203","Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers",[90],"2019-02-22","2021-03-09","2016-01-13",[11697],"Tobacco Use Disorder",[11672,11699],"Zileuton",{"nctId":11701,"briefTitle":11702,"status":142,"phases":11703,"primaryCompletion":11704,"completion":7652,"start":11705,"enrollment":929,"conditions":11706,"interventions":11708},"NCT00983580","Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer",[90],"2016-10-07","2009-08-20",[11707],"Adenomatous Polyp",[11672,11709],"Eflornithine",{"trials":11711,"activeCount":101},[],{"trials":11713,"activeCount":101},[],{"trials":11715,"activeCount":101},[],{"intervention":952,"totalTrials":603,"cells":11717},{"EARLY_PHASE1":11718,"PHASE1":11720,"PHASE2":11722,"PHASE3":11736,"PHASE4":11738,"NA":11740},{"trials":11719,"activeCount":101},[],{"trials":11721,"activeCount":101},[],{"trials":11723,"activeCount":2548,"soonestReadout":232},[11724,11728,11732],{"nctId":874,"briefTitle":875,"status":128,"phases":11725,"primaryCompletion":232,"completion":877,"start":878,"enrollment":879,"conditions":11726,"interventions":11727},[90],[36],[882,883,677,643,63],{"nctId":944,"briefTitle":945,"status":142,"phases":11729,"primaryCompletion":947,"completion":947,"start":948,"enrollment":949,"conditions":11730,"interventions":11731},[90],[195,891],[677,63,643,952],{"nctId":1035,"briefTitle":1036,"status":142,"phases":11733,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":11734,"interventions":11735},[90],[960,1043,1044,1045,1046],[643,63,952,677],{"trials":11737,"activeCount":101},[],{"trials":11739,"activeCount":101},[],{"trials":11741,"activeCount":101},[],{"intervention":4967,"totalTrials":758,"cells":11743},{"EARLY_PHASE1":11744,"PHASE1":11746,"PHASE2":11752,"PHASE3":11769,"PHASE4":11771,"NA":11773},{"trials":11745,"activeCount":101},[],{"trials":11747,"activeCount":101},[11748],{"nctId":4950,"briefTitle":4951,"status":618,"phases":11749,"primaryCompletion":4953,"completion":4953,"start":4954,"enrollment":603,"conditions":11750,"interventions":11751},[89],[364,4956,4957,4958,4959,4960,4961,4962,4963,4964],[2924,2084,4966,2925,4967],{"trials":11753,"activeCount":2548,"soonestReadout":11758},[11754],{"nctId":11755,"briefTitle":11756,"status":155,"phases":11757,"primaryCompletion":11758,"completion":11758,"start":11759,"enrollment":421,"conditions":11760,"interventions":11768},"NCT02923778","Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery",[90],"2026-12-29","2019-12-31",[4462,4463,11761,11762,11763,11764,11765,11766,11767],"Sarcoma G2","Sarcoma G3","Soft Tissue Sarcoma","Soft Tissue Sarcoma of the Trunk and Extremities","Stage I Soft Tissue Sarcoma AJCC v7","Stage II Soft Tissue Sarcoma AJCC v7","Undifferentiated Pleomorphic Sarcoma",[4967],{"trials":11770,"activeCount":101},[],{"trials":11772,"activeCount":101},[],{"trials":11774,"activeCount":101},[],{"intervention":2257,"totalTrials":758,"cells":11776},{"EARLY_PHASE1":11777,"PHASE1":11779,"PHASE2":11792,"PHASE3":11798,"PHASE4":11800,"NA":11802},{"trials":11778,"activeCount":101},[],{"trials":11780,"activeCount":101},[11781],{"nctId":11782,"briefTitle":11783,"status":142,"phases":11784,"primaryCompletion":11785,"completion":11786,"start":11787,"enrollment":28,"conditions":11788,"interventions":11791},"NCT03388619","Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy",[89],"2023-12-29","2025-12-04","2018-01-17",[2252,2253,24,11789,11790],"Neoplasms of Prostate","Prostatic Cancer",[2257],{"trials":11793,"activeCount":2548,"soonestReadout":361},[11794],{"nctId":2246,"briefTitle":2247,"status":128,"phases":11795,"primaryCompletion":361,"completion":361,"start":2249,"enrollment":2250,"conditions":11796,"interventions":11797},[89,90],[2252,2253],[2255,2083,2256,212,2257],{"trials":11799,"activeCount":101},[],{"trials":11801,"activeCount":101},[],{"trials":11803,"activeCount":101},[],{"intervention":3249,"totalTrials":758,"cells":11805},{"EARLY_PHASE1":11806,"PHASE1":11808,"PHASE2":11810,"PHASE3":11820,"PHASE4":11822,"NA":11824},{"trials":11807,"activeCount":101},[],{"trials":11809,"activeCount":101},[],{"trials":11811,"activeCount":2548,"soonestReadout":2930},[11812,11816],{"nctId":3241,"briefTitle":3242,"status":347,"phases":11813,"primaryCompletion":3244,"completion":3244,"start":3245,"enrollment":97,"conditions":11814,"interventions":11815},[90],[3247,486,487],[3249,449],{"nctId":3865,"briefTitle":3866,"status":155,"phases":11817,"primaryCompletion":2930,"completion":2930,"start":3868,"enrollment":3869,"conditions":11818,"interventions":11819},[90],[3837,3871,3872,3873,3874,3875,3876,1867,1868,3877,1874,3878,3879,3880,3881],[3249,883],{"trials":11821,"activeCount":101},[],{"trials":11823,"activeCount":101},[],{"trials":11825,"activeCount":101},[],{"intervention":9977,"totalTrials":758,"cells":11827},{"EARLY_PHASE1":11828,"PHASE1":11830,"PHASE2":11832,"PHASE3":11845,"PHASE4":11847,"NA":11849},{"trials":11829,"activeCount":101},[],{"trials":11831,"activeCount":101},[],{"trials":11833,"activeCount":2548,"soonestReadout":284},[11834,11838],{"nctId":9967,"briefTitle":9968,"status":128,"phases":11835,"primaryCompletion":284,"completion":284,"start":9970,"enrollment":248,"conditions":11836,"interventions":11837},[90],[5540,9972,9973,9974],[9976,9977,9935,9978],{"nctId":11839,"briefTitle":11840,"status":142,"phases":11841,"primaryCompletion":6513,"completion":6513,"start":3129,"enrollment":2211,"conditions":11842,"interventions":11843},"NCT01281865","Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma",[89,90],[10226,10227,10228,1096],[11844,5456],"everolimus",{"trials":11846,"activeCount":101},[],{"trials":11848,"activeCount":101},[],{"trials":11850,"activeCount":101},[],{"intervention":11852,"totalTrials":758,"cells":11853},"N-803",{"EARLY_PHASE1":11854,"PHASE1":11856,"PHASE2":11858,"PHASE3":11885,"PHASE4":11887,"NA":11889},{"trials":11855,"activeCount":101},[],{"trials":11857,"activeCount":101},[],{"trials":11859,"activeCount":2548,"soonestReadout":11864},[11860,11873],{"nctId":11861,"briefTitle":11862,"status":3027,"phases":11863,"primaryCompletion":11864,"completion":11865,"start":900,"enrollment":3869,"conditions":11866,"interventions":11871},"NCT07574541","Multitargeted Recombinant Ad5 PSA\u002FMUC-1\u002FBrachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance",[90],"2027-06-15","2028-06-15",[11867,24,467,11868,11869,11870],"Adenocarcinoma","Carcinoma","Neoplasms, Glandular and Epithelial","Neoplasms by Histologic Type",[11872,11852],"TriAdeno vaccine",{"nctId":11874,"briefTitle":11875,"status":347,"phases":11876,"primaryCompletion":11877,"completion":11878,"start":900,"enrollment":28,"conditions":11879,"interventions":11883},"NCT05642195","Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer",[89,90],"2033-12-30","2035-12-30",[11880,11881,6058,11882],"Non-Small Cell Lung Cancer","Non-Small Cell Lung Carcinoma","Carcinomas",[11884,476,11852],"Montanide (Registered Trademark) ISA-51 VG Adjuvant",{"trials":11886,"activeCount":101},[],{"trials":11888,"activeCount":101},[],{"trials":11890,"activeCount":101},[],{"intervention":1859,"totalTrials":758,"cells":11892},{"EARLY_PHASE1":11893,"PHASE1":11895,"PHASE2":11897,"PHASE3":11907,"PHASE4":11909,"NA":11911},{"trials":11894,"activeCount":101},[],{"trials":11896,"activeCount":101},[],{"trials":11898,"activeCount":2548,"soonestReadout":9923},[11899,11903],{"nctId":1847,"briefTitle":1848,"status":142,"phases":11900,"primaryCompletion":1850,"completion":1851,"start":787,"enrollment":1852,"conditions":11901,"interventions":11902},[90],[1854,1855,1856,1857],[1859,278,167],{"nctId":10910,"briefTitle":10911,"status":155,"phases":11904,"primaryCompletion":9923,"completion":10913,"start":10914,"enrollment":638,"conditions":11905,"interventions":11906},[89,90],[10916,10917,10918],[1859,10901],{"trials":11908,"activeCount":101},[],{"trials":11910,"activeCount":101},[],{"trials":11912,"activeCount":101},[],{"intervention":290,"totalTrials":758,"cells":11914},{"EARLY_PHASE1":11915,"PHASE1":11917,"PHASE2":11919,"PHASE3":11929,"PHASE4":11931,"NA":11933},{"trials":11916,"activeCount":101},[],{"trials":11918,"activeCount":101},[],{"trials":11920,"activeCount":2548,"soonestReadout":284},[11921,11925],{"nctId":281,"briefTitle":282,"status":128,"phases":11922,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":11923,"interventions":11924},[90],[236,237,238],[277,278,289,96,290],{"nctId":345,"briefTitle":346,"status":347,"phases":11926,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":11927,"interventions":11928},[90],[353,354],[356,96,290],{"trials":11930,"activeCount":101},[],{"trials":11932,"activeCount":101},[],{"trials":11934,"activeCount":101},[],{"intervention":6109,"totalTrials":758,"cells":11936},{"EARLY_PHASE1":11937,"PHASE1":11939,"PHASE2":11945,"PHASE3":11951,"PHASE4":11953,"NA":11955},{"trials":11938,"activeCount":101},[],{"trials":11940,"activeCount":101},[11941],{"nctId":7081,"briefTitle":7082,"status":142,"phases":11942,"completion":3254,"start":7084,"enrollment":31,"conditions":11943,"interventions":11944},[89],[7086,7087,7088],[1405,6109,4966],{"trials":11946,"activeCount":2548,"soonestReadout":799},[11947],{"nctId":6095,"briefTitle":6096,"status":128,"phases":11948,"primaryCompletion":799,"completion":2114,"start":2423,"enrollment":1111,"conditions":11949,"interventions":11950},[90],[6099,6100,6101,5572,856,854,6102,3860,6103,6104,6105,6106,6107],[1139,2255,6109],{"trials":11952,"activeCount":101},[],{"trials":11954,"activeCount":101},[],{"trials":11956,"activeCount":101},[],{"intervention":8236,"totalTrials":758,"cells":11958},{"EARLY_PHASE1":11959,"PHASE1":11961,"PHASE2":11967,"PHASE3":11973,"PHASE4":11975,"NA":11977},{"trials":11960,"activeCount":101},[],{"trials":11962,"activeCount":101},[11963],{"nctId":8227,"briefTitle":8228,"status":347,"phases":11964,"primaryCompletion":2798,"completion":2798,"start":8230,"enrollment":28,"conditions":11965,"interventions":11966},[89],[8232,8233,8234,5016],[8236,1570,8237],{"trials":11968,"activeCount":2548,"soonestReadout":4693},[11969],{"nctId":11450,"briefTitle":11451,"status":128,"phases":11970,"primaryCompletion":4693,"completion":4693,"start":3425,"enrollment":3800,"conditions":11971,"interventions":11972},[89,90],[21,11454,11455,30,11419,162,163,164,11423],[8236,474],{"trials":11974,"activeCount":101},[],{"trials":11976,"activeCount":101},[],{"trials":11978,"activeCount":101},[],{"intervention":318,"totalTrials":758,"cells":11980},{"EARLY_PHASE1":11981,"PHASE1":11983,"PHASE2":11985,"PHASE3":11997,"PHASE4":11999,"NA":12001},{"trials":11982,"activeCount":101},[],{"trials":11984,"activeCount":101},[],{"trials":11986,"activeCount":2548,"soonestReadout":307},[11987,11993],{"nctId":11988,"briefTitle":11989,"status":142,"phases":11990,"primaryCompletion":3226,"completion":3226,"start":1911,"enrollment":2577,"conditions":11991,"interventions":11992},"NCT01255137","Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer",[90],[6107],[318],{"nctId":304,"briefTitle":305,"status":155,"phases":11994,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":11995,"interventions":11996},[90],[312,313,314,315,316],[318,96],{"trials":11998,"activeCount":101},[],{"trials":12000,"activeCount":101},[],{"trials":12002,"activeCount":101},[],{"intervention":6431,"totalTrials":758,"cells":12004},{"EARLY_PHASE1":12005,"PHASE1":12007,"PHASE2":12009,"PHASE3":12019,"PHASE4":12021,"NA":12023},{"trials":12006,"activeCount":101},[],{"trials":12008,"activeCount":101},[],{"trials":12010,"activeCount":2548,"soonestReadout":5611},[12011,12015],{"nctId":6421,"briefTitle":6422,"status":142,"phases":12012,"primaryCompletion":2304,"completion":5218,"start":6424,"enrollment":6425,"conditions":12013,"interventions":12014},[89,90],[917,841,6427,6428,6429],[2124,6431],{"nctId":6437,"briefTitle":6438,"status":155,"phases":12016,"primaryCompletion":5611,"completion":6440,"start":6441,"enrollment":3283,"conditions":12017,"interventions":12018},[90],[6443,2885,6444,6445,6446,6447],[2124,6431],{"trials":12020,"activeCount":101},[],{"trials":12022,"activeCount":101},[],{"trials":12024,"activeCount":101},[],{"intervention":3376,"totalTrials":758,"cells":12026},{"EARLY_PHASE1":12027,"PHASE1":12029,"PHASE2":12031,"PHASE3":12041,"PHASE4":12043,"NA":12045},{"trials":12028,"activeCount":101},[],{"trials":12030,"activeCount":101},[],{"trials":12032,"activeCount":2548,"soonestReadout":3359},[12033,12037],{"nctId":11608,"briefTitle":11609,"status":107,"phases":12034,"primaryCompletion":11611,"completion":11611,"start":11612,"enrollment":101,"conditions":12035,"interventions":12036},[90],[2427,2430],[6296,3376],{"nctId":3356,"briefTitle":3357,"status":155,"phases":12038,"primaryCompletion":3359,"completion":1108,"start":3360,"enrollment":421,"conditions":12039,"interventions":12040},[90],[3362,803,3363,3364,3365,3366,3367,3368,3369,3370,3371,3372,3373,2152,3374],[277,449,3376],{"trials":12042,"activeCount":101},[],{"trials":12044,"activeCount":101},[],{"trials":12046,"activeCount":101},[],{"intervention":779,"totalTrials":758,"cells":12048},{"EARLY_PHASE1":12049,"PHASE1":12051,"PHASE2":12057,"PHASE3":12067,"PHASE4":12069,"NA":12071},{"trials":12050,"activeCount":101},[],{"trials":12052,"activeCount":101},[12053],{"nctId":766,"briefTitle":767,"status":618,"phases":12054,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":12055,"interventions":12056},[89],[773,774,775,776,777],[667,279,779,63,780,781,212],{"trials":12058,"activeCount":2548,"soonestReadout":12063},[12059],{"nctId":12060,"briefTitle":12061,"status":155,"phases":12062,"primaryCompletion":12063,"completion":361,"start":12064,"enrollment":638,"conditions":12065,"interventions":12066},"NCT06400238","Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)",[90],"2023-01-27","2018-10-15",[300,21,119,30,4262],[779],{"trials":12068,"activeCount":101},[],{"trials":12070,"activeCount":101},[],{"trials":12072,"activeCount":101},[],{"intervention":12074,"totalTrials":2548,"cells":12075},"EP2\u002FEP4 Antagonist TPST-1495",{"EARLY_PHASE1":12076,"PHASE1":12078,"PHASE2":12080,"PHASE3":12090,"PHASE4":12092,"NA":12094},{"trials":12077,"activeCount":101},[],{"trials":12079,"activeCount":101},[],{"trials":12081,"activeCount":2548,"soonestReadout":2930},[12082],{"nctId":12083,"briefTitle":12084,"status":128,"phases":12085,"primaryCompletion":2930,"completion":2930,"start":12086,"enrollment":174,"conditions":12087,"interventions":12089},"NCT06557733","An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis",[90],"2026-03-31",[5573,12088],"Familial Adenomatous Polyposis",[12074],{"trials":12091,"activeCount":101},[],{"trials":12093,"activeCount":101},[],{"trials":12095,"activeCount":101},[],{"intervention":12097,"totalTrials":2548,"cells":12098},"PLX038",{"EARLY_PHASE1":12099,"PHASE1":12101,"PHASE2":12103,"PHASE3":12116,"PHASE4":12118,"NA":12120},{"trials":12100,"activeCount":101},[],{"trials":12102,"activeCount":101},[],{"trials":12104,"activeCount":2548,"soonestReadout":12109},[12105],{"nctId":12106,"briefTitle":12107,"status":128,"phases":12108,"primaryCompletion":12109,"completion":12110,"start":12111,"enrollment":12112,"conditions":12113,"interventions":12115},"NCT06161519","PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications",[89,90],"2028-11-14","2033-11-14","2024-01-31",146,[12114,5847,5849,394],"Glioma",[12097],{"trials":12117,"activeCount":101},[],{"trials":12119,"activeCount":101},[],{"trials":12121,"activeCount":101},[],{"intervention":2272,"totalTrials":2548,"cells":12123},{"EARLY_PHASE1":12124,"PHASE1":12126,"PHASE2":12128,"PHASE3":12134,"PHASE4":12136,"NA":12138},{"trials":12125,"activeCount":101},[],{"trials":12127,"activeCount":101},[],{"trials":12129,"activeCount":2548,"soonestReadout":2262},[12130],{"nctId":2259,"briefTitle":2260,"status":155,"phases":12131,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":12132,"interventions":12133},[90],[902,2267,2268,2269,2270],[1372,1138,1375,1141,2272,212,781,740],{"trials":12135,"activeCount":101},[],{"trials":12137,"activeCount":101},[],{"trials":12139,"activeCount":101},[],{"intervention":10778,"totalTrials":2548,"cells":12141},{"EARLY_PHASE1":12142,"PHASE1":12144,"PHASE2":12146,"PHASE3":12152,"PHASE4":12154,"NA":12156},{"trials":12143,"activeCount":101},[],{"trials":12145,"activeCount":101},[],{"trials":12147,"activeCount":2548,"soonestReadout":10772},[12148],{"nctId":10769,"briefTitle":10770,"status":128,"phases":12149,"primaryCompletion":10772,"completion":10773,"start":10774,"enrollment":10775,"conditions":12150,"interventions":12151},[90],[977,976,975,974,973],[10778,10779,10780,10760],{"trials":12153,"activeCount":101},[],{"trials":12155,"activeCount":101},[],{"trials":12157,"activeCount":101},[],{"intervention":10779,"totalTrials":2548,"cells":12159},{"EARLY_PHASE1":12160,"PHASE1":12162,"PHASE2":12164,"PHASE3":12170,"PHASE4":12172,"NA":12174},{"trials":12161,"activeCount":101},[],{"trials":12163,"activeCount":101},[],{"trials":12165,"activeCount":2548,"soonestReadout":10772},[12166],{"nctId":10769,"briefTitle":10770,"status":128,"phases":12167,"primaryCompletion":10772,"completion":10773,"start":10774,"enrollment":10775,"conditions":12168,"interventions":12169},[90],[977,976,975,974,973],[10778,10779,10780,10760],{"trials":12171,"activeCount":101},[],{"trials":12173,"activeCount":101},[],{"trials":12175,"activeCount":101},[],{"intervention":10780,"totalTrials":2548,"cells":12177},{"EARLY_PHASE1":12178,"PHASE1":12180,"PHASE2":12182,"PHASE3":12188,"PHASE4":12190,"NA":12192},{"trials":12179,"activeCount":101},[],{"trials":12181,"activeCount":101},[],{"trials":12183,"activeCount":2548,"soonestReadout":10772},[12184],{"nctId":10769,"briefTitle":10770,"status":128,"phases":12185,"primaryCompletion":10772,"completion":10773,"start":10774,"enrollment":10775,"conditions":12186,"interventions":12187},[90],[977,976,975,974,973],[10778,10779,10780,10760],{"trials":12189,"activeCount":101},[],{"trials":12191,"activeCount":101},[],{"trials":12193,"activeCount":101},[],{"intervention":12195,"totalTrials":2548,"cells":12196},"Mirdametinib",{"EARLY_PHASE1":12197,"PHASE1":12199,"PHASE2":12201,"PHASE3":12211,"PHASE4":12213,"NA":12215},{"trials":12198,"activeCount":101},[],{"trials":12200,"activeCount":101},[],{"trials":12202,"activeCount":2548,"soonestReadout":12207},[12203],{"nctId":12204,"briefTitle":12205,"status":128,"phases":12206,"primaryCompletion":12207,"completion":12207,"start":3982,"enrollment":552,"conditions":12208,"interventions":12210},"NCT07061951","Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia",[90],"2030-02-01",[12209,655,656,4540],"Recurrent Chronic Lymphocytic Leukemia",[12195],{"trials":12212,"activeCount":101},[],{"trials":12214,"activeCount":101},[],{"trials":12216,"activeCount":101},[],{"intervention":905,"totalTrials":2548,"cells":12218},{"EARLY_PHASE1":12219,"PHASE1":12221,"PHASE2":12223,"PHASE3":12229,"PHASE4":12231,"NA":12233},{"trials":12220,"activeCount":101},[],{"trials":12222,"activeCount":101},[],{"trials":12224,"activeCount":2548,"soonestReadout":898},[12225],{"nctId":895,"briefTitle":896,"status":128,"phases":12226,"primaryCompletion":898,"completion":899,"start":900,"enrollment":552,"conditions":12227,"interventions":12228},[90],[902,903],[905,63,643],{"trials":12230,"activeCount":101},[],{"trials":12232,"activeCount":101},[],{"trials":12234,"activeCount":101},[],{"intervention":10791,"totalTrials":2548,"cells":12236},{"EARLY_PHASE1":12237,"PHASE1":12239,"PHASE2":12241,"PHASE3":12247,"PHASE4":12249,"NA":12251},{"trials":12238,"activeCount":101},[],{"trials":12240,"activeCount":101},[],{"trials":12242,"activeCount":2548,"soonestReadout":10785},[12243],{"nctId":10782,"briefTitle":10783,"status":128,"phases":12244,"primaryCompletion":10785,"completion":1837,"start":2737,"enrollment":10786,"conditions":12245,"interventions":12246},[89,90],[10788,10789],[10791,10792,4698,10793],{"trials":12248,"activeCount":101},[],{"trials":12250,"activeCount":101},[],{"trials":12252,"activeCount":101},[],{"intervention":10793,"totalTrials":2548,"cells":12254},{"EARLY_PHASE1":12255,"PHASE1":12257,"PHASE2":12259,"PHASE3":12265,"PHASE4":12267,"NA":12269},{"trials":12256,"activeCount":101},[],{"trials":12258,"activeCount":101},[],{"trials":12260,"activeCount":2548,"soonestReadout":10785},[12261],{"nctId":10782,"briefTitle":10783,"status":128,"phases":12262,"primaryCompletion":10785,"completion":1837,"start":2737,"enrollment":10786,"conditions":12263,"interventions":12264},[89,90],[10788,10789],[10791,10792,4698,10793],{"trials":12266,"activeCount":101},[],{"trials":12268,"activeCount":101},[],{"trials":12270,"activeCount":101},[],{"intervention":9976,"totalTrials":2548,"cells":12272},{"EARLY_PHASE1":12273,"PHASE1":12275,"PHASE2":12277,"PHASE3":12283,"PHASE4":12285,"NA":12287},{"trials":12274,"activeCount":101},[],{"trials":12276,"activeCount":101},[],{"trials":12278,"activeCount":2548,"soonestReadout":284},[12279],{"nctId":9967,"briefTitle":9968,"status":128,"phases":12280,"primaryCompletion":284,"completion":284,"start":9970,"enrollment":248,"conditions":12281,"interventions":12282},[90],[5540,9972,9973,9974],[9976,9977,9935,9978],{"trials":12284,"activeCount":101},[],{"trials":12286,"activeCount":101},[],{"trials":12288,"activeCount":101},[],{"intervention":12290,"totalTrials":2548,"cells":12291},"18F-fluciclovine",{"EARLY_PHASE1":12292,"PHASE1":12294,"PHASE2":12296,"PHASE3":12307,"PHASE4":12309,"NA":12311},{"trials":12293,"activeCount":101},[],{"trials":12295,"activeCount":101},[],{"trials":12297,"activeCount":2548,"soonestReadout":2593},[12298],{"nctId":12299,"briefTitle":12300,"status":128,"phases":12301,"primaryCompletion":2593,"completion":12302,"start":3748,"enrollment":1074,"conditions":12303,"interventions":12306},"NCT06103838","18F-Fluciclovine PET\u002FCT in Multiple Myeloma",[90],"2031-12-06",[4747,12304,12305],"Newly Diagnosed Multiple Myeloma (NDMM)","Relapsed and\u002For Refractory Multiple Myeloma (RRMM)",[12290],{"trials":12308,"activeCount":101},[],{"trials":12310,"activeCount":101},[],{"trials":12312,"activeCount":101},[],{"intervention":12314,"totalTrials":2548,"cells":12315},"Curcumin",{"EARLY_PHASE1":12316,"PHASE1":12318,"PHASE2":12320,"PHASE3":12332,"PHASE4":12334,"NA":12336},{"trials":12317,"activeCount":101},[],{"trials":12319,"activeCount":101},[],{"trials":12321,"activeCount":2548,"soonestReadout":12326},[12322],{"nctId":12323,"briefTitle":12324,"status":155,"phases":12325,"primaryCompletion":12326,"completion":5011,"start":12327,"enrollment":234,"conditions":12328,"interventions":12331},"NCT02782949","Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia",[90],"2022-10-06","2017-04-04",[12329,12330],"Chronic Atrophic Gastritis","Gastric Carcinoma",[12314],{"trials":12333,"activeCount":101},[],{"trials":12335,"activeCount":101},[],{"trials":12337,"activeCount":101},[],{"intervention":12339,"totalTrials":2548,"cells":12340},"Tirzepatide",{"EARLY_PHASE1":12341,"PHASE1":12343,"PHASE2":12345,"PHASE3":12356,"PHASE4":12358,"NA":12360},{"trials":12342,"activeCount":101},[],{"trials":12344,"activeCount":101},[],{"trials":12346,"activeCount":2548,"soonestReadout":2114},[12347],{"nctId":12348,"briefTitle":12349,"status":3027,"phases":12350,"primaryCompletion":2114,"completion":1396,"start":12351,"enrollment":913,"conditions":12352,"interventions":12355},"NCT07349641","A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer",[90],"2026-07-06",[12353,12354],"Endometrial Atypical Hyperplasia\u002FEndometrioid Intraepithelial Neoplasia","FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma",[12339],{"trials":12357,"activeCount":101},[],{"trials":12359,"activeCount":101},[],{"trials":12361,"activeCount":101},[],{"intervention":11872,"totalTrials":2548,"cells":12363},{"EARLY_PHASE1":12364,"PHASE1":12366,"PHASE2":12368,"PHASE3":12374,"PHASE4":12376,"NA":12378},{"trials":12365,"activeCount":101},[],{"trials":12367,"activeCount":101},[],{"trials":12369,"activeCount":2548,"soonestReadout":11864},[12370],{"nctId":11861,"briefTitle":11862,"status":3027,"phases":12371,"primaryCompletion":11864,"completion":11865,"start":900,"enrollment":3869,"conditions":12372,"interventions":12373},[90],[11867,24,467,11868,11869,11870],[11872,11852],{"trials":12375,"activeCount":101},[],{"trials":12377,"activeCount":101},[],{"trials":12379,"activeCount":101},[],{"intervention":11218,"totalTrials":2548,"cells":12381},{"EARLY_PHASE1":12382,"PHASE1":12384,"PHASE2":12386,"PHASE3":12392,"PHASE4":12394,"NA":12396},{"trials":12383,"activeCount":101},[],{"trials":12385,"activeCount":101},[],{"trials":12387,"activeCount":2548,"soonestReadout":582},[12388],{"nctId":11210,"briefTitle":11211,"status":128,"phases":12389,"primaryCompletion":582,"completion":10501,"start":258,"enrollment":971,"conditions":12390,"interventions":12391},[90],[11214,9043,11215,11216],[11218,11201],{"trials":12393,"activeCount":101},[],{"trials":12395,"activeCount":101},[],{"trials":12397,"activeCount":101},[],{"intervention":979,"totalTrials":2548,"cells":12399},{"EARLY_PHASE1":12400,"PHASE1":12402,"PHASE2":12404,"PHASE3":12410,"PHASE4":12412,"NA":12414},{"trials":12401,"activeCount":101},[],{"trials":12403,"activeCount":101},[],{"trials":12405,"activeCount":2548,"soonestReadout":968},[12406],{"nctId":965,"briefTitle":966,"status":128,"phases":12407,"primaryCompletion":968,"completion":969,"start":970,"enrollment":971,"conditions":12408,"interventions":12409},[90],[973,974,975,976,977],[979,643,980,981,213,982,63],{"trials":12411,"activeCount":101},[],{"trials":12413,"activeCount":101},[],{"trials":12415,"activeCount":101},[],{"intervention":982,"totalTrials":2548,"cells":12417},{"EARLY_PHASE1":12418,"PHASE1":12420,"PHASE2":12422,"PHASE3":12428,"PHASE4":12430,"NA":12432},{"trials":12419,"activeCount":101},[],{"trials":12421,"activeCount":101},[],{"trials":12423,"activeCount":2548,"soonestReadout":968},[12424],{"nctId":965,"briefTitle":966,"status":128,"phases":12425,"primaryCompletion":968,"completion":969,"start":970,"enrollment":971,"conditions":12426,"interventions":12427},[90],[973,974,975,976,977],[979,643,980,981,213,982,63],{"trials":12429,"activeCount":101},[],{"trials":12431,"activeCount":101},[],{"trials":12433,"activeCount":101},[],{"intervention":12435,"totalTrials":2548,"cells":12436},"Obeticholic Acid",{"EARLY_PHASE1":12437,"PHASE1":12439,"PHASE2":12441,"PHASE3":12450,"PHASE4":12452,"NA":12454},{"trials":12438,"activeCount":101},[],{"trials":12440,"activeCount":101},[],{"trials":12442,"activeCount":2548,"soonestReadout":2234},[12443],{"nctId":12444,"briefTitle":12445,"status":128,"phases":12446,"primaryCompletion":2234,"completion":2234,"start":12447,"enrollment":28,"conditions":12448,"interventions":12449},"NCT04939051","Obeticholic Acid for Prevention in Barrett's Esophagus",[90],"2024-01-03",[11686,11687],[12435],{"trials":12451,"activeCount":101},[],{"trials":12453,"activeCount":101},[],{"trials":12455,"activeCount":101},[],{"intervention":12457,"totalTrials":2548,"cells":12458},"Rogaratinib",{"EARLY_PHASE1":12459,"PHASE1":12461,"PHASE2":12463,"PHASE3":12480,"PHASE4":12482,"NA":12484},{"trials":12460,"activeCount":101},[],{"trials":12462,"activeCount":101},[],{"trials":12464,"activeCount":2548,"soonestReadout":4693},[12465],{"nctId":12466,"briefTitle":12467,"status":155,"phases":12468,"primaryCompletion":4693,"completion":4693,"start":12469,"enrollment":1765,"conditions":12470,"interventions":12479},"NCT04595747","Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)",[90],"2021-05-03",[12471,12472,12473,12474,12475,12476,12477,12478],"Locally Advanced Gastrointestinal Stromal Tumor","Locally Advanced Sarcoma","Metastatic Gastrointestinal Stromal Tumor","Metastatic Sarcoma","Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8","Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8","Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8",[12457],{"trials":12481,"activeCount":101},[],{"trials":12483,"activeCount":101},[],{"trials":12485,"activeCount":101},[],{"intervention":12487,"totalTrials":2548,"cells":12488},"Nilotinib and Paclitaxel",{"EARLY_PHASE1":12489,"PHASE1":12491,"PHASE2":12493,"PHASE3":12504,"PHASE4":12506,"NA":12508},{"trials":12490,"activeCount":101},[],{"trials":12492,"activeCount":101},[],{"trials":12494,"activeCount":2548,"soonestReadout":12499},[12495],{"nctId":12496,"briefTitle":12497,"status":128,"phases":12498,"primaryCompletion":12499,"completion":12500,"start":12501,"enrollment":261,"conditions":12502,"interventions":12503},"NCT04449549","Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel",[90],"2027-04-02","2027-04-08","2020-08-24",[467],[12487],{"trials":12505,"activeCount":101},[],{"trials":12507,"activeCount":101},[],{"trials":12509,"activeCount":101},[],{"intervention":12511,"totalTrials":2548,"cells":12512},"68-Gallium DOTATATE",{"EARLY_PHASE1":12513,"PHASE1":12515,"PHASE2":12517,"PHASE3":12532,"PHASE4":12534,"NA":12536},{"trials":12514,"activeCount":101},[],{"trials":12516,"activeCount":101},[],{"trials":12518,"activeCount":2548,"soonestReadout":12523},[12519],{"nctId":12520,"briefTitle":12521,"status":128,"phases":12522,"primaryCompletion":12523,"completion":12524,"start":12525,"enrollment":12526,"conditions":12527,"interventions":12531},"NCT04074135","Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors",[90],"2036-01-30","2036-07-01","2020-06-02",740,[12528,12529,12530],"VHL Pancreatic Neuroendocrine Tumors","Von Hippel-Lindau Disease","Neuroendocrine Tumors",[12511],{"trials":12533,"activeCount":101},[],{"trials":12535,"activeCount":101},[],{"trials":12537,"activeCount":101},[],{"intervention":9784,"totalTrials":2548,"cells":12539},{"EARLY_PHASE1":12540,"PHASE1":12542,"PHASE2":12544,"PHASE3":12550,"PHASE4":12552,"NA":12554},{"trials":12541,"activeCount":101},[],{"trials":12543,"activeCount":101},[],{"trials":12545,"activeCount":2548,"soonestReadout":9777},[12546],{"nctId":9774,"briefTitle":9775,"status":155,"phases":12547,"primaryCompletion":9777,"completion":9778,"start":9779,"enrollment":234,"conditions":12548,"interventions":12549},[90],[263,6272,9781,2453,2454,9782],[9784,138],{"trials":12551,"activeCount":101},[],{"trials":12553,"activeCount":101},[],{"trials":12555,"activeCount":101},[],{"intervention":4697,"totalTrials":2548,"cells":12557},{"EARLY_PHASE1":12558,"PHASE1":12560,"PHASE2":12562,"PHASE3":12568,"PHASE4":12570,"NA":12572},{"trials":12559,"activeCount":101},[],{"trials":12561,"activeCount":101},[],{"trials":12563,"activeCount":2548,"soonestReadout":4692},[12564],{"nctId":4689,"briefTitle":4690,"status":3027,"phases":12565,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":159,"conditions":12566,"interventions":12567},[90],[4695],[4605,4697,1139,1016,1405,4698,4699,4700],{"trials":12569,"activeCount":101},[],{"trials":12571,"activeCount":101},[],{"trials":12573,"activeCount":101},[],{"intervention":4699,"totalTrials":2548,"cells":12575},{"EARLY_PHASE1":12576,"PHASE1":12578,"PHASE2":12580,"PHASE3":12586,"PHASE4":12588,"NA":12590},{"trials":12577,"activeCount":101},[],{"trials":12579,"activeCount":101},[],{"trials":12581,"activeCount":2548,"soonestReadout":4692},[12582],{"nctId":4689,"briefTitle":4690,"status":3027,"phases":12583,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":159,"conditions":12584,"interventions":12585},[90],[4695],[4605,4697,1139,1016,1405,4698,4699,4700],{"trials":12587,"activeCount":101},[],{"trials":12589,"activeCount":101},[],{"trials":12591,"activeCount":101},[],{"intervention":12593,"totalTrials":2548,"cells":12594},"Trastuzumab Emtansine",{"EARLY_PHASE1":12595,"PHASE1":12597,"PHASE2":12599,"PHASE3":12608,"PHASE4":12610,"NA":12612},{"trials":12596,"activeCount":101},[],{"trials":12598,"activeCount":101},[],{"trials":12600,"activeCount":2548,"soonestReadout":12605},[12601],{"nctId":12602,"briefTitle":12603,"status":155,"phases":12604,"primaryCompletion":12605,"completion":592,"start":9324,"enrollment":174,"conditions":12606,"interventions":12607},"NCT04439110","Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)",[90],"2019-03-09",[300,21,113,119,30,4262],[12593],{"trials":12609,"activeCount":101},[],{"trials":12611,"activeCount":101},[],{"trials":12613,"activeCount":101},[],{"intervention":12615,"totalTrials":2548,"cells":12616},"Taselisib",{"EARLY_PHASE1":12617,"PHASE1":12619,"PHASE2":12621,"PHASE3":12629,"PHASE4":12631,"NA":12633},{"trials":12618,"activeCount":101},[],{"trials":12620,"activeCount":101},[],{"trials":12622,"activeCount":2548,"soonestReadout":3006},[12623],{"nctId":12624,"briefTitle":12625,"status":155,"phases":12626,"primaryCompletion":3006,"completion":592,"start":9316,"enrollment":1111,"conditions":12627,"interventions":12628},"NCT04439175","Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)",[90],[300,21,113,119,30,4262],[12615],{"trials":12630,"activeCount":101},[],{"trials":12632,"activeCount":101},[],{"trials":12634,"activeCount":101},[],{"intervention":3793,"totalTrials":2548,"cells":12636},{"EARLY_PHASE1":12637,"PHASE1":12639,"PHASE2":12641,"PHASE3":12647,"PHASE4":12649,"NA":12651},{"trials":12638,"activeCount":101},[],{"trials":12640,"activeCount":101},[],{"trials":12642,"activeCount":2548,"soonestReadout":361},[12643],{"nctId":3786,"briefTitle":3787,"status":155,"phases":12644,"primaryCompletion":361,"completion":361,"start":3789,"enrollment":1074,"conditions":12645,"interventions":12646},[90],[190,3791,202,204,205,2543],[883,3793],{"trials":12648,"activeCount":101},[],{"trials":12650,"activeCount":101},[],{"trials":12652,"activeCount":101},[],{"intervention":12654,"totalTrials":2548,"cells":12655},"18F-NaF",{"EARLY_PHASE1":12656,"PHASE1":12658,"PHASE2":12660,"PHASE3":12673,"PHASE4":12675,"NA":12677},{"trials":12657,"activeCount":101},[],{"trials":12659,"activeCount":101},[],{"trials":12661,"activeCount":2548,"soonestReadout":12666},[12662],{"nctId":12663,"briefTitle":12664,"status":155,"phases":12665,"primaryCompletion":12666,"completion":12666,"start":12667,"enrollment":12668,"conditions":12669,"interventions":12670},"NCT03173924","18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer",[90],"2028-02-06","2017-06-06",96,[2348,10352,24,11790,2253],[12654,12671,12672],"18F-DCFPyL","18F-FDG",{"trials":12674,"activeCount":101},[],{"trials":12676,"activeCount":101},[],{"trials":12678,"activeCount":101},[],{"intervention":12671,"totalTrials":2548,"cells":12680},{"EARLY_PHASE1":12681,"PHASE1":12683,"PHASE2":12685,"PHASE3":12691,"PHASE4":12693,"NA":12695},{"trials":12682,"activeCount":101},[],{"trials":12684,"activeCount":101},[],{"trials":12686,"activeCount":2548,"soonestReadout":12666},[12687],{"nctId":12663,"briefTitle":12664,"status":155,"phases":12688,"primaryCompletion":12666,"completion":12666,"start":12667,"enrollment":12668,"conditions":12689,"interventions":12690},[90],[2348,10352,24,11790,2253],[12654,12671,12672],{"trials":12692,"activeCount":101},[],{"trials":12694,"activeCount":101},[],{"trials":12696,"activeCount":101},[],{"intervention":12672,"totalTrials":2548,"cells":12698},{"EARLY_PHASE1":12699,"PHASE1":12701,"PHASE2":12703,"PHASE3":12709,"PHASE4":12711,"NA":12713},{"trials":12700,"activeCount":101},[],{"trials":12702,"activeCount":101},[],{"trials":12704,"activeCount":2548,"soonestReadout":12666},[12705],{"nctId":12663,"briefTitle":12664,"status":155,"phases":12706,"primaryCompletion":12666,"completion":12666,"start":12667,"enrollment":12668,"conditions":12707,"interventions":12708},[90],[2348,10352,24,11790,2253],[12654,12671,12672],{"trials":12710,"activeCount":101},[],{"trials":12712,"activeCount":101},[],{"trials":12714,"activeCount":101},[],{"intervention":12716,"totalTrials":2548,"cells":12717},"Selpercatinib",{"EARLY_PHASE1":12718,"PHASE1":12720,"PHASE2":12722,"PHASE3":12753,"PHASE4":12755,"NA":12757},{"trials":12719,"activeCount":101},[],{"trials":12721,"activeCount":101},[],{"trials":12723,"activeCount":2548,"soonestReadout":307},[12724],{"nctId":12725,"briefTitle":12726,"status":155,"phases":12727,"primaryCompletion":307,"completion":1603,"start":12469,"enrollment":2548,"conditions":12728,"interventions":12752},"NCT04320888","Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial",[90],[5919,12729,12730,12731,12732,12733,115,12734,12735,116,5416,117,4530,5872,12736,12737,7386,12738,12739,12740,12741,12742,12743,12744,119,12745,12746,30,5418,120,4539,12747,5419,12748,7387,12749,12750,12751],"Recurrent Ependymoma","Recurrent Ewing Sarcoma","Recurrent Hepatoblastoma","Recurrent Histiocytic and Dendritic Cell Neoplasm","Recurrent Langerhans Cell Histiocytosis","Recurrent Malignant Germ Cell Tumor","Recurrent Malignant Glioma","Recurrent Peripheral Primitive Neuroectodermal Tumor","Recurrent Rhabdoid Tumor","Recurrent Soft Tissue Sarcoma","Recurrent WHO Grade 2 Glioma","Refractory Ependymoma","Refractory Ewing Sarcoma","Refractory Hepatoblastoma","Refractory Histiocytic and Dendritic Cell Neoplasm","Refractory Langerhans Cell Histiocytosis","Refractory Malignant Germ Cell Tumor","Refractory Malignant Glioma","Refractory Osteosarcoma","Refractory Rhabdoid Tumor","Refractory Soft Tissue Sarcoma","Refractory WHO Grade 2 Glioma","Wilms Tumor",[12716],{"trials":12754,"activeCount":101},[],{"trials":12756,"activeCount":101},[],{"trials":12758,"activeCount":101},[],{"intervention":12760,"totalTrials":2548,"cells":12761},"PT-112",{"EARLY_PHASE1":12762,"PHASE1":12764,"PHASE2":12766,"PHASE3":12778,"PHASE4":12780,"NA":12782},{"trials":12763,"activeCount":101},[],{"trials":12765,"activeCount":101},[],{"trials":12767,"activeCount":2548,"soonestReadout":799},[12768],{"nctId":12769,"briefTitle":12770,"status":128,"phases":12771,"primaryCompletion":799,"completion":3701,"start":12772,"enrollment":2265,"conditions":12773,"interventions":12777},"NCT05104736","PT-112 in Subjects With Thymoma and Thymic Carcinoma",[90],"2022-04-06",[12774,12775,12776],"Thymic Epithelial Tumor","Recurrent Thymoma","Thymic Cancer",[12760],{"trials":12779,"activeCount":101},[],{"trials":12781,"activeCount":101},[],{"trials":12783,"activeCount":101},[],{"intervention":9156,"totalTrials":2548,"cells":12785},{"EARLY_PHASE1":12786,"PHASE1":12788,"PHASE2":12790,"PHASE3":12796,"PHASE4":12798,"NA":12800},{"trials":12787,"activeCount":101},[],{"trials":12789,"activeCount":101},[],{"trials":12791,"activeCount":2548,"soonestReadout":3868},[12792],{"nctId":9148,"briefTitle":9149,"status":155,"phases":12793,"primaryCompletion":3868,"completion":4693,"start":9151,"enrollment":2883,"conditions":12794,"interventions":12795},[89,90],[960,9153,1045,1043,9154],[9156,2256,9157],{"trials":12797,"activeCount":101},[],{"trials":12799,"activeCount":101},[],{"trials":12801,"activeCount":101},[],{"intervention":9157,"totalTrials":2548,"cells":12803},{"EARLY_PHASE1":12804,"PHASE1":12806,"PHASE2":12808,"PHASE3":12814,"PHASE4":12816,"NA":12818},{"trials":12805,"activeCount":101},[],{"trials":12807,"activeCount":101},[],{"trials":12809,"activeCount":2548,"soonestReadout":3868},[12810],{"nctId":9148,"briefTitle":9149,"status":155,"phases":12811,"primaryCompletion":3868,"completion":4693,"start":9151,"enrollment":2883,"conditions":12812,"interventions":12813},[89,90],[960,9153,1045,1043,9154],[9156,2256,9157],{"trials":12815,"activeCount":101},[],{"trials":12817,"activeCount":101},[],{"trials":12819,"activeCount":101},[],{"intervention":3986,"totalTrials":2548,"cells":12821},{"EARLY_PHASE1":12822,"PHASE1":12824,"PHASE2":12826,"PHASE3":12832,"PHASE4":12834,"NA":12836},{"trials":12823,"activeCount":101},[],{"trials":12825,"activeCount":101},[],{"trials":12827,"activeCount":2548,"soonestReadout":3981},[12828],{"nctId":3978,"briefTitle":3979,"status":3027,"phases":12829,"primaryCompletion":3981,"completion":3981,"start":3982,"enrollment":3983,"conditions":12830,"interventions":12831},[90],[263,2454],[3976,3986,2217],{"trials":12833,"activeCount":101},[],{"trials":12835,"activeCount":101},[],{"trials":12837,"activeCount":101},[],{"intervention":12839,"totalTrials":2548,"cells":12840},"Tivozanib",{"EARLY_PHASE1":12841,"PHASE1":12843,"PHASE2":12845,"PHASE3":12856,"PHASE4":12858,"NA":12860},{"trials":12842,"activeCount":101},[],{"trials":12844,"activeCount":101},[],{"trials":12846,"activeCount":2548,"soonestReadout":2114},[12847],{"nctId":12848,"briefTitle":12849,"status":128,"phases":12850,"primaryCompletion":2114,"completion":1396,"start":12851,"enrollment":25,"conditions":12852,"interventions":12855},"NCT04645160","Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers",[89,90],"2022-03-04",[854,12853,12854],"Bile Duct Neoplasm","Biliary Tract Malignancy",[12839],{"trials":12857,"activeCount":101},[],{"trials":12859,"activeCount":101},[],{"trials":12861,"activeCount":101},[],{"intervention":12863,"totalTrials":2548,"cells":12864},"Sasanlimab",{"EARLY_PHASE1":12865,"PHASE1":12867,"PHASE2":12869,"PHASE3":12881,"PHASE4":12883,"NA":12885},{"trials":12866,"activeCount":101},[],{"trials":12868,"activeCount":101},[],{"trials":12870,"activeCount":2548,"soonestReadout":11003},[12871],{"nctId":12872,"briefTitle":12873,"status":128,"phases":12874,"primaryCompletion":11003,"completion":11003,"start":12875,"enrollment":248,"conditions":12876,"interventions":12879},"NCT05665361","Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)",[89,90],"2024-04-24",[12877,12878],"Advanced Clear Cell Renal Carcinoma (Ccrcc)","Papillary Renal Cell Carcinoma (Prcc)",[12863,12880],"Palbocicilib",{"trials":12882,"activeCount":101},[],{"trials":12884,"activeCount":101},[],{"trials":12886,"activeCount":101},[],{"intervention":12880,"totalTrials":2548,"cells":12888},{"EARLY_PHASE1":12889,"PHASE1":12891,"PHASE2":12893,"PHASE3":12899,"PHASE4":12901,"NA":12903},{"trials":12890,"activeCount":101},[],{"trials":12892,"activeCount":101},[],{"trials":12894,"activeCount":2548,"soonestReadout":11003},[12895],{"nctId":12872,"briefTitle":12873,"status":128,"phases":12896,"primaryCompletion":11003,"completion":11003,"start":12875,"enrollment":248,"conditions":12897,"interventions":12898},[89,90],[12877,12878],[12863,12880],{"trials":12900,"activeCount":101},[],{"trials":12902,"activeCount":101},[],{"trials":12904,"activeCount":101},[],{"intervention":12906,"totalTrials":2548,"cells":12907},"Iberdomide",{"EARLY_PHASE1":12908,"PHASE1":12910,"PHASE2":12912,"PHASE3":12922,"PHASE4":12924,"NA":12926},{"trials":12909,"activeCount":101},[],{"trials":12911,"activeCount":101},[],{"trials":12913,"activeCount":2548,"soonestReadout":2654},[12914],{"nctId":12915,"briefTitle":12916,"status":128,"phases":12917,"primaryCompletion":2654,"completion":2654,"start":12918,"enrollment":12919,"conditions":12920,"interventions":12921},"NCT06179888","Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma",[90],"2024-08-27",78,[4747],[12906],{"trials":12923,"activeCount":101},[],{"trials":12925,"activeCount":101},[],{"trials":12927,"activeCount":101},[],{"intervention":12929,"totalTrials":2548,"cells":12930},"Ulixertinib",{"EARLY_PHASE1":12931,"PHASE1":12933,"PHASE2":12935,"PHASE3":12950,"PHASE4":12952,"NA":12954},{"trials":12932,"activeCount":101},[],{"trials":12934,"activeCount":101},[],{"trials":12936,"activeCount":2548,"soonestReadout":12941},[12937],{"nctId":12938,"briefTitle":12939,"status":155,"phases":12940,"primaryCompletion":12941,"completion":10976,"start":12942,"enrollment":552,"conditions":12943,"interventions":12949},"NCT03698994","Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",[90],"2022-03-31","2018-11-14",[21,12944,12730,12945,12731,12732,12733,12734,116,5416,117,4530,5872,12736,12946,12737,7386,12738,12740,12741,12947,12742,12743,12744,12745,30,5418,120,4539,12747,5419,12948,12748,7387,12749,12751],"Recurrent Ependymal Tumor","Recurrent Glioma","Recurrent Primary Malignant Central Nervous System Neoplasm","Refractory Glioma","Refractory Primary Malignant Central Nervous System Neoplasm",[12929],{"trials":12951,"activeCount":101},[],{"trials":12953,"activeCount":101},[],{"trials":12955,"activeCount":101},[],{"intervention":10411,"totalTrials":2548,"cells":12957},{"EARLY_PHASE1":12958,"PHASE1":12960,"PHASE2":12962,"PHASE3":12968,"PHASE4":12970,"NA":12972},{"trials":12959,"activeCount":101},[],{"trials":12961,"activeCount":101},[],{"trials":12963,"activeCount":2548,"soonestReadout":10406},[12964],{"nctId":10403,"briefTitle":10404,"status":3027,"phases":12965,"primaryCompletion":10406,"completion":3029,"start":10407,"enrollment":2319,"conditions":12966,"interventions":12967},[90],[10409],[10411,5933,10412],{"trials":12969,"activeCount":101},[],{"trials":12971,"activeCount":101},[],{"trials":12973,"activeCount":101},[],{"intervention":10412,"totalTrials":2548,"cells":12975},{"EARLY_PHASE1":12976,"PHASE1":12978,"PHASE2":12980,"PHASE3":12986,"PHASE4":12988,"NA":12990},{"trials":12977,"activeCount":101},[],{"trials":12979,"activeCount":101},[],{"trials":12981,"activeCount":2548,"soonestReadout":10406},[12982],{"nctId":10403,"briefTitle":10404,"status":3027,"phases":12983,"primaryCompletion":10406,"completion":3029,"start":10407,"enrollment":2319,"conditions":12984,"interventions":12985},[90],[10409],[10411,5933,10412],{"trials":12987,"activeCount":101},[],{"trials":12989,"activeCount":101},[],{"trials":12991,"activeCount":101},[],{"intervention":12993,"totalTrials":2548,"cells":12994},"Panitumumab",{"EARLY_PHASE1":12995,"PHASE1":12997,"PHASE2":12999,"PHASE3":13009,"PHASE4":13011,"NA":13013},{"trials":12996,"activeCount":101},[],{"trials":12998,"activeCount":101},[],{"trials":13000,"activeCount":2548,"soonestReadout":2114},[13001],{"nctId":13002,"briefTitle":13003,"status":155,"phases":13004,"primaryCompletion":2114,"completion":2114,"start":2895,"enrollment":13005,"conditions":13006,"interventions":13007},"NCT05638295","Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)",[90],105,[21,486],[12993,13008],"Sotorasib",{"trials":13010,"activeCount":101},[],{"trials":13012,"activeCount":101},[],{"trials":13014,"activeCount":101},[],{"intervention":13008,"totalTrials":2548,"cells":13016},{"EARLY_PHASE1":13017,"PHASE1":13019,"PHASE2":13021,"PHASE3":13027,"PHASE4":13029,"NA":13031},{"trials":13018,"activeCount":101},[],{"trials":13020,"activeCount":101},[],{"trials":13022,"activeCount":2548,"soonestReadout":2114},[13023],{"nctId":13002,"briefTitle":13003,"status":155,"phases":13024,"primaryCompletion":2114,"completion":2114,"start":2895,"enrollment":13005,"conditions":13025,"interventions":13026},[90],[21,486],[12993,13008],{"trials":13028,"activeCount":101},[],{"trials":13030,"activeCount":101},[],{"trials":13032,"activeCount":101},[],{"intervention":10074,"totalTrials":2548,"cells":13034},{"EARLY_PHASE1":13035,"PHASE1":13037,"PHASE2":13039,"PHASE3":13045,"PHASE4":13047,"NA":13049},{"trials":13036,"activeCount":101},[],{"trials":13038,"activeCount":101},[],{"trials":13040,"activeCount":2548,"soonestReadout":2050},[13041],{"nctId":10067,"briefTitle":10068,"status":128,"phases":13042,"primaryCompletion":2050,"completion":2050,"start":10070,"enrollment":1111,"conditions":13043,"interventions":13044},[90],[1532,2681,10072,116],[10074,9874],{"trials":13046,"activeCount":101},[],{"trials":13048,"activeCount":101},[],{"trials":13050,"activeCount":101},[],{"intervention":13052,"totalTrials":2548,"cells":13053},"Lu-177-DOTATATE",{"EARLY_PHASE1":13054,"PHASE1":13056,"PHASE2":13058,"PHASE3":13072,"PHASE4":13074,"NA":13076},{"trials":13055,"activeCount":101},[],{"trials":13057,"activeCount":101},[],{"trials":13059,"activeCount":2548,"soonestReadout":10502},[13060],{"nctId":13061,"briefTitle":13062,"status":128,"phases":13063,"primaryCompletion":10502,"completion":13064,"start":13065,"enrollment":13066,"conditions":13067,"interventions":13070},"NCT03206060","Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma\u002F Paraganglioma",[90],"2033-01-01","2017-10-10",130,[13068,7676,12530,13069],"Pheochromocytoma","Neuroendocrine Neoplasms",[13052,13071],"Ga-68-DOTATATE",{"trials":13073,"activeCount":101},[],{"trials":13075,"activeCount":101},[],{"trials":13077,"activeCount":101},[],{"intervention":13071,"totalTrials":2548,"cells":13079},{"EARLY_PHASE1":13080,"PHASE1":13082,"PHASE2":13084,"PHASE3":13090,"PHASE4":13092,"NA":13094},{"trials":13081,"activeCount":101},[],{"trials":13083,"activeCount":101},[],{"trials":13085,"activeCount":2548,"soonestReadout":10502},[13086],{"nctId":13061,"briefTitle":13062,"status":128,"phases":13087,"primaryCompletion":10502,"completion":13064,"start":13065,"enrollment":13066,"conditions":13088,"interventions":13089},[90],[13068,7676,12530,13069],[13052,13071],{"trials":13091,"activeCount":101},[],{"trials":13093,"activeCount":101},[],{"trials":13095,"activeCount":101},[],{"intervention":13097,"totalTrials":2548,"cells":13098},"Pidnarulex",{"EARLY_PHASE1":13099,"PHASE1":13101,"PHASE2":13103,"PHASE3":13113,"PHASE4":13115,"NA":13117},{"trials":13100,"activeCount":101},[],{"trials":13102,"activeCount":101},[],{"trials":13104,"activeCount":2548,"soonestReadout":898},[13105],{"nctId":13106,"briefTitle":13107,"status":128,"phases":13108,"primaryCompletion":898,"completion":898,"start":13109,"enrollment":234,"conditions":13110,"interventions":13112},"NCT07069699","Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene",[89,90],"2026-10-13",[773,13111,517],"Double-Expressor Lymphoma",[13097],{"trials":13114,"activeCount":101},[],{"trials":13116,"activeCount":101},[],{"trials":13118,"activeCount":101},[],{"intervention":4005,"totalTrials":2548,"cells":13120},{"EARLY_PHASE1":13121,"PHASE1":13123,"PHASE2":13125,"PHASE3":13131,"PHASE4":13133,"NA":13135},{"trials":13122,"activeCount":101},[],{"trials":13124,"activeCount":101},[],{"trials":13126,"activeCount":2548,"soonestReadout":3999},[13127],{"nctId":3996,"briefTitle":3997,"status":128,"phases":13128,"primaryCompletion":3999,"completion":3999,"start":4000,"enrollment":4001,"conditions":13129,"interventions":13130},[90],[1485,4003],[58,667,2217,4005],{"trials":13132,"activeCount":101},[],{"trials":13134,"activeCount":101},[],{"trials":13136,"activeCount":101},[],{"intervention":13138,"totalTrials":2548,"cells":13139},"[18F]FAPI-74",{"EARLY_PHASE1":13140,"PHASE1":13142,"PHASE2":13144,"PHASE3":13157,"PHASE4":13159,"NA":13161},{"trials":13141,"activeCount":101},[],{"trials":13143,"activeCount":101},[],{"trials":13145,"activeCount":2548,"soonestReadout":5890},[13146],{"nctId":13147,"briefTitle":13148,"status":128,"phases":13149,"primaryCompletion":5890,"completion":13150,"start":851,"enrollment":13151,"conditions":13152,"interventions":13155},"NCT06503146","18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection",[90],"2030-06-01",320,[625,13153,915,13154,3331,1003,801,842,854,961],"Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)","Pheochromocytoma\u002FParaganglioma (PPGL)",[13138,13156],"[18F]FDG",{"trials":13158,"activeCount":101},[],{"trials":13160,"activeCount":101},[],{"trials":13162,"activeCount":101},[],{"intervention":13156,"totalTrials":2548,"cells":13164},{"EARLY_PHASE1":13165,"PHASE1":13167,"PHASE2":13169,"PHASE3":13175,"PHASE4":13177,"NA":13179},{"trials":13166,"activeCount":101},[],{"trials":13168,"activeCount":101},[],{"trials":13170,"activeCount":2548,"soonestReadout":5890},[13171],{"nctId":13147,"briefTitle":13148,"status":128,"phases":13172,"primaryCompletion":5890,"completion":13150,"start":851,"enrollment":13151,"conditions":13173,"interventions":13174},[90],[625,13153,915,13154,3331,1003,801,842,854,961],[13138,13156],{"trials":13176,"activeCount":101},[],{"trials":13178,"activeCount":101},[],{"trials":13180,"activeCount":101},[],{"intervention":13182,"totalTrials":2548,"cells":13183},"Afatinib Dimaleate",{"EARLY_PHASE1":13184,"PHASE1":13186,"PHASE2":13188,"PHASE3":13198,"PHASE4":13200,"NA":13202},{"trials":13185,"activeCount":101},[],{"trials":13187,"activeCount":101},[],{"trials":13189,"activeCount":2548,"soonestReadout":13194},[13190],{"nctId":13191,"briefTitle":13192,"status":155,"phases":13193,"primaryCompletion":13194,"completion":13195,"start":9324,"enrollment":421,"conditions":13196,"interventions":13197},"NCT04439136","Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)",[90],"2021-01-22","2027-03-03",[300,21,113,119,30,4262],[13182],{"trials":13199,"activeCount":101},[],{"trials":13201,"activeCount":101},[],{"trials":13203,"activeCount":101},[],{"intervention":13205,"totalTrials":2548,"cells":13206},"Tazemetostat",{"EARLY_PHASE1":13207,"PHASE1":13209,"PHASE2":13211,"PHASE3":13222,"PHASE4":13224,"NA":13226},{"trials":13208,"activeCount":101},[],{"trials":13210,"activeCount":101},[],{"trials":13212,"activeCount":2548,"soonestReadout":13217},[13213],{"nctId":13214,"briefTitle":13215,"status":155,"phases":13216,"primaryCompletion":13217,"completion":13218,"start":5880,"enrollment":1242,"conditions":13219,"interventions":13221},"NCT03348631","Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer",[90],"2023-07-28","2027-02-12",[13220,5222,251,2751,2752],"Recurrent Endometrial Endometrioid Adenocarcinoma",[13205],{"trials":13223,"activeCount":101},[],{"trials":13225,"activeCount":101},[],{"trials":13227,"activeCount":101},[],{"intervention":545,"totalTrials":2548,"cells":13229},{"EARLY_PHASE1":13230,"PHASE1":13232,"PHASE2":13234,"PHASE3":13240,"PHASE4":13242,"NA":13244},{"trials":13231,"activeCount":101},[],{"trials":13233,"activeCount":101},[],{"trials":13235,"activeCount":2548,"soonestReadout":505},[13236],{"nctId":502,"briefTitle":503,"status":155,"phases":13237,"primaryCompletion":505,"completion":506,"start":507,"enrollment":484,"conditions":13238,"interventions":13239},[90],[509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543],[96,545],{"trials":13241,"activeCount":101},[],{"trials":13243,"activeCount":101},[],{"trials":13245,"activeCount":101},[],{"intervention":2435,"totalTrials":685,"cells":13247},{"EARLY_PHASE1":13248,"PHASE1":13250,"PHASE2":13290,"PHASE3":13315,"PHASE4":13317,"NA":13319},{"trials":13249,"activeCount":101},[],{"trials":13251,"activeCount":603,"soonestReadout":2423},[13252,13260,13264,13268,13272,13278,13286],{"nctId":13253,"briefTitle":13254,"status":618,"phases":13255,"primaryCompletion":3282,"start":4996,"enrollment":28,"conditions":13256,"interventions":13257},"NCT00701298","Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors",[89],[15],[13258,13259],"peginterferon alfa-2b","decitabine",{"nctId":3936,"briefTitle":3937,"status":155,"phases":13261,"primaryCompletion":1603,"completion":1603,"start":3939,"enrollment":16,"conditions":13262,"interventions":13263},[89],[263,2427,2430,2432],[2435,3942,2217],{"nctId":6253,"briefTitle":6254,"status":142,"phases":13265,"primaryCompletion":6256,"start":6257,"enrollment":407,"conditions":13266,"interventions":13267},[89],[2426,33,2430,2432,6259,4132],[1137,2435,942],{"nctId":2420,"briefTitle":2421,"status":155,"phases":13269,"primaryCompletion":2423,"completion":405,"start":2424,"enrollment":484,"conditions":13270,"interventions":13271},[89],[2426,2427,2428,2429,2430,2431,2432,2433],[2435,124],{"nctId":13273,"briefTitle":13274,"status":618,"phases":13275,"primaryCompletion":1912,"start":11246,"enrollment":1195,"conditions":13276,"interventions":13277},"NCT00042796","Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",[89],[4175,8365,8367,4178,2432],[13259],{"nctId":13279,"briefTitle":13280,"status":142,"phases":13281,"primaryCompletion":6569,"start":4997,"enrollment":13282,"conditions":13283,"interventions":13284},"NCT00079378","Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[89],84,[4043,4167,4044,4045,4046,4047,33,655,656,4132],[13259,13285],"valproic acid",{"nctId":9568,"briefTitle":9569,"status":128,"phases":13287,"primaryCompletion":592,"completion":592,"start":9571,"enrollment":298,"conditions":13288,"interventions":13289},[89],[6272,2427,2430],[2435,3976,738],{"trials":13291,"activeCount":101},[13292,13305,13309],{"nctId":13293,"briefTitle":13294,"status":142,"phases":13295,"primaryCompletion":8267,"completion":6303,"start":3397,"enrollment":188,"conditions":13296,"interventions":13303},"NCT00085293","Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131",[90],[10271,13297,13298,13299,13300,13301,13302],"Stage IVA Follicular Thyroid Cancer","Stage IVA Papillary Thyroid Cancer","Stage IVB Follicular Thyroid Cancer","Stage IVB Papillary Thyroid Cancer","Stage IVC Follicular Thyroid Cancer","Stage IVC Papillary Thyroid Cancer",[2435,13304],"Recombinant thyrotropin alfa",{"nctId":4119,"briefTitle":4120,"status":142,"phases":13306,"primaryCompletion":4122,"completion":4123,"start":4124,"enrollment":4125,"conditions":13307,"interventions":13308},[90],[263,4127,4128,4129,4130,4131,4132],[980,1137,1374,2435,279,738],{"nctId":13310,"briefTitle":13311,"status":142,"phases":13312,"primaryCompletion":1053,"start":3390,"enrollment":2319,"conditions":13313,"interventions":13314},"NCT00054431","Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia",[90],[4034,4053,8366,8059,4060],[5456,13259],{"trials":13316,"activeCount":101},[],{"trials":13318,"activeCount":101},[],{"trials":13320,"activeCount":101},[],{"intervention":1597,"totalTrials":771,"cells":13322},{"EARLY_PHASE1":13323,"PHASE1":13325,"PHASE2":13357,"PHASE3":13367,"PHASE4":13369,"NA":13371},{"trials":13324,"activeCount":101},[],{"trials":13326,"activeCount":758,"soonestReadout":1658},[13327,13333,13341,13345,13349,13353],{"nctId":13328,"briefTitle":13329,"status":142,"phases":13330,"primaryCompletion":1230,"start":1977,"enrollment":339,"conditions":13331,"interventions":13332},"NCT00390052","3-AP in Treating Patients With Advanced or Metastatic Solid Tumors",[89],[15],[1597],{"nctId":13334,"briefTitle":13335,"status":142,"phases":13336,"primaryCompletion":13337,"completion":13337,"start":13338,"enrollment":28,"conditions":13339,"interventions":13340},"NCT00288093","3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery",[89],"2012-12-28","2006-12-20",[161,10336],[1671],{"nctId":4363,"briefTitle":4364,"status":142,"phases":13342,"primaryCompletion":4366,"start":3638,"enrollment":700,"conditions":13343,"interventions":13344},[89],[15],[1597,994],{"nctId":1572,"briefTitle":1573,"status":142,"phases":13346,"primaryCompletion":1575,"start":1576,"enrollment":339,"conditions":13347,"interventions":13348},[89],[1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594,1595],[1597,1598],{"nctId":1655,"briefTitle":1656,"status":155,"phases":13350,"primaryCompletion":1658,"completion":1659,"start":1660,"enrollment":1195,"conditions":13351,"interventions":13352},[89],[1662,1663,1664,1665,1666,1667,1539,1540,1542,1547,1550,1668,1669],[278,1671],{"nctId":9955,"briefTitle":9956,"status":155,"phases":13354,"primaryCompletion":9958,"completion":9213,"start":9959,"enrollment":25,"conditions":13355,"interventions":13356},[89],[9961,9962],[9935,1671],{"trials":13358,"activeCount":101},[13359,13363],{"nctId":1816,"briefTitle":1817,"status":142,"phases":13360,"primaryCompletion":1340,"start":1819,"enrollment":1765,"conditions":13361,"interventions":13362},[90],[1821,1579,1790,1591],[1597,1598],{"nctId":2001,"briefTitle":2002,"status":142,"phases":13364,"primaryCompletion":2004,"completion":1319,"start":1171,"enrollment":34,"conditions":13365,"interventions":13366},[90],[1578,1580,2006,2007,2008,2009,2010,1582,1592,1593,1594,1595,2011],[1597,1598],{"trials":13368,"activeCount":101},[],{"trials":13370,"activeCount":101},[],{"trials":13372,"activeCount":101},[],{"intervention":1555,"totalTrials":889,"cells":13374},{"EARLY_PHASE1":13375,"PHASE1":13377,"PHASE2":13452,"PHASE3":13466,"PHASE4":13468,"NA":13470},{"trials":13376,"activeCount":101},[],{"trials":13378,"activeCount":758,"soonestReadout":2576},[13379,13383,13387,13448],{"nctId":11500,"briefTitle":11501,"status":618,"phases":13380,"primaryCompletion":11503,"completion":11503,"start":11504,"enrollment":552,"conditions":13381,"interventions":13382},[89],[263,6272,11506,2454,33,11507,2430,11508,2432],[1555,1710],{"nctId":1524,"briefTitle":1525,"status":618,"phases":13384,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":685,"conditions":13385,"interventions":13386},[89],[1530,1531,1532,1533,1534,1535,1536,1537,1538,1539,1540,1541,1542,1543,1544,1545,1546,1547,1548,1549,1550,1551,1552,1553],[1555,278],{"nctId":13388,"briefTitle":13389,"status":155,"phases":13390,"primaryCompletion":13391,"completion":3039,"start":13392,"enrollment":214,"conditions":13393,"interventions":13447},"NCT04460937","Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers",[89],"2024-03-29","2021-04-09",[13394,13395,2918,13396,13397,7280,13398,13399,2920,13400,13401,13402,13403,13404,13405,13406,7286,2844,13407,13408,13409,13410,13411,13412,13413,13414,13415,13416,13417,13418,13419,13420,13421,13422,13423,13424,13425,13426,13427,13428,13429,13430,13431,13432,13433,13434,13435,13436,13437,13438,13439,13440,13441,13442,13443,13444,13445,13446,7297],"Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Distal Esophagus Adenocarcinoma","Gastric Cardia Adenocarcinoma","Metastatic Esophageal Adenocarcinoma","Metastatic Esophageal Squamous Cell Carcinoma","Metastatic Malignant Neoplasm in the Leptomeninges","Pathologic Stage III Esophageal Adenocarcinoma AJCC v8","Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8","Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8","Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8","Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8","Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8","Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8","Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8","Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8","Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8","Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Unresectable Esophageal Adenocarcinoma","Unresectable Esophageal Carcinoma","Unresectable Esophageal Squamous Cell Carcinoma",[1555],{"nctId":2573,"briefTitle":2574,"status":155,"phases":13449,"primaryCompletion":2576,"completion":361,"start":2133,"enrollment":2577,"conditions":13450,"interventions":13451},[89],[21,486,30,487],[1555,2554],{"trials":13453,"activeCount":101},[13454,13458],{"nctId":7374,"briefTitle":7375,"status":142,"phases":13455,"primaryCompletion":5218,"completion":5610,"start":7377,"enrollment":7378,"conditions":13456,"interventions":13457},[89,90],[7380,7381,7382,7383,5415,7384,7385,116,5416,117,7386,30,5418,120,7387],[1555,1102],{"nctId":13459,"briefTitle":13460,"status":142,"phases":13461,"primaryCompletion":13462,"completion":13462,"start":13463,"enrollment":25,"conditions":13464,"interventions":13465},"NCT03253679","AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification",[90],"2022-10-31","2019-01-16",[21,30],[1555],{"trials":13467,"activeCount":101},[],{"trials":13469,"activeCount":101},[],{"trials":13471,"activeCount":101},[],{"intervention":2634,"totalTrials":603,"cells":13473},{"EARLY_PHASE1":13474,"PHASE1":13476,"PHASE2":13486,"PHASE3":13495,"PHASE4":13497,"NA":13499},{"trials":13475,"activeCount":101},[],{"trials":13477,"activeCount":758,"soonestReadout":361},[13478,13482],{"nctId":7271,"briefTitle":7272,"status":155,"phases":13479,"primaryCompletion":592,"completion":592,"start":7274,"enrollment":2883,"conditions":13480,"interventions":13481},[89],[1607,7276,7277,1609,1611,7278,21,7279,1619,1620,1621,2918,1622,7280,7281,7282,3078,7283,6443,7284,7285,7286,486,7287,3045,5920,7288,7289,7290,5016,7291,7292,3603,7293,7294,7295,7296,7297,487,7298],[2684,2634],{"nctId":2627,"briefTitle":2628,"status":128,"phases":13483,"primaryCompletion":361,"completion":361,"start":2630,"enrollment":913,"conditions":13484,"interventions":13485},[89],[486,2632,487],[2554,2634],{"trials":13487,"activeCount":101},[13488],{"nctId":13489,"briefTitle":13490,"status":347,"phases":13491,"primaryCompletion":799,"completion":799,"start":13492,"enrollment":1054,"conditions":13493,"interventions":13494},"NCT04616560","Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma",[90],"2021-03-08",[790,5872],[2634],{"trials":13496,"activeCount":101},[],{"trials":13498,"activeCount":101},[],{"trials":13500,"activeCount":101},[],{"intervention":1640,"totalTrials":758,"cells":13502},{"EARLY_PHASE1":13503,"PHASE1":13505,"PHASE2":13515,"PHASE3":13517,"PHASE4":13519,"NA":13521},{"trials":13504,"activeCount":101},[],{"trials":13506,"activeCount":758,"soonestReadout":8986},[13507,13511],{"nctId":8983,"briefTitle":8984,"status":155,"phases":13508,"primaryCompletion":8986,"completion":8987,"start":8988,"enrollment":2211,"conditions":13509,"interventions":13510},[89],[8990,21,1615,8991,8992,8993,1967,2647,2610,2611,2612,8994,162,8995,1627,163,8996,8997,1634,164,8998,8999],[1640,289],{"nctId":1600,"briefTitle":1601,"status":155,"phases":13512,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":159,"conditions":13513,"interventions":13514},[89],[1606,1607,1608,1609,1610,1611,1612,1613,1614,21,1615,1616,1617,1618,1619,1620,1621,1622,1623,1624,1625,1626,1627,1628,1629,1630,1631,1632,1633,1634,1635,1636,1637,1638],[278,1640,167],{"trials":13516,"activeCount":101},[],{"trials":13518,"activeCount":101},[],{"trials":13520,"activeCount":101},[],{"trials":13522,"activeCount":101},[],{"intervention":5237,"totalTrials":407,"cells":13524},{"EARLY_PHASE1":13525,"PHASE1":13527,"PHASE2":13558,"PHASE3":13628,"PHASE4":13640,"NA":13642},{"trials":13526,"activeCount":101},[],{"trials":13528,"activeCount":2548,"soonestReadout":9945},[13529,13533,13537,13546,13550],{"nctId":9942,"briefTitle":9943,"status":128,"phases":13530,"primaryCompletion":9945,"completion":9945,"start":9946,"enrollment":339,"conditions":13531,"interventions":13532},[89],[9948,9949,9950,9951,9952],[9935,1832],{"nctId":5227,"briefTitle":5228,"status":142,"phases":13534,"primaryCompletion":5230,"start":3282,"enrollment":889,"conditions":13535,"interventions":13536},[89],[5232,5233,5234,5235,4826,4842,15],[5237,1033],{"nctId":13538,"briefTitle":13539,"status":142,"phases":13540,"primaryCompletion":13541,"completion":13541,"start":13542,"enrollment":421,"conditions":13543,"interventions":13544},"NCT00813423","Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy",[89],"2023-07-18","2010-02-19",[3131],[13545,1832],"Hydroxychloroquine",{"nctId":9453,"briefTitle":9454,"status":142,"phases":13547,"primaryCompletion":5445,"start":4562,"enrollment":19,"conditions":13548,"interventions":13549},[89],[5637,3259,3260,3261,15],[5237,3066],{"nctId":13551,"briefTitle":13552,"status":142,"phases":13553,"primaryCompletion":13554,"completion":13554,"start":13555,"enrollment":37,"conditions":13556,"interventions":13557},"NCT00499135","Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors",[89],"2014-05-14","2007-05-22",[3131,5232,4825,4826,4842],[1832],{"trials":13559,"activeCount":101},[13560,13564,13570,13576,13583,13589,13595,13601,13607,13611,13617],{"nctId":1824,"briefTitle":1825,"status":142,"phases":13561,"primaryCompletion":1827,"completion":1828,"start":1829,"enrollment":286,"conditions":13562,"interventions":13563},[89,90],[274,275],[277,278,279,1832],{"nctId":13565,"briefTitle":13566,"status":142,"phases":13567,"primaryCompletion":812,"completion":3129,"start":7645,"enrollment":827,"conditions":13568,"interventions":13569},"NCT00398112","Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[90],[5663,655,656],[5237],{"nctId":13571,"briefTitle":13572,"status":142,"phases":13573,"primaryCompletion":3304,"start":4715,"enrollment":609,"conditions":13574,"interventions":13575},"NCT00397787","Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine",[90],[3257,3258,3259,3261],[5237],{"nctId":13577,"briefTitle":13578,"status":142,"phases":13579,"primaryCompletion":10267,"completion":10267,"start":1340,"enrollment":25,"conditions":13580,"interventions":13582},"NCT00388037","Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",[90],[13581,1579,1992,3484,1584,1993,3487,1587,1994,3490,1589,1995,3493,1591,1996],"Recurrent Fallopian Tube Cancer",[5237],{"nctId":13584,"briefTitle":13585,"status":142,"phases":13586,"primaryCompletion":2017,"completion":8167,"start":2160,"enrollment":685,"conditions":13587,"interventions":13588},"NCT00451048","Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia",[90],[2453,4056,10520,4061],[5237],{"nctId":13590,"briefTitle":13591,"status":142,"phases":13592,"primaryCompletion":1310,"completion":5270,"start":3304,"enrollment":2577,"conditions":13593,"interventions":13594},"NCT00514137","Sunitinib in Treating Patients With Relapsed Multiple Myeloma",[90],[4262,1430,1431,1432],[5237],{"nctId":13596,"briefTitle":13597,"status":142,"phases":13598,"primaryCompletion":1320,"completion":1022,"start":813,"enrollment":1913,"conditions":13599,"interventions":13600},"NCT00378911","Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus",[90],[8169,10229],[5237],{"nctId":13602,"briefTitle":13603,"status":142,"phases":13604,"primaryCompletion":4611,"completion":7788,"start":1320,"enrollment":25,"conditions":13605,"interventions":13606},"NCT00499473","Sunitinib in Treating Patients With Recurrent Malignant Gliomas",[90],[4813,5275,4817,4818,4819,4820,5280,8148],[5237],{"nctId":6198,"briefTitle":6199,"status":142,"phases":13608,"primaryCompletion":6201,"start":6202,"enrollment":6203,"conditions":13609,"interventions":13610},[90],[5232,6205,6206,6207],[240,1832],{"nctId":13612,"briefTitle":13613,"status":142,"phases":13614,"primaryCompletion":3317,"completion":3317,"start":2487,"enrollment":2401,"conditions":13615,"interventions":13616},"NCT00387335","Sunitinib in Treating Patients With Recurrent and\u002For Metastatic Head and Neck Cancer",[90],[8269,7354,5296,5297,5298,5299,5300,5301,5346,5347,5348,5349,5350,5351],[5237],{"nctId":13618,"briefTitle":13619,"status":618,"phases":13620,"primaryCompletion":1309,"completion":1309,"start":5397,"enrollment":2211,"conditions":13621,"interventions":13627},"NCT00387426","Sunitinib in Treating Patients With Idiopathic Myelofibrosis",[90],[4034,13622,10422,13623,4043,4044,4045,4046,4047,4052,4053,2453,8060,13624,13625,4059,4786,654,1135,33,656,4794,4060,2432,657,659,661,663,4805,10423,4132,13626],"Acute Undifferentiated Leukemia","Adult Acute Myeloid Leukemia in Remission","Mast Cell Leukemia","Meningeal Chronic Myelogenous Leukemia","Untreated Hairy Cell Leukemia",[5237],{"trials":13629,"activeCount":101},[13630],{"nctId":13631,"briefTitle":13632,"status":142,"phases":13633,"primaryCompletion":13634,"completion":13635,"start":13636,"enrollment":13637,"conditions":13638,"interventions":13639},"NCT00693992","Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy",[91],"2013-11-08","2015-05-28","2008-06-15",210,[8913,1931],[1832],{"trials":13641,"activeCount":101},[],{"trials":13643,"activeCount":101},[],{"intervention":9245,"totalTrials":214,"cells":13645},{"EARLY_PHASE1":13646,"PHASE1":13648,"PHASE2":13664,"PHASE3":13670,"PHASE4":13683,"NA":13685},{"trials":13647,"activeCount":101},[],{"trials":13649,"activeCount":2548,"soonestReadout":9239},[13650,13654],{"nctId":9236,"briefTitle":9237,"status":155,"phases":13651,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":339,"conditions":13652,"interventions":13653},[89],[1620,3078,3238,9243,2613],[5018,489,9245],{"nctId":13655,"briefTitle":13656,"status":142,"phases":13657,"primaryCompletion":13658,"start":13659,"enrollment":25,"conditions":13660,"interventions":13661},"NCT01344031","MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer",[89],"2011-07-01","2011-04-21",[3133,3909,2613,3082],[13662,13663,9245],"Akt Inhibitor MK2206","Anastrozole",{"trials":13665,"activeCount":101},[13666],{"nctId":9880,"briefTitle":9881,"status":618,"phases":13667,"primaryCompletion":9883,"completion":9883,"start":9884,"enrollment":2548,"conditions":13668,"interventions":13669},[90],[1620,3238,9243],[5044,9245],{"trials":13671,"activeCount":101},[13672],{"nctId":13673,"briefTitle":13674,"status":142,"phases":13675,"primaryCompletion":13676,"completion":13677,"start":13678,"enrollment":13679,"conditions":13680,"interventions":13682},"NCT00390455","Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive",[91],"2014-07-01","2014-07-02","2006-09-15",295,[3133,1446,3134,13681,2613,3080,3081,3082],"Progesterone Receptor Positive",[9245,7509],{"trials":13684,"activeCount":101},[],{"trials":13686,"activeCount":101},[],{"intervention":6250,"totalTrials":214,"cells":13688},{"EARLY_PHASE1":13689,"PHASE1":13691,"PHASE2":13701,"PHASE3":13711,"PHASE4":13713,"NA":13715},{"trials":13690,"activeCount":101},[],{"trials":13692,"activeCount":2548,"soonestReadout":1603},[13693,13697],{"nctId":6244,"briefTitle":6245,"status":155,"phases":13694,"primaryCompletion":1603,"completion":1603,"start":6247,"enrollment":1765,"conditions":13695,"interventions":13696},[89],[2427,2430],[1137,1471,6250,6251],{"nctId":6289,"briefTitle":6290,"status":142,"phases":13698,"primaryCompletion":6292,"completion":6292,"start":6293,"enrollment":339,"conditions":13699,"interventions":13700},[89],[33,2430],[6296,1137,1471,6250],{"trials":13702,"activeCount":101},[13703,13707],{"nctId":6300,"briefTitle":6301,"status":142,"phases":13704,"primaryCompletion":6303,"completion":6303,"start":3155,"enrollment":6304,"conditions":13705,"interventions":13706},[90],[6306,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,2432,4132],[1998,1263,2324,1187],{"nctId":2315,"briefTitle":2316,"status":142,"phases":13708,"primaryCompletion":2318,"start":1276,"enrollment":2319,"conditions":13709,"interventions":13710},[90],[2296,2321,2297],[2323,2324,1082],{"trials":13712,"activeCount":101},[],{"trials":13714,"activeCount":101},[],{"trials":13716,"activeCount":101},[],{"intervention":6029,"totalTrials":603,"cells":13718},{"EARLY_PHASE1":13719,"PHASE1":13721,"PHASE2":13731,"PHASE3":13742,"PHASE4":13744,"NA":13746},{"trials":13720,"activeCount":101},[],{"trials":13722,"activeCount":2548,"soonestReadout":9056},[13723,13727],{"nctId":6021,"briefTitle":6022,"status":142,"phases":13724,"primaryCompletion":6024,"completion":6024,"start":6025,"enrollment":623,"conditions":13725,"interventions":13726},[89],[6027],[1569,1139,6029],{"nctId":9053,"briefTitle":9054,"status":155,"phases":13728,"primaryCompletion":9056,"completion":9057,"start":9058,"enrollment":9059,"conditions":13729,"interventions":13730},[89],[21],[6029,1653],{"trials":13732,"activeCount":101},[13733],{"nctId":13734,"briefTitle":13735,"status":618,"phases":13736,"primaryCompletion":7788,"completion":7788,"start":5724,"enrollment":188,"conditions":13737,"interventions":13740},"NCT01026324","Dinaciclib in Treating Patients With Stage III-IV Melanoma",[89,90],[13738,13739,1344],"Stage IIIB Melanoma","Stage IIIC Melanoma",[13741],"dinaciclib",{"trials":13743,"activeCount":101},[],{"trials":13745,"activeCount":101},[],{"trials":13747,"activeCount":101},[],{"intervention":1066,"totalTrials":603,"cells":13749},{"EARLY_PHASE1":13750,"PHASE1":13752,"PHASE2":13758,"PHASE3":13768,"PHASE4":13770,"NA":13772},{"trials":13751,"activeCount":101},[],{"trials":13753,"activeCount":2548,"soonestReadout":727},[13754],{"nctId":724,"briefTitle":725,"status":155,"phases":13755,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":13756,"interventions":13757},[89],[732,733,734,735],[63,737,279,738,58,739,212,667,740],{"trials":13759,"activeCount":101},[13760,13764],{"nctId":3584,"briefTitle":3585,"status":142,"phases":13761,"primaryCompletion":3587,"start":3397,"enrollment":37,"conditions":13762,"interventions":13763},[89,90],[3181,940,3189],[3590,1063,3591,1776,1080,750,1066],{"nctId":1049,"briefTitle":1050,"status":142,"phases":13765,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":13766,"interventions":13767},[90],[1056,1057,1058,1059,1060],[1062,1063,693,994,1064,1065,750,1066],{"trials":13769,"activeCount":101},[],{"trials":13771,"activeCount":101},[],{"trials":13773,"activeCount":101},[],{"intervention":2218,"totalTrials":603,"cells":13775},{"EARLY_PHASE1":13776,"PHASE1":13778,"PHASE2":13788,"PHASE3":13794,"PHASE4":13796,"NA":13798},{"trials":13777,"activeCount":101},[],{"trials":13779,"activeCount":2548,"soonestReadout":2209},[13780,13784],{"nctId":2437,"briefTitle":2438,"status":618,"phases":13781,"primaryCompletion":2440,"completion":2441,"start":756,"enrollment":758,"conditions":13782,"interventions":13783},[89],[915],[2444,2445,2218,710,706,1139],{"nctId":2206,"briefTitle":2207,"status":155,"phases":13785,"primaryCompletion":2209,"completion":418,"start":2210,"enrollment":2211,"conditions":13786,"interventions":13787},[89],[2213,2214],[2216,212,1016,2217,58,706,2218,2219],{"trials":13789,"activeCount":101},[13790],{"nctId":5939,"briefTitle":5940,"status":142,"phases":13791,"primaryCompletion":2262,"completion":5942,"start":5943,"enrollment":19,"conditions":13792,"interventions":13793},[89,90],[5945,687,2719],[2256,1407,151,706,5947,2218,1139,5948],{"trials":13795,"activeCount":101},[],{"trials":13797,"activeCount":101},[],{"trials":13799,"activeCount":101},[],{"intervention":2197,"totalTrials":758,"cells":13801},{"EARLY_PHASE1":13802,"PHASE1":13804,"PHASE2":13810,"PHASE3":13818,"PHASE4":13820,"NA":13822},{"trials":13803,"activeCount":101},[],{"trials":13805,"activeCount":2548,"soonestReadout":2189},[13806],{"nctId":2186,"briefTitle":2187,"status":155,"phases":13807,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1798,"conditions":13808,"interventions":13809},[89],[27,2193,2194,773],[2196,1082,2197,2198,2199,2200],{"trials":13811,"activeCount":101},[13812],{"nctId":13813,"briefTitle":13814,"status":142,"phases":13815,"primaryCompletion":4996,"completion":4996,"start":5976,"enrollment":407,"conditions":13816,"interventions":13817},"NCT00109005","Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma",[90],[36],[2197],{"trials":13819,"activeCount":101},[],{"trials":13821,"activeCount":101},[],{"trials":13823,"activeCount":101},[],{"intervention":3942,"totalTrials":603,"cells":13825},{"EARLY_PHASE1":13826,"PHASE1":13828,"PHASE2":13848,"PHASE3":13850,"PHASE4":13852,"NA":13854},{"trials":13827,"activeCount":101},[],{"trials":13829,"activeCount":2548,"soonestReadout":1603},[13830,13834,13844],{"nctId":3936,"briefTitle":3937,"status":155,"phases":13831,"primaryCompletion":1603,"completion":1603,"start":3939,"enrollment":16,"conditions":13832,"interventions":13833},[89],[263,2427,2430,2432],[2435,3942,2217],{"nctId":13835,"briefTitle":13836,"status":142,"phases":13837,"primaryCompletion":13838,"completion":13839,"start":13840,"enrollment":2586,"conditions":13841,"interventions":13843},"NCT03217266","Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma",[89],"2023-08-27","2025-09-04","2018-06-20",[13842,11763],"Resectable Soft Tissue Sarcoma",[3942],{"nctId":4597,"briefTitle":4598,"status":618,"phases":13845,"primaryCompletion":454,"completion":454,"start":4600,"enrollment":638,"conditions":13846,"interventions":13847},[89],[4602,4603,4262],[4605,1139,4606,1016,3942],{"trials":13849,"activeCount":101},[],{"trials":13851,"activeCount":101},[],{"trials":13853,"activeCount":101},[],{"trials":13855,"activeCount":101},[],{"intervention":180,"totalTrials":758,"cells":13857},{"EARLY_PHASE1":13858,"PHASE1":13860,"PHASE2":13870,"PHASE3":13872,"PHASE4":13874,"NA":13876},{"trials":13859,"activeCount":101},[],{"trials":13861,"activeCount":2548,"soonestReadout":172},[13862,13866],{"nctId":6754,"briefTitle":6755,"status":107,"phases":13863,"primaryCompletion":6757,"completion":6757,"start":6757,"enrollment":101,"conditions":13864,"interventions":13865},[89],[6759,6760,6761,6762,4783],[4556,180,4555,780],{"nctId":169,"briefTitle":170,"status":155,"phases":13867,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":13868,"interventions":13869},[89],[176,177,178],[180,96],{"trials":13871,"activeCount":101},[],{"trials":13873,"activeCount":101},[],{"trials":13875,"activeCount":101},[],{"trials":13877,"activeCount":101},[],{"intervention":5894,"totalTrials":758,"cells":13879},{"EARLY_PHASE1":13880,"PHASE1":13882,"PHASE2":13892,"PHASE3":13894,"PHASE4":13896,"NA":13898},{"trials":13881,"activeCount":101},[],{"trials":13883,"activeCount":2548,"soonestReadout":5890},[13884,13888],{"nctId":6908,"briefTitle":6909,"status":618,"phases":13885,"primaryCompletion":6911,"completion":6912,"start":6913,"enrollment":2548,"conditions":13886,"interventions":13887},[89],[1260,6915,6916,6917],[5894,5894,2216],{"nctId":5887,"briefTitle":5888,"status":128,"phases":13889,"primaryCompletion":5890,"completion":418,"start":5891,"enrollment":421,"conditions":13890,"interventions":13891},[89],[791],[5894,5895,151,1102],{"trials":13893,"activeCount":101},[],{"trials":13895,"activeCount":101},[],{"trials":13897,"activeCount":101},[],{"trials":13899,"activeCount":101},[],{"intervention":13901,"totalTrials":2548,"cells":13902},"Metarrestin",{"EARLY_PHASE1":13903,"PHASE1":13905,"PHASE2":13917,"PHASE3":13919,"PHASE4":13921,"NA":13923},{"trials":13904,"activeCount":101},[],{"trials":13906,"activeCount":2548,"soonestReadout":799},[13907],{"nctId":13908,"briefTitle":13909,"status":128,"phases":13910,"primaryCompletion":799,"completion":2114,"start":13911,"enrollment":5585,"conditions":13912,"interventions":13916},"NCT04222413","Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors",[89],"2020-10-27",[10918,13913,13914,13915,4467,5572],"Metastatic Pancreatic Cancer","Pediatric Solid Tumor","Advanced Breast Cancer",[13901],{"trials":13918,"activeCount":101},[],{"trials":13920,"activeCount":101},[],{"trials":13922,"activeCount":101},[],{"trials":13924,"activeCount":101},[],{"intervention":13926,"totalTrials":2548,"cells":13927},"TURALIO",{"EARLY_PHASE1":13928,"PHASE1":13930,"PHASE2":13942,"PHASE3":13944,"PHASE4":13946,"NA":13948},{"trials":13929,"activeCount":101},[],{"trials":13931,"activeCount":2548,"soonestReadout":361},[13932],{"nctId":13933,"briefTitle":13934,"status":128,"phases":13935,"primaryCompletion":361,"completion":2114,"start":13936,"enrollment":484,"conditions":13937,"interventions":13941},"NCT02390752","Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...",[89],"2015-04-29",[13938,13939,13940,625],"Neurofibroma, Plexiform","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Leukemia, Promyelocytic, Acute",[13926],{"trials":13943,"activeCount":101},[],{"trials":13945,"activeCount":101},[],{"trials":13947,"activeCount":101},[],{"trials":13949,"activeCount":101},[],{"intervention":644,"totalTrials":2548,"cells":13951},{"EARLY_PHASE1":13952,"PHASE1":13954,"PHASE2":13960,"PHASE3":13962,"PHASE4":13964,"NA":13966},{"trials":13953,"activeCount":101},[],{"trials":13955,"activeCount":2548,"soonestReadout":635},[13956],{"nctId":632,"briefTitle":633,"status":155,"phases":13957,"primaryCompletion":635,"completion":636,"start":637,"enrollment":638,"conditions":13958,"interventions":13959},[89],[640,641],[63,643,644],{"trials":13961,"activeCount":101},[],{"trials":13963,"activeCount":101},[],{"trials":13965,"activeCount":101},[],{"trials":13967,"activeCount":101},[],{"intervention":13969,"totalTrials":2548,"cells":13970},"pre-operative abemaciclib",{"EARLY_PHASE1":13971,"PHASE1":13973,"PHASE2":13983,"PHASE3":13985,"PHASE4":13987,"NA":13989},{"trials":13972,"activeCount":101},[],{"trials":13974,"activeCount":2548,"soonestReadout":5891},[13975],{"nctId":13976,"briefTitle":13977,"status":155,"phases":13978,"primaryCompletion":5891,"completion":2234,"start":13979,"enrollment":2548,"conditions":13980,"interventions":13981},"NCT05413304","Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis",[89],"2023-04-07",[12114],[13969,13982],"abemaciclib + temozolomide",{"trials":13984,"activeCount":101},[],{"trials":13986,"activeCount":101},[],{"trials":13988,"activeCount":101},[],{"trials":13990,"activeCount":101},[],{"intervention":13982,"totalTrials":2548,"cells":13992},{"EARLY_PHASE1":13993,"PHASE1":13995,"PHASE2":14001,"PHASE3":14003,"PHASE4":14005,"NA":14007},{"trials":13994,"activeCount":101},[],{"trials":13996,"activeCount":2548,"soonestReadout":5891},[13997],{"nctId":13976,"briefTitle":13977,"status":155,"phases":13998,"primaryCompletion":5891,"completion":2234,"start":13979,"enrollment":2548,"conditions":13999,"interventions":14000},[89],[12114],[13969,13982],{"trials":14002,"activeCount":101},[],{"trials":14004,"activeCount":101},[],{"trials":14006,"activeCount":101},[],{"trials":14008,"activeCount":101},[],{"intervention":6278,"totalTrials":2548,"cells":14010},{"EARLY_PHASE1":14011,"PHASE1":14013,"PHASE2":14019,"PHASE3":14021,"PHASE4":14023,"NA":14025},{"trials":14012,"activeCount":101},[],{"trials":14014,"activeCount":2548,"soonestReadout":1382},[14015],{"nctId":6266,"briefTitle":6267,"status":155,"phases":14016,"primaryCompletion":1382,"completion":6269,"start":6270,"enrollment":771,"conditions":14017,"interventions":14018},[89],[6272,6273,6274,2427,6275,2429,2430,6276,2431],[1137,643,4966,6278,6279],{"trials":14020,"activeCount":101},[],{"trials":14022,"activeCount":101},[],{"trials":14024,"activeCount":101},[],{"trials":14026,"activeCount":101},[],{"intervention":6279,"totalTrials":2548,"cells":14028},{"EARLY_PHASE1":14029,"PHASE1":14031,"PHASE2":14037,"PHASE3":14039,"PHASE4":14041,"NA":14043},{"trials":14030,"activeCount":101},[],{"trials":14032,"activeCount":2548,"soonestReadout":1382},[14033],{"nctId":6266,"briefTitle":6267,"status":155,"phases":14034,"primaryCompletion":1382,"completion":6269,"start":6270,"enrollment":771,"conditions":14035,"interventions":14036},[89],[6272,6273,6274,2427,6275,2429,2430,6276,2431],[1137,643,4966,6278,6279],{"trials":14038,"activeCount":101},[],{"trials":14040,"activeCount":101},[],{"trials":14042,"activeCount":101},[],{"trials":14044,"activeCount":101},[],{"intervention":2198,"totalTrials":2548,"cells":14046},{"EARLY_PHASE1":14047,"PHASE1":14049,"PHASE2":14055,"PHASE3":14057,"PHASE4":14059,"NA":14061},{"trials":14048,"activeCount":101},[],{"trials":14050,"activeCount":2548,"soonestReadout":2189},[14051],{"nctId":2186,"briefTitle":2187,"status":155,"phases":14052,"primaryCompletion":2189,"completion":2190,"start":2191,"enrollment":1798,"conditions":14053,"interventions":14054},[89],[27,2193,2194,773],[2196,1082,2197,2198,2199,2200],{"trials":14056,"activeCount":101},[],{"trials":14058,"activeCount":101},[],{"trials":14060,"activeCount":101},[],{"trials":14062,"activeCount":101},[],{"intervention":14064,"totalTrials":2548,"cells":14065},"UAE Inhibitor TAK-243",{"EARLY_PHASE1":14066,"PHASE1":14068,"PHASE2":14079,"PHASE3":14081,"PHASE4":14083,"NA":14085},{"trials":14067,"activeCount":101},[],{"trials":14069,"activeCount":2548,"soonestReadout":14074},[14070],{"nctId":14071,"briefTitle":14072,"status":128,"phases":14073,"primaryCompletion":14074,"completion":14074,"start":14075,"enrollment":5866,"conditions":14076,"interventions":14078},"NCT06223542","Studying TAK-243 in Patients With Advanced Cancer",[89],"2027-04-15","2025-03-24",[300,21,14077,486,116,30],"Indolent Non-Hodgkin Lymphoma",[14064],{"trials":14080,"activeCount":101},[],{"trials":14082,"activeCount":101},[],{"trials":14084,"activeCount":101},[],{"trials":14086,"activeCount":101},[],{"intervention":10338,"totalTrials":2548,"cells":14088},{"EARLY_PHASE1":14089,"PHASE1":14091,"PHASE2":14097,"PHASE3":14099,"PHASE4":14101,"NA":14103},{"trials":14090,"activeCount":101},[],{"trials":14092,"activeCount":2548,"soonestReadout":10333},[14093],{"nctId":10330,"briefTitle":10331,"status":155,"phases":14094,"primaryCompletion":10333,"completion":10334,"start":2277,"enrollment":827,"conditions":14095,"interventions":14096},[89],[1966,2658,3331,10336,9522],[10338,10339,5933],{"trials":14098,"activeCount":101},[],{"trials":14100,"activeCount":101},[],{"trials":14102,"activeCount":101},[],{"trials":14104,"activeCount":101},[],{"intervention":10339,"totalTrials":2548,"cells":14106},{"EARLY_PHASE1":14107,"PHASE1":14109,"PHASE2":14115,"PHASE3":14117,"PHASE4":14119,"NA":14121},{"trials":14108,"activeCount":101},[],{"trials":14110,"activeCount":2548,"soonestReadout":10333},[14111],{"nctId":10330,"briefTitle":10331,"status":155,"phases":14112,"primaryCompletion":10333,"completion":10334,"start":2277,"enrollment":827,"conditions":14113,"interventions":14114},[89],[1966,2658,3331,10336,9522],[10338,10339,5933],{"trials":14116,"activeCount":101},[],{"trials":14118,"activeCount":101},[],{"trials":14120,"activeCount":101},[],{"trials":14122,"activeCount":101},[],{"intervention":14124,"totalTrials":2548,"cells":14125},"aza-TdC",{"EARLY_PHASE1":14126,"PHASE1":14128,"PHASE2":14138,"PHASE3":14140,"PHASE4":14142,"NA":14144},{"trials":14127,"activeCount":101},[],{"trials":14129,"activeCount":2548,"soonestReadout":14134},[14130],{"nctId":14131,"briefTitle":14132,"status":128,"phases":14133,"primaryCompletion":14134,"completion":14134,"start":14135,"enrollment":6425,"conditions":14136,"interventions":14137},"NCT03366116","5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors",[89],"2026-09-30","2018-11-05",[467,3229],[14124],{"trials":14139,"activeCount":101},[],{"trials":14141,"activeCount":101},[],{"trials":14143,"activeCount":101},[],{"trials":14145,"activeCount":101},[],{"intervention":10865,"totalTrials":2548,"cells":14147},{"EARLY_PHASE1":14148,"PHASE1":14150,"PHASE2":14156,"PHASE3":14158,"PHASE4":14160,"NA":14162},{"trials":14149,"activeCount":101},[],{"trials":14151,"activeCount":2548,"soonestReadout":10858},[14152],{"nctId":10855,"briefTitle":10856,"status":155,"phases":14153,"primaryCompletion":10858,"completion":10858,"start":10859,"enrollment":1517,"conditions":14154,"interventions":14155},[89],[1609,7284,10861,10862,10863,2706,250,2760,252,7289,7292],[2888,10865],{"trials":14157,"activeCount":101},[],{"trials":14159,"activeCount":101},[],{"trials":14161,"activeCount":101},[],{"trials":14163,"activeCount":101},[],{"intervention":2219,"totalTrials":2548,"cells":14165},{"EARLY_PHASE1":14166,"PHASE1":14168,"PHASE2":14174,"PHASE3":14176,"PHASE4":14178,"NA":14180},{"trials":14167,"activeCount":101},[],{"trials":14169,"activeCount":2548,"soonestReadout":2209},[14170],{"nctId":2206,"briefTitle":2207,"status":155,"phases":14171,"primaryCompletion":2209,"completion":418,"start":2210,"enrollment":2211,"conditions":14172,"interventions":14173},[89],[2213,2214],[2216,212,1016,2217,58,706,2218,2219],{"trials":14175,"activeCount":101},[],{"trials":14177,"activeCount":101},[],{"trials":14179,"activeCount":101},[],{"trials":14181,"activeCount":101},[],{"intervention":48,"totalTrials":2548,"cells":14183},{"EARLY_PHASE1":14184,"PHASE1":14186,"PHASE2":14192,"PHASE3":14194,"PHASE4":14196,"NA":14198},{"trials":14185,"activeCount":101},[],{"trials":14187,"activeCount":2548,"soonestReadout":47},[14188],{"nctId":45,"briefTitle":46,"status":155,"phases":14189,"primaryCompletion":47,"completion":1461,"start":10178,"enrollment":638,"conditions":14190,"interventions":14191},[89],[21,1343,30,9335,10180,10181,10182,4767],[48,43],{"trials":14193,"activeCount":101},[],{"trials":14195,"activeCount":101},[],{"trials":14197,"activeCount":101},[],{"trials":14199,"activeCount":101},[],{"intervention":86,"totalTrials":2548,"cells":14201},{"EARLY_PHASE1":14202,"PHASE1":14204,"PHASE2":14243,"PHASE3":14245,"PHASE4":14247,"NA":14249},{"trials":14203,"activeCount":101},[],{"trials":14205,"activeCount":2548,"soonestReadout":85},[14206],{"nctId":83,"briefTitle":84,"status":155,"phases":14207,"primaryCompletion":85,"completion":14208,"start":14209,"enrollment":3255,"conditions":14210,"interventions":14242},[89],"2027-03-14","2016-02-01",[1606,14211,14212,14213,14214,14215,14216,14217,14218,14219,14220,10336,4958,14221,14222,14223,14224,4959,14225,14226,14227,14228,4960,14229,14230,14231,14232,4961,14233,14234,14235,14236,9522,4962,14237,14238,14239,4963,14240,14241,4964],"Stage II Esophageal Cancer AJCC v7","Stage II Pancreatic Cancer AJCC v6 and v7","Stage IIA Esophageal Cancer AJCC v7","Stage IIA Pancreatic Cancer AJCC v6 and v7","Stage IIB Esophageal Cancer AJCC v7","Stage IIB Pancreatic Cancer AJCC v6 and v7","Stage III Colon Cancer AJCC v7","Stage III Esophageal Cancer AJCC v7","Stage III Gastric Cancer AJCC v7","Stage III Liver Cancer","Stage III Small Intestinal Cancer AJCC v7","Stage IIIA Colon Cancer AJCC v7","Stage IIIA Esophageal Cancer AJCC v7","Stage IIIA Gastric Cancer AJCC v7","Stage IIIA Small Intestinal Cancer AJCC v7","Stage IIIB Colon Cancer AJCC v7","Stage IIIB Esophageal Cancer AJCC v7","Stage IIIB Gastric Cancer AJCC v7","Stage IIIB Small Intestinal Cancer AJCC v7","Stage IIIC Colon Cancer AJCC v7","Stage IIIC Esophageal Cancer AJCC v7","Stage IIIC Gastric Cancer AJCC v7","Stage IV Colon Cancer AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","Stage IV Liver Cancer","Stage IV Small Intestinal Cancer AJCC v7","Stage IVA Colon Cancer AJCC v7","Stage IVA Liver Cancer","Stage IVB Colon Cancer AJCC v7","Stage IVB Liver Cancer",[86],{"trials":14244,"activeCount":101},[],{"trials":14246,"activeCount":101},[],{"trials":14248,"activeCount":101},[],{"trials":14250,"activeCount":101},[],{"intervention":11008,"totalTrials":2548,"cells":14252},{"EARLY_PHASE1":14253,"PHASE1":14255,"PHASE2":14261,"PHASE3":14263,"PHASE4":14265,"NA":14267},{"trials":14254,"activeCount":101},[],{"trials":14256,"activeCount":2548,"soonestReadout":10407},[14257],{"nctId":11000,"briefTitle":11001,"status":128,"phases":14258,"primaryCompletion":10407,"completion":11003,"start":11004,"enrollment":827,"conditions":14259,"interventions":14260},[89],[11006],[11008,10993],{"trials":14262,"activeCount":101},[],{"trials":14264,"activeCount":101},[],{"trials":14266,"activeCount":101},[],{"trials":14268,"activeCount":101},[],{"intervention":14270,"totalTrials":2548,"cells":14271},"Defined Green Tea Catechin Extract",{"EARLY_PHASE1":14272,"PHASE1":14274,"PHASE2":14284,"PHASE3":14286,"PHASE4":14288,"NA":14290},{"trials":14273,"activeCount":101},[],{"trials":14275,"activeCount":2548,"soonestReadout":14280},[14276],{"nctId":14277,"briefTitle":14278,"status":155,"phases":14279,"primaryCompletion":14280,"completion":1961,"start":14281,"enrollment":2211,"conditions":14282,"interventions":14283},"NCT03278925","Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis",[89],"2023-06-16","2018-08-09",[10156],[14270],{"trials":14285,"activeCount":101},[],{"trials":14287,"activeCount":101},[],{"trials":14289,"activeCount":101},[],{"trials":14291,"activeCount":101},[],{"intervention":5895,"totalTrials":2548,"cells":14293},{"EARLY_PHASE1":14294,"PHASE1":14296,"PHASE2":14302,"PHASE3":14304,"PHASE4":14306,"NA":14308},{"trials":14295,"activeCount":101},[],{"trials":14297,"activeCount":2548,"soonestReadout":5890},[14298],{"nctId":5887,"briefTitle":5888,"status":128,"phases":14299,"primaryCompletion":5890,"completion":418,"start":5891,"enrollment":421,"conditions":14300,"interventions":14301},[89],[791],[5894,5895,151,1102],{"trials":14303,"activeCount":101},[],{"trials":14305,"activeCount":101},[],{"trials":14307,"activeCount":101},[],{"trials":14309,"activeCount":101},[],{"intervention":14311,"totalTrials":2548,"cells":14312},"Novobiocin Sodium",{"EARLY_PHASE1":14313,"PHASE1":14315,"PHASE2":14325,"PHASE3":14327,"PHASE4":14329,"NA":14331},{"trials":14314,"activeCount":101},[],{"trials":14316,"activeCount":2548,"soonestReadout":14321},[14317],{"nctId":14318,"briefTitle":14319,"status":128,"phases":14320,"primaryCompletion":14321,"completion":2983,"start":14322,"enrollment":5986,"conditions":14323,"interventions":14324},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[89],"2026-08-01","2023-07-06",[486,487],[14311],{"trials":14326,"activeCount":101},[],{"trials":14328,"activeCount":101},[],{"trials":14330,"activeCount":101},[],{"trials":14332,"activeCount":101},[],{"intervention":805,"totalTrials":2548,"cells":14334},{"EARLY_PHASE1":14335,"PHASE1":14337,"PHASE2":14343,"PHASE3":14345,"PHASE4":14347,"NA":14349},{"trials":14336,"activeCount":101},[],{"trials":14338,"activeCount":2548,"soonestReadout":361},[14339],{"nctId":796,"briefTitle":797,"status":128,"phases":14340,"primaryCompletion":361,"completion":799,"start":392,"enrollment":174,"conditions":14341,"interventions":14342},[89],[801,802,803],[63,805,643],{"trials":14344,"activeCount":101},[],{"trials":14346,"activeCount":101},[],{"trials":14348,"activeCount":101},[],{"trials":14350,"activeCount":101},[],{"intervention":1062,"totalTrials":19,"cells":14352},{"EARLY_PHASE1":14353,"PHASE1":14355,"PHASE2":14430,"PHASE3":14550,"PHASE4":14556,"NA":14558},{"trials":14354,"activeCount":101},[],{"trials":14356,"activeCount":101},[14357,14363,14367,14373,14377,14381,14389,14395,14401,14410,14416,14420,14424],{"nctId":14358,"briefTitle":14359,"status":618,"phases":14360,"primaryCompletion":1320,"start":6477,"enrollment":1517,"conditions":14361,"interventions":14362},"NCT00006773","Bortezomib in Treating Patients With Recurrent Glioma",[89],[4813,4815,4817,4818,4819,5287],[1062],{"nctId":6021,"briefTitle":6022,"status":142,"phases":14364,"primaryCompletion":6024,"completion":6024,"start":6025,"enrollment":623,"conditions":14365,"interventions":14366},[89],[6027],[1569,1139,6029],{"nctId":14368,"briefTitle":14369,"status":618,"phases":14370,"primaryCompletion":3317,"start":4639,"enrollment":700,"conditions":14371,"interventions":14372},"NCT00096005","Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas",[89],[3157,1281,4775,4776,1245,1246,3180,3181,3182,3183,3184,4681,3185,3186,4787,9449,3187,3188,940,3189,3190,4792,655,3200,1333,3201,3202,7597,3203,3204,11098,11099,3205,3206,3207,1059,3208,11100,662,3209,1334,3210,3211,4796,3212,3213,4797,9450,3214,3215,3216,1060,3217,11101,664,15,1251],[6287,1062],{"nctId":1557,"briefTitle":1558,"status":142,"phases":14374,"primaryCompletion":1560,"completion":1560,"start":1561,"enrollment":603,"conditions":14375,"interventions":14376},[89],[1563,1564,1565,1566,1567],[1569,1570,278],{"nctId":3530,"briefTitle":3531,"status":142,"phases":14378,"primaryCompletion":1426,"start":3533,"enrollment":2029,"conditions":14379,"interventions":14380},[89],[15],[1062,1776,1080],{"nctId":14382,"briefTitle":14383,"status":142,"phases":14384,"primaryCompletion":14385,"start":3453,"enrollment":2319,"conditions":14386,"interventions":14388},"NCT00091117","Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction",[89],"2013-03",[14387,5283],"Hepatic Complications",[1062],{"nctId":14390,"briefTitle":14391,"status":618,"phases":14392,"primaryCompletion":4165,"start":5976,"enrollment":159,"conditions":14393,"interventions":14394},"NCT00103272","17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer",[89],[4035,4036,4037,4038,4039,4040,4041,4042,4043,4044,4046,4047,4048,4050,4051,4775,4776,1245,1246,1135,33,3181,4787,9449,3187,3188,940,3189,3190,4792,655,656,4795,1248,1251],[6287,1062],{"nctId":14396,"briefTitle":14397,"status":142,"phases":14398,"primaryCompletion":5724,"start":3390,"enrollment":8066,"conditions":14399,"interventions":14400},"NCT00054483","Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction",[89],[3157,3158,1245,1246,3180,3181,3182,3183,3184,3185,3186,3187,3188,940,3189,3190,655,4262,1248,1432,3209,1334,3210,3211,3212,3213,3214,3215,3216,1060,3217,664,15,1251],[1062],{"nctId":14402,"briefTitle":14403,"status":142,"phases":14404,"primaryCompletion":14405,"completion":14406,"start":14407,"enrollment":37,"conditions":14408,"interventions":14409},"NCT00011778","PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck",[89],"2010-08-26","2013-02-08","2001-02-22",[576],[1062],{"nctId":14411,"briefTitle":14412,"status":142,"phases":14413,"primaryCompletion":4860,"completion":4860,"start":3115,"enrollment":700,"conditions":14414,"interventions":14415},"NCT00021216","Bortezomib in Treating Children With Advanced Solid Tumors",[89],[748],[1062],{"nctId":1692,"briefTitle":1693,"status":142,"phases":14417,"primaryCompletion":1329,"start":987,"enrollment":730,"conditions":14418,"interventions":14419},[89],[1564],[1697,1062,1598],{"nctId":5001,"briefTitle":5002,"status":142,"phases":14421,"primaryCompletion":1231,"start":5004,"enrollment":28,"conditions":14422,"interventions":14423},[89],[15],[1062,3065,1264],{"nctId":14425,"briefTitle":14426,"status":142,"phases":14427,"primaryCompletion":1576,"start":3638,"enrollment":700,"conditions":14428,"interventions":14429},"NCT00077467","Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia",[89],[4053,8365,8367,4178],[1062],{"trials":14431,"activeCount":101},[14432,14438,14442,14446,14450,14454,14461,14465,14469,14473,14477,14481,14487,14491,14495,14503,14509,14513,14520,14524,14531,14542,14546],{"nctId":14433,"briefTitle":14434,"status":142,"phases":14435,"primaryCompletion":3272,"completion":5858,"start":1241,"enrollment":339,"conditions":14436,"interventions":14437},"NCT00104871","Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy",[90],[11183,10271,11184,11185,11186,11187],[1569],{"nctId":8446,"briefTitle":8447,"status":142,"phases":14439,"primaryCompletion":3389,"completion":2292,"start":3273,"enrollment":623,"conditions":14440,"interventions":14441},[90],[1915,6532,6533,6534,3118,6536,6537,6520],[1062,8451],{"nctId":1049,"briefTitle":1050,"status":142,"phases":14443,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":14444,"interventions":14445},[90],[1056,1057,1058,1059,1060],[1062,1063,693,994,1064,1065,750,1066],{"nctId":11150,"briefTitle":11151,"status":142,"phases":14447,"primaryCompletion":5270,"completion":1299,"start":4611,"enrollment":455,"conditions":14448,"interventions":14449},[90],[10227,10228,1096],[4063,1062],{"nctId":11156,"briefTitle":11157,"status":142,"phases":14451,"primaryCompletion":649,"completion":3479,"start":4366,"enrollment":1913,"conditions":14452,"interventions":14453},[90],[4817,4818,4819,5287],[4063,1062],{"nctId":14455,"briefTitle":14456,"status":142,"phases":14457,"primaryCompletion":1022,"completion":1022,"start":14458,"enrollment":16,"conditions":14459,"interventions":14460},"NCT00023712","Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer",[90],"2001-11-05",[1821,1579],[1062],{"nctId":4162,"briefTitle":4163,"status":142,"phases":14462,"primaryCompletion":3226,"completion":3226,"start":4165,"enrollment":3869,"conditions":14463,"interventions":14464},[90],[4039,4040,4041,4042,4043,4167,4045,4046,4048,4168,4169,4170,4171,4172,4173,4174,4175,4176,4177,33,4178,2432],[4180,1187,1062,1080],{"nctId":7578,"briefTitle":7579,"status":142,"phases":14466,"primaryCompletion":7581,"completion":2027,"start":1340,"enrollment":34,"conditions":14467,"interventions":14468},[90],[7583,7584,7585,7586,7587,7588,7589,7590,7591,7592,4681,4793,7593,7594,7595,7596,7597,7598,4796,4799],[3591,1062,2166,750],{"nctId":3301,"briefTitle":3302,"status":142,"phases":14470,"primaryCompletion":3304,"start":1912,"enrollment":700,"conditions":14471,"interventions":14472},[90],[3306,3307,3308,3309,1343,1344],[1776,995,1062],{"nctId":3635,"briefTitle":3636,"status":142,"phases":14474,"primaryCompletion":1781,"start":3638,"enrollment":3639,"conditions":14475,"interventions":14476},[90],[3119,1772,3285],[3066,1776,1062],{"nctId":7793,"briefTitle":7794,"status":142,"phases":14478,"primaryCompletion":7796,"completion":7797,"start":7798,"enrollment":913,"conditions":14479,"interventions":14480},[90],[7105,7106,7107],[1569,2789],{"nctId":14482,"briefTitle":14483,"status":142,"phases":14484,"primaryCompletion":5634,"start":5976,"enrollment":913,"conditions":14485,"interventions":14486},"NCT00077441","Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)",[90],[4862,4863,4864,4890],[1062],{"nctId":6779,"briefTitle":6780,"status":142,"phases":14488,"primaryCompletion":1230,"completion":6782,"start":6530,"enrollment":1517,"conditions":14489,"interventions":14490},[90],[4862,4863,4864,4890],[1225,1062],{"nctId":7418,"briefTitle":7419,"status":142,"phases":14492,"primaryCompletion":4031,"completion":4031,"start":1819,"enrollment":9,"conditions":14493,"interventions":14494},[90],[5296,5297,5298,5299,5300,5301,5302,5303,5346,5347,5349,5352,7422,7423,7424,7425,7426,7427,7428,7429,7430,7431,7432,7433,7434],[1062,5106],{"nctId":14496,"briefTitle":14497,"status":142,"phases":14498,"primaryCompletion":14499,"start":14500,"enrollment":638,"conditions":14501,"interventions":14502},"NCT00025584","PS-341 in Treating Women With Metastatic Breast Cancer",[90],"2004-08","2001-08",[3117,3137],[1062],{"nctId":14504,"briefTitle":14505,"status":142,"phases":14506,"primaryCompletion":8167,"completion":8167,"start":3638,"enrollment":1913,"conditions":14507,"interventions":14508},"NCT00075881","Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma",[90],[1430,1431,1432],[1062],{"nctId":7051,"briefTitle":7052,"status":142,"phases":14510,"primaryCompletion":649,"completion":649,"start":3587,"enrollment":5714,"conditions":14511,"interventions":14512},[90],[7055,3119,3285],[1775,1062],{"nctId":14514,"briefTitle":14515,"status":142,"phases":14516,"primaryCompletion":14385,"completion":14385,"start":5976,"enrollment":5986,"conditions":14517,"interventions":14518},"NCT00108069","Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors",[90],[12114],[14519,1569],"Tamoxifen citrate",{"nctId":5787,"briefTitle":5788,"status":142,"phases":14521,"primaryCompletion":5790,"completion":5791,"start":5792,"enrollment":2265,"conditions":14522,"interventions":14523},[90],[5794,5795],[667,5758,1569,1569,5797],{"nctId":14525,"briefTitle":14526,"status":142,"phases":14527,"primaryCompletion":1310,"completion":1310,"start":1181,"enrollment":14528,"conditions":14529,"interventions":14530},"NCT00023764","Bortezomib in Treating Patients With Lymphoproliferative Disorders",[90],103,[3187,3188,940,3189],[1062],{"nctId":14532,"briefTitle":14533,"status":618,"phases":14534,"primaryCompletion":14535,"completion":14536,"start":14537,"enrollment":2401,"conditions":14538,"interventions":14540},"NCT00923247","A Targeted Phase I\u002FII Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",[89,90],"2016-04-01","2016-12-09","2009-02-19",[14539],"Medullary Thyroid Carcinoma",[1569,14541],"Vandetanib",{"nctId":9533,"briefTitle":9534,"status":142,"phases":14543,"primaryCompletion":1781,"start":2487,"enrollment":234,"conditions":14544,"interventions":14545},[90],[6506,9537],[1062,3066],{"nctId":5803,"briefTitle":5804,"status":142,"phases":14547,"primaryCompletion":5806,"completion":5807,"start":5808,"enrollment":651,"conditions":14548,"interventions":14549},[89,90],[4592,3189,3190,4530,655,5810,4531,4536,4537,4539,4540],[1569,1139,667,2143],{"trials":14551,"activeCount":101},[14552],{"nctId":6134,"briefTitle":6135,"status":142,"phases":14553,"primaryCompletion":6137,"completion":6138,"start":3479,"enrollment":375,"conditions":14554,"interventions":14555},[91],[4738,6140],[1081,1065,1062],{"trials":14557,"activeCount":101},[],{"trials":14559,"activeCount":101},[],{"intervention":5456,"totalTrials":188,"cells":14561},{"EARLY_PHASE1":14562,"PHASE1":14564,"PHASE2":14570,"PHASE3":14619,"PHASE4":14636,"NA":14638},{"trials":14563,"activeCount":101},[],{"trials":14565,"activeCount":101},[14566],{"nctId":8055,"briefTitle":8056,"status":618,"phases":14567,"primaryCompletion":5445,"start":5976,"enrollment":1195,"conditions":14568,"interventions":14569},[89],[4034,4053,8059,8060,4060],[5456,4566],{"trials":14571,"activeCount":101},[14572,14578,14584,14591,14597,14601,14605,14609,14613],{"nctId":14573,"briefTitle":14574,"status":618,"phases":14575,"primaryCompletion":3587,"start":3480,"enrollment":12668,"conditions":14576,"interventions":14577},"NCT00091078","Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery",[90],[7344],[3590,5456],{"nctId":14579,"briefTitle":14580,"status":142,"phases":14581,"primaryCompletion":649,"completion":649,"start":3638,"enrollment":34,"conditions":14582,"interventions":14583},"NCT00075400","Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer",[90],[8169,5556],[5456],{"nctId":14585,"briefTitle":14586,"status":142,"phases":14587,"primaryCompletion":987,"start":9425,"enrollment":14588,"conditions":14589,"interventions":14590},"NCT00052949","Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer",[90],91,[3120],[5456],{"nctId":14592,"briefTitle":14593,"status":142,"phases":14594,"primaryCompletion":5958,"start":1764,"conditions":14595,"interventions":14596},"NCT00039585","Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor",[90],[2569,1003,1821],[5456],{"nctId":5449,"briefTitle":5450,"status":142,"phases":14598,"primaryCompletion":1171,"completion":1171,"start":5452,"enrollment":421,"conditions":14599,"interventions":14600},[89,90],[1343,5454,1344,15],[5456,1033],{"nctId":7519,"briefTitle":7520,"status":142,"phases":14602,"primaryCompletion":1763,"completion":1763,"start":1257,"enrollment":2029,"conditions":14603,"interventions":14604},[90],[18],[2924,7524],{"nctId":13310,"briefTitle":13311,"status":142,"phases":14606,"primaryCompletion":1053,"start":3390,"enrollment":2319,"conditions":14607,"interventions":14608},[90],[4034,4053,8366,8059,4060],[5456,13259],{"nctId":11839,"briefTitle":11840,"status":142,"phases":14610,"primaryCompletion":6513,"completion":6513,"start":3129,"enrollment":2211,"conditions":14611,"interventions":14612},[89,90],[10226,10227,10228,1096],[11844,5456],{"nctId":14614,"briefTitle":14615,"status":142,"phases":14616,"primaryCompletion":7645,"start":4142,"enrollment":421,"conditions":14617,"interventions":14618},"NCT00036751","Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer",[90],[1821,1579,1790,1591],[5456],{"trials":14620,"activeCount":101},[14621,14629],{"nctId":14622,"briefTitle":14623,"status":618,"phases":14624,"primaryCompletion":1053,"completion":5985,"start":1288,"enrollment":14625,"conditions":14626,"interventions":14627},"NCT00009906","Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor",[91],748,[7344],[14628],"Imatinib Mesylate",{"nctId":14630,"briefTitle":14631,"status":142,"phases":14632,"primaryCompletion":1217,"start":2181,"enrollment":14633,"conditions":14634,"interventions":14635},"NCT00041197","Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery",[91],732,[7344],[5456],{"trials":14637,"activeCount":101},[],{"trials":14639,"activeCount":101},[],{"intervention":3299,"totalTrials":685,"cells":14641},{"EARLY_PHASE1":14642,"PHASE1":14644,"PHASE2":14663,"PHASE3":14704,"PHASE4":14710,"NA":14712},{"trials":14643,"activeCount":101},[],{"trials":14645,"activeCount":101},[14646,14659],{"nctId":14647,"briefTitle":14648,"status":142,"phases":14649,"primaryCompletion":14650,"completion":14651,"start":14652,"enrollment":1041,"conditions":14653,"interventions":14657},"NCT02101905","Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma",[89],"2021-10-19","2024-10-30","2016-11-07",[4632,14654,14655,148,14656,4821,354],"Anaplastic Ependymoma","Anaplastic Oligodendroglioma","Mixed Glioma",[14658,7509],"Lapatinib",{"nctId":11431,"briefTitle":11432,"status":142,"phases":14660,"primaryCompletion":11434,"completion":11434,"start":9770,"enrollment":19,"conditions":14661,"interventions":14662},[89],[11436,3909,2613,3082],[474,7509,1455],{"trials":14664,"activeCount":101},[14665,14671,14675,14679,14685,14691,14697],{"nctId":14666,"briefTitle":14667,"status":142,"phases":14668,"primaryCompletion":1977,"start":3526,"enrollment":6854,"conditions":14669,"interventions":14670},"NCT00098631","Lapatinib in Treating Patients With Recurrent and\u002For Metastatic Head and Neck Cancer",[90],[8207,7354,5296,5297,5298,5299,5300,5301,2058,5346,5347,5348,5349,5350,5351,7365],[3299],{"nctId":3292,"briefTitle":3293,"status":142,"phases":14672,"primaryCompletion":3295,"completion":786,"start":1319,"enrollment":827,"conditions":14673,"interventions":14674},[90],[3297,1220,1221],[3299,995,3122],{"nctId":7501,"briefTitle":7502,"status":142,"phases":14676,"primaryCompletion":7504,"completion":7505,"start":7506,"enrollment":609,"conditions":14677,"interventions":14678},[90],[1446,2613,3080,3081,3082],[2924,1099,7509],{"nctId":14680,"briefTitle":14681,"status":142,"phases":14682,"primaryCompletion":2293,"start":4639,"enrollment":623,"conditions":14683,"interventions":14684},"NCT00095667","Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer",[90],[2321,2297],[3299],{"nctId":14686,"briefTitle":14687,"status":142,"phases":14688,"primaryCompletion":813,"completion":813,"start":4612,"enrollment":28,"conditions":14689,"interventions":14690},"NCT00114283","Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer",[90],[5295,5296,5297,5298,5299,5300,5301,5302,5303,2058,5346,5349,8270,8271,7422,7423,7424,8272,7425,8273,8274,7426,7427,7428,8275,7429,8276,8277,7430,7431,7432,8278,7433,7434],[3299],{"nctId":14692,"briefTitle":14693,"status":142,"phases":14694,"primaryCompletion":2293,"completion":2293,"start":1241,"enrollment":339,"conditions":14695,"interventions":14696},"NCT00099060","Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme",[89,90],[3664],[3299],{"nctId":14698,"briefTitle":14699,"status":142,"phases":14700,"primaryCompletion":14701,"completion":14701,"start":4639,"enrollment":2294,"conditions":14702,"interventions":14703},"NCT00101036","Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery",[90],"2009-01",[4862,4863,4864,4890,7352,7353,7363,7364],[3299],{"trials":14705,"activeCount":101},[14706],{"nctId":13673,"briefTitle":13674,"status":142,"phases":14707,"primaryCompletion":13676,"completion":13677,"start":13678,"enrollment":13679,"conditions":14708,"interventions":14709},[91],[3133,1446,3134,13681,2613,3080,3081,3082],[9245,7509],{"trials":14711,"activeCount":101},[],{"trials":14713,"activeCount":101},[],{"intervention":3122,"totalTrials":685,"cells":14715},{"EARLY_PHASE1":14716,"PHASE1":14718,"PHASE2":14735,"PHASE3":14777,"PHASE4":14783,"NA":14785},{"trials":14717,"activeCount":101},[],{"trials":14719,"activeCount":101},[14720,14724,14731],{"nctId":11431,"briefTitle":11432,"status":142,"phases":14721,"primaryCompletion":11434,"completion":11434,"start":9770,"enrollment":19,"conditions":14722,"interventions":14723},[89],[11436,3909,2613,3082],[474,7509,1455],{"nctId":14725,"briefTitle":14726,"status":142,"phases":14727,"primaryCompletion":3638,"start":4259,"enrollment":31,"conditions":14728,"interventions":14729},"NCT00022529","BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors",[89],[15],[14730,3122],"BMS-214662",{"nctId":3112,"briefTitle":3113,"status":142,"phases":14732,"primaryCompletion":1309,"start":3115,"enrollment":827,"conditions":14733,"interventions":14734},[89],[1219,3117,2706,3118,3119,1579,3120],[3122,995,3123],{"trials":14736,"activeCount":101},[14737,14743,14750,14754,14764,14768],{"nctId":14738,"briefTitle":14739,"status":142,"phases":14740,"primaryCompletion":5461,"start":5115,"enrollment":13282,"conditions":14741,"interventions":14742},"NCT00004883","Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2",[90],[3119,1772,3285],[3122],{"nctId":14744,"briefTitle":14745,"status":142,"phases":14746,"primaryCompletion":1781,"start":14747,"enrollment":3983,"conditions":14748,"interventions":14749},"NCT00024154","Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer",[90],"2002-02",[1219,3117,3137],[3122,3342],{"nctId":3292,"briefTitle":3293,"status":142,"phases":14751,"primaryCompletion":3295,"completion":786,"start":1319,"enrollment":827,"conditions":14752,"interventions":14753},[90],[3297,1220,1221],[3299,995,3122],{"nctId":14755,"briefTitle":14756,"status":142,"phases":14757,"primaryCompletion":14758,"completion":14759,"start":14760,"enrollment":1798,"conditions":14761,"interventions":14763},"NCT00006089","Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",[90],"2007-09-04","2010-01-31","2000-09-18",[1941,14762,5549,1546,9411],"ERBB2 Gene Amplification",[1455],{"nctId":11357,"briefTitle":11358,"status":142,"phases":14765,"primaryCompletion":4272,"start":6478,"enrollment":19,"conditions":14766,"interventions":14767},[90],[3297,1219,3117,3137],[3122,818],{"nctId":14769,"briefTitle":14770,"status":107,"phases":14771,"primaryCompletion":14772,"completion":14772,"start":14773,"enrollment":101,"conditions":14774,"interventions":14775},"NCT01679743","GRN1005 for Brain Metastases From Breast or Lung Cancer",[90],"2014-08-11","2012-08-29",[18,2718,1291,687],[1455,14776],"GRN 1005",{"trials":14778,"activeCount":101},[14779],{"nctId":1437,"briefTitle":1438,"status":142,"phases":14780,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":1443,"conditions":14781,"interventions":14782},[91],[1445,1446,1447,1448,1449,1450,1451],[1453,63,737,449,1454,1455],{"trials":14784,"activeCount":101},[],{"trials":14786,"activeCount":101},[],{"intervention":3470,"totalTrials":771,"cells":14788},{"EARLY_PHASE1":14789,"PHASE1":14791,"PHASE2":14793,"PHASE3":14832,"PHASE4":14850,"NA":14852},{"trials":14790,"activeCount":101},[],{"trials":14792,"activeCount":101},[],{"trials":14794,"activeCount":101},[14795,14803,14812,14818,14822],{"nctId":14796,"briefTitle":14797,"status":142,"phases":14798,"primaryCompletion":1952,"start":14799,"enrollment":638,"conditions":14800,"interventions":14801},"NCT00017316","Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma",[90],"2001-03",[2490],[14802,3470],"semaxanib",{"nctId":14804,"briefTitle":14805,"status":142,"phases":14806,"primaryCompletion":3273,"completion":4366,"start":14807,"enrollment":1074,"conditions":14808,"interventions":14810},"NCT00025220","Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus",[90],"2001-09",[14809,556],"Recurrent Uterine Corpus Sarcoma",[14811],"Thalidomide",{"nctId":14813,"briefTitle":14814,"status":618,"phases":14815,"primaryCompletion":4715,"start":3254,"enrollment":1111,"conditions":14816,"interventions":14817},"NCT00009984","Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer",[90],[655,656],[819,3470],{"nctId":5430,"briefTitle":5431,"status":142,"phases":14819,"completion":4639,"start":5433,"conditions":14820,"interventions":14821},[90],[4842,5233],[1033,3470],{"nctId":14823,"briefTitle":14824,"status":142,"phases":14825,"primaryCompletion":1781,"start":14807,"enrollment":1074,"conditions":14826,"interventions":14831},"NCT00025467","Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer",[90],[14827,1941,14828,14829,14830,2706],"Endometrial Adenoacanthoma","Endometrial Adenosquamous Cell Carcinoma","Endometrial Clear Cell Carcinoma","Endometrial Papillary Serous Carcinoma",[3470],{"trials":14833,"activeCount":101},[14834,14838,14846],{"nctId":6125,"briefTitle":6126,"status":142,"phases":14835,"primaryCompletion":1576,"completion":5634,"start":4142,"conditions":14836,"interventions":14837},[91],[6129],[1065,6131,3470,6132],{"nctId":14839,"briefTitle":14840,"status":142,"phases":14841,"primaryCompletion":4032,"start":3254,"enrollment":14842,"conditions":14843,"interventions":14845},"NCT00033254","Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases",[91],332,[14844],"Tumors Metastatic to Brain",[3470],{"nctId":3464,"briefTitle":3465,"status":618,"phases":14847,"primaryCompletion":3389,"completion":3317,"start":3099,"enrollment":3467,"conditions":14848,"interventions":14849},[91],[687],[1776,995,3470],{"trials":14851,"activeCount":101},[],{"trials":14853,"activeCount":101},[],{"intervention":14855,"totalTrials":214,"cells":14856},"sulindac",{"EARLY_PHASE1":14857,"PHASE1":14859,"PHASE2":14861,"PHASE3":14890,"PHASE4":14901,"NA":14903},{"trials":14858,"activeCount":101},[],{"trials":14860,"activeCount":101},[],{"trials":14862,"activeCount":101},[14863,14872,14882],{"nctId":14864,"briefTitle":14865,"status":618,"phases":14866,"primaryCompletion":14867,"completion":14867,"start":7628,"enrollment":603,"conditions":14868,"interventions":14870},"NCT01856322","Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer",[90],"2015-01",[856,14869,5574],"Liver Metastasis",[14871],"Sulindac",{"nctId":14873,"briefTitle":14874,"status":142,"phases":14875,"primaryCompletion":4996,"completion":4996,"start":1576,"enrollment":14876,"conditions":14877,"interventions":14879},"NCT00335504","Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia",[90],85,[843,14878,844],"Precancerous Condition",[14880,14855,14881],"oligofructose-enriched inulin","atorvastatin calcium",{"nctId":14883,"briefTitle":14884,"status":142,"phases":14885,"primaryCompletion":3272,"completion":1329,"start":2487,"enrollment":14886,"conditions":14887,"interventions":14889},"NCT00368927","Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia",[90],61,[14878,14888,11697],"Stage I Non-small Cell Lung Cancer",[14855],{"trials":14891,"activeCount":101},[14892],{"nctId":14893,"briefTitle":14894,"status":142,"phases":14895,"primaryCompletion":5444,"completion":5444,"start":14896,"enrollment":14897,"conditions":14898,"interventions":14899},"NCT00118365","Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps",[91],"1998-07",375,[14878],[14900,14855],"eflornithine",{"trials":14902,"activeCount":101},[],{"trials":14904,"activeCount":101},[],{"intervention":14906,"totalTrials":214,"cells":14907},"GM-CSF",{"EARLY_PHASE1":14908,"PHASE1":14910,"PHASE2":14923,"PHASE3":14951,"PHASE4":14961,"NA":14963},{"trials":14909,"activeCount":101},[],{"trials":14911,"activeCount":101},[14912],{"nctId":14913,"briefTitle":14914,"status":142,"phases":14915,"primaryCompletion":14916,"completion":14916,"start":14917,"enrollment":1517,"conditions":14918,"interventions":14921},"NCT00001512","Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines",[89],"2010-03-05","1996-09-09",[14919,14920,27],"B Cell Lymphoma","Follicular Lymphoma",[14922,14906],"Id-KLH Vaccine",{"trials":14924,"activeCount":101},[14925,14936],{"nctId":14926,"briefTitle":14927,"status":142,"phases":14928,"primaryCompletion":14929,"completion":14930,"start":14931,"enrollment":34,"conditions":14932,"interventions":14933},"NCT00005780","Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma",[90],"2021-06-09","2021-06-16","2000-06-01",[5795,5794],[14934,14906,14935],"EPOCH-R","Idiotype vaccine",{"nctId":14937,"briefTitle":14938,"status":142,"phases":14939,"primaryCompletion":14940,"completion":14940,"start":14941,"enrollment":28,"conditions":14942,"interventions":14944},"NCT00001564","A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas",[90],"2007-10-25","1996-12-23",[14943,5969],"Ewing's Sarcoma",[14945,14946,14947,14948,704,14949,14906,14950],"EF-1 Peptide","EF-2 Peptide","PXFK Peptide","E7 Peptide","IL-4","CD40 Ligand",{"trials":14952,"activeCount":101},[14953],{"nctId":14954,"briefTitle":14955,"status":142,"phases":14956,"completion":3480,"start":14957,"enrollment":28,"conditions":14958,"interventions":14959},"NCT00001561","Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation",[91],"1996-11",[10953,4747],[14960,14906],"Myeloma Immunoglobulin Idiotype Vaccine-KLH",{"trials":14962,"activeCount":101},[],{"trials":14964,"activeCount":101},[],{"intervention":1454,"totalTrials":214,"cells":14966},{"EARLY_PHASE1":14967,"PHASE1":14969,"PHASE2":14971,"PHASE3":14981,"PHASE4":14991,"NA":14993},{"trials":14968,"activeCount":101},[],{"trials":14970,"activeCount":101},[],{"trials":14972,"activeCount":101},[14973,14977],{"nctId":8122,"briefTitle":8123,"status":142,"phases":14974,"primaryCompletion":4928,"completion":4928,"start":1170,"enrollment":1331,"conditions":14975,"interventions":14976},[90],[3428,5549,5551,5552,8126,8127,5554,5555],[8129,1454,2143],{"nctId":14514,"briefTitle":14515,"status":142,"phases":14978,"primaryCompletion":14385,"completion":14385,"start":5976,"enrollment":5986,"conditions":14979,"interventions":14980},[90],[12114],[14519,1569],{"trials":14982,"activeCount":101},[14983,14987],{"nctId":5619,"briefTitle":5620,"status":142,"phases":14984,"primaryCompletion":5622,"completion":5623,"start":5624,"enrollment":5625,"conditions":14985,"interventions":14986},[91],[3909,2613,5627,3082],[53,5629,1454],{"nctId":1437,"briefTitle":1438,"status":142,"phases":14988,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":1443,"conditions":14989,"interventions":14990},[91],[1445,1446,1447,1448,1449,1450,1451],[1453,63,737,449,1454,1455],{"trials":14992,"activeCount":101},[],{"trials":14994,"activeCount":101},[],{"intervention":14900,"totalTrials":603,"cells":14996},{"EARLY_PHASE1":14997,"PHASE1":14999,"PHASE2":15001,"PHASE3":15007,"PHASE4":15021,"NA":15023},{"trials":14998,"activeCount":101},[],{"trials":15000,"activeCount":101},[],{"trials":15002,"activeCount":101},[15003],{"nctId":11701,"briefTitle":11702,"status":142,"phases":15004,"primaryCompletion":11704,"completion":7652,"start":11705,"enrollment":929,"conditions":15005,"interventions":15006},[90],[11707],[11672,11709],{"trials":15008,"activeCount":101},[15009,15013],{"nctId":14893,"briefTitle":14894,"status":142,"phases":15010,"primaryCompletion":5444,"completion":5444,"start":14896,"enrollment":14897,"conditions":15011,"interventions":15012},[91],[14878],[14900,14855],{"nctId":15014,"briefTitle":15015,"status":142,"phases":15016,"completion":1053,"start":15017,"enrollment":15018,"conditions":15019,"interventions":15020},"NCT00003814","Eflornithine in Treating Patients With Bladder Cancer",[91],"1999-02",450,[961],[14900],{"trials":15022,"activeCount":101},[],{"trials":15024,"activeCount":101},[],{"intervention":10365,"totalTrials":603,"cells":15026},{"EARLY_PHASE1":15027,"PHASE1":15029,"PHASE2":15031,"PHASE3":15041,"PHASE4":15047,"NA":15049},{"trials":15028,"activeCount":101},[],{"trials":15030,"activeCount":101},[],{"trials":15032,"activeCount":101},[15033,15037],{"nctId":10360,"briefTitle":10361,"status":142,"phases":15034,"completion":745,"start":4232,"conditions":15035,"interventions":15036},[90],[2490],[818,1349,993,10365,10366],{"nctId":11363,"briefTitle":11364,"status":142,"phases":15038,"completion":987,"start":5004,"conditions":15039,"interventions":15040},[90],[2490],[818,1347,1349,10365],{"trials":15042,"activeCount":101},[15043],{"nctId":10429,"briefTitle":10430,"status":142,"phases":15044,"primaryCompletion":10432,"completion":8414,"start":10433,"enrollment":10434,"conditions":15045,"interventions":15046},[91],[3308,10436,3773,10437,1343,10438,10439,10440,10441,10442,10443,10444,10180,10445,10181,10446,10182,10447,4767,10448],[5933,10450],{"trials":15048,"activeCount":101},[],{"trials":15050,"activeCount":101},[],{"intervention":2166,"totalTrials":603,"cells":15052},{"EARLY_PHASE1":15053,"PHASE1":15055,"PHASE2":15057,"PHASE3":15067,"PHASE4":15073,"NA":15075},{"trials":15054,"activeCount":101},[],{"trials":15056,"activeCount":101},[],{"trials":15058,"activeCount":101},[15059,15063],{"nctId":7785,"briefTitle":7786,"status":142,"phases":15060,"primaryCompletion":1170,"completion":7788,"start":715,"enrollment":28,"conditions":15061,"interventions":15062},[90],[7583,7584,7585,7587,4681],[7791,2166,3401,3066],{"nctId":7578,"briefTitle":7579,"status":142,"phases":15064,"primaryCompletion":7581,"completion":2027,"start":1340,"enrollment":34,"conditions":15065,"interventions":15066},[90],[7583,7584,7585,7586,7587,7588,7589,7590,7591,7592,4681,4793,7593,7594,7595,7596,7597,7598,4796,4799],[3591,1062,2166,750],{"trials":15068,"activeCount":101},[15069],{"nctId":2157,"briefTitle":2158,"status":142,"phases":15070,"primaryCompletion":2160,"start":1979,"enrollment":2161,"conditions":15071,"interventions":15072},[91],[1767,2163,1769,1770,1771,1772],[2165,1598,2166,1776,995],{"trials":15074,"activeCount":101},[],{"trials":15076,"activeCount":101},[],{"intervention":3708,"totalTrials":758,"cells":15078},{"EARLY_PHASE1":15079,"PHASE1":15081,"PHASE2":15091,"PHASE3":15093,"PHASE4":15099,"NA":15101},{"trials":15080,"activeCount":101},[],{"trials":15082,"activeCount":101},[15083],{"nctId":15084,"briefTitle":15085,"status":142,"phases":15086,"completion":1181,"start":3107,"enrollment":28,"conditions":15087,"interventions":15089},"NCT00001944","Vinorelbine and XR9576 to Treat Cancer",[89],[18,15088,687,1003],"Cancer",[3708,15090],"XR9576",{"trials":15092,"activeCount":101},[],{"trials":15094,"activeCount":101},[15095],{"nctId":3698,"briefTitle":3699,"status":107,"phases":15096,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":15097,"interventions":15098},[91],[3704,3705],[3707,1511,277,279,289,1101,2789,883,3708],{"trials":15100,"activeCount":101},[],{"trials":15102,"activeCount":101},[],{"intervention":1389,"totalTrials":758,"cells":15104},{"EARLY_PHASE1":15105,"PHASE1":15107,"PHASE2":15109,"PHASE3":15115,"PHASE4":15121,"NA":15123},{"trials":15106,"activeCount":101},[],{"trials":15108,"activeCount":101},[],{"trials":15110,"activeCount":101},[15111],{"nctId":1254,"briefTitle":1255,"status":142,"phases":15112,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":15113,"interventions":15114},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"trials":15116,"activeCount":101},[15117],{"nctId":1378,"briefTitle":1379,"status":142,"phases":15118,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":15119,"interventions":15120},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"trials":15122,"activeCount":101},[],{"trials":15124,"activeCount":101},[],{"intervention":1390,"totalTrials":758,"cells":15126},{"EARLY_PHASE1":15127,"PHASE1":15129,"PHASE2":15131,"PHASE3":15140,"PHASE4":15146,"NA":15148},{"trials":15128,"activeCount":101},[],{"trials":15130,"activeCount":101},[],{"trials":15132,"activeCount":101},[15133],{"nctId":15134,"briefTitle":15135,"status":618,"phases":15136,"primaryCompletion":3453,"start":6833,"enrollment":638,"conditions":15137,"interventions":15138},"NCT00005982","506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma",[90],[9449,4792],[15139],"nelarabine",{"trials":15141,"activeCount":101},[15142],{"nctId":1378,"briefTitle":1379,"status":142,"phases":15143,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":15144,"interventions":15145},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"trials":15147,"activeCount":101},[],{"trials":15149,"activeCount":101},[],{"intervention":1434,"totalTrials":758,"cells":15151},{"EARLY_PHASE1":15152,"PHASE1":15154,"PHASE2":15162,"PHASE3":15164,"PHASE4":15170,"NA":15172},{"trials":15153,"activeCount":101},[],{"trials":15155,"activeCount":101},[15156],{"nctId":15157,"briefTitle":15158,"status":142,"phases":15159,"primaryCompletion":1576,"start":6861,"enrollment":700,"conditions":15160,"interventions":15161},"NCT00003765","O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors",[89],[3664],[5961,1434],{"trials":15163,"activeCount":101},[],{"trials":15165,"activeCount":101},[15166],{"nctId":1423,"briefTitle":1424,"status":142,"phases":15167,"primaryCompletion":1426,"start":1427,"enrollment":1428,"conditions":15168,"interventions":15169},[91],[1430,1431,1432],[1032,1434,1081,693,1082,1435],{"trials":15171,"activeCount":101},[],{"trials":15173,"activeCount":101},[],{"intervention":15175,"totalTrials":2548,"cells":15176},"edrecolomab",{"EARLY_PHASE1":15177,"PHASE1":15179,"PHASE2":15181,"PHASE3":15183,"PHASE4":15196,"NA":15198},{"trials":15178,"activeCount":101},[],{"trials":15180,"activeCount":101},[],{"trials":15182,"activeCount":101},[],{"trials":15184,"activeCount":101},[15185],{"nctId":15186,"briefTitle":15187,"status":142,"phases":15188,"primaryCompletion":4272,"start":15189,"enrollment":15190,"conditions":15191,"interventions":15195},"NCT00002968","Edrecolomab in Treating Patients With Stage II Colon Cancer",[91],"1997-05",2100,[5050,5051,15192,15193,15194],"Stage IIA Colon Cancer","Stage IIB Colon Cancer","Stage IIC Colon Cancer",[15175],{"trials":15197,"activeCount":101},[],{"trials":15199,"activeCount":101},[],{"intervention":1360,"totalTrials":2548,"cells":15201},{"EARLY_PHASE1":15202,"PHASE1":15204,"PHASE2":15206,"PHASE3":15208,"PHASE4":15214,"NA":15216},{"trials":15203,"activeCount":101},[],{"trials":15205,"activeCount":101},[],{"trials":15207,"activeCount":101},[],{"trials":15209,"activeCount":101},[15210],{"nctId":1353,"briefTitle":1354,"status":142,"phases":15211,"primaryCompletion":715,"start":1356,"enrollment":1357,"conditions":15212,"interventions":15213},[91],[27],[750,1063,1360,693,994,1082,1032],{"trials":15215,"activeCount":101},[],{"trials":15217,"activeCount":101},[],{"intervention":7144,"totalTrials":2548,"cells":15219},{"EARLY_PHASE1":15220,"PHASE1":15222,"PHASE2":15224,"PHASE3":15226,"PHASE4":15232,"NA":15234},{"trials":15221,"activeCount":101},[],{"trials":15223,"activeCount":101},[],{"trials":15225,"activeCount":101},[],{"trials":15227,"activeCount":101},[15228],{"nctId":7137,"briefTitle":7138,"status":142,"phases":15229,"completion":7035,"start":7140,"enrollment":7141,"conditions":15230,"interventions":15231},[91],[36],[1081,7144,7145],{"trials":15233,"activeCount":101},[],{"trials":15235,"activeCount":101},[],{"intervention":7145,"totalTrials":2548,"cells":15237},{"EARLY_PHASE1":15238,"PHASE1":15240,"PHASE2":15242,"PHASE3":15244,"PHASE4":15250,"NA":15252},{"trials":15239,"activeCount":101},[],{"trials":15241,"activeCount":101},[],{"trials":15243,"activeCount":101},[],{"trials":15245,"activeCount":101},[15246],{"nctId":7137,"briefTitle":7138,"status":142,"phases":15247,"completion":7035,"start":7140,"enrollment":7141,"conditions":15248,"interventions":15249},[91],[36],[1081,7144,7145],{"trials":15251,"activeCount":101},[],{"trials":15253,"activeCount":101},[],{"intervention":1391,"totalTrials":2548,"cells":15255},{"EARLY_PHASE1":15256,"PHASE1":15258,"PHASE2":15260,"PHASE3":15262,"PHASE4":15268,"NA":15270},{"trials":15257,"activeCount":101},[],{"trials":15259,"activeCount":101},[],{"trials":15261,"activeCount":101},[],{"trials":15263,"activeCount":101},[15264],{"nctId":1378,"briefTitle":1379,"status":142,"phases":15265,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":15266,"interventions":15267},[91],[1386,1387],[1389,63,1137,1374,1139,737,1140,1375,1141,1390,1376,212,1391,740],{"trials":15269,"activeCount":101},[],{"trials":15271,"activeCount":101},[],{"intervention":15273,"totalTrials":2548,"cells":15274},"FLAC chemotherapy with GM-CSF",{"EARLY_PHASE1":15275,"PHASE1":15277,"PHASE2":15279,"PHASE3":15281,"PHASE4":15294,"NA":15296},{"trials":15276,"activeCount":101},[],{"trials":15278,"activeCount":101},[],{"trials":15280,"activeCount":101},[],{"trials":15282,"activeCount":101},[15283],{"nctId":15284,"briefTitle":15285,"status":142,"phases":15286,"completion":3398,"start":15287,"enrollment":6425,"conditions":15288,"interventions":15293},"NCT00001338","A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer",[91],"1993-06",[1291,15289,15290,15291,15292],"Fever","Hematologic Diseases","Neutropenia","Sepsis",[15273],{"trials":15295,"activeCount":101},[],{"trials":15297,"activeCount":101},[],{"intervention":1419,"totalTrials":2548,"cells":15299},{"EARLY_PHASE1":15300,"PHASE1":15302,"PHASE2":15304,"PHASE3":15306,"PHASE4":15312,"NA":15314},{"trials":15301,"activeCount":101},[],{"trials":15303,"activeCount":101},[],{"trials":15305,"activeCount":101},[],{"trials":15307,"activeCount":101},[15308],{"nctId":1409,"briefTitle":1410,"status":142,"phases":15309,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":1074,"conditions":15310,"interventions":15311},[91],[1416,18,1417,63,780],[780,63,1419,1420,1421],{"trials":15313,"activeCount":101},[],{"trials":15315,"activeCount":101},[],{"intervention":1421,"totalTrials":2548,"cells":15317},{"EARLY_PHASE1":15318,"PHASE1":15320,"PHASE2":15322,"PHASE3":15324,"PHASE4":15330,"NA":15332},{"trials":15319,"activeCount":101},[],{"trials":15321,"activeCount":101},[],{"trials":15323,"activeCount":101},[],{"trials":15325,"activeCount":101},[15326],{"nctId":1409,"briefTitle":1410,"status":142,"phases":15327,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":1074,"conditions":15328,"interventions":15329},[91],[1416,18,1417,63,780],[780,63,1419,1420,1421],{"trials":15331,"activeCount":101},[],{"trials":15333,"activeCount":101},[],{"intervention":3707,"totalTrials":2548,"cells":15335},{"EARLY_PHASE1":15336,"PHASE1":15338,"PHASE2":15340,"PHASE3":15342,"PHASE4":15348,"NA":15350},{"trials":15337,"activeCount":101},[],{"trials":15339,"activeCount":101},[],{"trials":15341,"activeCount":101},[],{"trials":15343,"activeCount":101},[15344],{"nctId":3698,"briefTitle":3699,"status":107,"phases":15345,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":101,"conditions":15346,"interventions":15347},[91],[3704,3705],[3707,1511,277,279,289,1101,2789,883,3708],{"trials":15349,"activeCount":101},[],{"trials":15351,"activeCount":101},[],{"intervention":5629,"totalTrials":2548,"cells":15353},{"EARLY_PHASE1":15354,"PHASE1":15356,"PHASE2":15358,"PHASE3":15360,"PHASE4":15366,"NA":15368},{"trials":15355,"activeCount":101},[],{"trials":15357,"activeCount":101},[],{"trials":15359,"activeCount":101},[],{"trials":15361,"activeCount":101},[15362],{"nctId":5619,"briefTitle":5620,"status":142,"phases":15363,"primaryCompletion":5622,"completion":5623,"start":5624,"enrollment":5625,"conditions":15364,"interventions":15365},[91],[3909,2613,5627,3082],[53,5629,1454],{"trials":15367,"activeCount":101},[],{"trials":15369,"activeCount":101},[],{"intervention":15371,"totalTrials":2548,"cells":15372},"zidovudine",{"EARLY_PHASE1":15373,"PHASE1":15375,"PHASE2":15377,"PHASE3":15379,"PHASE4":15391,"NA":15393},{"trials":15374,"activeCount":101},[],{"trials":15376,"activeCount":101},[],{"trials":15378,"activeCount":101},[],{"trials":15380,"activeCount":101},[15381],{"nctId":15382,"briefTitle":15383,"status":142,"phases":15384,"completion":6833,"start":15385,"enrollment":1517,"conditions":15386,"interventions":15389},"NCT00001267","A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine",[91],"1990-10",[15387,15388],"AIDS-Related Complex","Acquired Immunodeficiency Syndrome",[15371,15390],"2',3'-dideoxyinosine",{"trials":15392,"activeCount":101},[],{"trials":15394,"activeCount":101},[],{"intervention":15390,"totalTrials":2548,"cells":15396},{"EARLY_PHASE1":15397,"PHASE1":15399,"PHASE2":15401,"PHASE3":15403,"PHASE4":15409,"NA":15411},{"trials":15398,"activeCount":101},[],{"trials":15400,"activeCount":101},[],{"trials":15402,"activeCount":101},[],{"trials":15404,"activeCount":101},[15405],{"nctId":15382,"briefTitle":15383,"status":142,"phases":15406,"completion":6833,"start":15385,"enrollment":1517,"conditions":15407,"interventions":15408},[91],[15387,15388],[15371,15390],{"trials":15410,"activeCount":101},[],{"trials":15412,"activeCount":101},[],{"intervention":6131,"totalTrials":2548,"cells":15414},{"EARLY_PHASE1":15415,"PHASE1":15417,"PHASE2":15419,"PHASE3":15421,"PHASE4":15427,"NA":15429},{"trials":15416,"activeCount":101},[],{"trials":15418,"activeCount":101},[],{"trials":15420,"activeCount":101},[],{"trials":15422,"activeCount":101},[15423],{"nctId":6125,"briefTitle":6126,"status":142,"phases":15424,"primaryCompletion":1576,"completion":5634,"start":4142,"conditions":15425,"interventions":15426},[91],[6129],[1065,6131,3470,6132],{"trials":15428,"activeCount":101},[],{"trials":15430,"activeCount":101},[],{"intervention":6132,"totalTrials":2548,"cells":15432},{"EARLY_PHASE1":15433,"PHASE1":15435,"PHASE2":15437,"PHASE3":15439,"PHASE4":15445,"NA":15447},{"trials":15434,"activeCount":101},[],{"trials":15436,"activeCount":101},[],{"trials":15438,"activeCount":101},[],{"trials":15440,"activeCount":101},[15441],{"nctId":6125,"briefTitle":6126,"status":142,"phases":15442,"primaryCompletion":1576,"completion":5634,"start":4142,"conditions":15443,"interventions":15444},[91],[6129],[1065,6131,3470,6132],{"trials":15446,"activeCount":101},[],{"trials":15448,"activeCount":101},[],{"intervention":5129,"totalTrials":2548,"cells":15450},{"EARLY_PHASE1":15451,"PHASE1":15453,"PHASE2":15455,"PHASE3":15457,"PHASE4":15463,"NA":15465},{"trials":15452,"activeCount":101},[],{"trials":15454,"activeCount":101},[],{"trials":15456,"activeCount":101},[],{"trials":15458,"activeCount":101},[15459],{"nctId":5121,"briefTitle":5122,"status":142,"phases":15460,"primaryCompletion":1781,"start":5124,"enrollment":5125,"conditions":15461,"interventions":15462},[91],[5127,4983,4941,4942,4945,4946],[3065,5129],{"trials":15464,"activeCount":101},[],{"trials":15466,"activeCount":101},[],{"intervention":5137,"totalTrials":2548,"cells":15468},{"EARLY_PHASE1":15469,"PHASE1":15471,"PHASE2":15473,"PHASE3":15475,"PHASE4":15481,"NA":15483},{"trials":15470,"activeCount":101},[],{"trials":15472,"activeCount":101},[],{"trials":15474,"activeCount":101},[],{"trials":15476,"activeCount":101},[15477],{"nctId":5131,"briefTitle":5132,"status":142,"phases":15478,"primaryCompletion":5103,"completion":5103,"start":4997,"enrollment":5134,"conditions":15479,"interventions":15480},[91],[5127,4943],[5106,4948,1264,3065,1697,5137],{"trials":15482,"activeCount":101},[],{"trials":15484,"activeCount":101},[],{"intervention":1453,"totalTrials":2548,"cells":15486},{"EARLY_PHASE1":15487,"PHASE1":15489,"PHASE2":15491,"PHASE3":15493,"PHASE4":15499,"NA":15501},{"trials":15488,"activeCount":101},[],{"trials":15490,"activeCount":101},[],{"trials":15492,"activeCount":101},[],{"trials":15494,"activeCount":101},[15495],{"nctId":1437,"briefTitle":1438,"status":142,"phases":15496,"primaryCompletion":1440,"completion":1441,"start":1442,"enrollment":1443,"conditions":15497,"interventions":15498},[91],[1445,1446,1447,1448,1449,1450,1451],[1453,63,737,449,1454,1455],{"trials":15500,"activeCount":101},[],{"trials":15502,"activeCount":101},[],{"intervention":4236,"totalTrials":2548,"cells":15504},{"EARLY_PHASE1":15505,"PHASE1":15507,"PHASE2":15509,"PHASE3":15511,"PHASE4":15517,"NA":15519},{"trials":15506,"activeCount":101},[],{"trials":15508,"activeCount":101},[],{"trials":15510,"activeCount":101},[],{"trials":15512,"activeCount":101},[15513],{"nctId":4228,"briefTitle":4229,"status":142,"phases":15514,"primaryCompletion":4231,"start":4232,"enrollment":4233,"conditions":15515,"interventions":15516},[91],[4037,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,4132],[1187,1263,1080,4236],{"trials":15518,"activeCount":101},[],{"trials":15520,"activeCount":101},[],{"intervention":15522,"totalTrials":2548,"cells":15523},"Nystatin",{"EARLY_PHASE1":15524,"PHASE1":15526,"PHASE2":15528,"PHASE3":15530,"PHASE4":15542,"NA":15544},{"trials":15525,"activeCount":101},[],{"trials":15527,"activeCount":101},[],{"trials":15529,"activeCount":101},[],{"trials":15531,"activeCount":101},[15532],{"nctId":15533,"briefTitle":15534,"status":142,"phases":15535,"completion":15536,"start":5124,"enrollment":13282,"conditions":15537,"interventions":15541},"NCT00001812","A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2",[91],"2000-08",[15538,15539,15540],"Candidiasis, Oral","Gastrointestinal Diseases","Stomatitis",[15522],{"trials":15543,"activeCount":101},[],{"trials":15545,"activeCount":101},[],{"intervention":14960,"totalTrials":2548,"cells":15547},{"EARLY_PHASE1":15548,"PHASE1":15550,"PHASE2":15552,"PHASE3":15554,"PHASE4":15560,"NA":15562},{"trials":15549,"activeCount":101},[],{"trials":15551,"activeCount":101},[],{"trials":15553,"activeCount":101},[],{"trials":15555,"activeCount":101},[15556],{"nctId":14954,"briefTitle":14955,"status":142,"phases":15557,"completion":3480,"start":14957,"enrollment":28,"conditions":15558,"interventions":15559},[91],[10953,4747],[14960,14906],{"trials":15561,"activeCount":101},[],{"trials":15563,"activeCount":101},[],{"intervention":2154,"totalTrials":2548,"cells":15565},{"EARLY_PHASE1":15566,"PHASE1":15568,"PHASE2":15570,"PHASE3":15572,"PHASE4":15578,"NA":15580},{"trials":15567,"activeCount":101},[],{"trials":15569,"activeCount":101},[],{"trials":15571,"activeCount":101},[],{"trials":15573,"activeCount":101},[15574],{"nctId":2145,"briefTitle":2146,"status":142,"phases":15575,"primaryCompletion":2148,"completion":2149,"start":1717,"enrollment":2150,"conditions":15576,"interventions":15577},[91],[801,2152],[278,737,2154,2155,43],{"trials":15579,"activeCount":101},[],{"trials":15581,"activeCount":101},[],{"intervention":2155,"totalTrials":2548,"cells":15583},{"EARLY_PHASE1":15584,"PHASE1":15586,"PHASE2":15588,"PHASE3":15590,"PHASE4":15596,"NA":15598},{"trials":15585,"activeCount":101},[],{"trials":15587,"activeCount":101},[],{"trials":15589,"activeCount":101},[],{"trials":15591,"activeCount":101},[15592],{"nctId":2145,"briefTitle":2146,"status":142,"phases":15593,"primaryCompletion":2148,"completion":2149,"start":1717,"enrollment":2150,"conditions":15594,"interventions":15595},[91],[801,2152],[278,737,2154,2155,43],{"trials":15597,"activeCount":101},[],{"trials":15599,"activeCount":101},[],{"intervention":4749,"totalTrials":2548,"cells":15601},{"EARLY_PHASE1":15602,"PHASE1":15604,"PHASE2":15606,"PHASE3":15608,"PHASE4":15614,"NA":15616},{"trials":15603,"activeCount":101},[],{"trials":15605,"activeCount":101},[],{"trials":15607,"activeCount":101},[],{"trials":15609,"activeCount":101},[15610],{"nctId":4742,"briefTitle":4743,"status":142,"phases":15611,"primaryCompletion":4745,"completion":270,"start":269,"enrollment":2548,"conditions":15612,"interventions":15613},[91],[4747],[4749,1016],{"trials":15615,"activeCount":101},[],{"trials":15617,"activeCount":101},[],{"intervention":2165,"totalTrials":2548,"cells":15619},{"EARLY_PHASE1":15620,"PHASE1":15622,"PHASE2":15624,"PHASE3":15626,"PHASE4":15632,"NA":15634},{"trials":15621,"activeCount":101},[],{"trials":15623,"activeCount":101},[],{"trials":15625,"activeCount":101},[],{"trials":15627,"activeCount":101},[15628],{"nctId":2157,"briefTitle":2158,"status":142,"phases":15629,"primaryCompletion":2160,"start":1979,"enrollment":2161,"conditions":15630,"interventions":15631},[91],[1767,2163,1769,1770,1771,1772],[2165,1598,2166,1776,995],{"trials":15633,"activeCount":101},[],{"trials":15635,"activeCount":101},[],{"intervention":1185,"totalTrials":2577,"cells":15637},{"EARLY_PHASE1":15638,"PHASE1":15640,"PHASE2":15664,"PHASE3":15719,"PHASE4":15721,"NA":15723},{"trials":15639,"activeCount":101},[],{"trials":15641,"activeCount":101},[15642,15649,15653,15660],{"nctId":15643,"briefTitle":15644,"status":142,"phases":15645,"primaryCompletion":6569,"start":3526,"enrollment":28,"conditions":15646,"interventions":15648},"NCT00101296","Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[89],[6306,11176,4037,4038,4039,15647,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,33,4132],"Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)",[1185],{"nctId":5855,"briefTitle":5856,"status":142,"phases":15650,"primaryCompletion":1320,"completion":5858,"start":988,"enrollment":3255,"conditions":15651,"interventions":15652},[89],[4817,4818,4819],[5861,151],{"nctId":15654,"briefTitle":15655,"status":142,"phases":15656,"primaryCompletion":1989,"start":15536,"enrollment":700,"conditions":15657,"interventions":15659},"NCT00005967","Tipifarnib in Treating Patients With Advanced Hematologic Cancer",[89],[15658,1260,27,6129,10520],"Chronic Myeloproliferative Disorders",[1185],{"nctId":5897,"briefTitle":5898,"status":142,"phases":15661,"primaryCompletion":1320,"completion":1320,"start":988,"enrollment":3255,"conditions":15662,"interventions":15663},[89],[4817,4818,4819],[1185,5874],{"trials":15665,"activeCount":101},[15666,15672,15676,15687,15691,15695,15702,15709,15713],{"nctId":15667,"briefTitle":15668,"status":142,"phases":15669,"primaryCompletion":5634,"start":9425,"enrollment":421,"conditions":15670,"interventions":15671},"NCT00060125","Tipifarnib in Treating Patients With Metastatic Malignant Melanoma",[90],[1343,1344],[1185],{"nctId":8073,"briefTitle":8074,"status":142,"phases":15673,"primaryCompletion":1329,"completion":3129,"start":7645,"enrollment":8076,"conditions":15674,"interventions":15675},[90],[1343,1344],[8069,1185,4566],{"nctId":15677,"briefTitle":15678,"status":142,"phases":15679,"primaryCompletion":15680,"completion":15681,"start":3662,"enrollment":25,"conditions":15682,"interventions":15686},"NCT02210858","Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders",[89,90],"2004-11-12","2017-03",[15683,4052,8059,2453,15684,4057,15685],"Accelerated Phase of Disease","Chronic Phase of Disease","Recurrent Disease",[5861],{"nctId":8131,"briefTitle":8132,"status":142,"phases":15688,"primaryCompletion":3227,"completion":8134,"start":715,"enrollment":4001,"conditions":15689,"interventions":15690},[89,90],[4817,4818,4819,5287],[8069,1774,1185,4566],{"nctId":1178,"briefTitle":1179,"status":142,"phases":15692,"primaryCompletion":987,"start":1181,"enrollment":248,"conditions":15693,"interventions":15694},[90],[1183],[1185,1186,819,1187,693,1188],{"nctId":15696,"briefTitle":15697,"status":142,"phases":15698,"primaryCompletion":11556,"completion":11556,"start":3638,"enrollment":2883,"conditions":15699,"interventions":15701},"NCT00079339","Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma",[89,90],[15700],"Untreated Childhood Brain Stem Glioma",[1185],{"nctId":15703,"briefTitle":15704,"status":142,"phases":15705,"primaryCompletion":5634,"start":717,"enrollment":15706,"conditions":15707,"interventions":15708},"NCT00093418","S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia",[90],296,[4037,4038,4039,4040,4041,4042,13623,4043,4167,4044,4046,4047,4048,4050,4051,33,4132],[1185],{"nctId":1213,"briefTitle":1214,"status":142,"phases":15710,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":1074,"conditions":15711,"interventions":15712},[89,90],[18,1219,1220,1221,1222,1223],[1185,995,1225,693],{"nctId":15714,"briefTitle":15715,"status":142,"phases":15716,"primaryCompletion":987,"start":2181,"enrollment":1913,"conditions":15717,"interventions":15718},"NCT00045396","A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And\u002FOr Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)",[90],[13623,4043,4167,4044,4045,4046,4047,4056,4061],[1185],{"trials":15720,"activeCount":101},[],{"trials":15722,"activeCount":101},[],{"trials":15724,"activeCount":101},[],{"intervention":1998,"totalTrials":188,"cells":15726},{"EARLY_PHASE1":15727,"PHASE1":15729,"PHASE2":15774,"PHASE3":15794,"PHASE4":15796,"NA":15798},{"trials":15728,"activeCount":101},[],{"trials":15730,"activeCount":101},[15731,15735,15739,15746,15754,15758,15762,15768],{"nctId":11059,"briefTitle":11060,"status":142,"phases":15732,"primaryCompletion":11062,"start":1426,"enrollment":339,"conditions":15733,"interventions":15734},[89],[4053,1135,33,4616,4060,10423,4132],[1998,4063],{"nctId":11074,"briefTitle":11075,"status":142,"phases":15736,"primaryCompletion":4996,"start":1576,"enrollment":1074,"conditions":15737,"interventions":15738},[89],[15],[1998,4063],{"nctId":15740,"briefTitle":15741,"status":142,"phases":15742,"primaryCompletion":6869,"start":3088,"enrollment":28,"conditions":15743,"interventions":15745},"NCT00012181","Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas",[89],[5363,4659,4660,4661,4789,6504,4790,5869,4662,5870,4791,5871,4665,4666,6505,1029,117,5872,15744,6507,4793,748],"Recurrent Retinoblastoma",[1998],{"nctId":15747,"briefTitle":15748,"status":142,"phases":15749,"start":15750,"conditions":15751,"interventions":15753},"NCT00019344","Flavopiridol in Treating Patients With Refractory Cancer",[89],"1997-08",[27,24,15752,15],"Small Intestine Cancer",[1998],{"nctId":4993,"briefTitle":4994,"status":142,"phases":15755,"primaryCompletion":4996,"start":4997,"enrollment":730,"conditions":15756,"interventions":15757},[89],[15],[1998,3065,4948,1264],{"nctId":9439,"briefTitle":9440,"status":142,"phases":15759,"primaryCompletion":1310,"start":1952,"enrollment":16,"conditions":15760,"interventions":15761},[89],[15],[3066,1998],{"nctId":15763,"briefTitle":15764,"status":618,"phases":15765,"primaryCompletion":5103,"start":3526,"enrollment":6854,"conditions":15766,"interventions":15767},"NCT00101231","Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia",[89],[4035,4036,4037,4038,4039,4040,4041,4042,4043,4044,4046,4047,4048,4050,4051,4053,1135,33,4060],[1998],{"nctId":15769,"briefTitle":15770,"status":618,"phases":15771,"primaryCompletion":5103,"start":5397,"enrollment":339,"conditions":15772,"interventions":15773},"NCT00377104","Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[89],[5663,3168,3178,657,658,659,661,662,663,664],[1998],{"trials":15775,"activeCount":101},[15776,15780,15784,15788],{"nctId":6300,"briefTitle":6301,"status":142,"phases":15777,"primaryCompletion":6303,"completion":6303,"start":3155,"enrollment":6304,"conditions":15778,"interventions":15779},[90],[6306,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,2432,4132],[1998,1263,2324,1187],{"nctId":7032,"briefTitle":7033,"status":142,"phases":15781,"completion":1276,"start":7035,"conditions":15782,"interventions":15783},[89,90],[18],[1998,1775],{"nctId":1985,"briefTitle":1986,"status":142,"phases":15785,"primaryCompletion":649,"completion":1988,"start":1989,"enrollment":1990,"conditions":15786,"interventions":15787},[90],[1579,1992,1584,1993,1587,1994,1589,1995,1591,1996],[1598,1998,1999],{"nctId":15789,"briefTitle":15790,"status":618,"phases":15791,"primaryCompletion":4611,"completion":5103,"start":5976,"enrollment":609,"conditions":15792,"interventions":15793},"NCT00098371","Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia",[90],[5663,654,656],[1998],{"trials":15795,"activeCount":101},[],{"trials":15797,"activeCount":101},[],{"trials":15799,"activeCount":101},[],{"intervention":819,"totalTrials":375,"cells":15801},{"EARLY_PHASE1":15802,"PHASE1":15804,"PHASE2":15817,"PHASE3":15855,"PHASE4":15857,"NA":15859},{"trials":15803,"activeCount":101},[],{"trials":15805,"activeCount":101},[15806,15810],{"nctId":5659,"briefTitle":5660,"status":618,"phases":15807,"primaryCompletion":4900,"start":1231,"enrollment":31,"conditions":15808,"interventions":15809},[89],[5663,1260,654,656,657,659,661,663],[5665,819,1063],{"nctId":15811,"briefTitle":15812,"status":142,"phases":15813,"start":15814,"conditions":15815,"interventions":15816},"NCT00019838","UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia",[89],"1999-07",[1260,27],[2184,819],{"trials":15818,"activeCount":101},[15819,15823,15827,15831,15835,15839,15843,15847,15851],{"nctId":809,"briefTitle":810,"status":142,"phases":15820,"primaryCompletion":812,"completion":812,"start":813,"enrollment":188,"conditions":15821,"interventions":15822},[90],[815],[817,818,750,693,819],{"nctId":14813,"briefTitle":14814,"status":618,"phases":15824,"primaryCompletion":4715,"start":3254,"enrollment":1111,"conditions":15825,"interventions":15826},[90],[655,656],[819,3470],{"nctId":1068,"briefTitle":1069,"status":142,"phases":15828,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":15829,"interventions":15830},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"nctId":5742,"briefTitle":5743,"status":142,"phases":15832,"primaryCompletion":1230,"completion":1230,"start":3526,"enrollment":949,"conditions":15833,"interventions":15834},[90],[5663,657,659,661,663],[5747,1063,819],{"nctId":1156,"briefTitle":1157,"status":142,"phases":15836,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":15837,"interventions":15838},[90],[657,659,661,663],[63,1165,1016,667],{"nctId":1178,"briefTitle":1179,"status":142,"phases":15840,"primaryCompletion":987,"start":1181,"enrollment":248,"conditions":15841,"interventions":15842},[90],[1183],[1185,1186,819,1187,693,1188],{"nctId":1227,"briefTitle":1228,"status":618,"phases":15844,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":603,"conditions":15845,"interventions":15846},[90],[195,891],[693,819,677,1234,1235],{"nctId":1296,"briefTitle":1297,"status":618,"phases":15848,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":15849,"interventions":15850},[89,90],[1291,1302],[991,1304,750,993,693,994,819,995,722],{"nctId":1337,"briefTitle":1338,"status":618,"phases":15852,"primaryCompletion":1340,"start":1341,"enrollment":16,"conditions":15853,"interventions":15854},[90],[1343,1344],[693,819,1346,1347,1348,1349,750,818],{"trials":15856,"activeCount":101},[],{"trials":15858,"activeCount":101},[],{"trials":15860,"activeCount":101},[],{"intervention":3123,"totalTrials":685,"cells":15862},{"EARLY_PHASE1":15863,"PHASE1":15865,"PHASE2":15891,"PHASE3":15922,"PHASE4":15924,"NA":15926},{"trials":15864,"activeCount":101},[],{"trials":15866,"activeCount":101},[15867,15873,15877,15883,15887],{"nctId":15868,"briefTitle":15869,"status":142,"phases":15870,"primaryCompletion":4142,"start":14896,"enrollment":484,"conditions":15871,"interventions":15872},"NCT00003330","Interleukin-12 in Treating Patients With Advanced Cancer",[89],[15],[3123],{"nctId":11243,"briefTitle":11244,"status":618,"phases":15874,"primaryCompletion":1275,"start":11246,"enrollment":421,"conditions":15875,"interventions":15876},[89],[117],[3123,818],{"nctId":15878,"briefTitle":15879,"status":142,"phases":15880,"primaryCompletion":6477,"start":746,"enrollment":700,"conditions":15881,"interventions":15882},"NCT00003439","Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer",[89],[15088],[3123],{"nctId":11266,"briefTitle":11267,"status":142,"phases":15884,"primaryCompletion":4272,"start":1979,"enrollment":37,"conditions":15885,"interventions":15886},[89],[15],[3123,818],{"nctId":3112,"briefTitle":3113,"status":142,"phases":15888,"primaryCompletion":1309,"start":3115,"enrollment":827,"conditions":15889,"interventions":15890},[89],[1219,3117,2706,3118,3119,1579,3120],[3122,995,3123],{"trials":15892,"activeCount":101},[15893,15897,15901,15907,15918],{"nctId":5703,"briefTitle":5704,"status":142,"phases":15894,"primaryCompletion":5706,"start":5707,"enrollment":3639,"conditions":15895,"interventions":15896},[90],[1245,1246,3187,3188,3189,655,1248],[1063,3123],{"nctId":4139,"briefTitle":4140,"status":142,"phases":15898,"primaryCompletion":4142,"start":1356,"enrollment":421,"conditions":15899,"interventions":15900},[90],[27],[750,3123,1080,3591],{"nctId":15902,"briefTitle":15903,"status":142,"phases":15904,"primaryCompletion":3453,"start":5707,"enrollment":1074,"conditions":15905,"interventions":15906},"NCT00026143","Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma",[90],[1343,1344],[3123,3092],{"nctId":15908,"briefTitle":15909,"status":618,"phases":15910,"primaryCompletion":14867,"completion":15911,"start":1230,"enrollment":685,"conditions":15912,"interventions":15913},"NCT01307618","Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma",[90],"2015-02",[1343,4843],[15914,15915,15916,15917],"NA17.A2 Peptide Vaccine","Recombinant MAGE-3.1 Antigen","Recombinant Interleukin-12","MART-1 Antigen",{"nctId":3394,"briefTitle":3395,"status":142,"phases":15919,"completion":3397,"start":3398,"conditions":15920,"interventions":15921},[90],[625],[3123,995,3401],{"trials":15923,"activeCount":101},[],{"trials":15925,"activeCount":101},[],{"trials":15927,"activeCount":101},[],{"intervention":6287,"totalTrials":685,"cells":15929},{"EARLY_PHASE1":15930,"PHASE1":15932,"PHASE2":15976,"PHASE3":15988,"PHASE4":15990,"NA":15992},{"trials":15931,"activeCount":101},[],{"trials":15933,"activeCount":101},[15934,15938,15942,15946,15950,15954,15965,15969],{"nctId":14368,"briefTitle":14369,"status":618,"phases":15935,"primaryCompletion":3317,"start":4639,"enrollment":700,"conditions":15936,"interventions":15937},[89],[3157,1281,4775,4776,1245,1246,3180,3181,3182,3183,3184,4681,3185,3186,4787,9449,3187,3188,940,3189,3190,4792,655,3200,1333,3201,3202,7597,3203,3204,11098,11099,3205,3206,3207,1059,3208,11100,662,3209,1334,3210,3211,4796,3212,3213,4797,9450,3214,3215,3216,1060,3217,11101,664,15,1251],[6287,1062],{"nctId":6950,"briefTitle":6951,"status":142,"phases":15939,"primaryCompletion":1231,"completion":3317,"start":1172,"enrollment":2319,"conditions":15940,"interventions":15941},[89],[2321,2297,15],[6287,1775],{"nctId":7327,"briefTitle":7328,"status":142,"phases":15943,"primaryCompletion":1575,"start":3671,"enrollment":1765,"conditions":15944,"interventions":15945},[89],[15],[6287,5106],{"nctId":6281,"briefTitle":6282,"status":142,"phases":15947,"primaryCompletion":1275,"start":4639,"enrollment":1517,"conditions":15948,"interventions":15949},[89],[4034,4035,4036,4037,4038,4039,4040,4041,4042,4043,4044,4046,4047,4048,4050,4051,4053,2453,4056,4058,1135,33,6285,4060,2432,4061],[6287,1187],{"nctId":14390,"briefTitle":14391,"status":618,"phases":15951,"primaryCompletion":4165,"start":5976,"enrollment":159,"conditions":15952,"interventions":15953},[89],[4035,4036,4037,4038,4039,4040,4041,4042,4043,4044,4046,4047,4048,4050,4051,4775,4776,1245,1246,1135,33,3181,4787,9449,3187,3188,940,3189,3190,4792,655,656,4795,1248,1251],[6287,1062],{"nctId":15955,"briefTitle":15956,"status":142,"phases":15957,"primaryCompletion":4032,"start":15958,"enrollment":1074,"conditions":15959,"interventions":15964},"NCT00004241","17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma",[89],"1999-10",[1281,15960,4775,4776,15961,1245,4784,15962,15963,1246,7346,11097,3180,3181,3182,3183,4681,3185,3186,10227,4787,9449,1029,3187,3188,940,3189,3190,4792,5872,655,8169,4795,1248,3209,1334,3210,3211,4796,3212,3213,1096,4797,9450,3214,3215,3216,1060,3217,11101,664,10192,15],"AIDS-related Primary CNS Lymphoma","Chondrosarcoma","Metastatic Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Metastatic Osteosarcoma",[6287],{"nctId":11511,"briefTitle":11512,"status":618,"phases":15966,"primaryCompletion":1023,"start":4032,"enrollment":700,"conditions":15967,"interventions":15968},[89],[3158,4775,4776,1245,4784,1246,11515,3180,3181,3182,3183,3184,4681,3185,3186,4787,9449,3187,3188,940,3189,3190,4792,655,4795,1248,3200,1333,3201,3202,7597,3203,3204,11098,11099,3205,3206,3207,1059,3208,11100,662,3209,1334,3210,3211,4796,3212,3213,4797,9450,3214,3215,3216,1060,3217,11101,664,15,1251],[6287,11517],{"nctId":15970,"briefTitle":15971,"status":618,"phases":15972,"primaryCompletion":650,"start":15973,"enrollment":1990,"conditions":15974,"interventions":15975},"NCT00019708","Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",[89],"1999-06",[1245,1246,2193,3180,3181,3182,3183,3185,3186,3187,3188,940,3190,655,1248,3209,1334,3210,3211,3212,3213,3214,3215,3216,1060,3217,664,15],[6287],{"trials":15977,"activeCount":101},[15978,15982],{"nctId":9483,"briefTitle":9484,"status":142,"phases":15979,"primaryCompletion":650,"completion":4878,"start":987,"enrollment":1041,"conditions":15980,"interventions":15981},[90],[1821,1579,1790,1591],[3066,6287],{"nctId":15983,"briefTitle":15984,"status":142,"phases":15985,"primaryCompletion":1021,"completion":2004,"start":1241,"enrollment":623,"conditions":15986,"interventions":15987},"NCT00118248","Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer",[90],[10271,11186,11187,11188],[6287],{"trials":15989,"activeCount":101},[],{"trials":15991,"activeCount":101},[],{"trials":15993,"activeCount":101},[],{"intervention":1099,"totalTrials":651,"cells":15995},{"EARLY_PHASE1":15996,"PHASE1":15998,"PHASE2":16011,"PHASE3":16053,"PHASE4":16055,"NA":16057},{"trials":15997,"activeCount":101},[],{"trials":15999,"activeCount":101},[16000,16007],{"nctId":16001,"briefTitle":16002,"status":142,"phases":16003,"primaryCompletion":5724,"start":1231,"enrollment":1798,"conditions":16004,"interventions":16005},"NCT00609141","IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor or Other Solid Tumor",[89],[1029,748],[16006],"cixutumumab",{"nctId":10114,"briefTitle":10115,"status":142,"phases":16008,"primaryCompletion":10117,"start":1021,"enrollment":1195,"conditions":16009,"interventions":16010},[89],[5532,5533,5534,5546],[1099,43],{"trials":16012,"activeCount":101},[16013,16017,16021,16025,16029,16040,16044],{"nctId":1804,"briefTitle":1805,"status":142,"phases":16014,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":16015,"interventions":16016},[90],[1811,1812],[278,1099,279,1814],{"nctId":1086,"briefTitle":1087,"status":142,"phases":16018,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":16019,"interventions":16020},[90],[1092,1093,1094,1095,1096,1097],[1099,63,1100,737,279,1101,1102,151,1103],{"nctId":3312,"briefTitle":3313,"status":618,"phases":16022,"primaryCompletion":3315,"completion":3316,"start":3317,"enrollment":1090,"conditions":16023,"interventions":16024},[90],[1928,3319,3320,3321,3322],[53,277,1099,449],{"nctId":7501,"briefTitle":7502,"status":142,"phases":16026,"primaryCompletion":7504,"completion":7505,"start":7506,"enrollment":609,"conditions":16027,"interventions":16028},[90],[1446,2613,3080,3081,3082],[2924,1099,7509],{"nctId":16030,"briefTitle":16031,"status":142,"phases":16032,"primaryCompletion":7628,"completion":6513,"start":14701,"enrollment":5585,"conditions":16033,"interventions":16039},"NCT00831844","Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors",[90],[1092,10226,16034,16035,5868,16036,10227,6504,5870,5871,16037,16038,117,5872,15744,6507],"Childhood Hepatoblastoma","Childhood Synovial Sarcoma","Recurrent Adrenocortical Carcinoma","Recurrent Ewing Sarcoma\u002FPeripheral Primitive","Neuroectodermal Tumor",[16006],{"nctId":8152,"briefTitle":8153,"status":142,"phases":16041,"primaryCompletion":8155,"completion":8156,"start":826,"enrollment":1765,"conditions":16042,"interventions":16043},[89,90],[3135,2613,3082],[1099,2143],{"nctId":16045,"briefTitle":16046,"status":142,"phases":16047,"primaryCompletion":14385,"completion":4714,"start":4929,"enrollment":827,"conditions":16048,"interventions":16052},"NCT01413191","Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye",[90],[3306,16049,3308,16050,3309,16051],"Ciliary Body and Choroid Melanoma, Small Size","Metastatic Intraocular Melanoma","Stage IV Intraocular Melanoma",[1099],{"trials":16054,"activeCount":101},[],{"trials":16056,"activeCount":101},[],{"trials":16058,"activeCount":101},[],{"intervention":3342,"totalTrials":771,"cells":16060},{"EARLY_PHASE1":16061,"PHASE1":16063,"PHASE2":16065,"PHASE3":16123,"PHASE4":16125,"NA":16127},{"trials":16062,"activeCount":101},[],{"trials":16064,"activeCount":101},[],{"trials":16066,"activeCount":101},[16067,16074,16088,16094,16098,16102,16108,16117],{"nctId":16068,"briefTitle":16069,"status":142,"phases":16070,"completion":2487,"start":16071,"conditions":16072,"interventions":16073},"NCT00049556","Gefitinib in Treating Patients With Cervical Cancer",[90],"2002-10",[960,2569,1003,1821],[3342],{"nctId":16075,"briefTitle":16076,"status":142,"phases":16077,"primaryCompletion":3227,"completion":3317,"start":16078,"enrollment":8066,"conditions":16079,"interventions":16087},"NCT00042991","Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas",[89,90],"2002-07",[16080,16081,15700,16082,16083,16084,16085,16086],"Untreated Childhood Anaplastic Astrocytoma","Untreated Childhood Anaplastic Oligodendroglioma","Untreated Childhood Giant Cell Glioblastoma","Untreated Childhood Glioblastoma","Untreated Childhood Gliomatosis Cerebri","Untreated Childhood Gliosarcoma","Untreated Childhood Oligodendroglioma",[3342],{"nctId":16089,"briefTitle":16090,"status":142,"phases":16091,"primaryCompletion":4272,"start":14799,"enrollment":4001,"conditions":16092,"interventions":16093},"NCT00014170","Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[90],[4817,4818,4819],[3342],{"nctId":14744,"briefTitle":14745,"status":142,"phases":16095,"primaryCompletion":1781,"start":14747,"enrollment":3983,"conditions":16096,"interventions":16097},[90],[1219,3117,3137],[3122,3342],{"nctId":3336,"briefTitle":3337,"status":142,"phases":16099,"primaryCompletion":1576,"start":1764,"enrollment":3339,"conditions":16100,"interventions":16101},[90],[1767,2163,1768,1769,1770,1771,1772],[995,1776,3342],{"nctId":16103,"briefTitle":16104,"status":142,"phases":16105,"primaryCompletion":1330,"start":3254,"enrollment":3891,"conditions":16106,"interventions":16107},"NCT00052208","Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme",[89,90],[4817,4818,4819],[3342],{"nctId":16109,"briefTitle":16110,"status":142,"phases":16111,"primaryCompletion":7018,"completion":7018,"start":4612,"enrollment":4349,"conditions":16112,"interventions":16115},"NCT00126555","Gefitinib in Treating Patients Who Are Undergoing Surgery and\u002For Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer",[90],[16113,16114],"Recurrent Skin Cancer","Squamous Cell Carcinoma of the Skin",[16116],"Gefitinib",{"nctId":16118,"briefTitle":16119,"status":142,"phases":16120,"primaryCompletion":1241,"start":7340,"enrollment":443,"conditions":16121,"interventions":16122},"NCT00029003","Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],[1768,3119,1772,3285],[3342],{"trials":16124,"activeCount":101},[],{"trials":16126,"activeCount":101},[],{"trials":16128,"activeCount":101},[],{"intervention":3590,"totalTrials":1024,"cells":16130},{"EARLY_PHASE1":16131,"PHASE1":16133,"PHASE2":16139,"PHASE3":16167,"PHASE4":16169,"NA":16171},{"trials":16132,"activeCount":101},[],{"trials":16134,"activeCount":101},[16135],{"nctId":9445,"briefTitle":9446,"status":618,"phases":16136,"primaryCompletion":3389,"start":1276,"enrollment":310,"conditions":16137,"interventions":16138},[89],[1245,1246,3180,3181,3182,3183,4681,3185,3186,4787,9449,3187,3188,940,3189,3190,655,1248,3209,1334,3210,3211,4796,3212,3213,4797,9450,3214,3215,3216,1060,3217,664,15],[3590,3066],{"trials":16140,"activeCount":101},[16141,16145,16149,16153,16159,16163],{"nctId":5689,"briefTitle":5690,"status":142,"phases":16142,"primaryCompletion":1022,"completion":1022,"start":3390,"enrollment":1765,"conditions":16143,"interventions":16144},[90],[4782,1245,4784,1246,3180,3181,3182,3183,3184,3185,3186,3187,3188,940,3189,3190,655,4795,1248,1250,1251],[3590,1063],{"nctId":14573,"briefTitle":14574,"status":618,"phases":16146,"primaryCompletion":3587,"start":3480,"enrollment":12668,"conditions":16147,"interventions":16148},[90],[7344],[3590,5456],{"nctId":3584,"briefTitle":3585,"status":142,"phases":16150,"primaryCompletion":3587,"start":3397,"enrollment":37,"conditions":16151,"interventions":16152},[89,90],[3181,940,3189],[3590,1063,3591,1776,1080,750,1066],{"nctId":16154,"briefTitle":16155,"status":142,"phases":16156,"primaryCompletion":1320,"start":9425,"enrollment":16,"conditions":16157,"interventions":16158},"NCT00062244","Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia",[89,90],[1251],[3590],{"nctId":5732,"briefTitle":5733,"status":618,"phases":16160,"primaryCompletion":2293,"start":1576,"enrollment":3869,"conditions":16161,"interventions":16162},[90],[3205,3206,3207,3214,3215,3216],[3590,1063],{"nctId":3668,"briefTitle":3669,"status":142,"phases":16164,"primaryCompletion":3671,"start":3273,"enrollment":913,"conditions":16165,"interventions":16166},[90],[3673,3120],[3590,1776,1080],{"trials":16168,"activeCount":101},[],{"trials":16170,"activeCount":101},[],{"trials":16172,"activeCount":101},[],{"intervention":4555,"totalTrials":1024,"cells":16174},{"EARLY_PHASE1":16175,"PHASE1":16177,"PHASE2":16203,"PHASE3":16229,"PHASE4":16231,"NA":16233},{"trials":16176,"activeCount":101},[],{"trials":16178,"activeCount":101},[16179,16183,16187,16194],{"nctId":6754,"briefTitle":6755,"status":107,"phases":16180,"primaryCompletion":6757,"completion":6757,"start":6757,"enrollment":101,"conditions":16181,"interventions":16182},[89],[6759,6760,6761,6762,4783],[4556,180,4555,780],{"nctId":4543,"briefTitle":4544,"status":142,"phases":16184,"primaryCompletion":4546,"completion":4547,"start":4548,"enrollment":34,"conditions":16185,"interventions":16186},[89],[4550,4551,4552,4553],[4555,1016,4556,1139],{"nctId":16188,"briefTitle":16189,"status":142,"phases":16190,"start":15750,"conditions":16191,"interventions":16192},"NCT00019318","Depsipeptide in Treating Patients With Solid Tumors",[89],[27],[16193],"romidepsin",{"nctId":16195,"briefTitle":16196,"status":618,"phases":16197,"completion":16198,"start":16199,"enrollment":889,"conditions":16200,"interventions":16202},"NCT01445340","Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma",[89],"2012-06-29","2007-04-21",[16201,4550,467],"Mycosis Fungoides",[4555],{"trials":16204,"activeCount":101},[16205,16211,16217],{"nctId":16206,"briefTitle":16207,"status":618,"phases":16208,"primaryCompletion":3155,"completion":3155,"start":5397,"enrollment":651,"conditions":16209,"interventions":16210},"NCT00383565","FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],[3181,3189],[16193],{"nctId":16212,"briefTitle":16213,"status":142,"phases":16214,"primaryCompletion":1053,"completion":1240,"start":745,"enrollment":234,"conditions":16215,"interventions":16216},"NCT00066638","FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90],[7106,7107,301],[4555],{"nctId":16218,"briefTitle":16219,"status":142,"phases":16220,"primaryCompletion":16221,"completion":16222,"start":16223,"enrollment":16224,"conditions":16225,"interventions":16228},"NCT00007345","Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma",[90],"2015-01-26","2015-07-27","2001-03-08",131,[16226,16227],"Cutaneous T Cell Lymphoma","Peripheral T Cell Lymphoma",[4555],{"trials":16230,"activeCount":101},[],{"trials":16232,"activeCount":101},[],{"trials":16234,"activeCount":101},[],{"intervention":13662,"totalTrials":1024,"cells":16236},{"EARLY_PHASE1":16237,"PHASE1":16239,"PHASE2":16245,"PHASE3":16290,"PHASE4":16292,"NA":16294},{"trials":16238,"activeCount":101},[],{"trials":16240,"activeCount":101},[16241],{"nctId":13655,"briefTitle":13656,"status":142,"phases":16242,"primaryCompletion":13658,"start":13659,"enrollment":25,"conditions":16243,"interventions":16244},[89],[3133,3909,2613,3082],[13662,13663,9245],{"trials":16246,"activeCount":101},[16247,16254,16263,16269,16277,16284],{"nctId":16248,"briefTitle":16249,"status":142,"phases":16250,"primaryCompletion":6513,"completion":6513,"start":3155,"enrollment":1195,"conditions":16251,"interventions":16252},"NCT01349933","Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",[90],[5299,5349],[16253],"Akt inhibitor MK2206",{"nctId":16255,"briefTitle":16256,"status":142,"phases":16257,"primaryCompletion":7481,"completion":16258,"start":14385,"enrollment":827,"conditions":16259,"interventions":16262},"NCT01802320","Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery",[90],"2015-08-05",[16260,16261,5145,5146,4822,4824,4827,4830,4832,4835,4837,4839,4844,4845,4846,4847],"Colon Mucinous Adenocarcinoma","Colon Signet Ring Cell Adenocarcinoma",[13662],{"nctId":16264,"briefTitle":16265,"status":142,"phases":16266,"primaryCompletion":5087,"completion":5087,"start":1240,"enrollment":28,"conditions":16267,"interventions":16268},"NCT01277757","Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer",[90],[2613,1222,1223,3137],[13662],{"nctId":16270,"briefTitle":16271,"status":618,"phases":16272,"primaryCompletion":4900,"completion":4900,"start":3155,"enrollment":188,"conditions":16273,"interventions":16276},"NCT01319539","MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer",[90],[3132,3133,3134,11436,3136,13681,6518,6519,16274,16275,1221,1222,1223,1637],"Stage IIA Breast Cancer","Stage IIB Breast Cancer",[13662],{"nctId":16278,"briefTitle":16279,"status":142,"phases":16280,"primaryCompletion":16281,"completion":16281,"start":3155,"enrollment":889,"conditions":16282,"interventions":16283},"NCT01283035","A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer",[90],"2014-12",[7346,250,251,252],[13662],{"nctId":16285,"briefTitle":16286,"status":142,"phases":16287,"primaryCompletion":6513,"completion":5858,"start":3282,"enrollment":3255,"conditions":16288,"interventions":16289},"NCT01253447","AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90],[4037,4038,4039,4040,4041,4042,4043,4167,4044,4046,4047,4048,4050,4051,33],[16253],{"trials":16291,"activeCount":101},[],{"trials":16293,"activeCount":101},[],{"trials":16295,"activeCount":101},[],{"intervention":1349,"totalTrials":889,"cells":16297},{"EARLY_PHASE1":16298,"PHASE1":16300,"PHASE2":16302,"PHASE3":16331,"PHASE4":16333,"NA":16335},{"trials":16299,"activeCount":101},[],{"trials":16301,"activeCount":101},[],{"trials":16303,"activeCount":101},[16304,16308,16312,16316,16320,16327],{"nctId":10360,"briefTitle":10361,"status":142,"phases":16305,"completion":745,"start":4232,"conditions":16306,"interventions":16307},[90],[2490],[818,1349,993,10365,10366],{"nctId":11346,"briefTitle":11347,"status":142,"phases":16309,"completion":3397,"start":6477,"conditions":16310,"interventions":16311},[90],[2490,15],[818,1349,11351],{"nctId":11363,"briefTitle":11364,"status":142,"phases":16313,"completion":987,"start":5004,"conditions":16314,"interventions":16315},[90],[2490],[818,1347,1349,10365],{"nctId":11388,"briefTitle":11389,"status":142,"phases":16317,"completion":3587,"start":1952,"conditions":16318,"interventions":16319},[90],[2490],[818,1347,1349],{"nctId":16321,"briefTitle":16322,"status":142,"phases":16323,"primaryCompletion":3304,"start":4612,"enrollment":22,"conditions":16324,"interventions":16325},"NCT00109811","Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer",[90],[2296,2321],[16326,1349],"PSA:154-163(155L) peptide vaccine",{"nctId":1337,"briefTitle":1338,"status":618,"phases":16328,"primaryCompletion":1340,"start":1341,"enrollment":16,"conditions":16329,"interventions":16330},[90],[1343,1344],[693,819,1346,1347,1348,1349,750,818],{"trials":16332,"activeCount":101},[],{"trials":16334,"activeCount":101},[],{"trials":16336,"activeCount":101},[],{"intervention":2184,"totalTrials":889,"cells":16338},{"EARLY_PHASE1":16339,"PHASE1":16341,"PHASE2":16363,"PHASE3":16369,"PHASE4":16371,"NA":16373},{"trials":16340,"activeCount":101},[],{"trials":16342,"activeCount":101},[16343,16347,16351,16355,16359],{"nctId":2178,"briefTitle":2179,"status":142,"phases":16344,"primaryCompletion":1022,"start":2181,"conditions":16345,"interventions":16346},[89],[27,15],[2184,1082],{"nctId":3523,"briefTitle":3524,"status":142,"phases":16348,"primaryCompletion":3526,"start":3254,"enrollment":28,"conditions":16349,"interventions":16350},[89],[15],[1776,2184],{"nctId":4987,"briefTitle":4988,"status":142,"phases":16352,"start":4231,"conditions":16353,"interventions":16354},[89],[15],[2184,3065,1264],{"nctId":15811,"briefTitle":15812,"status":142,"phases":16356,"start":15814,"conditions":16357,"interventions":16358},[89],[1260,27],[2184,819],{"nctId":7337,"briefTitle":7338,"status":142,"phases":16360,"primaryCompletion":3129,"start":7340,"enrollment":623,"conditions":16361,"interventions":16362},[89],[4863,7342,7343,3673,7344,7345,5509,7346,7347,7348,5286,4890,7349,5288,7350,3117,1578,4941,2706,7351,5289,7352,7353,3118,5510,5290,5291,5292,7354,5293,5294,3119,1579,4823,3259,2321,4942,5295,3120,7355,5296,5297,5298,5299,5300,5301,5302,5303,7356,7357,4795,5337,7358,5338,7359,3137,4945,7360,7361,5339,6520,5340,5341,5342,5343,5344,3285,1591,4841,3261,2297,4946,5345,5346,5347,5348,5349,5350,5351,5352,5353,1592,1594,7362,7363,7364,15,7365],[2184,5106],{"trials":16364,"activeCount":101},[16365],{"nctId":6866,"briefTitle":6867,"status":142,"phases":16366,"primaryCompletion":5445,"completion":5445,"start":6869,"enrollment":3255,"conditions":16367,"interventions":16368},[90],[3673,3120],[1031,2184],{"trials":16370,"activeCount":101},[],{"trials":16372,"activeCount":101},[],{"trials":16374,"activeCount":101},[],{"intervention":9468,"totalTrials":838,"cells":16376},{"EARLY_PHASE1":16377,"PHASE1":16379,"PHASE2":16397,"PHASE3":16411,"PHASE4":16413,"NA":16415},{"trials":16378,"activeCount":101},[],{"trials":16380,"activeCount":101},[16381,16385,16391],{"nctId":9463,"briefTitle":9464,"status":142,"phases":16382,"primaryCompletion":2292,"start":5445,"enrollment":827,"conditions":16383,"interventions":16384},[89],[5637,3259,3260,3261,15],[9468,3066],{"nctId":16386,"briefTitle":16387,"status":618,"phases":16388,"primaryCompletion":4561,"start":1318,"enrollment":2401,"conditions":16389,"interventions":16390},"NCT01269411","RO4929097 in Treating Patients With Recurrent Invasive Gliomas",[89],[4815,4816,4817,4818,4819,4820,5287],[9468],{"nctId":16392,"briefTitle":16393,"status":142,"phases":16394,"primaryCompletion":1319,"start":3227,"enrollment":31,"conditions":16395,"interventions":16396},"NCT01096355","Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies",[89],[15],[9468],{"trials":16398,"activeCount":101},[16399,16405],{"nctId":16400,"briefTitle":16401,"status":107,"phases":16402,"primaryCompletion":4031,"start":1911,"enrollment":101,"conditions":16403,"interventions":16404},"NCT01216787","RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery",[90],[13738,13739,1344],[9468],{"nctId":16406,"briefTitle":16407,"status":618,"phases":16408,"primaryCompletion":11581,"completion":11581,"start":1329,"enrollment":298,"conditions":16409,"interventions":16410},"NCT01122901","Gamma-Secretase\u002FNotch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma",[90],[4817,4818,4819,5287],[9468],{"trials":16412,"activeCount":101},[],{"trials":16414,"activeCount":101},[],{"trials":16416,"activeCount":101},[],{"intervention":4849,"totalTrials":838,"cells":16418},{"EARLY_PHASE1":16419,"PHASE1":16421,"PHASE2":16438,"PHASE3":16452,"PHASE4":16454,"NA":16456},{"trials":16420,"activeCount":101},[],{"trials":16422,"activeCount":101},[16423,16427,16431],{"nctId":11553,"briefTitle":11554,"status":618,"phases":16424,"primaryCompletion":4714,"completion":4714,"start":11556,"enrollment":2577,"conditions":16425,"interventions":16426},[89],[3132,3134,3136,2613,1222,1223,3137,1637],[4849,1814],{"nctId":4808,"briefTitle":4809,"status":142,"phases":16428,"primaryCompletion":4811,"completion":4811,"start":3272,"enrollment":552,"conditions":16429,"interventions":16430},[89],[4813,4814,4815,4816,4817,4818,4819,4820,3131,3135,4821,2613,4822,1343,3320,251,4823,3332,4824,4825,3260,4826,4827,4828,3485,4829,4830,4831,1222,4832,4833,3488,4834,4835,4836,1223,4837,3491,4838,4839,4840,3137,3321,3494,4841,3261,4842,4843,4844,4845,4846,4847],[4849,68],{"nctId":16432,"briefTitle":16433,"status":618,"phases":16434,"primaryCompletion":11581,"completion":11581,"start":5270,"enrollment":455,"conditions":16435,"interventions":16436},"NCT01193881","RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",[89],[3320,3321],[16437,4849],"Erlotinib Hydrochloride",{"trials":16439,"activeCount":101},[16440,16448],{"nctId":16441,"briefTitle":16442,"status":618,"phases":16443,"primaryCompletion":16444,"completion":16444,"start":16445,"enrollment":838,"conditions":16446,"interventions":16447},"NCT01217411","RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer",[89,90],"2011-11-30","2010-10-01",[3131,274,3134,11436,3135,2844,2613,2118,275,1343,3082,4767,6445],[4849],{"nctId":7101,"briefTitle":7102,"status":107,"phases":16449,"primaryCompletion":1319,"start":1329,"enrollment":101,"conditions":16450,"interventions":16451},[90],[7105,7106,7107,301],[4849,1405],{"trials":16453,"activeCount":101},[],{"trials":16455,"activeCount":101},[],{"trials":16457,"activeCount":101},[],{"intervention":2323,"totalTrials":838,"cells":16459},{"EARLY_PHASE1":16460,"PHASE1":16462,"PHASE2":16464,"PHASE3":16498,"PHASE4":16500,"NA":16502},{"trials":16461,"activeCount":101},[],{"trials":16463,"activeCount":101},[],{"trials":16465,"activeCount":101},[16466,16475,16479,16486,16492],{"nctId":16467,"briefTitle":16468,"status":142,"phases":16469,"primaryCompletion":16470,"completion":16470,"start":16471,"enrollment":1517,"conditions":16472,"interventions":16473},"NCT01168232","Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer",[90],"2013-11-26","2010-09-07",[14809,5556],[16474],"Ixabepilone",{"nctId":2315,"briefTitle":2316,"status":142,"phases":16476,"primaryCompletion":2318,"start":1276,"enrollment":2319,"conditions":16477,"interventions":16478},[90],[2296,2321,2297],[2323,2324,1082],{"nctId":16480,"briefTitle":16481,"status":142,"phases":16482,"primaryCompletion":4996,"completion":1230,"start":717,"enrollment":16483,"conditions":16484,"interventions":16485},"NCT00087139","Ixabepilone in Treating Patients With Metastatic Prostate Cancer",[90],124,[2296,2321,2297],[2323],{"nctId":16487,"briefTitle":16488,"status":142,"phases":16489,"primaryCompletion":1171,"completion":1171,"start":3671,"enrollment":3869,"conditions":16490,"interventions":16491},"NCT00095979","Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer",[90],[1941,2706,7360],[2323],{"nctId":16493,"briefTitle":16494,"status":142,"phases":16495,"primaryCompletion":3317,"completion":3317,"start":16078,"enrollment":2883,"conditions":16496,"interventions":16497},"NCT00025155","Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy",[90],[1821,1579],[2323],{"trials":16499,"activeCount":101},[],{"trials":16501,"activeCount":101},[],{"trials":16503,"activeCount":101},[],{"intervention":16505,"totalTrials":838,"cells":16506},"saracatinib",{"EARLY_PHASE1":16507,"PHASE1":16509,"PHASE2":16511,"PHASE3":16549,"PHASE4":16551,"NA":16553},{"trials":16508,"activeCount":101},[],{"trials":16510,"activeCount":101},[],{"trials":16512,"activeCount":101},[16513,16520,16526,16532,16543],{"nctId":16514,"briefTitle":16515,"status":618,"phases":16516,"primaryCompletion":8134,"completion":2292,"start":1329,"enrollment":25,"conditions":16517,"interventions":16519},"NCT01267266","Saracatinib in Treating Patients With Prostate Cancer",[90],[16518,2321,2297],"Hormone-resistant Prostate Cancer",[16505],{"nctId":16521,"briefTitle":16522,"status":142,"phases":16523,"primaryCompletion":1052,"completion":1052,"start":1023,"enrollment":19,"conditions":16524,"interventions":16525},"NCT00638937","AZD0530 to Treat Recurrent Stage IIIB\u002FIV NSCLC Previously Treated With Combination Chemotherapy",[90],[3119,1772,3285],[16505],{"nctId":16527,"briefTitle":16528,"status":142,"phases":16529,"primaryCompletion":1230,"completion":1230,"start":987,"enrollment":188,"conditions":16530,"interventions":16531},"NCT00559507","Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery",[90],[7343,1219,7348,3117,1222,1223,3137],[16505],{"nctId":16533,"briefTitle":16534,"status":618,"phases":16535,"primaryCompletion":5270,"completion":6513,"start":7581,"enrollment":1195,"conditions":16536,"interventions":16542},"NCT00718809","Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer",[90],[16537,16538,16539,16540,16541],"Invasive Thymoma and Thymic Carcinoma","Recurrent Thymoma and Thymic Carcinoma","Stage III Thymoma","Stage IVA Thymoma","Stage IVB Thymoma",[16505],{"nctId":16544,"briefTitle":16545,"status":142,"phases":16546,"primaryCompletion":1575,"completion":1575,"start":7645,"enrollment":31,"conditions":16547,"interventions":16548},"NCT00513071","AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy",[90],[16518,2321],[16505],{"trials":16550,"activeCount":101},[],{"trials":16552,"activeCount":101},[],{"trials":16554,"activeCount":101},[],{"intervention":16556,"totalTrials":838,"cells":16557},"ziv-aflibercept",{"EARLY_PHASE1":16558,"PHASE1":16560,"PHASE2":16568,"PHASE3":16602,"PHASE4":16604,"NA":16606},{"trials":16559,"activeCount":101},[],{"trials":16561,"activeCount":101},[16562],{"nctId":16563,"briefTitle":16564,"status":142,"phases":16565,"primaryCompletion":3227,"start":4165,"enrollment":2029,"conditions":16566,"interventions":16567},"NCT00622414","Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors",[89],[748],[16556],{"trials":16569,"activeCount":101},[16570,16581,16588,16595],{"nctId":16571,"briefTitle":16572,"status":142,"phases":16573,"primaryCompletion":8167,"completion":5103,"start":5444,"enrollment":623,"conditions":16574,"interventions":16579},"NCT00729157","Aflibercept in Treating Patients With Recurrent and\u002For Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy",[90],[7655,16575,16576,16577,16578],"Stage III Thyroid Gland Follicular Carcinoma","Stage III Thyroid Gland Papillary Carcinoma","Stage IV Thyroid Gland Follicular Carcinoma","Stage IV Thyroid Gland Papillary Carcinoma",[16580],"Ziv-Aflibercept",{"nctId":16582,"briefTitle":16583,"status":142,"phases":16584,"primaryCompletion":716,"completion":3129,"start":1340,"enrollment":1195,"conditions":16585,"interventions":16587},"NCT00369655","VEGF Trap in Treating Patients With Metastatic Breast Cancer",[90],[16586,3117,3137],"Metastatic Breast Cancer",[16556],{"nctId":16589,"briefTitle":16590,"status":142,"phases":16591,"primaryCompletion":650,"completion":5858,"start":4715,"enrollment":2401,"conditions":16592,"interventions":16594},"NCT00407485","VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium",[90],[10298,7684,10299,7685,7686,7687,7688,2899,10301,16593,7689,7690,7691],"Stage III Urethral Cancer",[16556],{"nctId":16596,"briefTitle":16597,"status":142,"phases":16598,"primaryCompletion":2017,"completion":5562,"start":5397,"enrollment":2346,"conditions":16599,"interventions":16601},"NCT00390234","Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma",[90],[2569,16600,1730,7346,1579,8169,1790,10191,1591,10192,5556,10229],"Female Reproductive Cancer",[16556],{"trials":16603,"activeCount":101},[],{"trials":16605,"activeCount":101},[],{"trials":16607,"activeCount":101},[],{"intervention":704,"totalTrials":838,"cells":16609},{"EARLY_PHASE1":16610,"PHASE1":16612,"PHASE2":16622,"PHASE3":16640,"PHASE4":16642,"NA":16644},{"trials":16611,"activeCount":101},[],{"trials":16613,"activeCount":101},[16614,16618],{"nctId":695,"briefTitle":696,"status":618,"phases":16615,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":16616,"interventions":16617},[89],[702],[704,63,705,643,706,707,708,709,710],{"nctId":712,"briefTitle":713,"status":618,"phases":16619,"primaryCompletion":715,"completion":716,"start":717,"enrollment":603,"conditions":16620,"interventions":16621},[89],[719],[704,721,63,643,722],{"trials":16623,"activeCount":101},[16624,16632,16636],{"nctId":16625,"briefTitle":16626,"status":142,"phases":16627,"completion":1181,"start":14896,"enrollment":16628,"conditions":16629,"interventions":16630},"NCT00001705","Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence",[90],141,[36,7088],[16631,704],"GP100 peptide",{"nctId":14937,"briefTitle":14938,"status":142,"phases":16633,"primaryCompletion":14940,"completion":14940,"start":14941,"enrollment":28,"conditions":16634,"interventions":16635},[90],[14943,5969],[14945,14946,14947,14948,704,14949,14906,14950],{"nctId":1306,"briefTitle":1307,"status":142,"phases":16637,"primaryCompletion":1309,"completion":1310,"start":715,"enrollment":34,"conditions":16638,"interventions":16639},[90],[195],[1313,63,704,643],{"trials":16641,"activeCount":101},[],{"trials":16643,"activeCount":101},[],{"trials":16645,"activeCount":101},[],{"intervention":5980,"totalTrials":214,"cells":16647},{"EARLY_PHASE1":16648,"PHASE1":16650,"PHASE2":16658,"PHASE3":16680,"PHASE4":16682,"NA":16684},{"trials":16649,"activeCount":101},[],{"trials":16651,"activeCount":101},[16652],{"nctId":16653,"briefTitle":16654,"status":142,"phases":16655,"primaryCompletion":716,"start":4272,"enrollment":339,"conditions":16656,"interventions":16657},"NCT00063973","Cilengitide in Treating Children With Refractory Primary Brain Tumors",[89],[4642,4643,4644,4645,4646,4647,4648,4649,4650,4651,4652,4653,4654,4655,4656,4657,5363,4658,4659,4660,4661,4662,4663,4664,4665,4666],[5980],{"trials":16659,"activeCount":101},[16660,16666,16676],{"nctId":16661,"briefTitle":16662,"status":142,"phases":16663,"primaryCompletion":987,"start":6869,"enrollment":1277,"conditions":16664,"interventions":16665},"NCT00103337","Cilengitide in Treating Patients With Metastatic Prostate Cancer",[90],[2321,2297],[5980],{"nctId":16667,"briefTitle":16668,"status":142,"phases":16669,"primaryCompletion":3479,"completion":16670,"start":6869,"enrollment":455,"conditions":16671,"interventions":16675},"NCT00121238","Cilengitide in Treating Patients With Prostate Cancer",[90],"2015-11",[2321,16672,16673,16674,7008],"Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer",[5980],{"nctId":5973,"briefTitle":5974,"status":142,"phases":16677,"primaryCompletion":5103,"completion":5103,"start":5976,"enrollment":5977,"conditions":16678,"interventions":16679},[89,90],[4817,4818,4819],[5980,5874],{"trials":16681,"activeCount":101},[],{"trials":16683,"activeCount":101},[],{"trials":16685,"activeCount":101},[],{"intervention":630,"totalTrials":214,"cells":16687},{"EARLY_PHASE1":16688,"PHASE1":16690,"PHASE2":16700,"PHASE3":16716,"PHASE4":16718,"NA":16720},{"trials":16689,"activeCount":101},[],{"trials":16691,"activeCount":101},[16692,16696],{"nctId":616,"briefTitle":617,"status":618,"phases":16693,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":16694,"interventions":16695},[89],[625,36,626,627],[629,63,630],{"nctId":679,"briefTitle":680,"status":618,"phases":16697,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":16698,"interventions":16699},[89],[687,688,689,625,690],[692,630,693],{"trials":16701,"activeCount":101},[16702,16708],{"nctId":16703,"briefTitle":16704,"status":142,"phases":16705,"primaryCompletion":6782,"completion":14385,"start":3272,"enrollment":13282,"conditions":16706,"interventions":16707},"NCT01021215","Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers",[89,90],[11697],[11699,630],{"nctId":16709,"briefTitle":16710,"status":107,"phases":16711,"enrollment":101,"conditions":16712,"interventions":16714},"NCT00025051","Celecoxib in Preventing Skin Cancer",[90],[16713],"Non-melanomatous Skin Cancer",[16715],"celecoxib",{"trials":16717,"activeCount":101},[],{"trials":16719,"activeCount":101},[],{"trials":16721,"activeCount":101},[],{"intervention":14541,"totalTrials":214,"cells":16723},{"EARLY_PHASE1":16724,"PHASE1":16726,"PHASE2":16728,"PHASE3":16762,"PHASE4":16764,"NA":16766},{"trials":16725,"activeCount":101},[],{"trials":16727,"activeCount":101},[],{"trials":16729,"activeCount":101},[16730,16739,16750,16758],{"nctId":16731,"briefTitle":16732,"status":618,"phases":16733,"primaryCompletion":1763,"completion":11062,"start":1340,"enrollment":188,"conditions":16734,"interventions":16738},"NCT00445549","Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90],[16735,16736,16737],"Ovarian Neoplasms","Fallopian Tube Neoplasms","Peritoneal Neoplasms",[14541],{"nctId":16740,"briefTitle":16741,"status":142,"phases":16742,"primaryCompletion":16743,"completion":16744,"start":16745,"enrollment":407,"conditions":16746,"interventions":16749},"NCT00514046","Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer",[89,90],"2019-12-10","2020-11-01","2007-07-20",[14539,16747,16748],"Multiple Endocrine Neoplasia Type 2A","Multiple Endocrine Neoplasia Type 2B",[14541],{"nctId":16751,"briefTitle":16752,"status":618,"phases":16753,"primaryCompletion":5445,"completion":5445,"start":10518,"enrollment":603,"conditions":16754,"interventions":16756},"NCT01372813","Vandetanib to Treat Advanced Kidney Cancer",[90],[16755],"Advanced Clear Cell Renal Carcinoma",[16757],"vandetanib",{"nctId":14532,"briefTitle":14533,"status":618,"phases":16759,"primaryCompletion":14535,"completion":14536,"start":14537,"enrollment":2401,"conditions":16760,"interventions":16761},[89,90],[14539],[1569,14541],{"trials":16763,"activeCount":101},[],{"trials":16765,"activeCount":101},[],{"trials":16767,"activeCount":101},[],{"intervention":16769,"totalTrials":214,"cells":16770},"Trametinib",{"EARLY_PHASE1":16771,"PHASE1":16773,"PHASE2":16796,"PHASE3":16817,"PHASE4":16819,"NA":16821},{"trials":16772,"activeCount":101},[],{"trials":16774,"activeCount":101},[16775,16785],{"nctId":16776,"briefTitle":16777,"status":142,"phases":16778,"primaryCompletion":16779,"completion":16779,"start":16780,"enrollment":34,"conditions":16781,"interventions":16783},"NCT01935973","Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer",[89],"2015-09-08","2013-09-30",[1941,1943,3431,1944,3432,16782],"Recurrent Uterine Corpus Cancer",[16769,16784],"Uprosertib",{"nctId":16786,"briefTitle":16787,"status":618,"phases":16788,"primaryCompletion":16789,"completion":3075,"start":16790,"enrollment":2401,"conditions":16791,"interventions":16794},"NCT02097225","Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",[89],"2019-03-31","2014-05-29",[16792,16793,486,195,9335,10180,10181,10182,4767,6160],"BRAF V600E Mutation Present","BRAF V600K Mutation Present",[16795,2625,16769],"Dabrafenib",{"trials":16797,"activeCount":101},[16798,16808],{"nctId":16799,"briefTitle":16800,"status":142,"phases":16801,"primaryCompletion":1365,"completion":1365,"start":16802,"enrollment":1913,"conditions":16803,"interventions":16807},"NCT03148275","Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery",[90],"2017-06-20",[16804,16805,16806],"Locally Advanced Epithelioid Hemangioendothelioma","Metastatic Epithelioid Hemangioendothelioma","Unresectable Epithelioid Hemangioendothelioma",[16769],{"nctId":16809,"briefTitle":16810,"status":142,"phases":16811,"primaryCompletion":16812,"completion":16813,"start":16814,"enrollment":37,"conditions":16815,"interventions":16816},"NCT01989598","Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90],"2019-08-31","2020-09-28","2013-10-30",[6027,301],[16769,16784],{"trials":16818,"activeCount":101},[],{"trials":16820,"activeCount":101},[],{"trials":16822,"activeCount":101},[],{"intervention":3092,"totalTrials":214,"cells":16824},{"EARLY_PHASE1":16825,"PHASE1":16827,"PHASE2":16833,"PHASE3":16851,"PHASE4":16853,"NA":16855},{"trials":16826,"activeCount":101},[],{"trials":16828,"activeCount":101},[16829],{"nctId":3085,"briefTitle":3086,"status":142,"phases":16830,"primaryCompletion":3088,"start":3089,"enrollment":28,"conditions":16831,"interventions":16832},[89],[1003,1821],[3092,3093,995,1031],{"trials":16834,"activeCount":101},[16835,16843,16847],{"nctId":16836,"briefTitle":16837,"status":142,"phases":16838,"primaryCompletion":1181,"start":16839,"enrollment":1852,"conditions":16840,"interventions":16841},"NCT00002574","Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",[90],"1994-09",[1260],[3092,16842],"omacetaxine mepesuccinate",{"nctId":15902,"briefTitle":15903,"status":142,"phases":16844,"primaryCompletion":3453,"start":5707,"enrollment":1074,"conditions":16845,"interventions":16846},[90],[1343,1344],[3123,3092],{"nctId":5494,"briefTitle":5495,"status":142,"phases":16848,"primaryCompletion":2292,"completion":2292,"start":3115,"enrollment":2294,"conditions":16849,"interventions":16850},[90],[1343,4843],[5499,53],{"trials":16852,"activeCount":101},[],{"trials":16854,"activeCount":101},[],{"trials":16856,"activeCount":101},[],{"intervention":16858,"totalTrials":214,"cells":16859},"fenretinide",{"EARLY_PHASE1":16860,"PHASE1":16862,"PHASE2":16873,"PHASE3":16893,"PHASE4":16895,"NA":16897},{"trials":16861,"activeCount":101},[],{"trials":16863,"activeCount":101},[16864],{"nctId":16865,"briefTitle":16866,"status":142,"phases":16867,"completion":16868,"start":16869,"enrollment":16870,"conditions":16871,"interventions":16872},"NCT00001378","A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer",[89],"2000-11","1994-01",75,[18,1291],[16858],{"trials":16874,"activeCount":101},[16875,16881,16887],{"nctId":16876,"briefTitle":16877,"status":142,"phases":16878,"primaryCompletion":6530,"start":14807,"enrollment":421,"conditions":16879,"interventions":16880},"NCT00026091","Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer",[90],[1579,1992,1591,1996],[16858],{"nctId":16882,"briefTitle":16883,"status":142,"phases":16884,"primaryCompletion":3480,"start":16868,"enrollment":22,"conditions":16885,"interventions":16886},"NCT00009971","Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer",[90],[687],[16858],{"nctId":16888,"briefTitle":16889,"status":142,"phases":16890,"primaryCompletion":14701,"completion":14701,"start":1257,"enrollment":4349,"conditions":16891,"interventions":16892},"NCT00080899","Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer",[90],[2296,2321],[16858],{"trials":16894,"activeCount":101},[],{"trials":16896,"activeCount":101},[],{"trials":16898,"activeCount":101},[],{"intervention":16900,"totalTrials":603,"cells":16901},"EF5",{"EARLY_PHASE1":16902,"PHASE1":16904,"PHASE2":16920,"PHASE3":16944,"PHASE4":16946,"NA":16948},{"trials":16903,"activeCount":101},[],{"trials":16905,"activeCount":101},[16906],{"nctId":16907,"briefTitle":16908,"status":618,"phases":16909,"primaryCompletion":1340,"start":1330,"enrollment":730,"conditions":16910,"interventions":16919},"NCT00110032","Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors",[89],[4813,4814,4815,4816,5273,5274,16911,5275,16912,5276,4817,4818,4819,16913,5277,5278,11583,16914,4820,16915,5280,8147,16916,5282,16917,16918,5284],"Adult Craniopharyngioma","Adult Ependymoblastoma","Adult Grade I Meningioma","Adult Meningeal Hemangiopericytoma","Adult Myxopapillary Ependymoma","Adult Pineoblastoma","Adult Subependymoma","Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)",[16900],{"trials":16921,"activeCount":101},[16922,16932],{"nctId":16923,"briefTitle":16924,"status":142,"phases":16925,"primaryCompletion":3304,"completion":5858,"start":1764,"enrollment":31,"conditions":16926,"interventions":16931},"NCT02154399","EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer",[90],[16927,16928,16929,16930,4828,4833],"Stage IA Non-Small Cell Lung Carcinoma","Stage IB Non-Small Cell Lung Carcinoma","Stage IIA Non-Small Cell Lung Carcinoma","Stage IIB Non-Small Cell Lung Carcinoma",[16900],{"nctId":16933,"briefTitle":16934,"status":142,"phases":16935,"primaryCompletion":3480,"start":5706,"enrollment":1074,"conditions":16936,"interventions":16943},"NCT00107445","EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer",[90],[1821,16937,16938,16939,2006,16940,16941,2008,2009,2010,16942,1790,7360,1591,1592,1594],"Stage I Endometrial Carcinoma","Stage I Ovarian Epithelial Cancer","Stage IA Cervical Cancer","Stage II Endometrial Carcinoma","Stage II Ovarian Epithelial Cancer","Stage III Endometrial Carcinoma",[16900],{"trials":16945,"activeCount":101},[],{"trials":16947,"activeCount":101},[],{"trials":16949,"activeCount":101},[],{"intervention":14802,"totalTrials":603,"cells":16951},{"EARLY_PHASE1":16952,"PHASE1":16954,"PHASE2":16956,"PHASE3":16975,"PHASE4":16977,"NA":16979},{"trials":16953,"activeCount":101},[],{"trials":16955,"activeCount":101},[],{"trials":16957,"activeCount":101},[16958,16962,16969],{"nctId":14796,"briefTitle":14797,"status":142,"phases":16959,"primaryCompletion":1952,"start":14799,"enrollment":638,"conditions":16960,"interventions":16961},[90],[2490],[14802,3470],{"nctId":16963,"briefTitle":16964,"status":142,"phases":16965,"primaryCompletion":1288,"start":1979,"enrollment":19,"conditions":16966,"interventions":16967},"NCT00005942","Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy",[89,90],[2453,4058,33,4616,6285],[16968,14802],"liposomal daunorubicin citrate",{"nctId":16970,"briefTitle":16971,"status":618,"phases":16972,"primaryCompletion":745,"start":1288,"enrollment":234,"conditions":16973,"interventions":16974},"NCT00009919","SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment",[90],[5233,4842],[14802],{"trials":16976,"activeCount":101},[],{"trials":16978,"activeCount":101},[],{"trials":16980,"activeCount":101},[],{"intervention":6242,"totalTrials":603,"cells":16982},{"EARLY_PHASE1":16983,"PHASE1":16985,"PHASE2":16995,"PHASE3":17001,"PHASE4":17003,"NA":17005},{"trials":16984,"activeCount":101},[],{"trials":16986,"activeCount":101},[16987,16991],{"nctId":6237,"briefTitle":6238,"status":142,"phases":16988,"primaryCompletion":1309,"start":1952,"enrollment":2883,"conditions":16989,"interventions":16990},[89],[4043,4044,4045,4046,4047,33],[6242,1187],{"nctId":9398,"briefTitle":9399,"status":142,"phases":16992,"primaryCompletion":2293,"start":3638,"enrollment":421,"conditions":16993,"interventions":16994},[89],[15],[6242,3066],{"trials":16996,"activeCount":101},[16997],{"nctId":7004,"briefTitle":7005,"status":142,"phases":16998,"primaryCompletion":2293,"start":5452,"enrollment":1765,"conditions":16999,"interventions":17000},[89,90],[3119,2321,7008,1771,1772,3285,2297,15],[6242,1775],{"trials":17002,"activeCount":101},[],{"trials":17004,"activeCount":101},[],{"trials":17006,"activeCount":101},[],{"intervention":3263,"totalTrials":603,"cells":17008},{"EARLY_PHASE1":17009,"PHASE1":17011,"PHASE2":17021,"PHASE3":17027,"PHASE4":17029,"NA":17031},{"trials":17010,"activeCount":101},[],{"trials":17012,"activeCount":101},[17013,17017],{"nctId":4256,"briefTitle":4257,"status":142,"phases":17014,"primaryCompletion":4259,"start":4260,"enrollment":827,"conditions":17015,"interventions":17016},[89],[3180,3181,3182,3185,3186,940,3189,656,4262,1432],[3263,1032],{"nctId":4269,"briefTitle":4270,"status":142,"phases":17018,"primaryCompletion":4272,"start":3115,"enrollment":188,"conditions":17019,"interventions":17020},[89],[1279,4274,1281,1282],[3263,1032],{"trials":17022,"activeCount":101},[17023],{"nctId":3251,"briefTitle":3252,"status":142,"phases":17024,"primaryCompletion":650,"completion":650,"start":3254,"enrollment":3255,"conditions":17025,"interventions":17026},[90],[3257,3258,3259,3260,3261],[995,3263],{"trials":17028,"activeCount":101},[],{"trials":17030,"activeCount":101},[],{"trials":17032,"activeCount":101},[],{"intervention":3277,"totalTrials":603,"cells":17034},{"EARLY_PHASE1":17035,"PHASE1":17037,"PHASE2":17039,"PHASE3":17059,"PHASE4":17061,"NA":17063},{"trials":17036,"activeCount":101},[],{"trials":17038,"activeCount":101},[],{"trials":17040,"activeCount":101},[17041,17051,17055],{"nctId":17042,"briefTitle":17043,"status":142,"phases":17044,"primaryCompletion":17045,"completion":17046,"start":17047,"enrollment":37,"conditions":17048,"interventions":17049},"NCT02273362","Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver",[89,90],"2020-02-11","2022-03-10","2014-11-24",[10156,801],[17050,16437],"Erlotinib",{"nctId":3269,"briefTitle":3270,"status":142,"phases":17052,"primaryCompletion":3272,"completion":3272,"start":3273,"enrollment":3274,"conditions":17053,"interventions":17054},[90],[1784,2569,1785,1732,1787,1788,1789,1790,1591],[995,1776,3277],{"nctId":8143,"briefTitle":8144,"status":142,"phases":17056,"primaryCompletion":650,"completion":5858,"start":5976,"enrollment":8066,"conditions":17057,"interventions":17058},[89,90],[4813,4815,5275,4817,4818,4819,4820,8147,8148,8149,5287],[3277,4566],{"trials":17060,"activeCount":101},[],{"trials":17062,"activeCount":101},[],{"trials":17064,"activeCount":101},[],{"intervention":17066,"totalTrials":603,"cells":17067},"recombinant fowlpox-TRICOM vaccine",{"EARLY_PHASE1":17068,"PHASE1":17070,"PHASE2":17079,"PHASE3":17091,"PHASE4":17093,"NA":17095},{"trials":17069,"activeCount":101},[],{"trials":17071,"activeCount":101},[17072],{"nctId":17073,"briefTitle":17074,"status":618,"phases":17075,"primaryCompletion":650,"start":7340,"enrollment":1517,"conditions":17076,"interventions":17077},"NCT00030693","Vaccine Therapy in Treating Patients With Metastatic Solid Tumors",[89],[15],[17078,17066],"recombinant fowlpox-B7.1 vaccine",{"trials":17080,"activeCount":101},[17081,17087],{"nctId":17082,"briefTitle":17083,"status":618,"phases":17084,"primaryCompletion":5958,"start":1257,"enrollment":31,"conditions":17085,"interventions":17086},"NCT00087373","Vaccine Therapy in Treating Patients With Metastatic Melanoma",[90],[1343,1344],[17066],{"nctId":10395,"briefTitle":10396,"status":142,"phases":17088,"primaryCompletion":5103,"completion":5103,"start":2160,"enrollment":1913,"conditions":17089,"interventions":17090},[90],[24],[5933,10400,10401],{"trials":17092,"activeCount":101},[],{"trials":17094,"activeCount":101},[],{"trials":17096,"activeCount":101},[],{"intervention":4977,"totalTrials":603,"cells":17098},{"EARLY_PHASE1":17099,"PHASE1":17101,"PHASE2":17107,"PHASE3":17124,"PHASE4":17126,"NA":17128},{"trials":17100,"activeCount":101},[],{"trials":17102,"activeCount":101},[17103],{"nctId":4969,"briefTitle":4970,"status":142,"phases":17104,"primaryCompletion":4972,"completion":4972,"start":4973,"enrollment":2211,"conditions":17105,"interventions":17106},[89],[4975],[4977,2084,1140,2925],{"trials":17108,"activeCount":101},[17109,17115],{"nctId":17110,"briefTitle":17111,"status":142,"phases":17112,"primaryCompletion":5087,"completion":1645,"start":6782,"enrollment":4349,"conditions":17113,"interventions":17114},"NCT01637961","Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus",[90],[14809,556],[4977],{"nctId":17116,"briefTitle":17117,"status":142,"phases":17118,"primaryCompletion":17119,"start":17120,"enrollment":1953,"conditions":17121,"interventions":17123},"NCT01653028","Alisertib in Treating Patients With Advanced or Metastatic Sarcoma",[90],"2015-08-02","2012-08-22",[4471,10227,7706,17122,7707,7709,4482,4483],"Recurrent Liposarcoma",[4977],{"trials":17125,"activeCount":101},[],{"trials":17127,"activeCount":101},[],{"trials":17129,"activeCount":101},[],{"intervention":5961,"totalTrials":603,"cells":17131},{"EARLY_PHASE1":17132,"PHASE1":17134,"PHASE2":17144,"PHASE3":17150,"PHASE4":17152,"NA":17154},{"trials":17133,"activeCount":101},[],{"trials":17135,"activeCount":101},[17136,17140],{"nctId":7554,"briefTitle":7555,"status":618,"phases":17137,"primaryCompletion":1341,"start":1257,"enrollment":22,"conditions":17138,"interventions":17139},[89],[15],[3591,5961],{"nctId":15157,"briefTitle":15158,"status":142,"phases":17141,"primaryCompletion":1576,"start":6861,"enrollment":700,"conditions":17142,"interventions":17143},[89],[3664],[5961,1434],{"trials":17145,"activeCount":101},[17146],{"nctId":5954,"briefTitle":5955,"status":142,"phases":17147,"primaryCompletion":5957,"completion":1329,"start":5958,"enrollment":623,"conditions":17148,"interventions":17149},[90],[3664],[5961,5874],{"trials":17151,"activeCount":101},[],{"trials":17153,"activeCount":101},[],{"trials":17155,"activeCount":101},[],{"intervention":991,"totalTrials":603,"cells":17157},{"EARLY_PHASE1":17158,"PHASE1":17160,"PHASE2":17166,"PHASE3":17176,"PHASE4":17178,"NA":17180},{"trials":17159,"activeCount":101},[],{"trials":17161,"activeCount":101},[17162],{"nctId":6956,"briefTitle":6957,"status":618,"phases":17163,"primaryCompletion":2293,"start":1257,"enrollment":1074,"conditions":17164,"interventions":17165},[89],[3673,4941,3119,4942,3120,4945,3285,4946],[991,992,1775,993],{"trials":17167,"activeCount":101},[17168,17172],{"nctId":984,"briefTitle":985,"status":142,"phases":17169,"completion":987,"start":988,"conditions":17170,"interventions":17171},[90],[18],[991,992,993,693,994,995],{"nctId":1296,"briefTitle":1297,"status":618,"phases":17173,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":17174,"interventions":17175},[89,90],[1291,1302],[991,1304,750,993,693,994,819,995,722],{"trials":17177,"activeCount":101},[],{"trials":17179,"activeCount":101},[],{"trials":17181,"activeCount":101},[],{"intervention":6967,"totalTrials":603,"cells":17183},{"EARLY_PHASE1":17184,"PHASE1":17186,"PHASE2":17201,"PHASE3":17211,"PHASE4":17213,"NA":17215},{"trials":17185,"activeCount":101},[],{"trials":17187,"activeCount":101},[17188,17197],{"nctId":17189,"briefTitle":17190,"status":142,"phases":17191,"completion":1288,"start":17192,"enrollment":827,"conditions":17193,"interventions":17196},"NCT00001381","A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder",[89],"1994-03",[17194,17195],"Bladder Neoplasms","Carcinoma, Transitional Cell",[6967],{"nctId":6962,"briefTitle":6963,"status":142,"phases":17198,"primaryCompletion":716,"start":4272,"enrollment":339,"conditions":17199,"interventions":17200},[89],[3119,1772,3285],[6967,1775,3066],{"trials":17202,"activeCount":101},[17203],{"nctId":17204,"briefTitle":17205,"status":142,"phases":17206,"completion":5057,"start":15385,"enrollment":1111,"conditions":17207,"interventions":17209},"NCT00001266","A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma",[90],[17208],"Prostatic Neoplasm",[17210],"Suramin",{"trials":17212,"activeCount":101},[],{"trials":17214,"activeCount":101},[],{"trials":17216,"activeCount":101},[],{"intervention":17218,"totalTrials":603,"cells":17219},"irofulven",{"EARLY_PHASE1":17220,"PHASE1":17222,"PHASE2":17230,"PHASE3":17245,"PHASE4":17247,"NA":17249},{"trials":17221,"activeCount":101},[],{"trials":17223,"activeCount":101},[17224],{"nctId":17225,"briefTitle":17226,"status":142,"phases":17227,"primaryCompletion":1576,"start":746,"enrollment":188,"conditions":17228,"interventions":17229},"NCT00003370","Irofulven in Treating Children With Recurrent or Refractory Solid Tumors",[89],[748],[17218],{"trials":17231,"activeCount":101},[17232,17239],{"nctId":17233,"briefTitle":17234,"status":142,"phases":17235,"completion":1989,"start":17236,"conditions":17237,"interventions":17238},"NCT00019552","Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer",[90],"1998-09",[2569,1003,1821],[17218],{"nctId":17240,"briefTitle":17241,"status":142,"phases":17242,"primaryCompletion":649,"completion":649,"start":745,"enrollment":14886,"conditions":17243,"interventions":17244},"NCT00053365","Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer",[90],[1821,1579],[17218],{"trials":17246,"activeCount":101},[],{"trials":17248,"activeCount":101},[],{"trials":17250,"activeCount":101},[],{"intervention":17252,"totalTrials":603,"cells":17253},"apolizumab",{"EARLY_PHASE1":17254,"PHASE1":17256,"PHASE2":17271,"PHASE3":17279,"PHASE4":17281,"NA":17283},{"trials":17255,"activeCount":101},[],{"trials":17257,"activeCount":101},[17258,17264],{"nctId":17259,"briefTitle":17260,"status":142,"phases":17261,"primaryCompletion":715,"start":3088,"enrollment":638,"conditions":17262,"interventions":17263},"NCT00017472","Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia",[89],[1245,1246,3177,3178,1135,33,3190,655,656,1248,3208,662,3217,664],[17252],{"nctId":17265,"briefTitle":17266,"status":142,"phases":17267,"primaryCompletion":1330,"start":17268,"enrollment":638,"conditions":17269,"interventions":17270},"NCT00004101","Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma",[89],"1999-11",[27],[17252],{"trials":17272,"activeCount":101},[17273],{"nctId":17274,"briefTitle":17275,"status":142,"phases":17276,"primaryCompletion":1912,"start":14499,"enrollment":22,"conditions":17277,"interventions":17278},"NCT00089154","Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[90],[3178,655,656,662,664],[17252],{"trials":17280,"activeCount":101},[],{"trials":17282,"activeCount":101},[],{"trials":17284,"activeCount":101},[],{"intervention":9201,"totalTrials":603,"cells":17286},{"EARLY_PHASE1":17287,"PHASE1":17289,"PHASE2":17299,"PHASE3":17315,"PHASE4":17317,"NA":17319},{"trials":17288,"activeCount":101},[],{"trials":17290,"activeCount":101},[17291,17295],{"nctId":10150,"briefTitle":10151,"status":142,"phases":17292,"primaryCompletion":10153,"completion":4411,"start":10154,"enrollment":1041,"conditions":17293,"interventions":17294},[89],[10156,10157,10158,486,10159,116,3754,10160,6160],[9201,10162,43],{"nctId":9192,"briefTitle":9193,"status":142,"phases":17296,"primaryCompletion":3075,"completion":9195,"start":9196,"enrollment":2029,"conditions":17297,"interventions":17298},[89],[9198,9199,8911,8912,8913,6445],[9201,5373],{"trials":17300,"activeCount":101},[17301],{"nctId":17302,"briefTitle":17303,"status":618,"phases":17304,"primaryCompletion":17305,"completion":17306,"start":17307,"enrollment":310,"conditions":17308,"interventions":17313},"NCT03366103","Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors",[89,90],"2021-07-28","2022-09-21","2018-03-20",[486,275,116,30,17309,17310,17311,17312,6160],"Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7","Stage IIIA Lung Small Cell Carcinoma AJCC v7","Stage IIIB Lung Small Cell Carcinoma AJCC v7","Stage IV Lung Small Cell Carcinoma AJCC v7",[9201,17314],"Vistusertib",{"trials":17316,"activeCount":101},[],{"trials":17318,"activeCount":101},[],{"trials":17320,"activeCount":101},[],{"intervention":1919,"totalTrials":603,"cells":17322},{"EARLY_PHASE1":17323,"PHASE1":17325,"PHASE2":17327,"PHASE3":17344,"PHASE4":17346,"NA":17348},{"trials":17324,"activeCount":101},[],{"trials":17326,"activeCount":101},[],{"trials":17328,"activeCount":101},[17329,17333,17340],{"nctId":1907,"briefTitle":1908,"status":142,"phases":17330,"primaryCompletion":1910,"completion":1911,"start":1912,"enrollment":1913,"conditions":17331,"interventions":17332},[90],[1915,1916,1917],[1919,1775,1598],{"nctId":17334,"briefTitle":17335,"status":142,"phases":17336,"primaryCompletion":11556,"completion":3129,"start":1241,"enrollment":19,"conditions":17337,"interventions":17339},"NCT00098254","BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer",[90],[17338],"Non-Small-Cell Lung Carcinoma",[1919],{"nctId":5515,"briefTitle":5516,"status":142,"phases":17341,"primaryCompletion":5518,"completion":5519,"start":5520,"enrollment":913,"conditions":17342,"interventions":17343},[90],[5522,2569,2568],[53,1919],{"trials":17345,"activeCount":101},[],{"trials":17347,"activeCount":101},[],{"trials":17349,"activeCount":101},[],{"intervention":2444,"totalTrials":603,"cells":17351},{"EARLY_PHASE1":17352,"PHASE1":17354,"PHASE2":17369,"PHASE3":17379,"PHASE4":17381,"NA":17383},{"trials":17353,"activeCount":101},[],{"trials":17355,"activeCount":101},[17356,17360],{"nctId":2437,"briefTitle":2438,"status":618,"phases":17357,"primaryCompletion":2440,"completion":2441,"start":756,"enrollment":758,"conditions":17358,"interventions":17359},[89],[915],[2444,2445,2218,710,706,1139],{"nctId":17361,"briefTitle":17362,"status":618,"phases":17363,"primaryCompletion":17364,"completion":17364,"start":17365,"enrollment":838,"conditions":17366,"interventions":17367},"NCT03436732","Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma",[89],"2019-04-30","2018-02-28",[915],[2444,17368],"SEL-110",{"trials":17370,"activeCount":101},[17371],{"nctId":17372,"briefTitle":17373,"status":142,"phases":17374,"primaryCompletion":17375,"completion":2655,"start":910,"enrollment":421,"conditions":17376,"interventions":17377},"NCT02810418","Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and\u002For Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors",[89,90],"2019-01-02",[467,917],[2444,17378,2444],"Nab-Paclitaxel",{"trials":17380,"activeCount":101},[],{"trials":17382,"activeCount":101},[],{"trials":17384,"activeCount":101},[],{"intervention":8887,"totalTrials":603,"cells":17386},{"EARLY_PHASE1":17387,"PHASE1":17389,"PHASE2":17401,"PHASE3":17416,"PHASE4":17418,"NA":17420},{"trials":17388,"activeCount":101},[],{"trials":17390,"activeCount":101},[17391],{"nctId":17392,"briefTitle":17393,"status":142,"phases":17394,"completion":3398,"start":10387,"enrollment":1765,"conditions":17395,"interventions":17400},"NCT00005912","Voriconazole to Prevent Systemic Fungal Infections in Children",[89],[17396,17397,17398,17399],"Aspergillosis","Candidiasis","Fungal Diseases","Mycoses",[8887],{"trials":17402,"activeCount":101},[17403,17407],{"nctId":8878,"briefTitle":8879,"status":142,"phases":17404,"primaryCompletion":8881,"completion":1010,"start":8882,"enrollment":685,"conditions":17405,"interventions":17406},[90],[8884],[58,8886,8887,8888,8889,8890,8891,8892],{"nctId":17408,"briefTitle":17409,"status":142,"phases":17410,"completion":6869,"start":5057,"conditions":17411,"interventions":17413},"NCT00059878","Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections",[90],[17412,15],"Infection",[17414,17415],"recombinant interferon gamma","voriconazole",{"trials":17417,"activeCount":101},[],{"trials":17419,"activeCount":101},[],{"trials":17421,"activeCount":101},[],{"intervention":722,"totalTrials":603,"cells":17423},{"EARLY_PHASE1":17424,"PHASE1":17426,"PHASE2":17432,"PHASE3":17442,"PHASE4":17444,"NA":17446},{"trials":17425,"activeCount":101},[],{"trials":17427,"activeCount":101},[17428],{"nctId":712,"briefTitle":713,"status":618,"phases":17429,"primaryCompletion":715,"completion":716,"start":717,"enrollment":603,"conditions":17430,"interventions":17431},[89],[719],[704,721,63,643,722],{"trials":17433,"activeCount":101},[17434,17438],{"nctId":1254,"briefTitle":1255,"status":142,"phases":17435,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":17436,"interventions":17437},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"nctId":1296,"briefTitle":1297,"status":618,"phases":17439,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":17440,"interventions":17441},[89,90],[1291,1302],[991,1304,750,993,693,994,819,995,722],{"trials":17443,"activeCount":101},[],{"trials":17445,"activeCount":101},[],{"trials":17447,"activeCount":101},[],{"intervention":1347,"totalTrials":603,"cells":17449},{"EARLY_PHASE1":17450,"PHASE1":17452,"PHASE2":17454,"PHASE3":17468,"PHASE4":17470,"NA":17472},{"trials":17451,"activeCount":101},[],{"trials":17453,"activeCount":101},[],{"trials":17455,"activeCount":101},[17456,17460,17464],{"nctId":11363,"briefTitle":11364,"status":142,"phases":17457,"completion":987,"start":5004,"conditions":17458,"interventions":17459},[90],[2490],[818,1347,1349,10365],{"nctId":11388,"briefTitle":11389,"status":142,"phases":17461,"completion":3587,"start":1952,"conditions":17462,"interventions":17463},[90],[2490],[818,1347,1349],{"nctId":1337,"briefTitle":1338,"status":618,"phases":17465,"primaryCompletion":1340,"start":1341,"enrollment":16,"conditions":17466,"interventions":17467},[90],[1343,1344],[693,819,1346,1347,1348,1349,750,818],{"trials":17469,"activeCount":101},[],{"trials":17471,"activeCount":101},[],{"trials":17473,"activeCount":101},[],{"intervention":3219,"totalTrials":603,"cells":17475},{"EARLY_PHASE1":17476,"PHASE1":17478,"PHASE2":17484,"PHASE3":17500,"PHASE4":17502,"NA":17504},{"trials":17477,"activeCount":101},[],{"trials":17479,"activeCount":101},[17480],{"nctId":3152,"briefTitle":3153,"status":142,"phases":17481,"primaryCompletion":3155,"completion":3155,"start":1171,"enrollment":700,"conditions":17482,"interventions":17483},[89],[3157,3158,3159,1244,3160,3161,3162,3163,3164,3165,3166,1056,3167,3168,1245,1246,3169,1247,3170,3171,3172,3173,3174,3175,3176,1057,3177,3178,3179,3180,3181,3182,3183,3184,3185,3186,3187,3188,940,3189,3190,655,1248,3191,1249,3192,3193,3194,3195,3196,3197,3198,1058,3199,658,3200,1333,3201,3202,3203,3204,3205,3206,3207,1059,3208,662,3209,1334,3210,3211,3212,3213,3214,3215,3216,1060,3217,664,15,1251],[3219,995,1776],{"trials":17485,"activeCount":101},[17486,17492],{"nctId":17487,"briefTitle":17488,"status":142,"phases":17489,"primaryCompletion":4359,"completion":4359,"start":1231,"enrollment":3274,"conditions":17490,"interventions":17491},"NCT00540722","Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme",[90],[4817,4818,4819,5287],[3219],{"nctId":17493,"briefTitle":17494,"status":142,"phases":17495,"primaryCompletion":4878,"completion":4359,"start":1309,"enrollment":1041,"conditions":17496,"interventions":17499},"NCT00848016","Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery",[90],[16036,17497,17498],"Stage III Adrenocortical Carcinoma","Stage IV Adrenocortical Carcinoma",[3219],{"trials":17501,"activeCount":101},[],{"trials":17503,"activeCount":101},[],{"trials":17505,"activeCount":101},[],{"intervention":17507,"totalTrials":758,"cells":17508},"Exemestane",{"EARLY_PHASE1":17509,"PHASE1":17511,"PHASE2":17513,"PHASE3":17536,"PHASE4":17538,"NA":17540},{"trials":17510,"activeCount":101},[],{"trials":17512,"activeCount":101},[],{"trials":17514,"activeCount":101},[17515,17525],{"nctId":17516,"briefTitle":17517,"status":142,"phases":17518,"primaryCompletion":9868,"completion":17519,"start":17520,"enrollment":421,"conditions":17521,"interventions":17524},"NCT03300557","Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium\u002FEndometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer",[90],"2025-08-14","2017-11-15",[17522,12353,3428,12354,17523],"Atypical Hyperplasia","FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma",[17507],{"nctId":17526,"briefTitle":17527,"status":142,"phases":17528,"primaryCompletion":17529,"completion":17530,"start":17531,"enrollment":17532,"conditions":17533,"interventions":17535},"NCT02598557","Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer",[90],"2019-10-03","2023-02-02","2016-12-06",180,[17534,3910,1447,1448,3911,1449,1450],"Stage 0 Breast Cancer AJCC v6 and v7",[17507],{"trials":17537,"activeCount":101},[],{"trials":17539,"activeCount":101},[],{"trials":17541,"activeCount":101},[],{"intervention":17543,"totalTrials":758,"cells":17544},"Tandutinib",{"EARLY_PHASE1":17545,"PHASE1":17547,"PHASE2":17549,"PHASE3":17565,"PHASE4":17567,"NA":17569},{"trials":17546,"activeCount":101},[],{"trials":17548,"activeCount":101},[],{"trials":17550,"activeCount":101},[17551,17558],{"nctId":17552,"briefTitle":17553,"status":142,"phases":17554,"primaryCompletion":11556,"completion":11556,"start":813,"enrollment":827,"conditions":17555,"interventions":17557},"NCT00390468","Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases",[90],[869,17556,24],"Pain",[17543],{"nctId":17559,"briefTitle":17560,"status":142,"phases":17561,"primaryCompletion":1575,"completion":1763,"start":4715,"enrollment":685,"conditions":17562,"interventions":17563},"NCT00408902","Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer",[90],[5232,5233,4842],[17564],"tandutinib",{"trials":17566,"activeCount":101},[],{"trials":17568,"activeCount":101},[],{"trials":17570,"activeCount":101},[],{"intervention":1346,"totalTrials":758,"cells":17572},{"EARLY_PHASE1":17573,"PHASE1":17575,"PHASE2":17577,"PHASE3":17587,"PHASE4":17589,"NA":17591},{"trials":17574,"activeCount":101},[],{"trials":17576,"activeCount":101},[],{"trials":17578,"activeCount":101},[17579,17583],{"nctId":11278,"briefTitle":11279,"status":3060,"phases":17580,"start":1427,"enrollment":443,"conditions":17581,"interventions":17582},[90],[11282],[818,11284,1346],{"nctId":1337,"briefTitle":1338,"status":618,"phases":17584,"primaryCompletion":1340,"start":1341,"enrollment":16,"conditions":17585,"interventions":17586},[90],[1343,1344],[693,819,1346,1347,1348,1349,750,818],{"trials":17588,"activeCount":101},[],{"trials":17590,"activeCount":101},[],{"trials":17592,"activeCount":101},[],{"intervention":14934,"totalTrials":758,"cells":17594},{"EARLY_PHASE1":17595,"PHASE1":17597,"PHASE2":17599,"PHASE3":17617,"PHASE4":17619,"NA":17621},{"trials":17596,"activeCount":101},[],{"trials":17598,"activeCount":101},[],{"trials":17600,"activeCount":101},[17601,17613],{"nctId":17602,"briefTitle":17603,"status":142,"phases":17604,"primaryCompletion":17605,"completion":17606,"start":17607,"enrollment":17608,"conditions":17609,"interventions":17611},"NCT01092182","Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma",[90],"2020-09-30","2023-02-16","2010-03-25",194,[773,17610,522],"Diffuse Large B-cell Lymphoma, c-MYC Positive",[14934,17612],"EPOCH-RR",{"nctId":14926,"briefTitle":14927,"status":142,"phases":17614,"primaryCompletion":14929,"completion":14930,"start":14931,"enrollment":34,"conditions":17615,"interventions":17616},[90],[5795,5794],[14934,14906,14935],{"trials":17618,"activeCount":101},[],{"trials":17620,"activeCount":101},[],{"trials":17622,"activeCount":101},[],{"intervention":14658,"totalTrials":758,"cells":17624},{"EARLY_PHASE1":17625,"PHASE1":17627,"PHASE2":17633,"PHASE3":17644,"PHASE4":17646,"NA":17648},{"trials":17626,"activeCount":101},[],{"trials":17628,"activeCount":101},[17629],{"nctId":14647,"briefTitle":14648,"status":142,"phases":17630,"primaryCompletion":14650,"completion":14651,"start":14652,"enrollment":1041,"conditions":17631,"interventions":17632},[89],[4632,14654,14655,148,14656,4821,354],[14658,7509],{"trials":17634,"activeCount":101},[17635],{"nctId":17636,"briefTitle":17637,"status":618,"phases":17638,"primaryCompletion":17639,"completion":17639,"start":17640,"enrollment":1798,"conditions":17641,"interventions":17643},"NCT01264081","Lapatinib in Stage IV Melanoma With ERBB4 Mutations",[90],"2013-11-22","2011-05-20",[17642],"Malignant Melanoma",[14658],{"trials":17645,"activeCount":101},[],{"trials":17647,"activeCount":101},[],{"trials":17649,"activeCount":101},[],{"intervention":5665,"totalTrials":758,"cells":17651},{"EARLY_PHASE1":17652,"PHASE1":17654,"PHASE2":17660,"PHASE3":17666,"PHASE4":17668,"NA":17670},{"trials":17653,"activeCount":101},[],{"trials":17655,"activeCount":101},[17656],{"nctId":5659,"briefTitle":5660,"status":618,"phases":17657,"primaryCompletion":4900,"start":1231,"enrollment":31,"conditions":17658,"interventions":17659},[89],[5663,1260,654,656,657,659,661,663],[5665,819,1063],{"trials":17661,"activeCount":101},[17662],{"nctId":5768,"briefTitle":5769,"status":107,"phases":17663,"primaryCompletion":2004,"start":3282,"enrollment":101,"conditions":17664,"interventions":17665},[89,90],[1245,1246,3187,3188,3189,3190,1248],[5773,5665,1063],{"trials":17667,"activeCount":101},[],{"trials":17669,"activeCount":101},[],{"trials":17671,"activeCount":101},[],{"intervention":666,"totalTrials":758,"cells":17673},{"EARLY_PHASE1":17674,"PHASE1":17676,"PHASE2":17682,"PHASE3":17688,"PHASE4":17690,"NA":17692},{"trials":17675,"activeCount":101},[],{"trials":17677,"activeCount":101},[17678],{"nctId":646,"briefTitle":647,"status":618,"phases":17679,"primaryCompletion":649,"start":650,"enrollment":651,"conditions":17680,"interventions":17681},[89],[653,654,655,656,657,658,659,660,661,662,663,664],[666,63,667],{"trials":17683,"activeCount":101},[17684],{"nctId":5084,"briefTitle":5085,"status":142,"phases":17685,"primaryCompletion":5087,"completion":5087,"start":4611,"enrollment":700,"conditions":17686,"interventions":17687},[90],[5089,5090,5091,5092,4823,5093,5094,5095,4841],[666,2084,1140,2925],{"trials":17689,"activeCount":101},[],{"trials":17691,"activeCount":101},[],{"trials":17693,"activeCount":101},[],{"intervention":919,"totalTrials":758,"cells":17695},{"EARLY_PHASE1":17696,"PHASE1":17698,"PHASE2":17700,"PHASE3":17710,"PHASE4":17712,"NA":17714},{"trials":17697,"activeCount":101},[],{"trials":17699,"activeCount":101},[],{"trials":17701,"activeCount":101},[17702,17706],{"nctId":907,"briefTitle":908,"status":142,"phases":17703,"primaryCompletion":910,"completion":911,"start":912,"enrollment":913,"conditions":17704,"interventions":17705},[89,90],[915,916,917],[919,63,920,921],{"nctId":1144,"briefTitle":1145,"status":142,"phases":17707,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":37,"conditions":17708,"interventions":17709},[90],[1151,1152,1153],[919,460,63],{"trials":17711,"activeCount":101},[],{"trials":17713,"activeCount":101},[],{"trials":17715,"activeCount":101},[],{"intervention":16784,"totalTrials":758,"cells":17717},{"EARLY_PHASE1":17718,"PHASE1":17720,"PHASE2":17726,"PHASE3":17732,"PHASE4":17734,"NA":17736},{"trials":17719,"activeCount":101},[],{"trials":17721,"activeCount":101},[17722],{"nctId":16776,"briefTitle":16777,"status":142,"phases":17723,"primaryCompletion":16779,"completion":16779,"start":16780,"enrollment":34,"conditions":17724,"interventions":17725},[89],[1941,1943,3431,1944,3432,16782],[16769,16784],{"trials":17727,"activeCount":101},[17728],{"nctId":16809,"briefTitle":16810,"status":142,"phases":17729,"primaryCompletion":16812,"completion":16813,"start":16814,"enrollment":37,"conditions":17730,"interventions":17731},[90],[6027,301],[16769,16784],{"trials":17733,"activeCount":101},[],{"trials":17735,"activeCount":101},[],{"trials":17737,"activeCount":101},[],{"intervention":11699,"totalTrials":758,"cells":17739},{"EARLY_PHASE1":17740,"PHASE1":17742,"PHASE2":17744,"PHASE3":17754,"PHASE4":17756,"NA":17758},{"trials":17741,"activeCount":101},[],{"trials":17743,"activeCount":101},[],{"trials":17745,"activeCount":101},[17746,17750],{"nctId":11690,"briefTitle":11691,"status":142,"phases":17747,"primaryCompletion":11693,"completion":11694,"start":11695,"enrollment":2346,"conditions":17748,"interventions":17749},[90],[11697],[11672,11699],{"nctId":16703,"briefTitle":16704,"status":142,"phases":17751,"primaryCompletion":6782,"completion":14385,"start":3272,"enrollment":13282,"conditions":17752,"interventions":17753},[89,90],[11697],[11699,630],{"trials":17755,"activeCount":101},[],{"trials":17757,"activeCount":101},[],{"trials":17759,"activeCount":101},[],{"intervention":17761,"totalTrials":758,"cells":17762},"sorafenib",{"EARLY_PHASE1":17763,"PHASE1":17765,"PHASE2":17771,"PHASE3":17779,"PHASE4":17781,"NA":17783},{"trials":17764,"activeCount":101},[],{"trials":17766,"activeCount":101},[17767],{"nctId":10150,"briefTitle":10151,"status":142,"phases":17768,"primaryCompletion":10153,"completion":4411,"start":10154,"enrollment":1041,"conditions":17769,"interventions":17770},[89],[10156,10157,10158,486,10159,116,3754,10160,6160],[9201,10162,43],{"trials":17772,"activeCount":101},[17773],{"nctId":17774,"briefTitle":17775,"status":142,"phases":17776,"primaryCompletion":4165,"completion":8134,"start":1576,"enrollment":2883,"conditions":17777,"interventions":17778},"NCT00217620","S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas",[90],[625],[17761],{"trials":17780,"activeCount":101},[],{"trials":17782,"activeCount":101},[],{"trials":17784,"activeCount":101},[],{"intervention":16842,"totalTrials":758,"cells":17786},{"EARLY_PHASE1":17787,"PHASE1":17789,"PHASE2":17791,"PHASE3":17803,"PHASE4":17805,"NA":17807},{"trials":17788,"activeCount":101},[],{"trials":17790,"activeCount":101},[],{"trials":17792,"activeCount":101},[17793,17797],{"nctId":16836,"briefTitle":16837,"status":142,"phases":17794,"primaryCompletion":1181,"start":16839,"enrollment":1852,"conditions":17795,"interventions":17796},[90],[1260],[3092,16842],{"nctId":17798,"briefTitle":17799,"status":142,"phases":17800,"primaryCompletion":3480,"start":17268,"enrollment":234,"conditions":17801,"interventions":17802},"NCT00006364","Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia",[90],[8366,8059,8060,4060],[16842],{"trials":17804,"activeCount":101},[],{"trials":17806,"activeCount":101},[],{"trials":17808,"activeCount":101},[],{"intervention":992,"totalTrials":758,"cells":17810},{"EARLY_PHASE1":17811,"PHASE1":17813,"PHASE2":17819,"PHASE3":17825,"PHASE4":17827,"NA":17829},{"trials":17812,"activeCount":101},[],{"trials":17814,"activeCount":101},[17815],{"nctId":6956,"briefTitle":6957,"status":618,"phases":17816,"primaryCompletion":2293,"start":1257,"enrollment":1074,"conditions":17817,"interventions":17818},[89],[3673,4941,3119,4942,3120,4945,3285,4946],[991,992,1775,993],{"trials":17820,"activeCount":101},[17821],{"nctId":984,"briefTitle":985,"status":142,"phases":17822,"completion":987,"start":988,"conditions":17823,"interventions":17824},[90],[18],[991,992,993,693,994,995],{"trials":17826,"activeCount":101},[],{"trials":17828,"activeCount":101},[],{"trials":17830,"activeCount":101},[],{"intervention":3334,"totalTrials":758,"cells":17832},{"EARLY_PHASE1":17833,"PHASE1":17835,"PHASE2":17844,"PHASE3":17850,"PHASE4":17852,"NA":17854},{"trials":17834,"activeCount":101},[],{"trials":17836,"activeCount":101},[17837],{"nctId":17838,"briefTitle":17839,"status":142,"phases":17840,"primaryCompletion":17841,"completion":17841,"start":4165,"enrollment":1111,"conditions":17842,"interventions":17843},"NCT00602277","Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy",[89],"2016-08",[250,251,252],[3334],{"trials":17845,"activeCount":101},[17846],{"nctId":3325,"briefTitle":3326,"status":142,"phases":17847,"primaryCompletion":3328,"completion":3329,"start":1329,"enrollment":1331,"conditions":17848,"interventions":17849},[90],[2658,3331,3332,3261],[277,449,3334],{"trials":17851,"activeCount":101},[],{"trials":17853,"activeCount":101},[],{"trials":17855,"activeCount":101},[],{"intervention":13663,"totalTrials":758,"cells":17857},{"EARLY_PHASE1":17858,"PHASE1":17860,"PHASE2":17866,"PHASE3":17872,"PHASE4":17874,"NA":17876},{"trials":17859,"activeCount":101},[],{"trials":17861,"activeCount":101},[17862],{"nctId":13655,"briefTitle":13656,"status":142,"phases":17863,"primaryCompletion":13658,"start":13659,"enrollment":25,"conditions":17864,"interventions":17865},[89],[3133,3909,2613,3082],[13662,13663,9245],{"trials":17867,"activeCount":101},[17868],{"nctId":10287,"briefTitle":10288,"status":142,"phases":17869,"primaryCompletion":1171,"completion":8266,"start":1330,"enrollment":638,"conditions":17870,"interventions":17871},[89,90],[3117,3137],[8069,10292],{"trials":17873,"activeCount":101},[],{"trials":17875,"activeCount":101},[],{"trials":17877,"activeCount":101},[],{"intervention":10175,"totalTrials":758,"cells":17879},{"EARLY_PHASE1":17880,"PHASE1":17882,"PHASE2":17888,"PHASE3":17896,"PHASE4":17898,"NA":17900},{"trials":17881,"activeCount":101},[],{"trials":17883,"activeCount":101},[17884],{"nctId":10170,"briefTitle":10171,"status":142,"phases":17885,"primaryCompletion":3272,"start":4860,"enrollment":234,"conditions":17886,"interventions":17887},[89],[656,4262,1432,663,15],[10175,8069],{"trials":17889,"activeCount":101},[17890],{"nctId":17891,"briefTitle":17892,"status":142,"phases":17893,"primaryCompletion":4562,"start":6530,"enrollment":5986,"conditions":17894,"interventions":17895},"NCT00082966","Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma",[90],[7583,7585,7587,4681],[10175],{"trials":17897,"activeCount":101},[],{"trials":17899,"activeCount":101},[],{"trials":17901,"activeCount":101},[],{"intervention":397,"totalTrials":758,"cells":17903},{"EARLY_PHASE1":17904,"PHASE1":17906,"PHASE2":17908,"PHASE3":17926,"PHASE4":17928,"NA":17930},{"trials":17905,"activeCount":101},[],{"trials":17907,"activeCount":101},[],{"trials":17909,"activeCount":101},[17910,17922],{"nctId":17911,"briefTitle":17912,"status":618,"phases":17913,"primaryCompletion":17914,"completion":17915,"start":17916,"enrollment":188,"conditions":17917,"interventions":17920},"NCT03190967","T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery",[89,90],"2021-06-28","2023-06-13","2018-04-18",[18,17918,17919],"Brain Metastasis","Brain Cancer",[17921,397],"T-DM1",{"nctId":388,"briefTitle":389,"status":142,"phases":17923,"primaryCompletion":391,"completion":391,"start":392,"enrollment":298,"conditions":17924,"interventions":17925},[90],[394,148,395],[397,398,96,399],{"trials":17927,"activeCount":101},[],{"trials":17929,"activeCount":101},[],{"trials":17931,"activeCount":101},[],{"intervention":17414,"totalTrials":758,"cells":17933},{"EARLY_PHASE1":17934,"PHASE1":17936,"PHASE2":17946,"PHASE3":17952,"PHASE4":17954,"NA":17956},{"trials":17935,"activeCount":101},[],{"trials":17937,"activeCount":101},[17938],{"nctId":17939,"briefTitle":17940,"status":142,"phases":17941,"primaryCompletion":1989,"start":17942,"enrollment":188,"conditions":17943,"interventions":17944},"NCT00004032","Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer",[89],"1997-10",[1579],[17945,17414],"ALVAC-hB7.1",{"trials":17947,"activeCount":101},[17948],{"nctId":17408,"briefTitle":17409,"status":142,"phases":17949,"completion":6869,"start":5057,"conditions":17950,"interventions":17951},[90],[17412,15],[17414,17415],{"trials":17953,"activeCount":101},[],{"trials":17955,"activeCount":101},[],{"trials":17957,"activeCount":101},[],{"intervention":14881,"totalTrials":758,"cells":17959},{"EARLY_PHASE1":17960,"PHASE1":17962,"PHASE2":17973,"PHASE3":17979,"PHASE4":17981,"NA":17983},{"trials":17961,"activeCount":101},[],{"trials":17963,"activeCount":101},[17964],{"nctId":17965,"briefTitle":17966,"status":142,"phases":17967,"primaryCompletion":8167,"completion":8167,"start":716,"enrollment":971,"conditions":17968,"interventions":17972},"NCT00637481","A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer",[89],[17969,18,17970,17971],"Atypical Ductal Breast Hyperplasia","Ductal Breast Carcinoma in Situ","Lobular Breast Carcinoma in Situ",[14881],{"trials":17974,"activeCount":101},[17975],{"nctId":14873,"briefTitle":14874,"status":142,"phases":17976,"primaryCompletion":4996,"completion":4996,"start":1576,"enrollment":14876,"conditions":17977,"interventions":17978},[90],[843,14878,844],[14880,14855,14881],{"trials":17980,"activeCount":101},[],{"trials":17982,"activeCount":101},[],{"trials":17984,"activeCount":101},[],{"intervention":4180,"totalTrials":758,"cells":17986},{"EARLY_PHASE1":17987,"PHASE1":17989,"PHASE2":17991,"PHASE3":18001,"PHASE4":18003,"NA":18005},{"trials":17988,"activeCount":101},[],{"trials":17990,"activeCount":101},[],{"trials":17992,"activeCount":101},[17993,17997],{"nctId":5375,"briefTitle":5376,"status":618,"phases":17994,"primaryCompletion":4715,"start":3526,"enrollment":1357,"conditions":17995,"interventions":17996},[90],[4035,4036,4037,4038,4039,4040,4041,4042,4043,4048,4050,4051,4168,4169,4170,4171,4173,4174,4175,4176,4177,2432,4132,5379],[4180,1187,1033],{"nctId":4162,"briefTitle":4163,"status":142,"phases":17998,"primaryCompletion":3226,"completion":3226,"start":4165,"enrollment":3869,"conditions":17999,"interventions":18000},[90],[4039,4040,4041,4042,4043,4167,4045,4046,4048,4168,4169,4170,4171,4172,4173,4174,4175,4176,4177,33,4178,2432],[4180,1187,1062,1080],{"trials":18002,"activeCount":101},[],{"trials":18004,"activeCount":101},[],{"trials":18006,"activeCount":101},[],{"intervention":18008,"totalTrials":758,"cells":18009},"Tariquidar",{"EARLY_PHASE1":18010,"PHASE1":18012,"PHASE2":18026,"PHASE3":18037,"PHASE4":18039,"NA":18041},{"trials":18011,"activeCount":101},[],{"trials":18013,"activeCount":101},[18014],{"nctId":18015,"briefTitle":18016,"status":142,"phases":18017,"primaryCompletion":18018,"completion":11695,"start":18019,"enrollment":1041,"conditions":18020,"interventions":18025},"NCT00011414","Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors",[89],"2007-11-28","2001-02-15",[18021,625,18022,18023,18024],"Wilms' Tumor","Adenaocortical Carcinoma","Refractory Cancer","Coldrhood Cancer",[18008],{"trials":18027,"activeCount":101},[18028],{"nctId":18029,"briefTitle":18030,"status":142,"phases":18031,"primaryCompletion":18032,"completion":18032,"start":18033,"enrollment":188,"conditions":18034,"interventions":18035},"NCT00082368","PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy",[90],"2014-04-14","2004-05-16",[15088],[18008,18036],"Tc-94m Sestamibi",{"trials":18038,"activeCount":101},[],{"trials":18040,"activeCount":101},[],{"trials":18042,"activeCount":101},[],{"intervention":476,"totalTrials":758,"cells":18044},{"EARLY_PHASE1":18045,"PHASE1":18047,"PHASE2":18049,"PHASE3":18059,"PHASE4":18061,"NA":18063},{"trials":18046,"activeCount":101},[],{"trials":18048,"activeCount":101},[],{"trials":18050,"activeCount":101},[18051,18055],{"nctId":11874,"briefTitle":11875,"status":347,"phases":18052,"primaryCompletion":11877,"completion":11878,"start":900,"enrollment":28,"conditions":18053,"interventions":18054},[89,90],[11880,11881,6058,11882],[11884,476,11852],{"nctId":462,"briefTitle":463,"status":107,"phases":18056,"primaryCompletion":465,"completion":465,"start":465,"enrollment":101,"conditions":18057,"interventions":18058},[89,90],[467,468,469,470,471,472],[96,474,475,476],{"trials":18060,"activeCount":101},[],{"trials":18062,"activeCount":101},[],{"trials":18064,"activeCount":101},[],{"intervention":18066,"totalTrials":758,"cells":18067},"Ad5CMV-p53 gene",{"EARLY_PHASE1":18068,"PHASE1":18070,"PHASE2":18080,"PHASE3":18091,"PHASE4":18093,"NA":18095},{"trials":18069,"activeCount":101},[],{"trials":18071,"activeCount":101},[18072],{"nctId":18073,"briefTitle":18074,"status":142,"phases":18075,"primaryCompletion":11246,"start":4260,"enrollment":339,"conditions":18076,"interventions":18079},"NCT00003167","Gene Therapy in Treating Patients With Advanced Bladder Cancer",[89],[7686,18077,18078,10301,7689,7690],"Stage I Bladder Cancer","Stage II Bladder Cancer",[18066],{"trials":18081,"activeCount":101},[18082],{"nctId":18083,"briefTitle":18084,"status":142,"phases":18085,"primaryCompletion":7645,"start":745,"enrollment":2883,"conditions":18086,"interventions":18090},"NCT00064103","Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx",[89,90],[18087,1043,18088,18089,7434],"Lip and Oral Cavity Cancer","Stage 0 Lip and Oral Cavity Cancer","Stage 0 Oropharyngeal Cancer",[18066],{"trials":18092,"activeCount":101},[],{"trials":18094,"activeCount":101},[],{"trials":18096,"activeCount":101},[],{"intervention":1079,"totalTrials":758,"cells":18098},{"EARLY_PHASE1":18099,"PHASE1":18101,"PHASE2":18107,"PHASE3":18113,"PHASE4":18115,"NA":18117},{"trials":18100,"activeCount":101},[],{"trials":18102,"activeCount":101},[18103],{"nctId":10470,"briefTitle":10471,"status":142,"phases":18104,"primaryCompletion":787,"completion":10473,"start":10474,"enrollment":421,"conditions":18105,"interventions":18106},[89],[10476,5223,10477,10478,10479,6446,6447],[10481,4769],{"trials":18108,"activeCount":101},[18109],{"nctId":1068,"briefTitle":1069,"status":142,"phases":18110,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":18111,"interventions":18112},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"trials":18114,"activeCount":101},[],{"trials":18116,"activeCount":101},[],{"trials":18118,"activeCount":101},[],{"intervention":751,"totalTrials":758,"cells":18120},{"EARLY_PHASE1":18121,"PHASE1":18123,"PHASE2":18129,"PHASE3":18135,"PHASE4":18137,"NA":18139},{"trials":18122,"activeCount":101},[],{"trials":18124,"activeCount":101},[18125],{"nctId":742,"briefTitle":743,"status":142,"phases":18126,"primaryCompletion":745,"start":746,"enrollment":188,"conditions":18127,"interventions":18128},[89],[748],[750,693,751],{"trials":18130,"activeCount":101},[18131],{"nctId":1949,"briefTitle":1950,"status":142,"phases":18132,"primaryCompletion":1021,"completion":1021,"start":1952,"enrollment":1953,"conditions":18133,"interventions":18134},[90],[1955],[751,1598,1080],{"trials":18136,"activeCount":101},[],{"trials":18138,"activeCount":101},[],{"trials":18140,"activeCount":101},[],{"intervention":18142,"totalTrials":758,"cells":18143},"vinblastine",{"EARLY_PHASE1":18144,"PHASE1":18146,"PHASE2":18156,"PHASE3":18162,"PHASE4":18164,"NA":18166},{"trials":18145,"activeCount":101},[],{"trials":18147,"activeCount":101},[18148],{"nctId":18149,"briefTitle":18150,"status":142,"phases":18151,"completion":3398,"start":18152,"enrollment":730,"conditions":18153,"interventions":18154},"NCT00001570","A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer",[89],"1997-02",[719,7088],[18155,18142],"PSC 833",{"trials":18157,"activeCount":101},[18158],{"nctId":4408,"briefTitle":4409,"status":142,"phases":18159,"primaryCompletion":3789,"completion":4411,"start":4412,"enrollment":623,"conditions":18160,"interventions":18161},[89,90],[4414,4415,4416,1503,4417,4418,1504,4419,1505,1506,1508,939],[1511,4421,737,4422],{"trials":18163,"activeCount":101},[],{"trials":18165,"activeCount":101},[],{"trials":18167,"activeCount":101},[],{"intervention":18169,"totalTrials":758,"cells":18170},"Pioglitazone Hydrochloride",{"EARLY_PHASE1":18171,"PHASE1":18173,"PHASE2":18175,"PHASE3":18192,"PHASE4":18194,"NA":18196},{"trials":18172,"activeCount":101},[],{"trials":18174,"activeCount":101},[],{"trials":18176,"activeCount":101},[18177,18183],{"nctId":18178,"briefTitle":18179,"status":618,"phases":18180,"primaryCompletion":3226,"completion":7018,"start":3155,"enrollment":889,"conditions":18181,"interventions":18182},"NCT01342770","Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer",[90],[16927,16928,16929,16930,4828],[18169],{"nctId":18184,"briefTitle":18185,"status":142,"phases":18186,"primaryCompletion":18187,"completion":18187,"start":745,"enrollment":1195,"conditions":18188,"interventions":18190},"NCT00099021","Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia",[90],"2008-06-27",[1564,18189],"Oral Leukoplakia",[18191],"pioglitazone hydrochloride",{"trials":18193,"activeCount":101},[],{"trials":18195,"activeCount":101},[],{"trials":18197,"activeCount":101},[],{"intervention":3110,"totalTrials":758,"cells":18199},{"EARLY_PHASE1":18200,"PHASE1":18202,"PHASE2":18208,"PHASE3":18214,"PHASE4":18216,"NA":18218},{"trials":18201,"activeCount":101},[],{"trials":18203,"activeCount":101},[18204],{"nctId":3104,"briefTitle":3105,"status":142,"phases":18205,"start":3107,"conditions":18206,"interventions":18207},[89],[687,869],[3110,995],{"trials":18209,"activeCount":101},[18210],{"nctId":5061,"briefTitle":5062,"status":142,"phases":18211,"completion":3587,"start":1241,"conditions":18212,"interventions":18213},[90],[856,869],[5066,3065,3110,1264,1081,4948],{"trials":18215,"activeCount":101},[],{"trials":18217,"activeCount":101},[],{"trials":18219,"activeCount":101},[],{"intervention":5758,"totalTrials":758,"cells":18221},{"EARLY_PHASE1":18222,"PHASE1":18224,"PHASE2":18226,"PHASE3":18236,"PHASE4":18238,"NA":18240},{"trials":18223,"activeCount":101},[],{"trials":18225,"activeCount":101},[],{"trials":18227,"activeCount":101},[18228,18232],{"nctId":5749,"briefTitle":5750,"status":142,"phases":18229,"primaryCompletion":5752,"completion":5752,"start":5753,"enrollment":2586,"conditions":18230,"interventions":18231},[90],[5755,5756],[738,667,5758],{"nctId":5787,"briefTitle":5788,"status":142,"phases":18233,"primaryCompletion":5790,"completion":5791,"start":5792,"enrollment":2265,"conditions":18234,"interventions":18235},[90],[5794,5795],[667,5758,1569,1569,5797],{"trials":18237,"activeCount":101},[],{"trials":18239,"activeCount":101},[],{"trials":18241,"activeCount":101},[],{"intervention":9437,"totalTrials":758,"cells":18243},{"EARLY_PHASE1":18244,"PHASE1":18246,"PHASE2":18252,"PHASE3":18258,"PHASE4":18260,"NA":18262},{"trials":18245,"activeCount":101},[],{"trials":18247,"activeCount":101},[18248],{"nctId":9429,"briefTitle":9430,"status":347,"phases":18249,"primaryCompletion":3019,"completion":3019,"start":2813,"enrollment":5986,"conditions":18250,"interventions":18251},[89],[9433,163,164,9434],[9436,167,9437],{"trials":18253,"activeCount":101},[18254],{"nctId":17372,"briefTitle":17373,"status":142,"phases":18255,"primaryCompletion":17375,"completion":2655,"start":910,"enrollment":421,"conditions":18256,"interventions":18257},[89,90],[467,917],[2444,17378,2444],{"trials":18259,"activeCount":101},[],{"trials":18261,"activeCount":101},[],{"trials":18263,"activeCount":101},[],{"intervention":13285,"totalTrials":758,"cells":18265},{"EARLY_PHASE1":18266,"PHASE1":18268,"PHASE2":18274,"PHASE3":18280,"PHASE4":18282,"NA":18284},{"trials":18267,"activeCount":101},[],{"trials":18269,"activeCount":101},[18270],{"nctId":13279,"briefTitle":13280,"status":142,"phases":18271,"primaryCompletion":6569,"start":4997,"enrollment":13282,"conditions":18272,"interventions":18273},[89],[4043,4167,4044,4045,4046,4047,33,655,656,4132],[13259,13285],{"trials":18275,"activeCount":101},[18276],{"nctId":5982,"briefTitle":5983,"status":142,"phases":18277,"primaryCompletion":1052,"completion":5985,"start":1576,"enrollment":5986,"conditions":18278,"interventions":18279},[90],[5988,5989],[151,5991],{"trials":18281,"activeCount":101},[],{"trials":18283,"activeCount":101},[],{"trials":18285,"activeCount":101},[],{"intervention":3102,"totalTrials":758,"cells":18287},{"EARLY_PHASE1":18288,"PHASE1":18290,"PHASE2":18296,"PHASE3":18304,"PHASE4":18306,"NA":18308},{"trials":18289,"activeCount":101},[],{"trials":18291,"activeCount":101},[18292],{"nctId":3095,"briefTitle":3096,"status":142,"phases":18293,"primaryCompletion":3098,"start":3099,"enrollment":188,"conditions":18294,"interventions":18295},[89],[1771],[995,1776,3102],{"trials":18297,"activeCount":101},[18298],{"nctId":18299,"briefTitle":18300,"status":142,"phases":18301,"primaryCompletion":650,"completion":650,"start":1320,"enrollment":609,"conditions":18302,"interventions":18303},"NCT00387790","Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma",[90],[15700],[3102],{"trials":18305,"activeCount":101},[],{"trials":18307,"activeCount":101},[],{"trials":18309,"activeCount":101},[],{"intervention":15917,"totalTrials":758,"cells":18311},{"EARLY_PHASE1":18312,"PHASE1":18314,"PHASE2":18316,"PHASE3":18326,"PHASE4":18328,"NA":18330},{"trials":18313,"activeCount":101},[],{"trials":18315,"activeCount":101},[],{"trials":18317,"activeCount":101},[18318,18322],{"nctId":15908,"briefTitle":15909,"status":618,"phases":18319,"primaryCompletion":14867,"completion":15911,"start":1230,"enrollment":685,"conditions":18320,"interventions":18321},[90],[1343,4843],[15914,15915,15916,15917],{"nctId":1337,"briefTitle":1338,"status":618,"phases":18323,"primaryCompletion":1340,"start":1341,"enrollment":16,"conditions":18324,"interventions":18325},[90],[1343,1344],[693,819,1346,1347,1348,1349,750,818],{"trials":18327,"activeCount":101},[],{"trials":18329,"activeCount":101},[],{"trials":18331,"activeCount":101},[],{"intervention":18333,"totalTrials":758,"cells":18334},"Cholecalciferol",{"EARLY_PHASE1":18335,"PHASE1":18337,"PHASE2":18347,"PHASE3":18358,"PHASE4":18360,"NA":18362},{"trials":18336,"activeCount":101},[],{"trials":18338,"activeCount":101},[18339],{"nctId":18340,"briefTitle":18341,"status":142,"phases":18342,"primaryCompletion":8167,"completion":1052,"start":6782,"enrollment":37,"conditions":18343,"interventions":18345},"NCT01447355","Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation",[89],[18344,891],"Healthy, no Evidence of Disease",[18346],"cholecalciferol",{"trials":18348,"activeCount":101},[18349],{"nctId":18350,"briefTitle":18351,"status":142,"phases":18352,"primaryCompletion":18353,"completion":18353,"start":4713,"enrollment":310,"conditions":18354,"interventions":18356},"NCT01325311","Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer",[90],"2014-07",[18355,16672,16673,16674],"Prostate Adenocarcinoma",[18333,18357],"Genistein",{"trials":18359,"activeCount":101},[],{"trials":18361,"activeCount":101},[],{"trials":18363,"activeCount":101},[],{"intervention":18357,"totalTrials":758,"cells":18365},{"EARLY_PHASE1":18366,"PHASE1":18368,"PHASE2":18370,"PHASE3":18388,"PHASE4":18390,"NA":18392},{"trials":18367,"activeCount":101},[],{"trials":18369,"activeCount":101},[],{"trials":18371,"activeCount":101},[18372,18376],{"nctId":18350,"briefTitle":18351,"status":142,"phases":18373,"primaryCompletion":18353,"completion":18353,"start":4713,"enrollment":310,"conditions":18374,"interventions":18375},[90],[18355,16672,16673,16674],[18333,18357],{"nctId":18377,"briefTitle":18378,"status":142,"phases":18379,"primaryCompletion":18380,"completion":18380,"start":18381,"enrollment":1074,"conditions":18382,"interventions":18387},"NCT00118040","Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer",[90],"2010-08-15","2005-06-24",[18383,18384,18385,18386],"Recurrent Bladder Carcinoma","Stage I Bladder Cancer AJCC v6 and v7","Stage II Bladder Cancer AJCC v6 and v7","Stage III Bladder Cancer AJCC v6 and v7",[18357],{"trials":18389,"activeCount":101},[],{"trials":18391,"activeCount":101},[],{"trials":18393,"activeCount":101},[],{"intervention":5492,"totalTrials":758,"cells":18395},{"EARLY_PHASE1":18396,"PHASE1":18398,"PHASE2":18400,"PHASE3":18410,"PHASE4":18412,"NA":18414},{"trials":18397,"activeCount":101},[],{"trials":18399,"activeCount":101},[],{"trials":18401,"activeCount":101},[18402,18406],{"nctId":5483,"briefTitle":5484,"status":142,"phases":18403,"primaryCompletion":5486,"completion":5486,"start":5487,"enrollment":2280,"conditions":18404,"interventions":18405},[90],[5232,4825,4842,5489,5490],[5492,53],{"nctId":5580,"briefTitle":5581,"status":142,"phases":18407,"primaryCompletion":5583,"completion":5584,"start":5103,"enrollment":5585,"conditions":18408,"interventions":18409},[89,90],[4813,4815,4817,4818,4819,4820,4821],[5492,53],{"trials":18411,"activeCount":101},[],{"trials":18413,"activeCount":101},[],{"trials":18415,"activeCount":101},[],{"intervention":1294,"totalTrials":758,"cells":18417},{"EARLY_PHASE1":18418,"PHASE1":18420,"PHASE2":18422,"PHASE3":18432,"PHASE4":18434,"NA":18436},{"trials":18419,"activeCount":101},[],{"trials":18421,"activeCount":101},[],{"trials":18423,"activeCount":101},[18424,18428],{"nctId":1285,"briefTitle":1286,"status":142,"phases":18425,"completion":1288,"start":1289,"enrollment":913,"conditions":18426,"interventions":18427},[90],[18,1291],[1268,1293,1294,693,995,1225],{"nctId":5566,"briefTitle":5567,"status":618,"phases":18429,"primaryCompletion":1604,"completion":1604,"start":5569,"enrollment":28,"conditions":18430,"interventions":18431},[90],[5571,5572,5573,5574,856],[5576,5577,53,5578,4966,2925,2924,5578],{"trials":18433,"activeCount":101},[],{"trials":18435,"activeCount":101},[],{"trials":18437,"activeCount":101},[],{"intervention":18439,"totalTrials":758,"cells":18440},"ispinesib",{"EARLY_PHASE1":18441,"PHASE1":18443,"PHASE2":18451,"PHASE3":18459,"PHASE4":18461,"NA":18463},{"trials":18442,"activeCount":101},[],{"trials":18444,"activeCount":101},[18445],{"nctId":18446,"briefTitle":18447,"status":618,"phases":18448,"primaryCompletion":3227,"start":4639,"enrollment":25,"conditions":18449,"interventions":18450},"NCT00101244","SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma",[89],[3157,1245,1246,3180,3181,3182,3183,3184,4681,3185,3186,3187,3188,940,3189,3190,655,1248,3209,1334,3210,3211,4796,3212,3213,3214,3215,3216,1060,3217,664,15,1251],[18439],{"trials":18452,"activeCount":101},[18453],{"nctId":18454,"briefTitle":18455,"status":142,"phases":18456,"primaryCompletion":2160,"start":4032,"enrollment":1074,"conditions":18457,"interventions":18458},"NCT00354250","Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer",[90],[5233,4826,4842],[18439],{"trials":18460,"activeCount":101},[],{"trials":18462,"activeCount":101},[],{"trials":18464,"activeCount":101},[],{"intervention":817,"totalTrials":2548,"cells":18466},{"EARLY_PHASE1":18467,"PHASE1":18469,"PHASE2":18471,"PHASE3":18477,"PHASE4":18479,"NA":18481},{"trials":18468,"activeCount":101},[],{"trials":18470,"activeCount":101},[],{"trials":18472,"activeCount":101},[18473],{"nctId":809,"briefTitle":810,"status":142,"phases":18474,"primaryCompletion":812,"completion":812,"start":813,"enrollment":188,"conditions":18475,"interventions":18476},[90],[815],[817,818,750,693,819],{"trials":18478,"activeCount":101},[],{"trials":18480,"activeCount":101},[],{"trials":18482,"activeCount":101},[],{"intervention":831,"totalTrials":2548,"cells":18484},{"EARLY_PHASE1":18485,"PHASE1":18487,"PHASE2":18489,"PHASE3":18495,"PHASE4":18497,"NA":18499},{"trials":18486,"activeCount":101},[],{"trials":18488,"activeCount":101},[],{"trials":18490,"activeCount":101},[18491],{"nctId":821,"briefTitle":822,"status":142,"phases":18492,"primaryCompletion":824,"completion":825,"start":826,"enrollment":827,"conditions":18493,"interventions":18494},[89,90],[829],[831,643,63],{"trials":18496,"activeCount":101},[],{"trials":18498,"activeCount":101},[],{"trials":18500,"activeCount":101},[],{"intervention":11447,"totalTrials":2548,"cells":18502},{"EARLY_PHASE1":18503,"PHASE1":18505,"PHASE2":18507,"PHASE3":18513,"PHASE4":18515,"NA":18517},{"trials":18504,"activeCount":101},[],{"trials":18506,"activeCount":101},[],{"trials":18508,"activeCount":101},[18509],{"nctId":11441,"briefTitle":11442,"status":142,"phases":18510,"primaryCompletion":6303,"completion":5985,"start":2487,"enrollment":11444,"conditions":18511,"interventions":18512},[89,90],[3320,4828,4833,3321],[11447,474,11448],{"trials":18514,"activeCount":101},[],{"trials":18516,"activeCount":101},[],{"trials":18518,"activeCount":101},[],{"intervention":11448,"totalTrials":2548,"cells":18520},{"EARLY_PHASE1":18521,"PHASE1":18523,"PHASE2":18525,"PHASE3":18531,"PHASE4":18533,"NA":18535},{"trials":18522,"activeCount":101},[],{"trials":18524,"activeCount":101},[],{"trials":18526,"activeCount":101},[18527],{"nctId":11441,"briefTitle":11442,"status":142,"phases":18528,"primaryCompletion":6303,"completion":5985,"start":2487,"enrollment":11444,"conditions":18529,"interventions":18530},[89,90],[3320,4828,4833,3321],[11447,474,11448],{"trials":18532,"activeCount":101},[],{"trials":18534,"activeCount":101},[],{"trials":18536,"activeCount":101},[],{"intervention":6060,"totalTrials":2548,"cells":18538},{"EARLY_PHASE1":18539,"PHASE1":18541,"PHASE2":18543,"PHASE3":18549,"PHASE4":18551,"NA":18553},{"trials":18540,"activeCount":101},[],{"trials":18542,"activeCount":101},[],{"trials":18544,"activeCount":101},[18545],{"nctId":6052,"briefTitle":6053,"status":618,"phases":18546,"primaryCompletion":6055,"completion":6055,"start":6056,"enrollment":1517,"conditions":18547,"interventions":18548},[89,90],[6058],[6060,6061,460,1139],{"trials":18550,"activeCount":101},[],{"trials":18552,"activeCount":101},[],{"trials":18554,"activeCount":101},[],{"intervention":6061,"totalTrials":2548,"cells":18556},{"EARLY_PHASE1":18557,"PHASE1":18559,"PHASE2":18561,"PHASE3":18567,"PHASE4":18569,"NA":18571},{"trials":18558,"activeCount":101},[],{"trials":18560,"activeCount":101},[],{"trials":18562,"activeCount":101},[18563],{"nctId":6052,"briefTitle":6053,"status":618,"phases":18564,"primaryCompletion":6055,"completion":6055,"start":6056,"enrollment":1517,"conditions":18565,"interventions":18566},[89,90],[6058],[6060,6061,460,1139],{"trials":18568,"activeCount":101},[],{"trials":18570,"activeCount":101},[],{"trials":18572,"activeCount":101},[],{"intervention":18574,"totalTrials":2548,"cells":18575},"TRC105",{"EARLY_PHASE1":18576,"PHASE1":18578,"PHASE2":18580,"PHASE3":18592,"PHASE4":18594,"NA":18596},{"trials":18577,"activeCount":101},[],{"trials":18579,"activeCount":101},[],{"trials":18581,"activeCount":101},[18582],{"nctId":18583,"briefTitle":18584,"status":142,"phases":18585,"primaryCompletion":6303,"completion":5985,"start":1240,"enrollment":2577,"conditions":18586,"interventions":18591},"NCT01328574","TRC105 in Adults With Advanced\u002FMetastatic Urothelial Carcinoma",[90],[2717,18587,18588,18589,18590],"Ureteral Neoplasms","Ureter Cancer","Neoplasm, Ureteral","Cancer of the Ureter",[18574],{"trials":18593,"activeCount":101},[],{"trials":18595,"activeCount":101},[],{"trials":18597,"activeCount":101},[],{"intervention":11284,"totalTrials":2548,"cells":18599},{"EARLY_PHASE1":18600,"PHASE1":18602,"PHASE2":18604,"PHASE3":18610,"PHASE4":18612,"NA":18614},{"trials":18601,"activeCount":101},[],{"trials":18603,"activeCount":101},[],{"trials":18605,"activeCount":101},[18606],{"nctId":11278,"briefTitle":11279,"status":3060,"phases":18607,"start":1427,"enrollment":443,"conditions":18608,"interventions":18609},[90],[11282],[818,11284,1346],{"trials":18611,"activeCount":101},[],{"trials":18613,"activeCount":101},[],{"trials":18615,"activeCount":101},[],{"intervention":17612,"totalTrials":2548,"cells":18617},{"EARLY_PHASE1":18618,"PHASE1":18620,"PHASE2":18622,"PHASE3":18628,"PHASE4":18630,"NA":18632},{"trials":18619,"activeCount":101},[],{"trials":18621,"activeCount":101},[],{"trials":18623,"activeCount":101},[18624],{"nctId":17602,"briefTitle":17603,"status":142,"phases":18625,"primaryCompletion":17605,"completion":17606,"start":17607,"enrollment":17608,"conditions":18626,"interventions":18627},[90],[773,17610,522],[14934,17612],{"trials":18629,"activeCount":101},[],{"trials":18631,"activeCount":101},[],{"trials":18633,"activeCount":101},[],{"intervention":846,"totalTrials":2548,"cells":18635},{"EARLY_PHASE1":18636,"PHASE1":18638,"PHASE2":18640,"PHASE3":18646,"PHASE4":18648,"NA":18650},{"trials":18637,"activeCount":101},[],{"trials":18639,"activeCount":101},[],{"trials":18641,"activeCount":101},[18642],{"nctId":833,"briefTitle":834,"status":618,"phases":18643,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":18644,"interventions":18645},[89,90],[840,841,842,843,844],[63,643,677,846],{"trials":18647,"activeCount":101},[],{"trials":18649,"activeCount":101},[],{"trials":18651,"activeCount":101},[],{"intervention":18653,"totalTrials":2548,"cells":18654},"pH Low Insertion Peptide-exatecan Conjugate CBX-12",{"EARLY_PHASE1":18655,"PHASE1":18657,"PHASE2":18659,"PHASE3":18670,"PHASE4":18672,"NA":18674},{"trials":18656,"activeCount":101},[],{"trials":18658,"activeCount":101},[],{"trials":18660,"activeCount":101},[18661],{"nctId":18662,"briefTitle":18663,"status":107,"phases":18664,"primaryCompletion":130,"completion":130,"start":18665,"enrollment":101,"conditions":18666,"interventions":18669},"NCT06730100","CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer",[90],"2026-02-17",[18667,18668,5016],"Metastatic Mismatch Repair Proficient Colorectal Carcinoma","Refractory Mismatch Repair Proficient Colorectal Carcinoma",[18653],{"trials":18671,"activeCount":101},[],{"trials":18673,"activeCount":101},[],{"trials":18675,"activeCount":101},[],{"intervention":18677,"totalTrials":2548,"cells":18678},"Pioglitazone",{"EARLY_PHASE1":18679,"PHASE1":18681,"PHASE2":18683,"PHASE3":18692,"PHASE4":18694,"NA":18696},{"trials":18680,"activeCount":101},[],{"trials":18682,"activeCount":101},[],{"trials":18684,"activeCount":101},[18685],{"nctId":18686,"briefTitle":18687,"status":618,"phases":18688,"primaryCompletion":3317,"completion":3317,"start":5444,"enrollment":2548,"conditions":18689,"interventions":18691},"NCT00923949","Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer",[90],[18690],"Non-Small-Cell Lung Cancer",[18677],{"trials":18693,"activeCount":101},[],{"trials":18695,"activeCount":101},[],{"trials":18697,"activeCount":101},[],{"intervention":2866,"totalTrials":2548,"cells":18699},{"EARLY_PHASE1":18700,"PHASE1":18702,"PHASE2":18704,"PHASE3":18710,"PHASE4":18712,"NA":18714},{"trials":18701,"activeCount":101},[],{"trials":18703,"activeCount":101},[],{"trials":18705,"activeCount":101},[18706],{"nctId":2853,"briefTitle":2854,"status":107,"phases":18707,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":101,"conditions":18708,"interventions":18709},[90],[2859,2860,2861,2862,2863,2696,2864,2717],[1690,2866],{"trials":18711,"activeCount":101},[],{"trials":18713,"activeCount":101},[],{"trials":18715,"activeCount":101},[],{"intervention":18717,"totalTrials":2548,"cells":18718},"Antigen direct immunotherapy: PROSTVAC-V",{"EARLY_PHASE1":18719,"PHASE1":18721,"PHASE2":18723,"PHASE3":18735,"PHASE4":18737,"NA":18739},{"trials":18720,"activeCount":101},[],{"trials":18722,"activeCount":101},[],{"trials":18724,"activeCount":101},[18725],{"nctId":18726,"briefTitle":18727,"status":142,"phases":18728,"primaryCompletion":18729,"completion":18729,"start":17307,"enrollment":421,"conditions":18730,"interventions":18731},"NCT03315871","Combination Immunotherapy in Biochemically Recurrent Prostate Cancer",[90],"2024-06-04",[24],[18717,18732,18733,18734],"Antigen direct immunotherapy: PROSTVAC-F","MSB0011359C","Antigen direct immunotherapy: CV301",{"trials":18736,"activeCount":101},[],{"trials":18738,"activeCount":101},[],{"trials":18740,"activeCount":101},[],{"intervention":18732,"totalTrials":2548,"cells":18742},{"EARLY_PHASE1":18743,"PHASE1":18745,"PHASE2":18747,"PHASE3":18753,"PHASE4":18755,"NA":18757},{"trials":18744,"activeCount":101},[],{"trials":18746,"activeCount":101},[],{"trials":18748,"activeCount":101},[18749],{"nctId":18726,"briefTitle":18727,"status":142,"phases":18750,"primaryCompletion":18729,"completion":18729,"start":17307,"enrollment":421,"conditions":18751,"interventions":18752},[90],[24],[18717,18732,18733,18734],{"trials":18754,"activeCount":101},[],{"trials":18756,"activeCount":101},[],{"trials":18758,"activeCount":101},[],{"intervention":18733,"totalTrials":2548,"cells":18760},{"EARLY_PHASE1":18761,"PHASE1":18763,"PHASE2":18765,"PHASE3":18771,"PHASE4":18773,"NA":18775},{"trials":18762,"activeCount":101},[],{"trials":18764,"activeCount":101},[],{"trials":18766,"activeCount":101},[18767],{"nctId":18726,"briefTitle":18727,"status":142,"phases":18768,"primaryCompletion":18729,"completion":18729,"start":17307,"enrollment":421,"conditions":18769,"interventions":18770},[90],[24],[18717,18732,18733,18734],{"trials":18772,"activeCount":101},[],{"trials":18774,"activeCount":101},[],{"trials":18776,"activeCount":101},[],{"intervention":18734,"totalTrials":2548,"cells":18778},{"EARLY_PHASE1":18779,"PHASE1":18781,"PHASE2":18783,"PHASE3":18789,"PHASE4":18791,"NA":18793},{"trials":18780,"activeCount":101},[],{"trials":18782,"activeCount":101},[],{"trials":18784,"activeCount":101},[18785],{"nctId":18726,"briefTitle":18727,"status":142,"phases":18786,"primaryCompletion":18729,"completion":18729,"start":17307,"enrollment":421,"conditions":18787,"interventions":18788},[90],[24],[18717,18732,18733,18734],{"trials":18790,"activeCount":101},[],{"trials":18792,"activeCount":101},[],{"trials":18794,"activeCount":101},[],{"intervention":3231,"totalTrials":2548,"cells":18796},{"EARLY_PHASE1":18797,"PHASE1":18799,"PHASE2":18801,"PHASE3":18807,"PHASE4":18809,"NA":18811},{"trials":18798,"activeCount":101},[],{"trials":18800,"activeCount":101},[],{"trials":18802,"activeCount":101},[18803],{"nctId":3223,"briefTitle":3224,"status":142,"phases":18804,"primaryCompletion":3226,"completion":3226,"start":3227,"enrollment":1517,"conditions":18805,"interventions":18806},[89,90],[2019,3229],[3231,277,449],{"trials":18808,"activeCount":101},[],{"trials":18810,"activeCount":101},[],{"trials":18812,"activeCount":101},[],{"intervention":860,"totalTrials":2548,"cells":18814},{"EARLY_PHASE1":18815,"PHASE1":18817,"PHASE2":18819,"PHASE3":18825,"PHASE4":18827,"NA":18829},{"trials":18816,"activeCount":101},[],{"trials":18818,"activeCount":101},[],{"trials":18820,"activeCount":101},[18821],{"nctId":848,"briefTitle":849,"status":107,"phases":18822,"primaryCompletion":851,"completion":851,"start":851,"enrollment":101,"conditions":18823,"interventions":18824},[90],[853,841,802,854,855,856,857,858],[860,677,643,63],{"trials":18826,"activeCount":101},[],{"trials":18828,"activeCount":101},[],{"trials":18830,"activeCount":101},[],{"intervention":18832,"totalTrials":2548,"cells":18833},"FR901228",{"EARLY_PHASE1":18834,"PHASE1":18836,"PHASE2":18838,"PHASE3":18846,"PHASE4":18848,"NA":18850},{"trials":18835,"activeCount":101},[],{"trials":18837,"activeCount":101},[],{"trials":18839,"activeCount":101},[18840],{"nctId":18841,"briefTitle":18842,"status":142,"phases":18843,"completion":4562,"start":10387,"conditions":18844,"interventions":18845},"NCT00020202","FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer",[90],[3673,1771,3285,3120,1772,3119],[18832],{"trials":18847,"activeCount":101},[],{"trials":18849,"activeCount":101},[],{"trials":18851,"activeCount":101},[],{"intervention":872,"totalTrials":2548,"cells":18853},{"EARLY_PHASE1":18854,"PHASE1":18856,"PHASE2":18858,"PHASE3":18864,"PHASE4":18866,"NA":18868},{"trials":18855,"activeCount":101},[],{"trials":18857,"activeCount":101},[],{"trials":18859,"activeCount":101},[18860],{"nctId":862,"briefTitle":863,"status":618,"phases":18861,"primaryCompletion":865,"completion":866,"start":867,"enrollment":339,"conditions":18862,"interventions":18863},[89,90],[869,195,870],[872,63,677,643],{"trials":18865,"activeCount":101},[],{"trials":18867,"activeCount":101},[],{"trials":18869,"activeCount":101},[],{"intervention":18871,"totalTrials":2548,"cells":18872},"18F-FLT",{"EARLY_PHASE1":18873,"PHASE1":18875,"PHASE2":18877,"PHASE3":18885,"PHASE4":18887,"NA":18889},{"trials":18874,"activeCount":101},[],{"trials":18876,"activeCount":101},[],{"trials":18878,"activeCount":101},[18879],{"nctId":18880,"briefTitle":18881,"status":142,"phases":18882,"primaryCompletion":4811,"completion":7788,"start":1763,"enrollment":443,"conditions":18883,"interventions":18884},"NCT00572728","Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer",[90],[16275,1221,1222,1223],[18871],{"trials":18886,"activeCount":101},[],{"trials":18888,"activeCount":101},[],{"trials":18890,"activeCount":101},[],{"intervention":5261,"totalTrials":2548,"cells":18892},{"EARLY_PHASE1":18893,"PHASE1":18895,"PHASE2":18897,"PHASE3":18903,"PHASE4":18905,"NA":18907},{"trials":18894,"activeCount":101},[],{"trials":18896,"activeCount":101},[],{"trials":18898,"activeCount":101},[18899],{"nctId":5254,"briefTitle":5255,"status":142,"phases":18900,"primaryCompletion":325,"completion":3007,"start":5257,"enrollment":455,"conditions":18901,"interventions":18902},[90],[5259],[5261,53],{"trials":18904,"activeCount":101},[],{"trials":18906,"activeCount":101},[],{"trials":18908,"activeCount":101},[],{"intervention":893,"totalTrials":2548,"cells":18910},{"EARLY_PHASE1":18911,"PHASE1":18913,"PHASE2":18915,"PHASE3":18921,"PHASE4":18923,"NA":18925},{"trials":18912,"activeCount":101},[],{"trials":18914,"activeCount":101},[],{"trials":18916,"activeCount":101},[18917],{"nctId":885,"briefTitle":886,"status":618,"phases":18918,"primaryCompletion":621,"completion":621,"start":888,"enrollment":889,"conditions":18919,"interventions":18920},[90],[36,891],[677,643,63,893],{"trials":18922,"activeCount":101},[],{"trials":18924,"activeCount":101},[],{"trials":18926,"activeCount":101},[],{"intervention":13304,"totalTrials":2548,"cells":18928},{"EARLY_PHASE1":18929,"PHASE1":18931,"PHASE2":18933,"PHASE3":18939,"PHASE4":18941,"NA":18943},{"trials":18930,"activeCount":101},[],{"trials":18932,"activeCount":101},[],{"trials":18934,"activeCount":101},[18935],{"nctId":13293,"briefTitle":13294,"status":142,"phases":18936,"primaryCompletion":8267,"completion":6303,"start":3397,"enrollment":188,"conditions":18937,"interventions":18938},[90],[10271,13297,13298,13299,13300,13301,13302],[2435,13304],{"trials":18940,"activeCount":101},[],{"trials":18942,"activeCount":101},[],{"trials":18944,"activeCount":101},[],{"intervention":18946,"totalTrials":2548,"cells":18947},"Birinapant",{"EARLY_PHASE1":18948,"PHASE1":18950,"PHASE2":18952,"PHASE3":18964,"PHASE4":18966,"NA":18968},{"trials":18949,"activeCount":101},[],{"trials":18951,"activeCount":101},[],{"trials":18953,"activeCount":101},[18954],{"nctId":18955,"briefTitle":18956,"status":618,"phases":18957,"primaryCompletion":18958,"completion":18959,"start":18960,"enrollment":375,"conditions":18961,"interventions":18963},"NCT01681368","Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer",[90],"2013-12-09","2014-04-30","2012-08-15",[18962,16737,16736],"Epithelial Ovarian Cancer",[18946],{"trials":18965,"activeCount":101},[],{"trials":18967,"activeCount":101},[],{"trials":18969,"activeCount":101},[],{"intervention":18971,"totalTrials":2548,"cells":18972},"Ferumoxytol",{"EARLY_PHASE1":18973,"PHASE1":18975,"PHASE2":18977,"PHASE3":18987,"PHASE4":18989,"NA":18991},{"trials":18974,"activeCount":101},[],{"trials":18976,"activeCount":101},[],{"trials":18978,"activeCount":101},[18979],{"nctId":18980,"briefTitle":18981,"status":142,"phases":18982,"primaryCompletion":18983,"completion":18983,"start":18984,"enrollment":5986,"conditions":18985,"interventions":18986},"NCT02141490","Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers",[90],"2018-11-20","2014-05-15",[24,961,11282],[18971],{"trials":18988,"activeCount":101},[],{"trials":18990,"activeCount":101},[],{"trials":18992,"activeCount":101},[],{"intervention":2283,"totalTrials":2548,"cells":18994},{"EARLY_PHASE1":18995,"PHASE1":18997,"PHASE2":18999,"PHASE3":19005,"PHASE4":19007,"NA":19009},{"trials":18996,"activeCount":101},[],{"trials":18998,"activeCount":101},[],{"trials":19000,"activeCount":101},[19001],{"nctId":2274,"briefTitle":2275,"status":142,"phases":19002,"primaryCompletion":2277,"completion":2278,"start":2279,"enrollment":2280,"conditions":19003,"interventions":19004},[90],[24],[2283,212],{"trials":19006,"activeCount":101},[],{"trials":19008,"activeCount":101},[],{"trials":19010,"activeCount":101},[],{"intervention":19012,"totalTrials":2548,"cells":19013},"pegylated interferon alfa",{"EARLY_PHASE1":19014,"PHASE1":19016,"PHASE2":19018,"PHASE3":19026,"PHASE4":19028,"NA":19030},{"trials":19015,"activeCount":101},[],{"trials":19017,"activeCount":101},[],{"trials":19019,"activeCount":101},[19020],{"nctId":19021,"briefTitle":19022,"status":142,"phases":19023,"primaryCompletion":1329,"completion":10267,"start":1764,"enrollment":22,"conditions":19024,"interventions":19025},"NCT00036569","A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas",[90],[4631],[19012],{"trials":19027,"activeCount":101},[],{"trials":19029,"activeCount":101},[],{"trials":19031,"activeCount":101},[],{"intervention":19033,"totalTrials":2548,"cells":19034},"BL22",{"EARLY_PHASE1":19035,"PHASE1":19037,"PHASE2":19039,"PHASE3":19047,"PHASE4":19049,"NA":19051},{"trials":19036,"activeCount":101},[],{"trials":19038,"activeCount":101},[],{"trials":19040,"activeCount":101},[19041],{"nctId":19042,"briefTitle":19043,"status":618,"phases":19044,"primaryCompletion":5270,"completion":5270,"start":1309,"enrollment":2548,"conditions":19045,"interventions":19046},"NCT00924040","Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia",[90],[9894],[19033],{"trials":19048,"activeCount":101},[],{"trials":19050,"activeCount":101},[],{"trials":19052,"activeCount":101},[],{"intervention":19054,"totalTrials":2548,"cells":19055},"Samotolisib",{"EARLY_PHASE1":19056,"PHASE1":19058,"PHASE2":19060,"PHASE3":19077,"PHASE4":19079,"NA":19081},{"trials":19057,"activeCount":101},[],{"trials":19059,"activeCount":101},[],{"trials":19061,"activeCount":101},[19062],{"nctId":19063,"briefTitle":19064,"status":142,"phases":19065,"primaryCompletion":19066,"completion":1961,"start":19067,"enrollment":827,"conditions":19068,"interventions":19076},"NCT03213678","Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K\u002FMTOR Mutations (A Pediatric MATCH Treatment Trial)",[90],"2023-09-30","2017-11-28",[21,19069,19070,395,12729,12730,12945,12731,12733,12734,116,5416,117,4530,5872,12736,118,7386,12738,12744,12745,30,120,4539,121,19071,19072,4482,19073,4483,19074,19075,12751],"Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Rhabdoid Tumor","Stage III Osteosarcoma AJCC v7","Stage IV Osteosarcoma AJCC v7","Stage IVA Osteosarcoma AJCC v7","Stage IVB Osteosarcoma AJCC v7",[19054],{"trials":19078,"activeCount":101},[],{"trials":19080,"activeCount":101},[],{"trials":19082,"activeCount":101},[],{"intervention":19084,"totalTrials":2548,"cells":19085},"E7 T Cell Receptor",{"EARLY_PHASE1":19086,"PHASE1":19088,"PHASE2":19090,"PHASE3":19102,"PHASE4":19104,"NA":19106},{"trials":19087,"activeCount":101},[],{"trials":19089,"activeCount":101},[],{"trials":19091,"activeCount":101},[19092],{"nctId":19093,"briefTitle":19094,"status":618,"phases":19095,"primaryCompletion":19096,"completion":19096,"start":566,"enrollment":2548,"conditions":19097,"interventions":19101},"NCT03937791","Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions",[90],"2020-06-22",[19098,19099,19100],"Squamous Lntraepithelial Lesions of Vulva","Neoplasms, Squamous Cell","Vulvar HSIL",[19084],{"trials":19103,"activeCount":101},[],{"trials":19105,"activeCount":101},[],{"trials":19107,"activeCount":101},[],{"intervention":19109,"totalTrials":2548,"cells":19110},"halofuginone hydrobromide",{"EARLY_PHASE1":19111,"PHASE1":19113,"PHASE2":19115,"PHASE3":19124,"PHASE4":19126,"NA":19128},{"trials":19112,"activeCount":101},[],{"trials":19114,"activeCount":101},[],{"trials":19116,"activeCount":101},[19117],{"nctId":19118,"briefTitle":19119,"status":142,"phases":19120,"primaryCompletion":1977,"start":9425,"enrollment":28,"conditions":19121,"interventions":19123},"NCT00064142","Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma",[90],[19122,4726],"AIDS-related Kaposi Sarcoma",[19109],{"trials":19125,"activeCount":101},[],{"trials":19127,"activeCount":101},[],{"trials":19129,"activeCount":101},[],{"intervention":920,"totalTrials":2548,"cells":19131},{"EARLY_PHASE1":19132,"PHASE1":19134,"PHASE2":19136,"PHASE3":19142,"PHASE4":19144,"NA":19146},{"trials":19133,"activeCount":101},[],{"trials":19135,"activeCount":101},[],{"trials":19137,"activeCount":101},[19138],{"nctId":907,"briefTitle":908,"status":142,"phases":19139,"primaryCompletion":910,"completion":911,"start":912,"enrollment":913,"conditions":19140,"interventions":19141},[89,90],[915,916,917],[919,63,920,921],{"trials":19143,"activeCount":101},[],{"trials":19145,"activeCount":101},[],{"trials":19147,"activeCount":101},[],{"intervention":921,"totalTrials":2548,"cells":19149},{"EARLY_PHASE1":19150,"PHASE1":19152,"PHASE2":19154,"PHASE3":19160,"PHASE4":19162,"NA":19164},{"trials":19151,"activeCount":101},[],{"trials":19153,"activeCount":101},[],{"trials":19155,"activeCount":101},[19156],{"nctId":907,"briefTitle":908,"status":142,"phases":19157,"primaryCompletion":910,"completion":911,"start":912,"enrollment":913,"conditions":19158,"interventions":19159},[89,90],[915,916,917],[919,63,920,921],{"trials":19161,"activeCount":101},[],{"trials":19163,"activeCount":101},[],{"trials":19165,"activeCount":101},[],{"intervention":19167,"totalTrials":2548,"cells":19168},"LB-100",{"EARLY_PHASE1":19169,"PHASE1":19171,"PHASE2":19173,"PHASE3":19188,"PHASE4":19190,"NA":19192},{"trials":19170,"activeCount":101},[],{"trials":19172,"activeCount":101},[],{"trials":19174,"activeCount":101},[19175],{"nctId":19176,"briefTitle":19177,"status":142,"phases":19178,"primaryCompletion":19179,"completion":19180,"start":19181,"enrollment":1024,"conditions":19182,"interventions":19187},"NCT03027388","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",[90],"2022-08-15","2022-08-31","2019-01-09",[19183,19184,19185,12114,19186],"Astrocytoma, Grades II, III and IV","Glioblastoma Multiforme","Giant Cell Glioblastoma","Oligodendrogliomas",[19167],{"trials":19189,"activeCount":101},[],{"trials":19191,"activeCount":101},[],{"trials":19193,"activeCount":101},[],{"intervention":19195,"totalTrials":2548,"cells":19196},"Savolitinib",{"EARLY_PHASE1":19197,"PHASE1":19199,"PHASE2":19201,"PHASE3":19227,"PHASE4":19229,"NA":19231},{"trials":19198,"activeCount":101},[],{"trials":19200,"activeCount":101},[],{"trials":19202,"activeCount":101},[19203],{"nctId":19204,"briefTitle":19205,"status":618,"phases":19206,"primaryCompletion":19207,"completion":2840,"start":19208,"enrollment":838,"conditions":19209,"interventions":19226},"NCT03592641","Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer",[90],"2021-07-31","2019-07-25",[5573,19210,4956,3045,366,19211,19212,19213,19214,19215,19216,7290,19217,19218,19219,19220,19221,19222,19223,19224,19225],"Metastatic Colon Adenocarcinoma","Stage IIIA Colon Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Colon Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8","Stage IV Rectal Cancer AJCC v8","Stage IVA Colon Cancer AJCC v8","Stage IVA Rectal Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVB Rectal Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8","Stage IVC Rectal Cancer AJCC v8","Unresectable Colon Adenocarcinoma","Unresectable Rectal Adenocarcinoma",[19195],{"trials":19228,"activeCount":101},[],{"trials":19230,"activeCount":101},[],{"trials":19232,"activeCount":101},[],{"intervention":19234,"totalTrials":2548,"cells":19235},"Rapamycin-Generated Autologous Th1\u002FTc1 Cells",{"EARLY_PHASE1":19236,"PHASE1":19238,"PHASE2":19240,"PHASE3":19251,"PHASE4":19253,"NA":19255},{"trials":19237,"activeCount":101},[],{"trials":19239,"activeCount":101},[],{"trials":19241,"activeCount":101},[19242],{"nctId":19243,"briefTitle":19244,"status":618,"phases":19245,"primaryCompletion":19246,"completion":19246,"start":867,"enrollment":1798,"conditions":19247,"interventions":19249},"NCT01239368","Th1\u002FTc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma",[89,90],"2017-08-16",[641,640,19248],"Myelomatosis",[19234,19250],"Th1\u002FTc1 Rapa Cell Therapy",{"trials":19252,"activeCount":101},[],{"trials":19254,"activeCount":101},[],{"trials":19256,"activeCount":101},[],{"intervention":19250,"totalTrials":2548,"cells":19258},{"EARLY_PHASE1":19259,"PHASE1":19261,"PHASE2":19263,"PHASE3":19269,"PHASE4":19271,"NA":19273},{"trials":19260,"activeCount":101},[],{"trials":19262,"activeCount":101},[],{"trials":19264,"activeCount":101},[19265],{"nctId":19243,"briefTitle":19244,"status":618,"phases":19266,"primaryCompletion":19246,"completion":19246,"start":867,"enrollment":1798,"conditions":19267,"interventions":19268},[89,90],[641,640,19248],[19234,19250],{"trials":19270,"activeCount":101},[],{"trials":19272,"activeCount":101},[],{"trials":19274,"activeCount":101},[],{"intervention":10366,"totalTrials":2548,"cells":19276},{"EARLY_PHASE1":19277,"PHASE1":19279,"PHASE2":19281,"PHASE3":19287,"PHASE4":19289,"NA":19291},{"trials":19278,"activeCount":101},[],{"trials":19280,"activeCount":101},[],{"trials":19282,"activeCount":101},[19283],{"nctId":10360,"briefTitle":10361,"status":142,"phases":19284,"completion":745,"start":4232,"conditions":19285,"interventions":19286},[90],[2490],[818,1349,993,10365,10366],{"trials":19288,"activeCount":101},[],{"trials":19290,"activeCount":101},[],{"trials":19292,"activeCount":101},[],{"intervention":19294,"totalTrials":2548,"cells":19295},"Denileukin diftitox",{"EARLY_PHASE1":19296,"PHASE1":19298,"PHASE2":19300,"PHASE3":19311,"PHASE4":19313,"NA":19315},{"trials":19297,"activeCount":101},[],{"trials":19299,"activeCount":101},[],{"trials":19301,"activeCount":101},[19302],{"nctId":19303,"briefTitle":19304,"status":618,"phases":19305,"primaryCompletion":19306,"completion":1827,"start":19307,"enrollment":407,"conditions":19308,"interventions":19310},"NCT00117845","Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia",[90],"2011-12-31","2005-07-11",[19309],"Leukemia, Adult T-Cell",[19294],{"trials":19312,"activeCount":101},[],{"trials":19314,"activeCount":101},[],{"trials":19316,"activeCount":101},[],{"intervention":19318,"totalTrials":2548,"cells":19319},"PF-03084014",{"EARLY_PHASE1":19320,"PHASE1":19322,"PHASE2":19324,"PHASE3":19336,"PHASE4":19338,"NA":19340},{"trials":19321,"activeCount":101},[],{"trials":19323,"activeCount":101},[],{"trials":19325,"activeCount":101},[19326],{"nctId":19327,"briefTitle":19328,"status":142,"phases":19329,"primaryCompletion":19330,"completion":337,"start":19331,"enrollment":407,"conditions":19332,"interventions":19335},"NCT01981551","Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors\u002FAggressive Fibromatosis",[90],"2018-12-30","2013-10-31",[19333,19334],"Desmoid Tumors","Aggressive Fibromatosis",[19318],{"trials":19337,"activeCount":101},[],{"trials":19339,"activeCount":101},[],{"trials":19341,"activeCount":101},[],{"intervention":19343,"totalTrials":2548,"cells":19344},"LY2606368",{"EARLY_PHASE1":19345,"PHASE1":19347,"PHASE2":19349,"PHASE3":19359,"PHASE4":19361,"NA":19363},{"trials":19346,"activeCount":101},[],{"trials":19348,"activeCount":101},[],{"trials":19350,"activeCount":101},[19351],{"nctId":19352,"briefTitle":19353,"status":618,"phases":19354,"primaryCompletion":19355,"completion":19355,"start":19356,"enrollment":9925,"conditions":19357,"interventions":19358},"NCT02203513","A Phase II Single Arm Pilot Study of the Chk1\u002F2 Inhibitor (LY2606368) in BRCA1\u002F2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer",[90],"2021-08-27","2015-01-20",[1003,18,24],[19343],{"trials":19360,"activeCount":101},[],{"trials":19362,"activeCount":101},[],{"trials":19364,"activeCount":101},[],{"intervention":19366,"totalTrials":2548,"cells":19367},"Micellar Paclitaxel",{"EARLY_PHASE1":19368,"PHASE1":19370,"PHASE2":19372,"PHASE3":19381,"PHASE4":19383,"NA":19385},{"trials":19369,"activeCount":101},[],{"trials":19371,"activeCount":101},[],{"trials":19373,"activeCount":101},[19374],{"nctId":19375,"briefTitle":19376,"status":142,"phases":19377,"completion":16071,"start":5004,"enrollment":37,"conditions":19378,"interventions":19380},"NCT00006276","Micellar Paclitaxel to Treat Severe Psoriasis",[90],[19379],"Psoriasis",[19366],{"trials":19382,"activeCount":101},[],{"trials":19384,"activeCount":101},[],{"trials":19386,"activeCount":101},[],{"intervention":1897,"totalTrials":2548,"cells":19388},{"EARLY_PHASE1":19389,"PHASE1":19391,"PHASE2":19393,"PHASE3":19399,"PHASE4":19401,"NA":19403},{"trials":19390,"activeCount":101},[],{"trials":19392,"activeCount":101},[],{"trials":19394,"activeCount":101},[19395],{"nctId":1861,"briefTitle":1862,"status":618,"phases":19396,"primaryCompletion":1864,"completion":1864,"start":1865,"enrollment":889,"conditions":19397,"interventions":19398},[90],[1867,1868,1869,1870,1871,1872,1873,1874,1875,1876,1877,1878,1879,1880,1881,1882,1883,1884,1885,1886,1887,1888,1889,1890,1891,1892,1893,1894,1895],[278,1897],{"trials":19400,"activeCount":101},[],{"trials":19402,"activeCount":101},[],{"trials":19404,"activeCount":101},[],{"intervention":963,"totalTrials":2548,"cells":19406},{"EARLY_PHASE1":19407,"PHASE1":19409,"PHASE2":19411,"PHASE3":19417,"PHASE4":19419,"NA":19421},{"trials":19408,"activeCount":101},[],{"trials":19410,"activeCount":101},[],{"trials":19412,"activeCount":101},[19413],{"nctId":954,"briefTitle":955,"status":618,"phases":19414,"primaryCompletion":957,"completion":957,"start":958,"enrollment":603,"conditions":19415,"interventions":19416},[89,90],[18,960,870,36,961],[677,643,63,963],{"trials":19418,"activeCount":101},[],{"trials":19420,"activeCount":101},[],{"trials":19422,"activeCount":101},[],{"intervention":19424,"totalTrials":2548,"cells":19425},"68Gallium DOTATATE",{"EARLY_PHASE1":19426,"PHASE1":19428,"PHASE2":19430,"PHASE3":19444,"PHASE4":19446,"NA":19448},{"trials":19427,"activeCount":101},[],{"trials":19429,"activeCount":101},[],{"trials":19431,"activeCount":101},[19432],{"nctId":19433,"briefTitle":19434,"status":142,"phases":19435,"primaryCompletion":19436,"completion":19437,"start":19438,"enrollment":19439,"conditions":19440,"interventions":19443},"NCT01967537","Evaluation of 68Gallium-DOTATATE PET\u002FCT for Detecting Neuroendocrine Tumors",[90],"2017-12-17","2018-03-12","2013-10-18",341,[12530,19441,19442],"Von Hippel-Lindau Syndrome","Hippel-Lindau Disease",[19424],{"trials":19445,"activeCount":101},[],{"trials":19447,"activeCount":101},[],{"trials":19449,"activeCount":101},[],{"intervention":19451,"totalTrials":2548,"cells":19452},"Decitabine\u002Fcedazuridine",{"EARLY_PHASE1":19453,"PHASE1":19455,"PHASE2":19457,"PHASE3":19470,"PHASE4":19472,"NA":19474},{"trials":19454,"activeCount":101},[],{"trials":19456,"activeCount":101},[],{"trials":19458,"activeCount":101},[19459],{"nctId":19460,"briefTitle":19461,"status":347,"phases":19462,"primaryCompletion":130,"completion":131,"start":12111,"enrollment":651,"conditions":19463,"interventions":19469},"NCT05960773","Decitabine\u002FCedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma",[90],[915,19464,19465,19466,19467,19468],"Malignant Mesothelioma (MM)","Early-stage Mesothelioma","Subclinical Mesothelioma","BRCA1-Associated Protein-1 (BAP1) Mutations","Early-stage BAP1-associated Malignancies",[19451],{"trials":19471,"activeCount":101},[],{"trials":19473,"activeCount":101},[],{"trials":19475,"activeCount":101},[],{"intervention":1005,"totalTrials":2548,"cells":19477},{"EARLY_PHASE1":19478,"PHASE1":19480,"PHASE2":19482,"PHASE3":19488,"PHASE4":19490,"NA":19492},{"trials":19479,"activeCount":101},[],{"trials":19481,"activeCount":101},[],{"trials":19483,"activeCount":101},[19484],{"nctId":997,"briefTitle":998,"status":618,"phases":19485,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":310,"conditions":19486,"interventions":19487},[89,90],[960,841,1003,915,687],[643,1005,63,677],{"trials":19489,"activeCount":101},[],{"trials":19491,"activeCount":101},[],{"trials":19493,"activeCount":101},[],{"intervention":19495,"totalTrials":2548,"cells":19496},"Pomegranate-Extract Pill",{"EARLY_PHASE1":19497,"PHASE1":19499,"PHASE2":19501,"PHASE3":19518,"PHASE4":19520,"NA":19522},{"trials":19498,"activeCount":101},[],{"trials":19500,"activeCount":101},[],{"trials":19502,"activeCount":101},[19503],{"nctId":19504,"briefTitle":19505,"status":142,"phases":19506,"primaryCompletion":19507,"completion":19508,"start":19509,"enrollment":174,"conditions":19510,"interventions":19517},"NCT02095145","Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance",[90],"2018-01-23","2019-09-26","2014-05-08",[19511,19512,19513,19514,19515,19516],"PSA Level Less Than or Equal to Fifteen","PSA Level Less Than Ten","Stage I Prostate Cancer AJCC v7","Stage II Prostate Cancer AJCC v7","Stage IIA Prostate Cancer AJCC v7","Stage IIB Prostate Cancer AJCC v7",[19495],{"trials":19519,"activeCount":101},[],{"trials":19521,"activeCount":101},[],{"trials":19523,"activeCount":101},[],{"intervention":17921,"totalTrials":2548,"cells":19525},{"EARLY_PHASE1":19526,"PHASE1":19528,"PHASE2":19530,"PHASE3":19536,"PHASE4":19538,"NA":19540},{"trials":19527,"activeCount":101},[],{"trials":19529,"activeCount":101},[],{"trials":19531,"activeCount":101},[19532],{"nctId":17911,"briefTitle":17912,"status":618,"phases":19533,"primaryCompletion":17914,"completion":17915,"start":17916,"enrollment":188,"conditions":19534,"interventions":19535},[89,90],[18,17918,17919],[17921,397],{"trials":19537,"activeCount":101},[],{"trials":19539,"activeCount":101},[],{"trials":19541,"activeCount":101},[],{"intervention":5717,"totalTrials":2548,"cells":19543},{"EARLY_PHASE1":19544,"PHASE1":19546,"PHASE2":19548,"PHASE3":19554,"PHASE4":19556,"NA":19558},{"trials":19545,"activeCount":101},[],{"trials":19547,"activeCount":101},[],{"trials":19549,"activeCount":101},[19550],{"nctId":5711,"briefTitle":5712,"status":618,"phases":19551,"primaryCompletion":650,"completion":650,"start":3088,"enrollment":5714,"conditions":19552,"interventions":19553},[89,90],[1245,1246,3187,3188,940,3190,655,1248,1251],[1063,5717,5718,5719,750],{"trials":19555,"activeCount":101},[],{"trials":19557,"activeCount":101},[],{"trials":19559,"activeCount":101},[],{"intervention":5718,"totalTrials":2548,"cells":19561},{"EARLY_PHASE1":19562,"PHASE1":19564,"PHASE2":19566,"PHASE3":19572,"PHASE4":19574,"NA":19576},{"trials":19563,"activeCount":101},[],{"trials":19565,"activeCount":101},[],{"trials":19567,"activeCount":101},[19568],{"nctId":5711,"briefTitle":5712,"status":618,"phases":19569,"primaryCompletion":650,"completion":650,"start":3088,"enrollment":5714,"conditions":19570,"interventions":19571},[89,90],[1245,1246,3187,3188,940,3190,655,1248,1251],[1063,5717,5718,5719,750],{"trials":19573,"activeCount":101},[],{"trials":19575,"activeCount":101},[],{"trials":19577,"activeCount":101},[],{"intervention":5719,"totalTrials":2548,"cells":19579},{"EARLY_PHASE1":19580,"PHASE1":19582,"PHASE2":19584,"PHASE3":19590,"PHASE4":19592,"NA":19594},{"trials":19581,"activeCount":101},[],{"trials":19583,"activeCount":101},[],{"trials":19585,"activeCount":101},[19586],{"nctId":5711,"briefTitle":5712,"status":618,"phases":19587,"primaryCompletion":650,"completion":650,"start":3088,"enrollment":5714,"conditions":19588,"interventions":19589},[89,90],[1245,1246,3187,3188,940,3190,655,1248,1251],[1063,5717,5718,5719,750],{"trials":19591,"activeCount":101},[],{"trials":19593,"activeCount":101},[],{"trials":19595,"activeCount":101},[],{"intervention":19597,"totalTrials":2548,"cells":19598},"BMN 673",{"EARLY_PHASE1":19599,"PHASE1":19601,"PHASE2":19603,"PHASE3":19613,"PHASE4":19615,"NA":19617},{"trials":19600,"activeCount":101},[],{"trials":19602,"activeCount":101},[],{"trials":19604,"activeCount":101},[19605],{"nctId":19606,"briefTitle":19607,"status":618,"phases":19608,"primaryCompletion":19609,"completion":19609,"start":19610,"enrollment":603,"conditions":19611,"interventions":19612},"NCT02326844","BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1\u002F2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment",[90],"2016-04-14","2015-03-02",[1003],[19597],{"trials":19614,"activeCount":101},[],{"trials":19616,"activeCount":101},[],{"trials":19618,"activeCount":101},[],{"intervention":7021,"totalTrials":2548,"cells":19620},{"EARLY_PHASE1":19621,"PHASE1":19623,"PHASE2":19625,"PHASE3":19631,"PHASE4":19633,"NA":19635},{"trials":19622,"activeCount":101},[],{"trials":19624,"activeCount":101},[],{"trials":19626,"activeCount":101},[19627],{"nctId":7015,"briefTitle":7016,"status":142,"phases":19628,"primaryCompletion":7018,"completion":6513,"start":3480,"enrollment":1765,"conditions":19629,"interventions":19630},[90],[18],[2083,7021,7022,5933],{"trials":19632,"activeCount":101},[],{"trials":19634,"activeCount":101},[],{"trials":19636,"activeCount":101},[],{"intervention":7022,"totalTrials":2548,"cells":19638},{"EARLY_PHASE1":19639,"PHASE1":19641,"PHASE2":19643,"PHASE3":19649,"PHASE4":19651,"NA":19653},{"trials":19640,"activeCount":101},[],{"trials":19642,"activeCount":101},[],{"trials":19644,"activeCount":101},[19645],{"nctId":7015,"briefTitle":7016,"status":142,"phases":19646,"primaryCompletion":7018,"completion":6513,"start":3480,"enrollment":1765,"conditions":19647,"interventions":19648},[90],[18],[2083,7021,7022,5933],{"trials":19650,"activeCount":101},[],{"trials":19652,"activeCount":101},[],{"trials":19654,"activeCount":101},[],{"intervention":19656,"totalTrials":2548,"cells":19657},"aflibercept",{"EARLY_PHASE1":19658,"PHASE1":19660,"PHASE2":19662,"PHASE3":19670,"PHASE4":19672,"NA":19674},{"trials":19659,"activeCount":101},[],{"trials":19661,"activeCount":101},[],{"trials":19663,"activeCount":101},[19664],{"nctId":19665,"briefTitle":19666,"status":618,"phases":19667,"primaryCompletion":3282,"completion":3155,"start":1340,"enrollment":889,"conditions":19668,"interventions":19669},"NCT00437034","Aflibercept for Relapsed Multiple Myeloma",[90],[1431,1432],[19656],{"trials":19671,"activeCount":101},[],{"trials":19673,"activeCount":101},[],{"trials":19675,"activeCount":101},[],{"intervention":14880,"totalTrials":2548,"cells":19677},{"EARLY_PHASE1":19678,"PHASE1":19680,"PHASE2":19682,"PHASE3":19688,"PHASE4":19690,"NA":19692},{"trials":19679,"activeCount":101},[],{"trials":19681,"activeCount":101},[],{"trials":19683,"activeCount":101},[19684],{"nctId":14873,"briefTitle":14874,"status":142,"phases":19685,"primaryCompletion":4996,"completion":4996,"start":1576,"enrollment":14876,"conditions":19686,"interventions":19687},[90],[843,14878,844],[14880,14855,14881],{"trials":19689,"activeCount":101},[],{"trials":19691,"activeCount":101},[],{"trials":19693,"activeCount":101},[],{"intervention":2313,"totalTrials":2548,"cells":19695},{"EARLY_PHASE1":19696,"PHASE1":19698,"PHASE2":19700,"PHASE3":19706,"PHASE4":19708,"NA":19710},{"trials":19697,"activeCount":101},[],{"trials":19699,"activeCount":101},[],{"trials":19701,"activeCount":101},[19702],{"nctId":2301,"briefTitle":2302,"status":142,"phases":19703,"primaryCompletion":2304,"completion":2305,"start":2306,"enrollment":2307,"conditions":19704,"interventions":19705},[90],[2309,2310,2311],[2313,212,1653],{"trials":19707,"activeCount":101},[],{"trials":19709,"activeCount":101},[],{"trials":19711,"activeCount":101},[],{"intervention":19713,"totalTrials":2548,"cells":19714},"BCG intravesical live",{"EARLY_PHASE1":19715,"PHASE1":19717,"PHASE2":19719,"PHASE3":19731,"PHASE4":19733,"NA":19735},{"trials":19716,"activeCount":101},[],{"trials":19718,"activeCount":101},[],{"trials":19720,"activeCount":101},[19721],{"nctId":19722,"briefTitle":19723,"status":142,"phases":19724,"primaryCompletion":19725,"completion":19726,"start":19727,"enrollment":22,"conditions":19728,"interventions":19729},"NCT02015104","Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG",[90],"2018-09-18","2019-05-02","2013-12-18",[961],[19713,19730],"PANVAC",{"trials":19732,"activeCount":101},[],{"trials":19734,"activeCount":101},[],{"trials":19736,"activeCount":101},[],{"intervention":19730,"totalTrials":2548,"cells":19738},{"EARLY_PHASE1":19739,"PHASE1":19741,"PHASE2":19743,"PHASE3":19749,"PHASE4":19751,"NA":19753},{"trials":19740,"activeCount":101},[],{"trials":19742,"activeCount":101},[],{"trials":19744,"activeCount":101},[19745],{"nctId":19722,"briefTitle":19723,"status":142,"phases":19746,"primaryCompletion":19725,"completion":19726,"start":19727,"enrollment":22,"conditions":19747,"interventions":19748},[90],[961],[19713,19730],{"trials":19750,"activeCount":101},[],{"trials":19752,"activeCount":101},[],{"trials":19754,"activeCount":101},[],{"intervention":19756,"totalTrials":2548,"cells":19757},"Baricitinib",{"EARLY_PHASE1":19758,"PHASE1":19760,"PHASE2":19762,"PHASE3":19774,"PHASE4":19776,"NA":19778},{"trials":19759,"activeCount":101},[],{"trials":19761,"activeCount":101},[],{"trials":19763,"activeCount":101},[19764],{"nctId":19765,"briefTitle":19766,"status":142,"phases":19767,"primaryCompletion":19768,"completion":19769,"start":10728,"enrollment":339,"conditions":19770,"interventions":19773},"NCT02759731","Study of Baricitinib, a JAK1\u002F2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation",[89,90],"2022-06-30","2024-05-30",[19771,19772],"Chronic Graft vs Host Disease","Chronic Graft-Versus-Host Disease",[19756],{"trials":19775,"activeCount":101},[],{"trials":19777,"activeCount":101},[],{"trials":19779,"activeCount":101},[],{"intervention":7791,"totalTrials":2548,"cells":19781},{"EARLY_PHASE1":19782,"PHASE1":19784,"PHASE2":19786,"PHASE3":19792,"PHASE4":19794,"NA":19796},{"trials":19783,"activeCount":101},[],{"trials":19785,"activeCount":101},[],{"trials":19787,"activeCount":101},[19788],{"nctId":7785,"briefTitle":7786,"status":142,"phases":19789,"primaryCompletion":1170,"completion":7788,"start":715,"enrollment":28,"conditions":19790,"interventions":19791},[90],[7583,7584,7585,7587,4681],[7791,2166,3401,3066],{"trials":19793,"activeCount":101},[],{"trials":19795,"activeCount":101},[],{"trials":19797,"activeCount":101},[],{"intervention":19799,"totalTrials":2548,"cells":19800},"rosiglitazone maleate",{"EARLY_PHASE1":19801,"PHASE1":19803,"PHASE2":19805,"PHASE3":19813,"PHASE4":19815,"NA":19817},{"trials":19802,"activeCount":101},[],{"trials":19804,"activeCount":101},[],{"trials":19806,"activeCount":101},[19807],{"nctId":19808,"briefTitle":19809,"status":142,"phases":19810,"primaryCompletion":7645,"start":5634,"enrollment":37,"conditions":19811,"interventions":19812},"NCT00369174","Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia",[90],[18189],[19799],{"trials":19814,"activeCount":101},[],{"trials":19816,"activeCount":101},[],{"trials":19818,"activeCount":101},[],{"intervention":19820,"totalTrials":2548,"cells":19821},"medroxyprogesterone",{"EARLY_PHASE1":19822,"PHASE1":19824,"PHASE2":19826,"PHASE3":19836,"PHASE4":19838,"NA":19840},{"trials":19823,"activeCount":101},[],{"trials":19825,"activeCount":101},[],{"trials":19827,"activeCount":101},[19828],{"nctId":19829,"briefTitle":19830,"status":142,"phases":19831,"primaryCompletion":987,"start":14747,"enrollment":3869,"conditions":19832,"interventions":19833},"NCT00033358","Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer",[90],[2570],[19820,19834,19835],"ethinyl estradiol","norgestrel",{"trials":19837,"activeCount":101},[],{"trials":19839,"activeCount":101},[],{"trials":19841,"activeCount":101},[],{"intervention":19834,"totalTrials":2548,"cells":19843},{"EARLY_PHASE1":19844,"PHASE1":19846,"PHASE2":19848,"PHASE3":19854,"PHASE4":19856,"NA":19858},{"trials":19845,"activeCount":101},[],{"trials":19847,"activeCount":101},[],{"trials":19849,"activeCount":101},[19850],{"nctId":19829,"briefTitle":19830,"status":142,"phases":19851,"primaryCompletion":987,"start":14747,"enrollment":3869,"conditions":19852,"interventions":19853},[90],[2570],[19820,19834,19835],{"trials":19855,"activeCount":101},[],{"trials":19857,"activeCount":101},[],{"trials":19859,"activeCount":101},[],{"intervention":19835,"totalTrials":2548,"cells":19861},{"EARLY_PHASE1":19862,"PHASE1":19864,"PHASE2":19866,"PHASE3":19872,"PHASE4":19874,"NA":19876},{"trials":19863,"activeCount":101},[],{"trials":19865,"activeCount":101},[],{"trials":19867,"activeCount":101},[19868],{"nctId":19829,"briefTitle":19830,"status":142,"phases":19869,"primaryCompletion":987,"start":14747,"enrollment":3869,"conditions":19870,"interventions":19871},[90],[2570],[19820,19834,19835],{"trials":19873,"activeCount":101},[],{"trials":19875,"activeCount":101},[],{"trials":19877,"activeCount":101},[],{"intervention":18036,"totalTrials":2548,"cells":19879},{"EARLY_PHASE1":19880,"PHASE1":19882,"PHASE2":19884,"PHASE3":19890,"PHASE4":19892,"NA":19894},{"trials":19881,"activeCount":101},[],{"trials":19883,"activeCount":101},[],{"trials":19885,"activeCount":101},[19886],{"nctId":18029,"briefTitle":18030,"status":142,"phases":19887,"primaryCompletion":18032,"completion":18032,"start":18033,"enrollment":188,"conditions":19888,"interventions":19889},[90],[15088],[18008,18036],{"trials":19891,"activeCount":101},[],{"trials":19893,"activeCount":101},[],{"trials":19895,"activeCount":101},[],{"intervention":8253,"totalTrials":2548,"cells":19897},{"EARLY_PHASE1":19898,"PHASE1":19900,"PHASE2":19902,"PHASE3":19908,"PHASE4":19910,"NA":19912},{"trials":19899,"activeCount":101},[],{"trials":19901,"activeCount":101},[],{"trials":19903,"activeCount":101},[19904],{"nctId":8245,"briefTitle":8246,"status":142,"phases":19905,"primaryCompletion":8248,"completion":8248,"start":8249,"enrollment":5714,"conditions":19906,"interventions":19907},[90],[3837,8251],[1570,8253],{"trials":19909,"activeCount":101},[],{"trials":19911,"activeCount":101},[],{"trials":19913,"activeCount":101},[],{"intervention":11884,"totalTrials":2548,"cells":19915},{"EARLY_PHASE1":19916,"PHASE1":19918,"PHASE2":19920,"PHASE3":19926,"PHASE4":19928,"NA":19930},{"trials":19917,"activeCount":101},[],{"trials":19919,"activeCount":101},[],{"trials":19921,"activeCount":101},[19922],{"nctId":11874,"briefTitle":11875,"status":347,"phases":19923,"primaryCompletion":11877,"completion":11878,"start":900,"enrollment":28,"conditions":19924,"interventions":19925},[89,90],[11880,11881,6058,11882],[11884,476,11852],{"trials":19927,"activeCount":101},[],{"trials":19929,"activeCount":101},[],{"trials":19931,"activeCount":101},[],{"intervention":1077,"totalTrials":2548,"cells":19933},{"EARLY_PHASE1":19934,"PHASE1":19936,"PHASE2":19938,"PHASE3":19944,"PHASE4":19946,"NA":19948},{"trials":19935,"activeCount":101},[],{"trials":19937,"activeCount":101},[],{"trials":19939,"activeCount":101},[19940],{"nctId":1068,"briefTitle":1069,"status":142,"phases":19941,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":19942,"interventions":19943},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"trials":19945,"activeCount":101},[],{"trials":19947,"activeCount":101},[],{"trials":19949,"activeCount":101},[],{"intervention":1078,"totalTrials":2548,"cells":19951},{"EARLY_PHASE1":19952,"PHASE1":19954,"PHASE2":19956,"PHASE3":19962,"PHASE4":19964,"NA":19966},{"trials":19953,"activeCount":101},[],{"trials":19955,"activeCount":101},[],{"trials":19957,"activeCount":101},[19958],{"nctId":1068,"briefTitle":1069,"status":142,"phases":19959,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":19960,"interventions":19961},[90],[625],[1077,1078,693,1079,994,1080,819,1081,1082,1083,1084,1032,738],{"trials":19963,"activeCount":101},[],{"trials":19965,"activeCount":101},[],{"trials":19967,"activeCount":101},[],{"intervention":1100,"totalTrials":2548,"cells":19969},{"EARLY_PHASE1":19970,"PHASE1":19972,"PHASE2":19974,"PHASE3":19980,"PHASE4":19982,"NA":19984},{"trials":19971,"activeCount":101},[],{"trials":19973,"activeCount":101},[],{"trials":19975,"activeCount":101},[19976],{"nctId":1086,"briefTitle":1087,"status":142,"phases":19977,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":19978,"interventions":19979},[90],[1092,1093,1094,1095,1096,1097],[1099,63,1100,737,279,1101,1102,151,1103],{"trials":19981,"activeCount":101},[],{"trials":19983,"activeCount":101},[],{"trials":19985,"activeCount":101},[],{"intervention":1103,"totalTrials":2548,"cells":19987},{"EARLY_PHASE1":19988,"PHASE1":19990,"PHASE2":19992,"PHASE3":19998,"PHASE4":20000,"NA":20002},{"trials":19989,"activeCount":101},[],{"trials":19991,"activeCount":101},[],{"trials":19993,"activeCount":101},[19994],{"nctId":1086,"briefTitle":1087,"status":142,"phases":19995,"primaryCompletion":1089,"completion":1089,"start":1022,"enrollment":1090,"conditions":19996,"interventions":19997},[90],[1092,1093,1094,1095,1096,1097],[1099,63,1100,737,279,1101,1102,151,1103],{"trials":19999,"activeCount":101},[],{"trials":20001,"activeCount":101},[],{"trials":20003,"activeCount":101},[],{"intervention":1123,"totalTrials":2548,"cells":20005},{"EARLY_PHASE1":20006,"PHASE1":20008,"PHASE2":20010,"PHASE3":20016,"PHASE4":20018,"NA":20020},{"trials":20007,"activeCount":101},[],{"trials":20009,"activeCount":101},[],{"trials":20011,"activeCount":101},[20012],{"nctId":1116,"briefTitle":1117,"status":142,"phases":20013,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":188,"conditions":20014,"interventions":20015},[89,90],[1044,960,1045,1046,1043],[643,63,1123,677],{"trials":20017,"activeCount":101},[],{"trials":20019,"activeCount":101},[],{"trials":20021,"activeCount":101},[],{"intervention":20023,"totalTrials":2548,"cells":20024},"Eovist",{"EARLY_PHASE1":20025,"PHASE1":20027,"PHASE2":20029,"PHASE3":20039,"PHASE4":20041,"NA":20043},{"trials":20026,"activeCount":101},[],{"trials":20028,"activeCount":101},[],{"trials":20030,"activeCount":101},[20031],{"nctId":20032,"briefTitle":20033,"status":142,"phases":20034,"primaryCompletion":20035,"completion":1924,"start":20036,"enrollment":339,"conditions":20037,"interventions":20038},"NCT01867424","Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer",[90],"2016-05-30","2013-05-14",[24],[20023],{"trials":20040,"activeCount":101},[],{"trials":20042,"activeCount":101},[],{"trials":20044,"activeCount":101},[],{"intervention":20046,"totalTrials":2548,"cells":20047},"CUDC-907",{"EARLY_PHASE1":20048,"PHASE1":20050,"PHASE2":20052,"PHASE3":20065,"PHASE4":20067,"NA":20069},{"trials":20049,"activeCount":101},[],{"trials":20051,"activeCount":101},[],{"trials":20053,"activeCount":101},[20054],{"nctId":20055,"briefTitle":20056,"status":618,"phases":20057,"primaryCompletion":20058,"completion":20058,"start":20059,"enrollment":1024,"conditions":20060,"interventions":20064},"NCT03002623","CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer",[90],"2018-02-12","2016-12-22",[20061,20062,20063],"Thyroid Neoplasms","Poorly Differentiated and Undifferentiated Thyroid Cancer","Differentiated Thyroid Cancer",[20046],{"trials":20066,"activeCount":101},[],{"trials":20068,"activeCount":101},[],{"trials":20070,"activeCount":101},[],{"intervention":20072,"totalTrials":2548,"cells":20073},"carboxyamidotriazole",{"EARLY_PHASE1":20074,"PHASE1":20076,"PHASE2":20078,"PHASE3":20087,"PHASE4":20089,"NA":20091},{"trials":20075,"activeCount":101},[],{"trials":20077,"activeCount":101},[],{"trials":20079,"activeCount":101},[20080],{"nctId":20081,"briefTitle":20082,"status":142,"phases":20083,"primaryCompletion":1912,"start":7035,"enrollment":20084,"conditions":20085,"interventions":20086},"NCT00006486","Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer",[90],335,[5233,4842],[20072],{"trials":20088,"activeCount":101},[],{"trials":20090,"activeCount":101},[],{"trials":20092,"activeCount":101},[],{"intervention":11340,"totalTrials":2548,"cells":20094},{"EARLY_PHASE1":20095,"PHASE1":20097,"PHASE2":20099,"PHASE3":20105,"PHASE4":20107,"NA":20109},{"trials":20096,"activeCount":101},[],{"trials":20098,"activeCount":101},[],{"trials":20100,"activeCount":101},[20101],{"nctId":11334,"briefTitle":11335,"status":142,"phases":20102,"completion":1341,"start":11337,"conditions":20103,"interventions":20104},[89,90],[856],[818,11340],{"trials":20106,"activeCount":101},[],{"trials":20108,"activeCount":101},[],{"trials":20110,"activeCount":101},[],{"intervention":17314,"totalTrials":2548,"cells":20112},{"EARLY_PHASE1":20113,"PHASE1":20115,"PHASE2":20117,"PHASE3":20123,"PHASE4":20125,"NA":20127},{"trials":20114,"activeCount":101},[],{"trials":20116,"activeCount":101},[],{"trials":20118,"activeCount":101},[20119],{"nctId":17302,"briefTitle":17303,"status":618,"phases":20120,"primaryCompletion":17305,"completion":17306,"start":17307,"enrollment":310,"conditions":20121,"interventions":20122},[89,90],[486,275,116,30,17309,17310,17311,17312,6160],[9201,17314],{"trials":20124,"activeCount":101},[],{"trials":20126,"activeCount":101},[],{"trials":20128,"activeCount":101},[],{"intervention":7117,"totalTrials":2548,"cells":20130},{"EARLY_PHASE1":20131,"PHASE1":20133,"PHASE2":20135,"PHASE3":20141,"PHASE4":20143,"NA":20145},{"trials":20132,"activeCount":101},[],{"trials":20134,"activeCount":101},[],{"trials":20136,"activeCount":101},[20137],{"nctId":7110,"briefTitle":7111,"status":142,"phases":20138,"completion":4562,"start":7113,"conditions":20139,"interventions":20140},[90],[1431,1432,7115],[7117,7118,1081,993],{"trials":20142,"activeCount":101},[],{"trials":20144,"activeCount":101},[],{"trials":20146,"activeCount":101},[],{"intervention":7118,"totalTrials":2548,"cells":20148},{"EARLY_PHASE1":20149,"PHASE1":20151,"PHASE2":20153,"PHASE3":20159,"PHASE4":20161,"NA":20163},{"trials":20150,"activeCount":101},[],{"trials":20152,"activeCount":101},[],{"trials":20154,"activeCount":101},[20155],{"nctId":7110,"briefTitle":7111,"status":142,"phases":20156,"completion":4562,"start":7113,"conditions":20157,"interventions":20158},[90],[1431,1432,7115],[7117,7118,1081,993],{"trials":20160,"activeCount":101},[],{"trials":20162,"activeCount":101},[],{"trials":20164,"activeCount":101},[],{"intervention":20166,"totalTrials":2548,"cells":20167},"Y-90 Humanized Anti-Tac",{"EARLY_PHASE1":20168,"PHASE1":20170,"PHASE2":20172,"PHASE3":20184,"PHASE4":20186,"NA":20188},{"trials":20169,"activeCount":101},[],{"trials":20171,"activeCount":101},[],{"trials":20173,"activeCount":101},[20174],{"nctId":20175,"briefTitle":20176,"status":142,"phases":20177,"primaryCompletion":2292,"completion":2292,"start":20178,"enrollment":1852,"conditions":20179,"interventions":20182},"NCT00001575","Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia",[89,90],"1997-04",[20180,20181],"Hodgkin's Disease","Lymphoma, Non-Hodgkin",[20166,20183],"Calcium-DTPA",{"trials":20185,"activeCount":101},[],{"trials":20187,"activeCount":101},[],{"trials":20189,"activeCount":101},[],{"intervention":20183,"totalTrials":2548,"cells":20191},{"EARLY_PHASE1":20192,"PHASE1":20194,"PHASE2":20196,"PHASE3":20202,"PHASE4":20204,"NA":20206},{"trials":20193,"activeCount":101},[],{"trials":20195,"activeCount":101},[],{"trials":20197,"activeCount":101},[20198],{"nctId":20175,"briefTitle":20176,"status":142,"phases":20199,"primaryCompletion":2292,"completion":2292,"start":20178,"enrollment":1852,"conditions":20200,"interventions":20201},[89,90],[20180,20181],[20166,20183],{"trials":20203,"activeCount":101},[],{"trials":20205,"activeCount":101},[],{"trials":20207,"activeCount":101},[],{"intervention":14935,"totalTrials":2548,"cells":20209},{"EARLY_PHASE1":20210,"PHASE1":20212,"PHASE2":20214,"PHASE3":20220,"PHASE4":20222,"NA":20224},{"trials":20211,"activeCount":101},[],{"trials":20213,"activeCount":101},[],{"trials":20215,"activeCount":101},[20216],{"nctId":14926,"briefTitle":14927,"status":142,"phases":20217,"primaryCompletion":14929,"completion":14930,"start":14931,"enrollment":34,"conditions":20218,"interventions":20219},[90],[5795,5794],[14934,14906,14935],{"trials":20221,"activeCount":101},[],{"trials":20223,"activeCount":101},[],{"trials":20225,"activeCount":101},[],{"intervention":20227,"totalTrials":2548,"cells":20228},"Glembatumumab Vedotin",{"EARLY_PHASE1":20229,"PHASE1":20231,"PHASE2":20233,"PHASE3":20242,"PHASE4":20244,"NA":20246},{"trials":20230,"activeCount":101},[],{"trials":20232,"activeCount":101},[],{"trials":20234,"activeCount":101},[20235],{"nctId":20236,"briefTitle":20237,"status":142,"phases":20238,"primaryCompletion":20239,"completion":1498,"start":11434,"enrollment":2401,"conditions":20240,"interventions":20241},"NCT02487979","Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma",[90],"2017-06-30",[5872],[20227],{"trials":20243,"activeCount":101},[],{"trials":20245,"activeCount":101},[],{"trials":20247,"activeCount":101},[],{"intervention":16968,"totalTrials":2548,"cells":20249},{"EARLY_PHASE1":20250,"PHASE1":20252,"PHASE2":20254,"PHASE3":20260,"PHASE4":20262,"NA":20264},{"trials":20251,"activeCount":101},[],{"trials":20253,"activeCount":101},[],{"trials":20255,"activeCount":101},[20256],{"nctId":16963,"briefTitle":16964,"status":142,"phases":20257,"primaryCompletion":1288,"start":1979,"enrollment":19,"conditions":20258,"interventions":20259},[89,90],[2453,4058,33,4616,6285],[16968,14802],{"trials":20261,"activeCount":101},[],{"trials":20263,"activeCount":101},[],{"trials":20265,"activeCount":101},[],{"intervention":5947,"totalTrials":2548,"cells":20267},{"EARLY_PHASE1":20268,"PHASE1":20270,"PHASE2":20272,"PHASE3":20278,"PHASE4":20280,"NA":20282},{"trials":20269,"activeCount":101},[],{"trials":20271,"activeCount":101},[],{"trials":20273,"activeCount":101},[20274],{"nctId":5939,"briefTitle":5940,"status":142,"phases":20275,"primaryCompletion":2262,"completion":5942,"start":5943,"enrollment":19,"conditions":20276,"interventions":20277},[89,90],[5945,687,2719],[2256,1407,151,706,5947,2218,1139,5948],{"trials":20279,"activeCount":101},[],{"trials":20281,"activeCount":101},[],{"trials":20283,"activeCount":101},[],{"intervention":5948,"totalTrials":2548,"cells":20285},{"EARLY_PHASE1":20286,"PHASE1":20288,"PHASE2":20290,"PHASE3":20296,"PHASE4":20298,"NA":20300},{"trials":20287,"activeCount":101},[],{"trials":20289,"activeCount":101},[],{"trials":20291,"activeCount":101},[20292],{"nctId":5939,"briefTitle":5940,"status":142,"phases":20293,"primaryCompletion":2262,"completion":5942,"start":5943,"enrollment":19,"conditions":20294,"interventions":20295},[89,90],[5945,687,2719],[2256,1407,151,706,5947,2218,1139,5948],{"trials":20297,"activeCount":101},[],{"trials":20299,"activeCount":101},[],{"trials":20301,"activeCount":101},[],{"intervention":10390,"totalTrials":2548,"cells":20303},{"EARLY_PHASE1":20304,"PHASE1":20306,"PHASE2":20308,"PHASE3":20314,"PHASE4":20316,"NA":20318},{"trials":20305,"activeCount":101},[],{"trials":20307,"activeCount":101},[],{"trials":20309,"activeCount":101},[20310],{"nctId":10384,"briefTitle":10385,"status":142,"phases":20311,"primaryCompletion":3526,"start":10387,"conditions":20312,"interventions":20313},[90],[24],[818,10390,10391,10392,993,10393],{"trials":20315,"activeCount":101},[],{"trials":20317,"activeCount":101},[],{"trials":20319,"activeCount":101},[],{"intervention":10391,"totalTrials":2548,"cells":20321},{"EARLY_PHASE1":20322,"PHASE1":20324,"PHASE2":20326,"PHASE3":20332,"PHASE4":20334,"NA":20336},{"trials":20323,"activeCount":101},[],{"trials":20325,"activeCount":101},[],{"trials":20327,"activeCount":101},[20328],{"nctId":10384,"briefTitle":10385,"status":142,"phases":20329,"primaryCompletion":3526,"start":10387,"conditions":20330,"interventions":20331},[90],[24],[818,10390,10391,10392,993,10393],{"trials":20333,"activeCount":101},[],{"trials":20335,"activeCount":101},[],{"trials":20337,"activeCount":101},[],{"intervention":10392,"totalTrials":2548,"cells":20339},{"EARLY_PHASE1":20340,"PHASE1":20342,"PHASE2":20344,"PHASE3":20350,"PHASE4":20352,"NA":20354},{"trials":20341,"activeCount":101},[],{"trials":20343,"activeCount":101},[],{"trials":20345,"activeCount":101},[20346],{"nctId":10384,"briefTitle":10385,"status":142,"phases":20347,"primaryCompletion":3526,"start":10387,"conditions":20348,"interventions":20349},[90],[24],[818,10390,10391,10392,993,10393],{"trials":20351,"activeCount":101},[],{"trials":20353,"activeCount":101},[],{"trials":20355,"activeCount":101},[],{"intervention":10393,"totalTrials":2548,"cells":20357},{"EARLY_PHASE1":20358,"PHASE1":20360,"PHASE2":20362,"PHASE3":20368,"PHASE4":20370,"NA":20372},{"trials":20359,"activeCount":101},[],{"trials":20361,"activeCount":101},[],{"trials":20363,"activeCount":101},[20364],{"nctId":10384,"briefTitle":10385,"status":142,"phases":20365,"primaryCompletion":3526,"start":10387,"conditions":20366,"interventions":20367},[90],[24],[818,10390,10391,10392,993,10393],{"trials":20369,"activeCount":101},[],{"trials":20371,"activeCount":101},[],{"trials":20373,"activeCount":101},[],{"intervention":8129,"totalTrials":2548,"cells":20375},{"EARLY_PHASE1":20376,"PHASE1":20378,"PHASE2":20380,"PHASE3":20386,"PHASE4":20388,"NA":20390},{"trials":20377,"activeCount":101},[],{"trials":20379,"activeCount":101},[],{"trials":20381,"activeCount":101},[20382],{"nctId":8122,"briefTitle":8123,"status":142,"phases":20383,"primaryCompletion":4928,"completion":4928,"start":1170,"enrollment":1331,"conditions":20384,"interventions":20385},[90],[3428,5549,5551,5552,8126,8127,5554,5555],[8129,1454,2143],{"trials":20387,"activeCount":101},[],{"trials":20389,"activeCount":101},[],{"trials":20391,"activeCount":101},[],{"intervention":10400,"totalTrials":2548,"cells":20393},{"EARLY_PHASE1":20394,"PHASE1":20396,"PHASE2":20398,"PHASE3":20404,"PHASE4":20406,"NA":20408},{"trials":20395,"activeCount":101},[],{"trials":20397,"activeCount":101},[],{"trials":20399,"activeCount":101},[20400],{"nctId":10395,"briefTitle":10396,"status":142,"phases":20401,"primaryCompletion":5103,"completion":5103,"start":2160,"enrollment":1913,"conditions":20402,"interventions":20403},[90],[24],[5933,10400,10401],{"trials":20405,"activeCount":101},[],{"trials":20407,"activeCount":101},[],{"trials":20409,"activeCount":101},[],{"intervention":16631,"totalTrials":2548,"cells":20411},{"EARLY_PHASE1":20412,"PHASE1":20414,"PHASE2":20416,"PHASE3":20422,"PHASE4":20424,"NA":20426},{"trials":20413,"activeCount":101},[],{"trials":20415,"activeCount":101},[],{"trials":20417,"activeCount":101},[20418],{"nctId":16625,"briefTitle":16626,"status":142,"phases":20419,"completion":1181,"start":14896,"enrollment":16628,"conditions":20420,"interventions":20421},[90],[36,7088],[16631,704],{"trials":20423,"activeCount":101},[],{"trials":20425,"activeCount":101},[],{"trials":20427,"activeCount":101},[],{"intervention":342,"totalTrials":2548,"cells":20429},{"EARLY_PHASE1":20430,"PHASE1":20432,"PHASE2":20434,"PHASE3":20440,"PHASE4":20442,"NA":20444},{"trials":20431,"activeCount":101},[],{"trials":20433,"activeCount":101},[],{"trials":20435,"activeCount":101},[20436],{"nctId":333,"briefTitle":334,"status":142,"phases":20437,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":20438,"interventions":20439},[89,90],[24],[342,96,343],{"trials":20441,"activeCount":101},[],{"trials":20443,"activeCount":101},[],{"trials":20445,"activeCount":101},[],{"intervention":343,"totalTrials":2548,"cells":20447},{"EARLY_PHASE1":20448,"PHASE1":20450,"PHASE2":20452,"PHASE3":20458,"PHASE4":20460,"NA":20462},{"trials":20449,"activeCount":101},[],{"trials":20451,"activeCount":101},[],{"trials":20453,"activeCount":101},[20454],{"nctId":333,"briefTitle":334,"status":142,"phases":20455,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":20456,"interventions":20457},[89,90],[24],[342,96,343],{"trials":20459,"activeCount":101},[],{"trials":20461,"activeCount":101},[],{"trials":20463,"activeCount":101},[],{"intervention":20465,"totalTrials":2548,"cells":20466},"Peptide loaded dendritic cell vaccine",{"EARLY_PHASE1":20467,"PHASE1":20469,"PHASE2":20471,"PHASE3":20482,"PHASE4":20484,"NA":20486},{"trials":20468,"activeCount":101},[],{"trials":20470,"activeCount":101},[],{"trials":20472,"activeCount":101},[20473],{"nctId":20474,"briefTitle":20475,"status":618,"phases":20476,"primaryCompletion":20477,"completion":20478,"start":20479,"enrollment":2548,"conditions":20480,"interventions":20481},"NCT03300843","Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer",[90],"2019-07-09","2019-09-16","2018-04-11",[36,840,18,1003,841],[20465],{"trials":20483,"activeCount":101},[],{"trials":20485,"activeCount":101},[],{"trials":20487,"activeCount":101},[],{"intervention":356,"totalTrials":2548,"cells":20489},{"EARLY_PHASE1":20490,"PHASE1":20492,"PHASE2":20494,"PHASE3":20500,"PHASE4":20502,"NA":20504},{"trials":20491,"activeCount":101},[],{"trials":20493,"activeCount":101},[],{"trials":20495,"activeCount":101},[20496],{"nctId":345,"briefTitle":346,"status":347,"phases":20497,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":20498,"interventions":20499},[90],[353,354],[356,96,290],{"trials":20501,"activeCount":101},[],{"trials":20503,"activeCount":101},[],{"trials":20505,"activeCount":101},[],{"intervention":20507,"totalTrials":2548,"cells":20508},"BEAM",{"EARLY_PHASE1":20509,"PHASE1":20511,"PHASE2":20513,"PHASE3":20525,"PHASE4":20527,"NA":20529},{"trials":20510,"activeCount":101},[],{"trials":20512,"activeCount":101},[],{"trials":20514,"activeCount":101},[20515],{"nctId":20516,"briefTitle":20517,"status":618,"phases":20518,"primaryCompletion":2564,"completion":20519,"start":20520,"enrollment":889,"conditions":20521,"interventions":20524},"NCT01468311","Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma",[89,90],"2020-10-22","2011-10-11",[20522,20523],"Hodgkin Disease","Hodgkin Lymphoma",[20507],{"trials":20526,"activeCount":101},[],{"trials":20528,"activeCount":101},[],{"trials":20530,"activeCount":101},[],{"intervention":20532,"totalTrials":2548,"cells":20533},"IFN-alpha with retinoic acid",{"EARLY_PHASE1":20534,"PHASE1":20536,"PHASE2":20538,"PHASE3":20548,"PHASE4":20550,"NA":20552},{"trials":20535,"activeCount":101},[],{"trials":20537,"activeCount":101},[],{"trials":20539,"activeCount":101},[20540],{"nctId":20541,"briefTitle":20542,"status":142,"phases":20543,"completion":3662,"start":20544,"enrollment":1074,"conditions":20545,"interventions":20547},"NCT00001509","A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor",[90],"1996-07",[20546,791],"Nephroblastoma",[20532],{"trials":20549,"activeCount":101},[],{"trials":20551,"activeCount":101},[],{"trials":20553,"activeCount":101},[],{"intervention":6886,"totalTrials":2548,"cells":20555},{"EARLY_PHASE1":20556,"PHASE1":20558,"PHASE2":20560,"PHASE3":20566,"PHASE4":20568,"NA":20570},{"trials":20557,"activeCount":101},[],{"trials":20559,"activeCount":101},[],{"trials":20561,"activeCount":101},[20562],{"nctId":6881,"briefTitle":6882,"status":142,"phases":20563,"primaryCompletion":5985,"completion":5985,"start":4561,"enrollment":1913,"conditions":20564,"interventions":20565},[90],[1812],[6886,2790],{"trials":20567,"activeCount":101},[],{"trials":20569,"activeCount":101},[],{"trials":20571,"activeCount":101},[],{"intervention":11351,"totalTrials":2548,"cells":20573},{"EARLY_PHASE1":20574,"PHASE1":20576,"PHASE2":20578,"PHASE3":20584,"PHASE4":20586,"NA":20588},{"trials":20575,"activeCount":101},[],{"trials":20577,"activeCount":101},[],{"trials":20579,"activeCount":101},[20580],{"nctId":11346,"briefTitle":11347,"status":142,"phases":20581,"completion":3397,"start":6477,"conditions":20582,"interventions":20583},[90],[2490,15],[818,1349,11351],{"trials":20585,"activeCount":101},[],{"trials":20587,"activeCount":101},[],{"trials":20589,"activeCount":101},[],{"intervention":2978,"totalTrials":2548,"cells":20591},{"EARLY_PHASE1":20592,"PHASE1":20594,"PHASE2":20596,"PHASE3":20602,"PHASE4":20604,"NA":20606},{"trials":20593,"activeCount":101},[],{"trials":20595,"activeCount":101},[],{"trials":20597,"activeCount":101},[20598],{"nctId":2970,"briefTitle":2971,"status":107,"phases":20599,"primaryCompletion":2973,"completion":2973,"start":2974,"enrollment":101,"conditions":20600,"interventions":20601},[90],[2976],[1690,2978],{"trials":20603,"activeCount":101},[],{"trials":20605,"activeCount":101},[],{"trials":20607,"activeCount":101},[],{"intervention":1176,"totalTrials":2548,"cells":20609},{"EARLY_PHASE1":20610,"PHASE1":20612,"PHASE2":20614,"PHASE3":20620,"PHASE4":20622,"NA":20624},{"trials":20611,"activeCount":101},[],{"trials":20613,"activeCount":101},[],{"trials":20615,"activeCount":101},[20616],{"nctId":1167,"briefTitle":1168,"status":142,"phases":20617,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":234,"conditions":20618,"interventions":20619},[90],[1174],[1176,279,780,781,63,212,738],{"trials":20621,"activeCount":101},[],{"trials":20623,"activeCount":101},[],{"trials":20625,"activeCount":101},[],{"intervention":14945,"totalTrials":2548,"cells":20627},{"EARLY_PHASE1":20628,"PHASE1":20630,"PHASE2":20632,"PHASE3":20638,"PHASE4":20640,"NA":20642},{"trials":20629,"activeCount":101},[],{"trials":20631,"activeCount":101},[],{"trials":20633,"activeCount":101},[20634],{"nctId":14937,"briefTitle":14938,"status":142,"phases":20635,"primaryCompletion":14940,"completion":14940,"start":14941,"enrollment":28,"conditions":20636,"interventions":20637},[90],[14943,5969],[14945,14946,14947,14948,704,14949,14906,14950],{"trials":20639,"activeCount":101},[],{"trials":20641,"activeCount":101},[],{"trials":20643,"activeCount":101},[],{"intervention":14946,"totalTrials":2548,"cells":20645},{"EARLY_PHASE1":20646,"PHASE1":20648,"PHASE2":20650,"PHASE3":20656,"PHASE4":20658,"NA":20660},{"trials":20647,"activeCount":101},[],{"trials":20649,"activeCount":101},[],{"trials":20651,"activeCount":101},[20652],{"nctId":14937,"briefTitle":14938,"status":142,"phases":20653,"primaryCompletion":14940,"completion":14940,"start":14941,"enrollment":28,"conditions":20654,"interventions":20655},[90],[14943,5969],[14945,14946,14947,14948,704,14949,14906,14950],{"trials":20657,"activeCount":101},[],{"trials":20659,"activeCount":101},[],{"trials":20661,"activeCount":101},[],{"intervention":14947,"totalTrials":2548,"cells":20663},{"EARLY_PHASE1":20664,"PHASE1":20666,"PHASE2":20668,"PHASE3":20674,"PHASE4":20676,"NA":20678},{"trials":20665,"activeCount":101},[],{"trials":20667,"activeCount":101},[],{"trials":20669,"activeCount":101},[20670],{"nctId":14937,"briefTitle":14938,"status":142,"phases":20671,"primaryCompletion":14940,"completion":14940,"start":14941,"enrollment":28,"conditions":20672,"interventions":20673},[90],[14943,5969],[14945,14946,14947,14948,704,14949,14906,14950],{"trials":20675,"activeCount":101},[],{"trials":20677,"activeCount":101},[],{"trials":20679,"activeCount":101},[],{"intervention":14948,"totalTrials":2548,"cells":20681},{"EARLY_PHASE1":20682,"PHASE1":20684,"PHASE2":20686,"PHASE3":20692,"PHASE4":20694,"NA":20696},{"trials":20683,"activeCount":101},[],{"trials":20685,"activeCount":101},[],{"trials":20687,"activeCount":101},[20688],{"nctId":14937,"briefTitle":14938,"status":142,"phases":20689,"primaryCompletion":14940,"completion":14940,"start":14941,"enrollment":28,"conditions":20690,"interventions":20691},[90],[14943,5969],[14945,14946,14947,14948,704,14949,14906,14950],{"trials":20693,"activeCount":101},[],{"trials":20695,"activeCount":101},[],{"trials":20697,"activeCount":101},[],{"intervention":14949,"totalTrials":2548,"cells":20699},{"EARLY_PHASE1":20700,"PHASE1":20702,"PHASE2":20704,"PHASE3":20710,"PHASE4":20712,"NA":20714},{"trials":20701,"activeCount":101},[],{"trials":20703,"activeCount":101},[],{"trials":20705,"activeCount":101},[20706],{"nctId":14937,"briefTitle":14938,"status":142,"phases":20707,"primaryCompletion":14940,"completion":14940,"start":14941,"enrollment":28,"conditions":20708,"interventions":20709},[90],[14943,5969],[14945,14946,14947,14948,704,14949,14906,14950],{"trials":20711,"activeCount":101},[],{"trials":20713,"activeCount":101},[],{"trials":20715,"activeCount":101},[],{"intervention":14950,"totalTrials":2548,"cells":20717},{"EARLY_PHASE1":20718,"PHASE1":20720,"PHASE2":20722,"PHASE3":20728,"PHASE4":20730,"NA":20732},{"trials":20719,"activeCount":101},[],{"trials":20721,"activeCount":101},[],{"trials":20723,"activeCount":101},[20724],{"nctId":14937,"briefTitle":14938,"status":142,"phases":20725,"primaryCompletion":14940,"completion":14940,"start":14941,"enrollment":28,"conditions":20726,"interventions":20727},[90],[14943,5969],[14945,14946,14947,14948,704,14949,14906,14950],{"trials":20729,"activeCount":101},[],{"trials":20731,"activeCount":101},[],{"trials":20733,"activeCount":101},[],{"intervention":1188,"totalTrials":2548,"cells":20735},{"EARLY_PHASE1":20736,"PHASE1":20738,"PHASE2":20740,"PHASE3":20746,"PHASE4":20748,"NA":20750},{"trials":20737,"activeCount":101},[],{"trials":20739,"activeCount":101},[],{"trials":20741,"activeCount":101},[20742],{"nctId":1178,"briefTitle":1179,"status":142,"phases":20743,"primaryCompletion":987,"start":1181,"enrollment":248,"conditions":20744,"interventions":20745},[90],[1183],[1185,1186,819,1187,693,1188],{"trials":20747,"activeCount":101},[],{"trials":20749,"activeCount":101},[],{"trials":20751,"activeCount":101},[],{"intervention":1199,"totalTrials":2548,"cells":20753},{"EARLY_PHASE1":20754,"PHASE1":20756,"PHASE2":20758,"PHASE3":20764,"PHASE4":20766,"NA":20768},{"trials":20755,"activeCount":101},[],{"trials":20757,"activeCount":101},[],{"trials":20759,"activeCount":101},[20760],{"nctId":1190,"briefTitle":1191,"status":142,"phases":20761,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":1195,"conditions":20762,"interventions":20763},[89,90],[960,870,1197,36,18],[1199,63,643,677],{"trials":20765,"activeCount":101},[],{"trials":20767,"activeCount":101},[],{"trials":20769,"activeCount":101},[],{"intervention":20771,"totalTrials":2548,"cells":20772},"Recombinant Fowlpox-GM-CSF",{"EARLY_PHASE1":20773,"PHASE1":20775,"PHASE2":20777,"PHASE3":20791,"PHASE4":20793,"NA":20795},{"trials":20774,"activeCount":101},[],{"trials":20776,"activeCount":101},[],{"trials":20778,"activeCount":101},[20779],{"nctId":20780,"briefTitle":20781,"status":142,"phases":20782,"primaryCompletion":20783,"completion":20784,"start":20785,"enrollment":22,"conditions":20786,"interventions":20787},"NCT00060528","Sequential Vaccinations in Prostate Cancer Patients",[89,90],"2006-03-07","2009-06-08","2003-05-22",[10352],[20771,20788,20789,20790],"Recombinant Fowlpox-PSA","Recombinant Vaccinia-PSA","Recombinant Human GM-CSF",{"trials":20792,"activeCount":101},[],{"trials":20794,"activeCount":101},[],{"trials":20796,"activeCount":101},[],{"intervention":20788,"totalTrials":2548,"cells":20798},{"EARLY_PHASE1":20799,"PHASE1":20801,"PHASE2":20803,"PHASE3":20809,"PHASE4":20811,"NA":20813},{"trials":20800,"activeCount":101},[],{"trials":20802,"activeCount":101},[],{"trials":20804,"activeCount":101},[20805],{"nctId":20780,"briefTitle":20781,"status":142,"phases":20806,"primaryCompletion":20783,"completion":20784,"start":20785,"enrollment":22,"conditions":20807,"interventions":20808},[89,90],[10352],[20771,20788,20789,20790],{"trials":20810,"activeCount":101},[],{"trials":20812,"activeCount":101},[],{"trials":20814,"activeCount":101},[],{"intervention":20789,"totalTrials":2548,"cells":20816},{"EARLY_PHASE1":20817,"PHASE1":20819,"PHASE2":20821,"PHASE3":20827,"PHASE4":20829,"NA":20831},{"trials":20818,"activeCount":101},[],{"trials":20820,"activeCount":101},[],{"trials":20822,"activeCount":101},[20823],{"nctId":20780,"briefTitle":20781,"status":142,"phases":20824,"primaryCompletion":20783,"completion":20784,"start":20785,"enrollment":22,"conditions":20825,"interventions":20826},[89,90],[10352],[20771,20788,20789,20790],{"trials":20828,"activeCount":101},[],{"trials":20830,"activeCount":101},[],{"trials":20832,"activeCount":101},[],{"intervention":20790,"totalTrials":2548,"cells":20834},{"EARLY_PHASE1":20835,"PHASE1":20837,"PHASE2":20839,"PHASE3":20845,"PHASE4":20847,"NA":20849},{"trials":20836,"activeCount":101},[],{"trials":20838,"activeCount":101},[],{"trials":20840,"activeCount":101},[20841],{"nctId":20780,"briefTitle":20781,"status":142,"phases":20842,"primaryCompletion":20783,"completion":20784,"start":20785,"enrollment":22,"conditions":20843,"interventions":20844},[89,90],[10352],[20771,20788,20789,20790],{"trials":20846,"activeCount":101},[],{"trials":20848,"activeCount":101},[],{"trials":20850,"activeCount":101},[],{"intervention":20852,"totalTrials":2548,"cells":20853},"5-Fluoro-2'-Deoxycytidine",{"EARLY_PHASE1":20854,"PHASE1":20856,"PHASE2":20858,"PHASE3":20868,"PHASE4":20870,"NA":20872},{"trials":20855,"activeCount":101},[],{"trials":20857,"activeCount":101},[],{"trials":20859,"activeCount":101},[20860],{"nctId":20861,"briefTitle":20862,"status":142,"phases":20863,"primaryCompletion":20864,"completion":20864,"start":11705,"enrollment":5866,"conditions":20865,"interventions":20867},"NCT00978250","A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)",[90],"2019-04-11",[9164,2718,20866,1291],"Urinary Bladder Neoplasms",[20852],{"trials":20869,"activeCount":101},[],{"trials":20871,"activeCount":101},[],{"trials":20873,"activeCount":101},[],{"intervention":2721,"totalTrials":2548,"cells":20875},{"EARLY_PHASE1":20876,"PHASE1":20878,"PHASE2":20880,"PHASE3":20886,"PHASE4":20888,"NA":20890},{"trials":20877,"activeCount":101},[],{"trials":20879,"activeCount":101},[],{"trials":20881,"activeCount":101},[20882],{"nctId":2710,"briefTitle":2711,"status":142,"phases":20883,"primaryCompletion":2713,"completion":2714,"start":2715,"enrollment":1990,"conditions":20884,"interventions":20885},[89,90],[2717,1197,2718,2719,24],[2721,2722],{"trials":20887,"activeCount":101},[],{"trials":20889,"activeCount":101},[],{"trials":20891,"activeCount":101},[],{"intervention":398,"totalTrials":2548,"cells":20893},{"EARLY_PHASE1":20894,"PHASE1":20896,"PHASE2":20898,"PHASE3":20904,"PHASE4":20906,"NA":20908},{"trials":20895,"activeCount":101},[],{"trials":20897,"activeCount":101},[],{"trials":20899,"activeCount":101},[20900],{"nctId":388,"briefTitle":389,"status":142,"phases":20901,"primaryCompletion":391,"completion":391,"start":392,"enrollment":298,"conditions":20902,"interventions":20903},[90],[394,148,395],[397,398,96,399],{"trials":20905,"activeCount":101},[],{"trials":20907,"activeCount":101},[],{"trials":20909,"activeCount":101},[],{"intervention":399,"totalTrials":2548,"cells":20911},{"EARLY_PHASE1":20912,"PHASE1":20914,"PHASE2":20916,"PHASE3":20922,"PHASE4":20924,"NA":20926},{"trials":20913,"activeCount":101},[],{"trials":20915,"activeCount":101},[],{"trials":20917,"activeCount":101},[20918],{"nctId":388,"briefTitle":389,"status":142,"phases":20919,"primaryCompletion":391,"completion":391,"start":392,"enrollment":298,"conditions":20920,"interventions":20921},[90],[394,148,395],[397,398,96,399],{"trials":20923,"activeCount":101},[],{"trials":20925,"activeCount":101},[],{"trials":20927,"activeCount":101},[],{"intervention":20929,"totalTrials":2548,"cells":20930},"incyclinide",{"EARLY_PHASE1":20931,"PHASE1":20933,"PHASE2":20935,"PHASE3":20943,"PHASE4":20945,"NA":20947},{"trials":20932,"activeCount":101},[],{"trials":20934,"activeCount":101},[],{"trials":20936,"activeCount":101},[20937],{"nctId":20938,"briefTitle":20939,"status":618,"phases":20940,"primaryCompletion":1341,"completion":11556,"start":1276,"enrollment":1111,"conditions":20941,"interventions":20942},"NCT00020683","A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma",[90],[19122,939],[20929,20929],{"trials":20944,"activeCount":101},[],{"trials":20946,"activeCount":101},[],{"trials":20948,"activeCount":101},[],{"intervention":20950,"totalTrials":2548,"cells":20951},"ZACTIMA",{"EARLY_PHASE1":20952,"PHASE1":20954,"PHASE2":20956,"PHASE3":20968,"PHASE4":20970,"NA":20972},{"trials":20953,"activeCount":101},[],{"trials":20955,"activeCount":101},[],{"trials":20957,"activeCount":101},[20958],{"nctId":20959,"briefTitle":20960,"status":142,"phases":20961,"primaryCompletion":20962,"completion":20963,"start":20964,"enrollment":19,"conditions":20965,"interventions":20967},"NCT00566995","Phase II Study of Vandetanib in Individuals With Kidney Cancer",[90],"2014-06-20","2015-03","2008-02-07",[870,20966],"Von Hippel Lindau",[20950],{"trials":20969,"activeCount":101},[],{"trials":20971,"activeCount":101},[],{"trials":20973,"activeCount":101},[],{"intervention":20975,"totalTrials":2548,"cells":20976},"PROSTVAC -V",{"EARLY_PHASE1":20977,"PHASE1":20979,"PHASE2":20981,"PHASE3":20993,"PHASE4":20995,"NA":20997},{"trials":20978,"activeCount":101},[],{"trials":20980,"activeCount":101},[],{"trials":20982,"activeCount":101},[20983],{"nctId":20984,"briefTitle":20985,"status":142,"phases":20986,"primaryCompletion":20987,"completion":20988,"start":20989,"enrollment":1128,"conditions":20990,"interventions":20991},"NCT02649439","Prostvac in Patients With Biochemically Recurrent Prostate Cancer",[90],"2019-03-28","2022-10-01","2015-12-22",[24],[20975,20992],"PROSTVAC-F",{"trials":20994,"activeCount":101},[],{"trials":20996,"activeCount":101},[],{"trials":20998,"activeCount":101},[],{"intervention":20992,"totalTrials":2548,"cells":21000},{"EARLY_PHASE1":21001,"PHASE1":21003,"PHASE2":21005,"PHASE3":21011,"PHASE4":21013,"NA":21015},{"trials":21002,"activeCount":101},[],{"trials":21004,"activeCount":101},[],{"trials":21006,"activeCount":101},[21007],{"nctId":20984,"briefTitle":20985,"status":142,"phases":21008,"primaryCompletion":20987,"completion":20988,"start":20989,"enrollment":1128,"conditions":21009,"interventions":21010},[90],[24],[20975,20992],{"trials":21012,"activeCount":101},[],{"trials":21014,"activeCount":101},[],{"trials":21016,"activeCount":101},[],{"intervention":5971,"totalTrials":2548,"cells":21018},{"EARLY_PHASE1":21019,"PHASE1":21021,"PHASE2":21023,"PHASE3":21029,"PHASE4":21031,"NA":21033},{"trials":21020,"activeCount":101},[],{"trials":21022,"activeCount":101},[],{"trials":21024,"activeCount":101},[21025],{"nctId":5963,"briefTitle":5964,"status":347,"phases":21026,"primaryCompletion":361,"completion":799,"start":5966,"enrollment":609,"conditions":21027,"interventions":21028},[89,90],[5968,5969],[5971,781,151],{"trials":21030,"activeCount":101},[],{"trials":21032,"activeCount":101},[],{"trials":21034,"activeCount":101},[],{"intervention":1983,"totalTrials":2548,"cells":21036},{"EARLY_PHASE1":21037,"PHASE1":21039,"PHASE2":21041,"PHASE3":21047,"PHASE4":21049,"NA":21051},{"trials":21038,"activeCount":101},[],{"trials":21040,"activeCount":101},[],{"trials":21042,"activeCount":101},[21043],{"nctId":1974,"briefTitle":1975,"status":618,"phases":21044,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":248,"conditions":21045,"interventions":21046},[90],[1981,625],[750,1598,1983,994,1264,1268],{"trials":21048,"activeCount":101},[],{"trials":21050,"activeCount":101},[],{"trials":21052,"activeCount":101},[],{"intervention":21054,"totalTrials":2548,"cells":21055},"bromodeoxyuridine",{"EARLY_PHASE1":21056,"PHASE1":21058,"PHASE2":21060,"PHASE3":21068,"PHASE4":21070,"NA":21072},{"trials":21057,"activeCount":101},[],{"trials":21059,"activeCount":101},[],{"trials":21061,"activeCount":101},[21062],{"nctId":21063,"briefTitle":21064,"status":142,"phases":21065,"primaryCompletion":2181,"start":15814,"enrollment":16870,"conditions":21066,"interventions":21067},"NCT00003832","Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer",[90],[16672,16673,16674],[21054],{"trials":21069,"activeCount":101},[],{"trials":21071,"activeCount":101},[],{"trials":21073,"activeCount":101},[],{"intervention":8293,"totalTrials":2548,"cells":21075},{"EARLY_PHASE1":21076,"PHASE1":21078,"PHASE2":21080,"PHASE3":21086,"PHASE4":21088,"NA":21090},{"trials":21077,"activeCount":101},[],{"trials":21079,"activeCount":101},[],{"trials":21081,"activeCount":101},[21082],{"nctId":8285,"briefTitle":8286,"status":347,"phases":21083,"primaryCompletion":8288,"completion":8288,"start":8289,"enrollment":2250,"conditions":21084,"interventions":21085},[90],[8291,197],[8293,1570],{"trials":21087,"activeCount":101},[],{"trials":21089,"activeCount":101},[],{"trials":21091,"activeCount":101},[],{"intervention":15914,"totalTrials":2548,"cells":21093},{"EARLY_PHASE1":21094,"PHASE1":21096,"PHASE2":21098,"PHASE3":21104,"PHASE4":21106,"NA":21108},{"trials":21095,"activeCount":101},[],{"trials":21097,"activeCount":101},[],{"trials":21099,"activeCount":101},[21100],{"nctId":15908,"briefTitle":15909,"status":618,"phases":21101,"primaryCompletion":14867,"completion":15911,"start":1230,"enrollment":685,"conditions":21102,"interventions":21103},[90],[1343,4843],[15914,15915,15916,15917],{"trials":21105,"activeCount":101},[],{"trials":21107,"activeCount":101},[],{"trials":21109,"activeCount":101},[],{"intervention":15915,"totalTrials":2548,"cells":21111},{"EARLY_PHASE1":21112,"PHASE1":21114,"PHASE2":21116,"PHASE3":21122,"PHASE4":21124,"NA":21126},{"trials":21113,"activeCount":101},[],{"trials":21115,"activeCount":101},[],{"trials":21117,"activeCount":101},[21118],{"nctId":15908,"briefTitle":15909,"status":618,"phases":21119,"primaryCompletion":14867,"completion":15911,"start":1230,"enrollment":685,"conditions":21120,"interventions":21121},[90],[1343,4843],[15914,15915,15916,15917],{"trials":21123,"activeCount":101},[],{"trials":21125,"activeCount":101},[],{"trials":21127,"activeCount":101},[],{"intervention":5773,"totalTrials":2548,"cells":21129},{"EARLY_PHASE1":21130,"PHASE1":21132,"PHASE2":21134,"PHASE3":21140,"PHASE4":21142,"NA":21144},{"trials":21131,"activeCount":101},[],{"trials":21133,"activeCount":101},[],{"trials":21135,"activeCount":101},[21136],{"nctId":5768,"briefTitle":5769,"status":107,"phases":21137,"primaryCompletion":2004,"start":3282,"enrollment":101,"conditions":21138,"interventions":21139},[89,90],[1245,1246,3187,3188,3189,3190,1248],[5773,5665,1063],{"trials":21141,"activeCount":101},[],{"trials":21143,"activeCount":101},[],{"trials":21145,"activeCount":101},[],{"intervention":21147,"totalTrials":2548,"cells":21148},"acetylsalicylic acid",{"EARLY_PHASE1":21149,"PHASE1":21151,"PHASE2":21153,"PHASE3":21162,"PHASE4":21164,"NA":21166},{"trials":21150,"activeCount":101},[],{"trials":21152,"activeCount":101},[],{"trials":21154,"activeCount":101},[21155],{"nctId":21156,"briefTitle":21157,"status":142,"phases":21158,"primaryCompletion":3389,"completion":4929,"start":4562,"enrollment":21159,"conditions":21160,"interventions":21161},"NCT00468910","Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer",[90],79,[843,14878,844],[21147],{"trials":21163,"activeCount":101},[],{"trials":21165,"activeCount":101},[],{"trials":21167,"activeCount":101},[],{"intervention":21169,"totalTrials":2548,"cells":21170},"18F-Fluciclatide",{"EARLY_PHASE1":21171,"PHASE1":21173,"PHASE2":21175,"PHASE3":21184,"PHASE4":21186,"NA":21188},{"trials":21172,"activeCount":101},[],{"trials":21174,"activeCount":101},[],{"trials":21176,"activeCount":101},[21177],{"nctId":21178,"briefTitle":21179,"status":107,"phases":21180,"primaryCompletion":5242,"completion":5242,"start":21181,"enrollment":101,"conditions":21182,"interventions":21183},"NCT01633255","[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment",[89,90],"2012-04-18",[719],[21169],{"trials":21185,"activeCount":101},[],{"trials":21187,"activeCount":101},[],{"trials":21189,"activeCount":101},[],{"intervention":3828,"totalTrials":2548,"cells":21191},{"EARLY_PHASE1":21192,"PHASE1":21194,"PHASE2":21196,"PHASE3":21202,"PHASE4":21204,"NA":21206},{"trials":21193,"activeCount":101},[],{"trials":21195,"activeCount":101},[],{"trials":21197,"activeCount":101},[21198],{"nctId":3804,"briefTitle":3805,"status":142,"phases":21199,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":31,"conditions":21200,"interventions":21201},[90],[3811,3812,3813,3814,3815,3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826],[3828,883],{"trials":21203,"activeCount":101},[],{"trials":21205,"activeCount":101},[],{"trials":21207,"activeCount":101},[],{"intervention":21209,"totalTrials":2548,"cells":21210},"Pegylated L-Asparaginase",{"EARLY_PHASE1":21211,"PHASE1":21213,"PHASE2":21215,"PHASE3":21224,"PHASE4":21226,"NA":21228},{"trials":21212,"activeCount":101},[],{"trials":21214,"activeCount":101},[],{"trials":21216,"activeCount":101},[21217],{"nctId":21218,"briefTitle":21219,"status":142,"phases":21220,"primaryCompletion":2017,"completion":2017,"start":1022,"enrollment":214,"conditions":21221,"interventions":21223},"NCT01313078","Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and\u002For Primary Peritoneal Cancer",[90],[16735,16736,21222],"Primary Peritoneal Neoplasms",[21209],{"trials":21225,"activeCount":101},[],{"trials":21227,"activeCount":101},[],{"trials":21229,"activeCount":101},[],{"intervention":14776,"totalTrials":2548,"cells":21231},{"EARLY_PHASE1":21232,"PHASE1":21234,"PHASE2":21236,"PHASE3":21242,"PHASE4":21244,"NA":21246},{"trials":21233,"activeCount":101},[],{"trials":21235,"activeCount":101},[],{"trials":21237,"activeCount":101},[21238],{"nctId":14769,"briefTitle":14770,"status":107,"phases":21239,"primaryCompletion":14772,"completion":14772,"start":14773,"enrollment":101,"conditions":21240,"interventions":21241},[90],[18,2718,1291,687],[1455,14776],{"trials":21243,"activeCount":101},[],{"trials":21245,"activeCount":101},[],{"trials":21247,"activeCount":101},[],{"intervention":7442,"totalTrials":2548,"cells":21249},{"EARLY_PHASE1":21250,"PHASE1":21252,"PHASE2":21254,"PHASE3":21260,"PHASE4":21262,"NA":21264},{"trials":21251,"activeCount":101},[],{"trials":21253,"activeCount":101},[],{"trials":21255,"activeCount":101},[21256],{"nctId":7437,"briefTitle":7438,"status":142,"phases":21257,"primaryCompletion":3479,"completion":4359,"start":987,"enrollment":407,"conditions":21258,"interventions":21259},[89,90],[5127,4983,4941,4942,4943,4944,4945,4946],[7442,1697,5106],{"trials":21261,"activeCount":101},[],{"trials":21263,"activeCount":101},[],{"trials":21265,"activeCount":101},[],{"intervention":21267,"totalTrials":2548,"cells":21268},"Ketorolac Rinse",{"EARLY_PHASE1":21269,"PHASE1":21271,"PHASE2":21273,"PHASE3":21284,"PHASE4":21286,"NA":21288},{"trials":21270,"activeCount":101},[],{"trials":21272,"activeCount":101},[],{"trials":21274,"activeCount":101},[21275],{"nctId":21276,"briefTitle":21277,"status":142,"phases":21278,"completion":1257,"start":21279,"enrollment":2294,"conditions":21280,"interventions":21283},"NCT00001698","Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR",[90],"1998-06",[21281,21282],"Leukoplakia","Periodontal Disease",[21267],{"trials":21285,"activeCount":101},[],{"trials":21287,"activeCount":101},[],{"trials":21289,"activeCount":101},[],{"intervention":475,"totalTrials":2548,"cells":21291},{"EARLY_PHASE1":21292,"PHASE1":21294,"PHASE2":21296,"PHASE3":21302,"PHASE4":21304,"NA":21306},{"trials":21293,"activeCount":101},[],{"trials":21295,"activeCount":101},[],{"trials":21297,"activeCount":101},[21298],{"nctId":462,"briefTitle":463,"status":107,"phases":21299,"primaryCompletion":465,"completion":465,"start":465,"enrollment":101,"conditions":21300,"interventions":21301},[89,90],[467,468,469,470,471,472],[96,474,475,476],{"trials":21303,"activeCount":101},[],{"trials":21305,"activeCount":101},[],{"trials":21307,"activeCount":101},[],{"intervention":21309,"totalTrials":2548,"cells":21310},"F-18 NaF",{"EARLY_PHASE1":21311,"PHASE1":21313,"PHASE2":21315,"PHASE3":21326,"PHASE4":21328,"NA":21330},{"trials":21312,"activeCount":101},[],{"trials":21314,"activeCount":101},[],{"trials":21316,"activeCount":101},[21317],{"nctId":21318,"briefTitle":21319,"status":142,"phases":21320,"primaryCompletion":21321,"completion":21321,"start":21322,"enrollment":1074,"conditions":21323,"interventions":21325},"NCT01240551","F-18 Sodium Fluoride in Prostate Cancer",[90],"2013-05-31","2010-11-30",[21324],"Prostate Neoplasm",[21309],{"trials":21327,"activeCount":101},[],{"trials":21329,"activeCount":101},[],{"trials":21331,"activeCount":101},[],{"intervention":21333,"totalTrials":2548,"cells":21334},"HPV 16 E7:12-20",{"EARLY_PHASE1":21335,"PHASE1":21337,"PHASE2":21339,"PHASE3":21354,"PHASE4":21356,"NA":21358},{"trials":21336,"activeCount":101},[],{"trials":21338,"activeCount":101},[],{"trials":21340,"activeCount":101},[21341],{"nctId":21342,"briefTitle":21343,"status":142,"phases":21344,"primaryCompletion":1216,"completion":1216,"start":5124,"enrollment":700,"conditions":21345,"interventions":21352},"NCT00003895","Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma",[90],[1343,21346,21347,21348,21349,21350,21351,13738,13739],"Stage IA Melanoma","Stage IB Melanoma","Stage IIA Melanoma","Stage IIB Melanoma","Stage IIC Melanoma","Stage IIIA Melanoma",[21333,21353],"gp100:209-217",{"trials":21355,"activeCount":101},[],{"trials":21357,"activeCount":101},[],{"trials":21359,"activeCount":101},[],{"intervention":21353,"totalTrials":2548,"cells":21361},{"EARLY_PHASE1":21362,"PHASE1":21364,"PHASE2":21366,"PHASE3":21372,"PHASE4":21374,"NA":21376},{"trials":21363,"activeCount":101},[],{"trials":21365,"activeCount":101},[],{"trials":21367,"activeCount":101},[21368],{"nctId":21342,"briefTitle":21343,"status":142,"phases":21369,"primaryCompletion":1216,"completion":1216,"start":5124,"enrollment":700,"conditions":21370,"interventions":21371},[90],[1343,21346,21347,21348,21349,21350,21351,13738,13739],[21333,21353],{"trials":21373,"activeCount":101},[],{"trials":21375,"activeCount":101},[],{"trials":21377,"activeCount":101},[],{"intervention":1999,"totalTrials":2548,"cells":21379},{"EARLY_PHASE1":21380,"PHASE1":21382,"PHASE2":21384,"PHASE3":21390,"PHASE4":21392,"NA":21394},{"trials":21381,"activeCount":101},[],{"trials":21383,"activeCount":101},[],{"trials":21385,"activeCount":101},[21386],{"nctId":1985,"briefTitle":1986,"status":142,"phases":21387,"primaryCompletion":649,"completion":1988,"start":1989,"enrollment":1990,"conditions":21388,"interventions":21389},[90],[1579,1992,1584,1993,1587,1994,1589,1995,1591,1996],[1598,1998,1999],{"trials":21391,"activeCount":101},[],{"trials":21393,"activeCount":101},[],{"trials":21395,"activeCount":101},[],{"intervention":21397,"totalTrials":2548,"cells":21398},"aminocamptothecin",{"EARLY_PHASE1":21399,"PHASE1":21401,"PHASE2":21403,"PHASE3":21412,"PHASE4":21414,"NA":21416},{"trials":21400,"activeCount":101},[],{"trials":21402,"activeCount":101},[],{"trials":21404,"activeCount":101},[21405],{"nctId":21406,"briefTitle":21407,"status":142,"phases":21408,"primaryCompletion":3273,"completion":1231,"start":21409,"enrollment":19,"conditions":21410,"interventions":21411},"NCT00002745","Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma",[90],"1996-04",[27],[21397],{"trials":21413,"activeCount":101},[],{"trials":21415,"activeCount":101},[],{"trials":21417,"activeCount":101},[],{"intervention":21419,"totalTrials":2548,"cells":21420},"rebimastat",{"EARLY_PHASE1":21421,"PHASE1":21423,"PHASE2":21425,"PHASE3":21433,"PHASE4":21435,"NA":21437},{"trials":21422,"activeCount":101},[],{"trials":21424,"activeCount":101},[],{"trials":21426,"activeCount":101},[21427],{"nctId":21428,"briefTitle":21429,"status":142,"phases":21430,"primaryCompletion":5057,"start":14500,"enrollment":2280,"conditions":21431,"interventions":21432},"NCT00024024","BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma",[89,90],[625],[21419],{"trials":21434,"activeCount":101},[],{"trials":21436,"activeCount":101},[],{"trials":21438,"activeCount":101},[],{"intervention":21440,"totalTrials":2548,"cells":21441},"Ruxolitinib",{"EARLY_PHASE1":21442,"PHASE1":21444,"PHASE2":21446,"PHASE3":21459,"PHASE4":21461,"NA":21463},{"trials":21443,"activeCount":101},[],{"trials":21445,"activeCount":101},[],{"trials":21447,"activeCount":101},[21448],{"nctId":21449,"briefTitle":21450,"status":618,"phases":21451,"primaryCompletion":21452,"completion":21453,"start":21454,"enrollment":3255,"conditions":21455,"interventions":21458},"NCT01712659","Ruxolitinib for Adult T-Cell Leukemia",[89,90],"2021-11-12","2022-01-18","2012-10-26",[21456,19309,21457],"T Cell Leukemia, Adult","T Cell Leukemia, HTLV I Associated",[21440,21440,21440,21440],{"trials":21460,"activeCount":101},[],{"trials":21462,"activeCount":101},[],{"trials":21464,"activeCount":101},[],{"intervention":21466,"totalTrials":2548,"cells":21467},"Mithramycin",{"EARLY_PHASE1":21468,"PHASE1":21470,"PHASE2":21472,"PHASE3":21483,"PHASE4":21485,"NA":21487},{"trials":21469,"activeCount":101},[],{"trials":21471,"activeCount":101},[],{"trials":21473,"activeCount":101},[21474],{"nctId":21475,"briefTitle":21476,"status":618,"phases":21477,"primaryCompletion":21478,"completion":21478,"start":21479,"enrollment":771,"conditions":21480,"interventions":21482},"NCT01610570","Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma",[89,90],"2014-05-21","2012-05-10",[21481,625],"Ewing Sarcoma",[21466],{"trials":21484,"activeCount":101},[],{"trials":21486,"activeCount":101},[],{"trials":21488,"activeCount":101},[],{"intervention":21490,"totalTrials":2548,"cells":21491},"HspE7",{"EARLY_PHASE1":21492,"PHASE1":21494,"PHASE2":21496,"PHASE3":21506,"PHASE4":21508,"NA":21510},{"trials":21493,"activeCount":101},[],{"trials":21495,"activeCount":101},[],{"trials":21497,"activeCount":101},[21498],{"nctId":21499,"briefTitle":21500,"status":142,"phases":21501,"primaryCompletion":1340,"start":1257,"enrollment":13282,"conditions":21502,"interventions":21505},"NCT00054041","Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia",[90],[960,21503,21504],"Cervical Intraepithelial Neoplasia Grade 3","Human Papilloma Virus Infection",[21490],{"trials":21507,"activeCount":101},[],{"trials":21509,"activeCount":101},[],{"trials":21511,"activeCount":101},[],{"intervention":1234,"totalTrials":2548,"cells":21513},{"EARLY_PHASE1":21514,"PHASE1":21516,"PHASE2":21518,"PHASE3":21524,"PHASE4":21526,"NA":21528},{"trials":21515,"activeCount":101},[],{"trials":21517,"activeCount":101},[],{"trials":21519,"activeCount":101},[21520],{"nctId":1227,"briefTitle":1228,"status":618,"phases":21521,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":603,"conditions":21522,"interventions":21523},[90],[195,891],[693,819,677,1234,1235],{"trials":21525,"activeCount":101},[],{"trials":21527,"activeCount":101},[],{"trials":21529,"activeCount":101},[],{"intervention":1235,"totalTrials":2548,"cells":21531},{"EARLY_PHASE1":21532,"PHASE1":21534,"PHASE2":21536,"PHASE3":21542,"PHASE4":21544,"NA":21546},{"trials":21533,"activeCount":101},[],{"trials":21535,"activeCount":101},[],{"trials":21537,"activeCount":101},[21538],{"nctId":1227,"briefTitle":1228,"status":618,"phases":21539,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":603,"conditions":21540,"interventions":21541},[90],[195,891],[693,819,677,1234,1235],{"trials":21543,"activeCount":101},[],{"trials":21545,"activeCount":101},[],{"trials":21547,"activeCount":101},[],{"intervention":21549,"totalTrials":2548,"cells":21550},"Inositol",{"EARLY_PHASE1":21551,"PHASE1":21553,"PHASE2":21555,"PHASE3":21567,"PHASE4":21569,"NA":21571},{"trials":21552,"activeCount":101},[],{"trials":21554,"activeCount":101},[],{"trials":21556,"activeCount":101},[21557],{"nctId":21558,"briefTitle":21559,"status":618,"phases":21560,"primaryCompletion":4811,"completion":4811,"start":3282,"enrollment":838,"conditions":21561,"interventions":21566},"NCT01111292","Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia",[89,90],[21562,21563,21564,21565],"Colon Carcinoma","Dysplasia in Crohn Disease","Low Grade Dysplasia in Ulcerative Colitis","Rectal Carcinoma",[21549],{"trials":21568,"activeCount":101},[],{"trials":21570,"activeCount":101},[],{"trials":21572,"activeCount":101},[],{"intervention":1265,"totalTrials":2548,"cells":21574},{"EARLY_PHASE1":21575,"PHASE1":21577,"PHASE2":21579,"PHASE3":21585,"PHASE4":21587,"NA":21589},{"trials":21576,"activeCount":101},[],{"trials":21578,"activeCount":101},[],{"trials":21580,"activeCount":101},[21581],{"nctId":1254,"briefTitle":1255,"status":142,"phases":21582,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":21583,"interventions":21584},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"trials":21586,"activeCount":101},[],{"trials":21588,"activeCount":101},[],{"trials":21590,"activeCount":101},[],{"intervention":1269,"totalTrials":2548,"cells":21592},{"EARLY_PHASE1":21593,"PHASE1":21595,"PHASE2":21597,"PHASE3":21603,"PHASE4":21605,"NA":21607},{"trials":21594,"activeCount":101},[],{"trials":21596,"activeCount":101},[],{"trials":21598,"activeCount":101},[21599],{"nctId":1254,"briefTitle":1255,"status":142,"phases":21600,"primaryCompletion":1257,"start":1258,"enrollment":286,"conditions":21601,"interventions":21602},[90],[1260],[750,1262,693,1263,1065,1080,1264,1265,1266,1267,1268,1269,1270,1032],{"trials":21604,"activeCount":101},[],{"trials":21606,"activeCount":101},[],{"trials":21608,"activeCount":101},[],{"intervention":5513,"totalTrials":2548,"cells":21610},{"EARLY_PHASE1":21611,"PHASE1":21613,"PHASE2":21615,"PHASE3":21621,"PHASE4":21623,"NA":21625},{"trials":21612,"activeCount":101},[],{"trials":21614,"activeCount":101},[],{"trials":21616,"activeCount":101},[21617],{"nctId":5505,"briefTitle":5506,"status":142,"phases":21618,"primaryCompletion":1320,"start":3390,"enrollment":1913,"conditions":21619,"interventions":21620},[90],[5509,5510,5511],[5513,1033],{"trials":21622,"activeCount":101},[],{"trials":21624,"activeCount":101},[],{"trials":21626,"activeCount":101},[],{"intervention":4421,"totalTrials":2548,"cells":21628},{"EARLY_PHASE1":21629,"PHASE1":21631,"PHASE2":21633,"PHASE3":21639,"PHASE4":21641,"NA":21643},{"trials":21630,"activeCount":101},[],{"trials":21632,"activeCount":101},[],{"trials":21634,"activeCount":101},[21635],{"nctId":4408,"briefTitle":4409,"status":142,"phases":21636,"primaryCompletion":3789,"completion":4411,"start":4412,"enrollment":623,"conditions":21637,"interventions":21638},[89,90],[4414,4415,4416,1503,4417,4418,1504,4419,1505,1506,1508,939],[1511,4421,737,4422],{"trials":21640,"activeCount":101},[],{"trials":21642,"activeCount":101},[],{"trials":21644,"activeCount":101},[],{"intervention":1304,"totalTrials":2548,"cells":21646},{"EARLY_PHASE1":21647,"PHASE1":21649,"PHASE2":21651,"PHASE3":21657,"PHASE4":21659,"NA":21661},{"trials":21648,"activeCount":101},[],{"trials":21650,"activeCount":101},[],{"trials":21652,"activeCount":101},[21653],{"nctId":1296,"briefTitle":1297,"status":618,"phases":21654,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":19,"conditions":21655,"interventions":21656},[89,90],[1291,1302],[991,1304,750,993,693,994,819,995,722],{"trials":21658,"activeCount":101},[],{"trials":21660,"activeCount":101},[],{"trials":21662,"activeCount":101},[],{"intervention":1313,"totalTrials":2548,"cells":21664},{"EARLY_PHASE1":21665,"PHASE1":21667,"PHASE2":21669,"PHASE3":21675,"PHASE4":21677,"NA":21679},{"trials":21666,"activeCount":101},[],{"trials":21668,"activeCount":101},[],{"trials":21670,"activeCount":101},[21671],{"nctId":1306,"briefTitle":1307,"status":142,"phases":21672,"primaryCompletion":1309,"completion":1310,"start":715,"enrollment":34,"conditions":21673,"interventions":21674},[90],[195],[1313,63,704,643],{"trials":21676,"activeCount":101},[],{"trials":21678,"activeCount":101},[],{"trials":21680,"activeCount":101},[],{"intervention":21682,"totalTrials":2548,"cells":21683},"Saliva sample collection",{"EARLY_PHASE1":21684,"PHASE1":21686,"PHASE2":21688,"PHASE3":21698,"PHASE4":21700,"NA":21702},{"trials":21685,"activeCount":101},[],{"trials":21687,"activeCount":101},[],{"trials":21689,"activeCount":101},[21690],{"nctId":21691,"briefTitle":21692,"status":142,"phases":21693,"primaryCompletion":3038,"completion":3038,"start":21694,"enrollment":14886,"conditions":21695,"interventions":21697},"NCT04301089","Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients",[90],"2021-03-18",[21696],"Anxiety",[21682],{"trials":21699,"activeCount":101},[],{"trials":21701,"activeCount":101},[],{"trials":21703,"activeCount":101},[],{"intervention":11378,"totalTrials":2548,"cells":21705},{"EARLY_PHASE1":21706,"PHASE1":21708,"PHASE2":21710,"PHASE3":21716,"PHASE4":21718,"NA":21720},{"trials":21707,"activeCount":101},[],{"trials":21709,"activeCount":101},[],{"trials":21711,"activeCount":101},[21712],{"nctId":11373,"briefTitle":11374,"status":142,"phases":21713,"primaryCompletion":2004,"completion":2004,"start":650,"enrollment":188,"conditions":21714,"interventions":21715},[90],[891,36,195],[677,11378],{"trials":21717,"activeCount":101},[],{"trials":21719,"activeCount":101},[],{"trials":21721,"activeCount":101},[],{"intervention":21723,"totalTrials":2548,"cells":21724},"Recombinant human interleukin-10",{"EARLY_PHASE1":21725,"PHASE1":21727,"PHASE2":21729,"PHASE3":21737,"PHASE4":21739,"NA":21741},{"trials":21726,"activeCount":101},[],{"trials":21728,"activeCount":101},[],{"trials":21730,"activeCount":101},[21731],{"nctId":21732,"briefTitle":21733,"status":142,"phases":21734,"completion":5004,"start":1356,"enrollment":700,"conditions":21735,"interventions":21736},"NCT00001797","Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis",[90],[19379],[21723],{"trials":21738,"activeCount":101},[],{"trials":21740,"activeCount":101},[],{"trials":21742,"activeCount":101},[],{"intervention":9166,"totalTrials":2548,"cells":21744},{"EARLY_PHASE1":21745,"PHASE1":21747,"PHASE2":21749,"PHASE3":21755,"PHASE4":21757,"NA":21759},{"trials":21746,"activeCount":101},[],{"trials":21748,"activeCount":101},[],{"trials":21750,"activeCount":101},[21751],{"nctId":9159,"briefTitle":9160,"status":142,"phases":21752,"primaryCompletion":9162,"completion":2813,"start":9151,"enrollment":1195,"conditions":21753,"interventions":21754},[89,90],[1564,9164],[2256,9166,9167],{"trials":21756,"activeCount":101},[],{"trials":21758,"activeCount":101},[],{"trials":21760,"activeCount":101},[],{"intervention":9167,"totalTrials":2548,"cells":21762},{"EARLY_PHASE1":21763,"PHASE1":21765,"PHASE2":21767,"PHASE3":21773,"PHASE4":21775,"NA":21777},{"trials":21764,"activeCount":101},[],{"trials":21766,"activeCount":101},[],{"trials":21768,"activeCount":101},[21769],{"nctId":9159,"briefTitle":9160,"status":142,"phases":21770,"primaryCompletion":9162,"completion":2813,"start":9151,"enrollment":1195,"conditions":21771,"interventions":21772},[89,90],[1564,9164],[2256,9166,9167],{"trials":21774,"activeCount":101},[],{"trials":21776,"activeCount":101},[],{"trials":21778,"activeCount":101},[],{"intervention":21780,"totalTrials":2548,"cells":21781},"Vemurafenib",{"EARLY_PHASE1":21782,"PHASE1":21784,"PHASE2":21786,"PHASE3":21801,"PHASE4":21803,"NA":21805},{"trials":21783,"activeCount":101},[],{"trials":21785,"activeCount":101},[],{"trials":21787,"activeCount":101},[21788],{"nctId":21789,"briefTitle":21790,"status":142,"phases":21791,"primaryCompletion":19768,"completion":1961,"start":3007,"enrollment":214,"conditions":21792,"interventions":21800},"NCT03220035","Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)",[90],[21,21793,21794,5849,21481,21795,21796,21797,395,790,1028,21798,21799,116,117,30,120,4539,121,19071,5969,11763,12751],"Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma","Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma","Hepatoblastoma","Langerhans Cell Histiocytosis","Malignant Germ Cell Tumor","Recurrent Childhood Central Nervous System Neoplasm","Recurrent Childhood Non-Hodgkin Lymphoma",[21780],{"trials":21802,"activeCount":101},[],{"trials":21804,"activeCount":101},[],{"trials":21806,"activeCount":101},[],{"intervention":3666,"totalTrials":2548,"cells":21808},{"EARLY_PHASE1":21809,"PHASE1":21811,"PHASE2":21813,"PHASE3":21819,"PHASE4":21821,"NA":21823},{"trials":21810,"activeCount":101},[],{"trials":21812,"activeCount":101},[],{"trials":21814,"activeCount":101},[21815],{"nctId":3659,"briefTitle":3660,"status":142,"phases":21816,"primaryCompletion":1977,"completion":1217,"start":3662,"enrollment":1074,"conditions":21817,"interventions":21818},[90],[3664],[1776,3666],{"trials":21820,"activeCount":101},[],{"trials":21822,"activeCount":101},[],{"trials":21824,"activeCount":101},[],{"intervention":21826,"totalTrials":2548,"cells":21827},"IMC-12",{"EARLY_PHASE1":21828,"PHASE1":21830,"PHASE2":21832,"PHASE3":21842,"PHASE4":21844,"NA":21846},{"trials":21829,"activeCount":101},[],{"trials":21831,"activeCount":101},[],{"trials":21833,"activeCount":101},[21834],{"nctId":21835,"briefTitle":21836,"status":142,"phases":21837,"primaryCompletion":4878,"completion":1089,"start":1021,"enrollment":3800,"conditions":21838,"interventions":21841},"NCT00965250","Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy",[90],[10720,690,21839,21840],"Thymic Carcinoid","Thymic Neuroendocrine Tumors",[21826],{"trials":21843,"activeCount":101},[],{"trials":21845,"activeCount":101},[],{"trials":21847,"activeCount":101},[],{"intervention":21849,"totalTrials":2548,"cells":21850},"preoperative dose intense chemotherapy",{"EARLY_PHASE1":21851,"PHASE1":21853,"PHASE2":21855,"PHASE3":21865,"PHASE4":21867,"NA":21869},{"trials":21852,"activeCount":101},[],{"trials":21854,"activeCount":101},[],{"trials":21856,"activeCount":101},[21857],{"nctId":21858,"briefTitle":21859,"status":142,"phases":21860,"completion":16071,"start":21861,"enrollment":13066,"conditions":21862,"interventions":21864},"NCT00001250","Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial",[90],"1989-12",[21863,7088],"Breast Neoplasm",[21849],{"trials":21866,"activeCount":101},[],{"trials":21868,"activeCount":101},[],{"trials":21870,"activeCount":101},[],{"intervention":1323,"totalTrials":2548,"cells":21872},{"EARLY_PHASE1":21873,"PHASE1":21875,"PHASE2":21877,"PHASE3":21883,"PHASE4":21885,"NA":21887},{"trials":21874,"activeCount":101},[],{"trials":21876,"activeCount":101},[],{"trials":21878,"activeCount":101},[21879],{"nctId":1315,"briefTitle":1316,"status":142,"phases":21880,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":339,"conditions":21881,"interventions":21882},[90],[36,891],[1323,63,643,677,1324],{"trials":21884,"activeCount":101},[],{"trials":21886,"activeCount":101},[],{"trials":21888,"activeCount":101},[],{"intervention":1324,"totalTrials":2548,"cells":21890},{"EARLY_PHASE1":21891,"PHASE1":21893,"PHASE2":21895,"PHASE3":21901,"PHASE4":21903,"NA":21905},{"trials":21892,"activeCount":101},[],{"trials":21894,"activeCount":101},[],{"trials":21896,"activeCount":101},[21897],{"nctId":1315,"briefTitle":1316,"status":142,"phases":21898,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":339,"conditions":21899,"interventions":21900},[90],[36,891],[1323,63,643,677,1324],{"trials":21902,"activeCount":101},[],{"trials":21904,"activeCount":101},[],{"trials":21906,"activeCount":101},[],{"intervention":8886,"totalTrials":2548,"cells":21908},{"EARLY_PHASE1":21909,"PHASE1":21911,"PHASE2":21913,"PHASE3":21919,"PHASE4":21921,"NA":21923},{"trials":21910,"activeCount":101},[],{"trials":21912,"activeCount":101},[],{"trials":21914,"activeCount":101},[21915],{"nctId":8878,"briefTitle":8879,"status":142,"phases":21916,"primaryCompletion":8881,"completion":1010,"start":8882,"enrollment":685,"conditions":21917,"interventions":21918},[90],[8884],[58,8886,8887,8888,8889,8890,8891,8892],{"trials":21920,"activeCount":101},[],{"trials":21922,"activeCount":101},[],{"trials":21924,"activeCount":101},[],{"intervention":8888,"totalTrials":2548,"cells":21926},{"EARLY_PHASE1":21927,"PHASE1":21929,"PHASE2":21931,"PHASE3":21937,"PHASE4":21939,"NA":21941},{"trials":21928,"activeCount":101},[],{"trials":21930,"activeCount":101},[],{"trials":21932,"activeCount":101},[21933],{"nctId":8878,"briefTitle":8879,"status":142,"phases":21934,"primaryCompletion":8881,"completion":1010,"start":8882,"enrollment":685,"conditions":21935,"interventions":21936},[90],[8884],[58,8886,8887,8888,8889,8890,8891,8892],{"trials":21938,"activeCount":101},[],{"trials":21940,"activeCount":101},[],{"trials":21942,"activeCount":101},[],{"intervention":8889,"totalTrials":2548,"cells":21944},{"EARLY_PHASE1":21945,"PHASE1":21947,"PHASE2":21949,"PHASE3":21955,"PHASE4":21957,"NA":21959},{"trials":21946,"activeCount":101},[],{"trials":21948,"activeCount":101},[],{"trials":21950,"activeCount":101},[21951],{"nctId":8878,"briefTitle":8879,"status":142,"phases":21952,"primaryCompletion":8881,"completion":1010,"start":8882,"enrollment":685,"conditions":21953,"interventions":21954},[90],[8884],[58,8886,8887,8888,8889,8890,8891,8892],{"trials":21956,"activeCount":101},[],{"trials":21958,"activeCount":101},[],{"trials":21960,"activeCount":101},[],{"intervention":8890,"totalTrials":2548,"cells":21962},{"EARLY_PHASE1":21963,"PHASE1":21965,"PHASE2":21967,"PHASE3":21973,"PHASE4":21975,"NA":21977},{"trials":21964,"activeCount":101},[],{"trials":21966,"activeCount":101},[],{"trials":21968,"activeCount":101},[21969],{"nctId":8878,"briefTitle":8879,"status":142,"phases":21970,"primaryCompletion":8881,"completion":1010,"start":8882,"enrollment":685,"conditions":21971,"interventions":21972},[90],[8884],[58,8886,8887,8888,8889,8890,8891,8892],{"trials":21974,"activeCount":101},[],{"trials":21976,"activeCount":101},[],{"trials":21978,"activeCount":101},[],{"intervention":8891,"totalTrials":2548,"cells":21980},{"EARLY_PHASE1":21981,"PHASE1":21983,"PHASE2":21985,"PHASE3":21991,"PHASE4":21993,"NA":21995},{"trials":21982,"activeCount":101},[],{"trials":21984,"activeCount":101},[],{"trials":21986,"activeCount":101},[21987],{"nctId":8878,"briefTitle":8879,"status":142,"phases":21988,"primaryCompletion":8881,"completion":1010,"start":8882,"enrollment":685,"conditions":21989,"interventions":21990},[90],[8884],[58,8886,8887,8888,8889,8890,8891,8892],{"trials":21992,"activeCount":101},[],{"trials":21994,"activeCount":101},[],{"trials":21996,"activeCount":101},[],{"intervention":8892,"totalTrials":2548,"cells":21998},{"EARLY_PHASE1":21999,"PHASE1":22001,"PHASE2":22003,"PHASE3":22009,"PHASE4":22011,"NA":22013},{"trials":22000,"activeCount":101},[],{"trials":22002,"activeCount":101},[],{"trials":22004,"activeCount":101},[22005],{"nctId":8878,"briefTitle":8879,"status":142,"phases":22006,"primaryCompletion":8881,"completion":1010,"start":8882,"enrollment":685,"conditions":22007,"interventions":22008},[90],[8884],[58,8886,8887,8888,8889,8890,8891,8892],{"trials":22010,"activeCount":101},[],{"trials":22012,"activeCount":101},[],{"trials":22014,"activeCount":101},[],{"intervention":22016,"totalTrials":2548,"cells":22017},"Autologus elutriated monocyte placebo vaccine",{"EARLY_PHASE1":22018,"PHASE1":22020,"PHASE2":22022,"PHASE3":22033,"PHASE4":22035,"NA":22037},{"trials":22019,"activeCount":101},[],{"trials":22021,"activeCount":101},[],{"trials":22023,"activeCount":101},[22024],{"nctId":22025,"briefTitle":22026,"status":618,"phases":22027,"primaryCompletion":22028,"completion":22028,"start":22029,"enrollment":1024,"conditions":22030,"interventions":22031},"NCT02362451","Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer",[90],"2020-02-13","2015-07-10",[10352,24],[22016,22032],"Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine",{"trials":22034,"activeCount":101},[],{"trials":22036,"activeCount":101},[],{"trials":22038,"activeCount":101},[],{"intervention":22032,"totalTrials":2548,"cells":22040},{"EARLY_PHASE1":22041,"PHASE1":22043,"PHASE2":22045,"PHASE3":22051,"PHASE4":22053,"NA":22055},{"trials":22042,"activeCount":101},[],{"trials":22044,"activeCount":101},[],{"trials":22046,"activeCount":101},[22047],{"nctId":22025,"briefTitle":22026,"status":618,"phases":22048,"primaryCompletion":22028,"completion":22028,"start":22029,"enrollment":1024,"conditions":22049,"interventions":22050},[90],[10352,24],[22016,22032],{"trials":22052,"activeCount":101},[],{"trials":22054,"activeCount":101},[],{"trials":22056,"activeCount":101},[],{"intervention":3841,"totalTrials":2548,"cells":22058},{"EARLY_PHASE1":22059,"PHASE1":22061,"PHASE2":22063,"PHASE3":22069,"PHASE4":22071,"NA":22073},{"trials":22060,"activeCount":101},[],{"trials":22062,"activeCount":101},[],{"trials":22064,"activeCount":101},[22065],{"nctId":3830,"briefTitle":3831,"status":107,"phases":22066,"primaryCompletion":3833,"completion":3833,"start":3833,"enrollment":101,"conditions":22067,"interventions":22068},[89,90],[3835,3836,687,3837,3838,1564],[3840,3841],{"trials":22070,"activeCount":101},[],{"trials":22072,"activeCount":101},[],{"trials":22074,"activeCount":101},[],{"intervention":5797,"totalTrials":2548,"cells":22076},{"EARLY_PHASE1":22077,"PHASE1":22079,"PHASE2":22081,"PHASE3":22087,"PHASE4":22089,"NA":22091},{"trials":22078,"activeCount":101},[],{"trials":22080,"activeCount":101},[],{"trials":22082,"activeCount":101},[22083],{"nctId":5787,"briefTitle":5788,"status":142,"phases":22084,"primaryCompletion":5790,"completion":5791,"start":5792,"enrollment":2265,"conditions":22085,"interventions":22086},[90],[5794,5795],[667,5758,1569,1569,5797],{"trials":22088,"activeCount":101},[],{"trials":22090,"activeCount":101},[],{"trials":22092,"activeCount":101},[],{"intervention":5577,"totalTrials":2548,"cells":22094},{"EARLY_PHASE1":22095,"PHASE1":22097,"PHASE2":22099,"PHASE3":22105,"PHASE4":22107,"NA":22109},{"trials":22096,"activeCount":101},[],{"trials":22098,"activeCount":101},[],{"trials":22100,"activeCount":101},[22101],{"nctId":5566,"briefTitle":5567,"status":618,"phases":22102,"primaryCompletion":1604,"completion":1604,"start":5569,"enrollment":28,"conditions":22103,"interventions":22104},[90],[5571,5572,5573,5574,856],[5576,5577,53,5578,4966,2925,2924,5578],{"trials":22106,"activeCount":101},[],{"trials":22108,"activeCount":101},[],{"trials":22110,"activeCount":101},[],{"intervention":2034,"totalTrials":2548,"cells":22112},{"EARLY_PHASE1":22113,"PHASE1":22115,"PHASE2":22117,"PHASE3":22123,"PHASE4":22125,"NA":22127},{"trials":22114,"activeCount":101},[],{"trials":22116,"activeCount":101},[],{"trials":22118,"activeCount":101},[22119],{"nctId":2023,"briefTitle":2024,"status":142,"phases":22120,"primaryCompletion":2026,"completion":2027,"start":2028,"enrollment":2029,"conditions":22121,"interventions":22122},[89,90],[2031,2032],[2034,278],{"trials":22124,"activeCount":101},[],{"trials":22126,"activeCount":101},[],{"trials":22128,"activeCount":101},[],{"intervention":22130,"totalTrials":2548,"cells":22131},"lovastatin",{"EARLY_PHASE1":22132,"PHASE1":22134,"PHASE2":22136,"PHASE3":22147,"PHASE4":22149,"NA":22151},{"trials":22133,"activeCount":101},[],{"trials":22135,"activeCount":101},[],{"trials":22137,"activeCount":101},[22138],{"nctId":22139,"briefTitle":22140,"status":142,"phases":22141,"primaryCompletion":3155,"completion":4561,"start":1053,"enrollment":2319,"conditions":22142,"interventions":22146},"NCT00462280","Lovastatin in Treating Patients At High Risk of Melanoma",[90],[14878,22143,22144,22145],"Stage 0 Melanoma","Stage I Melanoma","Stage II Melanoma",[22130],{"trials":22148,"activeCount":101},[],{"trials":22150,"activeCount":101},[],{"trials":22152,"activeCount":101},[],{"intervention":3850,"totalTrials":2548,"cells":22154},{"EARLY_PHASE1":22155,"PHASE1":22157,"PHASE2":22159,"PHASE3":22165,"PHASE4":22167,"NA":22169},{"trials":22156,"activeCount":101},[],{"trials":22158,"activeCount":101},[],{"trials":22160,"activeCount":101},[22161],{"nctId":3843,"briefTitle":3844,"status":618,"phases":22162,"primaryCompletion":3846,"completion":3846,"start":3847,"enrollment":443,"conditions":22163,"interventions":22164},[90],[394],[883,3850,151],{"trials":22166,"activeCount":101},[],{"trials":22168,"activeCount":101},[],{"trials":22170,"activeCount":101},[],{"intervention":22172,"totalTrials":2548,"cells":22173},"Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin",{"EARLY_PHASE1":22174,"PHASE1":22176,"PHASE2":22178,"PHASE3":22188,"PHASE4":22190,"NA":22192},{"trials":22175,"activeCount":101},[],{"trials":22177,"activeCount":101},[],{"trials":22179,"activeCount":101},[22180],{"nctId":22181,"briefTitle":22182,"status":142,"phases":22183,"primaryCompletion":22184,"completion":2727,"start":22185,"enrollment":310,"conditions":22186,"interventions":22187},"NCT00321555","LMB-2 to Treat Hairy Cell Leukemia",[90],"2016-08-24","2006-05-02",[9894],[22172],{"trials":22189,"activeCount":101},[],{"trials":22191,"activeCount":101},[],{"trials":22193,"activeCount":101},[],{"intervention":3010,"totalTrials":2548,"cells":22195},{"EARLY_PHASE1":22196,"PHASE1":22198,"PHASE2":22200,"PHASE3":22206,"PHASE4":22208,"NA":22210},{"trials":22197,"activeCount":101},[],{"trials":22199,"activeCount":101},[],{"trials":22201,"activeCount":101},[22202],{"nctId":3003,"briefTitle":3004,"status":142,"phases":22203,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":188,"conditions":22204,"interventions":22205},[89,90],[2610,2611,2612,250,251,252],[1690,3010,3011,3012],{"trials":22207,"activeCount":101},[],{"trials":22209,"activeCount":101},[],{"trials":22211,"activeCount":101},[],{"intervention":3011,"totalTrials":2548,"cells":22213},{"EARLY_PHASE1":22214,"PHASE1":22216,"PHASE2":22218,"PHASE3":22224,"PHASE4":22226,"NA":22228},{"trials":22215,"activeCount":101},[],{"trials":22217,"activeCount":101},[],{"trials":22219,"activeCount":101},[22220],{"nctId":3003,"briefTitle":3004,"status":142,"phases":22221,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":188,"conditions":22222,"interventions":22223},[89,90],[2610,2611,2612,250,251,252],[1690,3010,3011,3012],{"trials":22225,"activeCount":101},[],{"trials":22227,"activeCount":101},[],{"trials":22229,"activeCount":101},[],{"intervention":3012,"totalTrials":2548,"cells":22231},{"EARLY_PHASE1":22232,"PHASE1":22234,"PHASE2":22236,"PHASE3":22242,"PHASE4":22244,"NA":22246},{"trials":22233,"activeCount":101},[],{"trials":22235,"activeCount":101},[],{"trials":22237,"activeCount":101},[22238],{"nctId":3003,"briefTitle":3004,"status":142,"phases":22239,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":188,"conditions":22240,"interventions":22241},[89,90],[2610,2611,2612,250,251,252],[1690,3010,3011,3012],{"trials":22243,"activeCount":101},[],{"trials":22245,"activeCount":101},[],{"trials":22247,"activeCount":101},[],{"intervention":22249,"totalTrials":2548,"cells":22250},"homoharringtonine",{"EARLY_PHASE1":22251,"PHASE1":22253,"PHASE2":22255,"PHASE3":22263,"PHASE4":22265,"NA":22267},{"trials":22252,"activeCount":101},[],{"trials":22254,"activeCount":101},[],{"trials":22256,"activeCount":101},[22257],{"nctId":22258,"briefTitle":22259,"status":107,"phases":22260,"enrollment":101,"conditions":22261,"interventions":22262},"NCT00030355","Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia",[89,90],[1260],[22249],{"trials":22264,"activeCount":101},[],{"trials":22266,"activeCount":101},[],{"trials":22268,"activeCount":101},[],{"intervention":22270,"totalTrials":2548,"cells":22271},"Glycosylated Recombinant Human Interleukin-7",{"EARLY_PHASE1":22272,"PHASE1":22274,"PHASE2":22276,"PHASE3":22289,"PHASE4":22291,"NA":22293},{"trials":22273,"activeCount":101},[],{"trials":22275,"activeCount":101},[],{"trials":22277,"activeCount":101},[22278],{"nctId":22279,"briefTitle":22280,"status":618,"phases":22281,"primaryCompletion":1864,"completion":1864,"start":3155,"enrollment":2548,"conditions":22282,"interventions":22283},"NCT01339000","Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy",[90],[18,843,961],[22270,22284,22285,22286,22287,22288],"Diphtheria\u002FTetanus Vaccine","Polio Vaccine","Pneumococcal Vaccine","Hepatitis A Vaccine","Hepatitis B Vaccine",{"trials":22290,"activeCount":101},[],{"trials":22292,"activeCount":101},[],{"trials":22294,"activeCount":101},[],{"intervention":22284,"totalTrials":2548,"cells":22296},{"EARLY_PHASE1":22297,"PHASE1":22299,"PHASE2":22301,"PHASE3":22307,"PHASE4":22309,"NA":22311},{"trials":22298,"activeCount":101},[],{"trials":22300,"activeCount":101},[],{"trials":22302,"activeCount":101},[22303],{"nctId":22279,"briefTitle":22280,"status":618,"phases":22304,"primaryCompletion":1864,"completion":1864,"start":3155,"enrollment":2548,"conditions":22305,"interventions":22306},[90],[18,843,961],[22270,22284,22285,22286,22287,22288],{"trials":22308,"activeCount":101},[],{"trials":22310,"activeCount":101},[],{"trials":22312,"activeCount":101},[],{"intervention":22285,"totalTrials":2548,"cells":22314},{"EARLY_PHASE1":22315,"PHASE1":22317,"PHASE2":22319,"PHASE3":22325,"PHASE4":22327,"NA":22329},{"trials":22316,"activeCount":101},[],{"trials":22318,"activeCount":101},[],{"trials":22320,"activeCount":101},[22321],{"nctId":22279,"briefTitle":22280,"status":618,"phases":22322,"primaryCompletion":1864,"completion":1864,"start":3155,"enrollment":2548,"conditions":22323,"interventions":22324},[90],[18,843,961],[22270,22284,22285,22286,22287,22288],{"trials":22326,"activeCount":101},[],{"trials":22328,"activeCount":101},[],{"trials":22330,"activeCount":101},[],{"intervention":22286,"totalTrials":2548,"cells":22332},{"EARLY_PHASE1":22333,"PHASE1":22335,"PHASE2":22337,"PHASE3":22343,"PHASE4":22345,"NA":22347},{"trials":22334,"activeCount":101},[],{"trials":22336,"activeCount":101},[],{"trials":22338,"activeCount":101},[22339],{"nctId":22279,"briefTitle":22280,"status":618,"phases":22340,"primaryCompletion":1864,"completion":1864,"start":3155,"enrollment":2548,"conditions":22341,"interventions":22342},[90],[18,843,961],[22270,22284,22285,22286,22287,22288],{"trials":22344,"activeCount":101},[],{"trials":22346,"activeCount":101},[],{"trials":22348,"activeCount":101},[],{"intervention":22287,"totalTrials":2548,"cells":22350},{"EARLY_PHASE1":22351,"PHASE1":22353,"PHASE2":22355,"PHASE3":22361,"PHASE4":22363,"NA":22365},{"trials":22352,"activeCount":101},[],{"trials":22354,"activeCount":101},[],{"trials":22356,"activeCount":101},[22357],{"nctId":22279,"briefTitle":22280,"status":618,"phases":22358,"primaryCompletion":1864,"completion":1864,"start":3155,"enrollment":2548,"conditions":22359,"interventions":22360},[90],[18,843,961],[22270,22284,22285,22286,22287,22288],{"trials":22362,"activeCount":101},[],{"trials":22364,"activeCount":101},[],{"trials":22366,"activeCount":101},[],{"intervention":22288,"totalTrials":2548,"cells":22368},{"EARLY_PHASE1":22369,"PHASE1":22371,"PHASE2":22373,"PHASE3":22379,"PHASE4":22381,"NA":22383},{"trials":22370,"activeCount":101},[],{"trials":22372,"activeCount":101},[],{"trials":22374,"activeCount":101},[22375],{"nctId":22279,"briefTitle":22280,"status":618,"phases":22376,"primaryCompletion":1864,"completion":1864,"start":3155,"enrollment":2548,"conditions":22377,"interventions":22378},[90],[18,843,961],[22270,22284,22285,22286,22287,22288],{"trials":22380,"activeCount":101},[],{"trials":22382,"activeCount":101},[],{"trials":22384,"activeCount":101},[],{"intervention":16326,"totalTrials":2548,"cells":22386},{"EARLY_PHASE1":22387,"PHASE1":22389,"PHASE2":22391,"PHASE3":22397,"PHASE4":22399,"NA":22401},{"trials":22388,"activeCount":101},[],{"trials":22390,"activeCount":101},[],{"trials":22392,"activeCount":101},[22393],{"nctId":16321,"briefTitle":16322,"status":142,"phases":22394,"primaryCompletion":3304,"start":4612,"enrollment":22,"conditions":22395,"interventions":22396},[90],[2296,2321],[16326,1349],{"trials":22398,"activeCount":101},[],{"trials":22400,"activeCount":101},[],{"trials":22402,"activeCount":101},[],{"intervention":22404,"totalTrials":2548,"cells":22405},"Simvastatin",{"EARLY_PHASE1":22406,"PHASE1":22408,"PHASE2":22410,"PHASE3":22422,"PHASE4":22424,"NA":22426},{"trials":22407,"activeCount":101},[],{"trials":22409,"activeCount":101},[],{"trials":22411,"activeCount":101},[22412],{"nctId":22413,"briefTitle":22414,"status":142,"phases":22415,"primaryCompletion":22416,"completion":22417,"start":22418,"enrollment":771,"conditions":22419,"interventions":22421},"NCT02743364","Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis",[90],"2019-10-14","2022-05-11","2016-09-19",[22420],"Acute Pancreatitis",[22404],{"trials":22423,"activeCount":101},[],{"trials":22425,"activeCount":101},[],{"trials":22427,"activeCount":101},[],{"intervention":3093,"totalTrials":603,"cells":22429},{"EARLY_PHASE1":22430,"PHASE1":22432,"PHASE2":22454,"PHASE3":22456,"PHASE4":22458,"NA":22460},{"trials":22431,"activeCount":101},[],{"trials":22433,"activeCount":101},[22434,22443,22450],{"nctId":22435,"briefTitle":22436,"status":142,"phases":22437,"start":22438,"enrollment":1798,"conditions":22439,"interventions":22440},"NCT00019058","Radiation Therapy in Treating Patients With Glioblastoma",[89],"1995-04",[3664],[3093,22441,22442],"hydroxyurea","pentoxifylline",{"nctId":22444,"briefTitle":22445,"status":142,"phases":22446,"primaryCompletion":7035,"start":18152,"enrollment":339,"conditions":22447,"interventions":22448},"NCT00002909","Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma",[89],[27,15],[3093,22449],"oral sodium phenylbutyrate",{"nctId":3085,"briefTitle":3086,"status":142,"phases":22451,"primaryCompletion":3088,"start":3089,"enrollment":28,"conditions":22452,"interventions":22453},[89],[1003,1821],[3092,3093,995,1031],{"trials":22455,"activeCount":101},[],{"trials":22457,"activeCount":101},[],{"trials":22459,"activeCount":101},[],{"trials":22461,"activeCount":101},[],{"intervention":14730,"totalTrials":603,"cells":22463},{"EARLY_PHASE1":22464,"PHASE1":22466,"PHASE2":22484,"PHASE3":22486,"PHASE4":22488,"NA":22490},{"trials":22465,"activeCount":101},[],{"trials":22467,"activeCount":101},[22468,22474,22480],{"nctId":22469,"briefTitle":22470,"status":142,"phases":22471,"primaryCompletion":3480,"start":6478,"enrollment":421,"conditions":22472,"interventions":22473},"NCT00006242","BMS-214662 in Treating Patients With Advanced Solid Tumors",[89],[15],[14730],{"nctId":22475,"briefTitle":22476,"status":142,"phases":22477,"primaryCompletion":3453,"start":6833,"enrollment":700,"conditions":22478,"interventions":22479},"NCT00005973","BMS-214662 in Treating Patients With Solid Tumors",[89],[15,748],[14730],{"nctId":14725,"briefTitle":14726,"status":142,"phases":22481,"primaryCompletion":3638,"start":4259,"enrollment":31,"conditions":22482,"interventions":22483},[89],[15],[14730,3122],{"trials":22485,"activeCount":101},[],{"trials":22487,"activeCount":101},[],{"trials":22489,"activeCount":101},[],{"trials":22491,"activeCount":101},[],{"intervention":2625,"totalTrials":603,"cells":22493},{"EARLY_PHASE1":22494,"PHASE1":22496,"PHASE2":22510,"PHASE3":22512,"PHASE4":22514,"NA":22516},{"trials":22495,"activeCount":101},[],{"trials":22497,"activeCount":101},[22498,22502,22506],{"nctId":3072,"briefTitle":3073,"status":618,"phases":22499,"primaryCompletion":3075,"completion":3075,"start":3076,"enrollment":25,"conditions":22500,"interventions":22501},[89],[1607,3078,3079,1451,3080,3081,3082,1637],[2625,449],{"nctId":2600,"briefTitle":2601,"status":142,"phases":22503,"primaryCompletion":2603,"completion":2604,"start":2605,"enrollment":31,"conditions":22504,"interventions":22505},[89],[2607,486,2608,2609,2610,2611,2612,2613,2614,2615,2616,2617,2618,2619,2620,2621,2622,487,2623],[2554,2625],{"nctId":16786,"briefTitle":16787,"status":618,"phases":22507,"primaryCompletion":16789,"completion":3075,"start":16790,"enrollment":2401,"conditions":22508,"interventions":22509},[89],[16792,16793,486,195,9335,10180,10181,10182,4767,6160],[16795,2625,16769],{"trials":22511,"activeCount":101},[],{"trials":22513,"activeCount":101},[],{"trials":22515,"activeCount":101},[],{"trials":22517,"activeCount":101},[],{"intervention":22519,"totalTrials":758,"cells":22520},"Talazoparib",{"EARLY_PHASE1":22521,"PHASE1":22523,"PHASE2":22548,"PHASE3":22550,"PHASE4":22552,"NA":22554},{"trials":22522,"activeCount":101},[],{"trials":22524,"activeCount":101},[22525,22535],{"nctId":22526,"briefTitle":22527,"status":107,"phases":22528,"primaryCompletion":22529,"start":22530,"enrollment":101,"conditions":22531,"interventions":22533},"NCT02627430","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",[89],"2019-03","2016-03",[3131,3132,1725,3134,1735,22532,1739,3136,2613,250,251,252,1637],"Ovarian Serous Tumor",[22534,22519],"Hsp90 Inhibitor AT13387",{"nctId":22536,"briefTitle":22537,"status":107,"phases":22538,"primaryCompletion":22539,"start":1089,"enrollment":101,"conditions":22540,"interventions":22547},"NCT02567396","Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",[89],"2018-10",[3132,3837,3134,22541,1967,3136,5223,22542,6535,4828,3485,22543,6536,4833,3488,22544,6537,3491,22545,3321,3494,22546,1637],"Hormone-Resistant Prostate Cancer","Stage III Mesothelioma","Stage IIIA Small Cell Lung Carcinoma","Stage IIIB Small Cell Lung Carcinoma","Stage IV Mesothelioma","Stage IV Small Cell Lung Carcinoma",[22519],{"trials":22549,"activeCount":101},[],{"trials":22551,"activeCount":101},[],{"trials":22553,"activeCount":101},[],{"trials":22555,"activeCount":101},[],{"intervention":22557,"totalTrials":758,"cells":22558},"2-methoxyestradiol",{"EARLY_PHASE1":22559,"PHASE1":22561,"PHASE2":22574,"PHASE3":22576,"PHASE4":22578,"NA":22580},{"trials":22560,"activeCount":101},[],{"trials":22562,"activeCount":101},[22563,22569],{"nctId":22564,"briefTitle":22565,"status":142,"phases":22566,"start":14807,"conditions":22567,"interventions":22568},"NCT00030095","2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors",[89],[15],[22557],{"nctId":22570,"briefTitle":22565,"status":142,"phases":22571,"primaryCompletion":715,"start":3533,"enrollment":1074,"conditions":22572,"interventions":22573},"NCT00028821",[89],[4262,1432,15],[22557],{"trials":22575,"activeCount":101},[],{"trials":22577,"activeCount":101},[],{"trials":22579,"activeCount":101},[],{"trials":22581,"activeCount":101},[],{"intervention":4556,"totalTrials":758,"cells":22583},{"EARLY_PHASE1":22584,"PHASE1":22586,"PHASE2":22596,"PHASE3":22598,"PHASE4":22600,"NA":22602},{"trials":22585,"activeCount":101},[],{"trials":22587,"activeCount":101},[22588,22592],{"nctId":6754,"briefTitle":6755,"status":107,"phases":22589,"primaryCompletion":6757,"completion":6757,"start":6757,"enrollment":101,"conditions":22590,"interventions":22591},[89],[6759,6760,6761,6762,4783],[4556,180,4555,780],{"nctId":4543,"briefTitle":4544,"status":142,"phases":22593,"primaryCompletion":4546,"completion":4547,"start":4548,"enrollment":34,"conditions":22594,"interventions":22595},[89],[4550,4551,4552,4553],[4555,1016,4556,1139],{"trials":22597,"activeCount":101},[],{"trials":22599,"activeCount":101},[],{"trials":22601,"activeCount":101},[],{"trials":22603,"activeCount":101},[],{"intervention":22605,"totalTrials":758,"cells":22606},"SJG-136",{"EARLY_PHASE1":22607,"PHASE1":22609,"PHASE2":22623,"PHASE3":22625,"PHASE4":22627,"NA":22629},{"trials":22608,"activeCount":101},[],{"trials":22610,"activeCount":101},[22611,22617],{"nctId":22612,"briefTitle":22613,"status":142,"phases":22614,"primaryCompletion":4165,"start":5706,"enrollment":2586,"conditions":22615,"interventions":22616},"NCT00121290","SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",[89],[15],[22605],{"nctId":22618,"briefTitle":22619,"status":142,"phases":22620,"primaryCompletion":2160,"start":4639,"enrollment":700,"conditions":22621,"interventions":22622},"NCT00103220","SJG-136 in Treating Patients With Advanced Solid Tumors",[89],[15],[22605],{"trials":22624,"activeCount":101},[],{"trials":22626,"activeCount":101},[],{"trials":22628,"activeCount":101},[],{"trials":22630,"activeCount":101},[],{"intervention":16795,"totalTrials":758,"cells":22632},{"EARLY_PHASE1":22633,"PHASE1":22635,"PHASE2":22652,"PHASE3":22654,"PHASE4":22656,"NA":22658},{"trials":22634,"activeCount":101},[],{"trials":22636,"activeCount":101},[22637,22648],{"nctId":22638,"briefTitle":22639,"status":618,"phases":22640,"primaryCompletion":22641,"completion":22641,"start":22642,"enrollment":771,"conditions":22643,"interventions":22647},"NCT01907802","Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction",[89],"2015-12-16","2013-08-23",[22644,22645,22646,5223],"BRAF Gene Mutation","Hepatic Complication","Renal Failure",[16795],{"nctId":16786,"briefTitle":16787,"status":618,"phases":22649,"primaryCompletion":16789,"completion":3075,"start":16790,"enrollment":2401,"conditions":22650,"interventions":22651},[89],[16792,16793,486,195,9335,10180,10181,10182,4767,6160],[16795,2625,16769],{"trials":22653,"activeCount":101},[],{"trials":22655,"activeCount":101},[],{"trials":22657,"activeCount":101},[],{"trials":22659,"activeCount":101},[],{"intervention":710,"totalTrials":758,"cells":22661},{"EARLY_PHASE1":22662,"PHASE1":22664,"PHASE2":22674,"PHASE3":22676,"PHASE4":22678,"NA":22680},{"trials":22663,"activeCount":101},[],{"trials":22665,"activeCount":101},[22666,22670],{"nctId":2437,"briefTitle":2438,"status":618,"phases":22667,"primaryCompletion":2440,"completion":2441,"start":756,"enrollment":758,"conditions":22668,"interventions":22669},[89],[915],[2444,2445,2218,710,706,1139],{"nctId":695,"briefTitle":696,"status":618,"phases":22671,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":22672,"interventions":22673},[89],[702],[704,63,705,643,706,707,708,709,710],{"trials":22675,"activeCount":101},[],{"trials":22677,"activeCount":101},[],{"trials":22679,"activeCount":101},[],{"trials":22681,"activeCount":101},[],{"intervention":22534,"totalTrials":2548,"cells":22683},{"EARLY_PHASE1":22684,"PHASE1":22686,"PHASE2":22692,"PHASE3":22694,"PHASE4":22696,"NA":22698},{"trials":22685,"activeCount":101},[],{"trials":22687,"activeCount":101},[22688],{"nctId":22526,"briefTitle":22527,"status":107,"phases":22689,"primaryCompletion":22529,"start":22530,"enrollment":101,"conditions":22690,"interventions":22691},[89],[3131,3132,1725,3134,1735,22532,1739,3136,2613,250,251,252,1637],[22534,22519],{"trials":22693,"activeCount":101},[],{"trials":22695,"activeCount":101},[],{"trials":22697,"activeCount":101},[],{"trials":22699,"activeCount":101},[],{"intervention":22701,"totalTrials":2548,"cells":22702},"doxorubicin HCl liposome",{"EARLY_PHASE1":22703,"PHASE1":22705,"PHASE2":22718,"PHASE3":22720,"PHASE4":22722,"NA":22724},{"trials":22704,"activeCount":101},[],{"trials":22706,"activeCount":101},[22707],{"nctId":22708,"briefTitle":22709,"status":142,"phases":22710,"start":15814,"conditions":22711,"interventions":22717},"NCT00019630","Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors",[89],[22712,22713,22714,22715,22716],"Childhood Soft Tissue Sarcoma","Childhood Liver Cancer","Bone Cancer","Brain Tumor","Kidney Tumor",[22701],{"trials":22719,"activeCount":101},[],{"trials":22721,"activeCount":101},[],{"trials":22723,"activeCount":101},[],{"trials":22725,"activeCount":101},[],{"intervention":629,"totalTrials":2548,"cells":22727},{"EARLY_PHASE1":22728,"PHASE1":22730,"PHASE2":22736,"PHASE3":22738,"PHASE4":22740,"NA":22742},{"trials":22729,"activeCount":101},[],{"trials":22731,"activeCount":101},[22732],{"nctId":616,"briefTitle":617,"status":618,"phases":22733,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":22734,"interventions":22735},[89],[625,36,626,627],[629,63,630],{"trials":22737,"activeCount":101},[],{"trials":22739,"activeCount":101},[],{"trials":22741,"activeCount":101},[],{"trials":22743,"activeCount":101},[],{"intervention":22745,"totalTrials":2548,"cells":22746},"ECI301",{"EARLY_PHASE1":22747,"PHASE1":22749,"PHASE2":22762,"PHASE3":22764,"PHASE4":22766,"NA":22768},{"trials":22748,"activeCount":101},[],{"trials":22750,"activeCount":101},[22751],{"nctId":22752,"briefTitle":22753,"status":618,"phases":22754,"primaryCompletion":22755,"completion":22755,"start":22756,"enrollment":758,"conditions":22757,"interventions":22761},"NCT01441115","ECI301 and Radiation for Advanced or Metastatic Cancer",[89],"2013-04-24","2011-09-06",[15088,7088,22758,22759,22760],"Radiation Oncology","Neoplasm","Metastasis",[22745],{"trials":22763,"activeCount":101},[],{"trials":22765,"activeCount":101},[],{"trials":22767,"activeCount":101},[],{"trials":22769,"activeCount":101},[],{"intervention":22441,"totalTrials":2548,"cells":22771},{"EARLY_PHASE1":22772,"PHASE1":22774,"PHASE2":22780,"PHASE3":22782,"PHASE4":22784,"NA":22786},{"trials":22773,"activeCount":101},[],{"trials":22775,"activeCount":101},[22776],{"nctId":22435,"briefTitle":22436,"status":142,"phases":22777,"start":22438,"enrollment":1798,"conditions":22778,"interventions":22779},[89],[3664],[3093,22441,22442],{"trials":22781,"activeCount":101},[],{"trials":22783,"activeCount":101},[],{"trials":22785,"activeCount":101},[],{"trials":22787,"activeCount":101},[],{"intervention":22442,"totalTrials":2548,"cells":22789},{"EARLY_PHASE1":22790,"PHASE1":22792,"PHASE2":22798,"PHASE3":22800,"PHASE4":22802,"NA":22804},{"trials":22791,"activeCount":101},[],{"trials":22793,"activeCount":101},[22794],{"nctId":22435,"briefTitle":22436,"status":142,"phases":22795,"start":22438,"enrollment":1798,"conditions":22796,"interventions":22797},[89],[3664],[3093,22441,22442],{"trials":22799,"activeCount":101},[],{"trials":22801,"activeCount":101},[],{"trials":22803,"activeCount":101},[],{"trials":22805,"activeCount":101},[],{"intervention":15090,"totalTrials":2548,"cells":22807},{"EARLY_PHASE1":22808,"PHASE1":22810,"PHASE2":22816,"PHASE3":22818,"PHASE4":22820,"NA":22822},{"trials":22809,"activeCount":101},[],{"trials":22811,"activeCount":101},[22812],{"nctId":15084,"briefTitle":15085,"status":142,"phases":22813,"completion":1181,"start":3107,"enrollment":28,"conditions":22814,"interventions":22815},[89],[18,15088,687,1003],[3708,15090],{"trials":22817,"activeCount":101},[],{"trials":22819,"activeCount":101},[],{"trials":22821,"activeCount":101},[],{"trials":22823,"activeCount":101},[],{"intervention":13258,"totalTrials":2548,"cells":22825},{"EARLY_PHASE1":22826,"PHASE1":22828,"PHASE2":22834,"PHASE3":22836,"PHASE4":22838,"NA":22840},{"trials":22827,"activeCount":101},[],{"trials":22829,"activeCount":101},[22830],{"nctId":13253,"briefTitle":13254,"status":618,"phases":22831,"primaryCompletion":3282,"start":4996,"enrollment":28,"conditions":22832,"interventions":22833},[89],[15],[13258,13259],{"trials":22835,"activeCount":101},[],{"trials":22837,"activeCount":101},[],{"trials":22839,"activeCount":101},[],{"trials":22841,"activeCount":101},[],{"intervention":11241,"totalTrials":2548,"cells":22843},{"EARLY_PHASE1":22844,"PHASE1":22846,"PHASE2":22852,"PHASE3":22854,"PHASE4":22856,"NA":22858},{"trials":22845,"activeCount":101},[],{"trials":22847,"activeCount":101},[22848],{"nctId":11236,"briefTitle":11237,"status":618,"phases":22849,"primaryCompletion":4031,"completion":4031,"start":1763,"enrollment":603,"conditions":22850,"interventions":22851},[89],[869],[11241,677],{"trials":22853,"activeCount":101},[],{"trials":22855,"activeCount":101},[],{"trials":22857,"activeCount":101},[],{"trials":22859,"activeCount":101},[],{"intervention":22861,"totalTrials":2548,"cells":22862},"oral microencapsulated diindolylmethane",{"EARLY_PHASE1":22863,"PHASE1":22865,"PHASE2":22873,"PHASE3":22875,"PHASE4":22877,"NA":22879},{"trials":22864,"activeCount":101},[],{"trials":22866,"activeCount":101},[22867],{"nctId":22868,"briefTitle":22869,"status":142,"phases":22870,"primaryCompletion":1575,"completion":11062,"start":4715,"enrollment":2211,"conditions":22871,"interventions":22872},"NCT00392652","Diindolylmethane in Healthy Volunteers",[89],[18344],[22861],{"trials":22874,"activeCount":101},[],{"trials":22876,"activeCount":101},[],{"trials":22878,"activeCount":101},[],{"trials":22880,"activeCount":101},[],{"intervention":22882,"totalTrials":2548,"cells":22883},"CD22-CAR",{"EARLY_PHASE1":22884,"PHASE1":22886,"PHASE2":22904,"PHASE3":22906,"PHASE4":22908,"NA":22910},{"trials":22885,"activeCount":101},[],{"trials":22887,"activeCount":101},[22888],{"nctId":22889,"briefTitle":22890,"status":142,"phases":22891,"primaryCompletion":22892,"completion":22893,"start":1462,"enrollment":22894,"conditions":22895,"interventions":22903},"NCT02315612","Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies",[89],"2019-04-03","2024-10-29",134,[22896,22897,14920,22898,903,22899,902,22900,22901,22902],"NHL","Large Cell Lymphoma","ALL","B-precursor ALL","Acute Lymphocytic Leukemia","B-Non Hodgkin Lymphoma","B-NHL",[22882],{"trials":22905,"activeCount":101},[],{"trials":22907,"activeCount":101},[],{"trials":22909,"activeCount":101},[],{"trials":22911,"activeCount":101},[],{"intervention":22913,"totalTrials":2548,"cells":22914},"Akt inhibitor SR13668",{"EARLY_PHASE1":22915,"PHASE1":22917,"PHASE2":22925,"PHASE3":22927,"PHASE4":22929,"NA":22931},{"trials":22916,"activeCount":101},[],{"trials":22918,"activeCount":101},[22919],{"nctId":22920,"briefTitle":22921,"status":142,"phases":22922,"primaryCompletion":3317,"completion":3317,"start":4611,"enrollment":552,"conditions":22923,"interventions":22924},"NCT00896207","Studying Different Formulations of SR13668 in Healthy Volunteers",[89],[18344],[22913],{"trials":22926,"activeCount":101},[],{"trials":22928,"activeCount":101},[],{"trials":22930,"activeCount":101},[],{"trials":22932,"activeCount":101},[],{"intervention":22934,"totalTrials":2548,"cells":22935},"AFP464",{"EARLY_PHASE1":22936,"PHASE1":22938,"PHASE2":22947,"PHASE3":22949,"PHASE4":22951,"NA":22953},{"trials":22937,"activeCount":101},[],{"trials":22939,"activeCount":101},[22940],{"nctId":22941,"briefTitle":22942,"status":142,"phases":22943,"primaryCompletion":8266,"start":3587,"enrollment":22944,"conditions":22945,"interventions":22946},"NCT00348699","AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery",[89],68,[1219,3117,1579,1992,5233,3137,1591,1996,4842,15],[22934],{"trials":22948,"activeCount":101},[],{"trials":22950,"activeCount":101},[],{"trials":22952,"activeCount":101},[],{"trials":22954,"activeCount":101},[],{"intervention":22956,"totalTrials":2548,"cells":22957},"T-cell receptor alternate reading frame protein (TARP) peptide vaccine",{"EARLY_PHASE1":22958,"PHASE1":22960,"PHASE2":22972,"PHASE3":22974,"PHASE4":22976,"NA":22978},{"trials":22959,"activeCount":101},[],{"trials":22961,"activeCount":101},[22962],{"nctId":22963,"briefTitle":22964,"status":142,"phases":22965,"primaryCompletion":22966,"completion":22966,"start":22967,"enrollment":623,"conditions":22968,"interventions":22970},"NCT00972309","A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer",[89],"2015-02-04","2009-05-11",[22969,2253],"Prostate Specific Antigens",[22956,22971],"T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine",{"trials":22973,"activeCount":101},[],{"trials":22975,"activeCount":101},[],{"trials":22977,"activeCount":101},[],{"trials":22979,"activeCount":101},[],{"intervention":22971,"totalTrials":2548,"cells":22981},{"EARLY_PHASE1":22982,"PHASE1":22984,"PHASE2":22990,"PHASE3":22992,"PHASE4":22994,"NA":22996},{"trials":22983,"activeCount":101},[],{"trials":22985,"activeCount":101},[22986],{"nctId":22963,"briefTitle":22964,"status":142,"phases":22987,"primaryCompletion":22966,"completion":22966,"start":22967,"enrollment":623,"conditions":22988,"interventions":22989},[89],[22969,2253],[22956,22971],{"trials":22991,"activeCount":101},[],{"trials":22993,"activeCount":101},[],{"trials":22995,"activeCount":101},[],{"trials":22997,"activeCount":101},[],{"intervention":22999,"totalTrials":2548,"cells":23000},"Zolpidem",{"EARLY_PHASE1":23001,"PHASE1":23003,"PHASE2":23013,"PHASE3":23015,"PHASE4":23017,"NA":23019},{"trials":23002,"activeCount":101},[],{"trials":23004,"activeCount":101},[23005],{"nctId":23006,"briefTitle":23007,"status":142,"phases":23008,"primaryCompletion":23009,"completion":23009,"start":23010,"enrollment":188,"conditions":23011,"interventions":23012},"NCT03436745","The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females",[89],"2024-01-30","2019-01-22",[10352],[22999],{"trials":23014,"activeCount":101},[],{"trials":23016,"activeCount":101},[],{"trials":23018,"activeCount":101},[],{"trials":23020,"activeCount":101},[],{"intervention":23022,"totalTrials":2548,"cells":23023},"iodine I 131 monoclonal antibody CC49-deltaCH2",{"EARLY_PHASE1":23024,"PHASE1":23026,"PHASE2":23034,"PHASE3":23036,"PHASE4":23038,"NA":23040},{"trials":23025,"activeCount":101},[],{"trials":23027,"activeCount":101},[23028],{"nctId":23029,"briefTitle":23030,"status":142,"phases":23031,"primaryCompletion":1819,"start":5707,"enrollment":310,"conditions":23032,"interventions":23033},"NCT00023933","Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer",[89],[5127,4983,4941,4942,4945,4946],[23022],{"trials":23035,"activeCount":101},[],{"trials":23037,"activeCount":101},[],{"trials":23039,"activeCount":101},[],{"trials":23041,"activeCount":101},[],{"intervention":11647,"totalTrials":2548,"cells":23043},{"EARLY_PHASE1":23044,"PHASE1":23046,"PHASE2":23052,"PHASE3":23054,"PHASE4":23056,"NA":23058},{"trials":23045,"activeCount":101},[],{"trials":23047,"activeCount":101},[23048],{"nctId":11636,"briefTitle":11637,"status":142,"phases":23049,"primaryCompletion":11639,"completion":11639,"start":11640,"enrollment":375,"conditions":23050,"interventions":23051},[89],[11642,829,11643,11644,11645],[11647,5747],{"trials":23053,"activeCount":101},[],{"trials":23055,"activeCount":101},[],{"trials":23057,"activeCount":101},[],{"trials":23059,"activeCount":101},[],{"intervention":3756,"totalTrials":2548,"cells":23061},{"EARLY_PHASE1":23062,"PHASE1":23064,"PHASE2":23070,"PHASE3":23072,"PHASE4":23074,"NA":23076},{"trials":23063,"activeCount":101},[],{"trials":23065,"activeCount":101},[23066],{"nctId":3744,"briefTitle":3745,"status":142,"phases":23067,"primaryCompletion":3747,"completion":3748,"start":3749,"enrollment":16,"conditions":23068,"interventions":23069},[89],[3751,190,192,801,939,135,3752,3247,2885,486,195,2193,3704,3753,3705,3754,1626,1633,209],[3756,883],{"trials":23071,"activeCount":101},[],{"trials":23073,"activeCount":101},[],{"trials":23075,"activeCount":101},[],{"trials":23077,"activeCount":101},[],{"intervention":11260,"totalTrials":2548,"cells":23079},{"EARLY_PHASE1":23080,"PHASE1":23082,"PHASE2":23088,"PHASE3":23090,"PHASE4":23092,"NA":23094},{"trials":23081,"activeCount":101},[],{"trials":23083,"activeCount":101},[23084],{"nctId":11250,"briefTitle":11251,"status":618,"phases":23085,"primaryCompletion":4954,"completion":11253,"start":11254,"enrollment":2548,"conditions":23086,"interventions":23087},[89],[11256,11257,11258],[677,11260],{"trials":23089,"activeCount":101},[],{"trials":23091,"activeCount":101},[],{"trials":23093,"activeCount":101},[],{"trials":23095,"activeCount":101},[],{"intervention":23097,"totalTrials":2548,"cells":23098},"Bowman-Birk inhibitor concentrate",{"EARLY_PHASE1":23099,"PHASE1":23101,"PHASE2":23109,"PHASE3":23111,"PHASE4":23113,"NA":23115},{"trials":23100,"activeCount":101},[],{"trials":23102,"activeCount":101},[23103],{"nctId":23104,"briefTitle":23105,"status":142,"phases":23106,"primaryCompletion":1217,"start":1426,"enrollment":552,"conditions":23107,"interventions":23108},"NCT00287833","Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men",[89],[15],[23097],{"trials":23110,"activeCount":101},[],{"trials":23112,"activeCount":101},[],{"trials":23114,"activeCount":101},[],{"trials":23116,"activeCount":101},[],{"intervention":11425,"totalTrials":2548,"cells":23118},{"EARLY_PHASE1":23119,"PHASE1":23121,"PHASE2":23127,"PHASE3":23129,"PHASE4":23131,"NA":23133},{"trials":23120,"activeCount":101},[],{"trials":23122,"activeCount":101},[23123],{"nctId":11410,"briefTitle":11411,"status":107,"phases":23124,"primaryCompletion":11413,"completion":11413,"start":11413,"enrollment":101,"conditions":23125,"interventions":23126},[89],[300,21,11415,11416,11417,11418,535,119,30,11419,11420,162,11421,11422,163,164,11423],[474,11425],{"trials":23128,"activeCount":101},[],{"trials":23130,"activeCount":101},[],{"trials":23132,"activeCount":101},[],{"trials":23134,"activeCount":101},[],{"intervention":14922,"totalTrials":2548,"cells":23136},{"EARLY_PHASE1":23137,"PHASE1":23139,"PHASE2":23145,"PHASE3":23147,"PHASE4":23149,"NA":23151},{"trials":23138,"activeCount":101},[],{"trials":23140,"activeCount":101},[23141],{"nctId":14913,"briefTitle":14914,"status":142,"phases":23142,"primaryCompletion":14916,"completion":14916,"start":14917,"enrollment":1517,"conditions":23143,"interventions":23144},[89],[14919,14920,27],[14922,14906],{"trials":23146,"activeCount":101},[],{"trials":23148,"activeCount":101},[],{"trials":23150,"activeCount":101},[],{"trials":23152,"activeCount":101},[],{"intervention":23154,"totalTrials":2548,"cells":23155},"AZD7451",{"EARLY_PHASE1":23156,"PHASE1":23158,"PHASE2":23167,"PHASE3":23169,"PHASE4":23171,"NA":23173},{"trials":23157,"activeCount":101},[],{"trials":23159,"activeCount":101},[23160],{"nctId":23161,"briefTitle":23162,"status":142,"phases":23163,"primaryCompletion":5242,"completion":5242,"start":23164,"enrollment":2211,"conditions":23165,"interventions":23166},"NCT01468324","AZD7451 for Recurrent Gliomas",[89],"2011-10-05",[19184],[23154],{"trials":23168,"activeCount":101},[],{"trials":23170,"activeCount":101},[],{"trials":23172,"activeCount":101},[],{"trials":23174,"activeCount":101},[],{"intervention":676,"totalTrials":2548,"cells":23176},{"EARLY_PHASE1":23177,"PHASE1":23179,"PHASE2":23185,"PHASE3":23187,"PHASE4":23189,"NA":23191},{"trials":23178,"activeCount":101},[],{"trials":23180,"activeCount":101},[23181],{"nctId":669,"briefTitle":670,"status":107,"phases":23182,"primaryCompletion":672,"completion":672,"start":673,"enrollment":101,"conditions":23183,"interventions":23184},[89],[195],[676,63,643,677],{"trials":23186,"activeCount":101},[],{"trials":23188,"activeCount":101},[],{"trials":23190,"activeCount":101},[],{"trials":23192,"activeCount":101},[],{"intervention":9684,"totalTrials":2548,"cells":23194},{"EARLY_PHASE1":23195,"PHASE1":23197,"PHASE2":23203,"PHASE3":23205,"PHASE4":23207,"NA":23209},{"trials":23196,"activeCount":101},[],{"trials":23198,"activeCount":101},[23199],{"nctId":9672,"briefTitle":9673,"status":107,"phases":23200,"primaryCompletion":9675,"completion":9675,"start":9676,"enrollment":101,"conditions":23201,"interventions":23202},[89],[1619,1620,3909,9678,9679,9680,3238,9243,2609,9681,9682,9259],[2954,9684],{"trials":23204,"activeCount":101},[],{"trials":23206,"activeCount":101},[],{"trials":23208,"activeCount":101},[],{"trials":23210,"activeCount":101},[],{"intervention":5853,"totalTrials":2548,"cells":23212},{"EARLY_PHASE1":23213,"PHASE1":23215,"PHASE2":23221,"PHASE3":23223,"PHASE4":23225,"NA":23227},{"trials":23214,"activeCount":101},[],{"trials":23216,"activeCount":101},[23217],{"nctId":5841,"briefTitle":5842,"status":142,"phases":23218,"completion":5844,"start":5845,"enrollment":651,"conditions":23219,"interventions":23220},[89],[5847,5848,5849,5850,5851],[151,5853],{"trials":23222,"activeCount":101},[],{"trials":23224,"activeCount":101},[],{"trials":23226,"activeCount":101},[],{"trials":23228,"activeCount":101},[],{"intervention":17945,"totalTrials":2548,"cells":23230},{"EARLY_PHASE1":23231,"PHASE1":23233,"PHASE2":23239,"PHASE3":23241,"PHASE4":23243,"NA":23245},{"trials":23232,"activeCount":101},[],{"trials":23234,"activeCount":101},[23235],{"nctId":17939,"briefTitle":17940,"status":142,"phases":23236,"primaryCompletion":1989,"start":17942,"enrollment":188,"conditions":23237,"interventions":23238},[89],[1579],[17945,17414],{"trials":23240,"activeCount":101},[],{"trials":23242,"activeCount":101},[],{"trials":23244,"activeCount":101},[],{"trials":23246,"activeCount":101},[],{"intervention":23248,"totalTrials":2548,"cells":23249},"becatecarin",{"EARLY_PHASE1":23250,"PHASE1":23252,"PHASE2":23260,"PHASE3":23262,"PHASE4":23264,"NA":23266},{"trials":23251,"activeCount":101},[],{"trials":23253,"activeCount":101},[23254],{"nctId":23255,"briefTitle":23256,"status":142,"phases":23257,"primaryCompletion":1340,"start":3397,"enrollment":421,"conditions":23258,"interventions":23259},"NCT00087204","Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia",[89],[4043,4044,4045,4046,4047,4053,2453,4056,4058,1135,33,4616,6285,4060,2432,4061],[23248],{"trials":23261,"activeCount":101},[],{"trials":23263,"activeCount":101},[],{"trials":23265,"activeCount":101},[],{"trials":23267,"activeCount":101},[],{"intervention":23269,"totalTrials":2548,"cells":23270},"Retinoid 9cUAB30",{"EARLY_PHASE1":23271,"PHASE1":23273,"PHASE2":23288,"PHASE3":23290,"PHASE4":23292,"NA":23294},{"trials":23272,"activeCount":101},[],{"trials":23274,"activeCount":101},[23275],{"nctId":23276,"briefTitle":23277,"status":618,"phases":23278,"primaryCompletion":6216,"completion":6216,"start":729,"enrollment":2029,"conditions":23279,"interventions":23287},"NCT02876640","Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer",[89],[23280,23281,23282,23283,23284,23285,11215,23286,3909],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Early Stage Breast Carcinoma",[23269],{"trials":23289,"activeCount":101},[],{"trials":23291,"activeCount":101},[],{"trials":23293,"activeCount":101},[],{"trials":23295,"activeCount":101},[],{"intervention":23297,"totalTrials":2548,"cells":23298},"aminolevulinic acid hydrochloride",{"EARLY_PHASE1":23299,"PHASE1":23301,"PHASE2":23310,"PHASE3":23312,"PHASE4":23314,"NA":23316},{"trials":23300,"activeCount":101},[],{"trials":23302,"activeCount":101},[23303],{"nctId":23304,"briefTitle":23305,"status":618,"phases":23306,"primaryCompletion":5445,"completion":3479,"start":716,"enrollment":310,"conditions":23307,"interventions":23308},"NCT00571558","Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia",[89],[18189],[23297,23309],"photodynamic therapy",{"trials":23311,"activeCount":101},[],{"trials":23313,"activeCount":101},[],{"trials":23315,"activeCount":101},[],{"trials":23317,"activeCount":101},[],{"intervention":23309,"totalTrials":2548,"cells":23319},{"EARLY_PHASE1":23320,"PHASE1":23322,"PHASE2":23328,"PHASE3":23330,"PHASE4":23332,"NA":23334},{"trials":23321,"activeCount":101},[],{"trials":23323,"activeCount":101},[23324],{"nctId":23304,"briefTitle":23305,"status":618,"phases":23325,"primaryCompletion":5445,"completion":3479,"start":716,"enrollment":310,"conditions":23326,"interventions":23327},[89],[18189],[23297,23309],{"trials":23329,"activeCount":101},[],{"trials":23331,"activeCount":101},[],{"trials":23333,"activeCount":101},[],{"trials":23335,"activeCount":101},[],{"intervention":23337,"totalTrials":2548,"cells":23338},"resveratrol",{"EARLY_PHASE1":23339,"PHASE1":23341,"PHASE2":23349,"PHASE3":23351,"PHASE4":23353,"NA":23355},{"trials":23340,"activeCount":101},[],{"trials":23342,"activeCount":101},[23343],{"nctId":23344,"briefTitle":23345,"status":142,"phases":23346,"primaryCompletion":1171,"completion":1171,"start":5444,"enrollment":1517,"conditions":23347,"interventions":23348},"NCT00721877","Resveratrol in Healthy Adult Participants",[89],[18344],[23337],{"trials":23350,"activeCount":101},[],{"trials":23352,"activeCount":101},[],{"trials":23354,"activeCount":101},[],{"trials":23356,"activeCount":101},[],{"intervention":23358,"totalTrials":2548,"cells":23359},"4'-iodo-4'-deoxydoxorubicin",{"EARLY_PHASE1":23360,"PHASE1":23362,"PHASE2":23370,"PHASE3":23372,"PHASE4":23374,"NA":23376},{"trials":23361,"activeCount":101},[],{"trials":23363,"activeCount":101},[23364],{"nctId":23365,"briefTitle":23366,"status":618,"phases":23367,"primaryCompletion":3390,"start":7340,"enrollment":2401,"conditions":23368,"interventions":23369},"NCT00030381","Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis",[89],[6140],[23358],{"trials":23371,"activeCount":101},[],{"trials":23373,"activeCount":101},[],{"trials":23375,"activeCount":101},[],{"trials":23377,"activeCount":101},[],{"intervention":23379,"totalTrials":2548,"cells":23380},"Gardasil",{"EARLY_PHASE1":23381,"PHASE1":23383,"PHASE2":23398,"PHASE3":23400,"PHASE4":23402,"NA":23404},{"trials":23382,"activeCount":101},[],{"trials":23384,"activeCount":101},[23385],{"nctId":23386,"briefTitle":23387,"status":618,"phases":23388,"primaryCompletion":23389,"completion":23390,"start":23391,"enrollment":34,"conditions":23392,"interventions":23397},"NCT00798265","A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults",[89],"2012-09-22","2013-02-04","2009-06-29",[23393,23394,23395,23396],"Human Immunodeficiency Virus","Human Papillomavirus- 6, 11, 16, 18","Adolescent","Papillomavirus Vaccines",[23379],{"trials":23399,"activeCount":101},[],{"trials":23401,"activeCount":101},[],{"trials":23403,"activeCount":101},[],{"trials":23405,"activeCount":101},[],{"intervention":23407,"totalTrials":2548,"cells":23408},"phenylbutyrate",{"EARLY_PHASE1":23409,"PHASE1":23411,"PHASE2":23420,"PHASE3":23422,"PHASE4":23424,"NA":23426},{"trials":23410,"activeCount":101},[],{"trials":23412,"activeCount":101},[23413],{"nctId":23414,"briefTitle":23415,"status":142,"phases":23416,"completion":7035,"start":1782,"enrollment":638,"conditions":23417,"interventions":23419},"NCT00001565","Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy",[89],[23418,791],"Brain Neoplasms",[23407],{"trials":23421,"activeCount":101},[],{"trials":23423,"activeCount":101},[],{"trials":23425,"activeCount":101},[],{"trials":23427,"activeCount":101},[],{"intervention":23429,"totalTrials":2548,"cells":23430},"TdCyd",{"EARLY_PHASE1":23431,"PHASE1":23433,"PHASE2":23444,"PHASE3":23446,"PHASE4":23448,"NA":23450},{"trials":23432,"activeCount":101},[],{"trials":23434,"activeCount":101},[23435],{"nctId":23436,"briefTitle":23437,"status":142,"phases":23438,"primaryCompletion":23439,"completion":23440,"start":23441,"enrollment":2029,"conditions":23442,"interventions":23443},"NCT02423057","Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors",[89],"2019-03-19","2025-07-21","2015-05-18",[467,3229],[23429],{"trials":23445,"activeCount":101},[],{"trials":23447,"activeCount":101},[],{"trials":23449,"activeCount":101},[],{"trials":23451,"activeCount":101},[],{"intervention":23453,"totalTrials":2548,"cells":23454},"E7 TCR",{"EARLY_PHASE1":23455,"PHASE1":23457,"PHASE2":23468,"PHASE3":23470,"PHASE4":23472,"NA":23474},{"trials":23456,"activeCount":101},[],{"trials":23458,"activeCount":101},[23459],{"nctId":23460,"briefTitle":23461,"status":107,"phases":23462,"primaryCompletion":23463,"completion":23463,"start":23464,"enrollment":101,"conditions":23465,"interventions":23467},"NCT04411134","E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia",[89],"2020-07-14","2020-05-28",[23466],"Cervical Intraepithelial Neoplasia",[23453],{"trials":23469,"activeCount":101},[],{"trials":23471,"activeCount":101},[],{"trials":23473,"activeCount":101},[],{"trials":23475,"activeCount":101},[],{"intervention":692,"totalTrials":2548,"cells":23477},{"EARLY_PHASE1":23478,"PHASE1":23480,"PHASE2":23486,"PHASE3":23488,"PHASE4":23490,"NA":23492},{"trials":23479,"activeCount":101},[],{"trials":23481,"activeCount":101},[23482],{"nctId":679,"briefTitle":680,"status":618,"phases":23483,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":23484,"interventions":23485},[89],[687,688,689,625,690],[692,630,693],{"trials":23487,"activeCount":101},[],{"trials":23489,"activeCount":101},[],{"trials":23491,"activeCount":101},[],{"trials":23493,"activeCount":101},[],{"intervention":23495,"totalTrials":2548,"cells":23496},"R(+)XK469",{"EARLY_PHASE1":23497,"PHASE1":23499,"PHASE2":23508,"PHASE3":23510,"PHASE4":23512,"NA":23514},{"trials":23498,"activeCount":101},[],{"trials":23500,"activeCount":101},[23501],{"nctId":23502,"briefTitle":23503,"status":142,"phases":23504,"primaryCompletion":5724,"start":7340,"enrollment":14876,"conditions":23505,"interventions":23507},"NCT00028522","R(+)XK469 in Treating Patients With Advanced Neuroblastoma",[89],[23506,8374,117,8375],"Disseminated Neuroblastoma",[23495],{"trials":23509,"activeCount":101},[],{"trials":23511,"activeCount":101},[],{"trials":23513,"activeCount":101},[],{"trials":23515,"activeCount":101},[],{"intervention":23517,"totalTrials":2548,"cells":23518},"interleukin-1",{"EARLY_PHASE1":23519,"PHASE1":23521,"PHASE2":23531,"PHASE3":23533,"PHASE4":23535,"NA":23537},{"trials":23520,"activeCount":101},[],{"trials":23522,"activeCount":101},[23523],{"nctId":23524,"briefTitle":23525,"status":142,"phases":23526,"completion":1979,"start":23527,"enrollment":14876,"conditions":23528,"interventions":23530},"NCT00001270","Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma",[89],"1991-06",[1291,27,7088,23529],"Testicular Neoplasms",[23517],{"trials":23532,"activeCount":101},[],{"trials":23534,"activeCount":101},[],{"trials":23536,"activeCount":101},[],{"trials":23538,"activeCount":101},[],{"intervention":18155,"totalTrials":2548,"cells":23540},{"EARLY_PHASE1":23541,"PHASE1":23543,"PHASE2":23549,"PHASE3":23551,"PHASE4":23553,"NA":23555},{"trials":23542,"activeCount":101},[],{"trials":23544,"activeCount":101},[23545],{"nctId":18149,"briefTitle":18150,"status":142,"phases":23546,"completion":3398,"start":18152,"enrollment":730,"conditions":23547,"interventions":23548},[89],[719,7088],[18155,18142],{"trials":23550,"activeCount":101},[],{"trials":23552,"activeCount":101},[],{"trials":23554,"activeCount":101},[],{"trials":23556,"activeCount":101},[],{"intervention":23558,"totalTrials":2548,"cells":23559},"PU-H71",{"EARLY_PHASE1":23560,"PHASE1":23562,"PHASE2":23571,"PHASE3":23573,"PHASE4":23575,"NA":23577},{"trials":23561,"activeCount":101},[],{"trials":23563,"activeCount":101},[23564],{"nctId":23565,"briefTitle":23566,"status":618,"phases":23567,"primaryCompletion":865,"completion":865,"start":23568,"enrollment":407,"conditions":23569,"interventions":23570},"NCT01581541","PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment",[89],"2011-04-26",[3229,27],[23558],{"trials":23572,"activeCount":101},[],{"trials":23574,"activeCount":101},[],{"trials":23576,"activeCount":101},[],{"trials":23578,"activeCount":101},[],{"intervention":23580,"totalTrials":2548,"cells":23581},"Satraplatin",{"EARLY_PHASE1":23582,"PHASE1":23584,"PHASE2":23596,"PHASE3":23598,"PHASE4":23600,"NA":23602},{"trials":23583,"activeCount":101},[],{"trials":23585,"activeCount":101},[23586],{"nctId":23587,"briefTitle":23588,"status":142,"phases":23589,"primaryCompletion":23590,"completion":23591,"start":23592,"enrollment":651,"conditions":23593,"interventions":23595},"NCT01259479","Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors",[89],"2013-08-01","2015-05-29","2010-12-03",[3229,5989,23594],"Brain Metastases",[23580],{"trials":23597,"activeCount":101},[],{"trials":23599,"activeCount":101},[],{"trials":23601,"activeCount":101},[],{"trials":23603,"activeCount":101},[],{"intervention":8221,"totalTrials":2548,"cells":23605},{"EARLY_PHASE1":23606,"PHASE1":23608,"PHASE2":23614,"PHASE3":23616,"PHASE4":23618,"NA":23620},{"trials":23607,"activeCount":101},[],{"trials":23609,"activeCount":101},[23610],{"nctId":8210,"briefTitle":8211,"status":142,"phases":23611,"primaryCompletion":8213,"completion":8213,"start":8214,"enrollment":685,"conditions":23612,"interventions":23613},[89],[8216,8217,843,8218,8219],[1570,8221],{"trials":23615,"activeCount":101},[],{"trials":23617,"activeCount":101},[],{"trials":23619,"activeCount":101},[],{"trials":23621,"activeCount":101},[],{"intervention":23623,"totalTrials":2548,"cells":23624},"Celebrex",{"EARLY_PHASE1":23625,"PHASE1":23627,"PHASE2":23639,"PHASE3":23641,"PHASE4":23643,"NA":23645},{"trials":23626,"activeCount":101},[],{"trials":23628,"activeCount":101},[23629],{"nctId":23630,"briefTitle":23631,"status":618,"phases":23632,"primaryCompletion":23633,"completion":23633,"start":5957,"enrollment":1913,"conditions":23634,"interventions":23637},"NCT01258868","Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas",[89],"2016-06-13",[23635,688,687,23636,10720],"Mesolthelioma","Thoracic Sarcomas",[23623,23638],"Tumor cell vaccine",{"trials":23640,"activeCount":101},[],{"trials":23642,"activeCount":101},[],{"trials":23644,"activeCount":101},[],{"trials":23646,"activeCount":101},[],{"intervention":23638,"totalTrials":2548,"cells":23648},{"EARLY_PHASE1":23649,"PHASE1":23651,"PHASE2":23657,"PHASE3":23659,"PHASE4":23661,"NA":23663},{"trials":23650,"activeCount":101},[],{"trials":23652,"activeCount":101},[23653],{"nctId":23630,"briefTitle":23631,"status":618,"phases":23654,"primaryCompletion":23633,"completion":23633,"start":5957,"enrollment":1913,"conditions":23655,"interventions":23656},[89],[23635,688,687,23636,10720],[23623,23638],{"trials":23658,"activeCount":101},[],{"trials":23660,"activeCount":101},[],{"trials":23662,"activeCount":101},[],{"trials":23664,"activeCount":101},[],{"intervention":9436,"totalTrials":2548,"cells":23666},{"EARLY_PHASE1":23667,"PHASE1":23669,"PHASE2":23675,"PHASE3":23677,"PHASE4":23679,"NA":23681},{"trials":23668,"activeCount":101},[],{"trials":23670,"activeCount":101},[23671],{"nctId":9429,"briefTitle":9430,"status":347,"phases":23672,"primaryCompletion":3019,"completion":3019,"start":2813,"enrollment":5986,"conditions":23673,"interventions":23674},[89],[9433,163,164,9434],[9436,167,9437],{"trials":23676,"activeCount":101},[],{"trials":23678,"activeCount":101},[],{"trials":23680,"activeCount":101},[],{"trials":23682,"activeCount":101},[],{"intervention":23684,"totalTrials":2548,"cells":23685},"Depsipeptide",{"EARLY_PHASE1":23686,"PHASE1":23688,"PHASE2":23699,"PHASE3":23701,"PHASE4":23703,"NA":23705},{"trials":23687,"activeCount":101},[],{"trials":23689,"activeCount":101},[23690],{"nctId":23691,"briefTitle":23692,"status":618,"phases":23693,"primaryCompletion":23694,"completion":23694,"start":23695,"enrollment":4349,"conditions":23696,"interventions":23697},"NCT00094978","Depsipeptide\u002FFlavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum",[89],"2013-05-20","2004-10-25",[5945,6058,468,915],[23684,23698],"Flavopiridol",{"trials":23700,"activeCount":101},[],{"trials":23702,"activeCount":101},[],{"trials":23704,"activeCount":101},[],{"trials":23706,"activeCount":101},[],{"intervention":23698,"totalTrials":2548,"cells":23708},{"EARLY_PHASE1":23709,"PHASE1":23711,"PHASE2":23717,"PHASE3":23719,"PHASE4":23721,"NA":23723},{"trials":23710,"activeCount":101},[],{"trials":23712,"activeCount":101},[23713],{"nctId":23691,"briefTitle":23692,"status":618,"phases":23714,"primaryCompletion":23694,"completion":23694,"start":23695,"enrollment":4349,"conditions":23715,"interventions":23716},[89],[5945,6058,468,915],[23684,23698],{"trials":23718,"activeCount":101},[],{"trials":23720,"activeCount":101},[],{"trials":23722,"activeCount":101},[],{"trials":23724,"activeCount":101},[],{"intervention":4606,"totalTrials":2548,"cells":23726},{"EARLY_PHASE1":23727,"PHASE1":23729,"PHASE2":23735,"PHASE3":23737,"PHASE4":23739,"NA":23741},{"trials":23728,"activeCount":101},[],{"trials":23730,"activeCount":101},[23731],{"nctId":4597,"briefTitle":4598,"status":618,"phases":23732,"primaryCompletion":454,"completion":454,"start":4600,"enrollment":638,"conditions":23733,"interventions":23734},[89],[4602,4603,4262],[4605,1139,4606,1016,3942],{"trials":23736,"activeCount":101},[],{"trials":23738,"activeCount":101},[],{"trials":23740,"activeCount":101},[],{"trials":23742,"activeCount":101},[],{"intervention":22449,"totalTrials":2548,"cells":23744},{"EARLY_PHASE1":23745,"PHASE1":23747,"PHASE2":23753,"PHASE3":23755,"PHASE4":23757,"NA":23759},{"trials":23746,"activeCount":101},[],{"trials":23748,"activeCount":101},[23749],{"nctId":22444,"briefTitle":22445,"status":142,"phases":23750,"primaryCompletion":7035,"start":18152,"enrollment":339,"conditions":23751,"interventions":23752},[89],[27,15],[3093,22449],{"trials":23754,"activeCount":101},[],{"trials":23756,"activeCount":101},[],{"trials":23758,"activeCount":101},[],{"trials":23760,"activeCount":101},[],{"intervention":23762,"totalTrials":2548,"cells":23763},"PF-02341066\u002FPF-00299804",{"EARLY_PHASE1":23764,"PHASE1":23766,"PHASE2":23779,"PHASE3":23781,"PHASE4":23783,"NA":23785},{"trials":23765,"activeCount":101},[],{"trials":23767,"activeCount":101},[23768],{"nctId":23769,"briefTitle":23770,"status":618,"phases":23771,"primaryCompletion":788,"completion":23772,"start":23773,"enrollment":552,"conditions":23774,"interventions":23778},"NCT01441128","-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer",[89],"2015-02-26","2011-09-01",[23775,11867,23776,23777],"Carcinoma, Non-Small Cell Lung","Carcinoma, Squamous Cell","Carcinoma, Large Cell",[23762,23762],{"trials":23780,"activeCount":101},[],{"trials":23782,"activeCount":101},[],{"trials":23784,"activeCount":101},[],{"trials":23786,"activeCount":101},[],{"intervention":705,"totalTrials":2548,"cells":23788},{"EARLY_PHASE1":23789,"PHASE1":23791,"PHASE2":23797,"PHASE3":23799,"PHASE4":23801,"NA":23803},{"trials":23790,"activeCount":101},[],{"trials":23792,"activeCount":101},[23793],{"nctId":695,"briefTitle":696,"status":618,"phases":23794,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":23795,"interventions":23796},[89],[702],[704,63,705,643,706,707,708,709,710],{"trials":23798,"activeCount":101},[],{"trials":23800,"activeCount":101},[],{"trials":23802,"activeCount":101},[],{"trials":23804,"activeCount":101},[],{"intervention":707,"totalTrials":2548,"cells":23806},{"EARLY_PHASE1":23807,"PHASE1":23809,"PHASE2":23815,"PHASE3":23817,"PHASE4":23819,"NA":23821},{"trials":23808,"activeCount":101},[],{"trials":23810,"activeCount":101},[23811],{"nctId":695,"briefTitle":696,"status":618,"phases":23812,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":23813,"interventions":23814},[89],[702],[704,63,705,643,706,707,708,709,710],{"trials":23816,"activeCount":101},[],{"trials":23818,"activeCount":101},[],{"trials":23820,"activeCount":101},[],{"trials":23822,"activeCount":101},[],{"intervention":708,"totalTrials":2548,"cells":23824},{"EARLY_PHASE1":23825,"PHASE1":23827,"PHASE2":23833,"PHASE3":23835,"PHASE4":23837,"NA":23839},{"trials":23826,"activeCount":101},[],{"trials":23828,"activeCount":101},[23829],{"nctId":695,"briefTitle":696,"status":618,"phases":23830,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":23831,"interventions":23832},[89],[702],[704,63,705,643,706,707,708,709,710],{"trials":23834,"activeCount":101},[],{"trials":23836,"activeCount":101},[],{"trials":23838,"activeCount":101},[],{"trials":23840,"activeCount":101},[],{"intervention":709,"totalTrials":2548,"cells":23842},{"EARLY_PHASE1":23843,"PHASE1":23845,"PHASE2":23851,"PHASE3":23853,"PHASE4":23855,"NA":23857},{"trials":23844,"activeCount":101},[],{"trials":23846,"activeCount":101},[23847],{"nctId":695,"briefTitle":696,"status":618,"phases":23848,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":23849,"interventions":23850},[89],[702],[704,63,705,643,706,707,708,709,710],{"trials":23852,"activeCount":101},[],{"trials":23854,"activeCount":101},[],{"trials":23856,"activeCount":101},[],{"trials":23858,"activeCount":101},[],{"intervention":721,"totalTrials":2548,"cells":23860},{"EARLY_PHASE1":23861,"PHASE1":23863,"PHASE2":23869,"PHASE3":23871,"PHASE4":23873,"NA":23875},{"trials":23862,"activeCount":101},[],{"trials":23864,"activeCount":101},[23865],{"nctId":712,"briefTitle":713,"status":618,"phases":23866,"primaryCompletion":715,"completion":716,"start":717,"enrollment":603,"conditions":23867,"interventions":23868},[89],[719],[704,721,63,643,722],{"trials":23870,"activeCount":101},[],{"trials":23872,"activeCount":101},[],{"trials":23874,"activeCount":101},[],{"trials":23876,"activeCount":101},[],{"intervention":5246,"totalTrials":2548,"cells":23878},{"EARLY_PHASE1":23879,"PHASE1":23881,"PHASE2":23887,"PHASE3":23889,"PHASE4":23891,"NA":23893},{"trials":23880,"activeCount":101},[],{"trials":23882,"activeCount":101},[23883],{"nctId":5239,"briefTitle":5240,"status":142,"phases":23884,"completion":5242,"start":5243,"enrollment":188,"conditions":23885,"interventions":23886},[89],[467],[5246,53],{"trials":23888,"activeCount":101},[],{"trials":23890,"activeCount":101},[],{"trials":23892,"activeCount":101},[],{"trials":23894,"activeCount":101},[],{"intervention":13545,"totalTrials":2548,"cells":23896},{"EARLY_PHASE1":23897,"PHASE1":23899,"PHASE2":23905,"PHASE3":23907,"PHASE4":23909,"NA":23911},{"trials":23898,"activeCount":101},[],{"trials":23900,"activeCount":101},[23901],{"nctId":13538,"briefTitle":13539,"status":142,"phases":23902,"primaryCompletion":13541,"completion":13541,"start":13542,"enrollment":421,"conditions":23903,"interventions":23904},[89],[3131],[13545,1832],{"trials":23906,"activeCount":101},[],{"trials":23908,"activeCount":101},[],{"trials":23910,"activeCount":101},[],{"trials":23912,"activeCount":101},[],{"intervention":23914,"totalTrials":2548,"cells":23915},"monoclonal antibody mono-dgA-RFB4",{"EARLY_PHASE1":23916,"PHASE1":23918,"PHASE2":23926,"PHASE3":23928,"PHASE4":23930,"NA":23932},{"trials":23917,"activeCount":101},[],{"trials":23919,"activeCount":101},[23920],{"nctId":23921,"briefTitle":23922,"status":142,"phases":23923,"start":16868,"conditions":23924,"interventions":23925},"NCT00007956","Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma",[89],[27],[23914],{"trials":23927,"activeCount":101},[],{"trials":23929,"activeCount":101},[],{"trials":23931,"activeCount":101},[],{"trials":23933,"activeCount":101},[],{"intervention":17368,"totalTrials":2548,"cells":23935},{"EARLY_PHASE1":23936,"PHASE1":23938,"PHASE2":23944,"PHASE3":23946,"PHASE4":23948,"NA":23950},{"trials":23937,"activeCount":101},[],{"trials":23939,"activeCount":101},[23940],{"nctId":17361,"briefTitle":17362,"status":618,"phases":23941,"primaryCompletion":17364,"completion":17364,"start":17365,"enrollment":838,"conditions":23942,"interventions":23943},[89],[915],[2444,17368],{"trials":23945,"activeCount":101},[],{"trials":23947,"activeCount":101},[],{"trials":23949,"activeCount":101},[],{"trials":23951,"activeCount":101},[],{"intervention":23953,"totalTrials":2548,"cells":23954},"TKM-080301",{"EARLY_PHASE1":23955,"PHASE1":23957,"PHASE2":23972,"PHASE3":23974,"PHASE4":23976,"NA":23978},{"trials":23956,"activeCount":101},[],{"trials":23958,"activeCount":101},[23959],{"nctId":23960,"briefTitle":23961,"status":142,"phases":23962,"primaryCompletion":23963,"completion":23963,"start":23964,"enrollment":2548,"conditions":23965,"interventions":23971},"NCT01437007","TKM 080301 for Primary or Secondary Liver Cancer",[89],"2012-06-21","2011-08-26",[23966,23967,23968,23969,23970],"Colorectal Cancer With Hepatic Metastases","Pancreas Cancer With Hepatic Metastase","Gastric Cancer With Hepatic Metastase","Breast Cancer With Hepatic Metastase","Ovarian Cancer With Hepatic Metastase",[23953],{"trials":23973,"activeCount":101},[],{"trials":23975,"activeCount":101},[],{"trials":23977,"activeCount":101},[],{"trials":23979,"activeCount":101},[],{"intervention":23981,"totalTrials":2548,"cells":23982},"carboxypeptidase-G2",{"EARLY_PHASE1":23983,"PHASE1":23985,"PHASE2":23995,"PHASE3":23997,"PHASE4":23999,"NA":24001},{"trials":23984,"activeCount":101},[],{"trials":23986,"activeCount":101},[23987],{"nctId":23988,"briefTitle":23989,"status":142,"phases":23990,"completion":3398,"start":23991,"enrollment":685,"conditions":23992,"interventions":23994},"NCT00001298","A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction",[89],"1992-03",[23993],"Kidney Diseases",[23981],{"trials":23996,"activeCount":101},[],{"trials":23998,"activeCount":101},[],{"trials":24000,"activeCount":101},[],{"trials":24002,"activeCount":101},[],{"intervention":6992,"totalTrials":2548,"cells":24004},{"EARLY_PHASE1":24005,"PHASE1":24007,"PHASE2":24013,"PHASE3":24015,"PHASE4":24017,"NA":24019},{"trials":24006,"activeCount":101},[],{"trials":24008,"activeCount":101},[24009],{"nctId":6969,"briefTitle":6970,"status":142,"phases":24010,"primaryCompletion":6972,"completion":6973,"start":3622,"enrollment":4349,"conditions":24011,"interventions":24012},[89],[1607,21,6975,1619,6976,6977,6978,1620,2309,3078,486,6979,6980,6981,6982,6983,6984,6985,6986,6987,6988,6989,6990,2596,1637,6160],[2083,6992],{"trials":24014,"activeCount":101},[],{"trials":24016,"activeCount":101},[],{"trials":24018,"activeCount":101},[],{"trials":24020,"activeCount":101},[],{"intervention":24022,"totalTrials":2548,"cells":24023},"indinavir",{"EARLY_PHASE1":24024,"PHASE1":24026,"PHASE2":24035,"PHASE3":24037,"PHASE4":24039,"NA":24041},{"trials":24025,"activeCount":101},[],{"trials":24027,"activeCount":101},[24028],{"nctId":24029,"briefTitle":24030,"status":142,"phases":24031,"completion":7035,"start":7113,"enrollment":2346,"conditions":24032,"interventions":24034},"NCT00001443","A Phase I \u002FII Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection",[89],[15388,24033],"HIV Infections",[24022],{"trials":24036,"activeCount":101},[],{"trials":24038,"activeCount":101},[],{"trials":24040,"activeCount":101},[],{"trials":24042,"activeCount":101},[],{"intervention":2598,"totalTrials":2548,"cells":24044},{"EARLY_PHASE1":24045,"PHASE1":24047,"PHASE2":24053,"PHASE3":24055,"PHASE4":24057,"NA":24059},{"trials":24046,"activeCount":101},[],{"trials":24048,"activeCount":101},[24049],{"nctId":2590,"briefTitle":2591,"status":107,"phases":24050,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":101,"conditions":24051,"interventions":24052},[89],[1620,2309,2596],[2598,2554],{"trials":24054,"activeCount":101},[],{"trials":24056,"activeCount":101},[],{"trials":24058,"activeCount":101},[],{"trials":24060,"activeCount":101},[],{"intervention":24062,"totalTrials":2548,"cells":24063},"9-cis-Retinoic Acid",{"EARLY_PHASE1":24064,"PHASE1":24066,"PHASE2":24075,"PHASE3":24077,"PHASE4":24079,"NA":24081},{"trials":24065,"activeCount":101},[],{"trials":24067,"activeCount":101},[24068],{"nctId":24069,"briefTitle":24070,"status":142,"phases":24071,"completion":3533,"start":24072,"enrollment":827,"conditions":24073,"interventions":24074},"NCT00001504","A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients",[89],"1996-05",[18,21863],[24062],{"trials":24076,"activeCount":101},[],{"trials":24078,"activeCount":101},[],{"trials":24080,"activeCount":101},[],{"trials":24082,"activeCount":101},[],{"intervention":24084,"totalTrials":2548,"cells":24085},"taxol",{"EARLY_PHASE1":24086,"PHASE1":24088,"PHASE2":24097,"PHASE3":24099,"PHASE4":24101,"NA":24103},{"trials":24087,"activeCount":101},[],{"trials":24089,"activeCount":101},[24090],{"nctId":24091,"briefTitle":24092,"status":142,"phases":24093,"completion":3662,"start":24094,"enrollment":1074,"conditions":24095,"interventions":24096},"NCT00001272","A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients",[89],"1991-09",[16735],[24084],{"trials":24098,"activeCount":101},[],{"trials":24100,"activeCount":101},[],{"trials":24102,"activeCount":101},[],{"trials":24104,"activeCount":101},[],{"intervention":24106,"totalTrials":2548,"cells":24107},"Lexatumumab alone",{"EARLY_PHASE1":24108,"PHASE1":24110,"PHASE2":24124,"PHASE3":24126,"PHASE4":24128,"NA":24130},{"trials":24109,"activeCount":101},[],{"trials":24111,"activeCount":101},[24112],{"nctId":24113,"briefTitle":24114,"status":618,"phases":24115,"primaryCompletion":24116,"completion":24117,"start":24118,"enrollment":28,"conditions":24119,"interventions":24120},"NCT00428272","HGS-ETR2 to Treat Children With Solid Tumors",[89],"2011-04-28","2015-10-09","2006-12-04",[14943,790,791,5969],[24106,24121,24122,24123],"Lexatumumab in combination","Interferon gamma 1b in combination","Gamma 1b potential expansion",{"trials":24125,"activeCount":101},[],{"trials":24127,"activeCount":101},[],{"trials":24129,"activeCount":101},[],{"trials":24131,"activeCount":101},[],{"intervention":24121,"totalTrials":2548,"cells":24133},{"EARLY_PHASE1":24134,"PHASE1":24136,"PHASE2":24142,"PHASE3":24144,"PHASE4":24146,"NA":24148},{"trials":24135,"activeCount":101},[],{"trials":24137,"activeCount":101},[24138],{"nctId":24113,"briefTitle":24114,"status":618,"phases":24139,"primaryCompletion":24116,"completion":24117,"start":24118,"enrollment":28,"conditions":24140,"interventions":24141},[89],[14943,790,791,5969],[24106,24121,24122,24123],{"trials":24143,"activeCount":101},[],{"trials":24145,"activeCount":101},[],{"trials":24147,"activeCount":101},[],{"trials":24149,"activeCount":101},[],{"intervention":24122,"totalTrials":2548,"cells":24151},{"EARLY_PHASE1":24152,"PHASE1":24154,"PHASE2":24160,"PHASE3":24162,"PHASE4":24164,"NA":24166},{"trials":24153,"activeCount":101},[],{"trials":24155,"activeCount":101},[24156],{"nctId":24113,"briefTitle":24114,"status":618,"phases":24157,"primaryCompletion":24116,"completion":24117,"start":24118,"enrollment":28,"conditions":24158,"interventions":24159},[89],[14943,790,791,5969],[24106,24121,24122,24123],{"trials":24161,"activeCount":101},[],{"trials":24163,"activeCount":101},[],{"trials":24165,"activeCount":101},[],{"trials":24167,"activeCount":101},[],{"intervention":24123,"totalTrials":2548,"cells":24169},{"EARLY_PHASE1":24170,"PHASE1":24172,"PHASE2":24178,"PHASE3":24180,"PHASE4":24182,"NA":24184},{"trials":24171,"activeCount":101},[],{"trials":24173,"activeCount":101},[24174],{"nctId":24113,"briefTitle":24114,"status":618,"phases":24175,"primaryCompletion":24116,"completion":24117,"start":24118,"enrollment":28,"conditions":24176,"interventions":24177},[89],[14943,790,791,5969],[24106,24121,24122,24123],{"trials":24179,"activeCount":101},[],{"trials":24181,"activeCount":101},[],{"trials":24183,"activeCount":101},[],{"trials":24185,"activeCount":101},[],{"intervention":764,"totalTrials":2548,"cells":24187},{"EARLY_PHASE1":24188,"PHASE1":24190,"PHASE2":24196,"PHASE3":24198,"PHASE4":24200,"NA":24202},{"trials":24189,"activeCount":101},[],{"trials":24191,"activeCount":101},[24192],{"nctId":753,"briefTitle":754,"status":618,"phases":24193,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":24194,"interventions":24195},[89],[760,761,653,762],[764,63,643],{"trials":24197,"activeCount":101},[],{"trials":24199,"activeCount":101},[],{"trials":24201,"activeCount":101},[],{"trials":24203,"activeCount":101},[],{"intervention":8478,"totalTrials":2548,"cells":24205},{"EARLY_PHASE1":24206,"PHASE1":24208,"PHASE2":24214,"PHASE3":24216,"PHASE4":24218,"NA":24220},{"trials":24207,"activeCount":101},[],{"trials":24209,"activeCount":101},[24210],{"nctId":8473,"briefTitle":8474,"status":142,"phases":24211,"primaryCompletion":4366,"start":1819,"enrollment":1517,"conditions":24212,"interventions":24213},[89],[1343,5233,5454,1344,4842],[1435,8478],{"trials":24215,"activeCount":101},[],{"trials":24217,"activeCount":101},[],{"trials":24219,"activeCount":101},[],{"trials":24221,"activeCount":101},[],{"intervention":10354,"totalTrials":2548,"cells":24223},{"EARLY_PHASE1":24224,"PHASE1":24226,"PHASE2":24232,"PHASE3":24234,"PHASE4":24236,"NA":24238},{"trials":24225,"activeCount":101},[],{"trials":24227,"activeCount":101},[24228],{"nctId":10345,"briefTitle":10346,"status":142,"phases":24229,"primaryCompletion":10348,"completion":10349,"start":10350,"enrollment":28,"conditions":24230,"interventions":24231},[89],[10352],[10354,10355,10356,5933],{"trials":24233,"activeCount":101},[],{"trials":24235,"activeCount":101},[],{"trials":24237,"activeCount":101},[],{"trials":24239,"activeCount":101},[],{"intervention":10355,"totalTrials":2548,"cells":24241},{"EARLY_PHASE1":24242,"PHASE1":24244,"PHASE2":24250,"PHASE3":24252,"PHASE4":24254,"NA":24256},{"trials":24243,"activeCount":101},[],{"trials":24245,"activeCount":101},[24246],{"nctId":10345,"briefTitle":10346,"status":142,"phases":24247,"primaryCompletion":10348,"completion":10349,"start":10350,"enrollment":28,"conditions":24248,"interventions":24249},[89],[10352],[10354,10355,10356,5933],{"trials":24251,"activeCount":101},[],{"trials":24253,"activeCount":101},[],{"trials":24255,"activeCount":101},[],{"trials":24257,"activeCount":101},[],{"intervention":10356,"totalTrials":2548,"cells":24259},{"EARLY_PHASE1":24260,"PHASE1":24262,"PHASE2":24268,"PHASE3":24270,"PHASE4":24272,"NA":24274},{"trials":24261,"activeCount":101},[],{"trials":24263,"activeCount":101},[24264],{"nctId":10345,"briefTitle":10346,"status":142,"phases":24265,"primaryCompletion":10348,"completion":10349,"start":10350,"enrollment":28,"conditions":24266,"interventions":24267},[89],[10352],[10354,10355,10356,5933],{"trials":24269,"activeCount":101},[],{"trials":24271,"activeCount":101},[],{"trials":24273,"activeCount":101},[],{"trials":24275,"activeCount":101},[],{"intervention":24277,"totalTrials":2548,"cells":24278},"Th2\u002FTc2 Cells",{"EARLY_PHASE1":24279,"PHASE1":24281,"PHASE2":24291,"PHASE3":24293,"PHASE4":24295,"NA":24297},{"trials":24280,"activeCount":101},[],{"trials":24282,"activeCount":101},[24283],{"nctId":24284,"briefTitle":24285,"status":142,"phases":24286,"primaryCompletion":24287,"completion":24287,"start":24288,"enrollment":2401,"conditions":24289,"interventions":24290},"NCT00079625","Stem Cell Transplant With Th2\u002FTc2 Cells to Treat Advanced Breast Cancer",[89],"2013-08-09","2004-03-05",[1291],[24277],{"trials":24292,"activeCount":101},[],{"trials":24294,"activeCount":101},[],{"trials":24296,"activeCount":101},[],{"trials":24298,"activeCount":101},[],{"intervention":24300,"totalTrials":2548,"cells":24301},"CDDO",{"EARLY_PHASE1":24302,"PHASE1":24304,"PHASE2":24314,"PHASE3":24316,"PHASE4":24318,"NA":24320},{"trials":24303,"activeCount":101},[],{"trials":24305,"activeCount":101},[24306],{"nctId":24307,"briefTitle":24308,"status":142,"phases":24309,"primaryCompletion":24310,"completion":24310,"start":24311,"enrollment":1024,"conditions":24312,"interventions":24313},"NCT00322140","CDDO to Treat Solid Tumors and Lymphomas",[89],"2008-01-14","2006-05-01",[3229,27],[24300],{"trials":24315,"activeCount":101},[],{"trials":24317,"activeCount":101},[],{"trials":24319,"activeCount":101},[],{"trials":24321,"activeCount":101},[],{"intervention":24323,"totalTrials":2548,"cells":24324},"Methylselenocysteine",{"EARLY_PHASE1":24325,"PHASE1":24327,"PHASE2":24336,"PHASE3":24338,"PHASE4":24340,"NA":24342},{"trials":24326,"activeCount":101},[],{"trials":24328,"activeCount":101},[24329],{"nctId":24330,"briefTitle":24331,"status":142,"phases":24332,"primaryCompletion":4714,"completion":18353,"start":4031,"enrollment":971,"conditions":24333,"interventions":24335},"NCT01497431","Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants",[89],[24334,9046],"No Evidence of Disease",[24323],{"trials":24337,"activeCount":101},[],{"trials":24339,"activeCount":101},[],{"trials":24341,"activeCount":101},[],{"trials":24343,"activeCount":101},[],{"intervention":24345,"totalTrials":2548,"cells":24346},"MVA-brachyury- TRICOM",{"EARLY_PHASE1":24347,"PHASE1":24349,"PHASE2":24360,"PHASE3":24362,"PHASE4":24364,"NA":24366},{"trials":24348,"activeCount":101},[],{"trials":24350,"activeCount":101},[24351],{"nctId":24352,"briefTitle":24353,"status":142,"phases":24354,"primaryCompletion":24355,"completion":17365,"start":24356,"enrollment":174,"conditions":24357,"interventions":24359},"NCT02179515","Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)",[89],"2017-04-06","2014-06-28",[687,18,24,24358,1003],"Tumors (Others)",[24345],{"trials":24361,"activeCount":101},[],{"trials":24363,"activeCount":101},[],{"trials":24365,"activeCount":101},[],{"trials":24367,"activeCount":101},[],{"intervention":24369,"totalTrials":2548,"cells":24370},"karenitecin",{"EARLY_PHASE1":24371,"PHASE1":24373,"PHASE2":24381,"PHASE3":24383,"PHASE4":24385,"NA":24387},{"trials":24372,"activeCount":101},[],{"trials":24374,"activeCount":101},[24375],{"nctId":24376,"briefTitle":24377,"status":142,"phases":24378,"start":3533,"conditions":24379,"interventions":24380},"NCT00014521","Karenitecin in Treating Patients With Recurrent Malignant Glioma",[89],[3664],[24369],{"trials":24382,"activeCount":101},[],{"trials":24384,"activeCount":101},[],{"trials":24386,"activeCount":101},[],{"trials":24388,"activeCount":101},[],{"intervention":24390,"totalTrials":2548,"cells":24391},"IgG-RFB4-SMPT-dgA",{"EARLY_PHASE1":24392,"PHASE1":24394,"PHASE2":24403,"PHASE3":24405,"PHASE4":24407,"NA":24409},{"trials":24393,"activeCount":101},[],{"trials":24395,"activeCount":101},[24396],{"nctId":24397,"briefTitle":24398,"status":142,"phases":24399,"completion":3088,"start":24400,"enrollment":339,"conditions":24401,"interventions":24402},"NCT00001271","A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma",[89],"1991-07",[14919],[24390],{"trials":24404,"activeCount":101},[],{"trials":24406,"activeCount":101},[],{"trials":24408,"activeCount":101},[],{"trials":24410,"activeCount":101},[],{"intervention":17078,"totalTrials":2548,"cells":24412},{"EARLY_PHASE1":24413,"PHASE1":24415,"PHASE2":24421,"PHASE3":24423,"PHASE4":24425,"NA":24427},{"trials":24414,"activeCount":101},[],{"trials":24416,"activeCount":101},[24417],{"nctId":17073,"briefTitle":17074,"status":618,"phases":24418,"primaryCompletion":650,"start":7340,"enrollment":1517,"conditions":24419,"interventions":24420},[89],[15],[17078,17066],{"trials":24422,"activeCount":101},[],{"trials":24424,"activeCount":101},[],{"trials":24426,"activeCount":101},[],{"trials":24428,"activeCount":101},[],{"intervention":24430,"totalTrials":2548,"cells":24431},"B-Lymphocyte Stimulator",{"EARLY_PHASE1":24432,"PHASE1":24434,"PHASE2":24443,"PHASE3":24445,"PHASE4":24447,"NA":24449},{"trials":24433,"activeCount":101},[],{"trials":24435,"activeCount":101},[24436],{"nctId":24437,"briefTitle":24438,"status":142,"phases":24439,"completion":14499,"start":5707,"enrollment":552,"conditions":24440,"interventions":24442},"NCT00024934","B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency",[89],[24441],"IgA Deficiency",[24430],{"trials":24444,"activeCount":101},[],{"trials":24446,"activeCount":101},[],{"trials":24448,"activeCount":101},[],{"trials":24450,"activeCount":101},[],{"intervention":793,"totalTrials":2548,"cells":24452},{"EARLY_PHASE1":24453,"PHASE1":24455,"PHASE2":24461,"PHASE3":24463,"PHASE4":24465,"NA":24467},{"trials":24454,"activeCount":101},[],{"trials":24456,"activeCount":101},[24457],{"nctId":783,"briefTitle":784,"status":142,"phases":24458,"primaryCompletion":786,"completion":787,"start":788,"enrollment":310,"conditions":24459,"interventions":24460},[89],[625,790,791,36],[793,794,63],{"trials":24462,"activeCount":101},[],{"trials":24464,"activeCount":101},[],{"trials":24466,"activeCount":101},[],{"trials":24468,"activeCount":101},[],{"intervention":794,"totalTrials":2548,"cells":24470},{"EARLY_PHASE1":24471,"PHASE1":24473,"PHASE2":24479,"PHASE3":24481,"PHASE4":24483,"NA":24485},{"trials":24472,"activeCount":101},[],{"trials":24474,"activeCount":101},[24475],{"nctId":783,"briefTitle":784,"status":142,"phases":24476,"primaryCompletion":786,"completion":787,"start":788,"enrollment":310,"conditions":24477,"interventions":24478},[89],[625,790,791,36],[793,794,63],{"trials":24480,"activeCount":101},[],{"trials":24482,"activeCount":101},[],{"trials":24484,"activeCount":101},[],{"trials":24486,"activeCount":101},[],{"intervention":24488,"totalTrials":2548,"cells":24489},"paclitaxel concurrent with radiation therapy",{"EARLY_PHASE1":24490,"PHASE1":24492,"PHASE2":24501,"PHASE3":24503,"PHASE4":24505,"NA":24507},{"trials":24491,"activeCount":101},[],{"trials":24493,"activeCount":101},[24494],{"nctId":24495,"briefTitle":24496,"status":142,"phases":24497,"completion":1257,"start":7113,"enrollment":638,"conditions":24498,"interventions":24500},"NCT00001442","A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer",[89],[24499,576],"Head and Neck Neoplasm",[24488],{"trials":24502,"activeCount":101},[],{"trials":24504,"activeCount":101},[],{"trials":24506,"activeCount":101},[],{"trials":24508,"activeCount":101},[],{"intervention":8237,"totalTrials":2548,"cells":24510},{"EARLY_PHASE1":24511,"PHASE1":24513,"PHASE2":24519,"PHASE3":24521,"PHASE4":24523,"NA":24525},{"trials":24512,"activeCount":101},[],{"trials":24514,"activeCount":101},[24515],{"nctId":8227,"briefTitle":8228,"status":347,"phases":24516,"primaryCompletion":2798,"completion":2798,"start":8230,"enrollment":28,"conditions":24517,"interventions":24518},[89],[8232,8233,8234,5016],[8236,1570,8237],{"trials":24520,"activeCount":101},[],{"trials":24522,"activeCount":101},[],{"trials":24524,"activeCount":101},[],{"trials":24526,"activeCount":101},[],{"intervention":24528,"totalTrials":2548,"cells":24529},"SS1(dsFv)-PE38 immunotoxin",{"EARLY_PHASE1":24530,"PHASE1":24532,"PHASE2":24541,"PHASE3":24543,"PHASE4":24545,"NA":24547},{"trials":24531,"activeCount":101},[],{"trials":24533,"activeCount":101},[24534],{"nctId":24535,"briefTitle":24536,"status":142,"phases":24537,"start":4272,"conditions":24538,"interventions":24540},"NCT00066651","Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors",[89],[960,2569,1564,687,24539,1003,841,1821],"Malignant Mesothelioma",[24528],{"trials":24542,"activeCount":101},[],{"trials":24544,"activeCount":101},[],{"trials":24546,"activeCount":101},[],{"trials":24548,"activeCount":101},[],{"intervention":24550,"totalTrials":2548,"cells":24551},"Epacadostat",{"EARLY_PHASE1":24552,"PHASE1":24564,"PHASE2":24566,"PHASE3":24568,"PHASE4":24570,"NA":24572},{"trials":24553,"activeCount":101},[24554],{"nctId":24555,"briefTitle":24556,"status":142,"phases":24557,"primaryCompletion":24558,"completion":24558,"start":24559,"enrollment":407,"conditions":24560,"interventions":24563},"NCT02042430","Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[88],"2016-11-29","2014-08-25",[24561,9410,24562,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757],"Stage III Fallopian Tube Cancer AJCC v7","Stage III Primary Peritoneal Cancer AJCC v7",[24550],{"trials":24565,"activeCount":101},[],{"trials":24567,"activeCount":101},[],{"trials":24569,"activeCount":101},[],{"trials":24571,"activeCount":101},[],{"trials":24573,"activeCount":101},[],{"intervention":24575,"totalTrials":2548,"cells":24576},"Amatuximab",{"EARLY_PHASE1":24577,"PHASE1":24588,"PHASE2":24590,"PHASE3":24592,"PHASE4":24594,"NA":24596},{"trials":24578,"activeCount":101},[24579],{"nctId":24580,"briefTitle":24581,"status":618,"phases":24582,"primaryCompletion":24583,"completion":24583,"start":24584,"enrollment":1024,"conditions":24585,"interventions":24587},"NCT01413451","Amatuximab for High Mesothelin Cancers",[88],"2013-11-15","2011-07-12",[24586,915,16735,6058],"Carcinoma, Pancreatic Ductal",[24575],{"trials":24589,"activeCount":101},[],{"trials":24591,"activeCount":101},[],{"trials":24593,"activeCount":101},[],{"trials":24595,"activeCount":101},[],{"trials":24597,"activeCount":101},[],{"intervention":24599,"totalTrials":2548,"cells":24600},"FPAC",{"EARLY_PHASE1":24601,"PHASE1":24612,"PHASE2":24614,"PHASE3":24616,"PHASE4":24618,"NA":24620},{"trials":24602,"activeCount":101},[24603],{"nctId":24604,"briefTitle":24605,"status":618,"phases":24606,"primaryCompletion":24607,"completion":5583,"start":24608,"enrollment":889,"conditions":24609,"interventions":24611},"NCT01086696","A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers",[88],"2014-08-20","2010-03-09",[18,687,870,24610],"Adrenal Cancer",[24599],{"trials":24613,"activeCount":101},[],{"trials":24615,"activeCount":101},[],{"trials":24617,"activeCount":101},[],{"trials":24619,"activeCount":101},[],{"trials":24621,"activeCount":101},[],{"intervention":24623,"totalTrials":2548,"cells":24624},"18F DCFBC",{"EARLY_PHASE1":24625,"PHASE1":24636,"PHASE2":24638,"PHASE3":24640,"PHASE4":24642,"NA":24644},{"trials":24626,"activeCount":101},[24627],{"nctId":24628,"briefTitle":24629,"status":142,"phases":24630,"primaryCompletion":144,"completion":24631,"start":24632,"enrollment":5585,"conditions":24633,"interventions":24634},"NCT02190279","18F-DCFBC PET\u002FCT in Prostate Cancer",[88],"2018-01-11","2014-07-12",[10352,24],[24623,24635],"Sodium",{"trials":24637,"activeCount":101},[],{"trials":24639,"activeCount":101},[],{"trials":24641,"activeCount":101},[],{"trials":24643,"activeCount":101},[],{"trials":24645,"activeCount":101},[],{"intervention":24635,"totalTrials":2548,"cells":24647},{"EARLY_PHASE1":24648,"PHASE1":24654,"PHASE2":24656,"PHASE3":24658,"PHASE4":24660,"NA":24662},{"trials":24649,"activeCount":101},[24650],{"nctId":24628,"briefTitle":24629,"status":142,"phases":24651,"primaryCompletion":144,"completion":24631,"start":24632,"enrollment":5585,"conditions":24652,"interventions":24653},[88],[10352,24],[24623,24635],{"trials":24655,"activeCount":101},[],{"trials":24657,"activeCount":101},[],{"trials":24659,"activeCount":101},[],{"trials":24661,"activeCount":101},[],{"trials":24663,"activeCount":101},[],{"intervention":24665,"totalTrials":2548,"cells":24666},"[F-18]-5-FLUORO-2'-DEOXYCYTIDINE",{"EARLY_PHASE1":24667,"PHASE1":24680,"PHASE2":24682,"PHASE3":24684,"PHASE4":24686,"NA":24688},{"trials":24668,"activeCount":101},[24669],{"nctId":24670,"briefTitle":24671,"status":618,"phases":24672,"primaryCompletion":24673,"completion":24674,"start":24675,"enrollment":838,"conditions":24676,"interventions":24677},"NCT01479348","Imaging Study for FdCyd and THU Cancer Treatment",[88],"2017-08-04","2019-01-11","2011-11-01",[9164,2718,20866,1291],[24665,24678,24679],"Tetrahydrouridine intravenous","Tetrahydrouridine",{"trials":24681,"activeCount":101},[],{"trials":24683,"activeCount":101},[],{"trials":24685,"activeCount":101},[],{"trials":24687,"activeCount":101},[],{"trials":24689,"activeCount":101},[],{"intervention":24678,"totalTrials":2548,"cells":24691},{"EARLY_PHASE1":24692,"PHASE1":24698,"PHASE2":24700,"PHASE3":24702,"PHASE4":24704,"NA":24706},{"trials":24693,"activeCount":101},[24694],{"nctId":24670,"briefTitle":24671,"status":618,"phases":24695,"primaryCompletion":24673,"completion":24674,"start":24675,"enrollment":838,"conditions":24696,"interventions":24697},[88],[9164,2718,20866,1291],[24665,24678,24679],{"trials":24699,"activeCount":101},[],{"trials":24701,"activeCount":101},[],{"trials":24703,"activeCount":101},[],{"trials":24705,"activeCount":101},[],{"trials":24707,"activeCount":101},[],{"intervention":24679,"totalTrials":2548,"cells":24709},{"EARLY_PHASE1":24710,"PHASE1":24716,"PHASE2":24718,"PHASE3":24720,"PHASE4":24722,"NA":24724},{"trials":24711,"activeCount":101},[24712],{"nctId":24670,"briefTitle":24671,"status":618,"phases":24713,"primaryCompletion":24673,"completion":24674,"start":24675,"enrollment":838,"conditions":24714,"interventions":24715},[88],[9164,2718,20866,1291],[24665,24678,24679],{"trials":24717,"activeCount":101},[],{"trials":24719,"activeCount":101},[],{"trials":24721,"activeCount":101},[],{"trials":24723,"activeCount":101},[],{"trials":24725,"activeCount":101},[],{"intervention":24727,"totalTrials":2548,"cells":24728},"111Indium CHX-A",{"EARLY_PHASE1":24729,"PHASE1":24738,"PHASE2":24740,"PHASE3":24742,"PHASE4":24744,"NA":24746},{"trials":24730,"activeCount":101},[24731],{"nctId":24732,"briefTitle":24733,"status":618,"phases":24734,"primaryCompletion":24607,"completion":24607,"start":24735,"enrollment":2577,"conditions":24736,"interventions":24737},"NCT01445054","111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer",[88],"2007-03-01",[18,24,687,843],[24727],{"trials":24739,"activeCount":101},[],{"trials":24741,"activeCount":101},[],{"trials":24743,"activeCount":101},[],{"trials":24745,"activeCount":101},[],{"trials":24747,"activeCount":101},[],{"intervention":1774,"totalTrials":375,"cells":24749},{"EARLY_PHASE1":24750,"PHASE1":24752,"PHASE2":24783,"PHASE3":24806,"PHASE4":24808,"NA":24810},{"trials":24751,"activeCount":101},[],{"trials":24753,"activeCount":101},[24754,24758,24762,24766,24775,24779],{"nctId":8203,"briefTitle":8204,"status":142,"phases":24755,"primaryCompletion":1052,"completion":1052,"start":1340,"enrollment":5986,"conditions":24756,"interventions":24757},[89],[5127,4983,4863,7342,7344,5509,8207,5286,4890,7349,5288,4941,7351,5289,7352,7353,3118,5510,5290,5291,5292,7354,5293,5294,3119,3259,4942,5295,7355,5296,5297,5298,5299,5300,5301,5302,5303,7356,7357,4795,5337,7358,5338,4945,7361,5339,6520,5340,5341,5342,5343,5344,3285,3261,4946,5345,5346,5347,5348,5349,5350,5351,5352,5353,7434,7363,7364],[1697,1774],{"nctId":9422,"briefTitle":9423,"status":142,"phases":24759,"primaryCompletion":1309,"start":9425,"enrollment":31,"conditions":24760,"interventions":24761},[89],[5637,3259,5638,3260],[1774,3066],{"nctId":5863,"briefTitle":5864,"status":142,"phases":24763,"primaryCompletion":3304,"start":4997,"enrollment":5866,"conditions":24764,"interventions":24765},[89],[5868,4658,4659,4660,4661,5869,4662,5870,5871,4665,117,5872],[1774,5874],{"nctId":24767,"briefTitle":24768,"status":142,"phases":24769,"primaryCompletion":1781,"start":7340,"enrollment":16870,"conditions":24770,"interventions":24774},"NCT00030498","Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction",[89],[4813,4814,4815,4816,5275,16912,4817,4818,4819,4820,16915,5280,8147,4862,16917,4863,24771,1219,5286,5287,4890,7349,5288,7686,3117,1578,4941,7351,5289,5290,5291,5292,2042,7354,5293,5294,3119,1579,3259,2321,4942,5295,5296,5297,5298,5299,5300,5301,5302,5303,24772,5638,24773,3260,1772,5337,7358,5338,7689,3137,4945,7361,5339,5340,5341,5342,5343,5344,3285,1591,3261,2297,4946,5345,5346,5347,5348,5349,5350,5351,5352,5353,1592,1594,15,7365],"Advanced Malignant Mesothelioma","Stage II Esophageal Cancer","Stage III Esophageal Cancer",[1774],{"nctId":16432,"briefTitle":16433,"status":618,"phases":24776,"primaryCompletion":11581,"completion":11581,"start":5270,"enrollment":455,"conditions":24777,"interventions":24778},[89],[3320,3321],[16437,4849],{"nctId":1760,"briefTitle":1761,"status":618,"phases":24780,"primaryCompletion":1763,"start":1764,"enrollment":1765,"conditions":24781,"interventions":24782},[89],[1767,1768,1769,1770,1771,1772],[1598,1080,1774,1775,995,1776],{"trials":24784,"activeCount":101},[24785,24789,24798,24802],{"nctId":17042,"briefTitle":17043,"status":142,"phases":24786,"primaryCompletion":17045,"completion":17046,"start":17047,"enrollment":37,"conditions":24787,"interventions":24788},[89,90],[10156,801],[17050,16437],{"nctId":24790,"briefTitle":24791,"status":618,"phases":24792,"primaryCompletion":715,"start":1241,"enrollment":3283,"conditions":24793,"interventions":24797},"NCT00087269","Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection",[90],[24794,3457,24795,24796,1771],"Stage IA Non-small Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer",[1774],{"nctId":8131,"briefTitle":8132,"status":142,"phases":24799,"primaryCompletion":3227,"completion":8134,"start":715,"enrollment":4001,"conditions":24800,"interventions":24801},[89,90],[4817,4818,4819,5287],[8069,1774,1185,4566],{"nctId":5441,"briefTitle":5442,"status":142,"phases":24803,"primaryCompletion":5444,"completion":5445,"start":2487,"enrollment":2029,"conditions":24804,"interventions":24805},[90],[4862,4863,4864,4890],[1033,1774],{"trials":24807,"activeCount":101},[],{"trials":24809,"activeCount":101},[],{"trials":24811,"activeCount":101},[24812],{"nctId":24813,"briefTitle":24814,"status":142,"phases":24815,"primaryCompletion":813,"start":717,"enrollment":7731,"conditions":24816,"interventions":24817},"NCT00085280","Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",[93],[3119,1772,3285],[1774],{"intervention":24819,"totalTrials":603,"cells":24820},"arsenic trioxide",{"EARLY_PHASE1":24821,"PHASE1":24823,"PHASE2":24831,"PHASE3":24840,"PHASE4":24842,"NA":24844},{"trials":24822,"activeCount":101},[],{"trials":24824,"activeCount":101},[24825],{"nctId":24826,"briefTitle":24827,"status":142,"phases":24828,"start":1979,"conditions":24829,"interventions":24830},"NCT00020111","Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma",[89],[1260,27],[24819],{"trials":24832,"activeCount":101},[24833],{"nctId":24834,"briefTitle":24835,"status":618,"phases":24836,"primaryCompletion":5976,"start":745,"enrollment":234,"conditions":24837,"interventions":24839},"NCT00061958","Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction",[90],[24838,24773,7361],"Adenocarcinoma of the Esophagus",[24819],{"trials":24841,"activeCount":101},[],{"trials":24843,"activeCount":101},[],{"trials":24845,"activeCount":101},[24846],{"nctId":24847,"briefTitle":24848,"status":618,"phases":24849,"primaryCompletion":4639,"start":3398,"enrollment":37,"conditions":24850,"interventions":24851},"NCT00005786","Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia",[93],[1245,1246,654,3183,3187,3188,3190,655,656,1248,1251],[24819],{"intervention":5066,"totalTrials":603,"cells":24853},{"EARLY_PHASE1":24854,"PHASE1":24856,"PHASE2":24858,"PHASE3":24868,"PHASE4":24870,"NA":24872},{"trials":24855,"activeCount":101},[],{"trials":24857,"activeCount":101},[],{"trials":24859,"activeCount":101},[24860,24864],{"nctId":5061,"briefTitle":5062,"status":142,"phases":24861,"completion":3587,"start":1241,"conditions":24862,"interventions":24863},[90],[856,869],[5066,3065,3110,1264,1081,4948],{"nctId":5068,"briefTitle":5069,"status":142,"phases":24865,"primaryCompletion":1320,"start":3088,"enrollment":421,"conditions":24866,"interventions":24867},[90],[856],[5066,3065,1264,4948],{"trials":24869,"activeCount":101},[],{"trials":24871,"activeCount":101},[],{"trials":24873,"activeCount":101},[24874],{"nctId":5177,"briefTitle":5178,"status":142,"phases":24875,"completion":987,"start":1764,"conditions":24876,"interventions":24877},[93],[856],[5066,3065,1264,4948],{"intervention":24879,"totalTrials":2548,"cells":24880},"2-Flourodeoxyglucose",{"EARLY_PHASE1":24881,"PHASE1":24883,"PHASE2":24885,"PHASE3":24887,"PHASE4":24889,"NA":24891},{"trials":24882,"activeCount":101},[],{"trials":24884,"activeCount":101},[],{"trials":24886,"activeCount":101},[],{"trials":24888,"activeCount":101},[],{"trials":24890,"activeCount":101},[],{"trials":24892,"activeCount":101},[24893],{"nctId":24894,"briefTitle":24895,"status":142,"phases":24896,"primaryCompletion":24897,"completion":24897,"start":24898,"enrollment":21159,"conditions":24899,"interventions":24900},"NCT00067821","Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity",[],"2019-05-10","2014-02-11",[5989],[24879],{"intervention":24902,"totalTrials":2548,"cells":24903},"proteomic profiling",{"EARLY_PHASE1":24904,"PHASE1":24906,"PHASE2":24908,"PHASE3":24910,"PHASE4":24912,"NA":24914},{"trials":24905,"activeCount":101},[],{"trials":24907,"activeCount":101},[],{"trials":24909,"activeCount":101},[],{"trials":24911,"activeCount":101},[],{"trials":24913,"activeCount":101},[],{"trials":24915,"activeCount":101},[24916],{"nctId":24917,"briefTitle":24918,"status":142,"phases":24919,"completion":987,"start":4231,"conditions":24920,"interventions":24921},"NCT00045331","Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer",[93],[24],[24902],{"intervention":24923,"totalTrials":2548,"cells":24924},"glucarpidase",{"EARLY_PHASE1":24925,"PHASE1":24927,"PHASE2":24929,"PHASE3":24931,"PHASE4":24933,"NA":24935},{"trials":24926,"activeCount":101},[],{"trials":24928,"activeCount":101},[],{"trials":24930,"activeCount":101},[],{"trials":24932,"activeCount":101},[],{"trials":24934,"activeCount":101},[],{"trials":24936,"activeCount":101},[24937],{"nctId":24938,"briefTitle":24939,"status":142,"phases":24940,"primaryCompletion":1217,"start":24941,"enrollment":685,"conditions":24942,"interventions":24944},"NCT00018967","Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate",[93],"1993-11",[24943,15,748],"Neurotoxicity",[24923],{"intervention":24946,"totalTrials":2548,"cells":24947},"pirfenidone",{"EARLY_PHASE1":24948,"PHASE1":24950,"PHASE2":24952,"PHASE3":24954,"PHASE4":24956,"NA":24958},{"trials":24949,"activeCount":101},[],{"trials":24951,"activeCount":101},[],{"trials":24953,"activeCount":101},[],{"trials":24955,"activeCount":101},[],{"trials":24957,"activeCount":101},[],{"trials":24959,"activeCount":101},[24960],{"nctId":24961,"briefTitle":24962,"status":142,"phases":24963,"completion":987,"start":5707,"conditions":24964,"interventions":24966},"NCT00020631","Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer",[93],[24965],"Radiation Fibrosis",[24946],{"intervention":24968,"totalTrials":2548,"cells":24969},"caspofungin acetate",{"EARLY_PHASE1":24970,"PHASE1":24972,"PHASE2":24974,"PHASE3":24976,"PHASE4":24978,"NA":24980},{"trials":24971,"activeCount":101},[],{"trials":24973,"activeCount":101},[],{"trials":24975,"activeCount":101},[],{"trials":24977,"activeCount":101},[],{"trials":24979,"activeCount":101},[],{"trials":24981,"activeCount":101},[24982],{"nctId":24983,"briefTitle":24984,"status":142,"phases":24985,"completion":745,"start":14799,"conditions":24986,"interventions":24988},"NCT00020527","Caspofungin Acetate in Treating Children With Fever and Neutropenia",[93],[24987,17412,11282,1260,27,791,15291,625],"Fever, Sweats, and Hot Flashes",[24968],{"intervention":24990,"totalTrials":2548,"cells":24991},"Allogeneic stem cell transplant",{"EARLY_PHASE1":24992,"PHASE1":24994,"PHASE2":24996,"PHASE3":24998,"PHASE4":25000,"NA":25002},{"trials":24993,"activeCount":101},[],{"trials":24995,"activeCount":101},[],{"trials":24997,"activeCount":101},[],{"trials":24999,"activeCount":101},[],{"trials":25001,"activeCount":101},[],{"trials":25003,"activeCount":101},[25004],{"nctId":25005,"briefTitle":25006,"status":618,"phases":25007,"primaryCompletion":25008,"completion":25009,"start":25010,"enrollment":3274,"conditions":25011,"interventions":25016},"NCT01326728","Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation",[],"2017-06-28","2017-07-14","2011-03-30",[25012,25013,902,25014,25015],"Chronic Myelogenous Leukemia","Acute Myelogenous Leukemia","Hodgkins Lymphoma","Non-Hodgkins Lymphoma",[24990]]